

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number
WO 03/072720 A2

(51) International Patent Classification⁷: C12N
(21) International Application Number: PCT/US03/05276
(22) International Filing Date: 21 February 2003 (21.02.2003)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/358,934 21 February 2002 (21.02.2002) US

(71) Applicants (for all designated States except US): MED-IMMUNE VACCINES, INC. [US/US]; 35 W. Watkins Mill Road, Gaithersburg, MD 20878 (US). VIRONOVA-TIVE BV [NL/NL]; P.O. Box 1738, NL-3000 DR Rotterdam (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HALLER, Aurelia [AT/US]; 313 Hillview Avenue, Redwood City, CA 94062 (US). TANG, Roderick [MY/US]; 730 Chestnut

Street, #3, San Carlos, CA 94070 (US). FOUCHIER, Ronaldus, Adrianus, Maria [NL/NL]; Essenburgsingel 44a, NL-3021 AR Rotterdam (NL). VAN DEN HOGEN, Bernadetta, Gerarda [NL/NL]; Essenburgsingel 44a, NL-3021 AR Rotterdam (NL). OSTERHAUS, Albertus, Dominicus, Marcellinus, Erasmus [NL/NL]; Dr. Breveestraat 16, NL-3981 CH Bunnik (NL).

(74) Agents: CORUZZI, Laura, A. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: RECOMBINANT PARAINFLUENZA VIRUS EXPRESSION SYSTEMS AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM METAPNEUMOVIRUS

Human 1 MSHEVVIIFSLITPQHLKESVLESCSTITRGTSLVLRGTWYTVFLEVEDVNLTC 60
M ++ ++ L+ P ++B+V RESCST+T GY SVLRGTWYTVF LE+G+VEN+TC
Turkey 1 MDVRIICLLFLISNPSSCIQETVBERSCSTVIRGYSVLRGTWYTVFLEIGNVENITC 60
Human 61 ADGPSLIKTELDLTKSALRELKTVSADQARKEQIEMFROSRFVLGALGVATAAAVTA 120
DGPSEI TEL LTK+ALREL+TVSADQ+A+B ++ +PR+ RFVLGALGVATAAAVTA
Turkey 61 MDGPSLIDTELVTKSALRELKTVSADQAKESRLSPRRRRFVLGALGVATAAAVTA 120
Human 121 GVAIAKTRLESEVTAIDKALKTNEAVSTLGVGRVLATAVRELEKDFVSENLTATRW 180
GVA+AKTRLE SE VTAIRKAL+ TRKAVSTLGVGRVLATAV +LK+P+SK LT AIB+N
Turkey 121 GVALAKTRLESEVTAIDKALKTNEAVSTLGVGRVLATAVNDLEKDFISGLTPTATW 180
Human 181 KCDIADLQAGVSPQFNRFLNVRQPSDNAGITPAISLDLWTDALAVSNMPTSSAQ 240
KC+IAD+KMA+SP Q NERFLNVRQPSD+AGIT A+SLDMDT EL RA++ NPTS+GO
Turkey 181 KCDIADLQAGVSPQFNRFLNVRQPSDAGITSAVSLDMDTDELVAIRKMPPTSSAQ 240
Human 241 IRLMLNRMVVRKGFGLIGVTVSSVITVQLPIFGVIDTPCHVKAAPSCSGKQNYA 300
I LML NRMVVRKGFGLIGV ++V+TVQLPIFGVI+TPCH V AAP C +KMFYA
Turkey 241 IRLMLNRMVVRKGFGLIGVTVSSVITVQLPIFGVIDTPCHVKAAPSCSGKQNYA 300
Human 301 CLLRDQGWYCNAGSTVYYPNKKDCETRGDHFVFCOTAGINVAQSGECHINISTWY 360
C+LRDQGWYCNAGST YYPN+ DCR R D+VFCOTAGINVA+ ++CH NIST+ YP
Turkey 301 CLLRDQGWYCNAGSTAYTPNKKDCETRGDHFVFCOTAGINVALEYSQCYHISTSKY 360
Human 361 CKVSTORHPISMVALSPLGALVACYKGVSCSIGSRVGLIKQLKGCSTYTNQDAQTVYI 420
CKVSTORHP+SMVAL+PLG LV+CY+ VSCSIGSN+VGLIKQL KGC++I N +ADT+TY
Turkey 361 CKVSTORHPISMVALTFLGGLVCSYCSVSCSIGSNKVGIIKQLKGCSTYTNQDAQTVYI 420
Human 421 DNTVYGLSKVGEORVIRKIPVSSSDFDPKVFEDQFNVALQGVYESIENSQALVDQSHRI 480
DNTVYGLSKV GEQ IKG VY ++B+P+ FFDQFNVALQGVYESI+ SQ L+D+SH +
Turkey 421 DNTVYGLSKVGEORVIRKIPVSSSDFDPKVFEDQFNVALQGVYESIDRSQDLKSHRI 480
Human 481 LSSARKSTGFIIVILLIIVLSTNMLVSVFII--IKTKRPTGAPPELSEGVNKGFT 536
L + K G I I++ +LG +L ++ ++RTK P P +G ++ ++
Turkey 481 LGADAKSGAGIAIIVVLIGIIFLLAVIYCSRVKTK-PKRDYPTATGSSMAVY 537

(57) Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.



European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *without international search report and to be republished upon receipt of that report*

**RECOMBINANT PARAINFLUENZA VIRUS EXPRESSION
SYSTEMS AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS
DERIVED FROM METAPNEUMOVIRUS**

5

This application claims priority to U.S. Provisional Patent Application No. 60/358,934, filed February 21, 2002, which is incorporated by reference herein in its entirety.

10 Copending and co-assigned U.S. Patent Application ___, filed on even date herewith, listing Ronaldus Fouchier, Bernadetta van den Hoogen, Albertus Osterhaus, Aurelia Haller, and Roderick Tang as Inventors, entitled "METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES", is incorporated herein by reference in its entirety.

15

1. INTRODUCTION

The present invention relates to recombinant parainfluenza virus (PIV) cDNA or RNA that may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the present invention encompasses vaccine preparations comprising chimeric PIV expressing a heterologous gene product, wherein the heterologous gene product is preferably an antigenic peptide or polypeptide. In one embodiment, the PIV vector of the invention expresses one, two, or three heterologous gene products that may be encoded by the same or different viruses. In a preferred embodiment, the heterologous sequence encodes a heterologous gene product that is an antigenic polypeptide from another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus (RSV), mammalian metapneumovirus, and avian pneumovirus. The vaccine preparations of the invention encompass multivalent vaccines, including bivalent and trivalent vaccine preparations. The multivalent vaccines of the invention may be administered in the form of one PIV vector expressing each heterologous antigenic sequence or two or more PIV vectors

20
25
30

each encoding different heterologous antigenic sequences. The vaccine preparations of the invention can be administered alone or in combination with other vaccines, prophylactic agents, or therapeutic agents.

5

2. BACKGROUND OF THE INVENTION

Parainfluenza viral infection results in serious respiratory tract disease in infants and children. (Tao *et al.*, 1999, Vaccine 17: 1100-08). Infectious parainfluenza viral infections account for approximately 20% of all hospitalizations of pediatric patients that suffer from respiratory tract infections worldwide. *Id.* An effective antiviral therapy is not available to treat PIV related diseases, and a vaccine to prevent PIV infection has not yet been approved.

10

PIV is a member of the genus respirovirus (PIV1, PIV3) or rubulavirus (PIV2, PIV4) of the paramyxoviridae family. PIV is made up of two structural modules: (1) an internal ribonucleoprotein core, or nucleocapsid, containing the viral genome, and (2) an outer, roughly spherical lipoprotein envelope. Its genome consists of a single strand of negative sense RNA, that is approximately 15,456 nucleotides in length and encodes at least eight polypeptides. These proteins include the nucleocapsid structural protein (NP, NC, or N depending on the genera), the phosphoprotein (P), the matrix protein (M), the fusion glycoprotein (F), the hemagglutinin-neuraminidase glycoprotein (HN), the large polymerase protein (L), and the C and D proteins of unknown function. *Id.*

15

20

The parainfluenza nucleocapsid protein (NP, NC, or N) contains two domains within each protein unit. These domains include: an amino-terminal domain, that comprises nearly two-thirds of the molecule and interacts directly with the RNA, and a carboxyl-terminal domain, that lies on the surface of the assembled nucleocapsid. A hinge is thought to exist at the junction of these two domains, thereby imparting some flexibility on this protein (see Fields *et al.* (ed.), 1991, FUNDAMENTAL VIROLOGY, 2nd ed, Raven Press, New York, incorporated by reference herein in its entirety). The matrix protein (M) is apparently involved in viral assembly, and it interacts with both the viral membrane and the nucleocapsid proteins. The phosphoprotein (P) is subject to phosphorylation and has been implicated in transcription regulation, methylation, phosphorylation and polyadenylation. Produced initially as an inactive precursor, the fusion glycoprotein (F) is cleaved upon

25

30

translation to produce two disulfide linked polypeptides. The active F protein interacts with the viral membrane where it facilitates penetration of the parainfluenza virion into host cells by promoting the fusion of the viral envelope with the host cell plasma membrane. *Id.* The
5 glycoprotein, hemagglutinin-neuraminidase (HN) protrudes from the envelope and imparts hemagglutinin and neuraminidase activities on the virus. HN has a strongly hydrophobic amino terminus that functions to anchor the HN protein into the lipid bilayer. *Id.* Finally, the large polymerase protein (L) plays an important role in both transcription and replication.
Id.

10 Bovine parainfluenza virus was first isolated in 1959 from calves showing signs of shipping fever. It has since been isolated from normal cattle, aborted fetuses, and cattle exhibiting signs of respiratory disease (Breker-Klassen *et al.*, 1996, Can. J. Vet. Res. 60: 228-236. *See also* Shibuta, 1977, Microbiol. Immunol. 23 (7), 617-628). Human and
15 bovine PIV3 share neutralizing epitopes but show distinct antigenic properties. Significant differences exist between the human and bovine viral strains in the HN protein. In fact, a bovine strain induces some neutralizing antibodies to hPIV infection while a human strain seems to induce a wider spectrum of neutralizing antibodies against human PIV3 (Van Wyke Coelingh *et al.*, 1990, J. Virol. 64:3833-3843).

20 The replication of all negative-strand RNA viruses, including PIV, is complicated by the absence of the cellular machinery that is required to replicate RNA. Additionally, the negative-strand genome must be transcribed into a positive-strand (mRNA) copy before translation can occur. Consequently, the genomic RNA alone cannot synthesize the required RNA-dependent RNA polymerase upon entry into the cell. The L, P and N proteins must
25 enter the host cell along with the genomic RNA.

It is hypothesized that most or all of the viral proteins that transcribe PIV mRNA also carry out the replication of the genome. The mechanism that regulates the alternative uses (*i.e.*, transcription or replication) of the same complement of proteins has not been clearly identified, but the process appears to involve the abundance of free forms of one or more of the nucleocapsid proteins. Directly following penetration of the virus, transcription is
30 initiated by the L protein using the negative-sense RNA in the nucleocapsid as a template.

Viral RNA synthesis is regulated such that it produces monocistronic mRNAs during transcription.

5 Following transcription, virus genome replication is the second essential event in infection by negative-strand RNA viruses. As with other negative-strand RNA viruses, virus genome replication in PIV is mediated by virus-specified proteins. The first products of replicative RNA synthesis are complementary copies (*i.e.*, plus-polarity) of the PIV genomic RNA (cRNA). These plus-stranded copies (anti-genomes) differ from the plus-stranded mRNA transcripts in the structure of their termini. Unlike the mRNA transcripts, the anti-
10 genomic cRNAs are not capped or methylated at the 5' termini, and they are not truncated nor polyadenylated at the 3' termini. The cRNAs are coterminal with their negative strand templates and contain all the genetic information in the complementary form. The cRNAs serve as templates for the synthesis of PIV negative-strand viral genomes (vRNAs).

15 The bPIV negative strand genomes (vRNAs) and antigenomes (cRNAs) are encapsidated by nucleocapsid proteins; the only unencapsidated RNA species are viral mRNAs. Replication and transcription of bPIV RNA occurs in the cytoplasm of the host cell. Assembly of the viral components appears to take place at the host cell plasma membrane where the mature virus is released by budding.

20 2.1. PARAMYXOVIRUS

Classically, as devastating agents of disease, paramyxoviruses account for many animal and human deaths worldwide each year. The Paramyxoviridae form a family within the order of Mononegavirales (negative-sense single stranded RNA viruses), consisting of the sub-families Paramyxovirinae and Pneumovirinae. The latter sub-family is at present
25 taxonomically divided in the genera Pneumovirus and Metapneumovirus (Pringle, 1999, Arch. Virol. 144/2, 2065-2070). Human respiratory syncytial virus (hRSV), a species of the Pneumovirus genus, is the single most important cause of lower respiratory tract infections during infancy and early childhood worldwide (Domachowske, & Rosenberg, 1999, Clin. Microbio. Rev. 12(2): 298-309). Other members of the Pneumovirus genus include the
30 bovine and ovine respiratory syncytial viruses and pneumonia virus of mice (PVM).

In the past decades several etiological agents of mammalian disease, in particular of respiratory tract illnesses (RTI), in particular of humans, have been identified (Evans, In: Viral Infections of Humans, Epidemiology and Control. 3th ed. (ed. Evans, A.S) 22-28
5 (Plenum Publishing Corporation, New York, 1989)). Classical etiological agents of RTI with mammals are respiratory syncytial viruses belonging to the genus Pneumovirus found with humans (hRSV) and ruminants such as cattle or sheep (bRSV and/or oRSV). In human RSV differences in reciprocal cross neutralization assays, reactivity of the G proteins in immunological assays and nucleotide sequences of the G gene are used to define two hRSV
10 antigenic subgroups. Within the subgroups the amino acid sequences show 94 % (subgroup A) or 98% (subgroup B) identity, while only 53% amino acid sequence identity is found between the subgroups. Additional variability is observed within subgroups based on monoclonal antibodies, RT-PCR assays and RNase protection assays. Viruses from both subgroups have a worldwide distribution and may occur during a single season. Infection
15 may occur in the presence of pre-existing immunity and the antigenic variation is not strictly required to allow re-infection. See, for example Sullender, 2000, Clinical Microbiology Reviews 13(1): 1-15; Collins et al. Fields Virology, ed. B.N. Knipe, Howley, P.M. 1996, Philadelphia: Lippencott-Raven. 1313-1351; Johnson et al., 1987, (Proc Natl Acad Sci USA, 84(16): 5625-9; Collins, in The Paramyxoviruses, D.W. Kingsbury, Editor. 1991, Plenum
20 Press: New York. p. 103-153.

Another classical Pneumovirus is the pneumonia virus of mice (PVM), in general only found with laboratory mice. However, a proportion of the illnesses observed among mammals can still not be attributed to known pathogens.

25

2.2. RSV INFECTIONS

Respiratory syncytial virus (RSV) is the leading cause of serious lower respiratory tract disease in infants and children (Feigen et al., eds., 1987, In: Textbook of Pediatric Infectious Diseases, WB Saunders, Philadelphia at pages 1653-1675; New Vaccine
Development, Establishing Priorities, Vol. 1, 1985, National Academy Press, Washington
30 DC at pages 397-409; and Ruuskanen *et al.*, 1993, Curr. Probl. Pediatr. 23:50-79). The yearly epidemic nature of RSV infection is evident worldwide, but the incidence and severity

of RSV disease in a given season vary by region (Hall, 1993, *Contemp. Pediatr.* 10:92-110). In temperate regions of the northern hemisphere, it usually begins in late fall and ends in late spring. Primary RSV infection occurs most often in children from 6 weeks to 2 years of age
5 and uncommonly in the first 4 weeks of life during nosocomial epidemics (Hall *et al.*, 1979, *New Engl. J. Med.* 300:393-396). Children at increased risk for RSV infection include, but are not limited to, preterm infants (Hall *et al.*, 1979, *New Engl. J. Med.* 300:393-396) and children with bronchopulmonary dysplasia (Groothuis *et al.*, 1988, *Pediatrics* 82:199-203), congenital heart disease (MacDonald *et al.*, *New Engl. J. Med.* 307:397-400), congenital or
10 acquired immunodeficiency (Ogra *et al.*, 1988, *Pediatr. Infect. Dis. J.* 7:246-249; and Pohl *et al.*, 1992, *J. Infect. Dis.* 165:166-169), and cystic fibrosis (Abman *et al.*, 1988, *J. Pediatr.* 113:826-830). The fatality rate in infants with heart or lung disease who are hospitalized with RSV infection is 3%-4% (Navas *et al.*, 1992, *J. Pediatr.* 121:348-354).

RSV infects adults as well as infants and children. In healthy adults, RSV causes
15 predominantly upper respiratory tract disease. It has recently become evident that some adults, especially the elderly, have symptomatic RSV infections more frequently than had been previously reported (Evans, A.S., eds., 1989, *Viral Infections of Humans. Epidemiology and Control*, 3rd ed., Plenum Medical Book, New York at pages 525-544). Several epidemics also have been reported among nursing home patients and
20 institutionalized young adults (Falsey, A.R., 1991, *Infect. Control Hosp. Epidemiol.* 12:602-608; and Garvie *et al.*, 1980, *Br. Med. J.* 281:1253-1254). Finally, RSV may cause serious disease in immunosuppressed persons, particularly bone marrow transplant patients (Hertz *et al.*, 1989, *Medicine* 68:269-281).

Treatment options for established RSV disease are limited. Severe RSV disease of
25 the lower respiratory tract often requires considerable supportive care, including administration of humidified oxygen and respiratory assistance (Fields *et al.*, eds, 1990, *Fields Virology*, 2nd ed., Vol. 1, Raven Press, New York at pages 1045-1072).

While a vaccine might prevent RSV infection, and/or RSV-related disease, no vaccine is yet licensed for this indication. A major obstacle to vaccine development is
30 safety. A formalin-inactivated vaccine, though immunogenic, unexpectedly caused a higher and more severe incidence of lower respiratory tract disease due to RSV in immunized

infants than in infants immunized with a similarly prepared trivalent parainfluenza vaccine (Kim et al., 1969, Am. J. Epidemiol. 89:422-434; and Kapikian *et al.*, 1969, Am. J. Epidemiol. 89:405-421). Several candidate RSV vaccines have been abandoned and others
5 are under development (Murphy et al., 1994, Virus Res. 32:13-36), but even if safety issues are resolved, vaccine efficacy must also be improved. A number of problems remain to be solved. Immunization would be required in the immediate neonatal period since the peak incidence of lower respiratory tract disease occurs at 2-5 months of age. The immaturity of
10 the neonatal immune response together with high titers of maternally acquired RSV antibody may be expected to reduce vaccine immunogenicity in the neonatal period (Murphy et al., 1988, J. Virol. 62:3907-3910; and Murphy et al., 1991, Vaccine 9:185-189). Finally, primary RSV infection and disease do not protect well against subsequent RSV disease (Henderson et al., 1979, New Engl. J. Med. 300:530-534).

Currently, the only approved approach to prophylaxis of RSV disease is passive
15 immunization. Initial evidence suggesting a protective role for IgG was obtained from observations involving maternal antibody in ferrets (Prince, G.A., Ph.D. diss., University of California, Los Angeles, 1975) and humans (Lambrecht *et al.*, 1976, J. Infect. Dis. 134:211-217; and Glezen et al., 1981, J. Pediatr. 98:708-715). Hemming et al. (Morell *et al.*, eds., 1986, Clinical Use of Intravenous Immunoglobulins, Academic Press, London at
20 pages 285-294) recognized the possible utility of RSV antibody in treatment or prevention of RSV infection during studies involving the pharmacokinetics of an intravenous immune globulin (IVIG) in newborns suspected of having neonatal sepsis. In this study, it was noted that one infant, whose respiratory secretions yielded RSV, recovered rapidly after IVIG
25 infusion. Subsequent analysis of the IVIG lot revealed an unusually high titer of RSV neutralizing antibody. This same group of investigators then examined the ability of hyperimmune serum or immune globulin, enriched for RSV neutralizing antibody, to protect cotton rats and primates against RSV infection (Prince et al., 1985, Virus Res. 3:193-206; Prince et al., 1990, J. Virol. 64:3091-3092; Hemming et al., 1985, J. Infect. Dis. 152:1083-1087; Prince et al., 1983, Infect. Immun. 42:81-87; and Prince et al., 1985, J.
30 Virol. 55:517-520). Results of these studies indicate that IVIG may be used to prevent RSV infection, in addition to treating or preventing RSV-related disorders.

Recent clinical studies have demonstrated the ability of this passively administered RSV hyperimmune globulin (RSV IVIG) to protect at-risk children from severe lower respiratory infection by RSV (Groothuis et al., 1993, *New Engl. J. Med.* 329:1524-1530; and
5 The PREVENT Study Group, 1997, *Pediatrics* 99:93-99). While this is a major advance in preventing RSV infection, this treatment poses certain limitations in its widespread use. First, RSV IVIG must be infused intravenously over several hours to achieve an effective dose. Second, the concentrations of active material in hyperimmune globulins are
10 insufficient to treat adults at risk or most children with compromised cardiopulmonary function. Third, intravenous infusion necessitates monthly hospital visits during the RSV season. Finally, it may prove difficult to select sufficient donors to produce a hyperimmune globulin for RSV to meet the demand for this product. Currently, only approximately 8% of normal donors have RSV neutralizing antibody titers high enough to qualify for the production of
15 hyperimmune globulin.

One way to improve the specific activity of the immunoglobulin would be to develop one or more highly potent RSV neutralizing monoclonal antibodies (MAbs). Such MAbs should be human or humanized in order to retain favorable pharmacokinetics and to avoid generating a human anti-mouse antibody response, as repeat dosing would be required throughout the RSV season. Two glycoproteins, F and G, on the surface of RSV have been
20 shown to be targets of neutralizing antibodies (Fields et al., 1990, *supra*; and Murphy et al., 1994, *supra*).

A humanized antibody directed to an epitope in the A antigenic site of the F protein of RSV, SYNAGIS®, is approved for intramuscular administration to pediatric patients for prevention of serious lower respiratory tract disease caused by RSV at recommended
25 monthly doses of 15 mg/kg of body weight throughout the RSV season (November through April in the northern hemisphere). SYNAGIS® is a composite of human (95%) and murine (5%) antibody sequences. See, Johnson et al., 1997, *J. Infect. Diseases* 176:1215-1224 and U.S. Patent No. 5,824,307, the entire contents of which are incorporated herein by reference. The human heavy chain sequence was derived from the constant domains of human IgG1
30 and the variable framework regions of the VH genes of Cor (Press et al., 1970, *Biochem. J.* 117:641-660) and Cess (Takashi et al., 1984, *Proc. Natl. Acad. Sci. USA* 81:194-198). The

human light chain sequence was derived from the constant domain of C and the variable framework regions of the VL gene K104 with J -4 (Bentley et al., 1980, Nature 288:5194-5198). The murine sequences derived from a murine monoclonal antibody, Mab
5 1129 (Beeler et al., 1989, J. Virology 63:2941-2950), in a process which involved the grafting of the murine complementarity determining regions into the human antibody frameworks.

2.3. AVIAN PNEUMOVIRUSES

10 Respiratory disease caused by an avian pneumovirus (APV) was first described in South Africa in the late 1970s (Buys et al., 1980, Turkey 28:36-46) where it had a devastating effect on the turkey industry. The disease in turkeys was characterized by sinusitis and rhinitis and was called turkey rhinotracheitis (TRT). The European isolates of APV have also been strongly implicated as factors in swollen head syndrome (SHS) in
15 chickens (O'Brien, 1985, Vet. Rec. 117:619-620). Originally, the disease appeared in broiler chicken flocks infected with Newcastle disease virus (NDV) and was assumed to be a secondary problem associated with Newcastle disease (ND). Antibody against European APV was detected in affected chickens after the onset of SHS (Cook et al., 1988, Avian Pathol. 17:403-410), thus implicating APV as the cause.

20 Avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis, an upper respiratory tract infection of turkeys (Giraud et al., 1986, Vet. Res. 119:606-607), is the sole member of the recently assigned Metapneumovirus genus, which, as said was until now not associated with infections, or what is more, with disease of mammals. Serological subgroups of APV can be
25 differentiated on the basis of nucleotide or amino acid sequences of the G glycoprotein and neutralization tests using monoclonal antibodies that also recognize the G glycoprotein. However, other differences in the nucleotide and amino acid sequences can be used to distinguish serological subgroups of APV. Within subgroups A, B and D, the G protein shows 98.5 to 99.7% aa sequence identity within subgroups while between the subgroups
30 only 31.2- 38% aa identity is observed. See for example Collins et al., 1993, Avian Pathology, 22: p. 469-479; Cook et al., 1993, Avian Pathology, 22: 257-273;

Bayon-Auboyer et al., J Gen Virol, 81(Pt 11): 2723-33; Seal, 1998, Virus Res, 58(1-2): 45-52; Bayon-Auboyer et al., 1999, Arch Virol, 144(6): 91-109; Juhasz, et al., 1994, J Gen Virol, 75(Pt 11): 2873-80.

5 A further serotype of APV is provided in WO00/20600, incorporated by reference herein, which describes the Colorado isolate of APV and compared it to known APV or TRT strains with in vitro serum neutralization tests. First, the Colorado isolate was tested against monospecific polyclonal antisera to recognized TRT isolates. The Colorado isolate was not neutralized by monospecific antisera to any of the TRT strains. It was, however, neutralized
10 by a hyperimmune antiserum raised against a subgroup A strain. This antiserum neutralized the homologous virus to a titre of 1:400 and the Colorado isolate to a titer of 1: 80. Using the above method, the Colorado isolate was then tested against TRT monoclonal antibodies. In each case, the reciprocal neutralization titer was <10. Monospecific antiserum raised to the Colorado isolate was also tested against TRT strains of both subgroups. None of the
15 TRT strains tested were neutralized by the antiserum to the Colorado isolate.

The Colorado strain of APV does not protect SPF chicks against challenge with either a subgroup A or a subgroup B strain of TRT virus. These results suggest that the Colorado isolate may be the first example of a further serotype of avian pneumovirus (See, Bayon-Auboyer et al., 2000, J. Gen. Vir. 81:2723-2733).

20 The avian pneumovirus is a single stranded, non-segmented RNA virus that belongs to the sub-family Pneumovirinae of the family Paramyxoviridae, genus metapneumovirus (Cavanagh and Barrett, 1988, Virus Res. 11:241-256; Ling et al., 1992, J. Gen. Virol. 73:1709-1715; Yu et al., 1992, J. Gen. Virol. 73:1355-1363). The Paramyxoviridae family is divided into two sub-families: the Paramyxovirinae and Pneumovirinae. The subfamily
25 Paramyxovirinae includes, but is not limited to, the genera: Paramyxovirus, Rubulavirus, and Morbillivirus. Recently, the sub-family Pneumovirinae was divided into two genera based on gene order, and sequence homology, i.e. pneumovirus and metapneumovirus (Naylor et al., 1998, J. Gen. Virol., 79:1393-1398; Pringle, 1998, Arch. Virol. 143:1449-1159). The pneumovirus genus includes, but is not limited to, human respiratory
30 syncytial virus (hRSV), bovine respiratory syncytial virus (bRSV), ovine respiratory syncytial virus, and mouse pneumovirus. The metapneumovirus genus includes, but is not

limited to, European avian pneumovirus (subgroups A and B), which is distinguished from hRSV, the type species for the genus pneumovirus (Naylor et al., 1998, J. Gen. Virol., 79:1393-1398; Pringle, 1998, Arch. Virol. 143:1449-1159). The US isolate of APV
5 represents a third subgroup (subgroup C) within metapneumovirus genus because it has been found to be antigenically and genetically different from European isolates (Seal, 1998, Virus Res. 58:45-52; Senne et al., 1998, In: Proc. 47th WPDC, California, pp. 67-68).

Electron microscopic examination of negatively stained APV reveals pleomorphic, sometimes spherical, virions ranging from 80 to 200 nm in diameter with long filaments
10 ranging from 1000 to 2000 nm in length (Collins and Gough, 1988, J. Gen. Virol. 69:909-916). The envelope is made of a membrane studded with spikes 13 to 15 nm in length. The nucleocapsid is helical, 14 nm in diameter and has 7 nm pitch. The nucleocapsid diameter is smaller than that of the genera Paramyxovirus and Morbillivirus, which usually have diameters of about 18 nm.

15 Avian pneumovirus infection is an emerging disease in the USA despite its presence elsewhere in the world in poultry for many years. In May 1996, a highly contagious respiratory disease of turkeys appeared in Colorado, and an APV was subsequently isolated at the National Veterinary Services Laboratory (NVSL) in Ames, Iowa (Senne et al., 1997, Proc. 134th Ann. Mtg., AVMA, pp. 190). Prior to this time, the United States and Canada
20 were considered free of avian pneumovirus (Pearson et al., 1993, In: Newly Emerging and Re-emerging Avian Diseases: Applied Research and Practical Applications for Diagnosis and Control, pp. 78-83; Hecker and Myers, 1993, Vet. Rec. 132:172). Early in 1997, the presence of APV was detected serologically in turkeys in Minnesota. By the time the first
25 confirmed diagnosis was made, APV infections had already spread to many farms. The disease is associated with clinical signs in the upper respiratory tract: foamy eyes, nasal discharge and swelling of the sinuses. It is exacerbated by secondary infections. Morbidity in infected birds can be as high as 100%. The mortality can range from 1 to 90% and is highest in six to twelve week old poults.

30 Avian pneumovirus is transmitted by contact. Nasal discharge, movement of affected birds, contaminated water, contaminated equipment; contaminated feed trucks and load-out activities can contribute to the transmission of the virus. Recovered turkeys are

thought to be carriers. Because the virus is shown to infect the epithelium of the oviduct of laying turkeys and because APV has been detected in young poults, egg transmission is considered a possibility.

5 A significant portion of human respiratory disease is caused by members of the viral sub-families Paramyxovirinae and Pneumovirinae, there still remains a need for an effective vaccine to confer protection against a variety of viruses that result in respiratory tract infection.

10 Citation or discussion of a reference herein shall not be construed as an admission that such is prior art to the present invention.

3. SUMMARY OF THE INVENTION

The present invention relates to recombinant parainfluenza virus cDNA and RNA that may be engineered to express heterologous or non-native gene products, in particular, to
15 express antigenic polypeptides and peptides. In one embodiment, the present invention relates to recombinant bovine or human parainfluenza viruses which are engineered to express heterologous antigens or immunogenic and/or antigenic fragments of heterologous antigens. In another embodiment of the invention, the recombinant bovine or human
20 parainfluenza viruses are engineered to express sequences that are non-native to the PIV genome, including mutated PIV nucleotide sequences. In particular, the invention relates to recombinant Kansas-strain bovine parainfluenza type 3 virus as well as cDNA and RNA molecules coding for the same. The present invention also relates to recombinant PIV that contain modifications that result in chimeric viruses with phenotypes more suitable for use
25 in vaccine formulations.

The present invention provides for the first time a chimeric PIV formulated as a vaccine that is able to confer protection against various viral infections, in particular, viruses that result in respiratory tract infections. In a specific embodiment, the present invention provides a vaccine that is able to confer protection against parainfluenza, influenza, or
30 respiratory syncytial viral infection. The present invention provides for the first time a vaccine that is able to confer protection against metapneumovirus infection in a mammalian host.

In accordance with the present invention, a recombinant virus is one derived from a bovine parainfluenza virus or a human parainfluenza virus that is encoded by endogenous or native genomic sequences or non-native genomic sequences. In accordance with the invention, a non-native sequence is one that is different from the native or endogenous genomic sequence due to one or more mutations, including, but not limited to, point mutations, rearrangements, insertions, deletions, etc. to the genomic sequence that may or may not result in a phenotypic change.

In accordance with the present invention, a chimeric virus of the invention is a recombinant bPIV or hPIV which further comprises one or more heterologous nucleotide sequences. In accordance with the invention, a chimeric virus may be encoded by a nucleotide sequence in which heterologous nucleotide sequences have been added to the genome or in which nucleotide sequences have been replaced with heterologous nucleotide sequences.

The present invention also relates to engineered recombinant parainfluenza viruses and viral vectors that encode combinations of heterologous sequences which encode gene products, including but not limited to, genes from different strains of PIV, influenza virus, respiratory syncytial virus, mammalian metapneumovirus (*e.g.*, human metapneumovirus), avian pneumovirus, measles, mumps, other viruses, pathogens, cellular genes, tumor antigens, or combinations thereof. Furthermore, the invention relates to engineered recombinant parainfluenza viruses that contain a nucleotide sequence derived from a metapneumovirus in combination with a nucleotide sequence derived from a respiratory syncytial virus, and further in combination with a nucleotide sequence derived from a human parainfluenza virus. The invention also encompasses recombinant parainfluenza vectors and viruses that are engineered to encode genes from different species and strains of the parainfluenza virus, including the F and HN genes of human PIV3.

In one embodiment, the PIV vector of the invention is engineered to express one or more heterologous sequences, wherein the heterologous sequences encode gene products that are preferably antigenic gene products. In a preferred embodiment, the PIV vector of the invention expresses one, two or three heterologous sequences that encode antigenic polypeptides and peptides. In some embodiments, the heterologous sequences are derived

from the same virus or from different viruses. In a preferred embodiment, the heterologous sequences encode heterologous gene products that are antigenic polypeptides from another species of PIV, such as a human PIV, a mutant strain of PIV, or from another negative strand
5 RNA virus, including but not limited to, influenza virus, respiratory syncytial virus (RSV), mammalian metapneumovirus (*e.g.*, human metapneumovirus (hMPV)), and avian pneumovirus. In one embodiment, the heterologous sequence encodes an immunogenic and/or antigenic fragment of a heterologous gene product.

10 In a preferred embodiment, the recombinant PIV is a bovine PIV type 3, or an attenuated human PIV type 3. In one embodiment, the sequences encoding fusion (F) protein, hemagglutinin (HN) glycoprotein, or other non-essential genes of the PIV genome are deleted and are substituted by heterologous antigenic sequences. In yet another embodiment, the PIV genome contains mutations or modifications, in addition to the
15 heterologous nucleotide sequences, that result in a chimeric virus having a phenotype that is more suitable for use in vaccine formulations, *e.g.*, an attenuated phenotype or a phenotype with enhanced antigenicity.

In a specific embodiment, the heterologous nucleotide sequence to be inserted into the PIV genome is derived from the nucleotide sequences encoding a F protein, a G protein or an HN protein. In certain embodiments, the nucleotide sequence to be inserted encodes a
20 chimeric F protein, a chimeric G protein or a chimeric HN protein. In a specific embodiment, the F protein comprises an ectodomain of a F protein of a metapneumovirus, a transmembrane domain of a F protein of a parainfluenza virus, and a luminal domain of a F protein of a parainfluenza virus. In certain embodiments, the nucleotide sequence to be
25 inserted encodes a F protein, wherein the transmembrane domain of the F protein is deleted so that a soluble F protein is expressed.

In another specific embodiment, the invention provides a chimeric virus comprising a PIV genome comprising a heterologous nucleotide sequence derived from a metapneumovirus. In a specific embodiment, the PIV virus is a Kansas-strain bovine
30 parainfluenza type 3 virus. In other embodiments, the PIV virus is a human parainfluenza virus with an attenuated phenotype. In yet other embodiments, the invention provides a chimeric bovine parainfluenza virus type 3/human parainfluenza virus engineered to contain

human parainfluenza F and HN genes in a bovine parainfluenza backbone. The chimeric virus may further comprise a heterologous nucleotide sequence derived from a metapneumovirus, and/or further comprise a heterologous nucleotide sequence derived from a respiratory syncytial virus.

In certain embodiments, the virus of the invention comprises heterologous nucleotide sequences derived from at least two different genes of a metapneumovirus. In a specific embodiment, the heterologous sequence is derived from a metapneumovirus, *e.g.*, avian pneumovirus and human metapneumovirus. More specifically, the heterologous sequence is derived from an avian pneumovirus, including avian pneumovirus type A, B, C or D, preferably C.

The present invention also provides vaccine preparations and immunogenic compositions comprising chimeric PIV expressing one or more heterologous antigenic sequences. In a specific embodiment, the present invention provides multivalent vaccines, including bivalent and trivalent vaccines. The multivalent vaccines of the invention may be administered in the form of one PIV vector expressing each heterologous antigenic sequence or two or more PIV vectors each encoding different heterologous antigenic sequences. In one embodiment, the vaccine preparation of the invention comprises chimeric PIV expressing one, two or three heterologous polypeptides, wherein the heterologous polypeptides can be encoded by sequences derived from one strain of the same virus, different strains of the same virus, or different viruses. Preferably, the heterologous antigenic sequences are derived from a negative strand RNA virus, including but not limited to, influenza virus, parainfluenza virus, respiratory syncytial virus (RSV), mammalian metapneumovirus (*e.g.*, human metapneumovirus (hMPV)), and avian pneumovirus (APV). The heterologous antigenic sequences include, but are not limited to, sequences that encode human parainfluenza virus F or HN protein, F protein of RSV, HA protein of influenza virus type A, B, and C, and F protein of human MPV and avian pneumovirus. More preferably, the vaccine preparation of the invention comprises attenuated chimeric viruses that are viable and infectious. In a preferred embodiment, the recombinant PIV is a bovine PIV type 3, or an attenuated strain of human PIV.

In one embodiment, the vaccine preparation comprises the chimeric virus of the present invention, wherein the F, HN, or some other nonessential genes of the PIV genome have been substituted or deleted. In a preferred embodiment, the vaccine preparation of the present invention is prepared by engineering a strain of PIV with an attenuated phenotype in an intended host. In another preferred embodiment, the vaccine preparation of the present invention is prepared by engineering an attenuated strain of PIV.

In another embodiment, the heterologous nucleotide sequence is added to the complete PIV genome. In certain embodiments, the PIV genome is engineered so that the heterologous sequences are inserted at position one, two, three, four, five or six, so that the heterologous sequences are expressed as the first, second, third, fourth, fifth, or sixth gene of the viral genome. In specific embodiments, the heterologous sequence is inserted at position one, two, or three of the viral genome. In certain embodiments, the intergenic region between the end of the coding sequence of an inserted heterologous gene and the start of the coding sequence of the downstream gene is altered to a desirable length, resulting in enhanced expression of the heterologous sequence or enhanced growth of the chimeric virus. Alternatively, the intergenic region is altered to a desirable length, with a potential to alter the expression of the heterologous sequence or growth of the recombinant or chimeric virus, *e.g.*, attenuated phenotype. In some embodiments, both the position of the insertion and the length of the intergenic region flanking a heterologous nucleotide sequence are engineered to select a recombinant or chimeric virus with desirable levels of expression of the heterologous sequence and desirable viral growth characteristics.

In certain embodiments, the invention provides a vaccine formulation comprising the recombinant or chimeric virus of the invention and a pharmaceutically acceptable excipient. In specific embodiments, the vaccine formulation of the invention is used to modulate the immune response of a subject, such as a human, a primate, a horse, a cow, a sheep, a pig, a goat, a dog, a cat, a rodent or a subject of avian species. In a more specific embodiment, the vaccine is used to modulate the immune response of a human infant or a child. In another embodiment, the present invention relates to vaccine formulations for veterinary uses. The vaccine preparation of the invention can be administered alone or in combination with other vaccines or other prophylactic or therapeutic agents.

3.1. CONVENTIONS AND ABBREVIATIONS

	cDNA	complementary DNA
5	CPE	cytopathic effects
	L	large protein
	M	matrix protein (lines inside of envelope)
	F	fusion glycoprotein
10	HN	hemagglutinin-neuraminidase glycoprotein
	N, NP or NC	nucleoprotein (associated with RNA and required for polymerase activity)
	P	phosphoprotein
	MOI	multiplicity of infection
15	NA	neuraminidase (envelope glycoprotein)
	PIV	parainfluenza virus
	bPIV	bovine parainfluenza virus
	bPIV3	bovine parainfluenza virus type 3
	hPIV	human parainfluenza virus
20	hPIV3	human parainfluenza virus type 3
	bPIV/hPIV or b/h PIV	recombinant bPIV with hPIV sequences
	b/h PIV3 or bPIV3/hPIV3	recombinant bPIV type 3 with hPIV type 3 sequences
25	nt	nucleotide
	RNP	ribonucleoprotein
	rRNP	recombinant RNP
	vRNA	genomic virus RNA
	cRNA	antigenomic virus RNA
30	hMPV	human metapneumovirus

	APV	avian pneumovirus
5	position	when position is used regarding engineering any virus, it refers to the position of the gene of the viral genome to be transcribed. For example, if a gene is located at position one, it is the first gene of the viral genome to be transcribed; if a gene is located at position two, it is the second gene of the viral genome to be transcribed.
10	position 1 of bPIV3, b/h PIV3 and derivatives thereof	nucleotide position 104 of the genome, or alternatively, the position of the first gene of the viral genome to be transcribed
15	position 2 of bPIV3, b/h PIV3 and derivatives thereof	nucleotide position 1774 of the genome, or alternatively the position between the first and the second open reading frame of the native parainfluenza virus, or alternatively, the position of the second gene of the viral genome to be transcribed
	position 3 of bPIV3, b/h PIV3 and derivatives thereof	nucleotide position 3724 of the genome, or alternatively the position between the second and the third open reading frame of the native parainfluenza virus, or alternatively, the position of the third gene of the viral genome to be transcribed.
20	position 4 of bPIV3, b/h PIV3 and derivatives thereof	nucleotide position 5042 of the genome, or alternatively the position between the third and the fourth open reading frame of the native parainfluenza virus, or alternatively, the position of the fourth gene of the viral genome to be transcribed.
25	position 5 of bPIV3, b/h PIV3 and derivatives thereof	nucleotide position 6790 of the genome, or alternatively the position between the fourth and the fifth open reading frame of the native parainfluenza virus, or alternatively, the position of the fifth gene of the viral genome to be transcribed.
30	position 6 of bPIV3, b/h PIV3 and derivatives thereof	nucleotide position 8631 of the genome, or alternatively the position between the fifth and the sixth open reading frame of the native parainfluenza virus, or alternatively, the position of the sixth gene of the viral genome to be transcribed.

4. DESCRIPTION OF FIGURES

Figure 1. Pairwise alignments of the amino acid sequence of the F protein of the human metapneumovirus with different F proteins from different avian pneumoviruses. Identical amino acids between the two sequences are indicated by the one-letter-symbol for the amino acid. Conserved amino acid exchanges between the two amino acid sequences are indicated by a "+" sign, and a space indicates a non-conserved amino acid exchange. A) Alignment of the human metapneumoviral F protein with the F protein of an avian pneumovirus isolated from Mallard Duck (85.6% identity in the ectodomain). B) Alignment of the human metapneumoviral F protein with the F protein of an avian pneumovirus isolated from Turkey (subgroup B; 75% identity in the ectodomain).

Figure 2. PCR fragments from nt 5255 to nt 6255 derived from three different isolates of the b/h PIV3 chimeric virus were amplified. The resulting 1 kb DNA fragments were digested with enzymes specific for the F gene of human PIV3. These enzymes do not cut in the corresponding fragment of bovine PIV3. The 1% agarose gel shows the undigested fragment (lanes 2,5, and 6) and the SacI or BgIII digested fragments (lanes 4, 6 and lanes 9, 10, and 11, respectively). The sample in lane 10 is undigested, however, upon a repeat of digestion with BgIII, this sample was cut (data not shown). Lanes 1 and 8 show a DNA size marker.

Figure 3. PCR fragments from nt 9075 to nt 10469 derived from three different isolates of the b/h PIV3 chimeric virus were amplified. The resulting 1.4kb DNA fragments were digested with enzymes specific for the L gene of bovine PIV3. These enzymes do not cut in the corresponding fragment of human PIV3. The 1% agarose gel shows the undigested 1.4 kb fragment (lanes 2, 5, and 8). The smaller DNA fragments produced by digestion with BamHI and PvuII are shown in lanes 3, 4, 6, 7, 9, and 10). Lane 1 shows a DNA size marker.

Figure 4. Six constructs, including the bPIV3/hPIV3 vector and b/h PIV3 vectored RSV F or G cDNA, are demonstrated. The bovine PIV3 F gene and HN gene are deleted

and replaced with human PIV3 F and HN gene respectively. The RSV F or G genes are cloned into either position 1 or position 2. All RSV genes are linked to the bPIV3 N-P intergenic region with the exception of RSV F1* (N-N), which is followed by the shorter bPIV3 N gene stop/N gene start sequences.

Figure 5. b/h PIV3 vectored RSV F or G gene displayed a positional effect. (A) is a Western blot analysis of chimeric virus-infected cell lysates. F protein was detected using monoclonal antibodies (MAbs) against the RSV F protein, and G protein was detected using polyclonal antibodies (PABs) against the RSV G protein. A 50 kDa band representing the F₁ fragment was detected in cells infected with all chimeric viruses as well as wild-type RSV. There was a greater accumulation of a 20 kDa F fragment in infected cell lysates of chimeric viruses compared to wild-type RSV. The experiment was done at MOI of 0.1, except that in lane 1, b/h PIV3 vectored RSV F1* N-N infections were repeated at a higher MOI of 1.0. Both the immature and glycosylated forms of RSV G protein that migrated at approximately 50 kDa and 90 kDa were detected. (B) is a Northern blot analysis, which showed that the mRNA transcription correlated with the result of the protein expression demonstrated in Figure 5A. Equal amounts of total RNA were separated on 1% agarose gels containing 1% formaldehyde and transferred to nylon membranes. The blots were hybridized with digoxigenin (DIG)-UTP-labeled riboprobes synthesized by in vitro transcription using a DIG RNA labeling kit. (C) is growth curves of chimeric viruses comprising b/h PIV3 vectored RSV F or G protein in Vero cells. Vero cells were grown to 90% confluence and infected at an MOI of 0.01. The infected monolayers were incubated at 37°C. Virus titers for each time point harvest were determined by TCID₅₀ assays, which were performed by inspecting visually for CPE following incubation at 37°C for 6 days.

Figure 6. The b/h PIV3 vectored enhanced green fluorescence protein (eGFP) constructs. The eGFP gene is introduced into the b/h PIV3 vector sequentially between all genes of PIV3 (only position 1, 2, 3, and 4 are shown here). The eGFP gene was linked to the bPIV3 N-P intergenic region. The b/h GFP 1 construct harbors the eGFP gene cassette in the 3' most proximal position of the b/h PIV3 genome. The b/h GFP 2 construct contains

the eGFP gene cassette between the N and P genes. The b/h GFP 3 construct contains the eGFP gene cassette between the P and M gene, and the b/h GFP4 construct contains the eGFP gene between M and F of b/h PIV3.

5

Figure 7. Positional effect of enhanced green fluorescence protein (eGFP) insertions in the b/h PIV3 genome. (A) shows the amount of green cells produced upon infecting Vero cells with b/h PIV3 vectored eGFP 1, 2, and 3 at MOI 0.1 and MOI 0.01 for 20 hours. The green cells were visualized by using a fluorescent microscope. (B) is a Western blot analysis of infected cell lysates. The blots were probed with a GFP MAb as well as a PIV3 PAb. PIV3 antibody was also used to show that the blots had same volume loading. (C) is growth curves of b/h PIV3 vectored GFP constructs (at position 1, 2, and 3) in Vero cells.

10

Figure 8. Constructs of b/h PIV3 vectored RSV F gene with different intergenic regions. The three constructs, RSV F1* N-N, RSV F2 N-P, and RSV F1 N-P are the same as the RSV F* (N-N), RSV F2, and RSV F1 in Figure 4 respectively. The distance between the N gene start sequence and the N gene translation start codon in RSV F1* N-N is only 10 nucleotides (nts) long. In contrast, this distance is 86 nts long in RSV F2 construct. RSV F1* N-N also uses the N gene start sequence rather than the P gene start sequence as is done in RSV F2 construct.

15

20

Figure 9. The length and/or nature of the intergenic region downstream of the inserted RSV gene has an effect on virus replication. (A) Western blot analysis of RSV F protein expression in chimeric viruses. Blots were probed with monoclonal antibodies against the RSV F protein. F1 protein levels expressed by RSV F1 construct and measured at 24 and 48 hours post-infection were close to the levels observed for RSV F2 construct, but much higher than those of RSV F1* N-N construct. (B) is multicycle growth curves comparing the kinetics of virus replication of RSV F1, RSV F1*N-N and RSV F2 constructs in Vero cells at an MOI of 0.1. Virus titers for each time point harvest were determined by plaque assays, which were performed by immunostaining with RSV polyclonal antisera for quantification after 5 days of incubation.

25

30

Figure 10. Constructs of trivalent b/h PIV3 vectored RSV F and hMPV F. Two virus genomes, each comprising a chimeric b/h PIV3 vector and a first heterologous sequences derived from a metapneumovirus F gene and a second heterologous sequence
5 derived from respiratory syncytial virus F gene, are shown here. Virus with either of the constructs has been amplified in Vero cells. The engineered virus as described can be used as a trivalent vaccine against the parainfluenza virus infection, metapneumovirus infection and the respiratory syncytial virus infection.

10 Figure 11. A construct harboring two RSV F genes. This construct can be used to determine virus growth kinetics, for RSV F protein production, and replication and immunogenicity in hamsters.

15 Figure 12. The chimeric b/h PIV3 vectored hMPV F constructs. The F gene of human metapneumovirus (hMPV) was inserted in position 1 or position 2 of the b/h PIV3 genome. The hMPV F gene cassette harbored the bPIV3 N-P intergenic region.

Figure 13. Immunoprecipitation and replication assays of b/h PIV3 vectored hMPV F gene (at position 2). (A) shows the immunoprecipitation of hMPV F protein using guinea
20 pig or human anti-hMPV antiserum. A specific band migrating at approximately 80 kDa was observed in the lysates of b/h PIV3 vectored hMPV F2. This size corresponds to the F precursor protein, F₀. Non-specific bands of different sizes were also observed in the b/h PIV3 and mock control lanes. (B) shows growth curves that were performed to determine the kinetics of virus replication of b/h PIV3/hMPV F2 and compare it to those observed for
25 b/h PIV3 and b/h PIV3/RSV F2 in Vero cells at an MOI of 0.1. (C) is growth curves that were performed to determine the kinetics of virus replication of b/h PIV3/hMPV F1 and compare it to those observed for b/h PIV3/hMPV F2 and b/h PIV3 in Vero cells at an MOI of 0.01.

30 Figure 14. A chimeric b/h PIV3 vectored soluble RSV F gene construct. This construct comprises a single copy of the soluble RSV F gene, a version of the RSV F gene

lacking the transmembrane and cytosolic domains. The advantage of this construct would be the inability of the soluble RSV F to be incorporated into the virion genome.

5

Figure 15. Immunostained b/h PIV3/hMPV F1 and b/h PIV3/hMPV F2. (A) the b/h PIV3/hMPV F1 virus were diluted and used to infect subconfluent Vero cells. Infected cells were overlaid with optiMEM media containing gentamycin and incubated at 35°C for 5 days. Cells were fixed and immunostained with guinea pig anti-hMPV sera. Expression of hMPV F is visualized by specific color development in the presence of the AEC substrate system. (B) the b/h PIV3/hMPV F2 virus were diluted and used to infect Vero cells.

10

Infected cells were overlaid with 1% methyl cellulose in EMEM/L-15 medium (JRH Biosciences; Lenexa, KS). Cells were incubated, fixed and then immunostained with anti-hMPV guinea pig sera. The anti-hMPV guinea pig serum is specific for hMPV 001 protein.

15

Figure 16. Virion fractionation of b/h PIV3 vectored RSV genes on sucrose gradients. These series experiments investigate whether the RSV proteins were incorporated into the b/h PIV3 virion. (A) shows control gradient of free RSV F (generated in baculovirus and C-terminally truncated). Majority of free RSV F was present in fractions 3, 4, 5, and 6. (B) shows that the biggest concentration of RSV virions was observed in fractions 10, 11 and 12. The RSV fractions were probed with RSV polyclonal antiserum as well as RSV F MAb. The fractions that contained the greatest amounts of RSV virions also showed the strongest signal for RSV F, suggesting that the RSV F protein co-migrated and associated with RSV virion. The last figure on (B) also shows that the fractions 10, 11 and 12 displayed the highest virus titer by plaque assay. (C) The b/h PIV3 virions may be more pleiomorphic and thus the spread of the peak fractions containing b/h PIV3 virions was more broad. (D) Sucrose gradient fractions of b/h PIV3/RSV F2 were analyzed with both a PIV polyclonal antiserum and an RSV F MAb. The fractions containing most of the virions were fractions 11, 12, 13 and 14, as shown by Western using the PIV3 antiserum.

20

25

Correspondingly, these were also the fractions that displayed the highest amounts of RSV F protein. Some free RSV F was also present in fractions 5 and 6. Fractions 11, 12, 13 and 14 displayed the peak virus titers. (E) The fractions containing the most virions of b/h

30

PIV3/RSV G2 (9, 10, 11 and 12) also showed the strongest signal for RSV G protein. Again, these were the fractions with the highest virus titers.

5

5. DESCRIPTION OF THE INVENTION

The present invention relates to recombinant parainfluenza cDNA and RNA constructs, including but not limited to, recombinant bovine and human PIV cDNA and RNA constructs, that may be used to express heterologous or non-native sequences.

10 In accordance with the present invention, a recombinant virus is one derived from a bovine parainfluenza virus or a human parainfluenza virus that is encoded by endogenous or native genomic sequences or non-native genomic sequences. In accordance with the invention, a non-native sequence is one that is different from the native or endogenous genomic sequence due to one or more mutations, including, but not limited to, point mutations, rearrangements, insertions, deletions, etc. to the genomic sequence that may or
15 may not result in a phenotypic change.

In accordance with the present invention, a chimeric virus of the invention is a recombinant bPIV or hPIV which further comprises one or more heterologous nucleotide sequences. In accordance with the invention, a chimeric virus may be encoded by a
20 nucleotide sequence in which heterologous nucleotide sequences have been added to the genome or in which nucleotide sequences have been replaced with heterologous nucleotide sequences. These recombinant and chimeric viruses and expression products may be used as vaccines suitable for administration to humans or animals. For example, the chimeric viruses of the invention may be used in vaccine formulations to confer protection against
25 pneumovirus, respiratory syncytial virus, parainfluenza virus, or influenza virus infection.

25 In one embodiment, the invention relates to PIV cDNA and RNA constructs that are derived from human or bovine PIV variants and are engineered to express one, two, or three heterologous sequences, preferably heterologous genes encoding foreign antigens and other products from a variety of pathogens, cellular genes, tumor antigens, and viruses. In particular, the heterologous sequences are derived from morbillivirus or a negative strand
30 RNA virus, including but not limited to, influenza virus, respiratory syncytial virus (RSV), mammalian metapneumovirus (e.g., human metapneumovirus variants A1, A2, B1, and B2),

and avian pneumovirus subgroups A, B, C and D. The mammalian MPVs can be a variant A1, A2, B1 or B2 mammalian MPV. However, the mammalian MPVs of the present invention may encompass additional variants of MPV yet to be identified, and are not limited
5 to variants A1, A2, B1, or B2. In another embodiment of the invention, the heterologous sequences are non-native PIV sequences, including mutated PIV sequences. In some embodiments, the heterologous sequences are derived from the same or from different viruses.

10 In a specific embodiment, the virus of the invention is a recombinant PIV comprising heterologous nucleotide sequences derived from human metapneumovirus or avian pneumovirus. The heterologous sequences to be inserted into the PIV genome include, but are not limited to, the sequences encoding the F, G and HN genes of human metapneumovirus variants A1, A2, B1 or B2, sequences encoding the F, G and HN genes of
15 avian pneumovirus type A, B, C or D, and immunogenic and/or antigenic fragments thereof.

15 In certain embodiments, the heterologous nucleotide sequence is added to the viral genome. In alternative embodiments, the heterologous nucleotide sequence is exchanged for an endogenous nucleotide sequence. The heterologous nucleotide sequence may be added or inserted at various positions of the PIV genome, *e.g.*, at position 1, 2, 3, 4, 5, or 6. In a preferred embodiment, the heterologous nucleotide sequence is added or inserted at position
20 1. In another preferred embodiment, the heterologous nucleotide sequence is added or inserted at position 2. In even another preferred embodiment, the heterologous nucleotide sequence is added or inserted at position 3. Inserting or adding heterologous nucleotide sequences at the lower-numbered positions of the virus generally results in stronger expression of the heterologous nucleotide sequence compared to insertion at higher-
25 numbered positions. This is due to a transcriptional gradient that occurs across the genome of the virus. However, virus replication efficiency must also be considered. For example, in the b/h PIV3 chimeric virus of the invention, insertion of a heterologous gene at position 1 delays replication kinetics *in vitro* and to a lesser degree also *in vivo* (*see* section 8, example 3 and Figure 5 as well as section 26, example 21). Therefore, inserting heterologous
30 nucleotide sequences at lower-numbered positions is the preferred embodiment of the invention if strong expression of the heterologous nucleotide sequence is desired. Most

preferably, a heterologous sequence is inserted at position 2 of a b/h PIV3 genome if strong expression of the heterologous sequence is desired. (See section 5.1.2. *infra* and section 8, example 3).

5 In some other embodiments, the recombinant or chimeric PIV genome is engineered such that the intergenic region between the end of the coding sequence of the heterologous gene and the start of the coding sequence of the downstream gene is altered. In yet some other embodiments, the virus of the invention comprises a recombinant or chimeric PIV genome engineered such that the heterologous nucleotide sequence is inserted at a position
10 selected from the group consisting of positions 1, 2, 3, 4, 5, and 6, and the intergenic region between the heterologous nucleotide sequence and the next downstream gene is altered. Appropriate assays may be used to determine the best mode of insertion (*i.e.*, which position to insert, and the length of the intergenic region) to achieve appropriate levels of gene expression and viral growth characteristics. For detail, *see* Section 5.1.2., *infra*.

15 In certain embodiments, the chimeric virus of the invention contains two different heterologous nucleotide sequences. The different heterologous nucleotide sequences may be inserted at various positions of the PIV genome. In a preferred embodiment, one heterologous nucleotide sequence is inserted at position 1 and another heterologous nucleotide sequence is added or inserted at position 2 or 3. In other embodiments of the
20 invention, additional heterologous nucleotide sequences are inserted at higher-numbered positions of the PIV genome. In accordance with the present invention, the position of the heterologous sequence refers to the order in which the sequences are transcribed from the viral genome, *e.g.*, a heterologous sequence at position 1 is the first gene sequence to be transcribed from the genome.

25 In certain embodiments of the invention, the heterologous nucleotide sequence to be inserted into the genome of the virus of the invention is derived from a negative strand RNA virus, including but not limited to, influenza virus, parainfluenza virus, respiratory syncytial virus, mammalian metapneumovirus, and avian pneumovirus. In a specific embodiment of the invention, the heterologous nucleotide sequence is derived from a human
30 metapneumovirus. In another specific embodiment, the heterologous nucleotide sequence is

derived from an avian pneumovirus. More specifically, the heterologous nucleotide sequence of the invention encodes a F, G or SH gene or a portion thereof of a human or avian metapneumovirus. In specific embodiments, a heterologous nucleotide sequences can be any
5 one of SEQ ID NO:1 through SEQ ID NO:5, SEQ ID NO:14, and SEQ ID NO:15 (see Table 16). In certain specific embodiments, the nucleotide sequence encodes a protein of any one of SEQ ID NO:6 through SEQ ID NO:13, SEQ ID NO:16, and SEQ ID NO:17 (see Table 16). In certain specific embodiments, the nucleotide sequence encodes a protein of any one of SEQ ID NO: 314 through 389.

10 In specific embodiments of the invention, a heterologous nucleotide sequence of the invention is derived from a type A avian pneumovirus. In other specific embodiments of the invention, a heterologous nucleotide sequence of the invention is derived from a type B avian pneumovirus. In even other specific embodiments of the invention, a heterologous nucleotide sequence of the invention is derived from a type C avian pneumovirus.

15 Phylogenetic analyses show that type A and type B are more closely related to each other than they are to type C (Seal, 2000, Animal Health Res. Rev. 1(1):67-72). Type A and type B are found in Europe whereas type C was first isolated in the U.S.

In another embodiment of the invention, the heterologous nucleotide sequence encodes a chimeric polypeptide, wherein the ectodomain contains antigenic sequences
20 derived from a virus other than the strain of PIV from which the vector backbone is derived, and the trans membrane and luminal domains are derived from PIV sequences. The resulting chimeric virus would impart antigenicity of the negative strand RNA virus of choice and would have an attenuated phenotype.

In a specific embodiment of the invention, the heterologous nucleotide sequence
25 encodes a chimeric F protein. Particularly, the ectodomain of the chimeric F protein is the ectodomain of a metapneumovirus, so that a human metapneumovirus or avian pneumovirus, and the transmembrane domain as well as the luminal domain are the transmembrane and luminal domains of a parainfluenza virus, such as a human or a bovine parainfluenza virus. While not bound by any theory, insertion of a chimeric F protein may further attenuate the
30 virus in an intended host but retain the antigenicity of the F protein attributed by its ectodomain.

The chimeric viruses of the invention may be used in vaccine formulations to confer protection against various infections, including but not limited to, pneumovirus infection, respiratory syncytial virus infection, parainfluenza virus infection, influenza virus infection, or a combination thereof. The present invention provides vaccine preparations comprising chimeric PIV expressing one or more heterologous antigenic sequences, including bivalent and trivalent vaccines. The bivalent and trivalent vaccines of the invention may be administered in the form of one PIV vector expressing each heterologous antigenic sequences or two or more PIV vectors each encoding different heterologous antigenic sequences. Preferably, the heterologous antigenic sequences are derived from a negative strand RNA virus, including but not limited to, influenza virus, parainfluenza virus, respiratory syncytial virus (RSV), mammalian metapneumovirus (*e.g.*, human metapneumovirus) and avian pneumovirus. Thus, the chimeric virions of the present invention may be engineered to create, *e.g.*, anti-human influenza vaccine, anti-human parainfluenza vaccine, anti-human RSV vaccine, and anti-human metapneumovirus vaccine. Preferably, the vaccine preparation of the invention comprises attenuated chimeric viruses that are viable and infectious. The vaccine preparation of the invention can be administered alone or in combination with other vaccines or other prophylactic or therapeutic agents.

The present invention also relates to the use of viral vectors and chimeric viruses to formulate vaccines against a broad range of viruses and/or antigens including tumor antigens. The viral vectors and chimeric viruses of the present invention may be used to modulate a subject's immune system by stimulating a humoral immune response, a cellular immune response or by stimulating tolerance to an antigen. As used herein, a subject refers to a human, a primate, a horse, a cow, a sheep, a pig, a goat, a dog, a cat, a rodent and a member of avian species. When delivering tumor antigens, the invention may be used to treat subjects having disease amenable to immune response mediated rejection, such as non-solid tumors or solid tumors of small size. It is also contemplated that delivery of tumor antigens by the viral vectors and chimeric viruses described herein will be useful for treatment subsequent to removal of large solid tumors. The invention may also be used to treat subjects who are suspected of having cancer.

The invention may be divided into the following stages solely for the purpose of description and not by way of limitation: (a) construction of recombinant cDNA and RNA templates; (b) expression of heterologous gene products using recombinant cDNA and RNA
5 templates; and ©) rescue of the heterologous genes in recombinant virus particles.

5.1. CONSTRUCTION OF THE RECOMBINANT cDNA AND RNA

The present invention encompasses recombinant or chimeric viruses encoded by viral
10 vectors derived from the genomes of parainfluenza virus, including both bovine parainfluenza virus and mammalian parainfluenza virus. In accordance with the present invention, a recombinant virus is one derived from a bovine parainfluenza virus or a mammalian parainfluenza virus that is encoded by endogenous or native genomic sequences or non-native genomic sequences. In accordance with the invention, a non-native sequence is one that is different from the native or endogenous genomic sequence due to one or more
15 mutations, including, but not limited to, point mutations, rearrangements, insertions, deletions etc. to the genomic sequence that may or may not result a phenotypic change. The recombinant viruses of the invention encompass those viruses encoded by viral vectors derived from the genomes of parainfluenza virus, including both bovine and mammalian parainfluenza virus, and may or may not, include nucleic acids that are non-native to the viral
20 genome. In accordance with the present invention, a viral vector which is derived from the genome of a parainfluenza virus is one that contains a nucleic acid sequence that encodes at least a part of one ORF of a parainfluenza virus.

The present invention also encompasses recombinant viruses comprising a viral
25 vector derived from a bovine and/or mammalian PIV genome which contains sequences which result in a virus having a phenotype more suitable for use in vaccine formulations, e.g., attenuated phenotype or enhanced antigenicity. The mutations and modifications can be in coding regions, in intergenic regions and in the leader and trailer sequences of the virus.

In accordance with the present invention, the viral vectors of the invention are derived from the genome of a mammalian parainfluenza virus, in particular a human parainfluenza
30 virus (hPIV). In particular embodiments of the invention, the viral vector is derived from the genome of a human parainfluenza virus type 3. In accordance with the present invention,

these viral vectors may or may not include nucleic acids that are non-native to the viral genome.

5 In accordance with the present invention, the viral vectors of the inventions are derived from the genome of a bovine parainfluenza virus (bPIV). In particular embodiments of the invention, the viral vector is derived from the genome of bovine parainfluenza virus type 3. In accordance to the present invention, these viral vectors may or may include nucleic acids that are non-native to the viral genome.

10 In accordance with the invention, a chimeric virus is a recombinant bPIV or hPIV which further comprises a heterologous nucleotide sequence. In accordance with the invention, a chimeric virus may be encoded by a nucleotide sequence in which heterologous nucleotide sequence have been added to the genome or in which endogenous or native nucleotide sequence have been replaced with heterologous nucleotide sequence. In accordance with the invention, the chimeric viruses are encoded by the viral vectors of the
15 invention which further comprise a heterologous nucleotide sequence. In accordance with the present invention, a chimeric virus is encoded by a viral vector that may or may not include nucleic acids that are non-native to the viral genome. In accordance with the invention, a chimeric virus is encoded by a viral vector to which heterologous nucleotide sequences have been added, inserted or substituted for native or non-native sequences.

20 A chimeric virus may be of particular use for the generation of recombinant vaccines protecting against two or more viruses (Tao et al., J. Virol. 72, 2955-2961; Durbin et al., 2000, J. Virol. 74, 6821-6831; Skiadopoulos et al., 1998, J. Virol. 72, 1762-1768 (1998); Teng et al., 2000, J. Virol. 74, 9317-9321). For example, it can be envisaged that a hPIV or bPIV virus vector expressing one or more proteins of another negative strand RNA virus,
25 e.g., MPV, or a RSV vector expressing one or more proteins of MPV will protect individuals vaccinated with such vector against both virus infections. A similar approach can be envisaged for other paramyxoviruses. Attenuated and replication-defective viruses may be of use for vaccination purposes with live vaccines as has been suggested for other viruses. (See, PCT WO 02/057302, at pp. 6 and 23, incorporated by reference herein).

30 In accordance with the present invention the heterologous to be incorporated into the viral vectors encoding the recombinant or chimeric viruses of the invention include

sequences obtained or derived from different strains of metapneumovirus, strains of avian pneumovirus, and other negative strand RNA viruses, including, but not limited to, RSV, PIV, influenza virus and other viruses, including morbillivirus.

5 In certain embodiments of the invention, the chimeric or recombinant viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more sequences, intergenic regions, termini sequences, or portions or entire ORF have been substituted with a heterologous or non-native sequence. In certain embodiments of the invention, the chimeric viruses of the invention are encoded by viral vectors derived from
10 viral genomes wherein one or more heterologous sequences have been added to the vector.

A specific embodiment of the present invention is a chimeric virus comprising a backbone encoded by nucleotide sequences derived from a parainfluenza virus genome. In a preferred embodiment, the PIV genome is derived from bovine PIV, such as the Kansas strain of bPIV3, or from human PIV. In a preferred embodiment, the PIV genome is derived
15 from the Kansas strain of bPIV3, in which bovine parainfluenza virus nucleotide sequences have been substituted with heterologous sequences or in which heterologous sequences have been added to the complete bPIV genome. A further specific embodiment of the present invention is a chimeric virus comprising a backbone encoded by nucleotide sequences derived from human parainfluenza virus type 3 genome, in which human parainfluenza virus
20 nucleotide sequences have been substituted with heterologous sequences or in which heterologous sequences have been added to the complete hPIV genome. An additional specific embodiment of the present invention is a chimeric virus comprising a backbone encoded by nucleotide sequences derived from bovine parainfluenza virus genome, such as the Kansas strain of bPIV3, in which (a) the bovine parainfluenza virus F gene and HN gene
25 have been substituted with the F gene and the HN gene of the human parainfluenza virus (bPIV/hPIV), and in which (b) heterologous sequences have been added to the complete bPIV genome.

The present invention also encompasses chimeric viruses comprising a backbone encoded by nucleotide sequences derived from the bPIV, the hPIV, or the bPIV/hPIV
30 genome containing mutations or modifications, in addition to heterologous sequences, that result in a chimeric virus having a phenotype more suitable for use in vaccine formulations,

e.g., attenuated phenotype or enhanced antigenicity. In accordance with this particular embodiment of the invention, a heterologous sequence in the context of a bovine PIV3 backbone may be any sequence heterologous to bPIV3.

5 Another specific embodiment of the present invention is a chimeric virus comprising a backbone encoded by nucleotide sequences derived from human PIV 1, 2, or 3 in which hPIV nucleotide sequences have been substituted with heterologous sequences or in which heterologous sequences have been added to the complete hPIV genome, with the proviso that the resulting chimeric virus is not a chimeric hPIV3 in which the hemagglutinin-
10 neuraminidase and fusion glycoproteins have been replaced by those of hPIV1. The present invention also encompasses chimeric viruses, comprising a backbone encoded by nucleotide sequences derived from a hPIV genome, containing mutations or modifications, in addition to heterologous sequences, that result in a chimeric virus having a phenotype more suitable for use in vaccine formulations, *e.g.*, attenuated phenotype or enhanced antigenicity.

15 Heterologous gene coding sequences flanked by the complement of the viral polymerase binding site/promoter, *e.g.*, the complement of 3'-PIV virus terminus of the present invention, or the complements of both the 3'- and 5'-PIV virus termini may be constructed using techniques known in the art. The resulting RNA templates may be of the negative-polarity and can contain appropriate terminal sequences that enable the viral RNA-
20 synthesizing apparatus to recognize the template. Alternatively, positive-polarity RNA templates, that contain appropriate terminal sequences which enable the viral RNA-synthesizing apparatus to recognize the template, may also be used. Recombinant DNA molecules containing these hybrid sequences can be cloned and transcribed by a DNA-directed RNA polymerase, such as bacteriophage T7 polymerase, T3 polymerase, the SP6
25 polymerase or a eukaryotic polymerase such as polymerase I and the like, for the *in vitro* or *in vivo* production of recombinant RNA templates that possess the appropriate viral sequences and that allow for viral polymerase recognition and activity.

In one embodiment, the PIV vector of the invention expresses one, two, or three heterologous sequences, encoding antigenic polypeptides and peptides. In some
30 embodiments, the heterologous sequences are derived from the same virus or from different viruses. In certain embodiments, more than one copy of the same heterologous nucleotide

sequences are inserted in the genome of a bovine parainfluenza virus, human parainfluenza virus, or bPIV/hPIV chimeric vector. In a preferred embodiment, two copies of the same heterologous nucleotide sequences are inserted to the genome of the virus of the invention.

5 In some embodiments, the heterologous nucleotide sequence is derived from a metapneumovirus, such as human metapneumovirus or an avian pneumovirus. In specific embodiments, the heterologous nucleotide sequence derived from a metapneumovirus is a F gene of the metapneumovirus. In other specific embodiments, the heterologous nucleotide sequence derived from a metapneumovirus is a G gene of the metapneumovirus. In some
10 other embodiments, the heterologous nucleotide sequence is derived from a respiratory syncytial virus. In specific embodiments, the heterologous nucleotide sequence derived from respiratory syncytial virus is a F gene of the respiratory syncytial virus. In other specific embodiments, the heterologous nucleotide sequence derived from respiratory syncytial virus is a G gene of the respiratory syncytial virus. When one or more heterologous nucleotide
15 sequences are inserted, the position of the insertion and the length of the intergenic region of each inserted copy can be manipulated and determined by different assays according to section 5.1.2. *infra*.

In certain embodiments, rescue of the chimeric virus or expression products may be achieved by reverse genetics in host cell systems where the host cells are transfected with
20 chimeric cDNA or RNA constructs. The RNA templates of the present invention are prepared by transcription of appropriate DNA sequences with a DNA-directed RNA polymerase. The RNA templates of the present invention may be prepared either *in vitro* or *in vivo* by transcription of appropriate DNA sequences using a DNA-directed RNA
25 polymerase such as bacteriophage T7 polymerase, T3 polymerase, the SP6 polymerase, or a eukaryotic polymerase such as polymerase I. In certain embodiments, the RNA templates of the present invention may be prepared either *in vitro* or *in vivo* by transcription of appropriate DNA sequences using a plasmid-based expression system as described in Hoffmann *et al.*,
2000, Proc. Natl. Acad. Sci. USA 97:6108-6113 or the unidirectional RNA polymerase I-
30 polymerase II transcription system as described in Hoffmann and Webster, 2000, J. Gen. Virol. 81:2843-2847. The resulting RNA templates of negative-polarity would contain appropriate terminal sequences that would enable the viral RNA-synthesizing apparatus to

recognize the template. Alternatively, positive-polarity RNA templates that contain appropriate terminal sequences and enable the viral RNA-synthesizing apparatus to recognize the template may also be used. Expression from positive polarity RNA templates may be achieved by transfection of plasmids having promoters that are recognized by the DNA-dependent RNA polymerase. For example, plasmid DNA, encoding positive RNA templates under the control of a T7 promoter, can be used in combination with the vaccinia virus or fowlpox T7 system.

Bicistronic mRNAs can be constructed to permit internal initiation of translation of viral sequences and to allow for the expression of foreign protein coding sequences from the regular terminal initiation site, or vice versa. Alternatively, a foreign protein may be expressed from an internal transcriptional unit in which the transcriptional unit has an initiation site and polyadenylation site. In another embodiment, the foreign gene is inserted into a PIV gene such that the resulting expressed protein is a fusion protein.

In certain embodiments, the invention relates to trivalent vaccines comprising a virus of the invention. In specific embodiments, the virus used for a trivalent vaccine is a chimeric bovine parainfluenza type 3/human parainfluenza type 3 virus containing a first heterologous nucleotide sequence derived from a metapneumovirus, such as human metapneumovirus or avian pneumovirus, and a second heterologous nucleotide sequence derived from respiratory syncytial virus. In an exemplary embodiment, such a trivalent vaccine would be specific to (a) the gene products of the F gene and the HN gene of the human parainfluenza virus; (b) the protein encoded by the heterologous nucleotide sequence derived from a metapneumovirus; and (c) the protein encoded by the heterologous nucleotide sequence derived from a respiratory syncytial virus. In a specific embodiment, the first heterologous nucleotide sequence is the F gene of the respiratory syncytial virus and is inserted in position 1, and the second heterologous nucleotide sequence is the F gene of the human metapneumovirus and is inserted in position 3. Many more combinations are encompassed by the present invention and some are shown by way of example in Table 1. For other combinations the F or G gene of an avian pneumovirus could be used. Further, nucleotide sequences encoding chimeric F proteins could be used (see *supra*). In some less preferred

embodiments, the heterologous nucleotide sequence can be inserted at higher-numbered positions of the viral genome.

5 **Table 1.** Exemplary arrangements of heterologous nucleotide sequences in the viruses used for trivalent vaccines.

	<u>Combination</u>	<u>Position 1</u>	<u>Position 2</u>	<u>Position 3</u>
10	1	F-gene of hMPV	F-gene of RSV	-
	2	F-gene of RSV	F-gene of hMPV	-
	3	-	F-gene of hMPV	F-gene of RSV
	4	-	F-gene of RSV	F-gene of hMPV
	5	F-gene of hMPV	-	F-gene of RSV
	6	F-gene of RSV	-	F-gene of hMPV
	7	G-gene of hMPV	G-gene of RSV	-
	8	G-gene of RSV	G-gene of hMPV	-
	9	-	G-gene of hMPV	G-gene of RSV
	10	-	G-gene of RSV	G-gene of hMPV
15	11	G-gene of hMPV	-	G-gene of RSV
	12	G-gene of RSV	-	G-gene of hMPV
	13	F-gene of hMPV	G-gene of RSV	-
	14	G-gene of RSV	F-gene of hMPV	-
	15	-	F-gene of hMPV	G-gene of RSV
	16	-	G-gene of RSV	F-gene of hMPV
	17	F-gene of hMPV	-	G-gene of RSV
	18	G-gene of RSV	-	F-gene of hMPV
	19	G-gene of hMPV	F-gene of RSV	-
	20	F-gene of RSV	G-gene of hMPV	-
20	21	-	G-gene of hMPV	F-gene of RSV
	22	-	F-gene of RSV	G-gene of hMPV
	23	G-gene of hMPV	-	F-gene of RSV
	24	F-gene of RSV	-	G-gene of hMPV

In some other embodiments, the intergenic region between a heterologous sequence and the start of the coding sequence of the downstream gene can be altered. For example, each gene listed on Table 1 may have a desirable length of the intergenic region. In an exemplary embodiment, a trivalent vaccine comprises a b/h PIV3 vector with a F gene of respiratory syncytial virus inserted at position 1, an altered intergenic region of 177 nucleotides (originally 75 nucleotides to the downstream N gene start codon AUG), and a F gene of human metapneumovirus inserted at position 3 with its natural intergenic region.

Many more combinations are encompassed by the present invention, as each insertion of a heterologous nucleotide sequence may be manipulated according to section 5.1.2., *infra*.

5 In a broader embodiment, the expression products and chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral antigens, tumor antigens and auto antigens involved in autoimmune disorders. One way to achieve this goal involves modifying existing PIV genes to contain foreign sequences in their respective external domains. Where the heterologous sequences are epitopes or antigens of pathogens, these chimeric viruses may be used to induce a protective immune
10 response against the disease agent from which these determinants are derived.

One approach for constructing these hybrid molecules is to insert the heterologous nucleotide sequence into a DNA complement of a PIV genome, *e.g.*, a hPIV, a bPIV, or a bPIV/hPIV, so that the heterologous sequence is flanked by the viral sequences required for viral polymerase activity; *i.e.*, the viral polymerase binding site/promoter, hereinafter referred
15 to as the viral polymerase binding site, and a polyadenylation site. In a preferred embodiment, the heterologous coding sequence is flanked by the viral sequences that comprise the replication promoters of the 5' and 3' termini, the gene start and gene end sequences, and the packaging signals that are found in the 5' and/or the 3' termini. In an alternative approach, oligonucleotides encoding the viral polymerase binding site, *e.g.*, the
20 complement of the 3'-terminus or both termini of the virus genomic segment can be ligated to the heterologous coding sequence to construct the hybrid molecule. The placement of a foreign gene or segment of a foreign gene within a target sequence was formerly dictated by the presence of appropriate restriction enzyme sites within the target sequence. However, recent advances in molecular biology have lessened this problem greatly. Restriction enzyme
25 sites can readily be placed anywhere within a target sequence through the use of site-directed mutagenesis (*e.g.*, see, for example, the techniques described by Kunkel, 1985, Proc. Natl. Acad. Sci. U.S.A. 82;488). Variations in polymerase chain reaction (PCR) technology, described *infra*, also allow for the specific insertion of sequences (*i.e.*, restriction enzyme sites) and also allow for the facile construction of hybrid molecules. Alternatively, PCR
30 reactions could be used to prepare recombinant templates without the need of cloning. For example, PCR reactions could be used to prepare double-stranded DNA molecules

containing a DNA-directed RNA polymerase promoter (*e.g.*, bacteriophage T3, T7 or SP6) and the hybrid sequence containing the heterologous gene and the PIV polymerase binding site. RNA templates could then be transcribed directly from this recombinant DNA. In yet
5 another embodiment, the recombinant RNA templates may be prepared by ligating RNAs specifying the negative polarity of the heterologous gene and the viral polymerase binding site using an RNA ligase.

In addition, one or more nucleotides can be added at the 3' end of the HN gene in the untranslated region to adhere to the "Rule of Six" which may be important in successful virus
10 rescue. The "Rule of Six" applies to many paramyxoviruses and requires that the number of nucleotides of an RNA genome be a factor of six to be functional. The addition of nucleotides can be accomplished by techniques known in the art such as using a commercial mutagenesis kits like the QuikChange mutagenesis kit (Stratagene). After addition of the
15 appropriate number of nucleotides, the correct DNA fragment, for example, a DNA fragment of the hPIV3 F and HN gene, can then be isolated upon digestion with the appropriate restriction enzyme and gel purification. Sequence requirements for viral polymerase activity and constructs that may be used in accordance with the invention are described in the subsections below.

Without being bound by theory, several parameters affect the rate of replication of the
20 recombinant virus and the level of expression of the heterologous sequence. In particular, the position of the heterologous sequence in bPIV, hPIV, b/h PIV and the length of the intergenic region that flanks the heterologous sequence determine rate of replication and expression level of the heterologous sequence.

In certain embodiments, the leader and or trailer sequence of the virus are modified
25 relative to the wild type virus. In certain more specific embodiments, the lengths of the leader and/or trailer are altered. In other embodiments, the sequence(s) of the leader and/or trailer are mutated relative to the wild type virus.

The production of a recombinant virus of the invention relies on the replication of a
30 partial or full-length copy of the negative sense viral RNA (vRNA) genome or a complementary copy thereof (cRNA). This vRNA or cRNA can be isolated from infectious virus, produced upon in-vitro transcription, or produced in cells upon transfection of nucleic

acids. Second, the production of recombinant negative strand virus relies on a functional polymerase complex. Typically, the polymerase complex of pneumoviruses consists of N, P, L and possibly M2 proteins, but is not necessarily limited thereto.

- 5 Polymerase complexes or components thereof can be isolated from virus particles, isolated from cells expressing one or more of the components, or produced upon transfection of specific expression vectors.

Infectious copies of MPV can be obtained when the above mentioned vRNA, cRNA, or vectors expressing these RNAs are replicated by the above mentioned polymerase complex 16 (Schnell *et al.*, 1994, EMBO J 13: 4195-4203; Collins *et al.*, 1995, PNAS 92: 11563-11567; Hoffmann *et al.*, 2000, PNAS 97: 6108-6113; Bridgen *et al.*, 1996, PNAS 93: 15400-15404; Palese *et al.*, 1996, PNAS 93: 11354-11358; Peeters *et al.*, 1999, J.Virol. 73: 5001-5009; Durbin *et al.*, 1997, Virology 235: 323-332).

- 15 The invention provides a host cell comprising a nucleic acid or a vector according to the invention. Plasmid or viral vectors containing the polymerase components of PIV (presumably N, P, L and M2, but not necessarily limited thereto) are generated in prokaryotic cells for the expression of the components in relevant cell types (bacteria, insect cells, eukaryotic cells). Plasmid or viral vectors containing full-length or partial copies of the PIV genome will be generated in prokaryotic cells for the expression of viral nucleic acids *in vitro* 20 or *in vivo*. The latter vectors may contain other viral sequences for the generation of chimeric viruses or chimeric virus proteins, may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses.

- 25 Infectious copies of PIV (being wild type, attenuated, replication-defective or chimeric) can be produced upon co-expression of the polymerase components according to the state-of-the-art technologies described above.

- In addition, eukaryotic cells, transiently or stably expressing one or more full-length or partial PIV proteins can be used. Such cells can be made by transfection (proteins or nucleic acid vectors), infection (viral vectors) or transduction (viral vectors) and may be 30 useful for complementation of mentioned wild type, attenuated, replication-defective or chimeric viruses.

... HETEROLOGOUS GENE SEQUENCES TO BE INSERTED

The present invention encompass engineering recombinant bovine or human parainfluenza viruses to express one or more heterologous sequences, wherein the
5 heterologous sequences encode gene products or fragments of gene products that are preferably antigenic and/or immunogenic. As used herein, the term "antigenic" refers to the ability of a molecule to bind antibody or MHC molecules. The term "immunogenic" refers to the ability of a molecule to generate immune response in a host.

In a preferred embodiment, the heterologous nucleotide sequence to be inserted is
10 derived from a negative strand RNA virus, including but not limited to, influenza virus, parainfluenza virus, respiratory syncytial virus, mammalian metapneumovirus (e.g., human metapneumovirus) and avian pneumovirus. In a preferred embodiment, the heterologous sequence to be inserted includes, but is not limited to, a sequence that encodes a F or HN gene of human PIV, a F gene of RSV, a HA gene of influenza virus type A, B, or C, a F gene
15 of human MPV, a F gene of avian pneumovirus, or an immunogenic and/or antigenic fragment thereof.

In some embodiments, the heterologous nucleotide sequence to be inserted is derived from a human metapneumovirus and/or an avian pneumovirus. In certain embodiments, the heterologous nucleotide sequence to be inserted is derived from (a) a human
20 metapneumovirus and a respiratory syncytial virus; and/or (b) an avian pneumovirus and a respiratory syncytial virus.

In certain preferred embodiments of the invention, the heterologous nucleotide sequence to be inserted is derived from a F gene from a human metapneumovirus and/or an avian pneumovirus. In certain embodiments, the F gene is derived from (a) a human
25 metapneumovirus and a respiratory syncytial virus; and/or (b) an avian pneumovirus and a respiratory syncytial virus.

In certain embodiments of the invention, the heterologous nucleotide sequence to be inserted is a G gene derived from a human metapneumovirus and/or an avian pneumovirus. In certain embodiments, the G gene is derived from (a) a human metapneumovirus and a
30 respiratory syncytial virus; and/or (b) an avian pneumovirus and a respiratory syncytial virus.

In certain embodiments, any combination of different F genes and/or different G genes derived from human metapneumovirus, avian pneumovirus, and respiratory syncytial virus can be inserted into the virus of the invention with the proviso that in all embodiments
5 at least one heterologous sequence derived from either human metapneumovirus or avian pneumovirus is present in the recombinant parainfluenza virus of the invention.

In certain embodiments, the nucleotide sequence to be inserted is a nucleotide sequence encoding a F protein derived from a human metapneumovirus. In certain other embodiments, the nucleotide sequence to be inserted is a nucleotide sequence encoding a G
10 protein derived from a human metapneumovirus. In yet other embodiments, the nucleotide sequence to be inserted is a nucleotide sequence encoding a F protein derived from an avian pneumovirus. In yet other embodiments, the nucleotide sequence to be inserted is a nucleotide sequence encoding a G protein derived from an avian pneumovirus. With the proviso that in all embodiments of the invention at least one heterologous nucleotide
15 sequence is derived from a metapneumovirus, the heterologous nucleotide sequence to be inserted encodes a F protein or a G protein of a respiratory syncytial virus.

In certain embodiments, the nucleotide sequence to be inserted encodes a chimeric F protein or a chimeric G protein. A chimeric F protein comprises parts of F proteins from different viruses, such as a human metapneumovirus, avian pneumovirus and/or respiratory
20 syncytial virus. A chimeric G protein comprises parts of G proteins from different viruses, such as a human metapneumovirus, avian pneumovirus and/or respiratory syncytial virus. In a specific embodiment, the F protein comprises an ectodomain of a F protein of a metapneumovirus, a transmembrane domain of a F protein of a parainfluenza virus, and luminal domain of a F protein of a parainfluenza virus. In certain embodiments, the nucleic
25 acid to be inserted encodes a F protein, wherein the transmembrane domain of the F protein is deleted so that a soluble F protein is expressed.

In certain specific embodiments, the heterologous nucleotide sequence of the invention is any one of SEQ ID NO:1 through SEQ ID NO:5, SEQ ID NO:14, and SEQ ID NO:15 (see Table 16). In certain specific embodiments, the nucleotide sequence encodes a
30 protein of any one of SEQ ID NO:6 through SEQ ID NO:13, SEQ ID NO:16, and SEQ ID

NO:17 (see Table 16). In certain specific embodiments, the nucleotide sequence encodes a protein of any one of SEQ ID NO. 314 to 389.

For heterologous nucleotide sequences derived from respiratory syncytial virus see,
5 *e.g.*, PCT/US98/20230, which is hereby incorporated by reference in its entirety.

In a preferred embodiment, heterologous gene sequences that can be expressed into the chimeric viruses of the invention include but are not limited to those encoding antigenic epitopes and glycoproteins of viruses, such as influenza glycoproteins, in particular hemagglutinin H5, H7, respiratory syncytial virus epitopes, New Castle Disease virus
10 epitopes, Sendai virus and infectious Laryngotracheitis virus (ILV), that result in respiratory disease. In a most preferred embodiment, the heterologous nucleotide sequences are derived from a metapneumovirus, such as human metapneumovirus and/or avian pneumovirus. In yet another embodiment of the invention, heterologous gene sequences that can be engineered into the chimeric viruses of the invention include, but are not limited to, those
15 encoding viral epitopes and glycoproteins of viruses, such as hepatitis B virus surface antigen, hepatitis A or C virus surface glycoproteins of Epstein Barr virus, glycoproteins of human papilloma virus, simian virus 5 or mumps virus, West Nile virus, Dengue virus, glycoproteins of herpesviruses, VPI of poliovirus, and sequences derived from a human immunodeficiency virus (HIV), preferably type 1 or type 2. In yet another embodiment,
20 heterologous gene sequences that can be engineered into chimeric viruses of the invention include, but are not limited to, those encoding Marek's Disease virus (MDV) epitopes, epitopes of infectious Bursal Disease virus (IBDV), epitopes of Chicken Anemia virus, infectious laryngotracheitis virus (ILV), Avian Influenza virus (AIV), rabies, feline leukemia virus, canine distemper virus, vesicular stomatitis virus, and swinepox virus (*see* Fields *et al.*
25 (ed.), 1991, FUNDAMENTAL VIROLOGY, Second Edition, Raven Press, New York, incorporated by reference herein in its entirety).

Other heterologous sequences of the present invention include those encoding antigens that are characteristic of autoimmune diseases. These antigens will typically be derived from the cell surface, cytoplasm, nucleus, mitochondria and the like of mammalian
30 tissues, including antigens characteristic of diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, pernicious anemia, Addison's disease,

scleroderma, autoimmune atrophic gastritis, juvenile diabetes, and discoid lupus erythromatosus.

Antigens that are allergens generally include proteins or glycoproteins, including
5 antigens derived from pollens, dust, molds, spores, dander, insects and foods. In addition, antigens that are characteristic of tumor antigens typically will be derived from the cell surface, cytoplasm, nucleus, organelles and the like of cells of tumor tissue. Examples include antigens characteristic of tumor proteins, including proteins encoded by mutated oncogenes; viral proteins associated with tumors; and glycoproteins. Tumors include, but are
10 not limited to, those derived from the types of cancer: lip, nasopharynx, pharynx and oral cavity, esophagus, stomach, colon, rectum, liver, gall bladder, pancreas, larynx, lung and bronchus, melanoma of skin, breast, cervix, uterine, ovary, bladder, kidney, uterus, brain and other parts of the nervous system, thyroid, prostate, testes, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma and leukemia.

15 In one specific embodiment of the invention, the heterologous sequences are derived from the genome of human immunodeficiency virus (HIV), preferably human immunodeficiency virus-1 or human immunodeficiency virus-2. In another embodiment of the invention, the heterologous coding sequences may be inserted within a PIV gene coding sequence such that a chimeric gene product, that contains the heterologous peptide sequence
20 within the PIV viral protein, is expressed. In such an embodiment of the invention, the heterologous sequences may also be derived from the genome of a human immunodeficiency virus, preferably of human immunodeficiency virus-1 or human immunodeficiency virus-2.

In instances whereby the heterologous sequences are HIV-derived, such sequences may include, but are not limited to sequences derived from the env gene (*i.e.*, sequences
25 encoding all or part of gp160, gp120, and/or gp41), the pol gene (*i.e.*, sequences encoding all or part of reverse transcriptase, endonuclease, protease, and/or integrase), the gag gene (*i.e.*, sequences encoding all or part of p7, p6, p55, p17/18, p24/25) tat, rev, nef, vif, vpu, vpr, and/or vpx.

In another embodiment, heterologous gene sequences that can be engineered into the
30 chimeric viruses include those that encode proteins with immunopotentiating activities. Examples of immunopotentiating proteins include, but are not limited to, cytokines,

interferon type 1, gamma interferon, colony stimulating factors, and interleukin -1, -2, -4, -5, -6, -12.

In addition, other heterologous gene sequences that may be engineered into the
 5 chimeric viruses include those encoding antigens derived from bacteria such as bacterial surface glycoproteins, antigens derived from fungi, and antigens derived from a variety of other pathogens and parasites. Examples of heterologous gene sequences derived from bacterial pathogens include, but are not limited to, those encoding antigens derived from species of the following genera: *Salmonella*, *Shigella*, *Chlamydia*, *Helicobacter*, *Yersinia*,
 10 *Bordatella*, *Pseudomonas*, *Neisseria*, *Vibrio*, *Haemophilus*, *Mycoplasma*, *Streptomyces*, *Treponema*, *Coxiella*, *Ehrlichia*, *Brucella*, *Streptobacillus*, *Fusospirocheta*, *Spirillum*, *Ureaplasma*, *Spirochaeta*, *Mycoplasma*, *Actinomycetes*, *Borrelia*, *Bacteroides*, *Trichomonas*, *Branhamella*, *Pasteurella*, *Clostridium*, *Corynebacterium*, *Listeria*, *Bacillus*, *Erysipelothrix*, *Rhodococcus*, *Escherichia*, *Klebsiella*, *Pseudomonas*, *Enterobacter*, *Serratia*,
 15 *Staphylococcus*, *Streptococcus*, *Legionella*, *Mycobacterium*, *Proteus*, *Campylobacter*, *Enterococcus*, *Acinetobacter*, *Morganella*, *Moraxella*, *Citrobacter*, *Rickettsia*, *Rochlameae*, as well as bacterial species such as: *P. aeruginosa*; *E. coli*, *P. cepacia*, *S. epidermis*, *E. faecalis*, *S. pneumonias*, *S. aureus*, *N. meningitidis*, *S. pyogenes*, *Pasteurella multocida*, *Treponema pallidum*, and *P. mirabilis*.

20 Examples of heterologous gene sequences derived from pathogenic fungi, include, but are not limited to, those encoding antigens derived from fungi such as *Cryptococcus neoformans*; *Blastomyces dermatitidis*; *Aiellomyces dermatitidis*; *Histoplasma capsulatum*; *Coccidioides immitis*; *Candida species*, including *C. albicans*, *C. tropicalis*, *C. parapsilosis*, *C. guilliermondii* and *C. krusei*, *Aspergillus species*, including *A. fumigatus*, *A. flavus* and *A. niger*, *Rhizopus species*; *Rhizomucor species*; *Cunninghammella species*; *Apophysomyces species*, including *A. saksenaea*, *A. mucor* and *A. absidia*; *Sporothrix schenckii*, *Paracoccidioides brasiliensis*; *Pseudallescheria boydii*, *Torulopsis glabrata*; *Trichophyton species*, *Microsporum species* and *Dermatophyres species*, as well as any other yeast or fungus now known or later identified to be pathogenic.

30 Finally, examples of heterologous gene sequences derived from parasites include, but are not limited to, those encoding antigens derived from members of the Apicomplexa

phylum such as, for example, *Babesia*, *Toxoplasma*, *Plasmodium*, *Eimeria*, *Isospora*, *Atoxoplasma*, *Cystoisospora*, *Hammondia*, *Besnotia*, *Sarcocystis*, *Frenkelia*, *Haemoproteus*, *Leucocytozoon*, *Theileria*, *Perkinsus* and *Gregarina* spp.; *Pneumocystis carinii*; members of

5 the Microspora phylum such as, for example, *Nosema*, *Enterocytozoon*, *Encephalitozoon*, *Septata*, *Mrazekia*, *Amblyospora*, *Ameson*, *Glugea*, *Pleistophora* and *Microsporidium* spp.; and members of the Ascetospora phylum such as, for example, *Haplosporidium* spp., as well as species including *Plasmodium falciparum*, *P. vivax*, *P. ovale*, *P. malaria*; *Toxoplasma gondii*; *Leishmania mexicana*, *L. tropica*, *L. major*, *L. aethiopica*, *L. donovani*, *Trypanosoma*

10 *cruzi*, *T. brucei*, *Schistosoma mansoni*, *S. haematobium*, *S. japonicum*; *Trichinella spiralis*; *Wuchereria bancrofti*; *Brugia malayi*; *Entamoeba histolytica*; *Enterobius vermicularis*; *Taenia solium*, *T. saginata*, *Trichomonas vaginalis*, *T. hominis*, *T. tenax*; *Giardia lamblia*; *Cryptosporidium parvum*; *Pneumocystis carinii*, *Babesia bovis*, *B. divergens*, *B. microti*, *Isospora belli*, *L. hominis*; *Dientamoeba fragilis*; *Onchocerca volvulus*; *Ascaris*

15 *lumbricoides*; *Necator americanus*; *Ancylostoma duodenale*; *Strongyloides stercoralis*; *Capillaria philippinensis*; *Angiostrongylus cantonensis*; *Hymenolepis nana*; *Diphyllobothrium latum*; *Echinococcus granulosus*, *E. multilocularis*; *Paragonimus westermani*, *P. caliensis*; *Chlonorchis sinensis*; *Opisthorchis felinae*, *G. Viverini*, *Fasciola hepatica*, *Sarcoptes scabiei*, *Pediculus humanus*; *Phthirus pubis*; and *Dermatobia hominis*,

20 as well as any other parasite now known or later identified to be pathogenic.

5.1.2. METAPNEUMOVIRAL SEQUENCES TO BE INSERTED

proteins of a mammalian MPV. The invention further relates to nucleic acid sequences encoding fusion proteins, wherein the fusion protein contains a protein of a

25 mammalian MPV or a fragment thereof and one or more peptides or proteins that are not derived from mammalian MPV. In a specific embodiment, a fusion protein of the invention contains a protein of a mammalian MPV or a fragment thereof and a peptide tag, such as, but not limited to a polyhistidine tag. The invention further relates to fusion proteins, wherein the fusion protein contains a protein of a mammalian MPV or a fragment thereof and one or

30 more peptides or proteins that are not derived from mammalian MPV. The invention also relates to derivatives of nucleic acids encoding a protein of a mammalian MPV. The

invention also relates to derivatives of proteins of a mammalian MPV. A derivative can be, but is not limited to, mutant forms of the protein, such as, but not limited to, additions, deletions, truncations, substitutions, and inversions. A derivative can further be a chimeric
5 form of the protein of the mammalian MPV, wherein at least one domain of the protein is derived from a different protein. A derivative can also be a form of a protein of a mammalian MPV that is covalently or non-covalently linked to another molecule, such as, *e.g.*, a drug.

The viral isolate termed NL/1/00 (also 00-1) is a mammalian MPV of variant A1 and
10 its genomic sequence is shown in SEQ ID NO:95. The viral isolate termed NL/17/00 is a mammalian MPV of variant A2 and its genomic sequence is shown in SEQ ID NO:96. The viral isolate termed NL/1/99 (also 99-1) is a mammalian MPV of variant B1 and its genomic sequence is shown in SEQ ID NO:94. The viral isolate termed NL/1/94 is a mammalian MPV of variant B2 and its genomic sequence is shown in SEQ ID NO:97. A list of
15 sequences disclosed in the present application and the corresponding SEQ ID Nos is set forth in Table 16.

The protein of a mammalian MPV can be a an N protein, a P protein, a M protein, a F protein, a M2-1 protein or a M2-2 protein or a fragment thereof. A fragment of a protein of a
mammalian MPV can be can be at least 25 amino acids, at least 50 amino acids, at least 75
20 amino acids, at least 100 amino acids, at least 125 amino acids, at least 150 amino acids, at least 175 amino acids, at least 200 amino acids, at least 225 amino acids, at least 250 amino acids, at least 275 amino acids, at least 300 amino acids, at least 325 amino acids, at least 350 amino acids, at least 375 amino acids, at least 400 amino acids, at least 425 amino acids, at least 450 amino acids, at least 475 amino acids, at least 500 amino acids, at least 750 amino
25 acids, at least 1000 amino acids, at least 1250 amino acids, at least 1500 amino acids, at least 1750 amino acids, at least 2000 amino acids or at least 2250 amino acids in length. A fragment of a protein of a mammalian MPV can be can be at most 25 amino acids, at most 50 amino acids, at most 75 amino acids, at most 100 amino acids, at most 125 amino acids, at most 150 amino acids, at most 175 amino acids, at most 200 amino acids, at most 225 amino
30 acids, at most 250 amino acids, at most 275 amino acids, at most 300 amino acids, at most 325 amino acids, at most 350 amino acids, at most 375 amino acids, at most 400 amino

acids, at most 425 amino acids, at most 450 amino acids, at most 475 amino acids, at most 500 amino acids, at most 750 amino acids, at most 1000 amino acids, at most 1250 amino acids, at most 1500 amino acids, at most 1750 amino acids, at most 2000 amino acids or at
5 most 2250 amino acids in length.

In certain embodiments of the invention, the protein of a mammalian MPV is a N protein, wherein the N protein is phylogenetically closer related to a N protein of a mammalian MPV, such as the N protein encoded by, *e.g.*, the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97, (see also Table 16 for a
10 description of the SEQ ID Nos) than it is related to the N protein of APV type C. In certain embodiments of the invention, the protein of a mammalian MPV is a P protein, wherein the P protein is phylogenetically closer related to a P protein of a mammalian MPV, such as the P protein encoded by, *e.g.*, the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97, than it is related to the N protein of APV type C. In certain
15 embodiments of the invention, the protein of a mammalian MPV is a M protein, wherein the M protein is closer related to a M protein of a mammalian MPV, such as the M protein encoded by, *e.g.*, the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97, than it is related to the M protein of APV type C. In certain embodiments of the invention, the protein of a mammalian MPV is a F protein, wherein the F protein is
20 phylogenetically closer related to a F protein of a mammalian MPV, such as the F protein encoded by, *e.g.*, the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97, than it is related to the F protein of APV type C. In certain embodiments of the invention, the protein of a mammalian MPV is a M2-1 protein, wherein the M2-1 protein is phylogenetically closer related to a M2-1 protein of a mammalian MPV, such as the M2-1
25 protein encoded by, *e.g.*, the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97, than it is related to the M2-1 protein of APV type C. In certain embodiments of the invention, the protein of a mammalian MPV is a M2-2 protein, wherein the M2-2 protein is phylogenetically closer related to a M2-2 protein of a mammalian MPV, such as the M2-2 protein encoded by, *e.g.*, the viral genome of SEQ ID NO:94, SEQ ID
30 NO:95, SEQ ID NO:96, or SEQ ID NO:97, than it is related to the M2-2 protein of APV type C. In certain embodiments of the invention, the protein of a mammalian MPV is a G protein,

wherein the G protein is phylogenetically closer related to a G protein of a mammalian MPV, such as the G protein encoded by, *e.g.*, the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97, than it is related to any protein of APV type C. In certain
5 embodiments of the invention, the protein of a mammalian MPV is a SH protein, wherein the SH protein is phylogenetically closer related to a SH protein of a mammalian MPV, such as the SH protein encoded by, *e.g.*, the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97, than it is related to any protein of APV type C. In certain
10 L protein is phylogenetically closer related to a L protein of a mammalian MPV, such as the SH protein encoded by, *e.g.*, the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97, than it is related to any protein of APV type C.

In certain embodiments of the invention, the protein of a mammalian MPV is a N protein, wherein the N protein is at least 60%, at least 65%, at least 70%, at least 75%, at
15 least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a N protein encoded by the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97 (the amino acid sequences of the respective N proteins are disclosed in SEQ ID NO:366-369; see also Table
16). In certain embodiments of the invention, the protein of a mammalian MPV is a N
20 protein, wherein the P protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a P protein encoded by the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97 (the amino acid sequences of the respective P proteins are disclosed in SEQ ID NO:78-85; see also Table 16). In certain
25 embodiments of the invention, the protein of a mammalian MPV is a M protein, wherein the M protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a M protein encoded by the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97 (the amino acid sequences of the respective M
30 proteins are disclosed in SEQ ID NO:358-361; see also Table 16). In certain embodiments of the invention, the protein of a mammalian MPV is a F protein, wherein the F protein is at

least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a F protein encoded by the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID

5 NO:96, or SEQ ID NO:97 (the amino acid sequences of the respective F proteins are disclosed in SEQ ID NO:18-25; see also Table 16). In certain embodiments of the invention, the protein of a mammalian MPV is a M2-1 protein, wherein the M2-1 protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a

10 M2-1 protein encoded by the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97 (the amino acid sequences of the respective M2-1 proteins are disclosed in SEQ ID NO:42-49; see also Table 16). In certain embodiments of the invention, the protein of a mammalian MPV is a M2-2 protein, wherein the M2-2 protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least

15 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a M2-2 protein encoded by the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97 (the amino acid sequences of the respective M2-2 proteins are disclosed in SEQ ID NO:50-57; see also Table 16). In certain embodiments of the invention, the protein of a mammalian MPV is a G protein, wherein the G protein is at least 60%, at

20 least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a G protein encoded by the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97 (the amino acid sequences of the respective G proteins are disclosed in SEQ ID NO:26-33; see also Table 16). In certain embodiments of the invention, the protein of a

25 mammalian MPV is a SH protein, wherein the SH protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a SH protein encoded by the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97 (the amino acid sequences of the respective SH proteins are disclosed in SEQ ID NO:86-93; see

30 also Table 16). In certain embodiments of the invention, the protein of a mammalian MPV is a L protein, wherein the L protein is at least 60%, at least 65%, at least 70%, at least 75%, at

least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a L protein encoded by the viral genome of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97 (the amino acid
5 sequences of the respective L proteins are disclosed in SEQ ID NO:34-41; see also Table 16).

A fragment of a protein of mammalian MPV is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the homologous protein encoded by the virus of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97 over the portion of the protein
10 that is homologous to the fragment. In a specific, illustrative embodiment, the invention provides a fragment of the F protein of a mammalian MPV that contains the ectodomain of the F protein and homologs thereof. The homolog of the fragment of the F protein that contains the ectodomain is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5%
15 identical to the corresponding fragment containing the ectodomain of the F protein encoded by a virus of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97 (the amino acid sequences of the respective F proteins are disclosed in SEQ ID NO:18-25; see also Table 16).

In certain embodiments, the invention provides a protein of a mammalian MPV of
20 subgroup A and fragments thereof. The invention provides a N protein of a mammalian MPV of subgroup A, wherein the N protein is phylogenetically closer related to the N protein encoded by a virus of SEQ ID NO:95 or SEQ ID NO:96 than it is related to the N protein encoded by a virus encoded by SEQ ID NO:94 or SEQ ID NO:97. The invention provides a G protein of a mammalian MPV of subgroup A, wherein the G protein is phylogenetically
25 closer related to the G protein encoded by a virus of SEQ ID NO:95 or SEQ ID NO:96 than it is related to the G protein encoded by a virus encoded by SEQ ID NO:94 or SEQ ID NO:97. The invention provides a P protein of a mammalian MPV of subgroup A, wherein the P protein is phylogenetically closer related to the P protein encoded by a virus of SEQ ID NO:95 or SEQ ID NO:96 than it is related to the P protein encoded by a virus encoded by
30 SEQ ID NO:94 or SEQ ID NO:97. The invention provides a M protein of a mammalian MPV of subgroup A, wherein the M protein is phylogenetically closer related to the M

protein encoded by a virus of SEQ ID NO:95 or SEQ ID NO:96 than it is related to the M protein encoded by a virus encoded by SEQ ID NO:94 or SEQ ID NO:97. The invention provides a N protein of a mammalian MPV of subgroup A, wherein the F protein is

5 phylogenetically closer related to the F protein encoded by a virus of SEQ ID NO:95 or SEQ ID NO:96 than it is related to the F protein encoded by a virus encoded by SEQ ID NO:94 or SEQ ID NO:97. The invention provides a M2-1 protein of a mammalian MPV of subgroup A, wherein the M2-1 protein is phylogenetically closer related to the M2-1 protein encoded by a virus of SEQ ID NO:95 or SEQ ID NO:96 than it is related to the M2-1 protein encoded

10 by a virus encoded by SEQ ID NO:94 or SEQ ID NO:97. The invention provides a M2-2 protein of a mammalian MPV of subgroup A, wherein the M2-2 protein is phylogenetically closer related to the M2-2 protein encoded by a virus of SEQ ID NO:95 or SEQ ID NO:96 than it is related to the M2-2 protein encoded by a virus encoded by SEQ ID NO:94 or SEQ ID NO:97. The invention provides a SH protein of a mammalian MPV of subgroup A,

15 wherein the SH protein is phylogenetically closer related to the SH protein encoded by a virus of SEQ ID NO:95 or SEQ ID NO:96 than it is related to the SH protein encoded by a virus encoded by SEQ ID NO:94 or SEQ ID NO:97. The invention provides a L protein of a mammalian MPV of subgroup A, wherein the L protein is phylogenetically closer related to the L protein encoded by a virus of SEQ ID NO:95 or SEQ ID NO:96 than it is related to the

20 L protein encoded by a virus encoded by SEQ ID NO:94 or SEQ ID NO:97.

In other embodiments, the invention provides a protein of a mammalian MPV of subgroup B or fragments thereof. The invention provides a N protein of a mammalian MPV of subgroup B, wherein the N protein is phylogenetically closer related to the N protein encoded by a virus of SEQ ID NO:94 or SEQ ID NO:97 than it is related to the N protein

25 encoded by a virus encoded by SEQ ID NO:95 or SEQ ID NO:96. The invention provides a G protein of a mammalian MPV of subgroup A, wherein the G protein is phylogenetically closer related to the G protein encoded by a virus of SEQ ID NO:94 or SEQ ID NO:97 than it is related to the G protein encoded by a virus encoded by SEQ ID NO:95 or SEQ ID NO:96. The invention provides a P protein of a mammalian MPV of subgroup A, wherein the P

30 protein is phylogenetically closer related to the P protein encoded by a virus of SEQ ID NO:94 or SEQ ID NO:97 than it is related to the P protein encoded by a virus encoded by

SEQ ID NO:95 or SEQ ID NO:96. The invention provides a M protein of a mammalian MPV of subgroup A, wherein the M protein is phylogenetically closer related to the M protein encoded by a virus of SEQ ID NO:94 or SEQ ID NO:97 than it is related to the M protein encoded by a virus encoded by SEQ ID NO:95 or SEQ ID NO:96. The invention provides a N protein of a mammalian MPV of subgroup A, wherein the F protein is phylogenetically closer related to the F protein encoded by a virus of SEQ ID NO:94 or SEQ ID NO:97 than it is related to the F protein encoded by a virus encoded by SEQ ID NO:95 or SEQ ID NO:96. The invention provides a M2-1 protein of a mammalian MPV of subgroup A, wherein the M2-1 protein is phylogenetically closer related to the M2-1 protein encoded by a virus of SEQ ID NO:94 or SEQ ID NO:97 than it is related to the M2-1 protein encoded by a virus encoded by SEQ ID NO:95 or SEQ ID NO:96. The invention provides a M2-2 protein of a mammalian MPV of subgroup A, wherein the M2-2 protein is phylogenetically closer related to the M2-2 protein encoded by a virus of SEQ ID NO:94 or SEQ ID NO:97 than it is related to the M2-2 protein encoded by a virus encoded by SEQ ID NO:95 or SEQ ID NO:96. The invention provides a SH protein of a mammalian MPV of subgroup A, wherein the SH protein is phylogenetically closer related to the SH protein encoded by a virus of SEQ ID NO:94 or SEQ ID NO:97 than it is related to the SH protein encoded by a virus encoded by SEQ ID NO:95 or SEQ ID NO:96. The invention provides a L protein of a mammalian MPV of subgroup A, wherein the L protein is phylogenetically closer related to the L protein encoded by a virus of SEQ ID NO:94 or SEQ ID NO:97 than it is related to the L protein encoded by a virus encoded by SEQ ID NO:95 or SEQ ID NO:96.

The invention provides a G protein of a mammalian MPV variant B1, wherein the G protein of a mammalian MPV variant B1 is phylogenetically closer related to the G protein of the prototype of variant B1, isolate NL/1/99, than it is related to the G protein of the prototype of variant A1, isolate NL/1/00, the G protein of the prototype of A2, isolate NL/17/00, or the G protein of the prototype of B2, isolate NL/1/94. The invention provides a G protein of a mammalian MPV variant B1, wherein the amino acid sequence of the G protein is at least 66%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the G protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:28). In a

specific embodiment, the G protein of a mammalian MPV has the amino acid sequence of SEQ ID NO:119-153. The invention provides a N protein of a mammalian MPV variant B1, wherein the N protein of a mammalian MPV variant B1 is phylogenetically closer related to the N protein of the prototype of variant B1, isolate NL/1/99, than it is related to the N protein of the prototype of variant A1, isolate NL/1/00, the N protein of the prototype of A2, isolate NL/17/00, or the N protein of the prototype of B2, isolate NL/1/94. The invention provides a N protein of a mammalian MPV variant B1, wherein the amino acid sequence of the N protein is at least 98.5% or at least 99% or at least 99.5% identical to the N protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:72). The invention provides a P protein of a mammalian MPV variant B1, wherein the P protein of a mammalian MPV variant B1 is phylogenetically closer related to the P protein of the prototype of variant B1, isolate NL/1/99, than it is related to the P protein of the prototype of variant A1, isolate NL/1/00, the P protein of the prototype of A2, isolate NL/17/00, or the P protein of the prototype of B2, isolate NL/1/94. The invention provides a P protein of a mammalian MPV variant B1, wherein the amino acid sequence of the P protein is at least 96%, at least 98%, or at least 99% or at least 99.5% identical the P protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:80). The invention provides a M protein of a mammalian MPV variant B1, wherein the M protein of a mammalian MPV variant B1 is phylogenetically closer related to the M protein of the prototype of variant B1, isolate NL/1/99, than it is related to the M protein of the prototype of variant A1, isolate NL/1/00, the M protein of the prototype of A2, isolate NL/17/00, or the M protein of the prototype of B2, isolate NL/1/94. The invention provides a M protein of a mammalian MPV variant B1, wherein the amino acid sequence of the M protein is identical to the M protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:64). The invention provides a F protein of a mammalian MPV variant B1, wherein the F protein of a mammalian MPV variant B1 is phylogenetically closer related to the F protein of variant B1, isolate NL/1/99, than it is related to the F protein of variant A1, isolate NL/1/00, the F protein of prototype A2, isolate NL/17/00, or the F protein of the prototype of B2, isolate NL/1/94. The invention provides a F protein of mammalian MPV variant B1, wherein the amino acid sequence of the F protein is identical at least 99%

identical, to the F protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:20). In a specific embodiment, the F protein of a mammalian MPV has the amino acid sequence of SEQ ID NO: 248-327. The invention provides a M2-1

5 protein of a mammalian MPV variant B1, wherein the M2-1 protein of a mammalian MPV variant B1 is phylogenetically closer related to the M2-1 protein of the prototype of variant B1, isolate NL/1/99, than it is related to the M2-1 protein of the prototype of variant A1, isolate NL/1/00, the M2-1 protein of the prototype of A2, isolate NL/17/00, or the M2-1 protein of the prototype of B2, isolate NL/1/94. The invention provides a M2-1 protein of a

10 mammalian MPV variant B1, wherein the amino acid sequence of the M2-1 protein is at least 98% or at least 99% or at least 99.5% identical the M2-1 protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:44). The invention provides a M2-2 protein of a mammalian MPV variant B1, wherein the M2-2 protein of a mammalian MPV variant B1 is phylogenetically closer related to the M2-2 protein of the

15 prototype of variant B1, isolate NL/1/99, than it is related to the M2-2 protein of the prototype of variant A1, isolate NL/1/00, the M2-2 protein of the prototype of A2, isolate NL/17/00, or the M2-2 protein of the prototype of B2, isolate NL/1/94. The invention provides a M2-2 protein of a mammalian MPV variant B1, wherein the amino acid sequence of the M2-2 protein is at least 99% or at least 99.5% identical the M2-2 protein of a

20 mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:52). The invention provides a SH protein of a mammalian MPV variant B1, wherein the SH protein of a mammalian MPV variant B1 is phylogenetically closer related to the SH protein of the prototype of variant B1, isolate NL/1/99, than it is related to the SH protein of the prototype of variant A1, isolate NL/1/00, the SH protein of the prototype of A2, isolate NL/17/00, or

25 the SH protein of the prototype of B2, isolate NL/1/94. The invention provides a SH protein of a mammalian MPV variant B1, wherein the amino acid sequence of the SH protein is at least 83%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical the SH protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:88). The invention provides a L protein of a mammalian

30 MPV variant B1, wherein the L protein of a mammalian MPV variant B1 is phylogenetically closer related to the L protein of the prototype of variant B1, isolate NL/1/99, than it is

related to the L protein of the prototype of variant A1, isolate NL/1/00, the L protein of the prototype of A2, isolate NL/17/00, or the L protein of the prototype of B2, isolate NL/1/94. The invention provides a L protein of a mammalian MPV variant B1, wherein the amino acid
5 sequence of the L protein is at least 99% or at least 99.5% identical the L protein a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:36).

The invention provides a G protein of a mammalian MPV variant A1, wherein the G protein of a mammalian MPV variant A1 is phylogenetically closer related to the G protein of the prototype of variant A1, isolate NL/1/00, than it is related to the G protein of the
10 prototype of variant B1, isolate NL/1/99, the G protein of the prototype of A2, isolate NL/17/00, or the G protein of the prototype of B2, isolate NL/1/94. The invention provides a G protein of a mammalian MPV variant A1, wherein the amino acid sequence of the G protein is at least 66%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the G protein of a
15 mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:26). The invention provides a N protein of a mammalian MPV variant A1, wherein the N protein of a mammalian MPV variant A1 is phylogenetically closer related to the N protein of the prototype of variant A1, isolate NL/1/00, than it is related to the N protein of the prototype of variant B1, isolate NL/1/99, the N protein of the prototype of A2, isolate NL/17/00, or the N
20 protein of the prototype of B2, isolate NL/1/94. The invention provides a N protein of a mammalian MPV variant A1, wherein the amino acid sequence of the N protein is at least 99.5% identical to the N protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:70). The invention provides a P protein of a mammalian MPV variant A1, wherein the P protein of a mammalian MPV variant A1 is phylogenetically
25 closer related to the P protein of the prototype of variant A1, isolate NL/1/00, than it is related to the P protein of the prototype of variant B1, isolate NL/1/99, the P protein of the prototype of A2, isolate NL/17/00, or the P protein of the prototype of B2, isolate NL/1/94. The invention provides a P protein of a mammalian MPV variant A1, wherein the amino acid sequence of the P protein is at least 96%, at least 98%, or at least 99% or at least 99.5%
30 identical to the P protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:78). The invention provides a M protein of a mammalian MPV

variant A1, wherein the M protein of a mammalian MPV variant A1 is phylogenetically closer related to the M protein of the prototype of variant A1, isolate NL/1/00, than it is related to the M protein of the prototype of variant B1, isolate NL/1/99, the M protein of the prototype of A2, isolate NL/17/00, or the M protein of the prototype of B2, isolate NL/1/94.

5 The invention provides a M protein of a mammalian MPV variant A1, wherein the amino acid sequence of the M protein is at least 99% or at least 99.5% identical to the M protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:62).

The invention provides a F protein of a mammalian MPV variant A1, wherein the F protein

10 of a mammalian MPV variant A1 is phylogenetically closer related to the F protein of the prototype of variant A1, isolate NL/1/00, than it is related to the F protein of the prototype of variant B1, isolate NL/1/99, the F protein of the prototype of A2, isolate NL/17/00, or the F protein of the prototype of B2, isolate NL/1/94. The invention provides a F protein of a mammalian MPV variant A1, wherein the amino acid sequence of the F protein is at least

15 98% or at least 99% or at least 99.5% identical to the F protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:18). The invention provides a M2-1 protein of a mammalian MPV variant A1, wherein the M2-1 protein of a mammalian MPV variant A1 is phylogenetically closer related to the M2-1 protein of the prototype of variant A1, isolate NL/1/00, than it is related to the M2-1 protein of the prototype of variant B1,

20 isolate NL/1/99, the M2-1 protein of the prototype of A2, isolate NL/17/00, or the M2-1 protein of the prototype of B2, isolate NL/1/94. The invention provides a M2-1 protein of a mammalian MPV variant A1, wherein the amino acid sequence of the M2-1 protein is at least 99% or at least 99.5% identical to the M2-1 protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:42). The invention provides a M2-2

25 protein of a mammalian MPV variant A1, wherein the M2-2 protein of a mammalian MPV variant A1 is phylogenetically closer related to the M2-2 protein of the prototype of variant A1, isolate NL/1/00, than it is related to the M2-2 protein of the prototype of variant B1, isolate NL/1/99, the M2-2 protein of the prototype of A2, isolate NL/17/00, or the M2-2 protein of the prototype of B2, isolate NL/1/94. The invention provides a M2-2 protein of a

30 mammalian MPV variant A1, wherein the amino acid sequence of the M2-2 protein is at least 96% or at least 99% or at least 99.5% identical to the M2-2 protein of a mammalian

MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:50). The invention provides a SH protein of a mammalian MPV variant A1, wherein the SH protein of a mammalian MPV variant A1 is phylogenetically closer related to the SH protein of the prototype of variant A1, isolate NL/1/00, than it is related to the SH protein of the prototype of variant B1, isolate NL/1/99, the SH protein of the prototype of A2, isolate NL/17/00, or the SH protein of the prototype of B2, isolate NL/1/94. The invention provides a SH protein of a mammalian MPV variant A1, wherein the amino acid sequence of the SH protein is at least 84%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the SH protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:86). The invention provides a L protein of a mammalian MPV variant A1, wherein the L protein of a mammalian MPV variant A1 is phylogenetically closer related to the L protein of the prototype of variant A1, isolate NL/1/00, than it is related to the L protein of the prototype of variant B1, isolate NL/1/99, the L protein of the prototype of A2, isolate NL/17/00, or the L protein of the prototype of B2, isolate NL/1/94. The invention provides a L protein of a mammalian MPV variant A1, wherein the amino acid sequence of the L protein is at least 99% or at least 99.5% identical to the L protein of a virus of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:34).

The invention provides a G protein of a mammalian MPV variant A2, wherein the G protein of a mammalian MPV variant A2 is phylogenetically closer related to the G protein of the prototype of variant A2, isolate NL/17/00, than it is related to the G protein of the prototype of variant B1, isolate NL/1/99, the G protein of the prototype of A1, isolate NL/1/00, or the G protein of the prototype of B2, isolate NL/1/94. The invention provides a G protein of a mammalian MPV variant A2, wherein the amino acid sequence of the G protein is at least 66%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or at least 99.5% identical to the G protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:27). The invention provides a N protein of a mammalian MPV variant A2, wherein the N protein of a mammalian MPV variant A2 is phylogenetically closer related to the N protein of the prototype of variant A2, isolate NL/17/00, than it is related to the N protein of the prototype of variant B1, isolate NL/1/99, the N protein of the prototype of A1, isolate NL/1/00, or the N

- protein of the prototype of B2, isolate NL/1/94. The invention provides a N protein of a mammalian MPV variant A2, wherein the amino acid sequence of the N protein at least 99.5% identical to the N protein of a mammalian MPV variant A2 as represented by the
- 5 prototype NL/17/00 (SEQ ID NO:71). The invention provides a P protein of a mammalian MPV variant A2, wherein the P protein of a mammalian MPV variant A2 is phylogenetically closer related to the P protein of the prototype of variant A2, isolate NL/17/00, than it is related to the P protein of the prototype of variant B1, isolate NL/1/99, the P protein of the prototype of A1, isolate NL/1/00, or the P protein of the prototype of B2, isolate NL/1/94.
- 10 The invention provides a P protein of a mammalian MPV variant A2, wherein the amino acid sequence of the P protein is at least 96%, at least 98%, at least 99% or at least 99.5% identical to the P protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:79). The invention provides a M protein of a mammalian MPV variant A2, wherein the M protein of a mammalian MPV variant A2 is phylogenetically
- 15 closer related to the M protein of the prototype of variant A2, isolate NL/17/00, than it is related to the M protein of the prototype of variant B1, isolate NL/1/99, the M protein of the prototype of A1, isolate NL/1/00, or the M protein of the prototype of B2, isolate NL/1/94. The invention provides a M protein of a mammalian MPV variant A2, wherein the amino acid sequence of the M protein is at least 99%, or at least 99.5% identical to the M protein of
- 20 a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:63). The invention provides a F protein of a mammalian MPV variant A2, wherein the F protein of a mammalian MPV variant A2 is phylogenetically closer related to the F protein of the prototype of variant A2, isolate NL/17/00, than it is related to the F protein of the prototype of variant B1, isolate NL/1/99, the F protein of the prototype of A1, isolate NL/1/00, or the F
- 25 protein of the prototype of B2, isolate NL/1/94. The invention provides a F protein of a mammalian MPV variant A2, wherein the amino acid sequence of the F protein is at least 98%, at least 99% or at least 99.5% identical to the F protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:19). The invention provides a M2-1 protein of a mammalian MPV variant A2, wherein the M2-1 protein of a mammalian
- 30 MPV variant A2 is phylogenetically closer related to the M2-1 protein of the prototype of variant A2, isolate NL/17/00, than it is related to the M2-1 protein of the prototype of variant

B1, isolate NL/1/99, the M2-1 protein of the prototype of A1, isolate NL/1/00, or the M2-1 protein of the prototype of B2, isolate NL/1/94. The invention provides a M2-1 protein of a mammalian MPV variant A2, wherein the amino acid sequence of the M2-1 protein is at
5 least 99%, or at least 99.5% identical to the M2-1 protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO: 43). The invention provides a M2-2 protein of a mammalian MPV variant A2, wherein the M2-2 protein of a mammalian MPV variant A2 is phylogenetically closer related to the M2-2 protein of the prototype of variant A2, isolate NL/17/00, than it is related to the M2-2 protein of the prototype of variant B1,
10 isolate NL/1/99, the M2-2 protein of the prototype of A1, isolate NL/1/00, or the M2-2 protein of the prototype of B2, isolate NL/1/94. The invention provides a M2-2 protein of a mammalian MPV variant A2, wherein the amino acid sequence of the M2-2 protein is at least 96%, at least 98%, at least 99% or at least 99.5% identical to the M2-2 protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:51).
15 The invention provides a SH protein of a mammalian MPV variant A2, wherein the SH protein of a mammalian MPV variant A2 is phylogenetically closer related to the SH protein of the prototype of variant A2, isolate NL/17/00, than it is related to the SH protein of the prototype of variant B1, isolate NL/1/99, the SH protein of the prototype of A1, isolate NL/1/00, or the SH protein of the prototype of B2, isolate NL/1/94. The invention provides a
20 SH protein of a mammalian MPV variant A2, wherein the amino acid sequence of the SH protein is at least 84%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or at least 99.5% identical to the SH protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:87). The invention provides a L protein of a mammalian MPV variant A2, wherein the L protein of a mammalian MPV variant A2 is
25 phylogenetically closer related to the L protein of the prototype of variant A2, isolate NL/17/00, than it is related to the L protein of the prototype of variant B1, isolate NL/1/99, the L protein of the prototype of A1, isolate NL/1/00, or the L protein of the prototype of B2, isolate NL/1/94. The invention provides a L protein of a mammalian MPV variant A2, wherein the amino acid sequence of the L protein is at least 99% or at least 99.5% identical
30 to the L protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:35).

The invention provides a G protein of a mammalian MPV variant B2, wherein the G protein of a mammalian MPV variant B2 is phylogenetically closer related to the G protein of the prototype of variant B2, isolate NL/1/94, than it is related to the G protein of the

5 prototype of variant B1, isolate NL/1/99, the G protein of the prototype of A1, isolate NL/1/00, or the G protein of the prototype of A2, isolate NL/17/00. The invention provides a G protein of a mammalian MPV variant B2, wherein the amino acid sequence of the G protein is at least 66%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the G protein of a

10 mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:29). The invention provides a N protein of a mammalian MPV variant B2, wherein the N protein of a mammalian MPV variant B2 is phylogenetically closer related to the N protein of the prototype of variant B2, isolate NL/1/94, than it is related to the N protein of the prototype of variant B1, isolate NL/1/99, the N protein of the prototype of A1, isolate NL/1/00, or the N

15 protein of the prototype of A2, isolate NL/17/00. The invention provides a N protein of a mammalian MPV variant B2, wherein the amino acid sequence of the N protein is at least 99% or at least 99.5% identical to the N protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:73). The invention provides a P protein of a mammalian MPV variant B2, wherein the P protein of a mammalian MPV variant B2 is

20 phylogenetically closer related to the P protein of the prototype of variant B2, isolate NL/1/94, than it is related to the P protein of the prototype of variant B1, isolate NL/1/99, the P protein of the prototype of A1, isolate NL/1/00, or the P protein of the prototype of A2, isolate NL/17/00. The invention provides a P protein of a mammalian MPV variant B2, wherein the amino acid sequence of the P protein is at least 96%, at least 98%, or at least

25 99% or at least 99.5% identical to the P protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:81). The invention provides a M protein of a mammalian MPV variant B2, wherein the M protein of a mammalian MPV variant B2 is phylogenetically closer related to the M protein of the prototype of variant B2, isolate NL/1/94, than it is related to the M protein of the prototype of variant B1, isolate NL/1/99,

30 the M protein of the prototype of A1, isolate NL/1/00, or the M protein of the prototype of A2, isolate NL/17/00. The invention provides a M protein of a mammalian MPV variant B2,

wherein the amino acid sequence of its M protein is identical to the M protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:65). The invention provides a F protein of a mammalian MPV variant B2, wherein the F protein of a mammalian MPV variant B2 is phylogenetically closer related to the F protein of the prototype of variant B2, isolate NL/1/94, than it is related to the F protein of the prototype of variant B1, isolate NL/1/99, the F protein of the prototype of A1, isolate NL/1/00, or the F protein of the prototype of A2, isolate NL/17/00. The invention provides a F protein of a mammalian MPV variant B2, wherein the amino acid sequence of the F protein is at least 99% or at least 99.5% identical to the F protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:21). The invention provides a M2-1 protein of a mammalian MPV variant B2, wherein the M2-1 protein of a mammalian MPV variant B2 is phylogenetically closer related to the M2-1 protein of the prototype of variant B2, isolate NL/1/94, than it is related to the M2-1 protein of the prototype of variant B1, isolate NL/1/99, the M2-1 protein of the prototype of A1, isolate NL/1/00, or the M2-1 protein of the prototype of A2, isolate NL/17/00. The invention provides a M2-1 protein of a mammalian MPV variant B2, wherein the amino acid sequence of the M2-1 protein is at least 98% or at least 99% or at least 99.5% identical to the M2-1 protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:45). The invention provides a M2-2 protein of a mammalian MPV variant B2, wherein the M2-2 protein of a mammalian MPV variant B2 is phylogenetically closer related to the M2-2 protein of the prototype of variant B2, isolate NL/1/94, than it is related to the M2-2 protein of the prototype of variant B1, isolate NL/1/99, the M2-2 protein of the prototype of A1, isolate NL/1/00, or the M2-2 protein of the prototype of A2, isolate NL/17/00. The invention provides a M2-2 protein of a mammalian MPV variant B2, wherein the amino acid sequence is at least 99% or at least 99.5% identical to the M2-2 protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:53). The invention provides a SH protein of a mammalian MPV variant B2, wherein the SH protein of a mammalian MPV variant B2 is phylogenetically closer related to the SH protein of the prototype of variant B2, isolate NL/1/94, than it is related to the SH protein of the prototype of variant B1, isolate NL/1/99, the SH protein of the prototype of A1, isolate NL/1/00, or the SH protein of the

prototype of A2, isolate NL/17/00. The invention provides a SH protein of a mammalian MPV variant B2, wherein the amino acid sequence of the SH protein is at least 84%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the SH protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:89). The invention provides a L protein of a mammalian MPV variant B2, wherein the L protein of a mammalian MPV variant B2 is phylogenetically closer related to the L protein of the prototype of variant B2, isolate NL/1/94, than it is related to the L protein of the prototype of variant B1, isolate NL/1/99, the L protein of the prototype of A1, isolate NL/1/00, or the L protein of the prototype of A2, isolate NL/17/00. The invention provides a L protein of a mammalian MPV variant B2, wherein the and/or if the amino acid sequence of the L protein is at least 99% or at least 99.5% identical to the L protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:37).

In certain embodiments, the percentage of sequence identity is based on an alignment of the full length proteins. In other embodiments, the percentage of sequence identity is based on an alignment of contiguous amino acid sequences of the proteins, wherein the amino acid sequences can be 25 amino acids, 50 amino acids, 75 amino acids, 100 amino acids, 125 amino acids, 150 amino acids, 175 amino acids, 200 amino acids, 225 amino acids, 250 amino acids, 275 amino acids, 300 amino acids, 325 amino acids, 350 amino acids, 375 amino acids, 400 amino acids, 425 amino acids, 450 amino acids, 475 amino acids, 500 amino acids, 750 amino acids, 1000 amino acids, 1250 amino acids, 1500 amino acids, 1750 amino acids, 2000 amino acids or 2250 amino acids in length.

The invention further provides nucleic acid sequences derived from a mammalian MPV. The invention also provides derivatives of nucleic acid sequences derived from a mammalian MPV. In certain specific embodiments the nucleic acids are modified.

In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a mammalian MPV as defined above. In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of subgroup A of a mammalian MPV as defined above. In a specific embodiment, the G gene of a mammalian MPV has the

nucleotide sequence of SEQ ID NO:98-132. In a specific embodiment, the F gene of a mammalian MPV has the nucleotide sequence of SEQ ID NO:168-247. In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of subgroup B of a mammalian MPV as defined above. In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of variant A1 of a mammalian MPV as defined above. In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of variant A2 of a mammalian MPV as defined above. In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of variant B1 of a mammalian MPV as defined above. In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of variant B2 of a mammalian MPV as defined above.

In certain embodiments, the invention provides a nucleotide sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the nucleotide sequence of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97. In certain embodiments, the nucleic acid sequence of the invention, is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to a fragment of the nucleotide sequence of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97, wherein the fragment is at least 25 nucleotides, at least 50 nucleotides, at least 75 nucleotides, at least 100 nucleotides, at least 150 nucleotides, at least 200 nucleotides, at least 250 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides, at least 750 nucleotides, at least 1,000 nucleotides, at least 1,250 nucleotides, at least 1,500 nucleotides, at least 1,750 nucleotides, at least 2,000 nucleotides, at least 2,00 nucleotides, at least 3,000 nucleotides, at least 4,000 nucleotides, at

least 5,000 nucleotides, at least 7,500 nucleotides, at least 10,000 nucleotides, at least 12,500 nucleotides, or at least 15,000 nucleotides in length. In a specific embodiment, the nucleic acid sequence of the invention is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% or 100% identical to one of the nucleotide sequences of SEQ ID NO:98-132; SEQ ID NO:168-247; SEQ ID NO:22-25; SEQ ID NO:30-33; SEQ ID NO:38-41; SEQ ID NO:46-49; SEQ ID NO:54-57; SEQ ID NO:58-61; SEQ ID NO:66-69; SEQ ID NO:74-77; SEQ ID NO:82-85; or SEQ ID NO:90-93.

10 In specific embodiments of the invention, a nucleic acid sequence of the invention is capable of hybridizing under low stringency, medium stringency or high stringency conditions to one of the nucleic acid sequences of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97. In specific embodiments of the invention, a nucleic acid sequence of the invention is capable of hybridizing under low stringency, medium stringency or high stringency conditions to one of the nucleic acid sequences of SEQ ID NO:98-132; SEQ ID NO:168-247; SEQ ID NO:22-25; SEQ ID NO:30-33; SEQ ID NO:38-41; SEQ ID NO:46-49; SEQ ID NO:54-57; SEQ ID NO:58-61; SEQ ID NO:66-69; SEQ ID NO:74-77; SEQ ID NO:82-85; or SEQ ID NO:90-93. In certain embodiments, a nucleic acid hybridizes over a length of at least 25 nucleotides, at least 50 nucleotides, at least 75 nucleotides, at least 100 nucleotides, at least 150 nucleotides, at least 200 nucleotides, at least 250 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides, at least 750 nucleotides, at least 1,000 nucleotides, at least 1,250 nucleotides, at least 1,500 nucleotides, at least 1,750 nucleotides, at least 2,000 nucleotides, at least 2,00 nucleotides, at least 3,000 nucleotides, at least 4,000 nucleotides, at least 5,000 nucleotides, at least 7,500 nucleotides, at least 10,000 nucleotides, at least 12,500 nucleotides, or at least 15,000 nucleotides with the nucleotide sequence of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97.

25 The invention further provides antibodies and antigen-binding fragments that bind specifically to a protein of a mammalian MPV. An antibody of the invention binds specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a mammalian MPV. In specific embodiments, the antibody is a human antibody or a humanized antibody. In certain

embodiments, an antibody of the invention binds specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a virus of subgroup A of a mammalian MPV. In certain other embodiments, an antibody of the invention binds specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a virus of subgroup B of a mammalian MPV. In certain, more specific, embodiments, an antibody of the invention binds specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a virus of variant A1 of a mammalian MPV. In other embodiments, the antibody of the invention binds specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a virus of subgroup A2 of a mammalian MPV. In certain embodiments, an antibody of the invention binds specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a virus of subgroup B1 of a mammalian MPV. In certain other embodiments, an antibody of the invention binds specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a virus of subgroup B2 of a mammalian MPV.

5.1.3. INSERTION OF THE HETEROLOGOUS GENE SEQUENCE

Insertion of a foreign gene sequence into a viral vector of the invention can be accomplished by either a complete replacement of a viral coding region with a heterologous sequence, or by a partial replacement of the same, or by adding the heterologous nucleotide sequence to the viral genome. Complete replacement would probably best be accomplished through the use of PCR-directed mutagenesis. Briefly, PCR-primer A would contain, from the 5' to 3' end: a unique restriction enzyme site, such as a class IIS restriction enzyme site (*i.e.*, a "shifter" enzyme; that recognizes a specific sequence but cleaves the DNA either upstream or downstream of that sequence); a stretch of nucleotides complementary to a region of the PIV gene; and a stretch of nucleotides complementary to the carboxy-terminus coding portion of the heterologous sequence. PCR-primer B would contain from the 5' to 3' end: a unique restriction enzyme site; a stretch of nucleotides complementary to a PIV gene;

and a stretch of nucleotides corresponding to the 5' coding portion of the foreign gene. After a PCR reaction using these primers with a cloned copy of the foreign gene, the product may be excised and cloned using the unique restriction sites. Digestion with the class IIS enzyme and transcription with the purified phage polymerase would generate an RNA molecule containing the exact untranslated ends of the PIV gene with a foreign gene insertion. In an alternate embodiment, PCR-primed reactions could be used to prepare double-stranded DNA containing the bacteriophage promoter sequence, and the hybrid gene sequence so that RNA templates can be transcribed directly without cloning.

10 A heterologous nucleotide sequence can be added or inserted at various positions of the virus of the invention. In one embodiment, the heterologous nucleotide sequence is added or inserted at position 1. In another embodiment, the heterologous nucleotide sequence is added or inserted at position 2. In another embodiment, the heterologous nucleotide sequence is added or inserted at position 3. In another embodiment, the
15 heterologous nucleotide sequence is added or inserted at position 4. In another embodiment, the heterologous nucleotide sequence is added or inserted at position 5. In yet another embodiment, the heterologous nucleotide sequence is added or inserted at position 6. As used herein, the term "position" refers to the position of the heterologous nucleotide sequence on the viral genome to be transcribed, *e.g.*, position 1 means that it is the first gene
20 to be transcribed, and position 2 means that it is the second gene to be transcribed. Inserting heterologous nucleotide sequences at the lower-numbered positions of the virus generally results in stronger expression of the heterologous nucleotide sequence compared to insertion at higher-numbered positions due to a transcriptional gradient that occurs across the genome of the virus. However, the transcriptional gradient also yields specific ratios of viral
25 mRNAs. Insertion of foreign genes will perturb these ratios and result in the synthesis of different amounts of viral proteins that may influence virus replication. Thus, both the transcriptional gradient and the replication kinetics must be considered when choosing an insertion site. For example, insertion of heterologous nucleotide sequence at position 2 of the b/h PIV3 vector results in the best replication rate and expression level of the
30 heterologous gene. Inserting heterologous nucleotide sequences at lower-numbered positions is the preferred embodiment of the invention if strong expression of the heterologous

nucleotide sequence is desired. In a preferred embodiment, the heterologous sequence is added or inserted at position 1, 2 or 3.

When inserting a heterologous nucleotide sequence into the virus of the invention,
 5 the intergenic region between the end of the coding sequence of the heterologous gene and the start of the coding sequence of the downstream gene can be altered to achieve a desired effect. As used herein, the term "intergenic region" refers to nucleotide sequence between the stop signal of one gene and the start codon (*e.g.*, AUG) of the coding sequence of the next downstream open reading frame. An intergenic region may comprise a non-coding
 10 region of a gene, *i.e.*, between the transcription start site and the start of the coding sequence (AUG) of the gene. This non-coding region occurs naturally in bPIV3 mRNAs and other viral genes, which is illustrated as non-limiting examples in Table 2:

Table 2: Lengths of Non-coding Regions for bPIV3 mRNAs

15	... CTT [Gene Start]	AUG ...
	N	45 nucleotides
	P	68 nucleotides
	M	21 nucleotides
20	F	201 nucleotides
	HN	62 nucleotides
	L	12 nucleotides
	b/h RSV F1	10 nucleotides
	b/h RSV F2	86 nucleotides
25	b/h RSV F1 NP-P	83 nucleotides

In various embodiments, the intergenic region between the heterologous nucleotide sequence and the downstream gene can be engineered, independently from each other, to be at least 10 nt in length, at least 20 nt in length, at least 30 nt in length, at least 50 nt in length,
 30 at least 75 nt in length, at least 100 nt in length, at least 125 nt in length, at least 150 nt in length, at least 175 nt in length or at least 200 nt in length. In certain embodiments, the

intergenic region between the heterologous nucleotide sequence and the downstream gene can be engineered, independently from each other, to be at most 10 nt in length, at most 20 nt in length, at most 30 nt in length, at most 50 nt in length, at most 75 nt in length, at most 100 nt in length, at most 125 nt in length, at most 150 nt in length, at most 175 nt in length or at most 200 nt in length. In various embodiments, the non-coding region of a desired gene in a virus genome can also be engineered, independently from each other, to be at least 10 nt in length, at least 20 nt in length, at least 30 nt in length, at least 50 nt in length, at least 75 nt in length, at least 100 nt in length, at least 125 nt in length, at least 150 nt in length, at least 175 nt in length or at least 200 nt in length. In certain embodiments, the non-coding region of a desired gene in a virus genome can also be engineered, independently from each other, to be at most 10 nt in length, at most 20 nt in length, at most 30 nt in length, at most 50 nt in length, at most 75 nt in length, at most 100 nt in length, at most 125 nt in length, at most 150 nt in length, at most 175 nt in length or at most 200 nt in length.

When inserting a heterologous nucleotide sequence, the positional effect and the intergenic region manipulation can be used in combination to achieve a desirable effect. For example, the heterologous nucleotide sequence can be added or inserted at a position selected from the group consisting of position 1, 2, 3, 4, 5, and 6, and the intergenic region between the heterologous nucleotide sequence and the next downstream gene can be altered (*see* Table 3). In an exemplary embodiment, hRSV F gene is inserted at position 1 of a b/h PIV3 vector, and the intergenic region between F gene and N gene (*i.e.*, the next downstream gene of F) is altered to 177 nucleotides. Many more combinations are encompassed by the present invention and some are shown by way of example in Table 3.

Table 3. Examples of mode of insertion of heterologous nucleotide sequences

		Position 1	Position 2	Position 3	Position 4	Position 5	Position 6
5	IGR ^a	10-20	10-20	10-20	10-20	10-20	10-20
	IGR	21-40	21-40	21-40	21-40	21-40	21-40
	IGR	41-60	41-60	41-60	41-60	41-60	41-60
	IGR	61-80	61-80	61-80	61-80	61-80	61-80
	IGR	81-100	81-100	81-100	81-100	81-100	81-100
10	IGR	101-120	101-120	101-120	101-120	101-120	101-120
	IGR	121-140	121-140	121-140	121-140	121-140	121-140
	IGR	141-160	141-160	141-160	141-160	141-160	141-160
	IGR	161-180	161-180	161-180	161-180	161-180	161-180
	IGR	181-200	181-200	181-200	181-200	181-200	181-200
15	IGR	201-220	201-220	201-220	201-220	201-220	201-220
	IGR	221-240	221-240	221-240	221-240	221-240	221-240
	IGR	241-260	241-260	241-260	241-260	241-260	241-260
	IGR	261-280	261-280	261-280	261-280	261-280	261-280
	IGR	281-300	281-300	281-300	281-300	281-300	281-300

^a Intergenic Region, measured in nucleotide.

Depending on the purpose (*e.g.*, to have strong immunogenicity) of the inserted heterologous nucleotide sequence, the position of the insertion and the length of the intergenic region of the inserted heterologous nucleotide sequence can be determined by various indexes including, but not limited to, replication kinetics and protein or mRNA expression levels, measured by following non-limiting examples of assays: plaque assay, fluorescent-focus assay, infectious center assay, transformation assay, endpoint dilution assay, efficiency of plating, electron microscopy, hemagglutination, measurement of viral enzyme activity, viral neutralization, hemagglutination inhibition, complement fixation, immunostaining, immunoprecipitation and immunoblotting, enzyme-linked immunosorbent assay, nucleic acid detection (*e.g.*, Southern blot analysis, Northern blot analysis, Western blot analysis), growth curve, employment of a reporter gene (*e.g.*, using a reporter gene, such as Green Fluorescence Protein (GFP) or enhanced Green Fluorescence Protein (eGFP), integrated to the viral genome the same fashion as the interested heterologous gene to observe the protein expression), or a combination thereof. Procedures of performing these

assays are well known in the art (*see, e.g.*, Flint et al., PRINCIPLES OF VIROLOGY, MOLECULAR BIOLOGY, PATHOGENESIS, AND CONTROL, 2000, ASM Press pp 25 - 56, the entire text is incorporated herein by reference), and non-limiting examples are given in the

5 Example sections, *infra*.

For example, expression levels can be determined by infecting cells in culture with a virus of the invention and subsequently measuring the level of protein expression by, *e.g.*, Western blot analysis or ELISA using antibodies specific to the gene product of the heterologous sequence, or measuring the level of RNA expression by, *e.g.*, Northern blot
10 analysis using probes specific to the heterologous sequence. Similarly, expression levels of the heterologous sequence can be determined by infecting an animal model and measuring the level of protein expressed from the heterologous sequence of the recombinant virus of the invention in the animal model. The protein level can be measured by obtaining a tissue sample from the infected animal and then subjecting the tissue sample to Western blot
15 analysis or ELISA, using antibodies specific to the gene product of the heterologous sequence. Further, if an animal model is used, the titer of antibodies produced by the animal against the gene product of the heterologous sequence can be determined by any technique known to the skilled artisan, including but not limited to, ELISA.

As the heterologous sequences can be homologous to a nucleotide sequence in the
20 genome of the virus, care should be taken that the probes and the antibodies are indeed specific to the heterologous sequence or its gene product.

In certain specific embodiments, expression levels of F-protein of RSV or hMPV from chimeric b/h PIV3 RSV or b/h PIV3 hMPV or b/h PIV3 RSV F and hMPV F can be determined by any technique known to the skilled artisan. Expression levels of the F-protein
25 can be determined by infecting cells in a culture with the chimeric virus of the invention and measuring the level of protein expression by, *e.g.*, Western blot analysis or ELISA using antibodies specific to the F-protein and/or the G-protein of hMPV, or measuring the level of RNA expression by, *e.g.*, Northern blot analysis using probes specific to the F-gene and/or the G-gene of human metapneumovirus. Similarly, expression levels of the heterologous
30 sequence can be determined using an animal model by infecting an animal and measuring the level of F-protein and/or G-protein in the animal model. The protein level can be measured

by obtaining a tissue sample from the infected animal and then subjecting the tissue sample to Western blot analysis or ELISA using antibodies specific to F-protein and/or G-protein of the heterologous sequence. Further, if an animal model is used, the titer of antibodies
5 produced by the animal against F-protein and/or G-protein can be determined by any technique known to the skilled artisan, including but not limited to, ELISA.

The rate of replication of a recombinant virus of the invention can be determined by any technique known to the skilled artisan.

In certain embodiments, to facilitate the identification of the optimal position of the
10 heterologous sequence in the viral genome and the optimal length of the intergenic region, the heterologous sequence encodes a reporter gene. Once the optimal parameters are determined, the reporter gene is replaced by a heterologous nucleotide sequence encoding an antigen of choice. Any reporter gene known to the skilled artisan can be used with the methods of the invention. For more detail, see section 5.5.

15 The rate of replication of the recombinant virus can be determined by any standard technique known to the skilled artisan. The rate of replication is represented by the growth rate of the virus and can be determined by plotting the viral titer over the time post infection. The viral titer can be measured by any technique known to the skilled artisan. In certain
20 embodiments, a suspension containing the virus is incubated with cells that are susceptible to infection by the virus. Cell types that can be used with the methods of the invention include, but are not limited to, Vero cells, LLC-MK-2 cells, Hep-2 cells, LF 1043 (HEL) cells, MRC-5 cells, WI-38 cells, 293 T cells, QT 6 cells, QT 35 cells, chicken embryo fibroblast (CEF), or tMK cells. Subsequent to the incubation of the virus with the cells, the number of infected cells is determined. In certain specific embodiments, the virus comprises a reporter gene.
25 Thus, the number of cells expressing the reporter gene is representative of the number of infected cells. In a specific embodiment, the virus comprises a heterologous nucleotide sequence encoding for eGFP, and the number of cells expressing eGFP, *i.e.*, the number of cells infected with the virus, is determined using FACS.

In certain embodiments, the replication rate of the recombinant virus of the invention
30 is at most 20 % of the replication rate of the wild type virus from which the recombinant virus is derived under the same conditions. The same conditions refer to the same initial titer

of virus, the same strain of cells, the same incubation temperature, growth medium, number of cells and other test conditions that may affect the replication rate. For example, the replication rate of b/h PIV3 with RSV's F gene in position 1 is at most 20 % of the
5 replication rate of bPIV3.

In certain embodiments, the replication rate of the recombinant virus of the invention is at most 5 %, at most 10 %, at most 20 %, at most 30 %, at most 40 %, at most 50 %, at most 75 %, at most 80 %, at most 90 % of the replication rate of the wild type virus from which the recombinant virus is derived under the same conditions. In certain embodiments,
10 the replication rate of the recombinant virus of the invention is at least 5 %, at least 10 %, at least 20 %, at least 30 %, at least 40 %, at least 50 %, at least 75 %, at least 80 %, at least 90 % of the replication rate of the wild type virus from which the recombinant virus is derived under the same conditions. In certain embodiments, the replication rate of the recombinant virus of the invention is between 5 % and 20 %, between 10 % and 40 %,
15 between 25 % and 50 %, between 40 % and 75 %, between 50 % and 80 %, or between 75 % and 90 % of the replication rate of the wild type virus from which the recombinant virus is derived under the same conditions.

In certain embodiments, the expression level of the heterologous sequence in the recombinant virus of the invention is at most 20 % of the expression level of the F-protein of
20 the wild type virus from which the recombinant virus is derived under the same conditions. The same conditions refer to the same initial titer of virus, the same strain of cells, the same incubation temperature, growth medium, number of cells and other test conditions that may affect the replication rate. For example, the expression level of the heterologous sequence of the F-protein of MPV in position 1 of bPIV3 is at most 20 % of the expression level of the
25 bovine F-protein of bPIV3.

In certain embodiments, the expression level of the heterologous sequence in the recombinant virus of the invention is at most 5 %, at most 10 %, at most 20 %, at most 30 %, at most 40 %, at most 50 %, at most 75 %, at most 80 %, at most 90 % of the expression level of the F-protein of the wild type virus from which the recombinant virus is derived
30 under the same conditions. In certain embodiments, the expression level of the heterologous sequence in the recombinant virus of the invention is at least 5 %, at least 10 %, at least 20

%, at least 30 %, at least 40 %, at least 50 %, at least 75 %, at least 80 %, at least 90 % of the expression level of the F-protein of the wild type virus from which the recombinant virus is derived under the same conditions. In certain embodiments, the expression level of the heterologous sequence in the recombinant virus of the invention is between 5 % and 20 %, between 10 % and 40 %, between 25 % and 50 %, between 40 % and 75 %, between 50 % and 80 %, or between 75 % and 90 % of the expression level of the F-protein of the wild type virus from which the recombinant virus is derived under the same conditions.

10 5.1.4. INSERTION OF THE HETEROLOGOUS GENE SEQUENCE INTO THE HN GENE

The protein responsible for the hemagglutinin and neuraminidase activities of PIV are coded for by a single gene, HN. The HN protein is a major surface glycoprotein of the virus. For a variety of viruses, such as parainfluenza, the hemagglutinin and neuraminidase proteins have been shown to contain a number of antigenic sites. Consequently, this protein is a potential target for the humoral immune response after infection. Therefore, substitution of antigenic sites of HN with a portion of a foreign protein may provide for a vigorous humoral response against this foreign peptide. If a sequence is inserted within the HN molecule, and it is expressed on the outside surface of the HN, it will be immunogenic. For example, a peptide derived from gp160 of HIV could replace an antigenic site of the HN protein, resulting in a humoral immune response to both gp160 and the HN protein. In a different approach, the foreign peptide sequence may be inserted within the antigenic site without deleting any viral sequences. Expression products of such constructs may be useful in vaccines against the foreign antigen, and may indeed circumvent a problem discussed earlier, that of propagation of the recombinant virus in the vaccinated host. An intact HN molecule with a substitution only in antigenic sites may allow for HN function and thus allow for the construction of a viable virus. Therefore, this virus can be grown without the need for additional helper functions. The virus may also be attenuated in other ways to avoid any danger of accidental escape.

30 Other hybrid constructions may be made to express proteins on the cell surface or enable them to be released from the cell. As a surface glycoprotein, HN has an amino-

terminal cleavable signal sequence necessary for transport to the cell surface, and a carboxy-terminal sequence necessary for membrane anchoring. In order to express an intact foreign protein on the cell surface, it may be necessary to use these HN signals to create a hybrid
5 protein. In this case, the fusion protein may be expressed as a separate fusion protein from an additional internal promoter. Alternatively, if only the transport signals are present and the membrane anchoring domain is absent, the protein may be secreted out of the cell.

5.1.5. CONSTRUCTION OF BICISTRONIC RNA

10 Bicistronic mRNA could be constructed to permit internal initiation of translation of viral sequences and allow for the expression of foreign protein coding sequences from the regular terminal initiation site. Alternatively, a bicistronic mRNA sequence may be constructed wherein the viral sequence is translated from the regular terminal open reading frame, while the foreign sequence is initiated from an internal site. Certain internal ribosome
15 entry site (IRES) sequences may be utilized. The IRES sequences that are chosen should be short enough to avoid interference with parainfluenza packaging limitations. Thus, it is preferable that the IRES chosen for such a bicistronic approach be no more than 500 nucleotides in length, with less than 250 nucleotides being of ideal length. In a specific embodiment, the IRES is derived from a picornavirus and does not include any additional
20 picornaviral sequences. Preferred IRES elements include, but are not limited to, the mammalian BiP IRES and the hepatitis C virus IRES.

Alternatively, a foreign protein may be expressed from a new internal transcriptional unit in which the transcriptional unit has an initiation site and polyadenylation site. In another embodiment, the foreign gene is inserted into a PIV gene such that the resulting
25 expressed protein is a fusion protein.

5.2. EXPRESSION OF HETEROLOGOUS GENE PRODUCTS USING RECOMBINANT cDNA AND RNA TEMPLATES

The recombinant templates prepared as described above can be used in a variety of ways to express the heterologous gene products in appropriate host cells or to create chimeric
30 viruses that express the heterologous gene products. In one embodiment, the recombinant cDNA can be used to transfect appropriate host cells and the resulting RNA may direct the

expression of the heterologous gene product at high levels. Host cell systems which provide for high levels of expression include continuous cell lines that supply viral functions such as cell lines superinfected with PIV, cell lines engineered to complement PIV functions, etc.

5 In an alternate embodiment of the invention, the recombinant templates may be used to transfect cell lines that express a viral polymerase protein in order to achieve expression of the heterologous gene product. To this end, transformed cell lines that express a polymerase protein such as the L protein may be utilized as appropriate host cells. Host cells may be similarly engineered to provide other viral functions or additional functions such as HN, NP
10 or N.

In another embodiment, a helper virus may provide the RNA polymerase protein utilized by the cells in order to achieve expression of the heterologous gene product. In yet another embodiment, cells may be transfected with vectors encoding viral proteins such as the N or NP, P, M2-1 and L proteins.

15 Different technique may be used to detect the expression of heterologous gene products (*see, e.g.*, Flint et al., PRINCIPLES OF VIROLOGY, MOLECULAR BIOLOGY, PATHOGENESIS, AND CONTROL, 2000, ASM Press pp 25 - 56, the entire text is incorporated herein by reference). In an exemplary assay, cells infected with the virus are permeabilized with methanol or acetone and incubated with an antibody raised against the heterologous
20 gene products. A second antibody that recognizes the first antibody is then added. This second antibody is usually conjugated to an indicator so that the expression of heterologous gene products may be visualized or detected.

5.3. RESCUE OF RECOMBINANT VIRUS PARTICLES

25 In order to prepare chimeric virus, modified cDNAs, virus RNAs, or RNA coding for the PIV genome and/or foreign proteins in the plus or minus sense may be used to transfect cells that provide viral proteins and functions required for replication and rescue. Alternatively, cells may be transfected with helper virus before, during, or after transfection by the DNA or RNA molecule coding for the PIV genome and/or foreign proteins. The
30 synthetic recombinant plasmid PIV DNAs and RNAs can be replicated and rescued into infectious virus particles by any number of techniques known in the art, as described in U.S.

Patent No. 5,166,057 issued November 24, 1992; in U.S. Patent No. 5,854,037 issued December 29, 1998; in European Patent Publication EP 0702085A1, published February 20, 1996; in U.S. Patent Application Serial No. 09/152,845; in International Patent Publications
5 PCT WO97/12032 published April 3, 1997; WO96/34625 published November 7, 1996; in European Patent Publication EP-A780475; WO 99/02657 published January 21, 1999; WO 98/53078 published November 26, 1998; WO 98/02530 published January 22, 1998; WO 99/15672 published April 1, 1999; WO 98/13501 published April 2, 1998; WO 97/06270 published February 20, 1997; and EPO 780 47SA1 published June 25, 1997, each of which is
10 incorporated by reference herein in its entirety.

In one embodiment of the present invention, synthetic recombinant viral RNAs that contain the non-coding regions of the negative strand virus RNA essential for the recognition by viral polymerases and for packaging signals necessary to generate a mature virion, may be prepared. There are a number of different approaches that may be used to apply the reverse
15 genetics approach to rescue negative strand RNA viruses. First, the recombinant RNAs are synthesized from a recombinant DNA template and reconstituted *in vitro* with purified viral polymerase complex to form recombinant ribonucleoproteins (RNPs) that can be used to transfect cells. In another approach, a more efficient transfection is achieved if the viral polymerase proteins are present during transcription of the synthetic RNAs either *in vitro* or
20 *in vivo*. With this approach the synthetic RNAs may be transcribed from cDNA plasmids that are either co-transcribed *in vitro* with cDNA plasmids encoding the polymerase proteins, or transcribed *in vivo* in the presence of polymerase proteins, *i.e.*, in cells which transiently or constitutively express the polymerase proteins.

In additional approaches described herein, the production of infectious chimeric virus
25 may be replicated in host cell systems that express a PIV viral polymerase protein (*e.g.*, in virus/host cell expression systems; transformed cell lines engineered to express a polymerase protein, etc.), so that infectious chimeric viruses are rescued. In this instance, helper virus need not be utilized since this function is provided by the viral polymerase proteins expressed.

30 In accordance with the present invention, any technique known to those of skill in the art may be used to achieve replication and rescue of recombinant and chimeric viruses. One

approach involves supplying viral proteins and functions required for replication *in vitro* prior to transfecting host cells. In such an embodiment, viral proteins may be supplied in the form of wild type virus, helper virus, purified viral proteins or recombinantly expressed viral proteins. The viral proteins may be supplied prior to, during or post transcription of the synthetic cDNAs or RNAs encoding the chimeric virus. The entire mixture may be used to transfect host cells. In another approach, viral proteins and functions required for replication may be supplied prior to or during transcription of the synthetic cDNAs or RNAs encoding the chimeric virus. In such an embodiment, viral proteins and functions required for replication are supplied in the form of wild type virus, helper virus, viral extracts, synthetic cDNAs or RNAs that express the viral proteins are introduced into the host cell via infection or transfection. This infection/transfection takes place prior to or simultaneous to the introduction of the synthetic cDNAs or RNAs encoding the chimeric virus.

In a particularly desirable approach, cells engineered to express all viral genes of the recombinant or chimeric virus of the invention may result in the production of infectious chimeric virus that contain the desired genotype; thus eliminating the need for a selection system. Theoretically, one can replace any one of the six genes or part of any one of the six genes encoding structural proteins of PIV with a foreign sequence. However, a necessary part of this equation is the ability to propagate the defective virus (defective because a normal viral gene product is missing or altered). A number of possible approaches are available to circumvent this problem. In one approach, a virus having a mutant protein can be grown in cell lines that are constructed to constitutively express the wild type version of the same protein. By this way, the cell line complements the mutation in the virus. Similar techniques may be used to construct transformed cell lines that constitutively express any of the PIV genes. These cell lines which are made to express the viral protein may be used to complement the defect in the recombinant virus and thereby propagate it. Alternatively, certain natural host range systems may be available to propagate recombinant virus.

In yet another embodiment, viral proteins and functions required for replication may be supplied as genetic material in the form of synthetic cDNAs or RNAs so that they are co-transcribed with the synthetic cDNAs or RNAs encoding the chimeric virus. In a particularly desirable approach, plasmids that express the chimeric virus and the viral polymerase and/or

- other viral functions are co-transfected into host cells. For example, plasmids encoding the genomic or antigenomic PIV RNA, either wild type or modified, may be co-transfected into host cells with plasmids encoding the PIV viral polymerase proteins NP or N, P, M2-1 or L.
- 5 Alternatively, rescue of chimeric b/h PIV3 virus may be accomplished by the use of Modified Vaccinia Virus Ankara (MVA) encoding T7 RNA polymerase, or a combination of MVA and plasmids encoding the polymerase proteins (N, P, and L). For example, MVA-T7 or Fowl Pox-T7 can be infected into Vero cells, LLC-MK-2 cells, Hep-2 cells, LF 1043 (HEL) cells, tMK cells, LLC-MK2, HUT 292, FRHL-2 (rhesus), FCL-1 (green monkey), WI-38
- 10 (human), MRC-5 (human) cells, 293 T cells, QT 6 cells, QT 35 cells and CEF cells. After infection with MVA-T7 or Fow Pox-T7, a full length antigenomic b/h PIV3 cDNA may be transfected into the HeLa or Vero cells together with the NP, P, M2-1 and L encoding expression plasmids. Alternatively, the polymerase may be provided by plasmid transfection. The cells and cell supernatant can subsequently be harvested and subjected to a single freeze-
- 15 thaw cycle. The resulting cell lysate may then be used to infect a fresh HeLa or Vero cell monolayer in the presence of 1-beta-D-arabinofuranosylcytosine (ara C), a replication inhibitor of vaccinia virus, to generate a virus stock. The supernatant and cells from these plates can then be harvested, freeze-thawed once, and the presence of bPIV3 virus particles detected by immunostaining of virus plaques using PIV3-specific antiserum.
- 20 Another approach to propagating the recombinant virus involves co-cultivation with wild-type virus. This could be done by simply taking recombinant virus and co-infecting cells with this and another wild-type virus (preferably a vaccine strain). The wild-type virus should complement for the defective virus gene product and allow growth of both the wild-type and recombinant virus. Alternatively, a helper virus may be used to support propagation
- 25 of the recombinant virus.

- In another approach, synthetic templates may be replicated in cells co-infected with recombinant viruses that express the PIV virus polymerase protein. In fact, this method may be used to rescue recombinant infectious virus in accordance with the invention. To this end, the PIV polymerase protein may be expressed in any expression vector/host cell system,
- 30 including but not limited to viral expression vectors (*e.g.*, vaccinia virus, adenovirus, baculovirus, etc.) or cell lines that express a polymerase protein (*e.g.*, see Krystal *et al.*, 1986,

Proc. Natl. Acad. Sci. USA 83: 2709-2713). Moreover, infection of host cells expressing all six PIV proteins may result in the production of infectious chimeric virus particles. It should be noted that it may be possible to construct a recombinant virus without altering virus viability. These altered viruses would then be growth competent and would not need helper functions to replicate.

5.4. ATTENUATION OF RECOMBINANT VIRUSES

The recombinant viruses of the invention can be further genetically engineered to exhibit an attenuated phenotype. In particular, the recombinant viruses of the invention exhibit an attenuated phenotype in a subject to which the virus is administered as a vaccine. Attenuation can be achieved by any method known to a skilled artisan. Without being bound by theory, the attenuated phenotype of the recombinant virus can be caused, *e.g.*, by using a virus that naturally does not replicate well in an intended host (*e.g.*, using a bovine PIV3 vector in human), by reduced replication of the viral genome, by reduced ability of the virus to infect a host cell, or by reduced ability of the viral proteins to assemble to an infectious viral particle relative to the wild type strain of the virus. The viability of certain sequences of the virus, such as the leader and the trailer sequence can be tested using a minigenome assay (*see* section 5.5.1).

The attenuated phenotypes of a recombinant virus of the invention can be tested by any method known to the artisan (*see, e.g.*, section 5.5). A candidate virus can, for example, be tested for its ability to infect a host or for the rate of replication in a cell culture system. In certain embodiments, a mini-genome system is used to test the attenuated virus when the gene that is altered is N, P, L, M2 or a combination thereof. In certain embodiments, growth curves at different temperatures are used to test the attenuated phenotype of the virus. For example, an attenuated virus is able to grow at 35°C, but not at 39°C or 40°C. In certain embodiments, different cell lines can be used to evaluate the attenuated phenotype of the virus. For example, an attenuated virus may only be able to grow in monkey cell lines but not the human cell lines, or the achievable virus titers in different cell lines are different for the attenuated virus. In certain embodiments, viral replication in the respiratory tract of a small animal model, including but not limited to, hamsters, cotton rats, mice and guinea pigs,

is used to evaluate the attenuated phenotypes of the virus. In other embodiments, the immune response induced by the virus, including but not limited to, the antibody titers (*e.g.*, assayed by plaque reduction neutralization assay or ELISA) is used to evaluate the attenuated phenotypes of the virus. In a specific embodiment, the plaque reduction neutralization assay or ELISA is carried out at a low dose. In certain embodiments, the ability of the recombinant virus to elicit pathological symptoms in an animal model can be tested. A reduced ability of the virus to elicit pathological symptoms in an animal model system is indicative of its attenuated phenotype. In a specific embodiment, the candidate viruses are tested in a monkey model for nasal infection, indicated by mucous production.

The viruses of the invention can be attenuated such that one or more of the functional characteristics of the virus are impaired. In certain embodiments, attenuation is measured in comparison to the wild type strain of the virus from which the attenuated virus is derived. In other embodiments, attenuation is determined by comparing the growth of an attenuated virus in different host systems. Thus, for a non-limiting example, a bovine PIV3 is said to be attenuated when grown in a human host if the growth of the bovine PIV3 in the human host is reduced compared to the growth of the bovine PIV3 in a bovine host.

In certain embodiments, the attenuated virus of the invention is capable of infecting a host, is capable of replicating in a host such that infectious viral particles are produced. In comparison to the wild type strain, however, the attenuated strain grows to lower titers or grows more slowly. Any technique known to the skilled artisan can be used to determine the growth curve of the attenuated virus and compare it to the growth curve of the wild type virus. For exemplary methods see Example section, *infra*. In a specific embodiment, the attenuated virus grows to a titer of less than 10^5 pfu/ml, of less than 10^4 pfu/ml, of less than 10^3 pfu/ml, or of less than 10^2 pfu/ml in Vero cells under conditions as described.

In certain embodiments, the attenuated virus of the invention (*e.g.*, a chimeric PIV3) cannot replicate in human cells as well as the wild type virus (*e.g.*, wild type PIV3) does. However, the attenuated virus can replicate well in a cell line that lack interferon functions, such as Vero cells.

In other embodiments, the attenuated virus of the invention is capable of infecting a host, of replicating in the host, and of causing proteins of the virus of the invention to be

inserted into the cytoplasmic membrane, but the attenuated virus does not cause the host to produce new infectious viral particles. In certain embodiments, the attenuated virus infects the host, replicates in the host, and causes viral proteins to be inserted in the cytoplasmic
5 membrane of the host with the same efficiency as the wild type mammalian virus. In other embodiments, the ability of the attenuated virus to cause viral proteins to be inserted into the cytoplasmic membrane into the host cell is reduced compared to the wild type virus. In certain embodiments, the ability of the attenuated mammalian virus to replicate in the host is reduced compared to the wild type virus. Any technique known to the skilled artisan can be
10 used to determine whether a virus is capable of infecting a mammalian cell, of replicating within the host, and of causing viral proteins to be inserted into the cytoplasmic membrane of the host. For illustrative methods see section 5.5.

In certain embodiments, the attenuated virus of the invention is capable of infecting a host. In contrast to a wild type PIV, however, the attenuated PIV cannot be replicated in the
15 host. In a specific embodiment, the attenuated virus can infect a host and can cause the host to insert viral proteins in its cytoplasmic membranes, but the attenuated virus is incapable of being replicated in the host. Any method known to the skilled artisan can be used to test whether the attenuated virus has infected the host and has caused the host to insert viral proteins in its cytoplasmic membranes.

20 In certain embodiments, the ability of the attenuated mammalian virus to infect a host is reduced compared to the ability of the wild type virus to infect the same host. Any technique known to the skilled artisan can be used to determine whether a virus is capable of infecting a host. For illustrative methods see section 5.5.

In certain embodiments, mutations (*e.g.*, missense mutations) are introduced into the
25 genome of the virus to generate a virus with an attenuated phenotype. Mutations (*e.g.*, missense mutations) can be introduced into the N-gene, the P-gene, the F-gene, the M2-gene, the M2-1-gene, the M2-2-gene, the SH-gene, the G-gene or the L-gene of the recombinant virus. Mutations can be additions, substitutions, deletions, or combinations thereof. In specific embodiments, a single amino acid deletion mutation for the N, P, L or M2 proteins
30 are introduced, which can be screened for functionality in the mini-genome assay system and be evaluated for predicted functionality in the virus. In more specific embodiments, the

missense mutation is a cold-sensitive mutation. In other embodiments, the missense mutation is a heat-sensitive mutation. In one embodiment, major phosphorylation sites of P protein of the virus is removed. In another embodiment, a mutation or mutations are
5 introduced into the L gene of the virus to generate a temperature sensitive strain. In yet another embodiment, the cleavage site of the F gene is mutated in such a way that cleavage does not occur or occurs at very low efficiency.

In other embodiments, deletions are introduced into the genome of the recombinant virus. In more specific embodiments, a deletion can be introduced into the N-gene, the P-
10 gene, the F-gene, the M2-gene, the M2-1-gene, the M2-2-gene, the SH-gene, the G-gene or the L-gene of the recombinant virus. In specific embodiments, the deletion is in the M2-gene of the recombinant virus of the present invention. In other specific embodiments, the deletion is in the SH-gene of the recombinant virus of the present invention. In yet another specific embodiment, both the M2-gene and the SH-gene are deleted.

15 In certain embodiments, the intergenic region of the recombinant virus is altered. In one embodiment, the length of the intergenic region is altered. See Section 5.1.2. for illustrative examples. In another embodiment, the intergenic regions are shuffled from 5' to 3' end of the viral genome.

In other embodiments, the genome position of a gene or genes of the recombinant
20 virus is changed. In one embodiment, the F or G gene is moved to the 3' end of the genome. In another embodiment, the N gene is moved to the 5' end of the genome.

In certain embodiments, attenuation of the virus is achieved by replacing a gene of the wild type virus with a gene of a virus of a different species. In illustrative embodiments, the N-gene, the P-gene, the F-gene, the M2-gene, the M2-1-gene, the M2-2-gene, the SH-gene,
25 the HN-gene or the L-gene of bPIV3 is replaced with the N-gene, the P-gene, the F-gene, the M2-gene, the M2-1-gene, the M2-2-gene, the SH-gene, the HN-gene or the L-gene, respectively, of hPIV3. In other illustrative embodiments, the N-gene, the P-gene, the F-gene, the M2-gene, the M2-1-gene, the M2-2-gene, the SH-gene, the HN-gene or the L-gene of hPIV3 is replaced with the N-gene, the P-gene, the F-gene, the M2-gene, the M2-1-gene,
30 the M2-2-gene, the SH-gene, the HN-gene or the L-gene, respectively, of bPIV3. In a

preferred embodiment, attenuation of the virus is achieved by replacing one or more polymerase associated genes (*e.g.*, N, P, L or M2) with genes of a virus of a different species.

In certain embodiments, attenuation of the virus is achieved by replacing or deleting
5 one or more specific domains of a protein of the wild type virus with domains derived from the corresponding protein of a virus of a different species. In an illustrative embodiment, the ectodomain of a F protein of bPIV3 is replaced with an ectodomain of a F protein of a metapneumovirus. In a preferred embodiment, one or more specific domains of L, N, or P
10 protein are replaced with domains derived from corresponding proteins of a virus of a different species. In another illustrative embodiment, the transmembrane domain of the F protein is deleted so that a soluble F protein is expressed.

In certain embodiments of the invention, the leader and/or trailer sequence of the recombinant virus of the invention can be modified to achieve an attenuated phenotype. In certain, more specific embodiments, the leader and/or trailer sequence is reduced in length
15 relative to the wild type virus by at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides or at least 6 nucleotides. In certain other, more specific embodiments, the sequence of the leader and/or trailer of the recombinant virus is mutated. In a specific embodiment, the leader and the trailer sequence are 100% complementary to each other. In other embodiments, 1 nucleotide, 2 nucleotides, 3
20 nucleotides, 4 nucleotides, 5 nucleotides, 6 nucleotides, 7 nucleotides, 8 nucleotides, 9 nucleotides, or 10 nucleotides are not complementary to each other where the remaining nucleotides of the leader and the trailer sequences are complementary to each other. In certain embodiments, the non-complementary nucleotides are identical to each other. In certain other embodiments, the non-complementary nucleotides are different from each other.
25 In other embodiments, if the non-complementary nucleotide in the trailer is purine, the corresponding nucleotide in the leader sequence is also a purine. In other embodiments, if the non-complementary nucleotide in the trailer is pyrimidine, the corresponding nucleotide in the leader sequence is also a purine.

When a live attenuated vaccine is used, its safety must also be considered. The
30 vaccine must not cause disease. Any techniques known in the art that can make a vaccine safe may be used in the present invention. In addition to attenuation techniques, other

techniques may be used. One non-limiting example is to use a soluble heterologous gene that cannot be incorporated into the virion membrane. For example, a single copy of the soluble RSV F gene, a version of the RSV gene lacking the transmembrane and cytosolic domains, can be used. Since it cannot be incorporated into the virion membrane, the virus tropism is not expected to change.

Various assays can be used to test the safety of a vaccine. *See* section 5.5., *infra*. Particularly, sucrose gradients and neutralization assays can be used. A sucrose gradient assay can be used to determine whether a heterologous protein is inserted in a virion. If the heterologous protein is inserted in the virion, the virion should be tested for its ability to cause symptoms even if the parental strain does not cause symptoms. Without bound by theory, if the heterologous protein is incorporated in the virion, the virus may have acquired new, possibly pathological, properties.

5.5. MEASUREMENT OF VIRAL TITER, EXPRESSION OF ANTIGENIC SEQUENCES, IMMUNOGENICITY AND OTHER CHARACTERISTICS OF CHIMERIC VIRUSES

A number of assays may be employed in accordance with the present invention in order to determine the rate of growth of a chimeric or recombinant virus in a cell culture system, an animal model system or in a subject. A number of assays may also be employed in accordance with the present invention in order to determine the requirements of the chimeric and recombinant viruses to achieve infection, replication and packaging of virions.

The assays described herein may be used to assay viral titre over time to determine the growth characteristics of the virus. In a specific embodiment, the viral titre is determined by obtaining a sample from the infected cells or the infected subject, preparing a serial dilution of the sample and infecting a monolayer of cells that are susceptible to infection with the virus at a dilution of the virus that allows for the emergence of single plaques. The plaques can then be counted and the viral titre express as plaque forming units per milliliter of sample. In a specific embodiment of the invention, the growth rate of a virus of the invention in a subject is estimated by the titer of antibodies against the virus in the subject. Without being bound by theory, the antibody titer in the subject reflects not only the viral

titer in the subject but also the antigenicity. If the antigenicity of the virus is constant, the increase of the antibody titer in the subject can be used to determine the growth curve of the virus in the subject. In a preferred embodiment, the growth rate of the virus in animals or humans is best tested by sampling biological fluids of a host at multiple time points post-infection and measuring viral titer.

The expression of heterologous gene sequence in a cell culture system or in a subject can be determined by any technique known to the skilled artisan. In certain embodiments, the expression of the heterologous gene is measured by quantifying the level of the transcript. The level of the transcript can be measured by Northern blot analysis or by RT-PCR using probes or primers, respectively, that are specific for the transcript. The transcript can be distinguished from the genome of the virus because the virus is in the antisense orientation whereas the transcript is in the sense orientation. In certain embodiments, the expression of the heterologous gene is measured by quantifying the level of the protein product of the heterologous gene. The level of the protein can be measured by Western blot analysis using antibodies that are specific to the protein.

In a specific embodiment, the heterologous gene is tagged with a peptide tag. The peptide tag can be detected using antibodies against the peptide tag. The level of peptide tag detected is representative for the level of protein expressed from the heterologous gene. Alternatively, the protein expressed from the heterologous gene can be isolated by virtue of the peptide tag. The amount of the purified protein correlates with the expression level of the heterologous gene. Such peptide tags and methods for the isolation of proteins fused to such a peptide tag are well known in the art. A variety of peptide tags known in the art may be used in the modification of the heterologous gene, such as, but not limited to, the immunoglobulin constant regions, polyhistidine sequence (Petty, 1996, Metal-chelate affinity chromatography, in Current Protocols in Molecular Biology, volume 1-3 (1994-1998). Ed. by Ausubel, F.M., Brent, R., Kunston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. Published by John Wiley and sons, Inc., USA, Greene Publish. Assoc. & Wiley Interscience), glutathione S-transferase (GST; Smith, 1993, Methods Mol. Cell Bio. 4:220-229), the *E. coli* maltose binding protein (Guan et al., 1987, Gene 67:21-30), various cellulose binding domains (U.S. patent 5,496,934; 5,202,247; 5,137,819; Tomme et al.,

- 1994, Protein Eng. 7:117-123), and the FLAG epitope (Short Protocols in Molecular Biology, 1999, Ed. Ausubel et al., John Wiley & Sons, Inc., Unit 10.11) etc. Other peptide tags are recognized by specific binding partners and thus facilitate isolation by affinity
- 5 binding to the binding partner, which is preferably immobilized and/or on a solid support. As will be appreciated by those skilled in the art, many methods can be used to obtain the coding region of the above-mentioned peptide tags, including but not limited to, DNA cloning, DNA amplification, and synthetic methods. Some of the peptide tags and reagents for their detection and isolation are available commercially.
- 10 Samples from a subject can be obtained by any method known to the skilled artisan. In certain embodiments, the sample consists of nasal aspirate, throat swab, sputum or broncho-alveolar lavage.

5.5.1. MINIGENOME CONSTRUCTS

- 15 Minireplicon constructs can be generated to contain an antisense reporter gene. Any reporter gene known to the skilled artisan can be used with the invention. In a specific embodiment, the reporter gene is CAT. In certain embodiments, the reporter gene can be flanked by the negative-sense bPIV or hPIV leader linked to the hepatitis delta ribozyme (Hep-d Ribo) and T7 polymerase termination (T-T7) signals, and the bPIV or hPIV trailer
- 20 sequence preceded by the T7 RNA polymerase promoter.
- In certain embodiments, the plasmid encoding the minireplicon is transfected into a host cell. The host cell expresses T7 RNA polymerase, the N gene, the P gene, the L gene, and the M2.1 gene. In certain embodiments, the host cell is transfected with plasmids encoding T7 RNA polymerase, the N gene, the P gene, the L gene, and the M2.1 gene. In
- 25 other embodiments, the plasmid encoding the minireplicon is transfected into a host cell and the host cell is infected with a helper virus.

The expression level of the reporter gene and/or its activity can be assayed by any method known to the skilled artisan, such as, but not limited to, the methods described in section 5.5.6.

- 30 In certain, more specific, embodiments, the minireplicon comprises the following elements, in the order listed: T7 RNA Polymerase or RNA polymerase I, leader sequence,

gene start, GFP, trailer sequence, Hepatitis delta ribozyme sequence or RNA polymerase I termination sequence. If T7 is used as RNA polymerase, Hepatitis delta ribozyme sequence should be used as termination sequence. If RNA polymerase I is used, RNA polymerase I termination sequence may be used as a termination signal. Dependent on the rescue system, the sequence of the minireplicon can be in the sense or antisense orientation. In certain embodiments, the leader sequence can be modified relative to the wild type leader sequence of the virus of the invention. The leader sequence can optionally be preceded by an AC. The T7 promoter sequence can be with or without a G-doublet or triplet, where the G-doublet or triplet provides for increased transcription.

In a specific embodiment, a cell is infected with a virus of the invention at T₀. 24 hours later, at T₂₄, the cell is transfected with a minireplicon construct. 48 hours after T₀ and 72 hours after T₀, the cells are tested for the expression of the reporter gene. If a fluorescent reporter gene product is used (*e.g.*, GFP), the expression of the reporter gene can be tested using FACS.

In another embodiment, a cell is transfected with six plasmids at T=0 hours. Cells are then harvested at T=40 hours and T=60 hours and analyzed for CAT or GFP expression.

In another specific embodiment, a cell is infected with MVA-T7 at T₀. 1 hour later, at T₁, the cell is transfected with a minireplicon construct. 24 hours after T₀, the cell is infected with a virus of the invention. 72 hours after T₀, the cells are tested for the expression of the reporter gene. If a fluorescent reporter gene product is used (*e.g.*, GFP), the expression of the reporter gene can be tested using FACS.

5.5.2. MEASUREMENT OF INCIDENCE OF INFECTION RATE

The incidence of infection can be determined by any method well-known in the art, including but not limited to, the testing of clinical samples (*e.g.*, nasal swabs) for the presence of an infection, *e.g.*, hMPV, RSV, hPIV, or bPIV/hPIV components can be detected by immunofluorescence assay (IFA) using an anti-hMPV-antigen antibody, an anti-RSV-antigen antibody, an anti-hPIV-antigen antibody, and/or an antibody that is specific to the gene product of the heterologous nucleotide sequence, respectively.

In certain embodiments, samples containing intact cells can be directly processed,

whereas isolates without intact cells should first be cultured on a permissive cell line (e.g. HEp-2 cells). In an illustrative embodiment, cultured cell suspensions are cleared by centrifugation at, e.g., 300xg for 5 minutes at room temperature, followed by a PBS, pH 7.4 (Ca⁺⁺ and Mg⁺⁺ free) wash under the same conditions. Cell pellets are resuspended in a small volume of PBS for analysis. Primary clinical isolates containing intact cells are mixed with PBS and centrifuged at 300xg for 5 minutes at room temperature. Mucus is removed from the interface with a sterile pipette tip and cell pellets are washed once more with PBS under the same conditions. Pellets are then resuspended in a small volume of PBS for analysis. Five to ten microliters of each cell suspension are spotted per 5 mm well on acetone washed 12-well HTC supercured glass slides and allowed to air dry. Slides are fixed in cold (-20°C) acetone for 10 minutes. Reactions are blocked by adding PBS - 1% BSA to each well followed by a 10 minute incubation at room temperature. Slides are washed three times in PBS - 0.1% Tween-20 and air dried. Ten microliters of each primary antibody reagent diluted to 250 ng/ml in blocking buffer is spotted per well and reactions are incubated in a humidified 37°C environment for 30 minutes. Slides are then washed extensively in three changes of PBS - 0.1% Tween-20 and air dried. Ten microliters of appropriate secondary conjugated antibody reagent diluted to 250 ng/ml in blocking buffer are spotted per respective well and reactions are incubated in a humidified 37°C environment for an additional 30 minutes. Slides are then washed in three changes of PBS - 0.1% Tween-20. Five microliters of PBS-50% glycerol-10 mM Tris pH 8.0-1 mM EDTA are spotted per reaction well and slides are mounted with cover slips. Each reaction well is subsequently analyzed by fluorescence microscopy at 200X power using a B-2A filter (EX 450-490 nm). Positive reactions are scored against an autofluorescent background obtained from unstained cells or cells stained with secondary reagent alone. RSV positive reactions are characterized by bright fluorescence punctuated with small inclusions in the cytoplasm of infected cells.

5.5.3. MEASUREMENT OF SERUM TITER

Antibody serum titer can be determined by any method well-known in the art, for example, but not limited to, the amount of antibody or antibody fragment in serum samples can be quantitated by a sandwich ELISA. Briefly, the ELISA consists of coating microtiter

plates overnight at 4°C with an antibody that recognizes the antibody or antibody fragment in the serum. The plates are then blocked for approximately 30 minutes at room temperature with PBS-Tween-0.5% BSA. Standard curves are constructed using purified antibody or antibody fragment diluted in PBS-BSA-BSA, and samples are diluted in PBS-BSA. The samples and standards are added to duplicate wells of the assay plate and are incubated for approximately 1 hour at room temperature. Next, the non-bound antibody is washed away with PBS-TWEEN and the bound antibody is treated with a labeled secondary antibody (e.g., horseradish peroxidase conjugated goat-anti-human IgG) for approximately 1 hour at room temperature. Binding of the labeled antibody is detected by adding a chromogenic substrate specific for the label and measuring the rate of substrate turnover, e.g., by a spectrophotometer. The concentration of antibody or antibody fragment levels in the serum is determined by comparison of the rate of substrate turnover for the samples to the rate of substrate turnover for the standard curve.

15

5.5.4. CHALLENGE STUDIES

This assay is used to determine the ability of the recombinant viruses of the invention and of the vaccines of the invention to prevent lower respiratory tract viral infection in an animal model system, including but not limited to, cotton rats, Syrian Golden hamsters, and Balb/c mice. The recombinant virus and/or the vaccine can be administered by intravenous (IV) route, by intramuscular (IM) route or by intranasal route (IN). The recombinant virus and/or the vaccine can be administered by any technique well-known to the skilled artisan. This assay is also used to correlate the serum concentration of antibodies with a reduction in lung titer of the virus to which the antibodies bind.

On day 0, groups of animals, including but not limited to, cotton rats (*Sigmodon hispidus*, average weight 100 g) and hamsters (e.g., Syrian Golden hamsters) are inoculated with the recombinant virus or the vaccine of interest or BSA by intramuscular injection, by intravenous injection, or by intranasal route. Prior to, concurrently with, or subsequent to administration of the recombinant virus or the vaccine of the invention, the animals are infected with wild type virus wherein the wild type virus is the virus against which the vaccine was generated. In certain embodiments, the animals are infected with the wild type

virus at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks or at least 4 weeks subsequent to the administration of the recombinant virus and/or the vaccine of the invention. In a preferred
5 embodiment, the animals are infected with the wild type virus 21 days subsequent to the administration of the recombinant virus and/or the vaccine of the invention. In another preferred embodiment, the animals are infected with the wild type virus 28 days subsequent to the administration of the recombinant virus and/or the vaccine of the invention.

After the infection, the animals are sacrificed, and their nasal turbinate tissue and/or
10 lung tissue are harvested and virus titers are determined by appropriate assays, *e.g.*, plaque assay and TCID₅₀ assay. Bovine serum albumin (BSA) 10 mg/kg can be used as a negative control. Antibody concentrations in the serum at the time of challenge can be determined using a sandwich ELISA.

15 5.5.5. CLINICAL TRIALS

Vaccines of the invention or fragments thereof that have been tested in *in vitro* assays and animal models may be further evaluated for safety, tolerance, immunogenicity, infectivity and pharmacokinetics in groups of normal healthy human volunteers, including all age groups. In a preferred embodiment, the healthy human volunteers are infants at about 6
20 weeks of age or older, children and adults. The volunteers are administered intranasally, intramuscularly, intravenously or by a pulmonary delivery system in a single dose of a recombinant virus of the invention and/or a vaccine of the invention. Multiple doses of virus and/or vaccine of the invention may be required in seronegative children 6 to 60 months of age. Multiple doses of virus and/or vaccine of the invention may also be required in the first
25 six months of life to stimulate local and systemic immunity and to overcome neutralization by maternal antibody. In a preferred embodiment, a primary dosing regimen at 2, 4, and 6 months of age and a booster dose at the beginning of the second year of life are used. A recombinant virus of the invention and/or a vaccine of the invention can be administered alone or concurrently with pediatric vaccines recommended at the corresponding ages.

30 In a preferred embodiment, double-blind randomized, placebo-controlled clinical trials are used. In a specific embodiment, a computer generated randomization schedule is

used. For example, each subject in the study will be enrolled as a single unit and assigned a unique case number. Multiple subjects within a single family will be treated as individuals for the purpose of enrollment. Parent/guardian, subjects, and investigators will remain
5 blinded to which treatment group subjects have been assigned for the duration of the study. Serologic and virologic studies will be performed by laboratory personnel blinded to treatment group assignment. However, it is expected that isolation of the vaccine virus from nasal wash fluid obtained after vaccination will identify likely vaccinees to the virology laboratory staff. The serologic and virologic staff are separate and the serology group will be
10 prevented from acquiring any knowledge of the culture results.

Each volunteer is preferably monitored for at least 12 hours prior to receiving the recombinant virus of the invention and/or a vaccine of the invention, and each volunteer will be monitored for at least fifteen minutes after receiving the dose at a clinical site. Then volunteers are monitored as outpatients on days 1-14, 21, 28, 35, 42, 49, and 56 postdose. In
15 a preferred embodiment, the volunteers are monitored for the first month after each vaccination as outpatients. All vaccine related serious adverse events will be reported for the entire duration of the trial. A serious adverse event is defined as an event that 1) results in death, 2) is immediately life threatening, 3) results in permanent or substantial disability, 4) results in or prolongs an existing in-patient hospitalization, 5) results in a congenital
20 anomaly, 6) is a cancer, or 7) is the result of an overdose of the study vaccine. Serious adverse events that are not vaccine related will be reported beginning on the day of the first vaccination (Day 0) and continue for 30 days following the last vaccination. Non-vaccine related serious adverse events will not be reported for 5 to 8 months after the 30 day reporting period following the last vaccination. A dose of vaccine/placebo will not be given
25 if a child has a vaccine-related serious adverse event following the previous dose. Any adverse event that is not considered vaccine related, but which is of concern, will be discussed by the clinical study monitor and the medical monitor before the decision to give another dose is made.

Blood samples are collected via an indwelling catheter or direct venipuncture (e.g., by
30 using 10 ml red-top Vacutainer tubes) at the following intervals: (1) prior to administering the dose of the recombinant virus of the invention and/or a vaccine of the invention; (2)

during the administration of the dose of the recombinant virus of the invention and/or a vaccine of the invention; (3) 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, and 48 hours after administering the dose of the recombinant virus of the invention and/or a vaccine of the invention; and (4) 3 days, 7 days 14 days, 21 days, 28 days, 35 days, 42 days, 49 days, and 56 days after administering the dose of the recombinant virus of the invention and/or a vaccine of the invention. In a specific embodiment, a total of 5 blood draws (3-5 ml each) are obtained, each just prior to the first, third and booster doses and approximately one month following the third dose and booster dose of administration of the vaccine or placebo. Samples are allowed to clot at room temperature and the serum is collected after centrifugation.

Sera are tested for strain-specific serum hemagglutination inhibition (HAI) antibody levels against the virus of the invention. Other indicators of immunogenicity such as IgG, IgA, or neutralizing antibodies are also tested. Serum antibody responses to one or more of the other vaccines given concurrently may be measured. The amount of antibodies generated against the recombinant virus of the invention and/or a vaccine of the invention in the samples from the patients can be quantitated by ELISA.

The concentration of antibody levels in the serum of volunteers are corrected by subtracting the predose serum level (background level) from the serum levels at each collection interval after administration of the dose of recombinant virus of the invention and/or a vaccine of the invention. For each volunteer the pharmacokinetic parameters are computed according to the model-independent approach (Gibaldi *et al.*, eds., 1982, *Pharmacokinetics*, 2nd edition, Marcel Dekker, New York) from the corrected serum antibody or antibody fragment concentrations.

Nasal washes obtained approximately 2, 3, 4, 5, 6, 7 or 8 days after each doses of vaccine/placebo will be cultured to detect shedding of the vaccine virus of the invention. In a preferred embodiment, nasal washes obtained 7 days after each doses of vaccine/placebo are cultured. A nasopharyngeal swab, a throat swab, or a nasal wash is also used to determine the presence of other viruses in volunteers with medically attended febrile illness (rectal temperature greater than or equal to 102° F) and/or croup, bronchiolitis, or pneumonia at any time during the study. Samples are shipped on dry ice to designated site for study. Assays

for isolation and quantitation of the vaccine virus of the invention and immunostaining assays using MAb to identify the vaccine virus of the invention are used (examples of such assays are given in the Example sections, *infra*). Nasal wash specimens may be tested for
5 other viruses and immune responses including IgG, IgA, and neutralizing antibody.

5.5.6. REPORTER GENES

In certain embodiments, assays for measurement of reporter gene expression in tissue culture or in animal models can be used with the methods of the invention. The nucleotide
10 sequence of the reporter gene is cloned into the virus, such as bPIV, hPIV, or b/hPIV3, wherein (i) the position of the reporter gene is changed and (ii) the length of the intergenic regions flanking the reporter gene are varied. Different combinations are tested to determine the optimal rate of expression of the reporter gene and the optimal replication rate of the virus comprising the reporter gene.

15 In certain embodiments, minigenome constructs are generated to include a reporter gene. The construction of minigenome constructs is described in section 5.5.1.

The abundance of the reporter gene product can be determined by any technique known to the skilled artisan. Such techniques include, but are not limited to, Northern blot analysis or Western blot analysis using probes or antibodies, respectively, that are specific to
20 the reporter gene.

In certain embodiments, the reporter gene emits a fluorescent signal that can be detected in a FACS. FACS can be used to detect cells in which the reporter gene is expressed.

Techniques for practicing the specific aspect of this invention will employ, unless
25 otherwise indicated, conventional techniques of molecular biology, microbiology, and recombinant DNA manipulation and production, which are routinely practiced by one of skill in the art. See, e.g., Sambrook, 1989, Molecular Cloning, A Laboratory Manual, Second Edition; DNA Cloning, Volumes I and II (Glover, Ed. 1985); and Transcription and Translation (Hames & Higgins, Eds. 1984).

30 The biochemical activity of the reporter gene product represents the expression level of the reporter gene. The total level of reporter gene activity depends also on the replication

rate of the recombinant virus of the invention. Thus, to determine the true expression level of the reporter gene from the recombinant virus, the total expression level should be divided by the titer of the recombinant virus in the cell culture or the animal model.

- 5 Reporter genes that can be used with the methods of invention include, but are not limited to, the genes listed in the Table 4 below:

Table 4: Reporter genes and the biochemical properties of the respective reporter gene products

10	Reporter Gene	Protein Activity & Measurement
	CAT (chloramphenicol acetyltransferase)	Transfers radioactive acetyl groups to chloramphenicol or detection by thin layer chromatography and autoradiography
	GAL (b-galactosidase)	Hydrolyzes colorless galactosides to yield colored products.
15	GUS (b-glucuronidase)	Hydrolyzes colorless glucuronides to yield colored products.
	LUC (luciferase)	Oxidizes luciferin, emitting photons
	GFP (green fluorescent protein)	fluorescent protein without substrate
20	SEAP (secreted alkaline phosphatase)	luminescence reaction with suitable substrates or with substrates that generate chromophores
	HRP (horseradish peroxidase)	in the presence of hydrogen oxide, oxidation of 3,3',5,5'-tetramethylbenzidine to form a colored complex
25	AP (alkaline phosphatase)	luminescence reaction with suitable substrates or with substrates that generate chromophores

- 30 The abundance of the reporter gene can be measured by, *inter alia*, Western blot analysis or Northern blot analysis or any other technique used for the quantification of transcription of a nucleotide sequence, the abundance of its mRNA its protein (see Short

Protocols in Molecular Biology, Ausubel *et al.* (editors), John Wiley & Sons, Inc., 4th edition, 1999). In certain embodiments, the activity of the reporter gene product is measured as a readout of reporter gene expression from the recombinant virus. For the quantification of the activity of the reporter gene product, biochemical characteristics of the reporter gene product can be investigated (see Table 1). The methods for measuring the biochemical activity of the reporter gene products are well-known to the skilled artisan. A more detailed description of illustrative reporter genes that can be used with the methods of the invention is set forth below.

10

LUCIFERASE

Luciferases are enzymes that emit light in the presence of oxygen and a substrate (luciferin) and which have been used for real-time, low-light imaging of gene expression in cell cultures, individual cells, whole organisms, and transgenic organisms (reviewed by Greer & Szalay, 2002, *Luminescence* 17(1):43-74).

As used herein, the term "luciferase" as used in relation to the invention is intended to embrace all luciferases, or recombinant enzymes derived from luciferases that have luciferase activity. The luciferase genes from fireflies have been well characterized, for example, from the *Photinus* and *Luciola* species (see, *e.g.*, International Patent Publication No. WO 95/25798 for *Photinus pyralis*, European Patent Application No. EP 0 524 448 for *Luciola cruciata* and *Luciola lateralis*, and Devine *et al.*, 1993, *Biochim. Biophys. Acta* 1173(2):121-132 for *Luciola mingrelica*. Other eucaryotic luciferase genes include, but are not limited to, the sea pansy (*Renilla reniformis*, see, *e.g.*, Lorenz *et al.*, 1991, *Proc Natl Acad Sci U S A* 88(10):4438-4442), and the glow worm (*Lampyrus noctiluca*, see *e.g.*, Sula-Newby *et al.*, 1996, *Biochem J.* 313:761-767). Bacterial luciferin-luciferase systems include, but are not limited to, the bacterial lux genes of terrestrial *Photorhabdus luminescens* (see, *e.g.*, Manukhov *et al.*, 2000, *Genetika* 36(3):322-30) and marine bacteria *Vibrio fischeri* and *Vibrio harveyi* (see, *e.g.*, Miyamoto *et al.*, 1988, *J Biol Chem.* 263(26):13393-9, and Cohn *et al.*, 1983, *Proc Natl Acad Sci USA.*, 80(1):120-3, respectively). The luciferases encompassed by the present invention also includes the mutant luciferases described in U.S. Patent No. 6,265,177 to Squirrell *et al.*, which is hereby incorporated by reference in its entirety.

GREEN FLUORESCENT PROTEIN

Green fluorescent protein ("GFP") is a 238 amino acid protein with amino acids 65 to 67 involved in the formation of the chromophore that does not require additional substrates or cofactors to fluoresce (see, *e.g.*, Prasher *et al.*, 1992, *Gene* 111:229-233; Yang *et al.*, 1996, *Nature Biotechnol.* 14:1252-1256; and Cody *et al.*, 1993, *Biochemistry* 32:1212-1218).

As used herein, the term "green fluorescent protein" or "GFP" as used in relation to the invention is intended to embrace all GFPs (including the various forms of GFPs that exhibit colors other than green), or recombinant enzymes derived from GFPs that have GFP activity. The native gene for GFP was cloned from the bioluminescent jellyfish *Aequorea victoria* (see, *e.g.*, Morin *et al.*, 1972, *J. Cell Physiol.* 77:313-318). Wild type GFP has a major excitation peak at 395 nm and a minor excitation peak at 470 nm. The absorption peak at 470 nm allows the monitoring of GFP levels using standard fluorescein isothiocyanate (FITC) filter sets. Mutants of the GFP gene have been found useful to enhance expression and to modify excitation and fluorescence. For example, mutant GFPs with alanine, glycine, isoleucine, or threonine substituted for serine at position 65 result in mutant GFPs with shifts in excitation maxima and greater fluorescence than wild type protein when excited at 488 nm (see, *e.g.*, Heim *et al.*, 1995, *Nature* 373:663-664); U.S. Patent No. 5,625,048; Delagrave *et al.*, 1995, *Biotechnology* 13:151-154; Cormack *et al.*, 1996, *Gene* 173:33-38; and Cramer *et al.*, 1996, *Nature Biotechnol.* 14:315-319). The ability to excite GFP at 488 nm permits the use of GFP with standard fluorescence activated cell sorting ("FACS") equipment. In another embodiment, GFPs are isolated from organisms other than the jellyfish, such as, but not limited to, the sea pansy, *Renilla reniformis*.

EGFP is a red-shifted variant of wild-type GFP (3-5) which has been optimized for brighter fluorescence and higher expression in mammalian cells. (Excitation maximum = 488 nm; emission maximum = 507 nm.) EGFP encodes the GFPmut1 variant which contains the double-amino-acid substitution of Phe-64 to Leu and Ser-65 to Thr. The coding sequence of the EGFP gene contains more than 190 silent base changes which correspond to human codon-usage preferences.

BETA GALACTOSIDASE

Beta galactosidase ("β-gal") is an enzyme that catalyzes the hydrolysis of b-galactosides, including lactose, and the galactoside analogs o-nitrophenyl-β-D-galactopyranoside ("ONPG") and chlorophenol red-b-D-galactopyranoside ("CPRG") (see, 5 *e.g.*, Nielsen *et al.*, 1983 Proc Natl Acad Sci USA 80(17):5198-5202; Eustice *et al.*, 1991, Biotechniques 11:739-742; and Henderson *et al.*, 1986, Clin. Chem. 32:1637-1641). The β-gal gene functions well as a reporter gene because the protein product is extremely stable, resistant to proteolytic degradation in cellular lysates, and easily assayed. When ONPG is 10 used as the substrate, β-gal activity can be quantitated with a spectrophotometer or a microplate reader.

As used herein, the term "beta galactosidase" or "β-gal" as used in relation to the invention is intended to embrace all b-gals, including *lacZ* gene products, or recombinant enzymes derived from b-gals which have b-gal activity. The b-gal gene functions well as a 15 reporter gene because the protein product is extremely stable, resistant to proteolytic degradation in cellular lysates, and easily assayed. In an embodiment where ONPG is the substrate, b-gal activity can be quantitated with a spectrophotometer or microplate reader to determine the amount of ONPG converted at 420 nm. In an embodiment when CPRG is the substrate, b-gal activity can be quantitated with a spectrophotometer or microplate reader to 20 determine the amount of CPRG converted at 570 to 595 nm.

CHLORAMPHENICOL ACETYLTRANSFERASE

Chloramphenicol acetyl transferase ("CAT") is commonly used as a reporter gene in mammalian cell systems because mammalian cells do not have detectable levels of CAT 25 activity. The assay for CAT involves incubating cellular extracts with radiolabeled chloramphenicol and appropriate co-factors, separating the starting materials from the product by, for example, thin layer chromatography ("TLC"), followed by scintillation counting (see, *e.g.*, U.S. Patent No. 5,726,041, which is hereby incorporated by reference in its entirety).

30 As used herein, the term "chloramphenicol acetyltransferase" or "CAT" as used in relation to the invention is intended to embrace all CATs, or recombinant enzymes derived from CAT which have CAT activity. While it is preferable that a reporter system which does

not require cell processing, radioisotopes, and chromatographic separations would be more amenable to high through-put screening, CAT as a reporter gene may be preferable in situations when stability of the reporter gene is important. For example, the CAT reporter protein has an *in vivo* half life of about 50 hours, which is advantageous when an accumulative versus a dynamic change type of result is desired.

SECRETED ALKALINE PHOSPHATASE

The secreted alkaline phosphatase ("SEAP") enzyme is a truncated form of alkaline phosphatase, in which the cleavage of the transmembrane domain of the protein allows it to be secreted from the cells into the surrounding media.

As used herein, the term "secreted alkaline phosphatase" or "SEAP" as used in relation to the invention is intended to embrace all SEAP or recombinant enzymes derived from SEAP which have alkaline phosphatase activity. SEAP activity can be detected by a variety of methods including, but not limited to, measurement of catalysis of a fluorescent substrate, immunoprecipitation, HPLC, and radiometric detection. The luminescent method is preferred due to its increased sensitivity over calorimetric detection methods. The advantages of using SEAP is that a cell lysis step is not required since the SEAP protein is secreted out of the cell, which facilitates the automation of sampling and assay procedures. A cell-based assay using SEAP for use in cell-based assessment of inhibitors of the Hepatitis C virus protease is described in U.S. Patent No. 6,280,940 to Potts *et al.* which is hereby incorporated by reference in its entirety.

5.5.7. CELL CULTURE SYSTEMS, EMBRYONATED EGGS, AND ANIMAL MODELS

Cell culture systems known in the art can be used to propagate or test activities of the viruses of the present invention. (See *e.g.*, Flint *et al.*, PRINCIPLES OF VIROLOGY, MOLECULAR BIOLOGY, PATHOGENESIS, AND CONTROL, 2000, ASM Press pp25-29, the entire text is incorporated herein by reference). Examples of such cell culture systems include, but are not limited to, primary cell culture that are prepared from animal tissues (*e.g.*, cell cultures derived from monkey kidney, human embryonic amnion, kidney, and foreskin, and chicken or mouse embryos); diploid cell strains that consist of a homogeneous

population of a single type and can divide up to 100 times before dying (*e.g.*, cell culture derived from human embryos, such as the WI-38 strain derived from human embryonic lung); and continuous cell lines consist of a single cell type that can be propagated indefinitely in culture (*e.g.*, HEp-2 cells, Hela cells, Vero cells, L and 3T3 cells, and BHK-21 cells).

Viruses of the invention can also be propagated in embryonated chicken eggs. At 5 to 14 days after fertilization, a hole is drilled in the shell and virus is injected into the site appropriate for its replication.

Any animal models known in the art can be used in the present invention to accomplish various purposes, such as to determine the effectiveness and safeness of vaccines of the invention. Examples of such animal models include, but are not limited to, cotton rats (*Sigmodon hispidus*), hamsters, mice, monkeys, and chimpanzees. In a preferred embodiment, Syrian Golden hamsters are used.

5.5.8. NEUTRALIZATION ASSAY

Neutralization assays can be carried out to address the important safety issue of whether the heterologous surface glycoproteins are incorporated into the virion which may result in an altered virus tropism phenotype. As used herein, the term "tropism" refers to the affinity of a virus for a particular cell type. Tropism is usually determined by the presence of cell receptors on specific cells which allow a virus to enter that and only that particular cell type. A neutralization assay is performed by using either MAbs of the heterologous surface glycoprotein (non-limiting example is the F protein of a negative strand RNA virus) or polyclonal antiserum comprising antibodies against the heterologous surface glycoprotein. Different dilution of the antibodies are tested to see whether the chimeric virus of the invention can be neutralized. The heterologous surface glycoprotein should not be present on the virion surface in an amount sufficient to result in antibody binding and neutralization.

5.5.9. SUCROSE GRADIENT ASSAY

The question of whether the heterologous proteins are incorporated into the virion can be further investigated by use of a biochemical assay. Infected cell lysates can be fractionated in 20 - 60% sucrose gradients, various fractions are collected and analyzed for

the presence and distribution of heterologous proteins and the vector proteins by Western blot. The fractions and the virus proteins can also be assayed for peak virus titers by plaque assay. Examples of sucrose gradient assay are given in section 23, *infra*. When the
5 heterologous proteins are associated with the virion, they will co-migrate with the virion.

5.6. VACCINE FORMULATIONS USING THE CHIMERIC VIRUSES

The invention encompasses vaccine formulations comprising the engineered negative strand RNA virus of the present invention. The recombinant PIV viruses of the present
10 invention may be used as a vehicle to express foreign epitopes that induce a protective response to any of a variety of pathogens. In a specific embodiment, the invention encompasses the use of recombinant bPIV viruses or attenuated hPIV that have been modified in vaccine formulations to confer protection against hPIV infection.

The vaccine preparations of the invention encompass multivalent vaccines, including
15 bivalent and trivalent vaccine preparations. The bivalent and trivalent vaccines of the invention may be administered in the form of one PIV vector expressing each heterologous antigenic sequence or two or more PIV vectors each encoding different heterologous antigenic sequences. For example, a first chimeric PIV expressing one or more heterologous antigenic sequences can be administered in combination with a second chimeric PIV
20 expressing one or more heterologous antigenic sequences, wherein the heterologous antigenic sequences in the second chimeric PIV are different from the heterologous antigenic sequences in the first chimeric PIV. The heterologous antigenic sequences in the first and the second chimeric PIV can be derived from the same virus but encode different proteins, or derived from different viruses. In a preferred embodiment, the heterologous antigenic
25 sequences in the first chimeric PIV are derived from respiratory syncytial virus, and the heterologous antigenic sequences in the second chimeric PIV are derived from human metapneumovirus. In another preferred embodiment, the heterologous antigenic sequences in the first chimeric PIV are derived from respiratory syncytial virus, and the heterologous antigenic sequences in the second chimeric PIV are derived from avian pneumovirus.

30 In certain preferred embodiments, the vaccine formulation of the invention is used to protect against infections caused by a negative strand RNA virus, including but not limited to, influenza virus, parainfluenza virus, respiratory syncytial virus, and mammalian

metapneumovirus (e.g., human metapneumovirus). More specifically, the vaccine formulation of the invention is used to protect against infections by a human metapneumovirus and/or an avian pneumovirus. In certain embodiments, the vaccine
5 formulation of the invention is used to protect against infections by (a) a human metapneumovirus and a respiratory syncytial virus; and/or (b) an avian pneumovirus and a respiratory syncytial virus.

In a preferred embodiment, the invention provides a proteinaceous molecule or metapneumovirus-specific viral protein or functional fragment thereof encoded by a nucleic
10 acid according to the invention. Useful proteinaceous molecules are for example derived from any of the genes or genomic fragments derivable from a virus according to the invention. Particularly useful are the F, SH and/or G protein or antigenic fragments thereof for inclusion as antigen or subunit immunogen, but inactivated whole virus can also be used. Particularly useful are also those proteinaceous substances that are encoded by recombinant
15 nucleic acid fragments that are identified for phylogenetic analyses, of course preferred are those that are within the preferred bounds and metes of ORFs useful in phylogenetic analyses, in particular for eliciting MPV specific antibody or T cell responses, whether in vivo (e.g. for protective purposes or for providing diagnostic antibodies) or in vitro (e.g. by phage display technology or another technique useful for generating synthetic antibodies).

20 A pharmaceutical composition comprising a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention can for example be used in a method for the treatment or prevention of a MPV infection and/or a respiratory illness comprising providing an individual with a pharmaceutical composition according to the invention. This is most useful when said individual is a human, specifically
25 when said human is below 5 years of age, since such infants and young children are most likely to be infected by a human MPV as provided herein. Generally, in the acute phase patients will suffer from upper respiratory symptoms predisposing for other respiratory and other diseases. Also lower respiratory illnesses may occur, predisposing for more and other serious conditions. The compositions of the invention can be used for the treatment of
30 immuno-compromised individuals including cancer patients, transplant recipients and the elderly.

The invention also provides methods to obtain an antiviral agent useful in the

treatment of respiratory tract illness comprising establishing a cell culture or experimental animal comprising a virus according to the invention, treating said culture or animal with an candidate antiviral agent, and determining the effect of said agent on said virus or its
5 infection of said culture or animal. The invention also provides use of an antiviral agent according to the invention for the preparation of a pharmaceutical composition, in particular for the preparation of a pharmaceutical composition for the treatment of respiratory tract illness, specifically when caused by an MPV infection or related disease, and provides a pharmaceutical composition comprising an antiviral agent according to the invention, useful
10 in a method for the treatment or prevention of an MPV infection or respiratory illness, said method comprising providing an individual with such a pharmaceutical composition.

In certain embodiments of the invention, the vaccine of the invention comprises mammalian metapneumovirus. In certain, more specific embodiments, the mammalian metapneumovirus is a human metapneumovirus. In a preferred embodiment, the mammalian
15 metapneumovirus to be used in a vaccine formulation has an attenuated phenotype. For methods to achieve an attenuated phenotype, see section 5.4.

The invention provides vaccine formulations for the prevention and treatment of infections with PIV, RSV, APV, and/or hMPV. In certain embodiments, the vaccine of the invention comprises recombinant and chimeric viruses of the invention. In certain
20 embodiments, the virus is attenuated.

In a specific embodiment, the vaccine comprises APV and the vaccine is used for the prevention and treatment for hMPV infections in humans. Without being bound by theory, because of the high degree of homology of the F protein of APV with the F protein of hMPV, infection with APV will result in the production of antibodies in the host that will cross-react
25 with hMPV and protect the host from infection with hMPV and related diseases.

In another specific embodiment, the vaccine comprises hMPV and the vaccine is used for the prevention and treatment for APV infection in birds, such as, but not limited to, in turkeys. Without being bound by theory, because of the high degree of homology of the F protein of APV with the F protein of hMPV, infection with hMPV will result in the
30 production of antibodies in the host that will cross-react with APV and protect the host from infection with APV and related diseases.

In certain embodiments, the vaccine formulation of the invention is used to protect

against infections by (a) a human metapneumovirus and a human parainfluenza virus; and/or (b) an avian pneumovirus and a human parainfluenza virus and related diseases.

In certain embodiments, the vaccine formulation of the invention is used to protect
5 against infections by (a) a human metapneumovirus, a respiratory syncytial virus, and a human parainfluenza virus; and/or (b) an avian pneumovirus, a respiratory syncytial virus, and a human parainfluenza virus and related diseases.

In certain embodiments, the vaccine formulation of the invention is used to protect against infections by a human metapneumovirus, a respiratory syncytial virus, and a human
10 parainfluenza virus. In certain other embodiments, the vaccine formulation of the invention is used to protect against infections by an avian pneumovirus, a respiratory syncytial virus, and a human parainfluenza virus, and related diseases.

Due to the high degree of homology among the F proteins of different viral species, for exemplary amino acid sequence comparisons see Figure 1, the vaccine formulations of
15 the invention can be used for protection from viruses different from the one from which the heterologous nucleotide sequence encoding the F protein was derived. In a specific exemplary embodiment, a vaccine formulation contains a virus comprising a heterologous nucleotide sequence derived from an avian pneumovirus type A, and the vaccine formulation is used to protect from infection by avian pneumovirus type A and avian pneumovirus type
20 B. In another specific exemplary embodiment, a vaccine formulation contains a virus comprising a heterologous nucleotide sequence derived from an avian pneumovirus subgroup C, and the vaccine formulation is used to protect from infection by avian pneumovirus subgroup C and avian pneumovirus subgroup D.

The invention encompasses vaccine formulations to be administered to humans and
25 animals that are useful to protect against PIV, hMPV, APV (including APV C and APV D), influenza, RSV, Sendai virus, mumps, laryngotracheitis virus, simianvirus 5, human papillomavirus, as well as other viruses, pathogens and related diseases. The invention further encompasses vaccine formulations to be administered to humans and animals that are useful to protect against human metapneumovirus infections, avian pneumovirus infections,
30 and related diseases.

In one embodiment, the invention encompasses vaccine formulations that are useful against domestic animal disease causing agents including rabies virus, feline leukemia virus

(FLV) and canine distemper virus. In yet another embodiment, the invention encompasses vaccine formulations that are useful to protect livestock against vesicular stomatitis virus, rabies virus, rinderpest virus, swinepox virus, and further, to protect wild animals against
5 rabies virus.

Attenuated viruses generated by the reverse genetics approach can be used in the vaccine and pharmaceutical formulations described herein. Reverse genetics techniques can also be used to engineer additional mutations to other viral genes important for vaccine production. For example, mutations in the 5' non-coding region may affect mRNA
10 translation, mutations in capsid proteins are believed to influence viral assembly, and temperature-sensitive and cold-adapted mutants are often less pathogenic than the parental virus. (*see, e.g.*, Flint et al., PRINCIPLES OF VIROLOGY, MOLECULAR BIOLOGY, PATHOGENESIS, AND CONTROL, 2000, ASM Press pp 670 - 683, the entire text is incorporated herein by reference). The epitopes of useful vaccine strain variants can be
15 engineered into the attenuated virus. Alternatively, completely foreign epitopes, including antigens derived from other viral or non-viral pathogens can be engineered into the attenuated strain. For example, antigens of non-related viruses such as HIV (gp160, gp120, gp41), parasite antigens (*e.g.*, malaria), bacterial or fungal antigens, or tumor antigens can be engineered into the attenuated strain. Alternatively, epitopes which alter the tropism of the
20 virus *in vivo* can be engineered into the chimeric attenuated viruses of the invention.

Virtually any heterologous gene sequence may be constructed into the chimeric viruses of the invention for use in vaccines. Preferably, moieties and peptides that act as biological response modifiers are constructed into the chimeric viruses of the invention for use in vaccines. Preferably, epitopes that induce a protective immune response to any of a
25 variety of pathogens, or antigens that bind neutralizing antibodies may be expressed by or as part of the chimeric viruses. For example, heterologous gene sequences that can be constructed into the chimeric viruses of the invention include, but are not limited to influenza and parainfluenza hemagglutinin neuraminidase and fusion glycoproteins such as the HN and F genes of human PIV3. In yet another embodiment, heterologous gene sequences that can
30 be engineered into the chimeric viruses include those that encode proteins with immunomodulating activities. Examples of immunomodulating proteins include, but are not limited to, cytokines, interferon type 1, gamma interferon, colony stimulating factors,

interleukin -1, -2, -4, -5, -6, -12, and antagonists of these agents.

In addition, heterologous gene sequences that can be constructed into the chimeric viruses of the invention for use in vaccines include but are not limited to sequences derived from a human immunodeficiency virus (HIV), preferably type 1 or type 2. In a preferred
5 embodiment, an immunogenic HIV-derived peptide that may be the source of an antigen may be constructed into a chimeric PIV that may then be used to elicit a vertebrate immune response. Such HIV-derived peptides may include, but are not limited to, sequences derived from the env gene (*i.e.*, sequences encoding all or part of gp160, gp120, and/or gp41), the pol
10 gene (*i.e.*, sequences encoding all or part of reverse transcriptase, endonuclease, protease, and/or integrase), the gag gene (*i.e.*, sequences encoding all or part of p7, p6, p55, p17/18, p24/25), tat, rev, nef, vif, vpu, vpr, and/or vpx.

Other heterologous sequences may be derived from hepatitis B virus surface antigen (HBsAg); hepatitis A or C virus surface antigens, the glycoproteins of Epstein Barr virus; the
15 glycoproteins of human papillomavirus; the glycoproteins of respiratory syncytial virus, parainfluenza virus, Sendai virus, simianvirus 5 or mumps virus; the glycoproteins of influenza virus; the glycoproteins of herpesviruses; VP1 of poliovirus; antigenic determinants of non-viral pathogens such as bacteria and parasites, to name but a few. In another embodiment, all or portions of immunoglobulin genes may be expressed. For
20 example, variable regions of anti-idiotypic immunoglobulins that mimic such epitopes may be constructed into the chimeric viruses of the invention.

Other heterologous sequences may be derived from tumor antigens, and the resulting chimeric viruses can be used to generate an immune response against the tumor cells leading to tumor regression *in vivo*. These vaccines may be used in combination with other
25 therapeutic regimens, including but not limited to, chemotherapy, radiation therapy, surgery, bone marrow transplantation, etc. for the treatment of tumors. In accordance with the present invention, recombinant viruses may be engineered to express tumor-associated antigens (TAAs), including but not limited to, human tumor antigens recognized by T cells (Robbins and Kawakami, 1996, Curr. Opin. Immunol. 8:628-636, incorporated herein by reference in
30 its entirety), melanocyte lineage proteins, including gp100, MART-1/MelanA, TRP-1 (gp75), tyrosinase; Tumor-specific widely shared antigens, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-1, N-acetylglucosaminyltransferase-V, p15; Tumor-specific mutated antigens,

β -catenin, MUM-1, CDK4; Nonmelanoma antigens for breast, ovarian, cervical and pancreatic carcinoma, HER-2/neu, human papillomavirus -E6, -E7, MUC-1.

In even other embodiments, a heterologous nucleotide sequence is derived from a
5 metapneumovirus, such as human metapneumovirus and/or avian pneumovirus. In even
other embodiments, the virus of the invention contains two different heterologous nucleotide
sequences wherein one is derived from a metapneumovirus, such as human
metapneumovirus and/or avian pneumovirus, and the other one is derived from a respiratory
syncytial virus. The heterologous nucleotide sequence encodes a F protein or a G protein of
10 the respective virus. In a specific embodiment, a heterologous nucleotide sequences encodes
a chimeric F protein, wherein the chimeric F protein contains the ectodomain of a F protein
of a metapneumovirus and the transmembrane domain as well as the luminal domain of a F
protein of a parainfluenza virus.

Either a live recombinant viral vaccine or an inactivated recombinant viral vaccine
15 can be formulated. A live vaccine may be preferred because multiplication in the host leads
to a prolonged stimulus of similar kind and magnitude to that occurring in natural infections,
and therefore, confers substantial, long-lasting immunity. Production of such live
recombinant virus vaccine formulations may be accomplished using conventional methods
involving propagation of the virus in cell culture or in the allantois of the chick embryo
20 followed by purification. Additionally, as bPIV has been demonstrated to be non-pathogenic
in humans, this virus is highly suited for use as a live vaccine.

In this regard, the use of genetically engineered PIV (vectors) for vaccine purposes
may desire the presence of attenuation characteristics in these strains. The introduction of
appropriate mutations (*e.g.*, deletions) into the templates used for transfection may provide
25 the novel viruses with attenuation characteristics. For example, specific missense mutations
that are associated with temperature sensitivity or cold adaption can be made into deletion
mutations. These mutations should be more stable than the point mutations associated with
cold or temperature sensitive mutants and reversion frequencies should be extremely low.

Alternatively, chimeric viruses with "suicide" characteristics may be constructed.
30 Such viruses would go through only one or a few rounds of replication within the host.
When used as a vaccine, the recombinant virus would go through limited replication cycle(s)
and induce a sufficient level of immune response but it would not go further in the human

host and cause disease. Recombinant viruses lacking one or more of the PIV genes or possessing mutated PIV genes would not be able to undergo successive rounds of replication. Defective viruses can be produced in cell lines which permanently express such a gene(s).

- 5 Viruses lacking an essential gene(s) would be replicated in these cell lines, however, when administered to the human host, they would not be able to complete a round of replication. Such preparations may transcribe and translate --in this abortive cycle -- a sufficient number of genes to induce an immune response. Alternatively, larger quantities of the strains could be administered, so that these preparations serve as inactivated (killed) virus vaccines. For
- 10 inactivated vaccines, it is preferred that the heterologous gene product be expressed as a viral component, so that the gene product is associated with the virion. The advantage of such preparations is that they contain native proteins and do not undergo inactivation by treatment with formalin or other agents used in the manufacturing of killed virus vaccines. Alternatively, mutated PIV made from cDNA may be highly attenuated so that it replicates
- 15 for only a few rounds.

- In certain embodiments, the vaccine of the invention comprises an attenuated virus. Without being bound by theory, the attenuated virus can be effective as a vaccine even if the attenuated virus is incapable of causing a cell to generate new infectious viral particles because the viral proteins are inserted in the cytoplasmic membrane of the host thus
- 20 stimulating an immune response.

- In another embodiment of this aspect of the invention, inactivated vaccine formulations may be prepared using conventional techniques to "kill" the chimeric viruses. Inactivated vaccines are "dead" in the sense that their infectivity has been destroyed. Ideally, the infectivity of the virus is destroyed without affecting its immunogenicity. In order to
- 25 prepare inactivated vaccines, the chimeric virus may be grown in cell culture or in the allantois of the chick embryo, purified by zonal ultracentrifugation, inactivated by formaldehyde or β -propiolactone, and pooled. The resulting vaccine is usually inoculated intramuscularly.

- Inactivated viruses may be formulated with a suitable adjuvant in order to enhance the
- 30 immunological response. Such adjuvants may include but are not limited to mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols, polyanions; peptides; oil emulsions; and potentially useful human adjuvants such as BCG,

Corynebacterium parvum, ISCOMS, and virosomes.

Many methods may be used to introduce the vaccine formulations described above, these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, percutaneous, and intranasal and inhalation routes. It may be preferable to introduce the chimeric virus vaccine formulation via the natural route of infection of the pathogen for which the vaccine is designed.

In certain embodiments, the invention relates to immunogenic compositions. The immunogenic compositions comprise a chimeric PIV. In certain embodiments, the immunogenic composition comprises an attenuated chimeric PIV. In certain embodiments, the immunogenic composition further comprises a pharmaceutically acceptable carrier.

Various techniques may be used to evaluate the effectiveness and safeness of a vaccine according to the present invention. An effective vaccine is a vaccine that protects vaccinated individuals from illness due to pathogens, by invoking proper innate, cellular, and humoral responses with minimal side effect. The vaccine must not cause disease. Any techniques that are able to measure the replication of the virus and the immune response of the vaccinated subject may be used to evaluate the vaccine. Non-limiting examples are given in the Example sections, *infra*.

5.6.1. DOSAGE REGIMENS AND ADMINISTRATION OF THE VACCINES OR IMMUNOGENIC PREPARATIONS OF THE INVENTION

The present invention provides vaccines and immunogenic preparations comprising chimeric PIV expressing one or more heterologous or non-native antigenic sequences. The vaccines or immunogenic preparations of the invention encompass single or multivalent vaccines, including bivalent and trivalent vaccines. The vaccines or immunogenic formulations of the invention are useful in providing protections against various viral infections. Particularly, the vaccines or immunogenic formulations of the invention provide protection against respiratory tract infections in a host.

A recombinant virus and/or a vaccine or immunogenic formulation of the invention can be administered alone or in combination with other vaccines. Preferably, a vaccine or immunogenic formulation of the invention is administered in combination with other vaccines or immunogenic formulations that provide protection against respiratory tract

diseases, such as but not limited to, respiratory syncytial virus vaccines, influenza vaccines, measles vaccines, mumps vaccines, rubella vaccines, pneumococcal vaccines, rickettsia vaccines, staphylococcus vaccines, whooping cough vaccines or vaccines against respiratory tract cancers. In a preferred embodiment, the virus and/or vaccine of the invention is administered concurrently with pediatric vaccines recommended at the corresponding ages. For example, at two, four or six months of age, the virus and/or vaccine of the invention can be administered concurrently with DtaP (IM), Hib (IM), Polio (IPV or OPV) and Hepatitis B (IM). At twelve or fifteen months of age, the virus and/or vaccine of the invention can be administered concurrently with Hib (IM), Polio (IPV or OPV), MMRI[®] (SubQ); Varivax[®] (SubQ), and hepatitis B (IM). The vaccines that can be used with the methods of invention are reviewed in various publications, *e.g.*, The Jordan Report 2000, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States, the content of which is incorporated herein by reference in its entirety.

A vaccine or immunogenic formulation of the invention may be administered to a subject *per se* or in the form of a pharmaceutical or therapeutic composition. Pharmaceutical compositions comprising an adjuvant and an immunogenic antigen of the invention (*e.g.*, a virus, a chimeric virus, a mutated virus) may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the immunogenic antigen of the invention into preparations which can be used pharmaceutically. Proper formulation is, or amongst others, dependent upon the route of administration chosen.

When a vaccine or immunogenic composition of the invention comprises adjuvants or is administered together with one or more adjuvants, the adjuvants that can be used include, but are not limited to, mineral salt adjuvants or mineral salt gel adjuvants, particulate adjuvants, microparticulate adjuvants, mucosal adjuvants, and immunostimulatory adjuvants. Examples of adjuvants include, but are not limited to, aluminum hydroxide, aluminum phosphate gel, Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, squalene or squalene oil-in-water adjuvant formulations, biodegradable and biocompatible polyesters,

polymerized liposomes, triterpenoid glycosides or saponins (*e.g.*, QuilA and QS-21, also sold under the trademark STIMULON, ISCOPREP), N-acetyl-muramyl-L-threonyl-D-isoglutamine (Threonyl-MDP, sold under the trademark TERMURTIDE), LPS,
5 monophosphoryl Lipid A (3D-MLA sold under the trademark MPL).

The subject to which the vaccine or an immunogenic composition of the invention is administered is preferably a mammal, most preferably a human, but can also be a non-human animal, including but not limited to, primates, cows, horses, sheep, pigs, fowl (*e.g.*, chickens, turkeys), goats, cats, dogs, hamsters, mice and rodents.

10 Many methods may be used to introduce the vaccine or the immunogenic composition of the invention, including but not limited to, oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, percutaneous, intranasal and inhalation routes, and via scarification (scratching through the top layers of skin, *e.g.*, using a bifurcated needle).

15 For topical administration, the vaccine or immunogenic preparations of the invention may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art.

For administration intranasally or by inhalation, the preparation for use according to the present invention can be conveniently delivered in the form of an aerosol spray
20 presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, *e.g.*, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the
25 compound and a suitable powder base such as lactose or starch.

For injection, the vaccine or immunogenic preparations may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the proteins
30 may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

Determination of an effective amount of the vaccine or immunogenic formulation for

administration is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.

An effective dose can be estimated initially from *in vitro* assays. For example, a dose
5 can be formulated in animal models to achieve an induction of an immunity response using techniques that are well known in the art. One having ordinary skill in the art could readily optimize administration to all animal species based on results described herein. Dosage amount and interval may be adjusted individually. For example, when used as an immunogenic composition, a suitable dose is an amount of the composition that when
10 administered as described above, is capable of eliciting an antibody response. When used as a vaccine, the vaccine or immunogenic formulations of the invention may be administered in about 1 to 3 doses for a 1-36 week period. Preferably, 1 or 2 doses are administered, at intervals of about 2 weeks to about 4 months, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual animals. A
15 suitable dose is an amount of the vaccine formulation that, when administered as described above, is capable of raising an immunity response in an immunized animal sufficient to protect the animal from an infection for at least 4 to 12 months. In general, the amount of the antigen present in a dose ranges from about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 mg, and preferably from about 100 pg to about 1 µg. Suitable
20 dose range will vary with the route of injection and the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

In a specific embodiment, the viruses and/or vaccines of the invention are administered at a starting single dose of at least 10^3 TCID₅₀, at least 10^4 TCID₅₀, at least 10^5 TCID₅₀, at least 10^6 TCID₅₀. In another specific embodiment, the virus and/or vaccines of the
25 invention are administered at multiple doses. In a preferred embodiment, a primary dosing regimen at 2, 4, and 6 months of age and a booster dose at the beginning of the second year of life are used. More preferably, each dose of at least 10^5 TCID₅₀, or at least 10^6 TCID₅₀ is given in a multiple dosing regimen. The replication rate of a virus can be used as an index to adjust the dosage of a vaccine in a clinical trial. For example, assays to test the replication
30 rate of a virus (*e.g.*, a growth curve, *see* Section 5.5. for available assays) can be used to compare the replication rate of the viruses and/or vaccines of the invention to that of the bPIV3, which was demonstrated in previous studies (*see* Clements *et al.*, J. Clin. Microbiol.

29:1175-82 (1991); Karron *et al.*, J. Infect. Dis. 171:1107-14 (1995); Karron *et al.*, Ped. Inf. Dis. J. 5:650-654 (1996). These studies showed that a bovine PIV3 vaccine is generally safe and well tolerated by healthy human volunteers, including adults, children 6-60 months of
5 age, and infants 2-6 months of age. In these studies, subjects have received at least a single dose of bPIV3 vaccine from 10^3 TCID₅₀ to 10^6 TCID₅₀. Twelve children received two doses of 10^5 TCID₅₀ PIV3 vaccine instead of one dose without untoward effects.). A comparable replication rate as to bPIV3 suggests that a comparable dosage may be used in a clinical trial. A lower replication rate compared to that of bPIV3 suggests that a higher dosage can be used.

10

5.6.1.1. CHALLENGE STUDIES

This assay is used to determine the ability of the recombinant viruses of the invention and of the vaccines of the invention to prevent lower respiratory tract viral infection in an animal model system, such as, but not limited to, cotton rats or hamsters. The recombinant
15 virus and/or the vaccine can be administered by intravenous (IV) route, by intramuscular (IM) route or by intranasal route (IN). The recombinant virus and/or the vaccine can be administered by any technique well-known to the skilled artisan. This assay is also used to correlate the serum concentration of antibodies with a reduction in lung titer of the virus to which the antibodies bind.

20 On day 0, groups of animals, such as, but not limited to, cotton rats (*Sigmodon hispidus*, average weight 100 g) cynomolgous macaques (average weight 2.0 kg) are administered the recombinant or chimeric virus or the vaccine of interest or BSA by intramuscular injection, by intravenous injection, or by intranasal route. Prior to, concurrently with, or subsequent to administration of the recombinant virus or the vaccine of
25 the invention, the animals are infected with wild type virus wherein the wild type virus is the virus against which the vaccine was generated. In certain embodiments, the animals are infected with the wild type virus at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, 1 week or 1 or more months subsequent to the administration of the recombinant virus and/or the vaccine of the invention.

30 After the infection, cotton rats are sacrificed, and their lung tissue is harvested and pulmonary virus titers are determined by plaque titration. Bovine serum albumin (BSA) 10 mg/kg is used as a negative control. Antibody concentrations in the serum at the time of

challenge are determined using a sandwich ELISA. Similarly, in macacques, virus titers in nasal and lung lavages can be measured.

5 **5.6.1.2. TARGET POPULATIONS**

In certain embodiments of the invention, the target population for the therapeutic and diagnostic methods of the invention is defined by age. In certain embodiments, the target population for the therapeutic and/or diagnostic methods of the invention is characterized by a disease or disorder in addition to a respiratory tract infection.

10 In a specific embodiment, the target population encompasses young children, below 2 years of age. In a more specific embodiment, the children below the age of 2 years do not suffer from illnesses other than respiratory tract infection.

In other embodiments, the target population encompasses patients above 5 years of age. In a more specific embodiment, the patients above the age of 5 years suffer from an
15 additional disease or disorder including cystic fibrosis, leukaemia, and non-Hodgkin lymphoma, or recently received bone marrow or kidney transplantation.

In a specific embodiment of the invention, the target population encompasses subjects in which the hMPV infection is associated with immunosuppression of the hosts. In a specific embodiment, the subject is an immunocompromised individual.

20 In certain embodiments, the target population for the methods of the invention encompasses the elderly.

In a specific embodiment, the subject to be treated with the methods of the invention was infected with hMPV in the winter months.

25 **5.6.1.3. CLINICAL TRIALS**

Vaccines of the invention or fragments thereof tested in *in vitro* assays and animal models may be further evaluated for safety, tolerance and pharmacokinetics in groups of normal healthy adult volunteers. The volunteers are administered intramuscularly, intravenously or by a pulmonary delivery system a single dose of a recombinant virus of the
30 invention and/or a vaccine of the invention. Each volunteer is monitored at least 24 hours prior to receiving the single dose of the recombinant virus of the invention and/or a vaccine of the invention and each volunteer will be monitored for at least 48 hours after receiving the

dose at a clinical site. Then volunteers are monitored as outpatients on days 3, 7, 14, 21, 28, 35, 42, 49, and 56 postdose.

Blood samples are collected via an indwelling catheter or direct venipuncture using
5 10 ml red-top Vacutainer tubes at the following intervals: (1) prior to administering the dose of the recombinant virus of the invention and/or a vaccine of the invention; (2) during the administration of the dose of the recombinant virus of the invention and/or a vaccine of the invention; (3) 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, and 48 hours after administering the dose of the
10 recombinant virus of the invention and/or a vaccine of the invention; and (4) 3 days, 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, 49 days, and 56 days after administering the dose of the recombinant virus of the invention and/or a vaccine of the invention. Samples are allowed to clot at room temperature and serum will be collected after centrifugation.

The amount of antibodies generated against the recombinant virus of the invention
15 and/or a vaccine of the invention in the samples from the patients can be quantitated by ELISA. T-cell immunity (cytotoxic and helper responses) in PBMC and lung and nasal lavages can also be monitored.

The concentration of antibody levels in the serum of volunteers are corrected by
subtracting the predose serum level (background level) from the serum levels at each
20 collection interval after administration of the dose of recombinant virus of the invention and/or a vaccine of the invention. For each volunteer the pharmacokinetic parameters are computed according to the model-independent approach (Gibaldi *et al.*, eds., 1982, Pharmacokinetics, 2nd edition, Marcel Dekker, New York) from the corrected serum antibody or antibody fragment concentrations.

25

The following examples are illustrative, but not limiting, of the present invention. Cells and Viruses used in the examples are maintained as follows: the RSV A2 strain and the bovine parainfluenza type 3/human parainfluenza type 3 vectored RSV viruses (bPIV3/hPIV3/RSV viruses) were grown in Vero cells in Opti-MEM (Gibco/BRL) in the
30 presence of gentamycin. The modified vaccinia virus Ankara (MVA-T7) or fowl-pox-T7 (FP-T7) which expressed the phage T7 RNA polymerase were grown in chicken embryonic kidney cells (SPAFAS). Vero, HeLa and Hep-2 cells were maintained in MEM (JRH

Biosciences) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, non-essential amino acids, and antibiotics.

5 6. **EXAMPLE 1: CONSTRUCTION AND CLONING OF CHIMERIC
BOVINE PARAINFLUENZA 3 / HUMAN PARAINFLUENZA 3 cDNA**

10 In order to substitute the F and HN genes of bPIV3 with those of hPIV3, additional restriction enzyme sites were introduced into the infectious bPIV3 cDNA. Using site-directed mutagenesis, a unique Nhe I site was introduced at nucleotide position 5041 and a Sal I site was introduced at nt 8529 of the bPIV3 cDNA. The modified full-length bPIV3 cDNA was treated with Nhe I and Sal I restriction enzymes and a ~14 kb DNA fragment encompassing all of the viral bPIV3 sequences except the F and HN genes, was isolated by gel purification.

15 To obtain the hPIV3 F and HN gene sequences, a 10 cm dish of confluent Vero cells was infected with a strain of hPIV3 (hPIV3/Tex/12084/1983). After 3 days of incubation at 37°C, the cells were harvested and total RNA was isolated using RNA STAT-LS 50 (Tel-Test Inc.). Viral cDNA was generated by reverse transcription using a hPIV3 specific oligo annealing at position 4828 of the hPIV3 genome. The hPIV3 F and HN genes were amplified by PCR (polymerase chain reaction) using Taq polymerase. The PCR product was cloned into the pT/A TOPO cloning vector (Invitrogen) and from two clones (#11 and #14) the hPIV3 F and HN genes were sequenced. Sequence analysis revealed that for clone #11, the F gene was correct, but the HN gene contained aberrant sequences; for clone #14, the HN gene was correct, but the F gene contained aberrant stop codons. Thus, a plasmid, containing functional hPIV3 F and HN genes, was constructed by combining the correct F gene of #11 with the correct HN gene of #14 in the following manner. Both hPIV3 plasmids (#11 and #14) were digested with NheI and EcoRI. A 1.6 kb fragment harboring the correct F gene was isolated from clone #11 and a 8.5 kb fragment containing the correct HN gene and plasmid sequences, was isolated from clone #14. The two fragments were ligated to produce the intact hPIV3 F and HN genes-containing plasmid. The correct sequence was confirmed by DNA sequence analysis. Finally, a single nucleotide was added at the 3' end of the HN gene in the untranslated region to satisfy the "Rule of Six." The addition of the single nucleotide was accomplished by using the QuikChange mutagenesis kit (Stratagene) and was

confirmed by DNA sequencing. The correct hPIV3 F and HN gene DNA fragment was then isolated by digestion with Nhe 1 and Sal 1 and a 3.5 kb DNA fragment was gel purified.

The full-length b/h PIV3 chimeric cDNA was constructed by ligating the 14.5 kb DNA fragment harboring bPIV3 sequences described above and the 3.5 kb DNA fragment containing the hPIV3 F and HN genes (see Figure 3). The full-length chimeric plasmid DNA was confirmed by extensive restriction enzyme mapping. In addition, the M/F and HN/L gene junctions of the chimeric construct were confirmed by DNA sequencing to both contain bPIV3 and hPIV3 sequences as well as a Nhe 1 and a Sal 1 restriction enzyme site, respectively.

7. EXAMPLE 2: CONSTRUCTION AND CLONING OF CHIMERIC BOVINE PARAINFLUENZA 3/HUMAN PARAINFLUENZA 3 VECTORED RESPIRATORY SYNCYTIAL VIRUS F OR G cDNAs

In order to determine the effects of RSV antigen insertions in position 1 or 2 of the b/h PIV3 genome on virus replication, respiratory syncytial virus (RSV) F and G genes were cloned into different positions of the chimeric bovine parainfluenza 3/human parainfluenza 3 vector (b/h PIV3 vector). See Figure 4.

In order to insert foreign genes into the bovine/human (b/h) PIV3 cDNA, AvrII restriction enzyme sites were introduced in the b/h PIV3 cDNA plasmid (Haller *et al.*, 2000; 2001, this is the same construct as in Example 6) by site-directed mutagenesis using the QuickChange kit (Stratagene). One AvrII site was introduced at nucleotide (nt) 104 in the b/h PIV3 genome altering four nucleotides using the following oligo 5'GAA ATC CTA AGA CCC TAG GCA TGT TGA GTC3' and its complement. This restriction enzyme site was used to insert the RSV genes in the first (most 3') position of the viral genome. Another AvrII site was introduced in the N-P intergenic region at nt 1774 changing two nucleotides using the following oligo 5'CCACA ACTCAATCAACCTAGGATTCATGGAAGACAATG 3' and its complement. This restriction site was used to insert the RSV genes in the second position between the N and P genes of b/h PIV3 (Figure 4). Full-length b/h PIV3 cDNAs harboring the AvrII sites at nts 104 and 1774 were tested for functionality by recovering viruses by reverse genetics.

Construction of RSV G cassette (N-P gene stop/start): A DNA fragment was

generated that contained the bPIV3 N-P intergenic region as well as the 3' end sequences of the RSV G gene, using the b/h PIV3 cDNA as PCR template. This fragment was generated by PCR using the following oligos: 5'CCCAACACACCACGCCAGTAGTCACAA
5 AGAGATGACCACTATCAC3' and 5'CCCAAGCTTCCTAGGTGAATCTTTG
GTTGATTGAGTTGTGG3'. This fragment was then used to carry out overlapping PCR to add the bPIV3 N-P intergenic region to the RSV G gene. For the second PCR reaction, a plasmid containing the RSV G and F gene was used as a DNA template, the oligo 5'CAGCGGATCCTAGGGGAGAAAAGTGTCGAAGAAAAATGTCC3' and an oligo
10 generated from the short PCR fragment above were used as primers. The resulting PCR fragment containing the RSV G gene linked to the bPIV3 N-P intergenic region and flanking AvrII restriction enzyme sites, was cloned into pGEM3. The RSV G gene was sequenced to confirm the presence of an intact open reading frame and the predicted amino acid sequences. The DNA fragments harboring the RSV G gene were inserted into the first or second position
15 using the AvrII restriction enzyme sites into a subclone harboring only the first 5200 nucleotides of the bPIV3 (1-5 bPIV3) genome that was linearized with AvrII. As used herein and other Examples, 1-5 bPIV3 refers to the nucleotide 1 to 5196 (or 5200) of bovine PIV3 genome. There is a BstB1 site at this location.

Construction of RSV F cassette (N-P gene start/stop): The RSV F gene fragment was
20 isolated by PCR from a full-length bPIV3/RSV F+G cDNA plasmid using oligos that added AvrII sites at the 5' and 3' end of the RSV F gene, and introduced into the 1-5 bPIV3 plasmid harboring the AvrII site at nt 1774, which was linearized with AvrII. The bPIV3 N-P intergenic region was isolated by PCR using 1-5 bPIV3/RSV G2 as a template. The oligo 5'GACGCGTCGACCACAAAGAGATGACCACTATCACC 3' and an oligo annealing in
25 the bPIV3 F gene were used to generate a PCR fragment containing the bPIV3 N-P intergenic region, AvrII site, and bPIV3 sequences up to nt 5200. The PCR fragment was digested with SalI and NheI, and added to the 1-5 bPIV3 plasmid harboring the RSV F gene in position 2, which was treated with SalI and NheI. To introduce the RSV F gene containing the N-P intergenic region into position 1, the 1.8 kb RSV F cassette was excised
30 using AvrII, and ligated into 1-5 bPIV3 containing the AvrII site at nt 104, which was linearized with AvrII.

Construction of the RSV F cassette with a short intergenic region (N stop/N start):

The generation of the RSV F gene with the short N-N intergenic region was accomplished by performing a PCR reaction using 1-5 bPIV3/RSV F2 as a template, the oligo 5'GCGCGTCGACCAAGTAAGAAAACTTAGGATTAAAGAACCCTAGGACTGTA3', and an oligo annealing upstream of the 5' end of the RSV F gene encompassing the AvrII restriction enzyme site. The PCR product containing the RSV F gene and the short N-N intergenic region, was digested with AvrII and introduced into 1-5 bPIV3 nt 104 which was linearized with AvrII.

After confirming proper orientation by restriction enzyme mapping, the plasmids harboring the RSV genes in the first position were digested with SphI and BssHII and 4 kb (1-5 bPIV3/RSV G1) or 4.8 kb (1-5 bPIV3/RSV F1) DNA fragments were isolated. In a second cloning step, the remainder of the b/h PIV3 genome was added as a SphI-BssHII 15.1 kb DNA fragment, yielding full-length cDNAs. The bPIV3 subclones, harboring the RSV genes in the second position, were cut with SphI and NheI, and 5.8 kb (bPIV3/RSV G2) and a 6.5 kb (bPIV3/RSV F2) DNA fragments were isolated. In a second cloning step, the rest of the b/h PIV3 genome was added as an NheI-SphI DNA fragment of 14 kb in size. The full-length chimeric b/h PIV3/RSV plasmids were propagated in STBL-2 cells (Gibco/BRL) that provided high yields of full-length virus cDNA plasmids.

8. EXAMPLE 3: BOVINE PARAINFLUENZA 3/HUMAN PARAINFLUENZA 3 VECTORED RESPIRATORY SYNCYTIAL VIRUS F OR G DISPLAYED A POSITIONAL EFFECT WITH REGARDS TO mRNA PRODUCTION AND PROTEIN EXPRESSION AS WELL AS VIRUS REPLICATION *IN VITRO*

Three experiments were performed to confirm the effective expression of the RSV F or G gene in the constructs of Example 2, and to determine positional effects of gene insertions in the PIV3 genome.

First, in order to demonstrate RSV protein expression by the chimeric viruses, a Western blot of chimeric virus-infected cell lysates was carried out and probed with RSV-specific antisera. See Figure 5A. Western blots were performed as follows: Chimeric viruses were used to infect (70-80%) subconfluent Vero cells at a MOI of 0.1 or 1.0. Forty-eight hours post infection the media overlay was removed and infected monolayers were washed once with 1 ml of PBS. The cells were subsequently lysed in 400 ml of Laemmli buffer

(Bio-Rad) containing 0.05% b-Mercaptoethanol (Sigma). 15 ml of each sample was separated on 12% Tris-HCl Ready Gel (Bio-Rad) and transferred to nylon membranes using a semi-dry transfer cell (Bio-Rad). Nylon membranes were rinsed in PBS [pH 7.6] containing 0.5% (v/v) Tween-20 (Sigma) (PBST) and blocked with PBST containing 5% (w/v) dry milk (PBST-M) for 20-30 minutes at room temperature. Membranes were incubated with either a mixture of RSV F monoclonal antibodies (WHO 1269, 1200, 1153, 1112, 1243, 1107) at a 1:1000 dilution in PBST-M or RSV G 10181 polyclonal antibody (Orbigen) at a 1:2000 dilution in PBST-M for 1 hour at room temperature. Following four washes with PBST, the membranes were incubated with a secondary horseradish peroxidase-conjugated goat anti-mouse antibody (Dako) at a 1:2000 dilution in PBST-M for 1 hour at room temperature. Membranes were washed 4 times with PBST and developed using a chemiluminescence substrate (Amersham Pharmacia) and exposed to Biomax Light Film (Kodak) for visualization of protein bands.

Consistent with the reduced replication efficiency of b/h/RSV F1*N-N in Vero cells (Figure 5C, *see* below), the amount of RSV F₁ detected at 48 hours post infection was about 10 times less than that present in b/h PIV3/RSV F2 or wild-type RSV A2 infected cells (compare lanes 2, 3, and 4, Figure 5A). A 50 kDa band representing the F₁ fragment was detected in cells infected with all chimeric viruses as well as wild-type RSV. However, there was greater accumulation of a 20 kDa F fragment in infected cell lysates of chimeric viruses compared to wild-type RSV. When b/h PIV3/RSV F1*N-N infections were repeated at a higher MOI of 1.0 (Figure 5A, lane 1), the F₁ fragment in b/h PIV3/RSV F1 infected cells accumulated to wild-type RSV levels at 48 hours post-infection. The relative amount of the 50 kDa and 20 kDa F₁ fragments in b/h PIV3/RSV F1 or b/h PIV3/RSV F2 infected cells was approximately 1:5. No F₀ was detected in cells infected with chimeric viruses indicating that the F₀ precursors were efficiently processed during b/h PIV3/RSV F1 and b/h PIV3/RSV F2 infections as was also observed in wild-type RSV infections.

The relative expression of RSV G in b/h PIV3/RSV G1, b/h PIV3/RSV G2 and wild-type RSV infected cells is shown in Figure 5A. Both the immature and glycosylated forms of RSV G that migrated at approximately 50 kDa and 90 kDa, respectively, were detected. b/h PIV3/RSV G1 infected cells showed levels of RSV G expression similar to that seen in wild-type RSV infected cells (lanes 1 and 3, Figure 5A). However, in b/h PIV3/RSV G2 infected

cells, the accumulation of RSV G was about 2-3 times more than that present in wild-type RSV infected cells (lanes 2 and 3, Figure 5A). Collectively, these data showed that the chimeric b/h PIV3/RSV efficiently expressed the RSV proteins in either position 1 or 2.

5 However, the viruses harboring the RSV genes in position 2 expressed higher levels of RSV proteins.

Next, Northern blot analysis showed that the mRNA transcription correlated with the result of the protein expression demonstrated by the Western blot, *see* Figure 5B. Northern blot was performed as follows: total cellular RNA was prepared from virus-infected cells

10 using Trizol LS (Life Technologies). The RNA was further purified by one phenol-chloroform extraction and precipitated with ethanol. RNA pellets were resuspended in diethyl pyrocarbonate-treated water and stored at -80°C . Equal amounts of total RNA were separated on 1% agarose gels containing 1% formaldehyde and transferred to nylon membranes (Amersham Pharmacia Biotech) using a Turboblottter apparatus (Schleicher &

15 Schuell). The blots were hybridized with digoxigenin (DIG)-UTP-labeled riboprobes synthesized by in vitro transcription using a DIG RNA labeling kit (Roche Molecular Biochemicals). Hybridization was carried out at 68°C for 12 h in Express Hyb solution (Clontech). The blots were washed at 68°C twice with 2X SSC (1X SSC contained 0.015 M NaCl with 0.015 M sodium citrate)-0.1% sodium dodecyl sulfate (SDS) followed by one

20 wash with 0.5X SSC-0.1% SDS and a final wash with 0.1X SSC-0.1% SDS. Signals from the hybridized probes were detected by using a DIG-Luminescent detection kit (Roche Molecular Biochemicals) and visualized by exposure to BioMax ML film (Kodak).

Northern analysis of b/h PIV3/RSV F1*N-N, b/h PIV3/RSV F2, b/h PIV3/RSV G1 and b/h PIV3/RSV G2 showed that the viral mRNA levels for RSV F or RSV G correlated

25 well with the RSV protein levels observed (Figure 5B). The lowest levels of RSV F mRNAs were observed for b/h PIV3/RSV F1*N-N which also displayed the least amount of RSV F protein produced. b/h PIV3/RSV G1 produced less RSV G mRNAs resulting in lower RSV G protein levels than was observed for b/h PIV3/RSV G2.

Finally, growth of different virus (with RSV F or G gene at either position 1 or

30 position 2) correlates with the results of the protein expression and the RNA transcription. The growth curve showed in Figure 5C was obtained as follows: Vero cells were grown to 90% confluence and infected at an MOI of 0.01 or 0.1 with b/h PIV3, b/h PIV3 RSV F1, b/h

PIV3 RSV G1, b/h PIV3 RSV F2, and b/h PIV3 RSV G2. The infected monolayers were incubated at 37°C. At 0, 24, 48, 72, 96 and 120 hours post-infection, cells and media were harvested together and stored at -70°C. Virus titers for each time point harvest were
5 determined by TCID₅₀ or plaque assays in Vero cells. TCID₅₀ assays were inspected visually for CPE following incubation at 37°C for 6 days, while plaque assays were immunostained with RSV polyclonal antisera for quantification after 5 days of incubation.

At an MOI of 0.01 in Vero cells, the chimeric viruses harboring the RSV G or F genes in the first position (b/h PIV3 RSV G1 and b/h PIV3 RSV F1*N-N) replicated at a
10 slower rate, yielded lower peak titers, and exhibited a greater lag phase than the viruses that contained the RSV genes in the second position. Peak titers of b/h PIV3/RSV F1*N-N and b/h PIV3/RSV G1 at 96 hours post-infection were 10^{6.7} and 10^{5.5} TCID₅₀/ml, respectively (Figure 5C). In contrast, peak titers of b/h PIV3/RSV F2 and b/h PIV3/RSV G2 were 10^{8.0} and 10^{7.4} at 72 and 96 hours post-infection, respectively (Figure 5C). The b/h PIV3 control
15 virus displayed peak titers of 10^{8.0} TCID₅₀/ml, respectively (Figure 5C). The b/h PIV3/RSV F2 yielded 1.3 log₁₀ higher titers than b/h PIV3/RSV F1*N-N. The b/h PIV3/RSV G2 replicated to 1.9 log₁₀ higher titers than b/h PIV3/RSV G1. The results indicated that the chimeric viruses harboring the RSV genes in the first position were delayed in onset for replication *in vitro* compared to chimeric viruses containing the RSV genes in the second
20 position.

To determine whether higher titers of b/h PIV3/RSV F1*N-N and b/h PIV3/RSV G1 could be achieved at all, the growth curves were repeated at a higher MOI of 0.1. At an MOI of 0.1, the peak titers of b/h PIV3/RSV F1*N-N and b/h PIV3/RSV G1 increased by 0.5 to 1.3 log₁₀ (data not shown). The lag phases of these viruses were reduced and peak titers were
25 achieved earlier during the growth cycle.

9. **EXAMPLE 4: POSITIONAL EFFECT OF eGFP INSERTIONS IN THE BOVINE PARAINFLUENZA 3/HUMAN PARAINFLUENZA 3 GENOME ON VIRUS REPLICATION**

The effect of gene insertions into the bovine/human PIV3 vector backbone was assessed systematically by introducing the eGFP gene sequentially between all genes of PIV3
30 and observing the effect on virus replication and eGFP expression (Figure 6). This type of assay investigates the importance of the transcriptional gradient observed for

paramyxoviruses that yields specific ratios of viral mRNAs. Insertion of foreign genes will perturb these ratios and result in the synthesis of different amounts of viral proteins which may influence virus replication. The eGFP gene was chosen for this assay since it will not be
5 incorporated into the virion membrane, and therefore should not interfere with viral processes such as packaging, budding, entry, etc. The eGFP gene was inserted into four positions of the b/h PIV3 genome, three of which were characterized for eGFP expression and virus replication. The eGFP gene cassette was linked to the bPIV3 N-P intergenic region. b/h GFP1 harbored the eGFP gene cassette in the 3' most proximal position of the
10 b/h PIV3 genome. b/h PIV3/GFP2 contained the eGFP gene cassette between the N and P genes of the b/h PIV3 genome. b/h PIV3/GFP3 was located between P and M, and b/h PIV3/GFP4 had the eGFP gene between M and F of b/h PIV3 (Figure 6).

Construction of the eGFP gene cassette: the template of the eGFP gene is commercially available, e.g., it can be purchased from BD Biosciences (pIRES2-EGFP) or
15 Clontech (pEGFP-N1). See Hoffmann *et al.*, Virology 267:310-317 (2000). The eGFP gene was isolated by PCR and the bPIV3 N-P intergenic region was added by employing the overlapping PCR method, using the following oligos: 5'ATTCCTAGGATGGTGAGCAAG
GGCG3', 5'GGACGAGCTGTACAAGTAAAAAATAGCACCTAATCATG3', and
5'CTACCTAGGTGAATCTTTGGTTG3'. The eGFP cassette was inserted into pCR2.1,
20 sequenced, and adherence to the rule-of-six was confirmed. Then the eGFP cassette was digested with AvrII, gel purified, and inserted into positions 1, 2, 3, and 4 of b/h PIV3 as described below.

Generation of full-length cDNAs harboring the eGFP gene in positions 1 and 2: the eGFP gene cassette was inserted into the 1-5 bPIV3 plasmids which contained bPIV3
25 sequences from nts 1 – 5200 and an AvrII restriction enzyme site either at nt 104 (position 1) or nt 1774 (position 2). After confirming proper orientation by restriction enzyme mapping, the plasmid harboring the eGFP gene in the first position was digested with SphI and BssHII and 4 kb (1-5 eGFP1) DNA fragments were isolated. Next, the rest of the b/h PIV3 genome was added as a SphI-BssHII 15.1 kb DNA fragment, yielding full-length cDNAs. For
30 generation of full-length cDNA comprising the eGFP in position 2, the bPIV3 subclones harboring the eGFP genes in the second position were cut with SphI and NheI, and 5.8 kb (1-5 eGFP2) DNA fragments were isolated. Next, the rest of the b/h PIV3 genome was added

as an NheI-SphI DNA fragment of 14 kb in size. The full-length chimeric b/h PIV3/eGFP plasmids were propagated in STBL-2 cells (Gibco/BRL) that provided high yields of full-length virus cDNA plasmids.

- 5 Generation of full-length cDNAs harboring the eGFP gene in positions 3 and 4: in order to insert the eGFP cassette into position 3 of the b/h PIV3 genome, an AvrII restriction enzyme site was introduced at nt 3730 in the P-M intergenic region of a subclone containing nts 1 – 5200 of bPIV3, altering two nucleotides. The following oligo and its complement
- 10 5'GGACTAATCAATCCTAGGAAACAATGAGCATCACC3'. The eGFP cassette was digested with AvrII and ligated into the AvrII linearized 1-5 bPIV3 subclone harboring the AvrII site at nt 3730. A 5.5 kb DNA fragment from SphI to NheI was isolated from the GFP containing subclone and introduced into the b/h PIV3 cDNA digested with SphI and NheI to produce a full-length plasmid. In order to add the eGFP gene cassette into position 4 of the
- 15 b/h PIV3 genome, a subclone containing b/h PIV3 sequences from nts 1- 8500 was generated. This subclone was linearized with NheI (nt 5042), and the eGFP cassette containing compatible AvrII ends was inserted. Then the subclone harboring the eGFP cassette was digested with SphI and XhoI and a 7.1 kb DNA fragment was isolated. The b/h PIV3 plasmid was treated with SphI and XhoI and a 11 kb fragment was produced. These
- 20 two DNA fragments were ligated to generate b/h PIV3/GFP4.

- The amount of eGFP produced by b/h PIV3/GFP1, 2, and 3 was assessed in two ways. First, the amount of green cells produced upon infecting Vero cells with b/h PIV3 GFP1, 2, and 3 at MOIs of 0.1 and 0.01 for 20 hours, was determined using a fluorescent microscope (Figure 7A). b/h PIV3/GFP3 produced strikingly fewer green cells than b/h
- 25 PIV3/GFP1 or 2.

- Secondly, western analysis was performed on infected cells and the blots were probed with a GFP MAbs as well as a PIV3 PAb. The initial observation that b/h PIV3/GFP3 produced dramatically less eGFP protein, was confirmed (Figure 7B). b/h PIV3 GFP1 and GFP2 produced similar amounts of eGFP protein. The western blots methods controlled for
- 30 same volume loading by probing with a PIV3 antibody (Figure 7B). Interestingly, all three viruses showed similar amounts of PIV3 proteins (the HN protein is the most prominent band) produced. These results suggested that b/h PIV3/GFP3 transcribed less GFP mRNAs

in position 3 as compared to positions 1 and 2. This data confirmed the presence of a transcriptional gradient of viral mRNAs in paramyxoviruses. The level of production of the PIV3 HN protein was not affected by the eGFP gene insertions (Figure 7B).

- 5 In order to determine whether the GFP gene insertions had an effect on the kinetics of virus replication of b/h PIV3/GFP1, 2, and 3, multicycle growth curves in Vero cells were carried out (Figure 7C). The growth curves showed that b/h PIV3/GFP1 had a delayed onset of virus replication at 24 and 48 hours post-infection than b/h PIV3/GFP2 or GFP3. However, the final peak titers obtained were similar for all three viruses. The kinetics of
- 10 replication for b/h PIV3/GFP2 and GFP3 were nearly identical (Figure 7C). Interestingly, the altered ratios of viral mRNAs did not appear to effect virus replication significantly.

**10. EXAMPLE 5: CONSTRUCTION AND CLONING OF CHIMERIC
BOVINE PARAINFLUENZA 3/HUMAN PARAINFLUENZA 3
VECTORED RESPIRATORY SYNCYTIAL VIRUS F WITH
DIFFERENT INTERGENIC REGIONS**

- 15 Three different constructs were used to determine the effect of intergenic region (nucleotides between each mRNA, e.g., nucleotides between the F gene and the N gene) on protein expression and viral replication. See Figure 8. The first construct was b/h PIV3 vectored RSV F1* N-N in position 1, which had a shorter bPIV N gene stop/N gene start sequence (RSV F1* N-N in Figure 4); the second construct was b/h PIV3 vectored RSV F at
- 20 position 1 (RSV F2 in Figure 4); and the last one was b/h PIV3 vectored RSV at position 1 (RSV F1 in Figure 4). All three constructs were generated according to the cloning strategies described in section 7, Example 2.

- The most dramatic difference between the two cassettes is the distance between the N gene start sequence and the N translation start codon in b/h PIV3/RSV F1*N-N which was
- 25 only 10 nts long. In contrast, this distance is 86 nts long in b/h PIV3/RSV F2. The other difference is the use of the N gene start sequence in b/h PIV3/RSV F1*N-N rather than the P gene start sequence as was done in b/h PIV3/RSV F2. In order to determine whether the distance between the transcription gene start and the translation start of a viral transcription unit has an effect on virus replication, the b/h PIV3/RSV F1 construct was generated that
- 30 contained the identical RSV F gene cassette as was used for b/h PIV3/RSV F2.

**11. EXAMPLE 6: THE LENGTH AND/OR NATURE OF THE
INTERGENIC REGION DOWNSTREAM OF THE RESPIRATORY
SYNCYTIAL VIRUS GENE HAS AN EFFECT ON VIRUS
REPLICATION**

5 The three constructs in Example 5 were used in the following experiments to
determine the effects of the intergenic region on viral protein expression and viral replication.
See Figure 9.

First, RSV F protein expression for b/h PIV3/RSV F1, b/h PIV3/RSV F1*N-N, and
b/h PIV3/RSV F2 was compared at 24 and 48 hrs post-infection at an MOI of 0.1 in Vero
10 cells using Western blots. Western blots were performed as follows: Chimeric viruses were
used to infect (70-80%) subconfluent Vero cells at a MOI of 0.1. Twenty-four hours and
forty-eight hours post infection the media overlay was removed and infected monolayers
were washed once with 1 ml of PBS. The cells were subsequently lysed in 400 µl of
Laemmli buffer (Bio-Rad) containing 0.05% β-Mercaptoethanol (Sigma). 15 µl of each
15 sample was separated on 12% Tris-HCl Ready Gel (Bio-Rad) and transferred to nylon
membranes using a semi-dry transfer cell (Bio-Rad). Nylon membranes were rinsed in PBS
(pH 7.6) containing 0.5% (v/v) Tween-20 (Sigma) (PBST) and blocked with PBST
containing 5% (w/v) dry milk (PBST-M) for 20-30 minutes at room temperature.
Membranes were incubated with either a mixture of RSV F monoclonal antibodies (WHO
20 1269, 1200, 1153, 1112, 1243, 1107) at a 1:1000 dilution in PBST-M in PBST-M for 1 hour
at room temperature. Following 4 washes with PBST, the membranes were incubated with a
secondary horseradish peroxidase-conjugated goat anti-mouse antibody (Dako) at a 1:2000
dilution in PBST-M for 1 hour at room temperature. Membranes were washed 4 times with
PBST and developed using a chemiluminescence substrate (Amersham Pharmacia) and
25 exposed to Biomax Light Film (Kodak) for visualization of protein bands.

b/h PIV3/RSV F1 expressed RSV F₁ protein levels at 24 and 48 hrs post-infection
close to the levels observed for b/h PIV3/RSV F2 but much higher than those of b/h
PIV3/RSV F1*N-N. Therefore, the spacing between the gene start element and the
translation start codon may be critical for virus replication. The N gene start sequences were
30 changed to P gene start sequences, however this change only incurred the alteration of a
single nucleotide. Either of these factors may be responsible for rescuing the RSV F protein

expression phenotype.

Next, multicycle growth curves were carried out to compare the kinetics of virus replication of b/h PIV3/RSV F1, b/h PIV3/RSV F1*N-N, and b/h PIV3/RSV F2 in Vero cells at an MOI of 0.1 (*see* Figure 9B), which was performed as follows: Vero cells were grown to 90% confluence and infected at an MOI of 0.1 with b/h PIV3, b/h PIV3/RSV F1*N-N, b/h PIV3/RSV F1, and b/h PIV3/RSV F2. The infected monolayers were incubated at 37°C. At 0, 24, 48, 72, and 96 hours post-infection, cells and media were harvested together and stored at -70°C. Virus titers for each time point harvest were determined by plaque assays in Vero cells. The plaque assays were immunostained with RSV polyclonal antisera for quantification after 5 days of incubation.

As was shown on Figure 9B, the onset of replication of b/h PIV3/RSV F1*N-N was delayed and peak titers were lower than those of b/h PIV3/RSV F2. In contrast, b/h PIV3/RSV F1 displayed a growth curve that was nearly identical to that observed for b/h PIV3/RSV F2.

12. EXAMPLE 7: CLONING OF TRIVALENT BOVINE PARAINFLUENZA 3/HUMAN PARAINFLUENZA 3 VECTORED CONSTRUCTS

The following examples relate to the generation of trivalent vaccines that harbor the surface glycoproteins (F and HN) of hPIV3, RSV F, and hMPV F to protect children from disease caused by RSV, hMPV and hPIV3 using a single live attenuated virus vaccine. These trivalent viruses were recovered by reverse genetics.

The construction of two virus genomes, each comprising a chimeric b/h PIV3 backbone with two additional heterologous sequence insertions, wherein one heterologous nucleotide sequence is derived from a metapneumovirus F gene and another heterologous nucleotide sequence is derived from a respiratory syncytial virus F gene, were done as follows (*see* Figure 10): plasmids b/h PIV3/RSV F2 or b/h PIV3/hMPV F2 was digested with SphI and NheI, and a 6.5 kb fragment was isolated. The full-length cDNA for b/h PIV3 RSV F1 or b/h PIV3/hMPV F1 was digested with SphI and NheI and a 14.8 kb DNA fragment was isolated and ligated with the 6.5 kb DNA fragment derived from plasmid b/h PIV3/RSV F2 or b/h PIV3/hMPV F2 to generate full-length viral cDNAs.

Virus with the above described constructs has been amplified in Vero cells. The engineered virus as described herein can be used as a trivalent vaccine against the parainfluenza virus infection, metapneumovirus infection, and the respiratory syncytial virus infection.

13. EXAMPLE 8: CLONING OF TWO RESPIRATORY SYNCYTIAL VIRUS F TO THE BOVINE PARAINFLUENZA 3/HUMAN PARAINFLUENZA 3 VECTOR

Chimeric viruses that carry two copies of the RSV F gene were designed in order to determine whether more RSV protein produced by the chimeric virus will result in an improved immunogenicity. This virus was rescued by reverse genetics, biologically cloned and amplified in Vero cells to yield a virus stock with a titer of 1×10^6 pfu/ml. This virus, b/h PIV3/RSV F1F2, can be used to assess for virus growth kinetics, for RSV F protein production, and for replication and immunogenicity in hamsters.

The constructs were generated in the following manner (see Figure 11): the 1-5 RSV F2 plasmid was digested with SphI and NheI, and a 6.5 kb fragment was isolated. The full-length cDNA for b/h PIV3 RSV F1 was digested with SphI and NheI and a 14.8 kb DNA fragment was isolated and ligated with the 6.5 kb DNA fragment derived from 1-5 bPIV3/RSV F2 to generate full-length viral cDNAs.

14. EXAMPLE 9: CONSTRUCTION AND CLONING OF BOVINE PARAINFLUENZA 3/HUMAN PARAINFLUENZA 3 VECTORED HUMAN METAPNEUMOVIRUS F cDNA

The F gene of human metapneumovirus (hMPV) was inserted in positions 1 and 2 of the b/h PIV3 genome (Figure 12). The hMPV F gene cassette harbored the bPIV3 N-P intergenic region. The hMPV F gene plasmid (pRF515) was used, and a single nucleotide mutation in the hMPV F gene was corrected (*i.e.*, nucleotide 3352 was corrected from C to T (wild type)), generating pRF515-M4. The bPIV3 N-P intergenic region was added at the 3' end of the hMPV F gene using overlapping PCR. For hMPV F, the overlapping PCR oligo was 5'GGCTTCATACCACATAATTAGAAAAATAGCA CCTAATCATGTTCTTACAATGGTCGACC 3'. During this cloning step, oligos were used at the 5' end (5' GCAGCCTAGGCCGCAATAACAATGTCTTGAAAGTGGTG ATC 3')

and at the 3' end of the hMPV F gene cassette (5' CTACCTAGGTGAATCTT TGGT TG 3') in the PCR reaction that contained AvrII restriction enzyme sites. The hMPV F gene cassette was adjusted to conform to the rule of six using QuickChange mutagenesis kit and the following oligos (5'CCTAGGCCGCAATAGACAATGT CTTGG 3', 5'CCAAGACATT GTCTATTGCGGCCTAGG 3'). Full-length b/h PIV3/hMPV F1 (position 1) and F2 (position 2) cDNA plasmids were generated in the same fashion as described in section 9, Example 4, *supra*, for b/h PIV3/eGFP1 and eGFP2.

10 **15. EXAMPLE 10: IMMUNOPRECIPITATION AND REPLICATION
 ASSAYS OF BOVINE PARAINFLUENZA 3/HUMAN
 PARAINFLUENZA 3 VECTORED HUMAN METAPNEUMOVIRUS F**

To confirm that the F protein was expressed in the b/h PIV3 vectored human metapneumovirus F at position 2 (hMPV F2), guinea pig or human antiserum were used to immunoprecipitate the hMPV F protein (*see* Figure 13A). For immunoprecipitation of the hMPV F protein expressed by b/h PIV3, Vero cells were infected with b/h PIV3 or b/h PIV3/hMPV F2 at an MOI of 0.1 or 0.05. Twenty-four hours post-infection, the cells were washed once with DME without cysteine and minus methionine (ICN) and incubated in the same media for 30 min. The media was removed and 0.5 ml DME lacking cysteine and methionine containing 100 µCi of [³⁵S]-Pro-Mix (Amersham) was added to the cells. The infected cells were incubated in the presence of ³⁵S-isotopes for 5 hours at 37°C. Media was removed and the infected cells were lysed in 0.3 M RIPA buffer containing protease inhibitors. The cell lysate was incubated with hMPV guinea pig or human polyclonal antisera and bound to IgG-agarose (Sigma). After washing three times with 0.5 M RIPA buffer, the samples were fractionated on a 10% protein gel. The gel was dried and exposed to X-ray film.

The expression of hMPV F protein by b/h PIV3/hMPV F2 was shown by immunoprecipitation using the gp and human anti-hMPV antisera (Figure 13A). Interestingly, a specific band migrating at approximately 80 kDa was observed in the lysates of b/h PIV3/hMPV F2. This size corresponded to the F precursor protein, F₀. Non-specific bands of different sizes were also observed in the b/h PIV3 and mock control lanes (Figure 13). This data suggested that the b/h PIV3/hMPV F2 expressed the hMPV F protein.

However, the hMPV antibody reagents available are limited and these antisera interact only with the precursor of the hMPV F protein. It could also be possible that the cleaved F1 is unstable and thus not easily visualized using this method.

5 Growth curves were performed to determine the kinetics of virus replication of b/h PIV3/hMPV F2 and compare them to those observed for b/h PIV3 and b/h PIV3/RSV F2 in Vero cells at an MOI of 0.1 (Figure 13B). The data showed that b/h PIV3/hMPV F2 displayed a delayed onset of replication at 24 hours post-infection compared to b/h PIV3/RSV F2. However, at 48 hours post-infection and beyond, a difference in replication
10 was no longer observed.

 Growth curves were also performed to determine the kinetics of viral replication of b/h PIV3/hMPV F1 and compare them to those observed for b/h PIV3/hMPV F2 and b/h PIV3 in Vero cells at an MOI of 0.01 (Figure 13C). The data showed that b/h PIV3/hMPV F1 had a delayed onset of replication and yields lower peak titers compared to b/h PIV3/hMPV
15 F2 or b/h PIV3. The plaque size of b/h hMPV F1 is also smaller compared to b/h hMPV F2.

 The chimeric viruses, b/h PIV3/hMPV F1 and F2 were also assessed for their ability to infect and replicate in Syrian Golden hamsters (Table 5). The results showed that b/h PIV3/hMPV F1 and F2 replicated in the nasal turbinates and lungs of hamsters to levels observed for b/h PIV3. Even hMPV replicated to titers of 5.3 and 3.6 log₁₀ TCID₅₀/g tissue
20 in the upper and lower respiratory tracts of hamsters. These data showed that b/h PIV3/hMPV F1 and F2 could efficiently infect and replicate in the respiratory tract of hamsters, demonstrating thereby that hamsters represent a suitable small animal model to determine immunogenicity of hMPV as well as utilize this animal model to evaluate hMPV vaccine candidates.

25

30

Table 5

**Replication of b/h PIV3 Expressing
the hMPV F Protein in Positions 1 or 2 in Hamsters**

5	Virus ^a	Mean virus titer on day 4 post-infection (log ₁₀ TCID ₅₀ /g tissue ± S.E.) ^b	
		Nasal turbinates	Lungs
	b/h PIV3	4.8 ± 0.2	5.6 ± 0.6
	b/h hMPV F1	5.3 ± 0.5	5.7 ± 0.4
10	b/h hMPV F2	5.7 ± 0.5	4.6 ± 0.3
	hMPV	5.3 ± 0.1	3.6 ± 0.3

^a Groups of six hamster were inoculated intranasally with 1x 10⁶ pfu of indicated virus.

^b Standard error

Note: TCID₅₀ assays were read for CPE on Day 10.

**16. EXAMPLE 11: CLONING OF THE SOLUBLE RESPIRATORY
SYNCYTIAL VIRUS F GENE CONSTRUCT**

A construct containing a single copy of the soluble RSV F gene, a version of the RSV F gene lacking the transmembrane and cytosolic domains, was also generated (Figure 14). This construct can be used to test for immunogenicity. Its advantage would be the inability of the soluble RSV F to be incorporated into the virion membrane. Therefore this virus may be viewed as a safer chimeric virus since its virus tropism is not expected to change. The cDNA plasmid for b/h PIV3/sol RSV F can be rescued by reverse genetics.

The plasmid 1-5/RSV F2 (described previously) was used as a DNA template for PCR. The oligo RSV f.2 (5'GCTGTAACAGAATTGCAGTTGC 3') (which anneals at nt 5946 of RSV) and the oligo 5'CGTGGTTCGACCATTGTAAGAACATGATTAGGTGCTAT TTTTATTTAATTTGTGGTGGATTACCGGC3' were employed to remove the transmembrane and cytoplasmic domains of RSV F, deleting 150 nucleotides. The resulting PCR fragment was digested with HpaI and SalI and introduced into 1-5 RSV F2 treated with HpaI and SalI to yield 1-5 bPIV3/sol RSV F. This plasmid was digested with SphI and NheI and the resulting fragment was introduced into a b/h PIV3 cDNA digested with SphI and NheI to generate a full-length cDNA.

17. EXAMPLE 12: EXPRESSION OF HUMAN METAPNEUMOVIRUS F IN CELLS INFECTED WITH BOVINE PARAINFLUENZA 3/HUMAN PARAINFLUENZA 3 VECTORED HUMAN METAPNEUMOVIRUS F

5 The b/h 104 hMPV F virus stocks were serially diluted 10 fold and used to infect subconfluent Vero cells. Infected cells were overlaid with optiMEM media containing gentamycin and incubated at 35°C for 5 days. Cells were fixed with 100% methanol and immunostained with 1:1000 dilution of anti-hMPV001 guinea pig sera followed by 1:1000 dilution of anti-guinea pig HRP conjugated antibodies. Expression of hMPV F is visualized
10 by specific color development in the presence of the AEC substrate system (DAKO corporation). See Figure 15A.

The b/h NP-P hMPV F virus stocks were serially diluted 10 fold and used to infect subconfluent Vero cells. Infected cells were overlaid with 1% methyl cellulose in EMEM/L-15 medium (JRH Biosciences; Lenexa, KS) supplemented with 1x L15/MEM
15 media containing penicillin/streptomycin, L-glutamine and fetal bovine serum. Infected cells were incubated at 35°C for 5 days, fixed with 100% methanol and immunostained with 1:1000 dilution of anti-hMPV001 guinea pig sera followed by 1:1000 dilution of anti-guinea pig HRP conjugated antibodies. (See Figure 15B). The anti hMPV001 guinea pig serum is specific for hMPV001 proteins and do not bind to b/h PIV3 proteins.

20

18. EXAMPLE 13: RESCUE OF CHIMERIC BOVINE PARAINFLUENZA TYPE 3 / HUMAN PARAINFLUENZA TYPE 3 VIRUS IN HELA CELLS AND VERO CELLS

Rescue of the chimeric b/h PIV3 virus was done using a similar procedure as for bPIV3 rescue. Rescue of b/h PIV3 chimeric virus by reverse genetics was carried out in
25 HeLa cells using LipofecTACE (Gibco/BRL). The 80% confluent HeLa cells, Hep-2 cells, or Vero cells were infected with MVA at an MOI of 4. One hour post-infection, the full-length anti-genomic b/h PIV3 cDNA (4 µg) was transfected into the infected HeLa or Vero cells together with the NP (0.4 µg), P (0.4 µg), and L/pCITE (0.2 µg) expression plasmids. Forty hours post-transfection, the cells and the cell supernatant were harvested (P0) and
30 subjected to a single freeze-thaw cycle. The resulting cell lysate was then used to infect a fresh Vero cell monolayer in the presence of 1-beta-D-arabinofuranosylcytosine (ara C), a

- replication inhibitor of vaccinia virus, to generate a P1 virus stock. The supernatant and cells from these plates were harvested, freeze-thawed once and the presence of bPIV3 virus particles was assayed for by immunostaining of virus plaques using PIV3-specific antiserum.
- 5 The cell lysates of the P1 harvest resulted in complete CPE of the Vero cell monolayers and immunostaining indicated the presence of an extensive virus infection.

19. **EXAMPLE 14: RESCUE OF BOVINE PARAINFLUENZA TYPE 3/HUMAN PARAINFLUENZA TYPE 3 VECTORED HUMAN METAPNEUMOVIRUS F VIRUSES**

- 10 The b/h PIV3 viruses expressing hMPV F at position one (b/h 104 hMPV F) or position two (b/h NP-P hMPV F) were obtained as follows. HEp-2 or Vero cells at 80-90% confluency in 6 well dishes were infected with Fowlpox-T7 at a multiplicity of infection (m.o.i.) of 0.1 to 0.3. Following infection with Fowlpox-T7, cells were washed once with PBS and transfected with the following amounts of plasmid DNA: full length b/h 104 hMPV
- 15 F or b/h NP-P hMPV F cDNA 2.0 µg, pCite N 0.4 µg, pCite P 0.4 µg, pCite L 0.2 µg. (The pCite plasmids have a T7 promoter followed by the IRES element derived from the encephalomyocarditis virus (EMCV)). Transfection was performed in the presence of Lipofectamine 2000 (Invitrogen) according to manufacturer's instruction. The transfection reaction was incubated at 33°C for 5 to 12 hours following which the media containing
- 20 lipofectamine 2000 was replaced with 2 ml of fresh OptiMEM containing gentamicin. The transfected cells were further incubated at 33°C for two days. Cells were stabilized with SPG and lysed by one freeze-thaw cycle at -80°C. The crude cell lysate was used to infect a new Vero monolayer in order to amplify rescued viruses.

25 20. **EXAMPLE 15: RESCUE OF BOVINE PARAINFLUENZA TYPE 3/HUMAN PARAINFLUENZA TYPE 3 VECTORED RESPIRATORY SYNCYTIAL VIRUS GENES BY REVERSE GENETICS**

- Infectious virus was recovered by reverse genetics in HeLa or HEp-2 cells using transfection methods described previously (see Example 13). Briefly, HEp-2 or Vero cells at
- 30 80-90% confluency in 6 well tissue culture dishes were infected with FP-T7 or MVA-T7 at a multiplicity of infection (m.o.i.) of 0.1 - 0.3 or 1 - 5 respectively. Following infection with FP-T7 or MVA-T7, cells were washed once with PBS and transfected with the following

amounts of plasmid DNA (2.0µg full-length b/h PIV3 RSV F or G cDNA, 0.4µg pCITE/N, 0.4µg pCITE/P, 0.2µg pCITE/L). Transfections were performed in the presence of Lipofectamine2000 (Invitrogen) according to manufacturer's instruction. The transfection reactions were incubated at 33°C for 5 to 12 hours following which the media containing Lipofectamine 2000 was replaced with 2 ml of fresh OptiMEM containing gentamicin. The transfected cells were incubated further at 33°C for two days. Cells were stabilized with SPG and lysed with one freeze-thaw cycle at -80°C. The crude cell lysate was used to infect a new Vero cell monolayer in order to amplify rescued viruses. The chimeric viruses were purified by limiting dilutions in Vero cells and high titer virus stocks of $10^6 - 10^8$ PFU/ml were generated. The RSV genes of the chimeric viruses were isolated by RT-PCR and the sequences were confirmed. Expression of the RSV proteins was confirmed by immunostaining of infected Vero cell monolayers with RSV goat polyclonal antiserum (Biogenesis).

15

21. EXAMPLE 16: CONFIRMATION OF CHIMERIC BOVINE PARAINFLUENZA TYPE 3 / HUMAN PARAINFLUENZA TYPE 3 VIRUS RESCUE BY RT-PCR

To ascertain that the rescued virus is chimeric in nature, *i.e.* the virus contains hPIV3 F and HN gene sequences in a bPIV3 backbone, the viral RNA genome was analyzed further by RT-PCR. Vero cells, infected with the P1 virus stock of three independently derived isolates of b/h PIV3 were harvested and total RNA was isolated. The viral RNA was amplified using an oligo that anneals at position 4757 of bPIV3. A viral region from nt 5255 to 6255 was amplified by PCR. The resulting 1 kb PCR fragment should contain hPIV3 sequences. This was confirmed by digestion with enzymes (SacI and Bgl II) specific for hPIV3 and that do not cut in the complementary region of bPIV3 (see Figure 2). As expected, SacI and Bgl II cut the PCR fragment into smaller fragments confirming that the isolated sequences are derived from hPIV3 (see lanes 3, 5, 7). In addition, a region in the polymerase L gene from nt 9075 to nt 10469 was amplified by PCR. This region should contain bPIV3 sequences. Again the resulting 1.4 kb PCR fragment was digested using enzyme specific for bPIV3 (PvuII and BamHI) that do not cut in the equivalent region of hPIV3 (Figure 3). The 1.4 kb fragment was indeed digested by both PvuII and BamHI

confirming that the polymerase gene is bPIV3 in origin (see lanes 3, 4, 6, 7, 9 and 10 of Figure 3). In summary, the RT-PCR analysis shows that the rescued b/h PIV3 virus is chimeric in nature. It contains hPIV3 F and HN genes in a bPIV3 genetic backbone.

5

**22. EXAMPLE 17: GENETIC STABILITY OF BOVINE
PARAINFLUENZA TYPE 3/HUMAN PARAINFLUENZA TYPE 3
VECTORED RESPIRATORY SYNCYTIAL VIRUS GENES**

In order to demonstrate that the b/h PIV3/RSV chimeric viruses are genetically stable and maintain the introduced RSV gene cassettes, infected cell lysates were serially blind
10 passaged ten times in Vero cells. Sub-confluent Vero cells in T25 flasks were infected with b/h PIV3/RSV at an MOI of 0.1 and incubated for 4 days at 33°C or until CPE was visible. At the end of the incubation period the infected cells and media were harvested, frozen and thawed two times, and the resulting cell lysate was used to infect a new T25 flask of Vero
15 cells. This cycle was repeated ten times. All cell lysates from P1 to P10 were analyzed by plaque assay and immunostaining with RSV polyclonal antisera for expression of RSV proteins and virus titers. At passage 10, the RSV gene cassettes were isolated by RT-PCR and the RSV gene sequences were verified by DNA sequence analysis (to identify possible nucleotide alterations). All of the isolates maintained the RSV gene cassettes and RSV
20 protein expression for the 10 passages analyzed (data not shown).

**23. EXAMPLE 18: VIRION FRACTIONATION OF BOVINE
PARAINFLUENZA TYPE 3/HUMAN PARAINFLUENZA TYPE 3
VECTORED RESPIRATORY SYNCYTIAL VIRUS GENES ON
SUCROSE GRADIENTS**

25 The question of whether the RSV proteins were incorporated into the b/h PIV3 virion was investigated further by use of a biochemical assay. Vero cells were inoculated with each of the chimeric b/h PIV3/RSV viruses at an MOI of 0.1. When maximum CPE was visible, the infected monolayers were frozen, thawed, and spun for 10 minutes at 2000 rpm. The clarified supernatants were spun through a 20% sucrose cushion at 100,000 x g for 90
30 minutes. The pellet was then resuspended in PBS and layered gently on top of a 20-66% sucrose gradient. The gradients were spun at 100,000 x g for 20 hours to achieve equilibrium. Eighteen 2 ml fractions were harvested starting from the top of the gradient. 0.4 ml of each

fraction was removed for virus titer determination. Each fraction was resuspended in 2 volumes of 20% PBS and concentrated by spinning at 100,000 x g for 1 hour. The pellet was then resuspended in 0.05 ml Laemmli buffer (Biorad) and analyzed for RSV and PIV3 proteins by Western blot, using an RSV F MAb (NuMax L1FR-S28R), RSV (Biogenesis) and bPIV3 (VMRD) polyclonal antisera. C-terminally truncated RSV F protein expressed in baculovirus that was purified to homogeneity, was also analyzed on a sucrose gradients.

The fractions were also analyzed for peak virus titers by plaque assay. Control gradients of free RSV F (generated in baculovirus and C-terminally truncated), RSV A2, and b/h PIV3 were carried out initially. The majority of free RSV F was present in fractions 3, 4, 5, and 6 in the top portion of the gradient (Figure 16A). The biggest concentration of RSV virions was observed in fractions 10, 11 and 12 (Figure 16B). The RSV fractions were probed with RSV polyclonal antiserum as well as with RSV F MAb. The fractions that contained the greatest amounts of RSV virions also showed the strongest signal for RSV F, suggesting that the RSV F protein co-migrated and associated with RSV virions (Figure 16B). These fractions also displayed the highest virus titers (Figure 16B). The b/h PIV3 virions may be more pleiomorphic and thus the spread of the peak fractions containing b/h PIV3 virions was more broad. b/h PIV3 virions were present in fractions 9, 10, 11, 12, and 13 (Figure 16C). Again the fractions harboring the most amounts of virions, also displayed the highest virus titers by plaque assay (Figure 16C). Sucrose gradient fractions of b/h PIV3/RSV F2 were analyzed with both a PIV3 polyclonal antiserum and an RSV F MAb (Figure 16D). The fractions containing most of the virions were fractions 11, 12, 13, and 14 as was shown by western using the PIV3 antiserum. Correspondingly, these were also the fractions that displayed the highest amounts of RSV F protein. However, some free RSV F was also present in fractions 5 and 6. Fractions 11, 12, 13 and 14 displayed the peak virus titers (Figure 16D). Similarly, the fractions containing the most virions of b/h PIV3/RSV G2 (fractions 9, 10, 11, and 12) also showed the strongest signal for RSV G protein (Figure 16E). Again these were the fractions with the highest virus titers (Figure 16E). Collectively these data suggested that the majority of the RSV F and G proteins co-migrated and associated with the b/h PIV3 virions. However, some free RSV proteins were also present in the top fractions of the gradients.

24. EXAMPLE 19: THE CHIMERIC BOVINE PARAINFLUENZA TYPE 3/HUMAN PARAINFLUENZA TYPE 3 VECTORED RESPIRATORY SYNCYTIAL VIRUS (RSV) COULD NOT BE NEUTRALIZED WITH RSV ANTISERA

5 In order to address the important safety question of whether the RSV surface glycoproteins incorporated into the b/h PIV3 virion resulted in an altered virus tropism phenotype, neutralization assays were carried out (Tables 6 and 7). RSV F MAbs (WHO 1200 MAb) neutralized 50% of wildtype RSV A2 at a 1:2000 dilution (Table 6). In contrast, even a dilution of 1:25 did not neutralize any of the chimeric b/h PIV3/RSV. Similarly, a
10 dilution of 1:400 of the polyclonal RSV antiserum (Biogenesis) neutralized 50% of RSV A2, but even a dilution of 1:15.6 did not neutralize b/hPIV3 RSV (Table 6).

Table 6

The b/h PIV3 RSV Chimeric Viruses are not Neutralized by RSV Antibodies

15	Virus used in neutralization assay	Reciprocal 50% neutralizing antibody dilution	
		RSV F MAb	RSV Ab
	RSV	2000	400.0
	b/h PIV3	<25	<15.6
	b/h RSV F1*N-N	<25	<15.6
20	b/h RSV F2	<25	<15.6
	b/h RSV G1	ND	<15.6
	b/h RSV G2	ND	<15.6

25 hPIV3 F MAb C191/9 neutralized 50% of b/h PIV3 as well as the b/h PIV3/RSV at a dilution of 1:500 (Table 7). An hPIV3 HN MAb 68/2 neutralized b/h PIV3 at a dilution of 1:16,000, and the b/h PIV3/RSV at a dilution of 1:32,000 (Table 7).

Table 7**The b/h PIV3 RSV Chimeric Viruses are Neutralized by hPIV3 Mabs**

5	Virus used in neutralization assay	Reciprocal 50% neutralizing antibody dilution	
		hPIV3 F MAb	hPIV3 HN MAb
	RSV	62.5	<500
	b/h PIV3	500	16000
	b/h RSV F1*N-N	500	32000
	b/h RSV F2	500	32000
10	b/h RSV G1	ND ^d	32000
	b/h RSV G2	ND	32000

^d not determined.

15 **25. EXAMPLE 20: THE CHIMERIC BOVINE PIV DEMONSTRATE ATTENUATED PHENOTYPES AND ELICIT STRONG PROTECTIVE RESPONSES WHEN ADMINISTERED *IN VIVO***

Five week old Syrian Golden hamsters were infected with 5×10^5 pfu of wildtype bPIV3, recombinant bPIV3, hPIV3, human/bovine PIV3, and placebo. The five different animal groups were kept separate in micro-isolator cages. Four days post-infection, the

20 animals were sacrificed. The nasal turbinates and lungs of the animals were homogenized and stored at -80°C . Virus present in the tissues was determined by TCID_{50} assays in MDBK cells at 37°C . Virus infection was confirmed by hemabsorption with guinea pig red blood cells. Table 8 shows the replication titers of the different PIV3 strains in hamsters in the lungs and nasal turbinates. Note that recombinant bPIV3 and the b/h PIV3 chimeric viruses

25 are attenuated in the lungs of the hamsters:

Table 8
Replication of PIV3 Viruses in Syrian
Golden Hamsters in the Nasal Turbinates and Lungs.

5	Replication of bPIV3, r-bPIV3, r-bPIV3(l), hPIV3 and Bovine/Human PIV3(l) in the Upper and Lower Respiratory Tract of Hamsters		
	Mean virus titer on day 4 postinfection (\log_{10} TCID ₅₀ /g tissue = S. E.) ^b		
	Virus ^a	Nasal turbinates	Lungs
	bPIV3	5.3 ± 0.3	5.3 ± 0.2
	r-bPIV3	5.0 ± 0.3	3.5 ± 0.2
10	r-bPIV3(l)	5.5 ± 0.2	5.4 ± 0.2
	hPIV3	4.9 ± 0.2	5.4 ± 0.2
	Bovine/human PIV3(l)	4.9 ± 0.2	4.5 ± 0.2

^a Groups of four hamsters were inoculated intranasally with 5×10^5 PFU of indicated virus.

^b Standard error.

Furthermore, serum samples collected from the hamsters prior to infection and at day 21 post-infection were analyzed in a hemagglutination inhibition assay. The serum samples were treated with receptor destroying enzyme (RDE, DENKA Seiken Co.) and non-specific agglutinins were removed by incubation with guinea pig red blood cells for 1 hour on ice.

20 Wildtype bPIV3 and hPIV3 were added to two-fold serially diluted hamster serum samples. Finally, guinea pig red blood cells (0.5%) were added, and hemagglutination was allowed to occur at room temperature. Table 9 shows the antibody response generated in the hamsters upon being infected with the different PIV3 strains. Note that the b/h PIV3 chimeric virus generates as strong an antibody response against hPIV3 as does wild type hPIV3, far

25 exceeding the response generated by the recombinant or wildtype bPIV3:

Table 9**Hemagglutination Inhibition Assay Using Serum from Hamsters Infected with Different PIV3 Viruses.**

5	Virus Used for Inoculation of the Hamsters	Hamster Serum Titers for	
		wt bPIV3	HPIV3
	Recombinant bPIV3	1:16	1:16
	Wt bPIV3	1:16	1:8
10	Wt hPIV3	1:4	1:128
	b/h PIV3 chimeric virus	1:8	1:128
	Placebo	<1:4	<1.4

These results demonstrate the properties of b/h PIV3 chimeric viruses of the present invention which make these recombinants suitable for use in vaccine formulations. Not only do the b/h PIV3 chimeric viruses demonstrate an attenuated phenotype when administered *in vivo*, but they also generate as strong an antibody response as the wildtype hPIV3. Thus, because the chimeric viruses of the present invention have a unique combination of having an attenuated phenotype and eliciting as strong an immune response as a wildtype hPIV, these chimeric viruses have the characteristics necessary for successful use in humans to inhibit and/or protect against infection with PIV.

26. EXAMPLE 21: REPLICATION OF BOVINE PARAINFLUENZA 3/HUMAN PARAINFLUENZA 3 VECTORED RESPIRATORY SYNCYTIAL VIRUS G OR F PROTEIN IN THE UPPER AND LOWER RESPIRATORY TRACT OF HAMSTERS

Five week old Syrian Golden hamsters (six animals per group) were infected intranasally with 1×10^6 pfu or 1×10^4 PFU of b/h PIV3, b/h PIV3/RSV, RSV A2, or placebo medium in a 100 ml volume. The different groups were maintained separately in micro-isolator cages. Four days post-infection, the nasal turbinates and lungs of the animals were harvested, homogenized and stored at -70°C . The titers of virus present in the tissues were determined by TCID₅₀ assays in Vero cells. For the challenge assays, the animals were inoculated on day 28 intranasally with 1×10^6 pfu/ml of hPIV3 or RSV A2. Four days post-

challenge, the nasal turbinates and lungs of the animals were isolated and assayed for challenge virus replication by plaque assays on Vero cells that were immunostained for quantification. Table 10 shows the replication titers of the different strains in hamsters in the
 5 lungs and nasal turbinates.

Table 10

**Replication of bovine/human PIV3 Expressing the
 RSV G or F proteins in the Upper and Lower Respiratory Tract of Hamsters.**

10	Virus ^a	Mean virus titer on day 4 postinfection (\log_{10} TCID ₅₀ /g tissue = S. E.) ^b	
		Nasal turbinates	Lungs
	b/h PIV3	4.8 ± 0.4	4.4 ± 0.3
	RSV A2	3.4 ± 0.5	3.3 ± 0.5
	b/h RSV G1	4.2 ± 0.7	2.9 ± 0.7
15	b/h RSV F1	3.9 ± 0.4	2.7 ± 0.2
	b/h RSV F1 N-P	4.6 ± 0.4	3.5 ± 0.2
	b/h RSV G2	4.2 ± 0.9	4.3 ± 0.2
	b/h RSV F2	4.6 ± 0.6	4.4 ± 0.5

^a Groups of four hamsters were inoculated intranasally with 5×10^6 PFU of indicated
 20 virus.

^b Standard error.

Syrian Golden hamsters represent a suitable small animal model to evaluate replication and immunogenicity of recombinant bPIV3 and hPIV3 genetically engineered viruses. It was expected that the introduction of the RSV antigens would not alter the ability
 25 of the chimeric b/h PIV3 to replicate in hamsters. The results showed that all of the chimeric viruses replicated to levels similar to those of b/h PIV3 in the nasal turbinates of hamsters (Table 10). In contrast, the chimeric viruses harboring the RSV genes in the first position displayed 1 – 1.5 \log_{10} reduced titers in the lungs of hamsters compared to b/h PIV3 (Table 10). The chimeric viruses containing the RSV genes in the second position replicated to
 30 similar titers observed for b/h PIV3 in the lower respiratory tract of hamsters (Table 10).

**27. EXAMPLE 22: BOVINE PARAINFLUENZA 3/HUMAN
PARAINFLUENZA 3 VECTORED RESPIRATORY SYNCYTIAL
VIRUS IMMUNIZED HAMSTERS WERE PROTECTED UPON
CHALLENGE WITH HUMAN PARAINFLUENZA 3 AND
RESPIRATORY SYNCYTIAL VIRUS A2**

5

On Day 28 post-immunization, the hamsters were challenged with 1×10^6 PFU of either RSV A2 or hPIV3 to evaluate the immunogenicity induced by the b/h PIV3/RSV. Animals that received the b/h PIV3/RSV were protected completely from RSV as well as hPIV3 (Table 11). Only the animals that were administered the placebo medium displayed high titers of challenge virus in the lower and upper respiratory tracts. This assay also

10 showed that animals immunized with RSV, were not protected from challenge with hPIV3. Similarly, animals vaccinated with hPIV3 displayed high titers of the RSV challenge virus (Table 11).

15

20

25

30

Table 11

**b/h PIV3/RSV Immunized Hamsters were
Protected Upon Challenge with hPIV3 and RSV A2**

5	Challenge	hPIV3		RSV A2	
	Virus:	Mean Virus Titer on Day 4 Post-challenge (\log_{10} TCID ₅₀ /g tissue \pm S.E.) ^{b,c}		Mean Virus Titer on Day 4 Post- challenge (\log_{10} pfu/g tissue \pm S.E.) ^b	
	Immunizing Virus ^a	Nasal turbinates	Lungs	Nasal Turbinates	Lungs
10	b/h PIV3	<1.2 \pm 0.0	<1.0 \pm 0.1	ND	ND
	b/h RSV G1	<1.2 \pm 0.1	<1.1 \pm 0.1	< 1.0 \pm 0.3	< 0.7 \pm 0.1
	b/h RSV F1	<1.2 \pm 0.2	<1.0 \pm 0.0	< 1.1 \pm 0.5	< 0.6 \pm 0.0
	b/h RSV F1 NP-P	<1.0 \pm 0.0	<1.0 \pm 0.0	< 0.8 \pm 0.1	< 0.5 \pm 0.0
	b/h RSV G2	<1.2 \pm 0.2	<1.1 \pm 0.2	< 0.8 \pm 0.1	< 0.8 \pm 0.3
15	b/h RSV F2	<1.2 \pm 0.1	<1.0 \pm 0.1	< 1.3 \pm 0.6	< 1.6 \pm 1.0
	RSV A2	4.5 \pm 0.6	4.8 \pm 0.6	< 0.6 \pm 0.2	< 0.6 \pm 0.1
	Placebo	4.4 \pm 0.1	4.1 \pm 0.1	3.6 \pm 0.8	3.1 \pm 0.7

^a Virus used to immunize groups of six hamsters on day 0.

^b On day 28, the hamsters were challenged with 10⁶ pfu of hPIV3 or RSV A2. Four days post-challenge, the lungs and nasal turbinates of the animals were harvested.

^c Standard error.

**28. EXAMPLE 23: VACCINATION OF HAMSTERS WITH BOVINE
PARAINFLUENZA 3/HUMAN PARAINFLUENZA 3 VECTORED
RESPIRATORY SYNCYTIAL VIRUS INDUCES SERUM HAI AND
NEUTRALIZING ANTIBODIES**

Prior to the challenge, serum samples were obtained on Day 28 from the immunized animals. The hamster sera were analyzed for the presence or RSV neutralizing antibodies using a 50% plaque reduction assay, and for PIV3 HAI serum antibodies by carrying out hemagglutination inhibition (HAI) assays (Table 8). 50% plaque reduction assay (neutralization assay) was carried out as follows: the hamster sera were two-fold serially

diluted, and incubated with 100 PFU of RSV A2 for one hour. Then the virus-serum mixtures were transferred to Vero cell monolayers and overlaid with methylcellulose. After 5 days of incubation at 35°C, the monolayers were immunostained using RSV polyclonal antiserum for quantification. Hemagglutination-inhibition (HAI) assays were performed by incubating serial two-fold dilutions of Day 28 hamster sera at 25°C for 30 min with hPIV3 in V-bottom 96-well plates. Subsequently, guinea pig erythrocytes were added to each well, incubation was continued for an additional 90 min, and the presence or absence of hemagglutination in each well was recorded.

10 The results showed that the viruses expressing the RSV F protein displayed RSV neutralizing antibody titers nearly as high as those observed with serum obtained from animals vaccinated with wildtype RSV (Table 12). In contrast, the viruses expressing the RSV G protein showed much lower levels of RSV neutralizing antibodies (Table 12). All of the chimeric b/h PIV3/RSV hamster sera showed levels of HAI serum antibodies that were
15 close to the levels observed for b/h PIV3 (Table 12). The results showed that the chimeric b/h PIV3 can infect and replicate efficiently in hamsters and elicit a protective immune response.

20

25

30

Table 12

**Vaccination of Hamsters with b/h PIV3/RSV
Induces Serum HAI and Neutralizing Antibodies**

5	Virus ^a	Neutralizing antibody response to RSV ^{b,c} (mean reciprocal log ₂ ± SE)	HAI antibody response to hPIV3 ^c (mean reciprocal log ₂ ± SE)
	RSV	7.9 ± 1.00	ND
	b/h RSV F1* N-N	7.8 ± 0.85	6.6 ± 0.5
10	b/h RSV F1	5.5 ± 0.53	5.5 ± 0.5
	b/h RSV G1	3.4 ± 0.50	6.6 ± 0.7
	b/h RSV F2	6.9 ± 0.65	6.7 ± 0.8
	b/h RSV G2	3.4 ± 0.50	5.2 ± 0.4
	b/h PIV3	ND	7.2 ± 0.5

15

^a Viruses used to immunize hamsters.

^b The neutralizing antibody titers were determined by a 50% plaque reduction assay.

^c The neutralizing antibody titers of hamster pre-serum were < 1.0 and the HAI antibody titers were < 4.0.

20

**29. EXAMPLE 24: VACCINATION OF HAMSTERS WITH LOW DOSE
OF BOVINE PARAINFLUENZA 3/HUMAN PARAINFLUENZA 3
VECTORED RESPIRATORY SYNCYTIAL VIRUS PROTECTED
HAMSTERS FROM CHALLENGE WITH RESPIRATORY
SYNCYTIAL VIRUS A2, AND INDUCES SERUM HAI AND
NEUTRALIZING ANTIBODIES**

25

In order to identify the best vaccine candidate, low dose virus with different constructs (*see* Example 2) were used to immunize hamsters. The results of the challenging experiments are summarized in Table 13.

30

Table 13

**b/h PIV3/RSV-Low Dose Immunized
Hamsters are Protected From Challenge with RSV A2**

5		Replication		Challenge with RSV A2	
		Mean Virus Titer on Day 4 Post-vaccination (log ₁₀ TCID ₅₀ /g tissue ± S.E.) ^{b,c}		Mean Virus Titer on Day 4 Post-challenge (log ₁₀ pfu/g tissue ± S.E.) ^b	
10	Immunizing Virus ^a	Nasal turbinates	Lungs	Nasal Turbinates	Lungs
	b/h PIV3	4.9 ± 0.5	4.8 ± 1.0	ND	ND
	b/h RSV G1	3.0 ± 0.8	3.1 ± 0.5	< 0.9 ± 0.5	< 0.7 ± 0.4
	b/h RSV F1* N-N	3.4 ± 0.1	3.5 ± 0.1	< 1.4 ± 0.7	< 0.5 ± 0.0
	b/h RSV G2	4.1 ± 0.6	3.8 ± 0.4	< 0.8 ± 0.0	< 0.5 ± 0.1
15	b/h RSV F2	5.2 ± 0.6	3.9 ± 0.4	< 0.7 ± 0.1	< 0.5 ± 0.1
	RSV A2	2.8 ± 0.3	2.7 ± 0.6	< 0.8 ± 0.1	< 0.5 ± 0.0
	Placebo	ND ^d	ND	3.0 ± 0.8	3.2 ± 0.9

^a Virus used to immunize groups of six hamsters on day 0 with a low dose of 10⁴ PFU/ml.

^b On day 28, the hamsters were challenged with 10⁶ pfu of RSV A2. Four days post-challenge, the lungs and nasal turbinates of the animals were harvested.

^c Standard error.

^d not determined.

Next, the neutralizing antibody titers were determined by a 50% plaque reduction assay (neutralization assay). Neutralization assays were performed for b/h PIV3, b/h PIV3/RSV chimeric viruses or RSV using Vero cells. Serial two-fold dilutions of RSV polyclonal antiserum (Biogenesis; Poole, England), an RSV F MA b (WHO 1200 MA b) obtained from MedImmune or hPIV3 F (C191/9) and HN (68/2) MAbs, were incubated with approximately 100 PFU of either b/h PIV3, b/h PIV3/RSV chimeric viruses or RSV in 0.5 ml

OptiMEM at RT for 60 min. Following the incubation, virus-serum mixtures were transferred to Vero cell monolayers, incubated at 35°C for 1 hour, overlaid with 1% methyl cellulose in EMEM/L-15 medium (JRH Biosciences; Lenexa, KS) and incubated at 35°C .

- 5 Six days post-inoculation, the infected cell monolayers were immunostained. Neutralization titers were expressed as the reciprocal of the highest serum dilution that inhibited 50% of viral plaques. Neutralization assays were also carried out for serum obtained on Day 28 post-infection from hamsters immunized with b/h PIV3, b/h PIV3/RSV chimeric viruses, or RSV A2. The hamster sera were two-fold serially diluted, and incubated with 100 PFU of RSV
- 10 A2 for one hour. Then the virus-serum mixtures were transferred to Vero cell monolayers and overlaid with methylcellulose. After 5 days of incubation at 35°C the monolayers were immunostained using RSV polyclonal antiserum for quantification. The neutralizing antibody titers of hamster pre-serum were < 1.0 and the HAI antibody titers were < 4.0. Hemagglutination-inhibition (HAI) assays were performed by incubating serial two-fold
- 15 dilutions of Day 28 hamster sera at 25°C for 30 min with hPIV3 in V-bottom 96-well plates. Subsequently, guinea pig erythrocytes were added to each well, incubation was continued for an additional 90 min, and the presence or absence of hemagglutination in each well was recorded. Table 14 summarizes the results:

20

25

30

Table 14

**Vaccination of Hamsters with Lower Doses of
b/h PIV3/RSV Induces Serum HAI and Neutralizing Antibodies**

5

Virus ^a	Neutralizing antibody response to RSV ^{b,c} (mean reciprocal log ₂ ± SE)	HAI antibody response to hPIV3 ^c (mean reciprocal log ₂ ± SE)
RSV	6.5 ± 0.7	ND
b/h RSV F1* N-N	2.5 ± 0.7	5.7 ± 0.6
b/h RSV G1	2.0 ± 0.0	6.0 ± 0.0
b/h RSV F2	3.8 ± 1.5	6.7 ± 0.6
b/h RSV G2	3.8 ± 1.3	5.5 ± 0.6
b/h PIV3	ND	6.5 ± 0.7

10

15

^a Viruses used to immunize hamsters at a low dose of 10⁴ pfu/ml.

^b The neutralizing antibody titers were determined by a 50% plaque reduction assay.

^c The neutralizing antibody titers of hamster pre-serum were < 1.0 and the HAI antibody titers were < 4.0.

20

The restricted replication phenotype of the chimeric viruses possessing RSV genes in the first position was exacerbated when the inoculation dose was reduced to 1 x 10⁴ PFU per animal. b/h PIV3/RSV F1 and G1 replicated in the upper respiratory tracts of hamsters to titers that were reduced by 1.0 – 2.0 log₁₀ compared to those of b/h PIV3 (Table 13). In contrast, b/h PIV3/RSV with the RSV genes in position 2, replicated in the upper respiratory tract to levels observed for b/h PIV3. Replication in the lungs of hamsters was also more restricted for the b/h PIV3/RSV harboring RSV genes in the first position (Table 13). In contrast, b/h PIV3/RSV F2 still replicated to high titers of 10^{5.2} and 10^{3.9} in the nasal turbinates and lungs, respectively (Table 13). The vaccinated hamsters were challenged on Day 28 with 1 x 10⁶ pfu of RSV A2 (Table 13). Despite the low levels of replication observed in the respiratory tracts of hamsters, the animals were protected in both the lower

25

30

and upper respiratory tract from challenge with RSV (Table 13). The degree of protection was as good as was observed for animals vaccinated with wt RSV. Only the animals that received placebo medium showed high virus titers in the nasal turbinates and lungs (Table 13). Serum was collected from the immunized hamsters on Day 28, and analyzed for the presence of RSV neutralizing and PIV3 HAI serum antibodies (Table 14). An approximately 50% drop in RSV neutralizing antibody titers was observed in sera obtained from hamsters immunized with b/h PIV3/RSV as compared to the titers observed for wt RSV sera (Table 14). But the sera obtained from animals that had received b/h PIV3 harboring the RSV genes in position 2, still displayed higher RSV neutralization antibody titers than was observed for sera from b/h PIV3/RSV with the RSV genes in position 1. The PIV3 HAI serum antibody titers were also slightly reduced compared to the b/h PIV3 sera (Table 14).

15 30. **EXAMPLE 25: BOVINE PARAINFLUENZA 3/HUMAN
PARAINFLUENZA 3 VECTORED HUMAN METAPNEUMOVIRUS F
IMMUNIZED HAMSTERS WERE PROTECTED UPON
CHALLENGE WITH HUMAN PARAINFLUENZA VIRUS 3 OR
HUMAN METAPNEUMOVIRUS NL/001**

Five groups of Syrian Golden Hamsters (each group had six hamsters) were immunized with b/h PIV3, b/h hMPV F1, b/h hMPV F2, hMPV or placebo respectively. The five different animal groups were kept separate in micro-isolator cages. On Day 28 post-immunization, the hamsters were challenged with 1×10^6 PFU of either hPIV3 or hMPV (NL/001 strain) to evaluate the immunogenicity induced by the b/h PIV3/hMPV F. Four days post-challenge, the animals were sacrificed. The nasal turbinates and lungs of the animals were homogenized and stored at -80°C . Virus present in the tissues was determined by TCID₅₀ assays in MDBK cells at 37°C . Virus infection was confirmed by hemabsorption with guinea pig red blood cells. Table 15 shows the replication titers of the PIV3 strain and the MPV strain in hamsters in the lungs and nasal turbinates.

Table 15

**b/h PIV3/hMPV F-Immunized Hamsters were Protected Upon Challenge with hPIV3
or hMPV/NL/001**

5	Challenge virus:	hPIV3		hMPV	
		Mean virus titer on day 4 post-challenge (\log_{10} TCID ₅₀ /g tissue \pm S.E) ^b		Mean virus titer on day 4 post-challenge (\log_{10} PFU/g tissue \pm S.E) ^b	
10	Immunizing virus ^a	Nasal Turbinates	Lungs	Nasal Turbinates	Lungs
	b/h PIV3	< 1.3 \pm 0.2	< 1.1 \pm 0.1	ND	
	b/h hMPV F1	< 1.3 \pm 0.1	< 1.1 \pm 0.1	3.5 \pm 0.8	< 0.5 \pm 0.2
	b/h hMPV F2	< 1.2 \pm 0.1	< 1.2 \pm 0.1	< 0.9 \pm 0.4	< 0.5 \pm 0.1
15	hMPV	ND		< 0.8 \pm 0.3	< 0.4 \pm 0.0
	Placebo	4.3 \pm 0.3	4.5 \pm 0.5	6.0 \pm 0.3	4.5 \pm 1.3

^a Virus used to immunize groups of six hamsters on day 0.

20 ^b On day 28, the hamsters were challenged with 10⁶ pfu of hPIV3 or hMPV. Four days post-challenge, the lungs and nasal turbinates of the animals were harvested.

ND = not determined.

The results showed that animals that received the b/h PIV3/hMPV F2 (F at position two) were protected completely from hMPV as well as hPIV3 (Table 15). However, b/h PIV3/hMPV F1 (F at position one) only reduced the titers of infected hMPV in the upper respiratory tract (e.g., nasal turbinates) by 2.5 logs, while it provided complete protection in the lower respiratory tract (e.g., the lung) from both hMPV and hPIV3 infection (Table 15). The animals that were administered the placebo medium displayed high titers of challenge virus in the lower and upper respiratory tracts (Table 15).

30

The present invention is not to be limited in scope by the specific described embodiments that are intended as single illustrations of individual aspects of the invention, and any constructs, viruses or enzymes that are functionally equivalent are within the scope
5 of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by
10 reference in their entireties.

15

20

25

30

Table 16**LEGEND FOR SEQUENCE LISTING****5**

SEQ ID NO:1 Human metapneumovirus isolate 00-1 matrix protein (M)
and fusion protein (F) genes

SEQ ID NO:2 Avian pneumovirus fusion protein gene, partial cds

10 SEQ ID NO:3 Avian pneumovirus isolate 1b fusion protein
mRNA, complete cds

SEQ ID NO:4 Turkey rhinotracheitis virus gene for fusion protein (F1
and F2 subunits), complete cds

15 SEQ ID NO:5 Avian pneumovirus matrix protein (M) gene, partial cds
and Avian pneumovirus fusion glycoprotein (F) gene,
complete cds

SEQ ID NO:6 paramyxovirus F protein hRSV B

SEQ ID NO:7 paramyxovirus F protein hRSV A2

20 SEQ ID NO:8 human metapneumovirus 01-71 (partial sequence)

SEQ ID NO:9 Human metapneumovirus isolate 00-1 matrix protein(M) and
fusion protein (F) genes

SEQ ID NO:10 Avian pneumovirus fusion protein gene, partial cds

25 SEQ ID NO:11 Avian pneumovirus isolate 1b fusion protein
mRNA, complete cds

SEQ ID NO:12 Turkey rhinotracheitis virus gene for fusion protein (F1
and F2 subunits), complete cds

SEQ ID NO:13 Avian pneumovirus fusion glycoprotein (F) gene, complete
cds

30

SEQ ID NO:14 Turkey rhinotracheitis virus (strain CVL14/1) attachment
protien (G) mRNA, complete cds

- SEQ ID NO:15 Turkey rhinotracheitis virus (strain 6574) attachment
protein (G), complete cds
- 5 SEQ ID NO:16 Turkey rhinotracheitis virus (strain CVL14/1) attachment
protein (G) mRNA, complete cds
- SEQ ID NO:17 Turkey rhinotracheitis virus (strain 6574) attachment
protein (G), complete cds
- SEQ ID NO:18 F protein sequence for HMPV isolate NL/1/00
- 10 SEQ ID NO:19 F protein sequence for HMPV isolate NL/17/00
- SEQ ID NO:20 F protein sequence for HMPV isolate NL/1/99
- SEQ ID NO:21 F protein sequence for HMPV isolate NL/1/94
- 15 SEQ ID NO:22 F-gene sequence for HMPV isolate NL/1/00
- SEQ ID NO:23 F-gene sequence for HMPV isolate NL/17/00
- SEQ ID NO:24 F-gene sequence for HMPV isolate NL/1/99
- 20 SEQ ID NO:25 F-gene sequence for HMPV isolate NL/1/94
- SEQ ID NO:26 G protein sequence for HMPV isolate NL/1/00
- SEQ ID NO:27 G protein sequence for HMPV isolate NL/17/00
- SEQ ID NO:28 G protein sequence for HMPV isolate NL/1/99
- 25 SEQ ID NO:29 G protein sequence for HMPV isolate NL/1/94
- SEQ ID NO:30 G-gene sequence for HMPV isolate NL/1/00
- SEQ ID NO:31 G-gene sequence for HMPV isolate NL/17/00
- 30 SEQ ID NO:32 G-gene sequence for HMPV isolate NL/1/99

SEQ ID NO:33 G-gene sequence for HMPV isolate NL/1/94

SEQ ID NO:34 L protein sequence for HMPV isolate NL/1/00

5 SEQ ID NO:35 L protein sequence for HMPV isolate NL/17/00

SEQ ID NO:36 L protein sequence for HMPV isolate NL/1/99

SEQ ID NO:37 L protein sequence for HMPV isolate NL/1/94

10 SEQ ID NO:38 L-gene sequence for HMPV isolate NL/1/00

SEQ ID NO:39 L-gene sequence for HMPV isolate NL/17/00

SEQ ID NO:40 L-gene sequence for HMPV isolate NL/1/99

SEQ ID NO:41 L-gene sequence for HMPV isolate NL/1/94

15 SEQ ID NO:42 M2-1 protein sequence for HMPV isolate NL/1/00

SEQ ID NO:43 M2-1 protein sequence for HMPV isolate NL/17/00

SEQ ID NO:44 M2-1 protein sequence for HMPV isolate NL/1/99

20 SEQ ID NO:45 M2-1 protein sequence for HMPV isolate NL/1/94

SEQ ID NO:46 M2-1 gene sequence for HMPV isolate NL/1/00

SEQ ID NO:47 M2-1 gene sequence for HMPV isolate NL/17/00

25 SEQ ID NO:48 M2-1 gene sequence for HMPV isolate NL/1/99

SEQ ID NO:49 M2-1 gene sequence for HMPV isolate NL/1/94

SEQ ID NO:50 M2-2 protein sequence for HMPV isolate NL/1/00

30 SEQ ID NO:51 M2-2 protein sequence for HMPV isolate NL/17/00

SEQ ID NO:52 M2-2 protein sequence for HMPV isolate NL/1/99

SEQ ID NO:53 M2-2 protein sequence for HMPV isolate NL/1/94

SEQ ID NO:54 M2-2 gene sequence for HMPV isolate NL/1/00

5 SEQ ID NO:55 M2-2 gene sequence for HMPV isolate NL/17/00

SEQ ID NO:56 M2-2 gene sequence for HMPV isolate NL/1/99

SEQ ID NO:57 M2-2 gene sequence for HMPV isolate NL/1/94

10 SEQ ID NO:58 M2 gene sequence for HMPV isolate NL/1/00

SEQ ID NO:59 M2 gene sequence for HMPV isolate NL/17/00

SEQ ID NO:60 M2 gene sequence for HMPV isolate NL/1/99

15 SEQ ID NO:61 M2 gene sequence for HMPV isolate NL/1/94

SEQ ID NO:62 M protein sequence for HMPV isolate NL/1/00

SEQ ID NO:63 M protein sequence for HMPV isolate NL/17/00

20 SEQ ID NO:64 M protein sequence for HMPV isolate NL/1/99

SEQ ID NO:65 M protein sequence for HMPV isolate NL/1/94

SEQ ID NO:66 M gene sequence for HMPV isolate NL/1/00

25 SEQ ID NO:67 M gene sequence for HMPV isolate NL/17/00

SEQ ID NO:68 M gene sequence for HMPV isolate NL/1/99

SEQ ID NO:69 M gene sequence for HMPV isolate NL/1/94

30 SEQ ID NO:70 N protein sequence for HMPV isolate NL/1/00

SEQ ID NO:71 N protein sequence for HMPV isolate NL/17/00

SEQ ID NO:72 N protein sequence for HMPV isolate NL/1/99

SEQ ID NO:73 N protein sequence for HMPV isolate NL/1/94

5 SEQ ID NO:74 N gene sequence for HMPV isolate NL/1/00

SEQ ID NO:75 N gene sequence for HMPV isolate NL/17/00

SEQ ID NO:76 N gene sequence for HMPV isolate NL/1/99

10 SEQ ID NO:77 N gene sequence for HMPV isolate NL/1/94

SEQ ID NO:78 P protein sequence for HMPV isolate NL/1/00

SEQ ID NO:79 P protein sequence for HMPV isolate NL/17/00

SEQ ID NO:80 P protein sequence for HMPV isolate NL/1/99

15 SEQ ID NO:81 P protein sequence for HMPV isolate NL/1/94

SEQ ID NO:82 P gene sequence for HMPV isolate NL/1/00

SEQ ID NO:83 P gene sequence for HMPV isolate NL/17/00

20 SEQ ID NO:84 P gene sequence for HMPV isolate NL/1/99

SEQ ID NO:85 P gene sequence for HMPV isolate NL/1/94

SEQ ID NO:86 SH protein sequence for HMPV isolate NL/1/00

25 SEQ ID NO:87 SH protein sequence for HMPV isolate NL/17/00

SEQ ID NO:88 SH protein sequence for HMPV isolate NL/1/99

SEQ ID NO:89 SH protein sequence for HMPV isolate NL/1/94

30 SEQ ID NO:90 SH gene sequence for HMPV isolate NL/1/00

SEQ ID NO:91 SH gene sequence for HMPV isolate NL/17/00

	SEQ ID NO:92	SH gene sequence for HMPV isolate NL/1/99
	SEQ ID NO:93	SH gene sequence for HMPV isolate NL/1/94
5	SEQ ID NO:94	isolate NL/1/99 (99-1) HMPV (Human Metapneumovirus) cDNA sequence
	SEQ ID NO:95	isolate NL/1/00 (00-1) HMPV cDNA sequence
	SEQ ID NO:96	isolate NL/17/00 HMPV cDNA sequence
10	SEQ ID NO:97	isolate NL/1/94 HMPV cDNA sequence
	SEQ ID NO:98	G-gene coding sequence for isolate NL/1/00 (A1)
	SEQ ID NO:99	G-gene coding sequence for isolate BR/2/01 (A1)
15	SEQ ID NO:100	G-gene coding sequence for isolate FL/4/01 (A1)
	SEQ ID NO:101	G-gene coding sequence for isolate FL/3/01 (A1)
	SEQ ID NO:102	G-gene coding sequence for isolate FL/8/01 (A1)
20	SEQ ID NO:103	G-gene coding sequence for isolate FL/10/01 (A1)
	SEQ ID NO:104	G-gene coding sequence for isolate NL/10/01 (A1)
	SEQ ID NO:105	G-gene coding sequence for isolate NL/2/02 (A1)
25	SEQ ID NO:106	G-gene coding sequence for isolate NL/17/00 (A2)
	SEQ ID NO:107	G-gene coding sequence for isolate NL/1/81 (A2)
	SEQ ID NO:108	G-gene coding sequence for isolate NL/1/93 (A2)
30	SEQ ID NO:109	G-gene coding sequence for isolate NL/2/93 (A2)
	SEQ ID NO:110	G-gene coding sequence for isolate NL/3/93 (A2)

SEQ ID NO:111 G-gene coding sequence for isolate NL/1/95 (A2)

SEQ ID NO:112 G-gene coding sequence for isolate NL/2/96 (A2)

5 SEQ ID NO:113 G-gene coding sequence for isolate NL/3/96 (A2)

SEQ ID NO:114 G-gene coding sequence for isolate NL/22/01 (A2)

SEQ ID NO:115 G-gene coding sequence for isolate NL/24/01 (A2)

10 SEQ ID NO:116 G-gene coding sequence for isolate NL/23/01 (A2)

SEQ ID NO:117 G-gene coding sequence for isolate NL/29/01 (A2)

SEQ ID NO:118 G-gene coding sequence for isolate NL/3/02 (A2)

15 SEQ ID NO:119 G-gene coding sequence for isolate NL/1/99 (B1)

SEQ ID NO:120 G-gene coding sequence for isolate NL/11/00 (B1)

SEQ ID NO:121 G-gene coding sequence for isolate NL/12/00 (B1)

20 SEQ ID NO:122 G-gene coding sequence for isolate NL/5/01 (B1)

SEQ ID NO:123 G-gene coding sequence for isolate NL/9/01 (B1)

SEQ ID NO:124 G-gene coding sequence for isolate NL/21/01 (B1)

25 SEQ ID NO:125 G-gene coding sequence for isolate NL/1/94 (B2)

SEQ ID NO:126 G-gene coding sequence for isolate NL/1/82 (B2)

SEQ ID NO:127 G-gene coding sequence for isolate NL/1/96 (B2)

SEQ ID NO:128 G-gene coding sequence for isolate NL/6/97 (B2)

30 SEQ ID NO:129 G-gene coding sequence for isolate NL/9/00 (B2)

- SEQ ID NO:130 G-gene coding sequence for isolate NL/3/01 (B2)
- SEQ ID NO:131 G-gene coding sequence for isolate NL/4/01 (B2)
- 5 SEQ ID NO:132 G-gene coding sequence for isolate UK/5/01 (B2)
- SEQ ID NO:133 G-protein sequence for isolate NL/1/00 (A1)
- SEQ ID NO:134 G-protein sequence for isolate BR/2/01 (A1)
- 10 SEQ ID NO:135 G-protein sequence for isolate FL/4/01 (A1)
- SEQ ID NO:136 G-protein sequence for isolate FL/3/01 (A1)
- SEQ ID NO:137 G-protein sequence for isolate FL/8/01 (A1)
- SEQ ID NO:138 G-protein sequence for isolate FL/10/01 (A1)
- 15 SEQ ID NO:139 G-protein sequence for isolate NL/10/01 (A1)
- SEQ ID NO:140 G-protein sequence for isolate NL/2/02 (A1)
- SEQ ID NO:141 G-protein sequence for isolate NL/17/00 (A2)
- 20 SEQ ID NO:142 G-protein sequence for isolate NL/1/81 (A2)
- SEQ ID NO:143 G-protein sequence for isolate NL/1/93 (A2)
- SEQ ID NO:144 G-protein sequence for isolate NL/2/93 (A2)
- 25 SEQ ID NO:145 G-protein sequence for isolate NL/3/93 (A2)
- SEQ ID NO:146 G-protein sequence for isolate NL/1/95 (A2)
- SEQ ID NO:147 G-protein sequence for isolate NL/2/96 (A2)
- 30 SEQ ID NO:148 G-protein sequence for isolate NL/3/96 (A2)
- SEQ ID NO:149 G-protein sequence for isolate NL/22/01 (A2)

SEQ ID NO:150 G-protein sequence for isolate NL/24/01 (A2)

SEQ ID NO:151 G-protein sequence for isolate NL/23/01 (A2)

5 SEQ ID NO:152 G-protein sequence for isolate NL/29/01 (A2)

SEQ ID NO:153 G-protein sequence for isolate NL/3/02 (A2)

SEQ ID NO:154 G-protein sequence for isolate NL/1/99 (B1)

10 SEQ ID NO:155 G-protein sequence for isolate NL/11/00 (B1)

SEQ ID NO:156 G-protein sequence for isolate NL/12/00 (B1)

SEQ ID NO:157 G-protein sequence for isolate NL/5/01 (B1)

15 SEQ ID NO:158 G-protein sequence for isolate NL/9/01 (B1)

SEQ ID NO:159 G-protein sequence for isolate NL/21/01 (B1)

SEQ ID NO:160 G-protein sequence for isolate NL/1/94 (B2)

20 SEQ ID NO:161 G-protein sequence for isolate NL/1/82 (B2)

SEQ ID NO:162 G-protein sequence for isolate NL/1/96 (B2)

SEQ ID NO:163 G-protein sequence for isolate NL/6/97 (B2)

25 SEQ ID NO:164 G-protein sequence for isolate NL/9/00 (B2)

SEQ ID NO:165 G-protein sequence for isolate NL/3/01 (B2)

SEQ ID NO:166 G-protein sequence for isolate NL/4/01 (B2)

SEQ ID NO:167 G-protein sequence for isolate NL/5/01 (B2)

30 SEQ ID NO:168 F-gene coding sequence for isolate NL/1/00

SEQ ID NO:169 F-gene coding sequence for isolate UK/1/00

SEQ ID NO:170 F-gene coding sequence for isolate NL/2/00

5 SEQ ID NO:171 F-gene coding sequence for isolate NL/13/00

SEQ ID NO:172 F-gene coding sequence for isolate NL/14/00

SEQ ID NO:173 F-gene coding sequence for isolate FL/3/01

10 SEQ ID NO:174 F-gene coding sequence for isolate FL/4/01

SEQ ID NO:175 F-gene coding sequence for isolate FL/8/01

SEQ ID NO:176 F-gene coding sequence for isolate UK/1/01

SEQ ID NO:177 F-gene coding sequence for isolate UK/7/01

15 SEQ ID NO:178 F-gene coding sequence for isolate FL/10/01

SEQ ID NO:179 F-gene coding sequence for isolate NL/6/01

SEQ ID NO:180 F-gene coding sequence for isolate NL/8/01

20 SEQ ID NO:181 F-gene coding sequence for isolate NL/10/01

SEQ ID NO:182 F-gene coding sequence for isolate NL/14/01

SEQ ID NO:183 F-gene coding sequence for isolate NL/20/01

25 SEQ ID NO:184 F-gene coding sequence for isolate NL/25/01

SEQ ID NO:185 F-gene coding sequence for isolate NL/26/01

SEQ ID NO:186 F-gene coding sequence for isolate NL/28/01

30 SEQ ID NO:187 F-gene coding sequence for isolate NL/30/01

SEQ ID NO:188 F-gene coding sequence for isolate BR/2/01

SEQ ID NO:189 F-gene coding sequence for isolate BR/3/01

5 SEQ ID NO:190 F-gene coding sequence for isolate NL/2/02

SEQ ID NO:191 F-gene coding sequence for isolate NL/4/02

SEQ ID NO:192 F-gene coding sequence for isolate NL/5/02

SEQ ID NO:193 F-gene coding sequence for isolate NL/6/02

10 SEQ ID NO:194 F-gene coding sequence for isolate NL/7/02

SEQ ID NO:195 F-gene coding sequence for isolate NL/9/02

SEQ ID NO:196 F-gene coding sequence for isolate FL/1/02

15 SEQ ID NO:197 F-gene coding sequence for isolate NL/1/81

SEQ ID NO:198 F-gene coding sequence for isolate NL/1/93

SEQ ID NO:199 F-gene coding sequence for isolate NL/2/93

20 SEQ ID NO:200 F-gene coding sequence for isolate NL/4/93

SEQ ID NO:201 F-gene coding sequence for isolate NL/1/95

SEQ ID NO:202 F-gene coding sequence for isolate NL/2/96

25 SEQ ID NO:203 F-gene coding sequence for isolate NL/3/96

SEQ ID NO:204 F-gene coding sequence for isolate NL/1/98

SEQ ID NO:205 F-gene coding sequence for isolate NL/17/00

SEQ ID NO:206 F-gene coding sequence for isolate NL/22/01

30 SEQ ID NO:207 F-gene coding sequence for isolate NL/29/01

SEQ ID NO:208 F-gene coding sequence for isolate NL/23/01

SEQ ID NO:209 F-gene coding sequence for isolate NL/17/01

5 SEQ ID NO:210 F-gene coding sequence for isolate NL/24/01

SEQ ID NO:211 F-gene coding sequence for isolate NL/3/02

SEQ ID NO:212 F-gene coding sequence for isolate NL/3/98

10 SEQ ID NO:213 F-gene coding sequence for isolate NL/1/99

SEQ ID NO:214 F-gene coding sequence for isolate NL/2/99

SEQ ID NO:215 F-gene coding sequence for isolate NL/3/99

SEQ ID NO:216 F-gene coding sequence for isolate NL/11/00

15 SEQ ID NO:217 F-gene coding sequence for isolate NL/12/00

SEQ ID NO:218 F-gene coding sequence for isolate NL/1/01

SEQ ID NO:219 F-gene coding sequence for isolate NL/5/01

20 SEQ ID NO:220 F-gene coding sequence for isolate NL/9/01

SEQ ID NO:221 F-gene coding sequence for isolate NL/19/01

SEQ ID NO:222 F-gene coding sequence for isolate NL/21/01

25 SEQ ID NO:223 F-gene coding sequence for isolate UK/11/01

SEQ ID NO:224 F-gene coding sequence for isolate FL/1/01

SEQ ID NO:225 F-gene coding sequence for isolate FL/2/01

30 SEQ ID NO:226 F-gene coding sequence for isolate FL/5/01

SEQ ID NO:227 F-gene coding sequence for isolate FL/7/01

SEQ ID NO:228 F-gene coding sequence for isolate FL/9/01

SEQ ID NO:229 F-gene coding sequence for isolate UK/10/01

5 SEQ ID NO:230 F-gene coding sequence for isolate NL/1/02

SEQ ID NO:231 F-gene coding sequence for isolate NL/1/94

SEQ ID NO:232 F-gene coding sequence for isolate NL/1/96

10 SEQ ID NO:233 F-gene coding sequence for isolate NL/6/97

SEQ ID NO:234 F-gene coding sequence for isolate NL/7/00

SEQ ID NO:235 F-gene coding sequence for isolate NL/9/00

15 SEQ ID NO:236 F-gene coding sequence for isolate NL/19/00

SEQ ID NO:237 F-gene coding sequence for isolate NL/28/00

SEQ ID NO:238 F-gene coding sequence for isolate NL/3/01

20 SEQ ID NO:239 F-gene coding sequence for isolate NL/4/01

SEQ ID NO:240 F-gene coding sequence for isolate NL/11/01

SEQ ID NO:241 F-gene coding sequence for isolate NL/15/01

25 SEQ ID NO:242 F-gene coding sequence for isolate NL/18/01

SEQ ID NO:243 F-gene coding sequence for isolate FL/6/01

SEQ ID NO:244 F-gene coding sequence for isolate UK/5/01

SEQ ID NO:245 F-gene coding sequence for isolate UK/8/01

30 SEQ ID NO:246 F-gene coding sequence for isolate NL/12/02

	SEQ ID NO:247	F-gene coding sequence for isolate HK/1/02
	SEQ ID NO:248	F-protein sequence for isolate NL/1/00
5	SEQ ID NO:249	F-protein sequence for isolate UK/1/00
	SEQ ID NO:250	F-protein sequence for isolate NL/2/00
	SEQ ID NO:251	F-protein sequence for isolate NL/13/00
10	SEQ ID NO:252	F-protein sequence for isolate NL/14/00
	SEQ ID NO:253	F-protein sequence for isolate FL/3/01
	SEQ ID NO:254	F-protein sequence for isolate FL/4/01
	SEQ ID NO:255	F-protein sequence for isolate FL/8/01
15	SEQ ID NO:256	F-protein sequence for isolate UK/1/01
	SEQ ID NO:257	F-protein sequence for isolate UK/7/01
	SEQ ID NO:258	F-protein sequence for isolate FL/10/01
20	SEQ ID NO:259	F-protein sequence for isolate NL/6/01
	SEQ ID NO:260	F-protein sequence for isolate NL/8/01
	SEQ ID NO:261	F-protein sequence for isolate NL/10/01
25	SEQ ID NO:262	F-protein sequence for isolate NL/14/01
	SEQ ID NO:263	F-protein sequence for isolate NL/20/01
	SEQ ID NO:264	F-protein sequence for isolate NL/25/01
30	SEQ ID NO:265	F-protein sequence for isolate NL/26/01
	SEQ ID NO:266	F-protein sequence for isolate NL/28/01

SEQ ID NO:267 F-protein sequence for isolate NL/30/01

SEQ ID NO:268 F-protein sequence for isolate BR/2/01

5 SEQ ID NO:269 F-protein sequence for isolate BR/3/01

SEQ ID NO:270 F-protein sequence for isolate NL/2/02

SEQ ID NO:271 F-protein sequence for isolate NL/4/02

10 SEQ ID NO:272 F-protein sequence for isolate NL/5/02

SEQ ID NO:273 F-protein sequence for isolate NL/6/02

SEQ ID NO:274 F-protein sequence for isolate NL/7/02

15 SEQ ID NO:275 F-protein sequence for isolate NL/9/02

SEQ ID NO:276 F-protein sequence for isolate FL/1/02

SEQ ID NO:277 F-protein sequence for isolate NL/1/81

20 SEQ ID NO:278 F-protein sequence for isolate NL/1/93

SEQ ID NO:279 F-protein sequence for isolate NL/2/93

SEQ ID NO:280 F-protein sequence for isolate NL/4/93

25 SEQ ID NO:281 F-protein sequence for isolate NL/1/95

SEQ ID NO:282 F-protein sequence for isolate NL/2/96

SEQ ID NO:283 F-protein sequence for isolate NL/3/96

SEQ ID NO:284 F-protein sequence for isolate NL/1/98

30 SEQ ID NO:285 F-protein sequence for isolate NL/17/00

SEQ ID NO:286 F-protein sequence for isolate NL/22/01

SEQ ID NO:287 F-protein sequence for isolate NL/29/01

5 SEQ ID NO:288 F-protein sequence for isolate NL/23/01

SEQ ID NO:289 F-protein sequence for isolate NL/17/01

SEQ ID NO:290 F-protein sequence for isolate NL/24/01

10 SEQ ID NO:291 F-protein sequence for isolate NL/3/02

SEQ ID NO:292 F-protein sequence for isolate NL/3/98

SEQ ID NO:293 F-protein sequence for isolate NL/1/99

15 SEQ ID NO:294 F-protein sequence for isolate NL/2/99

SEQ ID NO:295 F-protein sequence for isolate NL/3/99

SEQ ID NO:296 F-protein sequence for isolate NL/11/00

SEQ ID NO:297 F-protein sequence for isolate NL/12/00

20 SEQ ID NO:298 F-protein sequence for isolate NL/1/01

SEQ ID NO:299 F-protein sequence for isolate NL/5/01

SEQ ID NO:300 F-protein sequence for isolate NL/9/01

25 SEQ ID NO:301 F-protein sequence for isolate NL/19/01

SEQ ID NO:302 F-protein sequence for isolate NL/21/01

SEQ ID NO:303 F-protein sequence for isolate UK/11/01

30 SEQ ID NO:304 F-protein sequence for isolate FL/1/01

SEQ ID NO:305 F-protein sequence for isolate FL/2/01

SEQ ID NO:306 F-protein sequence for isolate FL/5/01

SEQ ID NO:307 F-protein sequence for isolate FL/7/01

5 SEQ ID NO:308 F-protein sequence for isolate FL/9/01

SEQ ID NO:309 F-protein sequence for isolate UK/10/01

SEQ ID NO:310 F-protein sequence for isolate NL/1/02

10 SEQ ID NO:311 F-protein sequence for isolate NL/1/94

SEQ ID NO:312 F-protein sequence for isolate NL/1/96

SEQ ID NO:313 F-protein sequence for isolate NL/6/97

15 SEQ ID NO:314 F-protein sequence for isolate NL/7/00

SEQ ID NO:315 F-protein sequence for isolate NL/9/00

SEQ ID NO:316 F-protein sequence for isolate NL/19/00

20 SEQ ID NO:317 F-protein sequence for isolate NL/28/00

SEQ ID NO:318 F-protein sequence for isolate NL/3/01

SEQ ID NO:319 F-protein sequence for isolate NL/4/01

25 SEQ ID NO:320 F-protein sequence for isolate NL/11/01

SEQ ID NO:321 F-protein sequence for isolate NL/15/01

SEQ ID NO:322 F-protein sequence for isolate NL/18/01

SEQ ID NO:323 F-protein sequence for isolate FL/6/01

30 SEQ ID NO:324 F-protein sequence for isolate UK/5/01

SEQ ID NO:325 F-protein sequence for isolate UK/8/01

SEQ ID NO:326 F-protein sequence for isolate NL/12/02

5 SEQ ID NO:327 F-protein sequence for isolate HK/1/02

10

15

20

25

30

WHAT IS CLAIMED IS:

- 5 1. A chimeric bovine parainfluenza virus type 3 comprising a heterologous nucleotide sequence encoding a metapneumovirus polypeptide.
2. A chimeric human parainfluenza virus type 3 comprising a heterologous nucleotide sequence encoding a metapneumovirus polypeptide.
- 10 3. A chimeric bovine parainfluenza virus type 3/human parainfluenza virus type 3 comprising a heterologous nucleotide sequence encoding a metapneumovirus polypeptide.
4. The virus of claim 1, 2, or 3, wherein said virus comprises heterologous nucleotide sequences derived from the same gene of a metapneumovirus.
- 15 5. The virus of claim 1, 2, or 3, wherein said virus comprises heterologous nucleotide sequences derived from at least two different genes of a metapneumovirus.
- 20 6. The virus of claim 1, 2, or 3, wherein one or more of the open reading frames in the genome of the virus have been replaced by an ORF which encodes one or more of (i) an avian pneumovirus (APV) F protein; (ii) an APV G protein; (iii) an APV SH protein; (iv) an APV N protein; (v) an APV P protein; (vi) an APV M2 protein; (vii) an APV M2-1 protein; (viii) an APV M2-2 protein; or (ix) an APV L protein.
- 25 7. The virus of claim 1, 2, or 3, wherein one or more of the open reading frames in the genome of virus have been replaced by an ORF which encodes one or more of (i) a mammalian metapneumovirus (MPV) F protein; (ii) a mammalian MPV G protein; (iii) a
- 30 mammalian metapneumovirus (MPV) F protein; (ii) a mammalian MPV G protein; (iii) a

mammalian MPV SH protein; (iv) a mammalian MPV N protein; (v) a mammalian MPV P protein; (vi) a mammalian MPV M2 protein; (vii) a mammalian MPV M2-1 protein; (viii) a mammalian MPV M2-2 protein; or (ix) a mammalian MPV L protein.

5

8. The virus of claim 6, wherein the avian pneumovirus is APV type A, APV type B, APV type C, or APV type D.

10 9. The virus of claim 7, wherein the mammalian MPV is variant A1, variant A2, variant B1, or variant B2.

10. The virus of claim 1, 2, or 3, wherein said heterologous nucleotide sequence is added to the complete genome of said virus.

15

11. The virus of claim 1, 2, or 3, wherein said nucleotide sequence is added at a nucleotide position of the parainfluenza virus genome of 104, 1774, and 3724.

20

12. The virus of claim 1, 2, or 3, wherein a nucleotide sequence of said parainfluenza virus has been substituted by said heterologous nucleotide sequence.

13. The virus of claim 1, 2, or 3, wherein the heterologous sequences are inserted into the genome of said parainfluenza virus, wherein the genome has been deleted of one or more genes.

25

14. The virus of claim 1, wherein said bovine parainfluenza virus is a Kansas-strain bovine parainfluenza virus type 3.

30

15. The virus of claim 1, 2, or 3, wherein said heterologous nucleotide sequence is derived from the nucleotide sequences encoding a F protein, a G protein or a fragment thereof.

5

16. The virus of claim 15, wherein said F protein comprises an ectodomain of a F protein of a metapneumovirus, a transmembrane domain of a F protein of a parainfluenza virus, and luminal domain of a F protein of a parainfluenza virus.

10

17. The virus of claim 1, 2, or 3, wherein said nucleotide sequence is SEQ ID Nos: 1 to 5, 14, or 15.

15

18. The virus of claim 1, 2, or 3, wherein said nucleotide sequence encodes a protein of SEQ ID Nos: 6 to 13, 16, or 17.

20

19. The virus of claim 1, 2, or 3, wherein said virus further comprises a heterologous nucleotide sequence derived from a respiratory syncytial virus or a mutated form of respiratory syncytial virus.

25

20. The virus of claim 19, wherein the respiratory syncytial virus is a respiratory syncytial virus type A, a respiratory syncytial virus type B, a bovine respiratory syncytial virus, or an ovine respiratory syncytial virus.

30

21. The virus of claim 19, wherein said sequence is derived from the nucleotide sequences encoding a F protein, a G protein or a fragment thereof of said respiratory syncytial virus.

22. The chimeric parainfluenza virus of claim 1, 2, or 3, wherein the genome of said virus contains mutations or modifications, in addition to said heterologous nucleotide sequences, which result in a chimeric virus having a phenotype more suitable for use in vaccine formulations such as an attenuated phenotype or a phenotype with enhanced antigenicity.

23. The chimeric parainfluenza virus of claim 1, 2, or 3, wherein the intergenic region of said heterologous nucleotide sequence is altered.

24. The chimeric parainfluenza virus of claim 1, 2, or 3, wherein said heterologous nucleotide sequence is added at a position of the parainfluenza virus genome selected from the group consisting of position 1, 2, 3, 4, 5, and 6, and wherein the intergenic region of said heterologous nucleotide sequence is altered.

25. A recombinant DNA or RNA molecule encoding the genome of the virus of claim 1, 2, or 3.

20

26. A recombinant DNA or RNA molecule encoding the genome of the virus of claim 18.

27. A vaccine formulation comprising the chimeric virus of claim 1, 2, or 3, and a pharmaceutically acceptable excipient.

25

28. A vaccine formulation comprising the chimeric virus of claim 18 and a pharmaceutically acceptable excipient.

30

29. The vaccine formulation of claim 27, wherein said chimeric virus comprises a genomic modification or mutation which results in an attenuated phenotype or enhanced antigenicity.
- 5
30. The vaccine formulation of claim 29, wherein said modification or mutation is derived from a naturally occurring mutant.
- 10
31. The vaccine formulation of claim 27, wherein said vaccine is used to modulate the immune response of humans, primates, horses, cows, sheep, pigs, goats, dogs, cats, avian species or rodents.
- 15
32. The vaccine formulation of claim 30, wherein the vaccine is used to modulate the immune response of a human infant or a child.
- 20
33. An immunogenic formulation comprising the chimeric virus of claim 1, 2, or 3, and a pharmaceutically acceptable excipient.
- 25
34. An immuniogenic formulation comprising the chimeric virus of claim 18 and a pharmaceutically acceptable excipient.
- 30
35. The immunogenic formulation of claim 33, wherein said chimeric virus comprises a genomic modification or mutation which results in an attenuated phenotype or enhanced antigenicity.
36. The immunogenic formulation of claim 35, wherein said modification or mutation is derived from a naturally occurring mutant.

37. The vaccine formulation of claim 33, wherein said vaccine is used to modulate the immune response of humans, primates, horses, cows, sheep, pigs, goats, dogs, cats, avian species or rodents.

5

38. The vaccine formulation of claim 36, wherein the vaccine is used to modulate the immune response of a human infant or a child.

10 39. A method for treating or preventing a respiratory tract infection in a mammal, said method comprising administering a vaccine of claim 27.

15 40. The method of claim 39, wherein the respiratory tract infection is a MPV infection.

41. The method of claim 39, wherein the respiratory tract infection is an infection with MPV, RSV, hPIV or a combination thereof.

20

42. The method of claim 39, wherein the subject is a human.

43. The method of claim 42, wherein the human subject is less than 5 years of age.

25

44. The method of claim 42, wherein the human subject is less than 2 years of age.

45. The method of claim 42, wherein the human subject suffers from a disease or a condition in addition to the respiratory tract infection.

30

46. The method of claim 45, wherein the disease or a condition is of cystic fibrosis, leukemia, non-Hodgkin lymphoma, asthma, and bone marrow transplantation and kidney transplantation.

5

47. The human subject of claim 42, wherein the human subject is an immunocompromised individual.

10 48. The human subject of claim 42, wherein the human subject is an elderly.

15

20

25

30

1/27

Human	1	MSWKVVIIFSLLITPQHGLKESYLEESCSTITEGYLSVLRGTWYTNVFTLEVGDVENLTC	60
		MSWKVV++ LL TP GL+ESYLEESCST+T GYLSVLRGTWYTNVFTLEVGDVENLTC	
Avian	1	MSWKVLLLVLATPTGGLEESYLEESCSTVTRGYLSVLRGTWYTNVFTLEVGDVENLTC	60
Human	61	ADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRFVLGAIALGVATAAAVTA	120
		DGPSLI+TEL+LTK+AL EL+TV ADQLA+E +I +PR++RFVLGAIALGVAT AAVTA	
Avian	61	TDGPSLIRTELELTKNLEELKTVPADQLAKEARIMSPRKARFVLGAIALGVATTA VTA	120
Human	121	GVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELKDFVSKNLTRAINKN	180
		GVAIAKTIRLE EV A1+ AL+ TNEAVSTLGNGVRVLATAV +LKDF+SK LT AINKN	
Avian	121	GVAIAKTIRLEGEVAAIRGALRNTNEAVSTLGNGVRVLATAVNDLKDFISKKLTPAINKN	180
Human	181	KCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQ	240
		KCDI+DLKMAVSF Q+NRRLNVVRQFSDNAGITPAISLDLMTDAEL RAVSNMPTS+GQ	
Avian	181	KCDISDLKMAVSFGQYNRRFLNVVRQFSDNAGITPAISLDLMTDAELVRAVSNMPTSSGQ	240
Human	241	IKLMLENRAMVRRKGFGFLIGVYGSSVIYVQLPIFGVIDTPCHIVKAAPSCSGKKGNYA	300
		I LMLENRAMVRRKGFG LIGVYG SV+YVQLPIFGVIDTPCH VKAAP CSGK G+YA	
Avian	241	INLMLENRAMVRRKGFGILIGVYGSSVYVQLPIFGVIDTPCHVKVKAAPLCSGKDGSYA	300
Human	301	CLLREDQGWYQNA GSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYP	360
		C LREDQGWYQNA GSTVYYPNE+DC R DHVFCDTAAGINVA++S+ECN NISTT YP	
Avian	301	CPLREDQGWYQNA GSTVYYPNEEDCVVRSDHVFCDTAAGINVAKESEECNRNISTTKYP	360
Human	361	CKVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQDADTVTI	420
		CKVSTGRHPISMVALSPLGALVACY GVSCSIGSN+VGII+ L KGCSYI+NQDADTVTI	
Avian	361	CKVSTGRHPISMVALSPLGALVACYDGVSCSIGSNKVGIIIRRLKGCSYISNQDADTVTI	420
Human	421	DNTVYQLSKVEGEQHVIGRPVSSSFDPVKFPEDQFNVALDQVFESIENSQALVDQSNRI	480
		DNTVYQLSKVEGEQH IKG+PVSS+FDV++FPEDQFN+ALDQVFES+E S+ L+DQSN+I	
Avian	421	DNTVYQLSKVEGEQHTIKGKPVSSNFDPIEFEDQFNIALDQVFESVEKSKNLIDQSNKI	480
Human	481	LSSAEKGNTGFIIVIIIAVLGSTMILVSVFIIKKTKRPTGAPPELSGVTN	532
		L S EKN GF+IVI LI +L + V +F ++KK K P E++GV N	
Avian	481	LDSTEKGNAGFVIVIALIVLLMLAAVGVGIFVVKRKAAPKFPMEHNGVNN	532

FIG. 1A

2/27

Human 1 MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTC 60
M ++ ++ L+ P ++E+Y EESCST+T GY SVLRTGWYTNVF LE+G+VEN+TC

Turkey 1 MDVRICLLLFLISNPSSCIQETYNEESCSTVTRGYKSVLRTGWYTNVFNLEIGNVENITC 60

Human 61 ADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRFVLGAIALGVATAAAVTA 120
DGPSLI TEL LTK+ALREL+TVSADQ+A+E ++ +PR+ RFVLGAIALGVATAAAVTA

Turkey 61 NDGPSLIDTELVLTKNALRELKTVSADQVAKESRLSSPRRRRFVLGAIALGVATAAAVTA 120

Human 121 GVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGV~VLATAVRELKDFVSKNLTRAINKN 180
GVA+AKTIRLE EV AIKNAL+ TNEAVSTLGNGVRVLATAV +LK+F+SK LT AIN+N

Turkey 121 GVALAKTIRLEGEVKAIKNALRNTNEAVSTLGNGVRVLATAVNDLKEFISKKLTPAINQN 180

Human 181 KCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQ 240
KC+IAD+KMA+SF Q NRRFLNVVRQFSD+AGIT A+SLDLMTD EL RA++ MPTS+GQ

Turkey 181 KCNIADIKMAISFGQNNRRFLNVVRQFSDSAGITSASVSLDLMTDDELVRRAINRMPTSSGQ 240

Human 241 IKLMLENRAMVRRKGFGFLIGVYGSSVIYMQLPFIGVIDTPCWIVKAAPSCSGKKGNYA 300
I LML NRAMVRRKGFG LIGVY +V+YMQLPFIGVI+TPCW V AAP C +KGNYA

Turkey 241 ISLMLNNRAMVRRKGFGILIGVYDGTVVYMQLPFIGVIETPCWRVVAAPLCRKEKGNYA 300

Human 301 CLLREDQGWYCNAGSTVYYPNKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYP 360
C+LREDQGWYC NAGST YYPN+ DCE R D+VFCDTAAGINVA + ++CN NIST+ YP

Turkey 301 CILREDQGWYCTNAGSTAYYPNKDDCEVRDDYVFCDTAAGINVALEVEQCNYNISTSKYP 360

Human 361 CKVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADVTI 420
CKVSTGRHP+SMVAL+PLG LV+CY+ VSCSIGSN+VGIIKQL KGC++I N +ADT+TI

Turkey 361 CKVSTGRHPVSMVALTPLGGLVSCYESVSCSIGSNKVGIIKQLGKGCTHIPNEADTITI 420

Human 421 DNTVYQLSKVEGEQHVIKGRPVSFFDPVKFPEDQFNVALDQVFESIENSQALVDQSNRI 480
DNTVYQLSKV GEQ IKG PV ++F+P+ FPEDQFNVALDQVFESI+ SQ L+D+SN +

Turkey 421 DNTVYQLSKVGEQRTIKGAPVVNNFNPILPEDQFNVALDQVFESIDRSQDLIDKSNL 480

Human 481 LSSAEKGNTGFIIIVIIILAVLGSTMILVSVFII--IKKTKRPTGAPPELSGVTNNGFI 536
L + K G I I+++ +LG +L ++ ++KTK P P +G ++ ++

Turkey 481 LGADAKSKAGIAIAIVVLVILGIFLLAVIYYCSRVRKTK-PKHDYPATTGHSSMAYV 537

FIG.1B

SUBSTITUTE SHEET (RULE 26)

3/27




FIG.2

4/27





FIG.3

5/27

Rescued bPIV3/hPIV3--Vectored RSV Constructs



Note: all RSV genes are linked to the bPIV3 N-P intergenic region with the exception of RSV F1* which is followed by the shorter bPIV3 N gene stop/N gene start sequences.

FIG.4

6/27

Expression of RSV F and G
Proteins from Chimeric Bovine/Human PIV3




FIG.5(A)

Expression of RSV F and G mRNAs
from Chimeric Bovine/Human PIV3




FIG.5(B)

SUBSTITUTE SHEET (RULE 26)

7/27





FIG. 5(C)

8/27

Positional Effect of eGFP Insertions in the PIV3
Genome on Virus Replication



b/h GFP5 and b/h GFP 6 construction in progress.

FIG.6

9/27





FIG. 7(A)

BEST AVAILABLE COPY

10/27



MOI of 0.1 in Vero cells
24 hours post-infection

FIG.7(B)

11/27

Growth Curves for b/h PV3/GFP1, 2, and 3
in Vero Cells, MOI = 0.1




FIG. 7(C)

12/27

Differences between b/h PIV3 RSV F1* and
b/h PIV3 RSV F2 Intergenic Regions




FIG.8

SUBSTITUTE SHEET (RULE 26)

13/27




FIG.9(A)

14/27





FIG.9(B)

15/27

Trivalent bPIV3/hPIV3 vectored Constructs




Status: Constructs were rescued, viruses are being amplified in Vero cells.

FIG.10

16/27

Cloning of Two RSV F to the b/h PV3 Vector



RSV F1F2

Status: Virus titer = 1.0×10^6 PFU/ml

Purpose: to study whether two RSV F genes will increase immunogenicity.

FIG.11

17/27

bPIV3/hPIV3 vectored hMPV F Constructs

1. b/h PIV3/hMPV F1



Status: Virus stocks generated

Titer: 5×10^6 PFU/ml

2. b/h PIV3/hMPV F2



Status: Virus stock generated

Titer: 1.5×10^7 PFU/ml

FIG.12




FIG.13(A)

19/27

Growth Curve of b/h PIV3/hMPV F2 in Vero Cells,

MOI = 0.1




FIG.13(B)

20/27




FIG. 13(C)

SUBSTITUTE SHEET (RULE 26)

21/27

Cloning of the Soluble RSV F Gene



Status: Full-length cDNA is being generated.
 Purpose: to study whether a soluble RSV F protein without the trans-membrane and intracellular domains will be immunogenic.

FIG.14

22/27

- b/h PIV3/hMPV F1
- liquid overlay on Vero cells
 - limiting dilution from 10^{-2} to 10^{-7}
 - immunostained with hMPV gp antiserum

-Immunostained b/h PIV3/hMPV F1




FIG.15(A)

- b/h PIV3/hMPV F2
- methyl cellulose overlay
 - on Vero cells
 - plaque assay from 10^{-2} to 10^{-7}
 - immunostained with hMPV gp antiserum

-Immunostained b/h PIV3/hMPV F2




FIG.15(B)

SUBSTITUTE SHEET (RULE 26)

23/27

Free RSV F Protein in 20 - 66% Sucrose Gradient
(baculovirus expressed; C terminal truncation)





FIG.16(A)

24/27



SUBSTITUTE SHEET (RULE 26)

25/27




FIG. 16(C)

26/27




FIG. 16(D)

27/27

b/h PIV3/RSV G2 Sucrose Gradient
(spun for 15 hrs @ 25,000 rpm)

66%

PBS 20% sucrose

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

82 —

bPIV3 PAb

40.6 —

32.2 —

82 —

RSV PAb

40.6 —

32.2 —

RSV G




FIG. 16(E)

SEQUENCE LISTING

<110> MedImmune Vaccines, Inc.
ViroNovative BV

<120> RECOMBINANT PARAINFLUENZA VIRUS
EXPRESSION SYSTEMS AND VACCINES
COMPRISING HETEROLOGOUS ANTIGENS
DERIVED FROM METAPNEUMOVIRUS

<130> 7682-061-228

<140> To be assigned

<141> Herewith

<150> 60/358,934

<151> 2002-02-21

<160> 327

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2507

<212> DNA

<213> metapneumovirus

<220>

<221> CDS

<222> (1) ... (2507)

<223> Human metapneumovirus isolate 00-1 matrix protein
(M) and fusion protein (F) genes

<400> 1

```

atggagtcct acctagtaga cacctatcaa ggcattcctt acacagcagc tgttcaagtt 60
gatctaataag aaaaggacct gttacctgca agcctaacaa tatgggtccc tttgtttcag 120
gccaacacac caccagcagt gctgctcgat cagctaaaaa ccctgacaat aaccactctg 180
tatgtctgtac cacaaaatgg tccaatactc aaagtgaatg catcagccca aggtgcagca 240
atgtctgtac ttcccaaaaa atttgaagtc aatgcgactg tagcactcga tgaatatagc 300
aaactggaat ttgacaaaact cacagctctgt gaagtaaaaa cagtttactt aacaaccatg 360
aaaccatacg ggatggatc aaaatttgtg agctcagcca aatcagttgg caaaaaaaca 420
catgatctaa tcgcactatg tgattttatg gatctagaaa agaacacacc tgttacaata 480
ccagcattca tcaaatcagt ttcaatcaaa gagagtgaat cagctactgt tgaagctgct 540
ataagcagtg aagcagacca agctctaaca caggccaaaa tgcacctta tgcgggatta 600
attatgatca tgactatgaa caatcccaaa ggcatattca aaaagcttgg agctgggact 660
caagtcatag tagaactagg agcatatgtc caggctgaaa gcataagcaa aatatgcaag 720
acttggagcc atcaagggac aagatatgtc ttgaagtcca gataacaacc aagcaccttg 780
gccaagagct actaacccta tctcatagat cataaagtca ccattctagt tatataaaaa 840
tcaagttaga acaagaatta aatcaatcaa gaacgggaca aataaaaaatg tcttggaag 900
tggtgatcat tttttcattg ttaataacac ctcaacacgg tcttaaagag agctacttag 960
aagagtcata tagcactata actgaaggat atctcagtg tctgaggaca ggttggtaca 1020
ccaatgtttt tacactggag gtaggcgatg tagagaacct tacatgtgcc gatggacca 1080
gcttaataaa aacagaatta gacctgacca aaagtgcact aagagagctc agaacagttt 1140
ctgctgatca actggcaaga gaggagcaaa ttgaaaatcc cagacaatct agattcggtc 1200
taggagcaat agcactcggg gttgcaactg cagctgcagt tacagcaggt gttgcaattg 1260
ccaaaaccat cgggcttgaa agtgaagtaa cagcaattaa gaatgcctc aaaaagacca 1320
atgaagcagt atctacattg gggaatggag ttcgtgtgtt ggcaactgca gtgagagagc 1380
tgaaagattt tgtgagcaag aatctaacac gtgcaatcaa caaaaacaag tgcgacattg 1440
ctgacctgaa aatggccgtt agcttcagtc aattcaacag aaggttccta aatgttgtgc 1500
ggcaattttc agacaacgct ggaataacac cagcaatatc tttggactta atgacagatg 1560
ctgaactagc cagagctgtt tocaacatgc caacatctgc aggacaaata aaactgatgt 1620

```



```

tggagaaccg tgcaatggta agaagaaaag ggttcggatt cctgatagga gtttacggaa 1680
gctccgtaat ttacatgggt caactgccaa tctttggggt tatagacacg ccttgctgga 1740
tagtaaaagc agccccttct tgttcaggaa aaaagggaag ctatgcttgc ctcttaagag 1800
aagaccaagg atggtattgt caaaatgcag ggtcaactgt ttactacca aatgaaaaag 1860
actgtgaaac aagaggagac catgtctttt gcgacacagc agcaggaatc aatgttgctg 1920
agcagtcaaa ggagtgcac ataaacatat ctactactaa ttacccatgc aaagttagca 1980
caggaagaca tcctatcagt atggttgac tatctctct tggggctttg gttgcttgct 2040
acaagggagt gagctgttcc attggcagca acagagtagg gatcatcaag caactgaaca 2100
aaggctgctc ttatataacc aaccaagacg cagacacagt gacaatagac aacactgtat 2160
accagctaag caaagttgaa ggcgaacagc atgttataaa aggaaggcca gtgtcaagca 2220
gctttgacct agtcaagttt cctgaagatc aattcaatgt tgcacttgac caagttttcg 2280
agagcattga gaacagtcag gccttggtgg atcaatcaaa cagaatccta agcagtgacg 2340
agaaaggaaa cactggcttc atcattgtaa taattcta tgcgtgcctt ggctctacca 2400
tgatcctagt gagtgttttt atcataataa agaaaacaaa gagaccacac ggagcacctc 2460
cagagctgag tgggtgcaca aacaatggct tcataccaca taattag 2507

```

<210> 2

<211> 1596

<212> DNA

<213> pneumovirus

<220>

<221> CDS

<222> (1) ... (1596)

<223> Avian pneumovirus fusion protein gene, partial cds

<400> 2

```

atgtcttgga aagtgggtact gctattggta ttgctagcta cccaacggg ggggctagaa 60
gaaagttatc tagaggagtc atgcagtact gttactagag gatacctgag tgttttgagg 120
acaggatggg atacaaatgt gttcacactt ggggttgagg atgtgaaaaa tctcacatgt 180
accgacgggc ccagcttaat aagaacagaa cttgaactga caaaaaatgc acttgaggaa 240
ctcaagacag tatcagcaga tcaattggca aaggaagcta ggataatgtc accaagaaaa 300
gcccggtttg ttctgggtgc catagcatta ggtgtggcaa ctgctgctgc tgtgacggct 360
ggtgtagcga tagccaagac aattaggcta gaaggagaag tggctgcaat caaaggtgctg 420
ctcaggaaaa caaatgaggg tgtatctaca ttaggaaatg gcgtgagggg acttgcaaca 480
gctgtgaatg atctcaagga ctttataagt aaaaaattga cacctgcaat aaacaggaac 540
aagtgtgaca tctcagacct taagatggca gtgagctttg gacaatacaa tgggaggttc 600
ctcaatgtgg taagacagtt ttctgacaat gcagggtatta cgctgcaat atctctagat 660
ttaatgactg acgctgagct tgtaagagct gtaagcaaca tgcccacatc ttcaggacag 720
atcaatctga tgcttgagaa tcgggcaatg gtcagaagga aaggatttgg gattttgatt 780
ggagtttatg tagctctgtt ggtctatata gtgcagcttc ctattttcgg tgtgatagat 840
acaccgtgtt ggaggggtgaa ggctgctcca ttatgttcag ggaaagacgg gaattatgca 900
tgtctcttgc gagaggacca aggttggtat tgtcaaaatg ctggatccac agtttattat 960
ccaaatgagg aggactgtga agtaagaagt gatcatgtgt tttgtgacac agcagctggg 1020
ataaatgtag caaaggagtc agaagagtgc aacaggaata tctcaacaac aaagtaccct 1080
tgcaaggtaa gtacagggcg tcaccaata agcatgggtg ccttatcacc actgggtgct 1140
ttggtagcct gttatgacgg tatgagttgt tccattggaa gcaacaagggt tgggaataatc 1200
agacctttgg ggaaaggggtg ttcatacatc agcaatcaag atgctgacac tgttacaatt 1260
gacaacacag tgtaccaatt gagcaaagt gaaggagaac aacacacaat taaaggggaag 1320
ccagtatcta gcaattttga ccctatagag ttccctgaag atcagttcaa cgtagccctg 1380
gatcaggtgt ttgaaaagtgt tgagaagagt cagaatctga tagaccagtc aaacaagata 1440
ttggtatgca ttgaaaaggg gaatgcagga tttgtcatag tgatagtcct cattgtcctg 1500
ctcatgtcgg cagcagttgg tgtgggtgtc ttctttgtgg ttaagaagag aaaagctgct 1560
cccaaattcc caatggaaat gaatgggtgt aacaac 1596

```

<210> 3

<211> 1666

<212> DNA

<213> pneumovirus

<220>

<221> CDS

<222> (14)...(1627)

<223> Avian pneumovirus isolate 1b fusion protein mRNA,
complete cds

<400> 3

```

gggacaagtg aaaatgtctt ggaaagtggg actgctattg gtattgctag ctaccccaac 60
gggggggcta gaagaaagt atctagagga gtcattcagt actgttacta gaggatacct 120
gagtgttttg aggacaggat ggtatacaaa tgtgttcaca cttgagggtg gagatgtgga 180
aaatctcaca tgtaccgacg ggcccagctt aataagaaca gaacttgaac tgacaaaaaa 240
tgcacttgag gaactcaaga cagtatcagc agatcaattg gcaaaggaag ctaggataat 300
gtcaccaaga aaagcccggg ttgttctggg tgccatagca ttaggtgtgg caactgctgc 360
tgctgtgacg gctgggtgtag cgatagccaa gacaattagg ctagaaggag aagtggctgc 420
aatcaagggt gcgctcagga aaacaaatga ggctgtatct acattaggaa atggcgtgag 480
gggtacttgca acagctgtga atgatctcaa ggactttata agtaaaaaat tgacacctgc 540
aataaacagg aacaagtgtg acatctcaga ccttaagatg gcagtgtgag ttggacaata 600
caatcggagg ttccctcaatg ttgtaagaca gttttctgac aatgcaggta ttacgcctgc 660
aatatctcta gatttaatga ctgacgctga gcttgtaaga gctgtaagca acatgcccac 720
atcttcagga cagatcaatc tgatgcttga gaatcgggca atggtcagaa ggaaaggatt 780
ttggattttg attggagttt atggtagctc tgggtctat atagtgcagc ttccctattt 840
cgggtgtgata gatacacctg gttggaaggt gaaggctgct ccattatgtt cagggaaaga 900
cgggaattat gcatgtctct tgcgagagga ccaagggttg tattgtcaaa atgctggatc 960
cacagtttat tatccaaatg aggaggactg tgaagtaaga agtgatcatg tgttttgtga 1020
cacagcagct gggataaatg tagcaaagga gtcagaagag tgcaacagga atatctcaac 1080
aacaagtagc ccttgcaagg taagtacagg gcgtcaccca ataagcatgg tggccttata 1140
accactgggt gctttggtag cctgttatga cgggtatgag tgttccattg gaagcaacaa 1200
gggttggaata atcagacctt tggggaaagg gtgttcatac atcagcaatc aagatgctga 1260
cactgttaca attgacaaca cagtgtacca attgagcaaa gttgaaggag aacaacacac 1320
aattaaaggg aagccagtat ctagcaattt tgaccctata gagttccctg aagatcagtt 1380
caacgtagcc ctggatcagg tgtttgaaag tgttgagaag agtcagaatc tgatagacca 1440
gtcaaacaag atattggata gcattgaaaa ggggaatgca ggatttgtca tagtgatagt 1500
cctcattgtc ctgctcatgc tggcagcagt tgggtgtggg gtcttctttg tgggttaagaa 1560
gagaaaagct gctcccaaat tcccaatgga aatgaatggg gtgaacaaca aaggatttat 1620
cccttaattt tagttattaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1666

```

<210> 4

<211> 1636

<212> DNA

<213> rhinotracheitis virus

<220>

<221> CDS

<222> (13)...(1629)

<223> Turkey rhinotracheitis virus gene for fusion
protein (F1 and F2 subunits), complete cds

<400> 4

```

gggacaagta ggatggatgt aagaatctgt ctctattgt tccttatatc taatcctagt 60
agctgcatac aagaacata caatgaagaa tcctgcagta ctgtaactag aggttataag 120
agtgtgttaa ggacagggtg gtatacgaat gtatttaacc tcgaaatagg gaatgttgag 180
aacatcactt gcaatgatgg acccagccta attgacactg agttagtact caciaagaat 240
gctttgaggg agctcaaaac agtgtcagct gatcaagtgg ctaaggaaaag cagactatcc 300
tcaccagga gacgtagatt tgtactgggt gcaatagcac ttggtgttgc gacagctgct 360
gccgtaacag ctgggtgtagc acttgcaaaag acaattagat tagagggaga ggtgaaggca 420
attaagaatg ccctccggaa cacaaatgag gcagtatcca cattagggaa tgggtgtgag 480
gtactagcaa ctgcagtcaa tgacctcaaa gaatttataa gtaaaaaatt gactcctgct 540
attaaccaga acaaatgcaa tatagcagat ataaagatgg caattagttt tggccaaaat 600
aacagaaggt tcctgaatgt ggtgaggcaa ttctctgata gtgcaggatc cacatcagct 660
gtgtctcttg atttaatgac agatgatgaa cttgttagag caattaacag aatgccaaact 720
tcatcaggac agattagttt gatgttgaa aatcgtgcca tgggtagaag gaaggggttt 780
ggtatattga ttggtgttta tgatggaacg gtcgtttata tgggtacaact gccatattc 840
ggcgtgattg agacacctg ttggagggtg gtggcagcac cactctgtag gaaagagaaa 900
ggcaattatg cttgtatact gagagaagat caagggtggg actgtacaaa tgctggctct 960

```

```

acagcttatt atcctaataa agatgattgt gaggtaaggg atgattatgt attttgtgac 1020
acagcagctg gcattaatgt ggccctagaa gttgaacagt gcaactataa catatcgact 1080
tctaaatacc catgcaaagt cagcacaggt agacaccctg tcagtatggt agccttaacc 1140
cccctagggg gtctagtgtc ttgttatgag agtgtaagtt gctccatagg tagcaataaa 1200
gtagggataa taaaacagct aggcaaaggg tgcaccacaa ttcccaacaa cgaagctgac 1260
acgataacca ttgataacac tgtgtaccaa ttgagcaagg ttgtaggcga acagaggacc 1320
ataaaaggag ctccagttgt gaacaatttt aocccaatat tattccctga ggatcagttc 1380
aatgtttgac ttgaccaagt atttgagagt atagatagat ctcaggactt aatagataag 1440
tctaacgact tgctaggtgc agatgccaaag agcaaggctg gaattgctat agcaatagta 1500
gtgctagtca ttctaggaat cttcttttta cttgcagtga tatattactg ttccagagtc 1560
cggaagacca aaccaaagca tgattaccgg gccacgacag gtcatagcag catggcctat 1620
gtcagttaag ttatatt 1636

```

<210> 5

<211> 1860

<212> DNA

<213> pneumovirus

<220>

<221> CDS

<222> (1) ... (110)

<223> Avian pneumovirus matrix protein (M) gene, partial
cgs

<220>

<221> CDS

<222> (216) ... (1829)

<223> Avian pneumovirus fusion glycoprotein (F) gene,
complete cds

<400> 5

```

gagttcaggt aatagtggag ttaggggcat acgttcaagc agaaagcata agcagaatct 60
gcaggaactg gagccaccag ggtacgagat atgtcctgaa gtcaagataa acacagagag 120
tacacttacc aaatcacagt aacaatttcg tttttaaccc tctcatagtt attacctagc 180
ttgatattat ttagaaaaaa ttgggacaag tgaataatgtc ttggaaagtg gtactgctat 240
tggtattgct agctacccca acggggggggc tagaagaaag ttatctagag gagtcatgca 300
gtactgttac tagaggatac ctgagtggtt tgaggacagg atgggtatata aatgtgttca 360
cacttgaggt tggagatgtg gaaaatctca catgtaccga cggggccagc ttaataagaa 420
cagaacttga actgacaaaa aatgcacttg aggaactcaa gacagtatca gcagatcaat 480
tggcaaaagg agctaggata atgtcaccaa gaaaagcccg gtttgttctg ggtgccatag 540
cattaggtgt ggcaactgct gctgctgtga cggctggtgt agcgatagcc aagacaatta 600
ggctagaagg agaagtggct gcaatcaagg gtgcgctcag gaaaacaaat gaggtgtat 660
ctacattagg aaatggcggt aggggtactt caacagctgt gaatgatctc aaggacttta 720
taagtaaaaa attgacacct gcaataaaca ggaacaagtg tgacatctca gaccttaaga 780
tggcagtgag ctttggacaa tacaatcgga ggttcctcaa tgttgtaaga cagttttctg 840
aacaatgcagg tattacgcct gcaatatctc tagatttaat gactgacgct gagcttgtaa 900
gagctgtaag caacatgccc acatcttcag gacagatcaa tctgatgctt gagaatcggg 960
caatgggtcag aaggaaagga tttgggattt tgattggagt ttatggtagc tctgtggtct 1020
atatagtgca gcttcctatt ttcgggtgtg tagatacacc gtgttggaag gtgaaggctg 1080
ctccattatg ttcagggaaa gacgggaatt atgcatgtct cttgcgagag gaccaagggt 1140
ggtattgtca aaatgctgga tccacagttt attatccaaa tgaggaggac tgtgaagtaa 1200
gaagtgtatc tgtgttttgt gacacagcag ctgggataaa tgtagcaaag ggtcagaag 1260
agtgcacagc gaatatctca acaacaaagt acccttgcaa ggtaagtaca gggcgtcacc 1320
caataagcat ggtggcetta tcaccaactg gtgcttttgt agcctgttat gacggtatga 1380
gttgttccat tggaagcaac aagggttgga taatcagacc tttggggaaa ggggtgttcat 1440
acatcagcaa tcaagatgct gacactgtta caattgacaa cacagtgtac caattgagca 1500
aagttgaagg agaacaacac acaattaaag ggaagccagt atctagcaat tttgacccta 1560
tagagttccc tgaagatcag ttcaacatag ccctggatca agtggttgaa agtggtgaga 1620
agagtcagaa tctgatagac cagtcacaaa agatattgga tagcattgaa aaggggaatg 1680
caggatttgt catagtgtga gtccctcatt tctgtctcat gctggcagca gttggtgtgg 1740
gtgtcttctt tgtggttaag aagagaaaag ctgctcccaa attcccaatg gaaatgaatg 1800
gtgtgaacaa caaaggattt atcccttaat tttagttact aaaaaattgg gacaagtga 1860

```

<210> 6
 <211> 574
 <212> PRT
 <213> paramyxovirus

<400> 6
 Met Glu Leu Leu Ile His Arg Leu Ser Ala Ile Phe Leu Thr Leu Ala
 1 5 10 15
 Ile Asn Ala Leu Tyr Leu Thr Ser Ser Gln Asn Ile Thr Glu Glu Phe
 20 25 30
 Tyr Gln Ser Thr Cys Ser Ala Val Ser Arg Gly Tyr Phe Ser Ala Leu
 35 40 45
 Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile
 50 55 60
 Lys Glu Thr Lys Cys Asn Gly Thr Asp Thr Lys Val Lys Leu Ile Lys
 65 70 75 80
 Gln Glu Leu Asp Lys Tyr Lys Asn Ala Val Thr Glu Leu Gln Leu Leu
 85 90 95
 Met Gln Asn Thr Pro Ala Ala Asn Asn Arg Ala Arg Arg Glu Ala Pro
 100 105 110
 Gln Tyr Met Asn Tyr Thr Ile Asn Thr Thr Lys Asn Leu Asn Val Ser
 115 120 125
 Ile Ser Lys Lys Arg Lys Arg Arg Phe Leu Gly Phe Leu Leu Gly Val
 130 135 140
 Gly Ser Ala Ile Ala Ser Gly Ile Ala Val Ser Lys Val Leu His Leu
 145 150 155 160
 Glu Gly Glu Val Asn Lys Ile Lys Asn Ala Leu Leu Ser Thr Asn Lys
 165 170 175
 Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val
 180 185 190
 Leu Asp Leu Lys Asn Tyr Ile Asn Asn Gln Leu Leu Pro Ile Val Asn
 195 200 205
 Gln Gln Ser Cys Arg Ile Ser Asn Ile Glu Thr Val Ile Glu Phe Gln
 210 215 220
 Gln Lys Asn Ser Arg Leu Leu Glu Ile Asn Arg Glu Phe Ser Val Asn
 225 230 235 240
 Ala Gly Val Thr Thr Pro Leu Ser Thr Tyr Met Leu Thr Asn Ser Glu
 245 250 255
 Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp Gln Lys Lys
 260 265 270
 Leu Met Ser Ser Asn Val Gln Ile Val Arg Gln Gln Ser Tyr Ser Ile
 275 280 285
 Met Ser Ile Ile Lys Glu Glu Val Leu Ala Tyr Val Val Gln Leu Pro
 290 295 300
 Ile Tyr Gly Val Ile Asp Thr Pro Cys Trp Lys Leu His Thr Ser Pro
 305 310 315 320
 Leu Cys Thr Thr Asn Ile Lys Glu Gly Ser Asn Ile Cys Leu Thr Arg
 325 330 335
 Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gly Ser Val Ser Phe Phe
 340 345 350
 Pro Gln Ala Asp Thr Cys Lys Val Gln Ser Asn Arg Val Phe Cys Asp
 355 360 365
 Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Val Ser Leu Cys Asn Thr
 370 375 380
 Asp Ile Phe Asn Ser Lys Tyr Asp Cys Lys Ile Met Thr Ser Lys Thr
 385 390 395 400
 Asp Ile Ser Ser Ser Val Ile Thr Ser Leu Gly Ala Ile Val Ser Cys
 405 410 415
 Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg Gly Ile Ile
 420 425 430
 Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys Gly Val Asp

435					440					445					
Thr	Val	Ser	Val	Gly	Asn	Thr	Leu	Tyr	Tyr	Val	Asn	Lys	Leu	Glu	Gly
450					455					460					
Lys	Asn	Leu	Tyr	Val	Lys	Gly	Glu	Pro	Ile	Ile	Asn	Tyr	Tyr	Asp	Pro
465					470					475					480
Leu	Val	Phe	Pro	Ser	Asp	Glu	Phe	Asp	Ala	Ser	Ile	Ser	Gln	Val	Asn
				485					490						495
Glu	Lys	Ile	Asn	Gln	Ser	Leu	Ala	Phe	Ile	Arg	Arg	Ser	Asp	Glu	Leu
			500					505						510	
Leu	His	Asn	Val	Asn	Thr	Gly	Lys	Ser	Thr	Thr	Asn	Ile	Met	Ile	Thr
	515					520					525				
Thr	Ile	Ile	Ile	Val	Ile	Ile	Val	Val	Leu	Leu	Ser	Leu	Ile	Ala	Ile
530					535					540					
Gly	Leu	Leu	Leu	Tyr	Cys	Lys	Ala	Lys	Asn	Thr	Pro	Val	Thr	Leu	Ser
545					550					555					560
Lys	Asp	Gln	Leu	Ser	Gly	Ile	Asn	Asn	Ile	Ala	Phe	Ser	Lys		
				565					570						

<210> 7
 <211> 574
 <212> PRT
 <213> paramyxovirus

<400> 7

Met	Glu	Leu	Leu	Ile	Leu	Lys	Ala	Asn	Ala	Ile	Thr	Thr	Ile	Leu	Thr
1				5					10					15	
Ala	Val	Thr	Phe	Cys	Phe	Ala	Ser	Gly	Gln	Asn	Ile	Thr	Glu	Glu	Phe
			20					25					30		
Tyr	Gln	Ser	Thr	Cys	Ser	Ala	Val	Ser	Lys	Gly	Tyr	Leu	Ser	Ala	Leu
			35				40					45			
Arg	Thr	Gly	Trp	Tyr	Thr	Ser	Val	Ile	Thr	Ile	Glu	Leu	Ser	Asn	Ile
	50					55				60					
Lys	Glu	Asn	Lys	Cys	Asn	Gly	Thr	Asp	Ala	Lys	Val	Lys	Leu	Ile	Lys
65					70					75					80
Gln	Glu	Leu	Asp	Lys	Tyr	Lys	Asn	Ala	Val	Thr	Glu	Leu	Gln	Leu	Leu
				85					90					95	
Met	Gln	Ser	Thr	Pro	Pro	Thr	Asn	Asn	Arg	Ala	Arg	Arg	Glu	Leu	Pro
			100					105					110		
Arg	Phe	Met	Asn	Tyr	Thr	Leu	Asn	Asn	Ala	Lys	Lys	Thr	Asn	Val	Thr
			115				120						125		
Leu	Ser	Lys	Lys	Arg	Lys	Arg	Arg	Phe	Leu	Gly	Phe	Leu	Leu	Gly	Val
	130					135					140				
Gly	Ser	Ala	Ile	Ala	Ser	Gly	Val	Ala	Val	Ser	Lys	Val	Leu	His	Leu
145					150					155					160
Glu	Gly	Glu	Val	Asn	Lys	Ile	Lys	Ser	Ala	Leu	Leu	Ser	Thr	Asn	Lys
				165					170					175	
Ala	Val	Val	Ser	Leu	Ser	Asn	Gly	Val	Ser	Val	Leu	Thr	Ser	Lys	Val
			180				185						190		
Leu	Asp	Leu	Lys	Asn	Tyr	Ile	Asp	Lys	Gln	Leu	Leu	Pro	Ile	Val	Asn
	195					200						205			
Lys	Gln	Ser	Cys	Ser	Ile	Ser	Asn	Ile	Glu	Thr	Val	Ile	Glu	Phe	Gln
	210					215					220				
Gln	Lys	Asn	Asn	Arg	Leu	Leu	Glu	Ile	Thr	Arg	Glu	Phe	Ser	Val	Asn
225					230					235					240
Ala	Gly	Val	Thr	Thr	Pro	Val	Ser	Thr	Tyr	Met	Leu	Thr	Asn	Ser	Glu
				245					250					255	
Leu	Leu	Ser	Leu	Ile	Asn	Asp	Met	Pro	Ile	Thr	Asn	Asp	Gln	Lys	Lys
			260				265						270		
Leu	Met	Ser	Asn	Asn	Val	Gln	Ile	Val	Arg	Gln	Gln	Ser	Tyr	Ser	Ile
			275				280						285		

```

Met Ser Ile Ile Lys Glu Glu Val Leu Ala Tyr Val Val Gln Leu Pro
  290                295                300
Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Lys Leu His Thr Ser Pro
  305                310                315                320
Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser Asn Ile Cys Leu Thr Arg
                325                330                335
Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gly Ser Val Ser Phe Phe
                340                345                350
Pro Gln Ala Glu Thr Cys Lys Val Gln Ser Asn Arg Val Phe Cys Asp
  355                360                365
Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Ile Asn Leu Cys Asn Val
  370                375                380
Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Ile Met Thr Ser Lys Thr
  385                390                395                400
Asp Val Ser Ser Ser Val Ile Thr Ser Leu Gly Ala Ile Val Ser Cys
                405                410                415
Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg Gly Ile Ile
                420                425                430
Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys Gly Met Asp
  435                440                445
Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys Gln Glu Gly
  450                455                460
Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile Asn Phe Tyr Asp Pro
  465                470                475                480
Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Ser Ile Ser Gln Val Asn
                485                490                495
Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Arg Lys Ser Asp Glu Leu
                500                505                510
Leu His Asn Val Asn Ala Gly Lys Ser Thr Thr Asn Ile Met Ile Thr
                515                520                525
Thr Ile Ile Ile Val Ile Ile Val Ile Leu Leu Ser Leu Ile Ala Val
  530                535                540
Gly Leu Leu Leu Tyr Cys Lys Ala Arg Ser Thr Pro Val Thr Leu Ser
  545                550                555                560
Lys Asp Gln Leu Ser Gly Ile Asn Asn Ile Ala Phe Ser Asn
                565                570

```

<210> 8
 <211> 121
 <212> PRT
 <213> metapneumovirus

```

<400> 8
Leu Leu Ile Thr Pro Gln His Gly Leu Lys Glu Ser Tyr Leu Glu Glu
  1                5                10                15
Ser Cys Ser Thr Ile Thr Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly
                20                25                30
Trp Tyr Thr Asn Val Phe Thr Leu Glu Val Gly Asp Val Glu Asn Leu
                35                40                45
Thr Cys Ala Asp Gly Pro Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr
  50                55                60
Lys Ser Ala Leu Arg Glu Leu Arg Thr Val Ser Ala Asp Gln Leu Ala
  65                70                75                80
Arg Glu Glu Gln Ile Glu Asn Pro Arg Gln Ser Arg Phe Val Leu Gly
                85                90                95
Ala Ile Ala Leu Gly Val Ala Thr Ala Ala Ala Val Thr Ala Gly Val
                100                105                110
Ala Ile Ala Lys Thr Ile Arg Leu Glu
                115                120

```

<210> 9
 <211> 539
 <212> PRT
 <213> metapneumovirus

<400> 9
 Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln
 1 5 10 15
 His Gly Leu Lys Glu Ser Tyr Leu Glu Ser Cys Ser Thr Ile Thr
 20 25 30
 Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe
 35 40 45
 Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ala Asp Gly Pro
 50 55 60
 Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu
 65 70 75 80
 Leu Arg Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu
 85 90 95
 Asn Pro Arg Gln Ser Arg Phe Val Leu Gly Ala Ile Ala Leu Gly Val
 100 105 110
 Ala Thr Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile
 115 120 125
 Arg Leu Glu Ser Glu Val Thr Ala Ile Lys Asn Ala Leu Lys Lys Thr
 130 135 140
 Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr
 145 150 155 160
 Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala
 165 170 175
 Ile Asn Lys Asn Lys Cys Asp Ile Ala Asp Leu Lys Met Ala Val Ser
 180 185 190
 Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser
 195 200 205
 Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp
 210 215 220
 Ala Glu Leu Ala Arg Ala Val Ser Asn Met Pro Thr Ser Ala Gly Gln
 225 230 235 240
 Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe
 245 250 255
 Gly Phe Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln
 260 265 270
 Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala
 275 280 285
 Ala Pro Ser Cys Ser Gly Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg
 290 295 300
 Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr
 305 310 315 320
 Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp
 325 330 335
 Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile
 340 345 350
 Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His
 355 360 365
 Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys
 370 375 380
 Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile
 385 390 395 400
 Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp
 405 410 415
 Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly
 420 425 430
 Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro
 435 440 445

Val Lys Phe Pro Glu Asp Gln Phe Asn Val Ala Leu Asp Gln Val Phe
 450 455 460
 Glu Ser Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile
 465 470 475 480
 Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile
 485 490 495
 Leu Ile Ala Val Leu Gly Ser Thr Met Ile Leu Val Ser Val Phe Ile
 500 505 510
 Ile Ile Lys Lys Thr Lys Arg Pro Thr Gly Ala Pro Pro Glu Leu Ser
 515 520 525
 Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn
 530 535

<210> 10

<211> 532

<212> PRT

<213> Avian pneumovirus

<400> 10

Met Ser Trp Lys Val Val Leu Leu Leu Val Leu Leu Ala Thr Pro Thr
 1 5 10 15
 Gly Gly Leu Glu Ser Tyr Leu Glu Ser Cys Ser Thr Val Thr
 20 25 30
 Arg Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe
 35 40 45
 Thr Leu Gly Val Gly Asp Val Lys Asn Leu Thr Cys Thr Asp Gly Pro
 50 55 60
 Ser Leu Ile Arg Thr Glu Leu Glu Leu Thr Lys Asn Ala Leu Glu Glu
 65 70 75 80
 Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Lys Glu Ala Arg Ile Met
 85 90 95
 Ser Pro Arg Lys Ala Arg Phe Val Leu Gly Ala Ile Ala Leu Gly Val
 100 105 110
 Ala Thr Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile
 115 120 125
 Arg Leu Glu Gly Glu Val Ala Ala Ile Lys Gly Ala Leu Arg Lys Thr
 130 135 140
 Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr
 145 150 155 160
 Ala Val Asn Asp Leu Lys Asp Phe Ile Ser Lys Lys Leu Thr Pro Ala
 165 170 175
 Ile Asn Arg Asn Lys Cys Asp Ile Ser Asp Leu Lys Met Ala Val Ser
 180 185 190
 Phe Gly Gln Tyr Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser
 195 200 205
 Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp
 210 215 220
 Ala Glu Leu Val Arg Ala Val Ser Asn Met Pro Thr Ser Ser Gly Gln
 225 230 235 240
 Ile Asn Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe
 245 250 255
 Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Val Tyr Ile Val Gln
 260 265 270
 Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Arg Val Lys Ala
 275 280 285
 Ala Pro Leu Cys Ser Gly Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg
 290 295 300
 Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr
 305 310 315 320
 Pro Asn Glu Glu Asp Cys Glu Val Arg Ser Asp His Val Phe Cys Asp
 325 330 335


```

Thr Ala Ala Gly Ile Asn Val Ala Lys Glu Ser Glu Glu Cys Asn Arg
      340      345      350
Asn Ile Ser Thr Thr Lys Tyr Pro Cys Lys Val Ser Thr Gly Arg His
      355      360      365
Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys
      370      375      380
Tyr Asp Gly Met Ser Cys Ser Ile Gly Ser Asn Lys Val Gly Ile Ile
      385      390      395      400
Arg Pro Leu Gly Lys Gly Cys Ser Tyr Ile Ser Asn Gln Asp Ala Asp
      405      410      415
Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly
      420      425      430
Glu Gln His Thr Ile Lys Gly Lys Pro Val Ser Ser Asn Phe Asp Pro
      435      440      445
Ile Glu Phe Pro Glu Asp Gln Phe Asn Val Ala Leu Asp Gln Val Phe
      450      455      460
Glu Ser Val Glu Lys Ser Gln Asn Leu Ile Asp Gln Ser Asn Lys Ile
      465      470      475      480
Leu Asp Ser Ile Glu Lys Gly Asn Ala Gly Phe Val Ile Val Ile Val
      485      490      495
Leu Ile Val Leu Leu Met Leu Ala Ala Val Gly Val Gly Val Phe Phe
      500      505      510
Val Val Lys Lys Arg Lys Ala Ala Pro Lys Phe Pro Met Glu Met Asn
      515      520      525
Gly Val Asn Asn
      530

```

<210> 11
 <211> 537
 <212> PRT
 <213> Avian pneumovirus

```

<400> 11
Met Ser Trp Lys Val Val Leu Leu Leu Val Leu Leu Ala Thr Pro Thr
  1      5      10      15
Gly Gly Leu Glu Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Val Thr
      20      25      30
Arg Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe
      35      40      45
Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Thr Asp Gly Pro
      50      55      60
Ser Leu Ile Arg Thr Glu Leu Glu Leu Thr Lys Asn Ala Leu Glu Glu
      65      70      75      80
Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Lys Glu Ala Arg Ile Met
      85      90      95
Ser Pro Arg Lys Ala Arg Phe Val Leu Gly Ala Ile Ala Leu Gly Val
      100      105      110
Ala Thr Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile
      115      120      125
Arg Leu Glu Gly Glu Val Ala Ala Ile Lys Gly Ala Leu Arg Lys Thr
      130      135      140
Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr
      145      150      155      160
Ala Val Asn Asp Leu Lys Asp Phe Ile Ser Lys Lys Leu Thr Pro Ala
      165      170      175
Ile Asn Arg Asn Lys Cys Asp Ile Ser Asp Leu Lys Met Ala Val Ser
      180      185      190
Phe Gly Gln Tyr Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser
      195      200      205
Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp
      210      215      220

```

Ala Glu Leu Val Arg Ala Val Ser Asn Met Pro Thr Ser Ser Gly Gln
 225 230 235 240
 Ile Asn Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe
 245 250 255
 Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Val Tyr Ile Val Gln
 260 265 270
 Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Lys Val Lys Ala
 275 280 285
 Ala Pro Leu Cys Ser Gly Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg
 290 295 300
 Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr
 305 310 315 320
 Pro Asn Glu Glu Asp Cys Glu Val Arg Ser Asp His Val Phe Cys Asp
 325 330 335
 Thr Ala Ala Gly Ile Asn Val Ala Lys Glu Ser Glu Glu Cys Asn Arg
 340 345 350
 Asn Ile Ser Thr Thr Lys Tyr Pro Cys Lys Val Ser Thr Gly Arg His
 355 360 365
 Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys
 370 375 380
 Tyr Asp Gly Met Ser Cys Ser Ile Gly Ser Asn Lys Val Gly Ile Ile
 385 390 395 400
 Arg Pro Leu Gly Lys Gly Cys Ser Tyr Ile Ser Asn Gln Asp Ala Asp
 405 410 415
 Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly
 420 425 430
 Glu Gln His Thr Ile Lys Gly Lys Pro Val Ser Ser Asn Phe Asp Pro
 435 440 445
 Ile Glu Phe Pro Glu Asp Gln Phe Asn Val Ala Leu Asp Gln Val Phe
 450 455 460
 Glu Ser Val Glu Lys Ser Gln Asn Leu Ile Asp Gln Ser Asn Lys Ile
 465 470 475 480
 Leu Asp Ser Ile Glu Lys Gly Asn Ala Gly Phe Val Ile Val Ile Val
 485 490 495
 Leu Ile Val Leu Leu Met Leu Ala Ala Val Gly Val Gly Val Phe Phe
 500 505 510
 Val Val Lys Lys Arg Lys Ala Ala Pro Lys Phe Pro Met Glu Met Asn
 515 520 525
 Gly Val Asn Asn Lys Gly Phe Ile Pro
 530 535

<210> 12

<211> 538

<212> PRT

<213> Turkey rhinotracheitis virus

<400> 12

Met Asp Val Arg Ile Cys Leu Leu Leu Phe Leu Ile Ser Asn Pro Ser
 1 5 10 15
 Ser Cys Ile Gln Glu Thr Tyr Asn Glu Glu Ser Cys Ser Thr Val Thr
 20 25 30
 Arg Gly Tyr Lys Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe
 35 40 45
 Asn Leu Glu Ile Gly Asn Val Glu Asn Ile Thr Cys Asn Asp Gly Pro
 50 55 60
 Ser Leu Ile Asp Thr Glu Leu Val Leu Thr Lys Asn Ala Leu Arg Glu
 65 70 75 80
 Leu Lys Thr Val Ser Ala Asp Gln Val Ala Lys Glu Ser Arg Leu Ser
 85 90 95
 Ser Pro Arg Arg Arg Phe Val Leu Gly Ala Ile Ala Leu Gly Val
 100 105 110

Ala Thr Ala Ala Ala Val Thr Ala Gly Val Ala Leu Ala Lys Thr Ile
 115 120 125
 Arg Leu Glu Gly Glu Val Lys Ala Ile Lys Asn Ala Leu Arg Asn Thr
 130 135 140
 Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr
 145 150 155 160
 Ala Val Asn Asp Leu Lys Glu Phe Ile Ser Lys Lys Leu Thr Pro Ala
 165 170 175
 Ile Asn Gln Asn Lys Cys Asn Ile Ala Asp Ile Lys Met Ala Ile Ser
 180 185 190
 Phe Gly Gln Asn Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser
 195 200 205
 Asp Ser Ala Gly Ile Thr Ser Ala Val Ser Leu Asp Leu Met Thr Asp
 210 215 220
 Asp Glu Leu Val Arg Ala Ile Asn Arg Met Pro Thr Ser Ser Gly Gln
 225 230 235 240
 Ile Ser Leu Met Leu Asn Asn Arg Ala Met Val Arg Arg Lys Gly Phe
 245 250 255
 Gly Ile Leu Ile Gly Val Tyr Asp Gly Thr Val Val Tyr Met Val Gln
 260 265 270
 Leu Pro Ile Phe Gly Val Ile Glu Thr Pro Cys Trp Arg Val Val Ala
 275 280 285
 Ala Pro Leu Cys Arg Lys Glu Lys Gly Asn Tyr Ala Cys Ile Leu Arg
 290 295 300
 Glu Asp Gln Gly Trp Tyr Cys Thr Asn Ala Gly Ser Thr Ala Tyr Tyr
 305 310 315 320
 Pro Asn Lys Asp Asp Cys Glu Val Arg Asp Asp Tyr Val Phe Cys Asp
 325 330 335
 Thr Ala Ala Gly Ile Asn Val Ala Leu Glu Val Glu Gln Cys Asn Tyr
 340 345 350
 Asn Ile Ser Thr Ser Lys Tyr Pro Cys Lys Val Ser Thr Gly Arg His
 355 360 365
 Pro Val Ser Met Val Ala Leu Thr Pro Leu Gly Gly Leu Val Ser Cys
 370 375 380
 Tyr Glu Ser Val Ser Cys Ser Ile Gly Ser Asn Lys Val Gly Ile Ile
 385 390 395 400
 Lys Gln Leu Gly Lys Gly Cys Thr His Ile Pro Asn Asn Glu Ala Asp
 405 410 415
 Thr Ile Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Val Gly
 420 425 430
 Glu Gln Arg Thr Ile Lys Gly Ala Pro Val Val Asn Asn Phe Asn Pro
 435 440 445
 Ile Leu Phe Pro Glu Asp Gln Phe Asn Val Ala Leu Asp Gln Val Phe
 450 455 460
 Glu Ser Ile Asp Arg Ser Gln Asp Leu Ile Asp Lys Ser Asn Asp Leu
 465 470 475 480
 Leu Gly Ala Asp Ala Lys Ser Lys Ala Gly Ile Ala Ile Ala Ile Val
 485 490 495
 Val Leu Val Ile Leu Gly Ile Phe Phe Leu Leu Ala Val Ile Tyr Tyr
 500 505 510
 Cys Ser Arg Val Arg Lys Thr Lys Pro Lys His Asp Tyr Pro Ala Thr
 515 520 525
 Thr Gly His Ser Ser Met Ala Tyr Val Ser
 530 535

<210> 13

<211> 537

<212> PRT

<213> Avian pneumovirus

<400> 13

```

Met Ser Trp Lys Val Val Leu Leu Leu Val Leu Leu Ala Thr Pro Thr
 1      5      10      15
Gly Gly Leu Glu Ser Tyr Leu Glu Ser Cys Ser Thr Val Thr
      20      25      30
Arg Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe
      35      40      45
Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Thr Asp Gly Pro
      50      55      60
Ser Leu Ile Arg Thr Glu Leu Glu Leu Thr Lys Asn Ala Leu Glu Glu
      65      70      75      80
Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Lys Glu Ala Arg Ile Met
      85      90      95
Ser Pro Arg Lys Ala Arg Phe Val Leu Gly Ala Ile Ala Leu Gly Val
      100      105      110
Ala Thr Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile
      115      120      125
Arg Leu Glu Gly Glu Val Ala Ala Ile Lys Gly Ala Leu Arg Lys Thr
      130      135      140
Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr
      145      150      155      160
Ala Val Asn Asp Leu Lys Asp Phe Ile Ser Lys Lys Leu Thr Pro Ala
      165      170      175
Ile Asn Arg Asn Lys Cys Asp Ile Ser Asp Leu Lys Met Ala Val Ser
      180      185      190
Phe Gly Gln Tyr Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser
      195      200      205
Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp
      210      215      220
Ala Glu Leu Val Arg Ala Val Ser Asn Met Pro Thr Ser Ser Gly Gln
      225      230      235      240
Ile Asn Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe
      245      250      255
Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Val Tyr Ile Val Gln
      260      265      270
Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Lys Val Lys Ala
      275      280      285
Ala Pro Leu Cys Ser Gly Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg
      290      295      300
Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr
      305      310      315      320
Pro Asn Glu Glu Asp Cys Glu Val Arg Ser Asp His Val Phe Cys Asp
      325      330      335
Thr Ala Ala Gly Ile Asn Val Ala Lys Glu Ser Glu Glu Cys Asn Arg
      340      345      350
Asn Ile Ser Thr Thr Lys Tyr Pro Cys Lys Val Ser Thr Gly Arg His
      355      360      365
Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys
      370      375      380
Tyr Asp Gly Met Ser Cys Ser Ile Gly Ser Asn Lys Val Gly Ile Ile
      385      390      395      400
Arg Pro Leu Gly Lys Gly Cys Ser Tyr Ile Ser Asn Gln Asp Ala Asp
      405      410      415
Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly
      420      425      430
Glu Gln His Thr Ile Lys Gly Lys Pro Val Ser Ser Asn Phe Asp Pro
      435      440      445
Ile Glu Phe Pro Glu Asp Gln Phe Asn Ile Ala Leu Asp Gln Val Phe
      450      455      460
Glu Ser Val Glu Lys Ser Gln Asn Leu Ile Asp Gln Ser Asn Lys Ile
      465      470      475      480
Leu Asp Ser Ile Glu Lys Gly Asn Ala Gly Phe Val Ile Val Ile Val
      485      490      495

```

Leu Ile Val Leu Leu Met Leu Ala Ala Val Gly Val Gly Val Phe Phe
 500 505 510
 Val Val Lys Lys Arg Lys Ala Ala Pro Lys Phe Pro Met Glu Met Asn
 515 520 525
 Gly Val Asn Asn Lys Gly Phe Ile Pro
 530 535

<210> 14
 <211> 1193
 <212> DNA
 <213> rhinotracheitis virus

<220>
 <221> CDS
 <222> (16)...(1191)
 <223> Turkey rhinotracheitis virus (strain CVL14/1)
 attachment protien (G) mRNA, complete cds

<400> 14
 gggacaagta tctctatggg gtccaaacta tatatggctc agggcaccag tgcatatcaa 60
 actgcagtggt ggttctggct ggacatcggg aggaggtaca tattggctat agtcctatca 120
 gctttcgggc tgacctgcac agtcactatt gcactcactg ttagcgtcat agttgaacag 180
 tcagtgttag aggagtgcag aaactacaat ggaggagata gagattggtg gtcaaccacc 240
 caggagcagc caactactgc accaagtgcg actccagcag gaaattatgg aggattacaa 300
 acggctcgaa caagaaagtc tgaaagctgt ttgcatgtgc aaatttctta tgggtgatatg 360
 tatagccgca gtgatactgt actgggtggg tttgattgta tgggcttatt ggttctttgc 420
 aaatcaggac caatttgtca gcgagataat caagttgacc caacagccct ctgccattgc 480
 agggtagatc tttcaagtgt ggactgctgc aagggtgaaca agattagcac taacagcagc 540
 accacctctg agccccagaa gaccaaccgg gcatggccta gccaaagaca cacagactcc 600
 gatccaaatc cccaaggcat aaccaccagc acagccactc tgctctcaac aagtctgggc 660
 ctcatgtcga catcgaagac tgggacacac aaatcagggc ccccccaagc cttgccgggg 720
 agcaacacca acggaaaaac aaccacagac cgagaaccag ggcccacaaa ccaaccaa 780
 tcaaccacca atggggcaaca caataaacac acccaacgaa tgacaccccc gccaaagtcac 840
 gacaacacaa gaaccatcct ccagcacaca acaccctggg aaaagacatt cagtacatac 900
 aagcccacac actctccgac caacgaatca gatcaatccc tccccacaa ccaaaacagc 960
 atcaactgtg aacattttga cccccaaagg aaggaaaaaa tctgctacag agtaggttct 1020
 tacaactcca atattacaaa gcaatgcaga attgatgtgc ctttgtgttc cacttatagc 1080
 acagtgtgca tgaaaacata ctataccgaa ccattcaact gttggaggcg tatctggcgt 1140
 tgcttgtgtg atgacggagt tgggtctggt gagtgggtgt gcactagtta act 1193

<210> 15
 <211> 1260
 <212> DNA
 <213> rhinotracheitis virus

<220>
 <221> CDS
 <222> (16)...(1260)
 <223> Turkey rhinotracheitis virus (strain 6574)
 attachment protein (G), complete cds

<400> 15
 gggacaagta tccagatggg gtcagagctc tacatcatag aggggggtgag ctcatctgaa 60
 atagtccctca agcaagtcct cagaaggagc caaaaaatac tgtaggact ggtgttatca 120
 gccttaggct tgacgtcac tagcactatt gttatatcta tttgtattag ttagaacag 180
 gtcaaattac gacagtgtgt ggacacttat tgggcggaaa atggatcctt acatccagga 240
 cagtcaacag aaaatacttc aacaagaggt aagactacaa caaaagacct tagaagatta 300
 caggcgactg gagcaggaaa gtttgagagc tgtgggtatg tgcaagttgt tgatgggtgat 360
 atgcatgac gcagttatgc tgtactgggt ggtgttgatt gtttgggctt attggctctt 420
 tgtgaatcag gaccaatttg tcaggagat acttggctcg aagacggaaa cttctgccga 480
 tgcacttttt cttcccatgg ggtgagttgc tgcaaaaaac ccaaaagcaa ggcaaccact 540

```

gcccagagga actccaaacc agctaacagc aaatcaactc ctccggtaca ttcagacagg 600
gccagcaaag aacataatcc ctcccaaggg gagcaacccc gcagggggcc aaccagcagc 660
aagacaacta ttgctagcac cccttcaaca gaggacactg ctaaaccaac gattagcaaa 720
cctaaactca ccatacaggcc ctgcgaaaga ggtccatccg gcagcacaaa agcagcctcc 780
agcaccacca gccacaagac caacaccaga ggaccagca agacgaccga ccagagaccc 840
cgacaccggac ccactcccga aaggcccaga caaacccaca gcacagcaac tccgcccccc 900
acaaccccaa tccacaaggg cggggcccca acccccaaac caacaacaga cctcaagggtc 960
aaccgaaggg aaggcagcac aagcccaact gcaatacaga aaaacccaac cacacaaagt 1020
aatcttgttg actgcacact gtctgatcca gatgagccac aaaggatttg ttaccaggta 1080
ggaacttaca atcctagtca atcgggaacc tgcaacatag aggttccaaa atgttccact 1140
tatgggcatg cttgtatggc tacattatat gacaccccat tcaactgctg gcgcaggacc 1200
aggagatgca tctgtgatgc cggaggggag ctgattgagt ggtgctgtac tagtcaataa 1260

```

<210> 16

<211> 391

<212> PRT

<213> Turkey rhinotracheitis virus

<400> 16

```

Met Gly Ser Lys Leu Tyr Met Ala Gln Gly Thr Ser Ala Tyr Gln Thr
 1           5           10           15
Ala Val Gly Phe Trp Leu Asp Ile Gly Arg Arg Tyr Ile Leu Ala Ile
 20           25           30
Val Leu Ser Ala Phe Gly Leu Thr Cys Thr Val Thr Ile Ala Leu Thr
 35           40           45
Val Ser Val Ile Val Glu Gln Ser Val Leu Glu Glu Cys Arg Asn Tyr
 50           55           60
Asn Gly Gly Asp Arg Asp Trp Trp Ser Thr Thr Gln Glu Gln Pro Thr
 65           70           75           80
Thr Ala Pro Ser Ala Thr Pro Ala Gly Asn Tyr Gly Gly Leu Gln Thr
 85           90           95
Ala Arg Thr Arg Lys Ser Glu Ser Cys Leu His Val Gln Ile Ser Tyr
 100          105          110
Gly Asp Met Tyr Ser Arg Ser Asp Thr Val Leu Gly Gly Phe Asp Cys
 115          120          125
Met Gly Leu Leu Val Leu Cys Lys Ser Gly Pro Ile Cys Gln Arg Asp
 130          135          140
Asn Gln Val Asp Pro Thr Ala Leu Cys His Cys Arg Val Asp Leu Ser
 145          150          155
Ser Val Asp Cys Cys Lys Val Asn Lys Ile Ser Thr Asn Ser Ser Thr
 165          170          175
Thr Ser Glu Pro Gln Lys Thr Asn Pro Ala Trp Pro Ser Gln Asp Asn
 180          185          190
Thr Asp Ser Asp Pro Asn Pro Gln Gly Ile Thr Thr Ser Thr Ala Thr
 195          200          205
Leu Leu Ser Thr Ser Leu Gly Leu Met Leu Thr Ser Lys Thr Gly Thr
 210          215          220
His Lys Ser Gly Pro Pro Gln Ala Leu Pro Gly Ser Asn Thr Asn Gly
 225          230          235
Lys Thr Thr Thr Asp Arg Glu Pro Gly Pro Thr Asn Gln Pro Asn Ser
 245          250          255
Thr Thr Asn Gly Gln His Asn Lys His Thr Gln Arg Met Thr Pro Pro
 260          265          270
Pro Ser His Asp Asn Thr Arg Thr Ile Leu Gln His Thr Thr Pro Trp
 275          280          285
Glu Lys Thr Phe Ser Thr Tyr Lys Pro Thr His Ser Pro Thr Asn Glu
 290          295          300
Ser Asp Gln Ser Leu Pro Thr Thr Gln Asn Ser Ile Asn Cys Glu His
 305          310          315          320
Phe Asp Pro Gln Gly Lys Glu Lys Ile Cys Tyr Arg Val Gly Ser Tyr
 325          330          335

```

Asn Ser Asn Ile Thr Lys Gln Cys Arg Ile Asp Val Pro Leu Cys Ser
 340 345 350
 Thr Tyr Ser Thr Val Cys Met Lys Thr Tyr Tyr Thr Glu Pro Phe Asn
 355 360 365
 Cys Trp Arg Arg Ile Trp Arg Cys Leu Cys Asp Asp Gly Val Gly Leu
 370 375 380
 Val Glu Trp Cys Cys Thr Ser
 385 390

<210> 17
 <211> 414
 <212> PRT
 <213> rhinotracheitis virus

<400> 17
 Met Gly Ser Glu Leu Tyr Ile Ile Glu Gly Val Ser Ser Ser Glu Ile
 1 5 10 15
 Val Leu Lys Gln Val Leu Arg Arg Ser Gln Lys Ile Leu Leu Gly Leu
 20 25 30
 Val Leu Ser Ala Leu Gly Leu Thr Leu Thr Ser Thr Ile Val Ile Ser
 35 40 45
 Ile Cys Ile Ser Val Glu Gln Val Lys Leu Arg Gln Cys Val Asp Thr
 50 55 60
 Tyr Trp Ala Glu Asn Gly Ser Leu His Pro Gly Gln Ser Thr Glu Asn
 65 70 75 80
 Thr Ser Thr Arg Gly Lys Thr Thr Thr Lys Asp Pro Arg Arg Leu Gln
 85 90 95
 Ala Thr Gly Ala Gly Lys Phe Glu Ser Cys Gly Tyr Val Gln Val Val
 100 105 110
 Asp Gly Asp Met His Asp Arg Ser Tyr Ala Val Leu Gly Gly Val Asp
 115 120 125
 Cys Leu Gly Leu Leu Ala Leu Cys Glu Ser Gly Pro Ile Cys Gln Gly
 130 135 140
 Asp Thr Trp Ser Glu Asp Gly Asn Phe Cys Arg Cys Thr Phe Ser Ser
 145 150 155 160
 His Gly Val Ser Cys Cys Lys Lys Pro Lys Ser Lys Ala Thr Thr Ala
 165 170 175
 Gln Arg Asn Ser Lys Pro Ala Asn Ser Lys Ser Thr Pro Pro Val His
 180 185 190
 Ser Asp Arg Ala Ser Lys Glu His Asn Pro Ser Gln Gly Glu Gln Pro
 195 200 205
 Arg Arg Gly Pro Thr Ser Ser Lys Thr Thr Ile Ala Ser Thr Pro Ser
 210 215 220
 Thr Glu Asp Thr Ala Lys Pro Thr Ile Ser Lys Pro Lys Leu Thr Ile
 225 230 235 240
 Arg Pro Ser Gln Arg Gly Pro Ser Gly Ser Thr Lys Ala Ala Ser Ser
 245 250 255
 Thr Pro Ser His Lys Thr Asn Thr Arg Gly Thr Ser Lys Thr Thr Asp
 260 265 270
 Gln Arg Pro Arg Thr Gly Pro Thr Pro Glu Arg Pro Arg Gln Thr His
 275 280 285
 Ser Thr Ala Thr Pro Pro Pro Thr Thr Pro Ile His Lys Gly Arg Ala
 290 295 300
 Pro Thr Pro Lys Pro Thr Thr Asp Leu Lys Val Asn Pro Arg Glu Gly
 305 310 315 320
 Ser Thr Ser Pro Thr Ala Ile Gln Lys Asn Pro Thr Thr Gln Ser Asn
 325 330 335
 Leu Val Asp Cys Thr Leu Ser Asp Pro Asp Glu Pro Gln Arg Ile Cys
 340 345 350
 Tyr Gln Val Gly Thr Tyr Asn Pro Ser Gln Ser Gly Thr Cys Asn Ile
 355 360 365

Glu Val Pro Lys Cys Ser Thr Tyr Gly His Ala Cys Met Ala Thr Leu
 370 375 380
 Tyr Asp Thr Pro Phe Asn Cys Trp Arg Arg Thr Arg Arg Cys Ile Cys
 385 390 395 400
 Asp Ser Gly Gly Glu Leu Ile Glu Trp Cys Cys Thr Ser Gln
 405 410

<210> 18
 <211> 539
 <212> PRT
 <213> human Metapneumo virus

<400> 18
 Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln
 1 5 10 15
 His Gly Leu Lys Glu Ser Tyr Leu Glu Ser Cys Ser Thr Ile Thr
 20 25 30
 Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe
 35 40 45
 Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ala Asp Gly Pro
 50 55 60
 Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu
 65 70 75 80
 Leu Arg Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu
 85 90 95
 Asn Pro Arg Gln Ser Arg Phe Val Leu Gly Ala Ile Ala Leu Gly Val
 100 105 110
 Ala Thr Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile
 115 120 125
 Arg Leu Glu Ser Glu Val Thr Ala Ile Lys Asn Ala Leu Lys Lys Thr
 130 135 140
 Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr
 145 150 155 160
 Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala
 165 170 175
 Ile Asn Lys Asn Lys Cys Asp Ile Ala Asp Leu Lys Met Ala Val Ser
 180 185 190
 Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser
 195 200 205
 Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp
 210 215 220
 Ala Glu Leu Ala Arg Ala Val Ser Asn Met Pro Thr Ser Ala Gly Gln
 225 230 235 240
 Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe
 245 250 255
 Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln
 260 265 270
 Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala
 275 280 285
 Ala Pro Ser Cys Ser Gly Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg
 290 295 300
 Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr
 305 310 315 320
 Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp
 325 330 335
 Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile
 340 345 350
 Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His
 355 360 365
 Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys
 370 375 380

Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile
 385 390 395 400
 Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp
 405 410 415
 Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly
 420 425 430
 Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro
 435 440 445
 Val Lys Phe Pro Glu Asp Gln Phe Asn Val Ala Leu Asp Gln Val Phe
 450 455 460
 Glu Ser Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile
 465 470 475 480
 Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile
 485 490 495
 Leu Ile Ala Val Leu Gly Ser Thr Met Ile Leu Val Ser Val Phe Ile
 500 505 510
 Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser
 515 520 525
 Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn
 530 535

<210> 19
 <211> 539
 <212> PRT
 <213> human Metapneumo virus

<400> 19
 Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln
 1 5 10 15
 His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr
 20 25 30
 Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe
 35 40 45
 Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro
 50 55 60
 Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu
 65 70 75 80
 Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu
 85 90 95
 Asn Pro Arg Gln Ser Arg Phe Val Leu Gly Ala Ile Ala Leu Gly Val
 100 105 110
 Ala Thr Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile
 115 120 125
 Arg Leu Glu Ser Glu Val Thr Ala Ile Lys Asn Ala Leu Lys Thr Thr
 130 135 140
 Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr
 145 150 155 160
 Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala
 165 170 175
 Ile Asn Lys Asn Lys Cys Asp Ile Asp Asp Leu Lys Met Ala Val Ser
 180 185 190
 Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser
 195 200 205
 Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp
 210 215 220
 Ala Glu Leu Ala Arg Ala Val Ser Asn Met Pro Thr Ser Ala Gly Gln
 225 230 235 240
 Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe
 245 250 255
 Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Thr Val Gln
 260 265 270

Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala
 275 280 285
 Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg
 290 295 300
 Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr
 305 310 315 320
 Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp
 325 330 335
 Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile
 340 345 350
 Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His
 355 360 365
 Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys
 370 375 380
 Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile
 385 390 395 400
 Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp
 405 410 415
 Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly
 420 425 430
 Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro
 435 440 445
 Ile Lys Phe Pro Glu Asp Gln Phe Asn Val Ala Leu Asp Gln Val Phe
 450 455 460
 Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile
 465 470 475 480
 Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile
 485 490 495
 Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile
 500 505 510
 Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser
 515 520 525
 Gly Val Thr Asn Asn Gly Phe Ile Pro His Ser
 530 535

<210> 20

<211> 539

<212> PRT

<213> human Metapneumo virus

<400> 20

Met Ser Trp Lys Val Met Ile Ile Ile Ser Leu Leu Ile Thr Pro Gln
 1 5 10 15
 His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr
 20 25 30
 Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe
 35 40 45
 Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Thr Asp Gly Pro
 50 55 60
 Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu
 65 70 75 80
 Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu
 85 90 95
 Asn Pro Arg Gln Ser Arg Phe Val Leu Gly Ala Ile Ala Leu Gly Val
 100 105 110
 Ala Thr Ala Ala Ala Val Thr Ala Gly Ile Ala Ile Ala Lys Thr Ile
 115 120 125
 Arg Leu Glu Ser Glu Val Asn Ala Ile Lys Gly Ala Leu Lys Gln Thr
 130 135 140
 Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr
 145 150 155 160

Ala Val Arg Glu Leu Lys Glu Phe Val Ser Lys Asn Leu Thr Ser Ala
 165 170 175
 Ile Asn Arg Asn Lys Cys Asp Ile Ala Asp Leu Lys Met Ala Val Ser
 180 185 190
 Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser
 195 200 205
 Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp
 210 215 220
 Ala Glu Leu Ala Arg Ala Val Ser Tyr Met Pro Thr Ser Ala Gly Gln
 225 230 235 240
 Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe
 245 250 255
 Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln
 260 265 270
 Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala
 275 280 285
 Ala Pro Ser Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg
 290 295 300
 Glu Asp Gln Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr
 305 310 315 320
 Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp
 325 330 335
 Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile
 340 345 350
 Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His
 355 360 365
 Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys
 370 375 380
 Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Trp Val Gly Ile Ile
 385 390 395 400
 Lys Gln Leu Pro Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp
 405 410 415
 Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly
 420 425 430
 Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro
 435 440 445
 Ile Lys Phe Pro Glu Asp Gln Phe Asn Val Ala Leu Asp Gln Val Phe
 450 455 460
 Glu Ser Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Lys Ile
 465 470 475 480
 Leu Asn Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Val Ile
 485 490 495
 Leu Val Ala Val Leu Gly Leu Thr Met Ile Ser Val Ser Ile Ile Ile
 500 505 510
 Ile Ile Lys Lys Thr Arg Lys Pro Thr Gly Ala Pro Pro Glu Leu Asn
 515 520 525
 Gly Val Thr Asn Gly Gly Phe Ile Pro His Ser
 530 535

<210> 21

<211> 539

<212> PRT

<213> human Metapneumo virus

<400> 21

Met Ser Trp Lys Val Met Ile Ile Ile Ser Leu Leu Ile Thr Pro Gln
 1 5 10 15
 His Gly Leu Lys Glu Ser Tyr Leu Glu Ser Cys Ser Thr Ile Thr
 20 25 30
 Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe
 35 40 45

```

Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Thr Asp Gly Pro
 50                               55                               60
Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu
 65                               70                               75                               80
Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu
                               85                               90                               95
Asn Pro Arg Gln Ser Arg Phe Val Leu Gly Ala Ile Ala Leu Gly Val
                               100                               105                               110
Ala Thr Ala Ala Val Thr Ala Gly Ile Ala Ile Ala Lys Thr Ile
                               115                               120                               125
Arg Leu Glu Ser Glu Val Asn Ala Ile Lys Gly Ala Leu Lys Thr Thr
                               130                               135                               140
Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr
 145                               150                               155                               160
Ala Val Arg Glu Leu Lys Glu Phe Val Ser Lys Asn Leu Thr Ser Ala
                               165                               170                               175
Ile Asn Lys Asn Lys Cys Asp Ile Ala Asp Leu Lys Met Ala Val Ser
                               180                               185                               190
Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser
                               195                               200                               205
Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp
 210                               215                               220
Ala Glu Leu Ala Arg Ala Val Ser Tyr Met Pro Thr Ser Ala Gly Gln
 225                               230                               235                               240
Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe
                               245                               250                               255
Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln
                               260                               265                               270
Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala
 275                               280                               285
Ala Pro Ser Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg
 290                               295                               300
Glu Asp Gln Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr
 305                               310                               315                               320
Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp
                               325                               330                               335
Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile
                               340                               345                               350
Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His
 355                               360                               365
Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys
 370                               375                               380
Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile
 385                               390                               395                               400
Lys Gln Leu Pro Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp
                               405                               410                               415
Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly
                               420                               425                               430
Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro
                               435                               440                               445
Ile Arg Phe Pro Glu Asp Gln Phe Asn Val Ala Leu Asp Gln Val Phe
 450                               455                               460
Glu Ser Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Lys Ile
 465                               470                               475                               480
Leu Asn Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile
                               485                               490                               495
Leu Ile Ala Val Leu Gly Leu Thr Met Ile Ser Val Ser Ile Ile Ile
                               500                               505                               510
Ile Ile Lys Lys Thr Arg Lys Pro Thr Gly Ala Pro Pro Glu Leu Asn
 515                               520                               525
Gly Val Thr Asn Gly Gly Phe Ile Pro His Ser
 530                               535

```

<210> 22
 <211> 1620
 <212> DNA
 <213> human Metapneumo virus

<400> 22
 atgtcttgga aagtggatgatttttttca ttgttaataa cacctcaaca cgggtcttaaa 60
 gagagctact tagaagagtc atgtagcact ataactgaag gatattctcag tgttctgagg 120
 acagggttgg acaccaatgt ttttacctg gaggtaggcg atgtagagaa ccttacatgt 180
 gccgatggac ccagcttaat aaaaacagaa ttagacctga ccaaaagtgc actaagagag 240
 ctcaaacag tttctgctga tcaactggca agagaggagc aaattgaaaa tcccagacaa 300
 tctagattcg ttctaggagc aatagcactc ggtgttgcaa ctgcagctgc agttacagca 360
 ggtgttgcaa ttgccaaaac catccggctt gaaagtgaag taacagcaat taagaatgcc 420
 ctcaaaaaga ccaatgaagc agtatctaca ttgggggaatg gagttcgtgt gttggcaact 480
 gcagtggag agctgaaaga tttgtgagc aagaatctaa cacgtgcaat caacaaaaac 540
 aagtgcgaca ttgctgacct gaaaatggcc gttagcttca gtcaattcaa cagaagggttc 600
 ctaaatgttg tgcggcaatt ttcagacaac gctggaataa caccagcaat atctttggac 660
 ttaatgacag atgctgaact agccagagct gtttccaaca tgccaacatc tgcaggacaa 720
 ataaaactga tgttgagaa ccgtgcaatg gtaagaagaa aagggttcgg aatcctgata 780
 ggagtttacg gaagctccgt aatttacatg gtgcaactgc caatctttgg ggttatagac 840
 acgccttgct ggatagtaaa agcagccctc tcttgttcag gaaaaaaggg aaactatgct 900
 tgcctcttaa gagaagacca aggatggtat tgtcaaaatg cagggtcaac tgtttactac 960
 ccaaatgaaa aagactgtga aacaagagga gaccatgtct tttgcgacac agcagcagga 1020
 atcaatgttg ctgagcagtc aaaggagtgc aacataaaca tatctactac taattaccca 1080
 tgcaaagtta gcacaggaag acatcctatc agtatggttg cactatctcc tcttggggct 1140
 ttggttgctt gctacaaggg agtgagctgt tccattggca gcaacagagt agggatcatc 1200
 aagcaactga acaaaggctg ctcttatata accaaccaag acgcagacac agtgacaata 1260
 gacaacactg tataccagct aagcaaagtt gaaggcgaac agcatgttat aaaaggaagg 1320
 ccagtgtcaa gcagctttga cccagtcaag tttcctgaag atcaattcaa tgttgcaact 1380
 gaccaagttt tgcagagcat tgagaacagt caggccttgg tggatcaatc aaacagaatc 1440
 ctaagcagtg cagagaaagg aaacactggc ttcattcatt taataattct aattgctgtc 1500
 cttggctcta ccattgatcct agtgagtgtt tttatcataa taaagaaaac aaagaaacc 1560
 acaggagcac ctccagagct gagtgggtgc acaacaatg gcttcatacc acataattag 1620

<210> 23
 <211> 1620
 <212> DNA
 <213> human Metapneumo virus

<400> 23
 atgtcttgga aagtggatgatttttttca ttgctaataa cacctcaaca cgggtcttaaa 60
 gagagctacc tagaagaatc atgtagcact ataactgagg gatattcttag tgttctgagg 120
 acagggttgg ataccaacgt ttttacatta gaggtgggtg atgtagaaaa ccttacatgt 180
 tctgatggac cttagcctaataaaaacagaa ttagatctga ccaaaagtgc actaagagag 240
 ctcaaaacag tctctgctga ccaattggca agagaggaac aaattgagaa tcccagacaa 300
 tctaggtttg ttctaggagc aatagcactc ggtgttgcaa cagcagctgc agtcacagca 360
 ggtgttgcaa ttgccaaaac catccggctt gagagtgaag tcacagcaat taagaatgcc 420
 ctcaaaacga ccaatgaagc agtatctaca ttgggggaatg gagttcagat gttggcaact 480
 gcagtggag agctaaaaga ctttgtgagc aagaatttaa ctggtgcaat caacaaaaac 540
 aagtgcgaca ttgatgacct aaaaatggct gttagcttca gtcaattcaa cagaagggtt 600
 ctaaatgttg tgcggcaatt ttcagacaat gctggaataa caccagcaat atctttggac 660
 ttaatgacag atgctgaact agccagggcc gtttctaaca tgccgacatc tgcaggacaa 720
 ataaaattga tgttgagaa ccgtgcgatg gtgcgaagaa aggggttcgg aatcctgata 780
 ggggtctacg ggagctccgt aatttacacg gtgcagctgc caatctttgg cgttatagac 840
 acgccttgct ggatagtaaa agcagccctc tcttgttccg aaaaaaaggg aaactatgct 900
 tgcctcttaa gagaagacca aggggtggtat tgtcagaatg cagggtcaac tgtttactac 960
 ccaaatgaga aagactgtga aacaagagga gaccatgtct tttgcgacac agcagcagga 1020
 attaatgttg ctgagcaatc aaaggagtgc aacatcaaca tatccactac aaattaccca 1080
 tgcaaagtca gcacaggaag acatcctatc agtatggttg cactgtctcc tcttggggct 1140
 ctggttgctt gctacaaagg agtaagctgt tccattggca gcaacagagt agggatcatc 1200

```

aagcagctga acaaagggtg ctcctatata accaaccaag atgcagacac agtgacaata 1260
gacaacactg tatatcagct aagcaaagtt gaggggtgaac agcatgttat aaaaggcaga 1320
ccagtgtcaa gcagcttttg tccaatcaag tttcctgaag atcaattcaa tgttgcaact 1380
gaccaagttt ttgagaacat tgaaaacagc caggccttag tagatcaatc aaacagaatc 1440
ctaagcagtg cagagaaaagg gaatactggc tttatcattg taataattct aattgctgtc 1500
cttggctcta gcatgatcct agtgagcatc ttcattataa tcaagaaaac aaagaaacca 1560
acgggagcac ctccagagct gagtgggtgc acaaacaatg gtttcatacc acacagttag 1620

```

<210> 24

<211> 1620

<212> DNA

<213> human Metapneumo virus

<400> 24

```

atgtcttggg aagtgatgat catcatttcg ttactcataa caccacagca cgggctaaag 60
gagagttatt tggaagaatc atgtagtact ataactgagg gatacctcag tgttttaaga 120
acaggctggg acactaatgt cttcacatta gaagttgggt atgttgaaaa tcttacatgt 180
actgatggac ctgacttaat caaaacagaa cttgatctaa caaaaagtgc ttttaaggaa 240
ctcaaaacag tctctgctga tcagttggcg agagaggagc aaattgaaaa tcccagacaa 300
tcaagatttg tcttaggtgc gatagctctc ggagttgcta cagcagcagc agtcacagca 360
ggcattgcaa tagccaaaac cataaggctt gagagtggag tgaatgcaat taaagggtgt 420
ctcaaaacaa ctaatgaagc agtatccaca ttagggaatg gtgtgcgggt cctagccact 480
gcagtggagc agctaaaaga atttgtgagc aaaaacctga ctagtgcatt caacaggaa 540
aaatgtgaca ttgctgatct gaagatggct gtcagcttca gtcaattcaa cagaagattt 600
ctaaatgttg tgccggcagtt ttcagacaat gcagggataa caccagcaat atcattggac 660
ctgatgactg atgctgagtt ggccagagct gtatcataca tgccaacatc tgcaggggcag 720
ataaaactga tgttggagaa ccgcgcgaatg gtaaggagaa aaggatttgg aatcctgata 780
ggggctctacg gaagctctgt gatttacatg gttcaattgc cgatctttgg tgtcatagat 840
agccttggtt ggtatcatca ggagctccc tcttgctcag aaaaaaacgg gaattatgct 900
tgccctcctaa gagaggatca aggggtggat tgtaaaaatg caggatctac tgtttactac 960
ccaaatgaaa aagactgcga aacaagaggt gatcatgttt tttgtgacac agcagcaggg 1020
atcaatgttg ctgagcaatc aagagaatgc aacatcaaca tatctactac caactaccca 1080
tgcaaagtca gcacaggaag acaccctata agcatgggtg cactatcacc tctcggtgct 1140
ttgggtggctt gctataaaagg ggtaagctgc tcgattggca gcaattgggt tggaatcatc 1200
aaacaattac ccaaaggctg ctcatacata accaaccagg atgcagacac tgtaacaatt 1260
gacaataaccg tgtatcaact aagcaaagtt gaaggtgaac agcatgtaat aaaagggaga 1320
ccagtttcaa gcagttttga tccaatcaag tttcctgagg atcagttcaa tgttgcgctt 1380
gatcaagtct tcgaaagcat tgagaacagt caggcactag tggaccagtc aaacaaaatt 1440
ctaaacagtg cagaaaaagg aaacactggg ttcattatcg tagtaatttt ggttgcgtgt 1500
cttggctcaa ccatgatttc agtgagcatc atcatcataa tcaagaaaac aaggaagccc 1560
acaggagcac ctccagagct gaatgggtgc accaacggcg gtttcatacc acatagttag 1620

```

<210> 25

<211> 1620

<212> DNA

<213> human Metapneumo virus

<400> 25

```

atgtcttggg aagtgatgat tatcatttcg ttactcataa cacctcagca cggactaaaa 60
gaaagttatt tagaagaatc atgtagtact ataactgaag gatattctcag tgttttaaga 120
acagggtggg acaccaatgt ctttacatta gaagttgggt atgttgaaaa tcttacatgt 180
actgatggac ctgacttaat caaaacagaa cttgacctaa ccaaagtgc tctgagagaa 240
ctcaaaacag tttctgctga tcagtttagc agagaagaac aaattgaaaa tcccagacaa 300
tcaaggtttg tcttaggtgc aatagctctt ggagttgcca cagcagcagc agtcacagca 360
ggcattgcaa tagccaaaac cataagactt gagagtgaag tgaatgcaat caaagggtgt 420
ctcaaaacaa ccaacgaggg agtatccaca ctaggaaatg gagtgcgagt cctagccact 480
gcagtaagag agctgaaaga atttgtgagc aaaaacctga ctagtgcgat caacaagaac 540
aaatgtgaca ttgctgatct gaagatggct gtcagcttca gtcaattcaa cagaagattc 600
ctaaatgttg tgccggcagtt ttcagacaat ccagggataa caccagcaat atcattggac 660
ctaagtactg atgctgagct ggccagagct gtatcataca tgccaacatc tgcaggacag 720

```

```

ataaaactaa tgtagagaa ccgtgcaatg gtgaggagaa aaggatttgg aatcttgata 780
ggggtctacg gaagctctgt gatttacatg gtccagctgc cgatctttgg tgtcatagat 840
acaccttggt ggataatcaa ggcagctccc tcttggtcag aaaaagatgg aaattatgct 900
tgccctctaa gagaggatca aggggtggtat tgcaaaaatg caggatccac tgtttactac 960
ccaaatgaaa aagactgcga aacaagaggt gatcatgttt tttgtgacac agcagcaggg 1020
atcaatgttg ctgagcaatc aagagaatgc aacatcaaca tatctaccac caactacca 1080
tgcaaagtca gcacaggaag acaccctatc agcatgggtg cactatcacc tctcggtgct 1140
ttggtagctt gctacaaggg ggtagctgc tcgattggca gtaatcgggt tggataaatc 1200
aaacaactac ctaaaggctg ctcatacata actaaccagg acgcagacac tgaacaatt 1260
gacaacactg tgtatcaact aagcaaagt gagggtgaac agcatgtaat aaaagggaga 1320
ccagtttcaa gcagttttga tccaatcagg tttcctgagg atcagttcaa tgttgcgctt 1380
gatcaagtct ttgaaagcat tgaaaacagt caagcactag tggaccagtc aaacaaaatt 1440
ctgaacagtg cagaaaaagg aaacactggg ttcattattg taataatttt gattgctgtt 1500
cttggtttaa ccatgatttc agtgagcatc atcatcataa tcaaaaaaac aaggaagccc 1560
acaggggcac ctccagagct gaatggtgtt accaacggcg gttttatacc gcatagttag 1620

```

<210> 26

<211> 236

<212> PRT

<213> human Metapneumo virus

<400> 26

```

Met Glu Val Lys Val Glu Asn Ile Arg Thr Ile Asp Met Leu Lys Ala
  1             5             10             15
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
      20             25             30
Leu Val Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
      35             40             45
Leu Ile Ile Asn Tyr Lys Met Gln Lys Asn Thr Ser Glu Ser Glu His
      50             55             60
His Thr Ser Ser Ser Pro Met Glu Ser Ser Arg Glu Thr Pro Thr Val
      65             70             75             80
Pro Thr Asp Asn Ser Asp Thr Asn Ser Ser Pro Gln His Pro Thr Gln
      85             90             95
Gln Ser Thr Glu Gly Ser Thr Leu Tyr Phe Ala Ala Ser Ala Ser Ser
      100            105            110
Pro Glu Thr Glu Pro Thr Ser Thr Pro Asp Thr Thr Asn Arg Pro Pro
      115            120            125
Phe Val Asp Thr His Thr Thr Pro Pro Ser Ala Ser Arg Thr Lys Thr
      130            135            140
Ser Pro Ala Val His Thr Lys Asn Asn Pro Arg Thr Ser Ser Arg Thr
      145            150            155            160
His Ser Pro Pro Arg Ala Thr Thr Arg Thr Ala Arg Arg Thr Thr Thr
      165            170            175
Leu Arg Thr Ser Ser Thr Arg Lys Arg Pro Ser Thr Ala Ser Val Gln
      180            185            190
Pro Asp Ile Ser Ala Thr Thr His Lys Asn Glu Glu Ala Ser Pro Ala
      195            200            205
Ser Pro Gln Thr Ser Ala Ser Thr Thr Arg Ile Gln Arg Lys Ser Val
      210            215            220
Glu Ala Asn Thr Ser Thr Thr Tyr Asn Gln Thr Ser
      225            230            235

```

<210> 27

<211> 219

<212> PRT

<213> human Metapneumo virus

<400> 27

Met Glu Val Lys Val Glu Asn Ile Arg Ala Ile Asp Met Leu Lys Ala

```

1           5           10           15
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
20           25           30
Leu Ile Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
35           40           45
Leu Ile Ile Asn Tyr Thr Ile Gln Lys Thr Thr Ser Glu Ser Glu His
50           55           60
His Thr Ser Ser Pro Pro Thr Glu Pro Asn Lys Glu Ala Ser Thr Ile
65           70           75
Ser Thr Asp Asn Pro Asp Ile Asn Pro Ser Ser Gln His Pro Thr Gln
85           90           95
Gln Ser Thr Glu Asn Pro Thr Leu Asn Pro Ala Ala Ser Ala Ser Pro
100          105          110
Ser Glu Thr Glu Pro Ala Ser Thr Pro Asp Thr Thr Asn Arg Leu Ser
115          120          125
Ser Val Asp Arg Ser Thr Ala Gln Pro Ser Glu Ser Arg Thr Lys Thr
130          135          140
Lys Pro Thr Val His Thr Ile Asn Asn Pro Asn Thr Ala Ser Ser Thr
145          150          155
Gln Ser Pro Pro Arg Thr Thr Thr Lys Ala Ile Arg Arg Ala Thr Thr
165          170          175
Phe Arg Met Ser Ser Thr Gly Lys Arg Pro Thr Thr Thr Leu Val Gln
180          185          190
Ser Asp Ser Ser Thr Thr Thr Gln Asn His Glu Glu Thr Gly Ser Ala
195          200          205
Asn Pro Gln Ala Ser Ala Ser Thr Met Gln Asn
210          215

```

<210> 28
 <211> 224
 <212> PRT
 <213> human Metapneumo virus

```

<400> 28
Met Glu Val Arg Val Glu Asn Ile Arg Ala Ile Asp Met Phe Lys Ala
1           5           10           15
Lys Ile Lys Asn Arg Ile Arg Ser Ser Arg Cys Tyr Arg Asn Ala Thr
20           25           30
Leu Ile Leu Ile Gly Leu Thr Ala Leu Ser Met Ala Leu Asn Ile Phe
35           40           45
Leu Ile Ile Asp His Ala Thr Leu Arg Asn Met Ile Lys Thr Glu Asn
50           55           60
Cys Ala Asn Met Pro Ser Ala Glu Pro Ser Lys Lys Thr Pro Met Thr
65           70           75
Ser Thr Ala Gly Pro Asn Thr Lys Pro Asn Pro Gln Gln Ala Thr Gln
85           90           95
Trp Thr Thr Glu Asn Ser Thr Ser Pro Val Ala Thr Pro Glu Gly His
100          105          110
Pro Tyr Thr Gly Thr Thr Gln Thr Ser Asp Thr Thr Ala Pro Gln Gln
115          120          125
Thr Thr Asp Lys His Thr Ala Pro Leu Lys Ser Thr Asn Glu Gln Ile
130          135          140
Thr Gln Thr Thr Thr Glu Lys Lys Thr Ile Arg Ala Thr Thr Gln Lys
145          150          155
Arg Glu Lys Gly Lys Glu Asn Thr Asn Gln Thr Thr Ser Thr Ala Ala
165          170          175
Thr Gln Thr Thr Asn Thr Thr Asn Gln Ile Arg Asn Ala Ser Glu Thr
180          185          190
Ile Thr Thr Ser Asp Arg Pro Arg Thr Asp Thr Thr Thr Gln Ser Ser
195          200          205
Glu Gln Thr Thr Arg Ala Thr Asp Pro Ser Ser Pro Pro His His Ala

```


210

215

220

<210> 29
 <211> 236
 <212> PRT
 <213> human Metapneumo virus

<400> 29
 Met Glu Val Arg Val Glu Asn Ile Arg Ala Ile Asp Met Phe Lys Ala
 1 5 10 15
 Lys Met Lys Asn Arg Ile Arg Ser Ser Lys Cys Tyr Arg Asn Ala Thr
 20 25 30
 Leu Ile Leu Ile Gly Leu Thr Ala Leu Ser Met Ala Leu Asn Ile Phe
 35 40 45
 Leu Ile Ile Asp Tyr Ala Met Leu Lys Asn Met Thr Lys Val Glu His
 50 55 60
 Cys Val Asn Met Pro Pro Val Glu Pro Ser Lys Lys Thr Pro Met Thr
 65 70 75 80
 Ser Ala Val Asp Leu Asn Thr Lys Pro Asn Pro Gln Gln Ala Thr Gln
 85 90 95
 Leu Ala Ala Glu Asp Ser Thr Ser Leu Ala Ala Thr Ser Glu Asp His
 100 105 110
 Leu His Thr Gly Thr Thr Pro Thr Pro Asp Ala Thr Val Ser Gln Gln
 115 120 125
 Thr Thr Asp Glu Tyr Thr Thr Leu Leu Arg Ser Thr Asn Arg Gln Thr
 130 135 140
 Thr Gln Thr Thr Thr Glu Lys Lys Pro Thr Gly Ala Thr Thr Lys Lys
 145 150 155 160
 Glu Thr Thr Thr Arg Thr Thr Ser Thr Ala Ala Thr Gln Thr Leu Asn
 165 170 175
 Thr Thr Asn Gln Thr Ser Tyr Val Arg Glu Ala Thr Thr Thr Ser Ala
 180 185 190
 Arg Ser Arg Asn Ser Ala Thr Thr Gln Ser Ser Asp Gln Thr Thr Gln
 195 200 205
 Ala Ala Asp Pro Ser Ser Gln Pro His His Thr Gln Lys Ser Thr Thr
 210 215 220
 Thr Thr Tyr Asn Thr Asp Thr Ser Ser Pro Ser Ser
 225 230 235

<210> 30
 <211> 708
 <212> DNA
 <213> human Metapneumo virus

<400> 30
 gaggtgaaag tggagaacat tcgaacaata gatatgctca aagcaagagt aaaaaatcgt 60
 gtggcagcga gcaaatgctt taaaaatgcc tctttgggtcc tcataggaat aactacattg 120
 agtattgccc tcaatatcta tctgatcata aactataaaa tgcaaaaaaa cacatctgaa 180
 tcagaacatc acaccagctc atcaccatg gaatccagca gagaaactcc aacggtcccc 240
 acagacaact cagacaccaa ctcaagccca cagcatccaa ctcaacagtc cacagaaggc 300
 tccacactct actttgcagc ctcagcaagc tcaccagaga cagaaccaac atcaaacacca 360
 gatacaacaa accgcccgcc cttcgtcgac acacacacaa caccaccaag cgcaagcaga 420
 acaaagacaa gtccggcgagt ccacacaaaa aacaacccaa ggacaagctc tagaacacat 480
 tctccaccac gggcaacgac aaggacggca cgcagaacca ccactctccg cacaagcagc 540
 acaagaaaga gaccgtccac agcatcagtc caacctgaca tcagcgcaac aaccacaaa 600
 aacgaagaag caagtccagc gagcccacaa acatctgcaa gcacaacaag aatacaaaag 660
 aaaagcgtgg aggccaaacac atcaacaaca tacaaccaa ctagttaa 708

<210> 31
 <211> 660

<212> DNA

<213> human Metapneumo virus

<400> 31

```

atggaggtga aagtagagaa cattcgagca atagacatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gtagcaaatg ctttaaaaat gcttctttaa tcctcatagg aataactaca 120
ctgagtatag ctctcaatat ctatctgac ataaactaca caatacaaaa aaccacatcc 180
gaatcagaac accacaccag ctacaccacc acagaaccca acaaggaagc ttcaacaatc 240
tccacagaca acccagacat caatccaagc tcacagcatc caactcaaca gtccacagaa 300
aaccacacac tcaaccccg cgcacacagc agcccatcag aaacagaacc agcatcaaca 360
ccagacacaa caaacccgct gtcctccgta gacaggtcca cagcacaacc aagtgaagc 420
agaacaaaga caaacccgac agtccacaca atcaacaacc caaacacagc ttccagtaca 480
caatccccac caccgacaac aacgaaggca atccgcagag ccaccacttt ccgcatgagc 540
agcaccaggaa aaagaccaac cacaacatta gtccagtccg acagcagcac cacaacccaa 600
aatcatgaag aaacaggttc agcgaaccca caggcgtctg caagcacaat gcaaaaactag 660

```

<210> 32

<211> 675

<212> DNA

<213> human Metapneumo virus

<400> 32

```

atggaagtaa gaggggagaa cattcgagcg atagacatgt tcaaagcaaa gataaaaaac 60
cgtataagaa gcagcagggtg ctatagaaat gctacactga tccttattgg actaacagcg 120
ttaagcatgg cacttaatat tttcctgac atcgatcatg caacattaag aaacatgac 180
aaaacagaaa actgtgctaa catgccgtcg gcagaaccaa gcaaaaagac cccaatgacc 240
tccacagcag gcccaaacac caaacccaat ccacagcaag caacacagtg gaccacagag 300
aactcaacat ccccgtagc aaccccagag ggccatccat acacagggac aactcaaaaca 360
tcagacacaa cagctcccca gcaaaccaca gacaaacaca cagcaccgct aaaatcaacc 420
aatgaacaga tcaaccagac aaccacagag aaaaagacaa tcagagcaac aaccacaaaa 480
agggaaaaag gaaaagaaaa cacaacccaa accacaagca cagctgcaac ccaaaccaacc 540
aacaccacca accaaatcag aaatgcaagt gagacaatca caacatccga cagacccaga 600
actgacacca caacccaaag cagcgaacag acaacccggg caacagacc aagctcccca 660
ccacaccatg catag

```

<210> 33

<211> 711

<212> DNA

<213> human Metapneumo virus

<400> 33

```

atggaagtaa gaggggagaa cattcgggca atagacatgt tcaaagcaaa aatgaaaaac 60
cgtataagaa gtagcaagtg ctatagaaat gctacactga tccttattgg attaacagca 120
ttaagtatgg cacttaatat ttttttaatc attgattatg caatgttaaa aaacatgacc 180
aaagtggaa actgtgttaa tatgccgccg gtagaaccaa gcaagaagac cccaatgacc 240
tctgcagtag acttaaacac caaacccaat ccacagcagg caacacagtt ggccgcagag 300
gattcaacat ctctagcagc aacctcagag gaccatctac acacagggac aactccaaca 360
ccagatgcaa cagtctctca gcaaaccaca gacgagtaca caacattgct gagatcaacc 420
aacagacaga ccacccaaac aaccacagag aaaaagccaa ccggagcaac aaccacaaaa 480
gaaaccacaa ctcgaaactac aagcacagct gcaacccaaa cactcaacac taccaccaa 540
actagctatg tgagagaggc aaccacaaca tccgccagat ccagaaacag tgccacaact 600
caaagcagcg accaaacaac ccaggcagca gacccaagct ccaacacaca ccatacacag 660
aaaagcacia caacaacata caacacagac acatcctctc caagtagtta a

```

<210> 34

<211> 2005

<212> PRT

<213> human Metapneumo virus

<400> 34

Met Asp Pro Leu Asn Glu Ser Thr Val Asn Val Tyr Leu Pro Asp Ser

```

1           5           10           15
Tyr Leu Lys Gly Val Ile Ser Phe Ser Glu Thr Asn Ala Ile Gly Ser
20           25           30
Cys Leu Leu Lys Arg Pro Tyr Leu Lys Asn Asp Asn Thr Ala Lys Val
35           40           45
Ala Ile Glu Asn Pro Val Ile Glu His Val Arg Leu Lys Asn Ala Val
50           55           60
Asn Ser Lys Met Lys Ile Ser Asp Tyr Lys Ile Val Glu Pro Val Asn
65           70           75           80
Met Gln His Glu Ile Met Lys Asn Val His Ser Cys Glu Leu Thr Leu
85           90           95
Leu Lys Gln Phe Leu Thr Arg Ser Lys Asn Ile Ser Thr Leu Lys Leu
100          105          110
Asn Met Ile Cys Asp Trp Leu Gln Leu Lys Ser Thr Ser Asp Asp Thr
115          120          125
Ser Ile Leu Ser Phe Ile Asp Val Glu Phe Ile Pro Ser Trp Val Ser
130          135          140
Asn Trp Phe Ser Asn Trp Tyr Asn Leu Asn Lys Leu Ile Leu Glu Phe
145          150          155          160
Arg Lys Glu Glu Val Ile Arg Thr Gly Ser Ile Leu Cys Arg Ser Leu
165          170          175
Gly Lys Leu Val Phe Val Val Ser Ser Tyr Gly Cys Ile Val Lys Ser
180          185          190
Asn Lys Ser Lys Arg Val Ser Phe Phe Thr Tyr Asn Gln Leu Leu Thr
195          200          205
Trp Lys Asp Val Met Leu Ser Arg Phe Asn Ala Asn Phe Cys Ile Trp
210          215          220
Val Ser Asn Ser Leu Asn Glu Asn Gln Glu Gly Leu Gly Leu Arg Ser
225          230          235          240
Asn Leu Gln Gly Ile Leu Thr Asn Lys Leu Tyr Glu Thr Val Asp Tyr
245          250          255
Met Leu Ser Leu Cys Cys Asn Glu Gly Phe Ser Leu Val Lys Glu Phe
260          265          270
Glu Gly Phe Ile Met Ser Glu Ile Leu Arg Ile Thr Glu His Ala Gln
275          280          285
Phe Ser Thr Arg Phe Arg Asn Thr Leu Leu Asn Gly Leu Thr Asp Gln
290          295          300
Leu Thr Lys Leu Lys Asn Lys Asn Arg Leu Arg Val His Gly Thr Val
305          310          315          320
Leu Glu Asn Asn Asp Tyr Pro Met Tyr Glu Val Val Leu Lys Leu Leu
325          330          335
Gly Asp Thr Leu Arg Cys Ile Lys Leu Leu Ile Asn Lys Asn Leu Glu
340          345          350
Asn Ala Ala Glu Leu Tyr Tyr Ile Phe Arg Ile Phe Gly His Pro Met
355          360          365
Val Asp Glu Arg Asp Ala Met Asp Ala Val Lys Leu Asn Asn Glu Ile
370          375          380
Thr Lys Ile Leu Arg Trp Glu Ser Leu Thr Glu Leu Arg Gly Ala Phe
385          390          395          400
Ile Leu Arg Ile Ile Lys Gly Phe Val Asp Asn Asn Lys Arg Trp Pro
405          410          415
Lys Ile Lys Asn Leu Lys Val Leu Ser Lys Arg Trp Thr Met Tyr Phe
420          425          430
Lys Ala Lys Ser Tyr Pro Ser Gln Leu Glu Leu Ser Glu Gln Asp Phe
435          440          445
Leu Glu Leu Ala Ala Ile Gln Phe Glu Gln Glu Phe Ser Val Pro Glu
450          455          460
Lys Thr Asn Leu Glu Met Val Leu Asn Asp Lys Ala Ile Ser Pro Pro
465          470          475          480
Lys Arg Leu Ile Trp Ser Val Tyr Pro Lys Asn Tyr Leu Pro Glu Lys
485          490          495
Ile Lys Asn Arg Tyr Leu Glu Glu Thr Phe Asn Ala Ser Asp Ser Leu

```

				500						505						510
Lys	Thr	Arg	Arg	Val	Leu	Glu	Tyr	Tyr	Leu	Lys	Asp	Asn	Lys	Phe	Asp	
		515						520					525			
Gln	Lys	Glu	Leu	Lys	Ser	Tyr	Val	Val	Lys	Gln	Glu	Tyr	Leu	Asn	Asp	
		530					535					540				
Lys	Asp	His	Ile	Val	Ser	Leu	Thr	Gly	Lys	Glu	Arg	Glu	Leu	Ser	Val	
545					550					555					560	
Gly	Arg	Met	Phe	Ala	Met	Gln	Pro	Gly	Lys	Gln	Arg	Gln	Ile	Gln	Ile	
				565					570						575	
Leu	Ala	Glu	Lys	Leu	Leu	Ala	Asp	Asn	Ile	Val	Pro	Phe	Phe	Pro	Glu	
				580					585					590		
Thr	Leu	Thr	Lys	Tyr	Gly	Asp	Leu	Asp	Leu	Gln	Arg	Ile	Met	Glu	Ile	
		595					600						605			
Lys	Ser	Glu	Leu	Ser	Ser	Ile	Lys	Thr	Arg	Arg	Asn	Asp	Ser	Tyr	Asn	
		610				615						620				
Asn	Tyr	Ile	Ala	Arg	Ala	Ser	Ile	Val	Thr	Asp	Leu	Ser	Lys	Phe	Asn	
625					630					635					640	
Gln	Ala	Phe	Arg	Tyr	Glu	Thr	Thr	Ala	Ile	Cys	Ala	Asp	Val	Ala	Asp	
				645					650						655	
Glu	Leu	His	Gly	Thr	Gln	Ser	Leu	Phe	Cys	Trp	Leu	His	Leu	Ile	Val	
			660					665						670		
Pro	Met	Thr	Thr	Met	Ile	Cys	Ala	Tyr	Arg	His	Ala	Pro	Pro	Glu	Thr	
		675					680						685			
Lys	Gly	Glu	Tyr	Asp	Ile	Asp	Lys	Ile	Glu	Glu	Gln	Ser	Gly	Leu	Tyr	
		690				695					700					
Arg	Tyr	His	Met	Gly	Gly	Ile	Glu	Gly	Trp	Cys	Gln	Lys	Leu	Trp	Thr	
705					710					715					720	
Met	Glu	Ala	Ile	Ser	Leu	Leu	Asp	Val	Val	Ser	Val	Lys	Thr	Arg	Cys	
				725					730						735	
Gln	Met	Thr	Ser	Leu	Leu	Asn	Gly	Asp	Asn	Gln	Ser	Ile	Asp	Val	Ser	
			740					745					750			
Lys	Pro	Val	Lys	Leu	Ser	Glu	Gly	Leu	Asp	Glu	Val	Lys	Ala	Asp	Tyr	
		755					760					765				
Ser	Leu	Ala	Val	Lys	Met	Leu	Lys	Glu	Ile	Arg	Asp	Ala	Tyr	Arg	Asn	
		770				775					780					
Ile	Gly	His	Lys	Leu	Lys	Glu	Gly	Glu	Thr	Tyr	Ile	Ser	Arg	Asp	Leu	
785					790					795					800	
Gln	Phe	Ile	Ser	Lys	Val	Ile	Gln	Ser	Glu	Gly	Val	Met	His	Pro	Thr	
				805					810					815		
Pro	Ile	Lys	Lys	Ile	Leu	Arg	Val	Gly	Pro	Trp	Ile	Asn	Thr	Ile	Leu	
			820					825					830			
Asp	Asp	Ile	Lys	Thr	Ser	Ala	Glu	Ser	Ile	Gly	Ser	Leu	Cys	Gln	Glu	
		835					840					845				
Leu	Glu	Phe	Arg	Gly	Glu	Ser	Ile	Ile	Val	Ser	Leu	Ile	Leu	Arg	Asn	
		850				855					860					
Phe	Trp	Leu	Tyr	Asn	Leu	Tyr	Met	His	Glu	Ser	Lys	Gln	His	Pro	Leu	
865					870					875					880	
Ala	Gly	Lys	Gln	Leu	Phe	Lys	Gln	Leu	Asn	Lys	Thr	Leu	Thr	Ser	Val	
				885					890					895		
Gln	Arg	Phe	Phe	Glu	Ile	Lys	Lys	Glu	Asn	Glu	Val	Val	Asp	Leu	Trp	
			900					905					910			
Met	Asn	Ile	Pro	Met	Gln	Phe	Gly	Gly	Asp	Pro	Val	Val	Phe	Tyr		
		915					920					925				
Arg	Ser	Phe	Tyr	Arg	Arg	Thr	Pro	Asp	Phe	Leu	Thr	Glu	Ala	Ile	Ser	
		930				935					940					
His	Val	Asp	Ile	Leu	Leu	Arg	Ile	Ser	Ala	Asn	Ile	Arg	Asn	Glu	Ala	
945					950					955					960	
Lys	Ile	Ser	Phe	Phe	Lys	Ala	Leu	Leu	Ser	Ile	Glu	Lys	Asn	Glu	Arg	
				965					970					975		
Ala	Thr	Leu	Thr	Leu	Met	Arg	Asp	Pro	Gln	Ala	Val	Gly	Ser	Glu		
			980				985					990				
Arg	Gln	Ala	Lys	Val	Thr	Ser	Asp	Ile	Asn	Arg	Thr	Ala	Val	Thr	Ser	

995 1000 1005
 Ile Leu Ser Leu Ser Pro Asn Gln Leu Phe Ser Asp Ser Ala Ile His
 1010 1015 1020
 Tyr Ser Arg Asn Glu Glu Val Gly Ile Ile Ala Asp Asn Ile Thr
 1025 1030 1035 1040
 Pro Val Tyr Pro His Gly Leu Arg Val Leu Tyr Glu Ser Leu Pro Phe
 1045 1050 1055
 His Lys Ala Glu Lys Val Val Asn Met Ile Ser Gly Thr Lys Ser Ile
 1060 1065 1070
 Thr Asn Leu Leu Gln Arg Thr Ser Ala Ile Asn Gly Glu Asp Ile Asp
 1075 1080 1085
 Arg Ala Val Ser Met Met Leu Glu Asn Leu Gly Leu Leu Ser Arg Ile
 1090 1095 1100
 Leu Ser Val Val Val Asp Ser Ile Glu Ile Pro Thr Lys Ser Asn Gly
 1105 1110 1115 1120
 Arg Leu Ile Cys Cys Gln Ile Ser Arg Thr Leu Arg Glu Thr Ser Trp
 1125 1130 1135
 Asn Asn Met Glu Ile Val Gly Val Thr Ser Pro Ser Ile Thr Thr Cys
 1140 1145 1150
 Met Asp Val Ile Tyr Ala Thr Ser Ser His Leu Lys Gly Ile Ile Ile
 1155 1160 1165
 Glu Lys Phe Ser Thr Asp Arg Thr Thr Arg Gly Gln Arg Gly Pro Lys
 1170 1175 1180
 Ser Pro Trp Val Gly Ser Ser Thr Gln Glu Lys Lys Leu Val Pro Val
 1185 1190 1195 1200
 Tyr Asn Arg Gln Ile Leu Ser Lys Gln Gln Arg Glu Gln Leu Glu Ala
 1205 1210 1215
 Ile Gly Lys Met Arg Trp Val Tyr Lys Gly Thr Pro Gly Leu Arg Arg
 1220 1225 1230
 Leu Leu Asn Lys Ile Cys Leu Gly Ser Leu Gly Ile Ser Tyr Lys Cys
 1235 1240 1245
 Val Lys Pro Leu Leu Pro Arg Phe Met Ser Val Asn Phe Leu His Arg
 1250 1255 1260
 Leu Ser Val Ser Ser Arg Pro Met Glu Phe Pro Ala Ser Val Pro Ala
 1265 1270 1275 1280
 Tyr Arg Thr Thr Asn Tyr His Phe Asp Thr Ser Pro Ile Asn Gln Ala
 1285 1290 1295
 Leu Ser Glu Arg Phe Gly Asn Glu Asp Ile Asn Leu Val Phe Gln Asn
 1300 1305 1310
 Ala Ile Ser Cys Gly Ile Ser Ile Met Ser Val Val Glu Gln Leu Thr
 1315 1320 1325
 Gly Arg Ser Pro Lys Gln Leu Val Leu Ile Pro Gln Leu Glu Glu Ile
 1330 1335 1340
 Asp Ile Met Pro Pro Pro Val Phe Gln Gly Lys Phe Asn Tyr Lys Leu
 1345 1350 1355 1360
 Val Asp Lys Ile Thr Ser Asp Gln His Ile Phe Ser Pro Asp Lys Ile
 1365 1370 1375
 Asp Met Leu Thr Leu Gly Lys Met Leu Met Pro Thr Ile Lys Gly Gln
 1380 1385 1390
 Lys Thr Asp Gln Phe Leu Asn Lys Arg Glu Asn Tyr Phe His Gly Asn
 1395 1400 1405
 Asn Leu Ile Glu Ser Leu Ser Ala Ala Leu Ala Cys His Trp Cys Gly
 1410 1415 1420
 Ile Leu Thr Glu Gln Cys Ile Glu Asn Asn Ile Phe Lys Lys Asp Trp
 1425 1430 1435 1440
 Gly Asp Gly Phe Ile Ser Asp His Ala Phe Met Asp Phe Lys Ile Phe
 1445 1450 1455
 Leu Cys Val Phe Lys Thr Lys Leu Leu Cys Ser Trp Gly Ser Gln Gly
 1460 1465 1470
 Lys Asn Ile Lys Asp Glu Asp Ile Val Asp Glu Ser Ile Asp Lys Leu
 1475 1480 1485
 Leu Arg Ile Asp Asn Thr Phe Trp Arg Met Phe Ser Lys Val Met Phe

1490	1495	1500
Glu Ser Lys Val Lys Lys Arg Ile Met Leu Tyr Asp Val Lys Phe Leu		
1505	1510	1515
Ser Leu Val Gly Tyr Ile Gly Phe Lys Asn Trp Phe Ile Glu Gln Leu		
	1525	1530
Arg Ser Ala Glu Leu His Glu Val Pro Trp Ile Val Asn Ala Glu Gly		
	1540	1545
Asp Leu Val Glu Ile Lys Ser Ile Lys Ile Tyr Leu Gln Leu Ile Glu		
	1555	1560
Gln Ser Leu Phe Leu Arg Ile Thr Val Leu Asn Tyr Thr Asp Met Ala		
	1570	1575
His Ala Leu Thr Arg Leu Ile Arg Lys Lys Leu Met Cys Asp Asn Ala		
1585	1590	1595
Leu Leu Thr Pro Ile Pro Ser Pro Met Val Asn Leu Thr Gln Val Ile		
	1605	1610
Asp Pro Thr Glu Gln Leu Ala Tyr Phe Pro Lys Ile Thr Phe Glu Arg		
	1620	1625
Leu Lys Asn Tyr Asp Thr Ser Ser Asn Tyr Ala Lys Gly Lys Leu Thr		
	1635	1640
Arg Asn Tyr Met Ile Leu Leu Pro Trp Gln His Val Asn Arg Tyr Asn		
	1650	1655
Phe Val Phe Ser Ser Thr Gly Cys Lys Val Ser Leu Lys Thr Cys Ile		
1665	1670	1675
Gly Lys Leu Met Lys Asp Leu Asn Pro Lys Val Leu Tyr Phe Ile Gly		
	1685	1690
Glu Gly Ala Gly Asn Trp Met Ala Arg Thr Ala Cys Glu Tyr Pro Asp		
	1700	1705
Ile Lys Phe Val Tyr Arg Ser Leu Lys Asp Asp Leu Asp His His Tyr		
	1715	1720
Pro Leu Glu Tyr Gln Arg Val Ile Gly Glu Leu Ser Arg Ile Ile Asp		
	1730	1735
Ser Gly Glu Gly Leu Ser Met Glu Thr Thr Asp Ala Thr Gln Lys Thr		
1745	1750	1755
His Trp Asp Leu Ile His Arg Val Ser Lys Asp Ala Leu Leu Ile Thr		
	1765	1770
Leu Cys Asp Ala Glu Phe Lys Asp Arg Asp Asp Phe Phe Lys Met Val		
	1780	1785
Ile Leu Trp Arg Lys His Val Leu Ser Cys Arg Ile Cys Thr Thr Tyr		
	1795	1800
Gly Thr Asp Leu Tyr Leu Phe Ala Lys Tyr His Ala Lys Asp Cys Asn		
	1810	1815
Val Lys Leu Pro Phe Phe Val Arg Ser Val Ala Thr Phe Ile Met Gln		
1825	1830	1835
Gly Ser Lys Leu Ser Gly Ser Glu Cys Tyr Ile Leu Leu Thr Leu Gly		
	1845	1850
His His Asn Asn Leu Pro Cys His Gly Glu Ile Gln Asn Ser Lys Met		
	1860	1865
Lys Ile Ala Val Cys Asn Asp Phe Tyr Ala Ala Lys Lys Leu Asp Asn		
	1875	1880
Lys Ser Ile Glu Ala Asn Cys Lys Ser Leu Leu Ser Gly Leu Arg Ile		
	1890	1895
Pro Ile Asn Lys Lys Glu Leu Asn Arg Gln Arg Leu Leu Thr Leu		
1905	1910	1915
Gln Ser Asn His Ser Ser Val Ala Thr Val Gly Gly Ser Lys Val Ile		
	1925	1930
Glu Ser Lys Trp Leu Thr Asn Lys Ala Asn Thr Ile Ile Asp Trp Leu		
	1940	1945
Glu His Ile Leu Asn Ser Pro Lys Gly Glu Leu Asn Tyr Asp Phe Phe		
	1955	1960
Glu Ala Leu Glu Asn Thr Tyr Pro Asn Met Ile Lys Leu Ile Asp Asn		
	1970	1975
Leu Gly Asn Ala Glu Ile Lys Lys Leu Ile Lys Val Thr Gly Tyr Met		
		1980

1985 1990 1995 2000
 Leu Val Ser Lys Lys
 2005

<210> 35
 <211> 2005
 <212> PRT
 <213> human Metapneumo virus

<400> 35
 Met Asp Pro Leu Asn Glu Ser Thr Val Asn Val Tyr Leu Pro Asp Ser
 1 5 10 15
 Tyr Leu Lys Gly Val Ile Ser Phe Ser Glu Thr Asn Ala Ile Gly Ser
 20 25 30
 Cys Leu Leu Lys Arg Pro Tyr Leu Lys Asn Asp Asn Thr Ala Lys Val
 35 40 45
 Ala Ile Glu Asn Pro Val Ile Glu His Val Arg Leu Lys Asn Ala Val
 50 55 60
 Asn Ser Lys Met Lys Ile Ser Asp Tyr Lys Val Val Glu Pro Val Asn
 65 70 75 80
 Met Gln His Glu Ile Met Lys Asn Val His Ser Cys Glu Leu Thr Leu
 85 90 95
 Leu Lys Gln Phe Leu Thr Arg Ser Lys Asn Ile Ser Thr Leu Lys Leu
 100 105 110
 Asn Met Ile Cys Asp Trp Leu Gln Leu Lys Ser Thr Ser Asp Asp Thr
 115 120 125
 Ser Ile Leu Ser Phe Ile Asp Val Glu Phe Ile Pro Ser Trp Val Ser
 130 135 140
 Asn Trp Phe Ser Asn Trp Tyr Asn Leu Asn Lys Leu Ile Leu Glu Phe
 145 150 155 160
 Arg Arg Glu Glu Val Ile Arg Thr Gly Ser Ile Leu Cys Arg Ser Leu
 165 170 175
 Gly Lys Leu Val Phe Ile Val Ser Ser Tyr Gly Cys Ile Val Lys Ser
 180 185 190
 Asn Lys Ser Lys Arg Val Ser Phe Phe Thr Tyr Asn Gln Leu Leu Thr
 195 200 205
 Trp Lys Asp Val Met Leu Ser Arg Phe Asn Ala Asn Phe Cys Ile Trp
 210 215 220
 Val Ser Asn Ser Leu Asn Glu Asn Gln Glu Gly Leu Gly Leu Arg Ser
 225 230 235 240
 Asn Leu Gln Gly Met Leu Thr Asn Lys Leu Tyr Glu Thr Val Asp Tyr
 245 250 255
 Met Leu Ser Leu Cys Cys Asn Glu Gly Phe Ser Leu Val Lys Glu Phe
 260 265 270
 Glu Gly Phe Ile Met Ser Glu Ile Leu Arg Ile Thr Glu His Ala Gln
 275 280 285
 Phe Ser Thr Arg Phe Arg Asn Thr Leu Leu Asn Gly Leu Thr Asp Gln
 290 295 300
 Leu Thr Lys Leu Lys Asn Lys Asn Arg Leu Arg Val His Gly Thr Val
 305 310 315 320
 Leu Glu Asn Asn Asp Tyr Pro Met Tyr Glu Val Val Leu Lys Leu Leu
 325 330 335
 Gly Asp Thr Leu Arg Cys Ile Lys Leu Leu Ile Asn Lys Asn Leu Glu
 340 345 350
 Asn Ala Ala Glu Leu Tyr Tyr Ile Phe Arg Ile Phe Gly His Pro Met
 355 360 365
 Val Asp Glu Arg Asp Ala Met Asp Ala Val Lys Leu Asn Asn Glu Ile
 370 375 380
 Thr Lys Ile Leu Arg Leu Glu Ser Leu Thr Glu Leu Arg Gly Ala Phe
 385 390 395 400
 Ile Leu Arg Ile Ile Lys Gly Phe Val Asp Asn Asn Lys Arg Trp Pro

405 410 415
 Lys Ile Lys Asn Leu Ile Val Leu Ser Lys Arg Trp Thr Met Tyr Phe
 420 425 430
 Lys Ala Lys Asn Tyr Pro Ser Gln Leu Glu Leu Ser Glu Gln Asp Phe
 435 440 445
 Leu Glu Leu Ala Ala Ile Gln Phe Glu Gln Glu Phe Ser Val Pro Glu
 450 455 460
 Lys Thr Asn Leu Glu Met Val Leu Asn Asp Lys Ala Ile Ser Pro Pro
 465 470 475 480
 Lys Arg Leu Ile Trp Ser Val Tyr Pro Lys Asn Tyr Leu Pro Glu Thr
 485 490 495
 Ile Lys Asn Arg Tyr Leu Glu Glu Thr Phe Asn Ala Ser Asp Ser Leu
 500 505 510
 Lys Thr Arg Arg Val Leu Glu Tyr Tyr Leu Lys Asp Asn Lys Phe Asp
 515 520 525
 Gln Lys Glu Leu Lys Ser Tyr Val Val Arg Gln Glu Tyr Leu Asn Asp
 530 535 540
 Lys Glu His Ile Val Ser Leu Thr Gly Lys Glu Arg Glu Leu Ser Val
 545 550 555 560
 Gly Arg Met Phe Ala Met Gln Pro Gly Lys Gln Arg Gln Ile Gln Ile
 565 570 575
 Leu Ala Glu Lys Leu Leu Ala Asp Asn Ile Val Pro Phe Phe Pro Glu
 580 585 590
 Thr Leu Thr Lys Tyr Gly Asp Leu Asp Leu Gln Arg Ile Met Glu Ile
 595 600 605
 Lys Ser Glu Leu Ser Ser Ile Lys Thr Arg Arg Asn Asp Ser Tyr Asn
 610 615 620
 Asn Tyr Ile Ala Arg Ala Ser Ile Val Thr Asp Leu Ser Lys Phe Asn
 625 630 635 640
 Gln Ala Phe Arg Tyr Glu Thr Thr Ala Ile Cys Ala Asp Val Ala Asp
 645 650 655
 Glu Leu His Gly Thr Gln Ser Leu Phe Cys Trp Leu His Leu Ile Val
 660 665 670
 Pro Met Thr Thr Met Ile Cys Ala Tyr Arg His Ala Pro Pro Glu Thr
 675 680 685
 Lys Gly Glu Tyr Asp Ile Asp Lys Ile Glu Glu Gln Ser Gly Leu Tyr
 690 695 700
 Arg Tyr His Met Gly Gly Ile Glu Gly Trp Cys Gln Lys Leu Trp Thr
 705 710 715 720
 Met Glu Ala Ile Ser Leu Leu Asp Val Val Ser Val Lys Thr Arg Cys
 725 730 735
 Gln Met Thr Ser Leu Leu Asn Gly Asp Asn Gln Ser Ile Asp Val Ser
 740 745 750
 Lys Pro Val Lys Leu Ser Glu Gly Leu Asp Glu Val Lys Ala Asp Tyr
 755 760 765
 Arg Leu Ala Ile Lys Met Leu Lys Glu Ile Arg Asp Ala Tyr Arg Asn
 770 775 780
 Ile Gly His Lys Leu Lys Glu Gly Glu Thr Tyr Ile Ser Arg Asp Leu
 785 790 795 800
 Gln Phe Ile Ser Lys Val Ile Gln Ser Glu Gly Val Met His Pro Thr
 805 810 815
 Pro Ile Lys Lys Val Leu Arg Val Gly Pro Trp Ile Asn Thr Ile Leu
 820 825 830
 Asp Asp Ile Lys Thr Ser Ala Glu Ser Ile Gly Ser Leu Cys Gln Glu
 835 840 845
 Leu Glu Phe Arg Gly Glu Ser Ile Ile Val Ser Leu Ile Leu Arg Asn
 850 855 860
 Phe Trp Leu Tyr Asn Leu Tyr Met His Glu Ser Lys Gln His Pro Leu
 865 870 875 880
 Ala Gly Lys Gln Leu Phe Lys Gln Leu Asn Lys Thr Leu Thr Ser Val
 885 890 895

Gln Arg Phe Phe Glu Ile Lys Lys Glu Asn Glu Val Val Asp Leu Trp
 900 905 910
 Met Asn Ile Pro Met Gln Phe Gly Gly Asp Pro Val Val Phe Tyr
 915 920 925
 Arg Ser Phe Tyr Arg Arg Thr Pro Asp Phe Leu Thr Glu Ala Ile Ser
 930 935 940
 His Val Asp Ile Leu Leu Lys Ile Ser Ala Asn Ile Lys Asn Glu Thr
 945 950 955 960
 Lys Val Ser Phe Phe Lys Ala Leu Leu Ser Ile Glu Lys Asn Glu Arg
 965 970 975
 Ala Thr Leu Thr Thr Leu Met Arg Asp Pro Gln Ala Val Gly Ser Glu
 980 985 990
 Arg Gln Ala Lys Val Thr Ser Asp Ile Asn Arg Thr Ala Val Thr Ser
 995 1000 1005
 Ile Leu Ser Leu Ser Pro Asn Gln Leu Phe Ser Asp Ser Ala Ile His
 1010 1015 1020
 Tyr Ser Arg Asn Glu Glu Glu Val Gly Ile Ile Ala Glu Asn Ile Thr
 1025 1030 1035 1040
 Pro Val Tyr Pro His Gly Leu Arg Val Leu Tyr Glu Ser Leu Pro Phe
 1045 1050 1055
 His Lys Ala Glu Lys Val Val Asn Met Ile Ser Gly Thr Lys Ser Ile
 1060 1065 1070
 Thr Asn Leu Leu Gln Arg Thr Ser Ala Ile Asn Gly Glu Asp Ile Asp
 1075 1080 1085
 Arg Ala Val Ser Met Met Leu Glu Asn Leu Gly Leu Leu Ser Arg Ile
 1090 1095 1100
 Leu Ser Val Val Val Asp Ser Ile Glu Ile Pro Ile Lys Ser Asn Gly
 1105 1110 1115 1120
 Arg Leu Ile Cys Cys Gln Ile Ser Arg Thr Leu Arg Glu Thr Ser Trp
 1125 1130 1135
 Asn Asn Met Glu Ile Val Gly Val Thr Ser Pro Ser Ile Thr Thr Cys
 1140 1145 1150
 Met Asp Val Ile Tyr Ala Thr Ser Ser His Leu Lys Gly Ile Ile Ile
 1155 1160 1165
 Glu Lys Phe Ser Thr Asp Arg Thr Thr Arg Gly Gln Arg Gly Pro Lys
 1170 1175 1180
 Ser Pro Trp Val Gly Ser Ser Thr Gln Glu Lys Lys Leu Val Pro Val
 1185 1190 1195 1200
 Tyr Asn Arg Gln Ile Leu Ser Lys Gln Gln Arg Glu Gln Leu Glu Ala
 1205 1210 1215
 Ile Gly Lys Met Arg Trp Val Tyr Lys Gly Thr Pro Gly Leu Arg Arg
 1220 1225 1230
 Leu Leu Asn Lys Ile Cys Leu Gly Ser Leu Gly Ile Ser Tyr Lys Cys
 1235 1240 1245
 Val Lys Pro Leu Leu Pro Arg Phe Met Ser Val Asn Phe Leu His Arg
 1250 1255 1260
 Leu Ser Val Ser Ser Arg Pro Met Glu Phe Pro Ala Ser Val Pro Ala
 1265 1270 1275 1280
 Tyr Arg Thr Thr Asn Tyr His Phe Asp Thr Ser Pro Ile Asn Gln Ala
 1285 1290 1295
 Leu Ser Glu Arg Phe Gly Asn Glu Asp Ile Asn Leu Val Phe Gln Asn
 1300 1305 1310
 Ala Ile Ser Cys Gly Ile Ser Ile Met Ser Val Val Glu Gln Leu Thr
 1315 1320 1325
 Gly Arg Ser Pro Lys Gln Leu Val Leu Ile Pro Gln Leu Glu Glu Ile
 1330 1335 1340
 Asp Ile Met Pro Pro Pro Val Phe Gln Gly Lys Phe Asn Tyr Lys Leu
 1345 1350 1355 1360
 Val Asp Lys Ile Thr Ser Asp Gln His Ile Phe Ser Pro Asp Lys Ile
 1365 1370 1375
 Asp Met Leu Thr Leu Gly Lys Met Leu Met Pro Thr Ile Lys Gly Gln
 1380 1385 1390

Lys Thr Asp Gln Phe Leu Asn Lys Arg Glu Asn Tyr Phe His Gly Asn
 1395 1400 1405
 Asn Leu Ile Glu Ser Leu Ser Ala Ala Leu Ala Cys His Trp Cys Gly
 1410 1415 1420
 Ile Leu Thr Glu Gln Cys Ile Glu Asn Asn Ile Phe Lys Lys Asp Trp
 1425 1430 1435 1440
 Gly Asp Gly Phe Ile Ser Asp His Ala Phe Met Asp Phe Lys Ile Phe
 1445 1450 1455
 Leu Cys Val Phe Lys Thr Lys Leu Leu Cys Ser Trp Gly Ser Gln Gly
 1460 1465 1470
 Lys Asn Ile Lys Asp Glu Asp Ile Val Asp Glu Ser Ile Asp Lys Leu
 1475 1480 1485
 Leu Arg Ile Asp Asn Thr Phe Trp Arg Met Phe Ser Lys Val Met Phe
 1490 1495 1500
 Glu Pro Lys Val Lys Lys Arg Ile Met Leu Tyr Asp Val Lys Phe Leu
 1505 1510 1515 1520
 Ser Leu Val Gly Tyr Ile Gly Phe Lys Asn Trp Phe Ile Glu Gln Leu
 1525 1530 1535
 Arg Ser Ala Glu Leu His Glu Ile Pro Trp Ile Val Asn Ala Glu Gly
 1540 1545 1550
 Asp Leu Val Glu Ile Lys Ser Ile Lys Ile Tyr Leu Gln Leu Ile Glu
 1555 1560 1565
 Gln Ser Leu Phe Leu Arg Ile Thr Val Leu Asn Tyr Thr Asp Met Ala
 1570 1575 1580
 His Ala Leu Thr Arg Leu Ile Arg Lys Lys Leu Met Cys Asp Asn Ala
 1585 1590 1595 1600
 Leu Leu Thr Pro Ile Ser Ser Pro Met Val Asn Leu Thr Gln Val Ile
 1605 1610 1615
 Asp Pro Thr Thr Gln Leu Asp Tyr Phe Pro Lys Ile Thr Phe Glu Arg
 1620 1625 1630
 Leu Lys Asn Tyr Asp Thr Ser Ser Asn Tyr Ala Lys Gly Lys Leu Thr
 1635 1640 1645
 Arg Asn Tyr Met Ile Leu Leu Pro Trp Gln His Val Asn Arg Tyr Asn
 1650 1655 1660
 Phe Val Phe Ser Ser Thr Gly Cys Lys Val Ser Leu Lys Thr Cys Ile
 1665 1670 1675 1680
 Gly Lys Leu Met Lys Asp Leu Asn Pro Lys Val Leu Tyr Phe Ile Gly
 1685 1690 1695
 Glu Gly Ala Gly Asn Trp Met Ala Arg Thr Ala Cys Glu Tyr Pro Asp
 1700 1705 1710
 Ile Lys Phe Val Tyr Arg Ser Leu Lys Asp Asp Leu Asp His His Tyr
 1715 1720 1725
 Pro Leu Glu Tyr Gln Arg Val Ile Gly Glu Leu Ser Arg Ile Ile Asp
 1730 1735 1740
 Ser Gly Glu Gly Leu Ser Met Glu Thr Thr Asp Ala Thr Gln Lys Thr
 1745 1750 1755 1760
 His Trp Asp Leu Ile His Arg Val Ser Lys Asp Ala Leu Leu Ile Thr
 1765 1770 1775
 Leu Cys Asp Ala Glu Phe Lys Asp Arg Asp Asp Phe Phe Lys Met Val
 1780 1785 1790
 Ile Leu Trp Arg Lys His Val Leu Ser Cys Arg Ile Cys Thr Thr Tyr
 1795 1800 1805
 Gly Thr Asp Leu Tyr Leu Phe Ala Lys Tyr His Ala Lys Asp Cys Asn
 1810 1815 1820
 Val Lys Leu Pro Phe Phe Val Arg Ser Val Ala Thr Phe Ile Met Gln
 1825 1830 1835 1840
 Gly Ser Lys Leu Ser Gly Ser Glu Cys Tyr Ile Leu Leu Thr Leu Gly
 1845 1850 1855
 His His Asn Ser Leu Pro Cys His Gly Glu Ile Gln Asn Ser Lys Met
 1860 1865 1870
 Lys Ile Ala Val Cys Asn Asp Phe Tyr Ala Ala Lys Lys Leu Asp Asn
 1875 1880 1885

Lys Ser Ile Glu Ala Asn Cys Lys Ser Leu Leu Ser Gly Leu Arg Ile
 1890 1895 1900
 Pro Ile Asn Lys Lys Glu Leu Asp Arg Gln Arg Arg Leu Leu Thr Leu
 1905 1910 1915 1920
 Gln Ser Asn His Ser Ser Val Ala Thr Val Gly Gly Ser Lys Ile Ile
 1925 1930 1935
 Glu Ser Lys Trp Leu Thr Asn Lys Ala Ser Thr Ile Ile Asp Trp Leu
 1940 1945 1950
 Glu His Ile Leu Asn Ser Pro Lys Gly Glu Leu Asn Tyr Asp Phe Phe
 1955 1960 1965
 Glu Ala Leu Glu Asn Thr Tyr Pro Asn Met Ile Lys Leu Ile Asp Asn
 1970 1975 1980
 Leu Gly Asn Ala Glu Ile Lys Lys Leu Ile Lys Val Thr Gly Tyr Met
 1985 1990 1995 2000
 Leu Val Ser Lys Lys
 2005

<210> 36
 <211> 2005
 <212> PRT
 <213> human Metapneumo virus

<400> 36
 Met Asp Pro Phe Cys Glu Ser Thr Val Asn Val Tyr Leu Pro Asp Ser
 1 5 10 15
 Tyr Leu Lys Gly Val Ile Ser Phe Ser Glu Thr Asn Ala Ile Gly Ser
 20 25 30
 Cys Leu Leu Lys Arg Pro Tyr Leu Lys Asn Asp Asn Thr Ala Lys Val
 35 40 45
 Ala Val Glu Asn Pro Val Val Glu His Val Arg Leu Arg Asn Ala Val
 50 55 60
 Met Thr Lys Met Lys Ile Ser Asp Tyr Lys Val Val Glu Pro Val Asn
 65 70 75 80
 Met Gln His Glu Ile Met Lys Asn Ile His Ser Cys Glu Leu Thr Leu
 85 90 95
 Leu Lys Gln Phe Leu Thr Arg Ser Lys Asn Ile Ser Ser Leu Lys Leu
 100 105 110
 Asn Met Ile Cys Asp Trp Leu Gln Leu Lys Ser Thr Ser Asp Asn Thr
 115 120 125
 Ser Ile Leu Asn Phe Ile Asp Val Glu Phe Ile Pro Val Trp Val Ser
 130 135 140
 Asn Trp Phe Ser Asn Trp Tyr Asn Leu Asn Lys Leu Ile Leu Glu Phe
 145 150 155 160
 Arg Arg Glu Glu Val Ile Arg Thr Gly Ser Ile Leu Cys Arg Ser Leu
 165 170 175
 Gly Lys Leu Val Phe Ile Val Ser Ser Tyr Gly Cys Val Val Lys Ser
 180 185 190
 Asn Lys Ser Lys Arg Val Ser Phe Phe Thr Tyr Asn Gln Leu Leu Thr
 195 200 205
 Trp Lys Asp Val Met Leu Ser Arg Phe Asn Ala Asn Phe Cys Ile Trp
 210 215 220
 Val Ser Asn Asn Leu Asn Lys Asn Gln Glu Gly Leu Gly Leu Arg Ser
 225 230 235 240
 Asn Leu Gln Gly Met Leu Thr Asn Lys Leu Tyr Glu Thr Val Asp Tyr
 245 250 255
 Met Leu Ser Leu Cys Cys Asn Glu Gly Phe Ser Leu Val Lys Glu Phe
 260 265 270
 Glu Gly Phe Ile Met Ser Glu Ile Leu Lys Ile Thr Glu His Ala Gln
 275 280 285
 Phe Ser Thr Arg Phe Arg Asn Thr Leu Leu Asn Gly Leu Thr Glu Gln
 290 295 300

Leu Ser Val Leu Lys Ala Lys Asn Arg Ser Arg Val Leu Gly Thr Ile
 305 310 315 320
 Leu Glu Asn Asn Asn Tyr Pro Met Tyr Glu Val Val Leu Lys Leu Leu
 325 330 335
 Gly Asp Thr Leu Lys Ser Ile Lys Leu Ile Asn Lys Asn Leu Glu
 340 345 350
 Asn Ala Ala Glu Leu Tyr Tyr Ile Phe Arg Ile Phe Gly His Pro Met
 355 360 365
 Val Asp Glu Arg Glu Ala Met Asp Ala Val Lys Leu Asn Asn Glu Ile
 370 375 380
 Thr Lys Ile Leu Lys Leu Glu Ser Leu Thr Glu Leu Arg Gly Ala Phe
 385 390 395 400
 Ile Leu Arg Ile Ile Lys Gly Phe Val Asp Asn Asn Lys Arg Trp Pro
 405 410 415
 Lys Ile Lys Asn Leu Lys Val Leu Ser Lys Arg Trp Ala Met Tyr Phe
 420 425 430
 Lys Ala Lys Ser Tyr Pro Ser Gln Leu Glu Leu Ser Val Gln Asp Phe
 435 440 445
 Leu Glu Leu Ala Ala Val Gln Phe Glu Gln Glu Phe Ser Val Pro Glu
 450 455 460
 Lys Thr Asn Leu Glu Met Val Leu Asn Asp Lys Ala Ile Ser Pro Pro
 465 470 475 480
 Lys Lys Leu Ile Trp Ser Val Tyr Pro Lys Asn Tyr Leu Pro Glu Thr
 485 490 495
 Ile Lys Asn Gln Tyr Leu Glu Glu Ala Phe Asn Ala Ser Asp Ser Gln
 500 505 510
 Arg Thr Arg Arg Val Leu Glu Phe Tyr Leu Lys Asp Cys Lys Phe Asp
 515 520 525
 Gln Lys Glu Leu Lys Arg Tyr Val Ile Lys Gln Glu Tyr Leu Asn Asp
 530 535 540
 Lys Asp His Ile Val Ser Leu Thr Gly Lys Glu Arg Glu Leu Ser Val
 545 550 555 560
 Gly Arg Met Phe Ala Met Gln Pro Gly Lys Gln Arg Gln Ile Gln Ile
 565 570 575
 Leu Ala Glu Lys Leu Leu Ala Asp Asn Ile Val Pro Phe Phe Pro Glu
 580 585 590
 Thr Leu Thr Lys Tyr Gly Asp Leu Asp Leu Gln Arg Ile Met Glu Ile
 595 600 605
 Lys Ser Glu Leu Ser Ser Ile Lys Thr Arg Lys Asn Asp Ser Tyr Asn
 610 615 620
 Asn Tyr Ile Ala Arg Ala Ser Ile Val Thr Asp Leu Ser Lys Phe Asn
 625 630 635 640
 Gln Ala Phe Arg Tyr Glu Thr Thr Ala Ile Cys Ala Asp Val Ala Asp
 645 650 655
 Glu Leu His Gly Thr Gln Ser Leu Phe Cys Trp Leu His Leu Ile Val
 660 665 670
 Pro Met Thr Thr Met Ile Cys Ala Tyr Arg His Ala Pro Pro Glu Thr
 675 680 685
 Lys Gly Glu Tyr Asp Ile Asp Lys Ile Gln Glu Gln Ser Gly Leu Tyr
 690 695 700
 Arg Tyr His Met Gly Gly Ile Glu Gly Trp Cys Gln Lys Leu Trp Thr
 705 710 715 720
 Met Glu Ala Ile Ser Leu Leu Asp Val Val Ser Val Lys Thr Arg Cys
 725 730 735
 Gln Met Thr Ser Leu Leu Asn Gly Asp Asn Gln Ser Ile Asp Val Ser
 740 745 750
 Lys Pro Val Lys Leu Ser Glu Gly Ile Asp Glu Val Lys Ala Asp Tyr
 755 760 765
 Ser Leu Ala Ile Arg Met Leu Lys Glu Ile Arg Asp Ala Tyr Lys Asn
 770 775 780
 Ile Gly His Lys Leu Lys Glu Gly Glu Thr Tyr Ile Ser Arg Asp Leu
 785 790 795 800

Gln Phe Ile Ser Lys Val Ile Gln Ser Glu Gly Val Met His Pro Thr
 805 810 815
 Pro Ile Lys Lys Ile Leu Arg Val Gly Pro Trp Ile Asn Thr Ile Leu
 820 825 830
 Asp Asp Ile Lys Thr Ser Ala Glu Ser Ile Gly Ser Leu Cys Gln Glu
 835 840 845
 Leu Glu Phe Arg Gly Glu Ser Ile Leu Val Ser Leu Ile Leu Arg Asn
 850 855 860
 Phe Trp Leu Tyr Asn Leu Tyr Met Tyr Glu Ser Lys Gln His Pro Leu
 865 870 875 880
 Ala Gly Lys Gln Leu Phe Lys Gln Leu Asn Lys Thr Leu Thr Ser Val
 885 890 895
 Gln Arg Phe Phe Glu Leu Lys Lys Glu Asn Asp Val Val Asp Leu Trp
 900 905 910
 Met Asn Ile Pro Met Gln Phe Gly Gly Gly Asp Pro Val Val Phe Tyr
 915 920 925
 Arg Ser Phe Tyr Arg Arg Thr Pro Asp Phe Leu Thr Glu Ala Ile Ser
 930 935 940
 His Val Asp Leu Leu Leu Lys Val Ser Asn Asn Ile Lys Asp Glu Thr
 945 950 955 960
 Lys Ile Arg Phe Phe Lys Ala Leu Leu Ser Ile Glu Lys Asn Glu Arg
 965 970 975
 Ala Thr Leu Thr Thr Leu Met Arg Asp Pro Gln Ala Val Gly Ser Glu
 980 985 990
 Arg Gln Ala Lys Val Thr Ser Asp Ile Asn Arg Thr Ala Val Thr Ser
 995 1000 1005
 Ile Leu Ser Leu Ser Pro Asn Gln Leu Phe Cys Asp Ser Ala Ile His
 1010 1015 1020
 Tyr Ser Arg Asn Glu Glu Glu Val Gly Ile Ile Ala Asp Asn Ile Thr
 1025 1030 1035 1040
 Pro Val Tyr Pro His Gly Leu Arg Val Leu Tyr Glu Ser Leu Pro Phe
 1045 1050 1055
 His Lys Ala Glu Lys Val Val Asn Met Ile Ser Gly Thr Lys Ser Ile
 1060 1065 1070
 Thr Asn Leu Leu Gln Arg Thr Ser Ala Ile Asn Gly Glu Asp Ile Asp
 1075 1080 1085
 Arg Ala Val Ser Met Met Leu Glu Asn Leu Gly Leu Leu Ser Arg Ile
 1090 1095 1100
 Leu Ser Val Ile Ile Asn Ser Ile Glu Ile Pro Ile Lys Ser Asn Gly
 1105 1110 1115 1120
 Arg Leu Ile Cys Cys Gln Ile Ser Lys Thr Leu Arg Glu Lys Ser Trp
 1125 1130 1135
 Asn Asn Met Glu Ile Val Gly Val Thr Ser Pro Ser Ile Val Thr Cys
 1140 1145 1150
 Met Asp Val Val Tyr Ala Thr Ser Ser His Leu Lys Gly Ile Ile Ile
 1155 1160 1165
 Glu Lys Phe Ser Thr Asp Lys Thr Thr Arg Gly Gln Arg Gly Pro Lys
 1170 1175 1180
 Ser Pro Trp Val Gly Ser Ser Thr Gln Glu Lys Lys Leu Val Pro Val
 1185 1190 1195 1200
 Tyr Asn Arg Gln Ile Leu Ser Lys Gln Gln Lys Glu Gln Leu Glu Ala
 1205 1210 1215
 Ile Gly Lys Met Arg Trp Val Tyr Lys Gly Thr Pro Gly Leu Arg Arg
 1220 1225 1230
 Leu Leu Asn Lys Ile Cys Ile Gly Ser Leu Gly Ile Ser Tyr Lys Cys
 1235 1240 1245
 Val Lys Pro Leu Leu Pro Arg Phe Met Ser Val Asn Phe Leu His Arg
 1250 1255 1260
 Leu Ser Val Ser Ser Arg Pro Met Glu Phe Pro Ala Ser Val Pro Ala
 1265 1270 1275 1280
 Tyr Arg Thr Thr Asn Tyr His Phe Asp Thr Ser Pro Ile Asn Gln Ala
 1285 1290 1295

Leu Ser Glu Arg Phe Gly Asn Glu Asp Ile Asn Leu Val Phe Gln Asn
 1300 1305 1310
 Ala Ile Ser Cys Gly Ile Ser Ile Met Ser Val Val Glu Gln Leu Thr
 1315 1320 1325
 Gly Arg Ser Pro Lys Gln Leu Val Leu Ile Pro Gln Leu Glu Glu Ile
 1330 1335 1340
 Asp Ile Met Pro Pro Pro Val Phe Gln Gly Lys Phe Asn Tyr Lys Leu
 1345 1350 1355 1360
 Val Asp Lys Ile Thr Ser Asp Gln His Ile Phe Ser Pro Asp Lys Ile
 1365 1370 1375
 Asp Ile Leu Thr Leu Gly Lys Met Leu Met Pro Thr Ile Lys Gly Gln
 1380 1385 1390
 Lys Thr Asp Gln Phe Leu Asn Lys Arg Glu Asn Tyr Phe His Gly Asn
 1395 1400 1405
 Asn Leu Ile Glu Ser Leu Ser Ala Ala Leu Ala Cys His Trp Cys Gly
 1410 1415 1420
 Ile Leu Thr Glu Gln Cys Ile Glu Asn Asn Ile Phe Arg Lys Asp Trp
 1425 1430 1435 1440
 Gly Asp Gly Phe Ile Ser Asp His Ala Phe Met Asp Phe Lys Val Phe
 1445 1450 1455
 Leu Cys Val Phe Lys Thr Lys Leu Leu Cys Ser Trp Gly Ser Gln Gly
 1460 1465 1470
 Lys Asn Val Lys Asp Glu Asp Ile Ile Asp Glu Ser Ile Asp Lys Leu
 1475 1480 1485
 Leu Arg Ile Asp Asn Thr Phe Trp Arg Met Phe Ser Lys Val Met Phe
 1490 1495 1500
 Glu Ser Lys Val Lys Lys Arg Ile Met Leu Tyr Asp Val Lys Phe Leu
 1505 1510 1515 1520
 Ser Leu Val Gly Tyr Ile Gly Phe Lys Asn Trp Phe Ile Glu Gln Leu
 1525 1530 1535
 Arg Val Val Glu Leu His Glu Val Pro Trp Ile Val Asn Ala Glu Gly
 1540 1545 1550
 Glu Leu Val Glu Ile Lys Ser Ile Lys Ile Tyr Leu Gln Leu Ile Glu
 1555 1560 1565
 Gln Ser Leu Ser Leu Arg Ile Thr Val Leu Asn Tyr Thr Asp Met Ala
 1570 1575 1580
 His Ala Leu Thr Arg Leu Ile Arg Lys Lys Leu Met Cys Asp Asn Ala
 1585 1590 1595 1600
 Leu Phe Asn Pro Ser Ser Ser Pro Met Phe Asn Leu Thr Gln Val Ile
 1605 1610 1615
 Asp Pro Thr Thr Gln Leu Asp Tyr Phe Pro Arg Ile Ile Phe Glu Arg
 1620 1625 1630
 Leu Lys Ser Tyr Asp Thr Ser Ser Asp Tyr Asn Lys Gly Lys Leu Thr
 1635 1640 1645
 Arg Asn Tyr Met Thr Leu Leu Pro Trp Gln His Val Asn Arg Tyr Asn
 1650 1655 1660
 Phe Val Phe Ser Ser Thr Gly Cys Lys Val Ser Leu Lys Thr Cys Ile
 1665 1670 1675 1680
 Gly Lys Leu Ile Lys Asp Leu Asn Pro Lys Val Leu Tyr Phe Ile Gly
 1685 1690 1695
 Glu Gly Ala Gly Asn Trp Met Ala Arg Thr Ala Cys Glu Tyr Pro Asp
 1700 1705 1710
 Ile Lys Phe Val Tyr Arg Ser Leu Lys Asp Asp Leu Asp His His Tyr
 1715 1720 1725
 Pro Leu Glu Tyr Gln Arg Val Ile Gly Asp Leu Asn Arg Val Ile Asp
 1730 1735 1740
 Ser Gly Glu Gly Leu Ser Met Glu Thr Thr Asp Ala Thr Gln Lys Thr
 1745 1750 1755 1760
 His Trp Asp Leu Ile His Arg Ile Ser Lys Asp Ala Leu Leu Ile Thr
 1765 1770 1775
 Leu Cys Asp Ala Glu Phe Lys Asn Arg Asp Asp Phe Phe Lys Met Val
 1780 1785 1790

Ile Leu Trp Arg Lys His Val Leu Ser Cys Arg Ile Cys Thr Ala Tyr
 1795 1800 1805
 Gly Thr Asp Leu Tyr Leu Phe Ala Lys Tyr His Ala Val Asp Cys Asn
 1810 1815 1820
 Ile Lys Leu Pro Phe Phe Val Arg Ser Val Ala Thr Phe Ile Met Gln
 1825 1830 1835 1840
 Gly Ser Lys Leu Ser Gly Ser Glu Cys Tyr Ile Leu Leu Thr Leu Gly
 1845 1850 1855
 His His Asn Asn Leu Pro Cys His Gly Glu Ile Gln Asn Ser Lys Met
 1860 1865 1870
 Arg Ile Ala Val Cys Asn Asp Phe Tyr Ala Ser Lys Lys Leu Asp Asn
 1875 1880 1885
 Lys Ser Ile Glu Ala Asn Cys Lys Ser Leu Leu Ser Gly Leu Arg Ile
 1890 1895 1900
 Pro Ile Asn Lys Lys Glu Leu Asn Arg Gln Lys Lys Leu Leu Thr Leu
 1905 1910 1915 1920
 Gln Ser Asn His Ser Ser Ile Ala Thr Val Gly Gly Ser Lys Ile Ile
 1925 1930 1935
 Glu Ser Lys Trp Leu Lys Asn Lys Ala Ser Thr Ile Ile Asp Trp Leu
 1940 1945 1950
 Glu His Ile Leu Asn Ser Pro Lys Gly Glu Leu Asn Tyr Asp Phe Phe
 1955 1960 1965
 Glu Ala Leu Glu Asn Thr Tyr Pro Asn Met Ile Lys Leu Ile Asp Asn
 1970 1975 1980
 Leu Gly Asn Ala Glu Ile Lys Lys Leu Ile Lys Val Thr Gly Tyr Met
 1985 1990 1995 2000
 Leu Val Ser Lys Lys
 2005

<210> 37

<211> 2005

<212> PRT

<213> human Metapneumo virus

<400> 37

Met Asp Pro Phe Cys Glu Ser Thr Val Asn Val Tyr Leu Pro Asp Ser
 1 5 10 15
 Tyr Leu Lys Gly Val Ile Ser Phe Ser Glu Thr Asn Ala Ile Gly Ser
 20 25 30
 Cys Leu Leu Lys Arg Pro Tyr Leu Lys Lys Asp Asn Thr Ala Lys Val
 35 40 45
 Ala Val Glu Asn Pro Val Val Glu His Val Arg Leu Arg Asn Ala Val
 50 55 60
 Met Thr Lys Met Lys Ile Ser Asp Tyr Lys Val Val Glu Pro Ile Asn
 65 70 75 80
 Met Gln His Glu Ile Met Lys Asn Ile His Ser Cys Glu Leu Thr Leu
 85 90 95
 Leu Lys Gln Phe Leu Thr Arg Ser Lys Asn Ile Ser Ser Leu Lys Leu
 100 105 110
 Ser Met Ile Cys Asp Trp Leu Gln Leu Lys Ser Thr Ser Asp Asn Thr
 115 120 125
 Ser Ile Leu Asn Phe Ile Asp Val Glu Phe Ile Pro Val Trp Val Ser
 130 135 140
 Asn Trp Phe Ser Asn Trp Tyr Asn Leu Asn Lys Leu Ile Leu Glu Phe
 145 150 155 160
 Arg Arg Glu Glu Val Ile Arg Thr Gly Ser Ile Leu Cys Arg Ser Leu
 165 170 175
 Gly Lys Leu Val Phe Ile Val Ser Ser Tyr Gly Cys Val Val Lys Ser
 180 185 190
 Asn Lys Ser Lys Arg Val Ser Phe Phe Thr Tyr Asn Gln Leu Leu Thr
 195 200 205

Trp Lys Asp Val Met Leu Ser Arg Phe Asn Ala Asn Phe Cys Ile Trp
 210 215 220
 Val Ser Asn Asn Leu Asn Lys Asn Gln Glu Gly Leu Gly Phe Arg Ser
 225 230 235 240
 Asn Leu Gln Gly Met Leu Thr Asn Lys Leu Tyr Glu Thr Val Asp Tyr
 245 250 255
 Met Leu Ser Leu Cys Ser Asn Glu Gly Phe Ser Leu Val Lys Glu Phe
 260 265 270
 Glu Gly Phe Ile Met Ser Glu Ile Leu Lys Ile Thr Glu His Ala Gln
 275 280 285
 Phe Ser Thr Arg Phe Arg Asn Thr Leu Leu Asn Gly Leu Thr Glu Gln
 290 295 300
 Leu Ser Met Leu Lys Ala Lys Asn Arg Ser Arg Val Leu Gly Thr Ile
 305 310 315 320
 Leu Glu Asn Asn Asp Tyr Pro Met Tyr Glu Val Val Leu Lys Leu Leu
 325 330 335
 Gly Asp Thr Leu Lys Ser Ile Lys Leu Ile Asn Lys Asn Leu Glu
 340 345 350
 Asn Ala Ala Glu Leu Tyr Tyr Ile Phe Arg Ile Phe Gly His Pro Met
 355 360 365
 Val Asp Glu Arg Glu Ala Met Asp Ala Val Lys Leu Asn Asn Glu Ile
 370 375 380
 Thr Lys Ile Leu Lys Leu Glu Ser Leu Thr Glu Leu Arg Gly Ala Phe
 385 390 395 400
 Ile Leu Arg Ile Ile Lys Gly Phe Val Asp Asn Asn Lys Arg Trp Pro
 405 410 415
 Lys Ile Lys Asn Leu Lys Val Leu Ser Lys Arg Trp Val Met Tyr Phe
 420 425 430
 Lys Ala Lys Ser Tyr Pro Ser Gln Leu Glu Leu Ser Val Gln Asp Phe
 435 440 445
 Leu Glu Leu Ala Ala Val Gln Phe Glu Gln Glu Phe Ser Val Pro Glu
 450 455 460
 Lys Thr Asn Leu Glu Met Val Leu Asn Asp Lys Ala Ile Ser Pro Pro
 465 470 475 480
 Lys Lys Leu Ile Trp Ser Val Tyr Pro Lys Asn Tyr Leu Pro Glu Ile
 485 490 495
 Ile Lys Asn Gln Tyr Leu Glu Glu Val Phe Asn Ala Ser Asp Ser Gln
 500 505 510
 Arg Thr Arg Arg Val Leu Glu Phe Tyr Leu Lys Asp Cys Lys Phe Asp
 515 520 525
 Gln Lys Asp Leu Lys Arg Tyr Val Leu Lys Gln Glu Tyr Leu Asn Asp
 530 535 540
 Lys Asp His Ile Val Ser Leu Thr Gly Lys Glu Arg Glu Leu Ser Val
 545 550 555 560
 Gly Arg Met Phe Ala Met Gln Pro Gly Lys Gln Arg Gln Ile Gln Ile
 565 570 575
 Leu Ala Glu Lys Leu Leu Ala Asp Asn Ile Val Pro Phe Phe Pro Glu
 580 585 590
 Thr Leu Thr Lys Tyr Gly Asp Leu Asp Leu Gln Arg Ile Met Glu Met
 595 600 605
 Lys Ser Glu Leu Ser Ser Ile Lys Thr Arg Lys Asn Asp Ser Tyr Asn
 610 615 620
 Asn Tyr Ile Ala Arg Ala Ser Ile Val Thr Asp Leu Ser Lys Phe Asn
 625 630 635 640
 Gln Ala Phe Arg Tyr Glu Thr Thr Ala Ile Cys Ala Asp Val Ala Asp
 645 650 655
 Glu Leu His Gly Thr Gln Ser Leu Phe Cys Trp Leu His Leu Ile Val
 660 665 670
 Pro Met Thr Thr Met Ile Cys Ala Tyr Arg His Ala Pro Pro Glu Thr
 675 680 685
 Lys Gly Glu Tyr Asp Ile Asp Lys Ile Glu Glu Gln Ser Gly Leu Tyr
 690 695 700

Arg	Tyr	His	Met	Gly	Gly	Ile	Glu	Gly	Trp	Cys	Gln	Lys	Leu	Trp	Thr
705					710					715					720
Met	Glu	Ala	Ile	Ser	Leu	Leu	Asp	Val	Val	Ser	Val	Lys	Thr	Arg	Cys
				725					730						735
Gln	Met	Thr	Ser	Leu	Leu	Asn	Gly	Asp	Asn	Gln	Ser	Ile	Asp	Val	Ser
			740					745					750		
Lys	Pro	Val	Lys	Leu	Ser	Glu	Gly	Ile	Asp	Glu	Val	Lys	Ala	Asp	Tyr
	755						760					765			
Ser	Leu	Ala	Ile	Lys	Met	Leu	Lys	Glu	Ile	Arg	Asp	Ala	Tyr	Lys	Asn
	770					775					780				
Ile	Gly	His	Lys	Leu	Lys	Glu	Gly	Glu	Thr	Tyr	Ile	Ser	Arg	Asp	Leu
785					790					795					800
Gln	Phe	Ile	Ser	Lys	Val	Ile	Gln	Ser	Glu	Gly	Val	Met	His	Pro	Thr
				805					810					815	
Pro	Ile	Lys	Lys	Ile	Leu	Arg	Val	Gly	Pro	Trp	Ile	Asn	Thr	Ile	Leu
			820					825					830		
Asp	Asp	Ile	Lys	Thr	Ser	Ala	Glu	Ser	Ile	Gly	Ser	Leu	Cys	Gln	Glu
		835					840					845			
Leu	Glu	Phe	Arg	Gly	Glu	Ser	Met	Leu	Val	Ser	Leu	Ile	Leu	Arg	Asn
	850					855					860				
Phe	Trp	Leu	Tyr	Asn	Leu	Tyr	Met	His	Glu	Ser	Lys	Gln	His	Pro	Leu
865					870					875					880
Ala	Gly	Lys	Gln	Leu	Phe	Lys	Gln	Leu	Asn	Lys	Thr	Leu	Thr	Ser	Val
				885					890					895	
Gln	Arg	Phe	Phe	Glu	Leu	Lys	Lys	Glu	Asn	Asp	Val	Val	Asp	Leu	Trp
			900					905					910		
Met	Asn	Ile	Pro	Met	Gln	Phe	Gly	Gly	Asp	Pro	Val	Val	Phe	Tyr	
		915					920					925			
Arg	Ser	Phe	Tyr	Arg	Arg	Thr	Pro	Asp	Phe	Leu	Thr	Glu	Ala	Ile	Ser
	930					935					940				
His	Val	Asp	Leu	Leu	Leu	Lys	Val	Ser	Asn	Asn	Ile	Lys	Asn	Glu	Thr
945					950					955					960
Lys	Ile	Arg	Phe	Phe	Lys	Ala	Leu	Leu	Ser	Ile	Glu	Lys	Asn	Glu	Arg
			965						970					975	
Ala	Thr	Leu	Thr	Thr	Leu	Met	Arg	Asp	Pro	Gln	Ala	Val	Gly	Ser	Glu
			980					985					990		
Arg	Gln	Ala	Lys	Val	Thr	Ser	Asp	Ile	Asn	Arg	Thr	Ala	Val	Thr	Ser
		995					1000					1005			
Ile	Leu	Ser	Leu	Ser	Pro	Asn	Gln	Leu	Phe	Cys	Asp	Ser	Ala	Ile	His
	1010					1015					1020				
Tyr	Ser	Arg	Asn	Glu	Glu	Glu	Val	Gly	Ile	Ile	Ala	Asp	Asn	Ile	Thr
1025					1030					1035					1040
Pro	Val	Tyr	Pro	His	Gly	Leu	Arg	Val	Leu	Tyr	Glu	Ser	Leu	Pro	Phe
			1045						1050					1055	
His	Lys	Ala	Glu	Lys	Val	Val	Asn	Met	Ile	Ser	Gly	Thr	Lys	Ser	Ile
			1060					1065					1070		
Thr	Asn	Leu	Leu	Gln	Arg	Thr	Ser	Ala	Ile	Asn	Gly	Glu	Asp	Ile	Asp
		1075				1080						1085			
Arg	Ala	Val	Ser	Met	Met	Leu	Glu	Asn	Leu	Gly	Leu	Leu	Ser	Arg	Ile
	1090					1095					1100				
Leu	Ser	Val	Ile	Ile	Asn	Ser	Ile	Glu	Ile	Pro	Ile	Lys	Ser	Asn	Gly
1105					1110					1115					1120
Arg	Leu	Ile	Cys	Cys	Gln	Ile	Ser	Lys	Thr	Leu	Arg	Glu	Lys	Ser	Trp
			1125						1130					1135	
Asn	Asn	Met	Glu	Ile	Val	Gly	Val	Thr	Ser	Pro	Ser	Ile	Val	Thr	Cys
		1140						1145					1150		
Met	Asp	Val	Val	Tyr	Ala	Thr	Ser	Ser	His	Leu	Lys	Gly	Ile	Ile	Ile
	1155					1160						1165			
Glu	Lys	Phe	Ser	Thr	Asp	Lys	Thr	Thr	Arg	Gly	Gln	Arg	Gly	Pro	Lys
	1170					1175					1180				
Ser	Pro	Trp	Val	Gly	Ser	Ser	Thr	Gln	Glu	Lys	Lys	Leu	Val	Pro	Val
1185					1190					1195					1200

Tyr Asn Arg Gln Ile Leu Ser Lys Gln Gln Lys Glu Gln Leu Glu Ala
 1205 1210 1215
 Ile Gly Lys Met Arg Trp Val Tyr Lys Gly Thr Pro Gly Leu Arg Arg
 1220 1225 1230
 Leu Leu Asn Lys Ile Cys Ile Gly Ser Leu Gly Ile Ser Tyr Lys Cys
 1235 1240 1245
 Val Lys Pro Leu Leu Pro Arg Phe Met Ser Val Asn Phe Leu His Arg
 1250 1255 1260
 Leu Ser Val Ser Ser Arg Pro Met Glu Phe Pro Ala Ser Val Pro Ala
 1265 1270 1275 1280
 Tyr Arg Thr Thr Asn Tyr His Phe Asp Thr Ser Pro Ile Asn Gln Ala
 1285 1290 1295
 Leu Ser Glu Arg Phe Gly Asn Glu Asp Ile Asn Leu Val Phe Gln Asn
 1300 1305 1310
 Ala Ile Ser Cys Gly Ile Ser Ile Met Ser Val Val Glu Gln Leu Thr
 1315 1320 1325
 Gly Arg Ser Pro Lys Gln Leu Val Leu Ile Pro Gln Leu Glu Glu Ile
 1330 1335 1340
 Asp Ile Met Pro Pro Pro Val Phe Gln Gly Lys Phe Asn Tyr Lys Leu
 1345 1350 1355 1360
 Val Asp Lys Ile Thr Ser Asp Gln His Ile Phe Ser Pro Asp Lys Ile
 1365 1370 1375
 Asp Ile Leu Thr Leu Gly Lys Met Leu Met Pro Thr Ile Lys Gly Gln
 1380 1385 1390
 Lys Thr Asp Gln Phe Leu Asn Lys Arg Glu Asn Tyr Phe His Gly Asn
 1395 1400 1405
 Asn Leu Ile Glu Ser Leu Ser Ala Ala Leu Ala Cys His Trp Cys Gly
 1410 1415 1420
 Ile Leu Thr Glu Gln Cys Val Glu Asn Asn Ile Phe Arg Lys Asp Trp
 1425 1430 1435 1440
 Gly Asp Gly Phe Ile Ser Asp His Ala Phe Met Asp Phe Lys Ile Phe
 1445 1450 1455
 Leu Cys Val Phe Lys Thr Lys Leu Leu Cys Ser Trp Gly Ser Gln Gly
 1460 1465 1470
 Lys Asn Val Lys Asp Glu Asp Ile Ile Asp Glu Ser Ile Asp Lys Leu
 1475 1480 1485
 Leu Arg Ile Asp Asn Thr Phe Trp Arg Met Phe Ser Lys Val Met Phe
 1490 1495 1500
 Glu Ser Lys Val Lys Lys Arg Ile Met Leu Tyr Asp Val Lys Phe Leu
 1505 1510 1515 1520
 Ser Leu Val Gly Tyr Ile Gly Phe Lys Asn Trp Phe Ile Glu Gln Leu
 1525 1530 1535
 Arg Val Val Glu Leu His Glu Val Pro Trp Ile Val Asn Ala Glu Gly
 1540 1545 1550
 Glu Leu Val Glu Ile Lys Pro Ile Lys Ile Tyr Leu Gln Leu Ile Glu
 1555 1560 1565
 Gln Ser Leu Ser Leu Arg Ile Thr Val Leu Asn Tyr Thr Asp Met Ala
 1570 1575 1580
 His Ala Leu Thr Arg Leu Ile Arg Lys Lys Leu Met Cys Asp Asn Ala
 1585 1590 1595 1600
 Leu Phe Asn Pro Ser Ser Ser Pro Met Phe Ser Leu Thr Gln Val Ile
 1605 1610 1615
 Asp Pro Thr Thr Gln Leu Asp Tyr Phe Pro Lys Val Ile Phe Glu Arg
 1620 1625 1630
 Leu Lys Ser Tyr Asp Thr Ser Ser Asp Tyr Asn Lys Gly Lys Leu Thr
 1635 1640 1645
 Arg Asn Tyr Met Thr Leu Leu Pro Trp Gln His Val Asn Arg Tyr Asn
 1650 1655 1660
 Phe Val Phe Ser Ser Thr Gly Cys Lys Ile Ser Leu Lys Thr Cys Ile
 1665 1670 1675 1680
 Gly Lys Leu Ile Lys Asp Leu Asn Pro Lys Val Leu Tyr Phe Ile Gly
 1685 1690 1695

Glu Gly Ala Gly Asn Trp Met Ala Arg Thr Ala Cys Glu Tyr Pro Asp
 1700 1705 1710
 Ile Lys Phe Val Tyr Arg Ser Leu Lys Asp Asp Leu Asp His His Tyr
 1715 1720 1725
 Pro Leu Glu Tyr Gln Arg Val Ile Gly Asp Leu Asn Arg Val Ile Asp
 1730 1735 1740
 Gly Gly Glu Gly Leu Ser Met Glu Thr Thr Asp Ala Thr Gln Lys Thr
 1745 1750 1755 1760
 His Trp Asp Leu Ile His Arg Ile Ser Lys Asp Ala Leu Leu Ile Thr
 1765 1770 1775
 Leu Cys Asp Ala Glu Phe Lys Asn Arg Asp Asp Phe Phe Lys Met Val
 1780 1785 1790
 Ile Leu Trp Arg Lys His Val Leu Ser Cys Arg Ile Cys Thr Ala Tyr
 1795 1800 1805
 Gly Thr Asp Leu Tyr Leu Phe Ala Lys Tyr His Ala Thr Asp Cys Asn
 1810 1815 1820
 Ile Lys Leu Pro Phe Phe Val Arg Ser Val Ala Thr Phe Ile Met Gln
 1825 1830 1835 1840
 Gly Ser Lys Leu Ser Gly Ser Glu Cys Tyr Ile Leu Leu Thr Leu Gly
 1845 1850 1855
 His His Asn Asn Leu Pro Cys His Gly Glu Ile Gln Asn Ser Lys Met
 1860 1865 1870
 Arg Ile Ala Val Cys Asn Asp Phe His Ala Ser Lys Lys Leu Asp Asn
 1875 1880 1885
 Lys Ser Ile Glu Ala Asn Cys Lys Ser Leu Leu Ser Gly Leu Arg Ile
 1890 1895 1900
 Pro Ile Asn Lys Lys Glu Leu Asn Arg Gln Lys Lys Leu Leu Thr Leu
 1905 1910 1915 1920
 Gln Ser Asn His Ser Ser Ile Ala Thr Val Gly Gly Ser Lys Ile Ile
 1925 1930 1935
 Glu Ser Lys Trp Leu Lys Asn Lys Ala Ser Thr Ile Ile Asp Trp Leu
 1940 1945 1950
 Glu His Ile Leu Asn Ser Pro Lys Gly Glu Leu Asn Tyr Asp Phe Phe
 1955 1960 1965
 Glu Ala Leu Glu Asn Thr Tyr Pro Asn Met Ile Lys Leu Ile Asp Asn
 1970 1975 1980
 Leu Gly Asn Ala Glu Ile Lys Lys Leu Ile Lys Val Pro Gly Tyr Met
 1985 1990 1995 2000
 Leu Val Ser Lys Lys
 2005

<210> 38

<211> 6018

<212> DNA

<213> human Metapneumo virus

<400> 38

atggatcctc tcaatgaatc cactgttaat gtctatcttc ctgactcata tcttaaagga 60
 gtgatttcct ttagtgagac taatgcaatt gggtcatgtc tcttaaaaag accttaccta 120
 aaaaatgaca aactgcaaa agttgccata gagaatcctg ttatcgagca tgtagactc 180
 aaaaatgcag tcaattctaa gatgaaaata tcagattaca agatagtaga gccagtaaac 240
 atgcaacatg aaattatgaa gaatgtacac agttgtgagc tcacattatt aaaacagttt 300
 ttaacaagga gtaaaaatat tagcactctc aaattaaata tgatatgtga ttggctgcag 360
 ttaaagtcta catcagatga tacctcaatc ctaagtttta tagatgtaga atttatacct 420
 agctgggttaa gcaattggtt tagtaattgg tacaatctca acaagttgat tctggaattc 480
 aggaaagaag aagtaataag aactggttca atcttgtgta gggtcattggg taaattagtt 540
 tttgttgtat catcatatgg atgtatagtc aagagcaaca aaagcaaaag agtgagcttc 600
 ttcacataca tcaactggtt aacatggaaa gatgtgatgt taagtagatt caatgcaaat 660
 ttttgtatat gggtaagcaa cagtctgaat gaaaatcaag aagggtcagg gttgagaagt 720
 aatctgcaag gcatattaac taataagcta tatgaaactg tagattatat gcttagttta 780
 tgttgcaatg aaggtttctc acttgtgaaa gagttcgaag gctttattat gagtgaatt 840

cttaggatta	ctgaacatgc	tcaattcagt	actagattta	gaaatacttt	attaaatgga	900
ttaactgatc	aattaacaaa	attaaaaaat	aaaaacagac	tcagagttca	tggtaccgtg	960
ttagaaaaata	atgattatcc	aatgtacgaa	gttgtaactta	agttattagg	agatactttg	1020
agatgtattta	aattattaat	caataaaaaac	ttagagaatg	ctgctgaatt	atactatata	1080
tttagaatat	tcggtcaccc	aatggtagat	gaaagagatg	caatggatgc	tgtcaaatata	1140
aacaatgaaa	tcacaaaaat	ccttaggtgg	gagagcttga	cagaactaag	aggggcattc	1200
atattaagga	ttatcaaagg	atgtgtagac	aacaacaaaa	gatggcccaa	aattaaaaaac	1260
ttaaaagtgc	ttagtaagag	atggactatg	tacttcaaaag	caaaaagtta	ccccagtcaa	1320
cctgaattaa	gcgaacaaga	tttttttagag	cctgtctgcaa	tacagtttga	acaagagttt	1380
tctgtccctg	aaaaaaccaa	ccttgagatg	gtattaaatg	ataaagctat	atcacctcct	1440
aaaagattaa	tatggtctgt	gtatccaaaa	aattacttac	ctgagaaaat	aaaaaatcga	1500
tatctagaag	agactttcaa	tgcaagtgat	agtctcaaaa	caagaagagt	actagagtac	1560
tatttgaaag	ataataaatt	cgaccaaaaa	gaacttaaaa	gttatgttgt	taaacaagaa	1620
tattttaaag	ataaggatca	tattgtctcg	ctaactggaa	aagaaagaga	attaagtgtg	1680
ggtagaatgt	ttgctatgca	accaggaaaa	cagcgacaaa	tacaaatatt	ggctgaaaaa	1740
ttgttagctg	ataatattgt	accttttttc	ccagaaacct	taacaaagta	tggtgatcta	1800
gatcttcaga	gaataatgga	aatcaaatcg	gaactttctt	ctattaaaaac	tagaagaaat	1860
gatagttata	ataattacat	tgcaagagca	tccatagtaa	cagatttaag	taagtccaac	1920
caagccttta	ggtatgaaac	tacagcgatc	tgtgcggatg	tagcagatga	actacatgga	1980
acacaaagcc	tattctgttg	gttacatctt	atcgcccta	tgacaacaat	gatatgtgcc	2040
tatagacatg	caccaccaga	aacaaaaggt	gaatatgata	tagataagat	agaagagcaa	2100
agtggtttat	atagatatca	tatgggtggt	attgaaggat	ggtgtcaaaa	actctggaca	2160
atggaagcta	tatctctatt	agatgttgtg	ctgttaaaaa	cacgatgtca	aatgacatct	2220
ttattaaacg	gtgacaacca	atcaatagat	gtaagtaaac	cagttaagtt	atctgagggg	2280
ttagatgaag	tgaaagcaga	ttatagcttg	gctgtaaaaa	tgttaaaaga	aataagagat	2340
gcatacagaa	atataggcca	taaacttaaa	gaaggggaaa	catatatatc	aagagatctt	2400
cagtttataa	gtaagggtgat	tcaatctgaa	ggagtaatgc	atcctacccc	tataaaaaag	2460
atcttaagag	tgggaccatg	gataaacaca	atattagatg	acattaaaaac	cagtgcagag	2520
tcaataggga	gtctatgtca	ggaattagaa	tttagggggg	aaagcataat	agttagtctg	2580
atattaagga	atttttggct	gtataattta	tacatgcatg	aatcaaagca	acacccctta	2640
gcaggggaagc	agttattcaa	acaactaaat	aaaacattaa	catcagtgcg	gagatttttt	2700
gaaataaaaa	aggaaaatga	agtagtagat	ctatggatga	acataccaat	gcagtttgga	2760
ggaggagatc	cagtagtctt	ctatagatct	ttctatagaa	ggacccctga	ttttttaact	2820
gaagcaatca	gtcatgtgga	tattctgtta	agaatatcag	ccaacataag	aaatgaagcg	2880
aaaataagtt	tcttcaaagc	cttactgtca	atagaaaaaa	atgaacgtgc	tacactgaca	2940
acactaatga	gagatcctca	agctgttggc	tcagagcgac	aagcaaaaag	aacaagtgat	3000
atcaatagaa	cagcagttac	cagcatctta	agtcctttct	caaatcaact	tttcagcgat	3060
agtgctatac	actacagtag	aaatgaagaa	gaggtcggaa	tcattgctga	caacataaca	3120
cctgtttatc	ctcatggact	gagagttttg	tatgaatcat	taccttttca	taaagctgaa	3180
aaagttgtga	atatgatatc	aggaaacgaa	tccataacca	acttattaca	gagaacatct	3240
gctattaatg	gtgaagatat	tgacagagct	gtatccatga	tgctggagaa	cctaggatta	3300
ttctatagaa	tattgtcagt	agttgttgat	agtatagaaa	ttccaaccaa	atctaattggt	3360
aggtgatata	gttgctcagat	atctagaacc	ctaagggaga	catcatggaa	taatatggaa	3420
atagttggag	taacatcccc	tagcatcact	acatgcatgg	atgtcatata	tgcaactagc	3480
tctcatattg	aagggataat	cattgaaaag	ttcagcactg	acagaaactac	aagaggtcaa	3540
agaggtccaa	agagcccttg	ggtagggctg	agcactcaag	agaaaaaatt	agttcctgtt	3600
tataacagac	aaattctttc	aaaacaacaa	agagaacagc	tagaagcaat	tggaaaaaatg	3660
agatgggtat	ataaagggac	accaggttta	agacgattac	tcaataagat	ttgtcttgga	3720
agttttaggca	ttagttacaa	atgtgtaaaa	cctttattac	ctaggtttat	gagtgtaaat	3780
ttcctacaca	ggttatctgt	cagtagtaga	cctatggaat	tcccagcatc	agttccagct	3840
tatagaacaa	caaattacca	ttttgacact	agtcctatta	atcaagcact	aagtggagaga	3900
tttgggaatg	aagatattaa	tttggctctt	caaaatgcaa	tcagctgtgg	aattagcata	3960
atgagtgtag	tagaacaatt	aactggtagg	agttccaaaac	agttagtttt	aatacctcaa	4020
ttagaagaaa	tagacattat	gccaccacca	gtgtttcaag	ggaaattcaa	ttataagcta	4080
gtagataaga	taacttctga	tcaacatata	ttcagtcacg	acaaaaataga	tatgttaaca	4140
ctgggggaaaa	tgctcatgcc	cactataaaa	ggtcagaaaa	cagatcagtt	cctgaacaag	4200
agagagaatt	atttccatgg	gaataatctt	attgagctct	tgtcagcagc	gttagcatgt	4260
cattgggtgtg	ggatattaac	agagcaatgt	atagaaaaata	atattttcaa	gaaagactgg	4320
ggtgacgggt	tcataatcgga	tcagtctttt	atggacttca	aaatattcct	atgtgtcttt	4380
aaaactaaac	ttttatgtag	ttgggggtcc	caagggaaaa	acattaaaga	tgagatata	4440
gtagatgaat	caatagataa	actgttaagg	attgataata	ctttttggag	aatgttcagc	4500
aaggttatgt	ttgaatcaaa	ggttaagaaa	aggataatgt	tatatgatgt	aaaattttcta	4560

```

tcattatgtag gttatatagg gtttaagaat tggtttatag aacagttgag atcagctgag 4620
ttgcatgagg taccttggat tgtcaatgcc gaaggtgatc tggttgagat caagtcaatt 4680
aaaatctatt tgcaactgat agagcaaagt ttatttttaa gaataactgt tttgaactat 4740
acagatattg caccatgctc cacaagatta atcagaaaga agttgatgtg tgataatgca 4800
ctattaactc cgattccatc cccaatgggt aatttaactc aagttattga tcctacagaa 4860
caattagctt atttccctaa gataacattt gaaaggctaa aaaattatga cactagttca 4920
aattatgcta aaggaaagct aacaaggaat tacatgatac tgttgccatg gcaacatgtt 4980
aatagatata actttgtctt tagttctact ggatgtaaag ttagtctaaa aacatgcatt 5040
ggaaaactta tgaaagatct aaacctaaa gttctgtact ttattggaga aggggcagga 5100
aattggatgg ccagaacagc atgtgaatat cctgacatca aatttgtata cagaagttaa 5160
aaagatgacc ttgatcatca ttatcctttg gaataccaga gagttatagg agaattaagc 5220
aggataatag atagcgggtg agggctttca atggaaacaa cagatgcaac tcaaaaaact 5280
cattgggatt tgatacacag agtaagcaaa gatgctttat taataacttt atgtgatgca 5340
gaatttaagg acagagatga tttttttaag atggtaattc tatggaggaa acatgtatta 5400
tcatgcagaa ttgacctac ttatgggaca gacctctatt tattcgcaa gttatgtct 5460
aaagactgca atgtaaaatt accttttttt gtgagatcag tagccacctt tattatgcaa 5520
ggtagtaaac tgtcaggctc agaattgctac atactcttaa cactaggcca ccacaacaat 5580
ttaccctgcc atggagaaat acaaaattct aagatgaaaa tagcagtgtg taatgatttt 5640
tatgtcgcaa aaaaacttga caataaatct attgaagcca actgtaaatc acttttatca 5700
gggctaagaa taccgataaa taagaaagaa ttaaatagac agagaagggt attaacacta 5760
caaagcaacc attcttctgt agcaacagtt ggaggtagca aggtcataga gtctaaatgg 5820
ttaacaaaca aggcaaacac aataattgat tggttagaac atatttttaa ttctccaaaa 5880
ggtgaattaa attatgattt ttttgaagca ttagaaaata cttaccctaa tatgattaaa 5940
ctaatagata atctagggaa tgcagagata aaaaaactga tcaaagtaac tggatatatg 6000
cttgtaagta aaaaatga

```

<210> 39

<211> 6018

<212> DNA

<213> human Metapneumo virus

<400> 39

```

atggatcctc ttaatgaatc cactgttaat gtctatctcc ctgattcgtc ccttaaagga 60
gtaatttctt ttagtgaaac taatgcaatt ggttcattgc tcttaaaaag accttactta 120
aaaaatgaca acactgcaaa agttgccata gagaatcctg ttattgagca tgtgagactc 180
aaaaatgcag tcaattctaa aatgaaaata tcagattaca aggtagtaga gccagtaaac 240
atgcaacatg aaataatgaa gaattgtcac agttgtgagc tcacactatt gaaacagttt 300
ttaacaagga gtaaaaaacat tagctacttc aaattaaata tgatatgtga ttggctgcaa 360
ttaaagtcta catcagatga tacctcaatc ctaagtttca tagatgtaga atttataact 420
agttgggtaa gcaactgggt tagtaattgg tacaatctca ataagttaat ttgggaattc 480
agaagagagg aagtaataag aaccggttca atcttatgca ggtcattggg taaattagtt 540
tttattgtat catcatacgg atgtatcgtc aagagcaaca aaagcaaaaag agtgagcttc 600
ttcacatata atcaactggt aacatggaaa gatgtgatgt taagtagatt taatgcgaat 660
ttttgtatat gggtaagcaa tagtctgaat gaaaatcagg aagggttagg gttaaagaat 720
aatctacaag gtatgttaac taataaacta tatgaaactg tagattatat gctaagttta 780
tggtgcaatg aaggtttctc acttgtaaaa gagttcgaag gttttattat gagtgaaatc 840
cttaggatta ctgaacatgc tcaattcagt actagattta gaaatacttt attaaatgga 900
ttaacagatc aattaacaaa attaaaaaat aaaaacagac tcagagttca tggtaaccga 960
ttagaaaata atgattatcc aatgtatgaa gttgtactta aattattagg agatactttg 1020
agatgtatca aattattaat caataaaaac tttagagaatg ctgcagaatt atactatata 1080
ttcagaattt ttggtcatcc aatggttagat gaaagagatg caatggatgc tgtcaaatta 1140
aacaatgaaa tcacaaaaat cctaagggtt gagagcttga cagaactaag aggagcattc 1200
atattaagga ttatcaaaag atttgtggac aacaacaaaa ggtggcccaa aattaaaaat 1260
ttaatagtgc ttagcaaaag atggactatg tacttcaaaag ctaaaaatta tcccagtcaa 1320
ctcgaattaa gtgaacaaga ctttctagag ctgtctgcaa tacaatttga acaagattt 1380
tctgttcctg aaaaaaccaa tcttgagatg gtattaaatg acaaaagccat atcacctcct 1440
aaaagattaa tatggtctgt gtatccaaag aattacttac ctgagacgat aaaaaatcga 1500
tatttagaag aaactttcaa tgcgagtgat agtctcaaaa caagaagagt actagagtac 1560
tattttaaag acaataaatt tgatcaaaag gaacttaaaa gttatgtagt tagacaagaa 1620
tattttaaag ataaggagca cattgtctca ttaactggaa aagaaagaga attaatgtta 1680

```

```

ggtagaatgt ttgctatgca accaggaaaa cagcgacaaa tacaaaattt ggcagaaaaa 1740
ttgttagctg ataacattgt acctttcttc ccggaacact taacaaagta tgggtgatcta 1800
gatcttcaga gaataatgga aatcaaatca gaactttctt ctatcaaac cagaagaaat 1860
gacagttata ataattacat tgcaagagca tccatagtaa cagatttgag caagttcaac 1920
caagccttta gatatgaaac tacagcgatc tgtgcggatg tagcagacga attacatgga 1980
acacaaagct tattctgttg gttacatctt atcggtccta tgactacaat gatatgtgcc 2040
tatagacatg caccaccaga aacaaaaggt gaatatgata tagataagat agaagagcaa 2100
agtggctctat atagatatca catgggcggg attgaaggat ggtgtcaaaa actctggaca 2160
atggaagcta tatctttatt ggatgttgta tctgtaaaga caggtgtgca aatgacatct 2220
ttattaaacg gtgataacca atcaatagat gtaagtaaac cagtcaagtt atctgaaggt 2280
ttagatgaag tgaaggcaga ttatcgctta gcaataaaaa tgctaaaaaga aataagagat 2340
gcatacagaa atataggcca taaacttaaa gaaggggaaa catatatatc aagggatctt 2400
caatttataa gcaagggtgat tcaatctgaa ggagtgtatg atcctacccc tataaaaaag 2460
gtcttgagag taggaccatg gataaacaca atattagatg acattaaaaac tagtgctgag 2520
tcaataggga gtctatgtca agaattagaa tttaggggag aaagcataat agttagtctg 2580
atattaagaa acttctgggt gtataactta tacatgcatg aatcaaagca acatcctttg 2640
gcagggaaac agttattcaa acaactaaat catcagtgca gagatttttt 2700
gaaattaaaa aggaaaaatga ggtagtagat ctatggatga acataccaat gcaatttgga 2760
ggaggagatc cagtagtctt ctatagatct ttctatagaa ggaccctga ttttttaact 2820
gaggcaatca gccatgtaga tattctgtta aaaatatcag ctaacataaa aaatgaaacg 2880
aaagtaagtt tcttcaaagc cttactatca atagaaaaaa atgaacgtgc tacactgaca 2940
acgctaataga gagatcctca agctgttgga tcagaacgac aagcaaaagt aacaagtgc 3000
atcaatagaa cagcagttac cagtatctta agtctttccc caaatcaact ttcagtgat 3060
agtgtctata actatagcag gaatgaagaa gaagtgggaa tcattgcaga aaacataaca 3120
cctgtttatc ctcatgggct gagagtatta tatgaatcat tgccctttca caaagctgaa 3180
aaagttgtaa acatgatatc agggacaaaa tctataacca acttattaca gagaacatcc 3240
gctattaatg gtgaagatat tgacagggct gtatctatga tgttgagaa tctaggatta 3300
ttatctagaa tattgtcagt agttgttgat agtatagaaa ttccaatcaa atctaagtgt 3360
aggctgatat gttgtcaaat ctctaggact ttaagagaga catcatggaa taatatggaa 3420
atagtggag taacatctcc tagcatcact atagtatgg atgtcatata tgcaactagt 3480
tctcatttga aggggataat tatagaaaag ttcagcactg acagaactac aaggggtcaa 3540
agaggtccaa aaagcccttg ggtagggtcg agtactcaag agaaaaaatt agtacctgtt 3600
tataacagac aaattctttc aaaacaacaa agagaacagc tagaagcaat tggaaaaatg 3660
agatgggtgt ataaagggac accaggcttg cgacgattac tcaacaagat ctgtcttggg 3720
agtttaggca ttagttacaa atgtgtaaaa cctttattac ctaggtttat gatgttaa 3780
ttcttataca ggttatctgt cagtagtaga cctatggaa tcccagcatc agttccagct 3840
tatagaacaa caaattacca tttcgacact agtcctatta atcaagcact aagttagata 3900
tttggaatg aagatattaa cttgggtctt caaaatgcga tcagctgtgg aattagcata 3960
atgagtgtag tagaacaatt aacaggtaga agcccaaaac agtttagttt aatacccaa 4020
ttagaagaaa tagacattat gccaccacca gtgtttcaag ggaaattcaa ttataaatta 4080
gtagataaga taacttctga tcaacatate ttcagtcggg acaaaaataga tatgttaaca 4140
ctagggaaaa tgctcatgcc tactataaaa ggtcagaaaa cagatcagtt cttaaataag 4200
agagagaatt atttccatgg gaacaatctt attgagctt tatcagcagc attagcatgt 4260
cattgggtgt ggatattaac agaacaatgc atagaaaata atattttcaa gaaggactgg 4320
ggtagcgggt ttatatcaga tcatgctttt atggacttca aaatatctct atgtgtcttt 4380
aaaactaaac ttttatgtag ttggggatcc caagggaaaa acattaaaga tgaagatata 4440
gtagatgaat caatagataa attgttaagg attgacaata ctttttgag aatgttcagc 4500
aaagttatgt ttgaaccaa agttaagaaa aggataatgt tatatgatgt aaaattccta 4560
tcactagtag gctacatagg gttaagaac tggtttatag agcagttgag atcagctgaa 4620
ttgcatgaaa taccttggat tgtcaatgcc gaaggtgatt tggttgagat caagtcaatt 4680
aaaatctatt tgcaactgat agaacaaagc ttatttttaa gaataactgt tttgaactat 4740
acagatatgg cacatgctct cacacgatta atcagaaaga agttaatgtg tgataatgca 4800
ctgttaaccc caatttcate cccaatggtt aacttaactc aagttattga tcccacaaca 4860
caattagatt acttcccaa gataacattc gaaaggctaa aaaattatga cacaagttca 4920
aattatgcta agggaaagct aacaagaaat tacatgatac tattgccatg gcagcatgtt 4980
aatagatata actttgtctt tagttctact ggatgtaaag ttagtctgaa aacatgtatt 5040
ggaaaactta tgaaagactt aaatcctaaa gttttgtact ttattggaga aggagcagga 5100
aattggatgg ccagaacagc atgtgaatat cctgatatta aatttgata tagaagtctg 5160
aaagatgacc ttgatcatca ttatctctg gaataccaga gagtgatagg tgaattaaagc 5220
agaatcatag atagtgggtg aggacttttc atggaaacaa cagacgcaac caaaaaact 5280
cattgggatt tgatacacag ggtaagcaaa ggtgctttat taataacttt atgtgatgca 5340
gaatttaagg acagagatga tttttttaag atggtaattc tatggagaaa acatgtatta 5400

```

```

tcatgcagaa tttgcactac ttatgggacg gacctctatt tattegcaaa gtatcatgct 5460
aaagactgca atgtaaaatt accttttttt gtgagatcag ttgctacttt cattatgcag 5520
ggtagttaagc tgcaggttc agaatgctac atactcttaa cactaggcca ccacaacagt 5580
ttaccttgcc atggagaaat acaaaattct aagatgaaaa tagcagtgtg taatgatttt 5640
tatgtctgcaa aaaaactcga caataaatca attgaagcta attgtaaatc acttttgtca 5700
gggctaagaa tacctataaa taagaaggaa ctagatagac agagaagatt attaactacta 5760
caaagcaatc attcttctgt ggcaacagtt ggcggtagca agatcataga gtctaaatgg 5820
ttaacaaaca aagcaagtac aataattgat tgggttagaac atatttttaa ttctccaaag 5880
ggcgaaattaa attatgattt ttttgaagca ttggagaaca cttaccctaa tatgattaaa 5940
ctaatagata acttagggaa tgcagagatt aaaaaactta tcaaagtaac aggatacatg 6000
cttgtaagta aaaaatga
6018

```

<210> 40

<211> 6018

<212> DNA

<213> human Metapneumo virus

<400> 40

```

atggatccct tttgtgaatc tactgttaat gtttatctcc ctgattcata tctcaaagga 60
gtaatatctt ttagtgaaac caatgcaatt ggatcatgtc ttttgaaaag accctatcta 120
aaaaatgaca aactgccaa agttgctgta gaaaaccctg ttgttgaaca tgtgaggctt 180
agaaatgcag tcatgacca aatgaagata tcagattata aagtgggtga accagttaat 240
atgcagcatg aaataatgaa aatatatcat agttgtgagc ttacattatt aaaacaattc 300
ttaacgagaa gcaaaaacat tagctctcta aaattaaata tgatatgtga ttggttacag 360
ttaaaatcca cttcagataa cacatcaatt ctcaatttta tagatgtgga gttcataccc 420
gtttgggttaa gcaattgggt cagtaactgg tataatctca ataaattaat cttagagttt 480
agaagagaag aagtaataag aactgggtca attttatgta gatcactagg caagttagtt 540
tttattgtat catcttatgg atgtgtagta aaaagcaaca aaagtaaaag agtgagcttt 600
ttcacctata accaactggt aacatggaaa gatgtgatgt taagtagatt caatgcaaac 660
ttttgtatat gggtaagtaa caacctgaac aaaaatcaag aaggactagg acttagaagc 720
aatctgcaag gtatgttaac caataaatta tatgaaactg ttgattacat gctaagccta 780
tgctgcaatg aaggattctc tctgggtgaa gagtttgaag gatttattat gagtgaatt 840
ctaaaaatta ctgagcatgc tcagttcagt actaggttta ggaatacttt attgaatggg 900
ttaactgaac aattatcagt gttgaaagct aagaacagat ctagagttct tggaactata 960
ttagaataca acaattaccc tatgtacgaa gtagtactta aattattagg ggacaccttg 1020
aaaagcataa agttattaat taacaagaat ttagaaaatg ctgcagaatt atattatata 1080
ttcagaattt ttggacaccc tatggttagat gagagggaag caatggatgc tggttaatta 1140
aacaatgaga ttacaaaaat tcttaaatga gagagtttaa cagaactaag aggagcattt 1200
atactaagaa ttataaaaagg gttttagtag aataataaaa gatggcctaa aattaagaat 1260
ttaaaagtgc tcagcaaaag atgggctatg tatttcaaag ctaaaagtta ccctagccaa 1320
cttgagctaa gtgtacaaga ttttttagaa cttgctgcag tacaatttga gcaggaattc 1380
tctgtacctg aaaaaaccaa ccttgagatg gtattaaatg ataaagcaat atcacctca 1440
aaaaagctaa tatgggtctg atatccaaaa aactacctgc ctgaaactat aaaaaatcaa 1500
tatttagaag aggccttcaa tgcaagtgc agccaaagaa caaggagagt cttagaattt 1560
tacttaaaag attgtaaatt tgatcaaaaa gaacttaaac gttatgtaat taaacaagag 1620
tatctgaatg acaaagacca cattgtctcg ttaactggga aggaaagaga attaatgtga 1680
ggtaggatgt ttgcaatgca accaggaaaa caaagacaga tacagatatt agctgagaaa 1740
cttctagctg ataattattg accttttttc ccagaaactt taacaaagta tgggtgacta 1800
gatctccaaa gaattatgga aataaaaatca gaactttctt ccattaaaac tagaaagaat 1860
gatagctaca acaattatat tgcaagggcc tctatagtaa cagacttaag taagttcaat 1920
caggccttta gatatgaaac cacagctata tgtgcagatg tagctgatga gttacatggg 1980
acacaaagct tattctgttg gttacatctt attgttccca tgactacaat gatatgtgca 2040
tacagacatg caccaccaga aacaaaaggg gaatatgata tagacaaaat acaagagcaa 2100
agcggattat acagatatca tatgggaggg attgaagggt ggtgccagaa gttatggaca 2160
atggaagcaa tatccttggt agatgtagta tctgtgaaga ctgctgtca gatgacctct 2220
ctattaaacg gagacaatca gtcaatagat gttagtaaag cagtaaaatt gtctgaagg 2280
atagatgaag taaaagcaga ctatagctta gcaattagaa tgcttaagaa aataagagat 2340
gcttataaaa acattgggtc taaactcaaa gaagggtgaa catatatatc aagggatctc 2400
caatttataa gtaagggtgat tcaatctgaa ggagtcatgc atcctacccc tataaaaaag 2460
atattaagag taggtccttg gataaatata atactagatg atattaaaac cagtgcagaa 2520

```

tcaataggaa	gtctatgtca	agaactagaa	ttcagagggg	agagtatact	agttagcttg	2580
atattaagga	atctctggct	gtataacttg	tacatgtatg	agtcaaaaaca	gcacccatta	2640
gctgggaagc	aactgttcaa	gcaattgaac	aaaacattaa	catctgtgca	gagatttttt	2700
gaactgaaga	aagaaaatga	tgtggttgac	ctatggatga	atataccaat	gcagtttgga	2760
gggggagatc	cagtagtttt	ttacagatct	ttttacagaa	ggactcccga	tttcctaact	2820
gaagcaatca	gccatgtgga	tttactgtta	aaagtgtcaa	acaatatcaa	agatgagact	2880
aagatacgat	ttttcaaagc	cttattatct	atagaaaaga	atgaacgtgc	tacattaaca	2940
acactaatga	gagaccctca	ggcagtagga	tcagaacgac	aagctaaggt	aacaagtgat	3000
ataaatagaa	cagcagttac	cagcatactg	agtctatctc	cgaatcagct	cttctgtgat	3060
agtgctatac	attatagtag	aaatgaggaa	gaagttggga	tcattgcaga	caacataaca	3120
cctgtctatc	ctcatgggct	gagagtgtct	tatgaatcac	taccttttca	taaggctgaa	3180
aaggttggtc	atatgatata	aggcacaag	tctataacta	atctattaca	gagaacatct	3240
gctatcaatg	gtgaagatat	tgatagagca	gtgtctatga	tgtagagaa	cttaggggtg	3300
ttatctagaa	tattgtcagt	aataattaat	agtatagaaa	taccaatcaa	gtccaatggc	3360
agattgatata	gctgtcaaat	ttccaagacc	ttgagagaaa	aatcatggaa	caatatggaa	3420
atagtaggag	tgacatctcc	tagtattgtg	acatgtatgg	atgttggtga	tgcaactagt	3480
tctcatTTaa	aaggaataat	tattgaaaaa	ttcagtagct	acaagaccac	aagaggtcag	3540
aggggaccaa	aaagcccctg	ggtaggatca	agcactcaag	agaaaaaatt	gggtccctgtt	3600
tataatagac	aaattctttc	aaaacaacaa	aaagagcaac	tggaagcaat	agggaaaatg	3660
aggtgggtgt	acaaaggaac	tccagggtca	agaagattgc	tcaacaagat	ttgcatagga	3720
agcttaggta	ttagctataa	atgtgtgaaa	cctttattac	caagattcat	gagtgtaaac	3780
ttcttacata	ggttatctgt	tagtagtaga	cccatggaat	tcccagcttc	tggtccagct	3840
tacaggacaa	caaattacca	ttttgacact	agtcacatca	accaagcatt	aagttagagg	3900
ttcgggaacg	aagacattaa	tttagtgttc	caaaatgcaa	tcagctgctg	aattagtata	3960
atgagtgttg	tagaacagtt	aactggtaga	agcccaaaac	aattagtcct	aatccctcaa	4020
ttagaagaga	tagatattat	gcctcctcct	gtatttcaag	gaaaattcaa	ttataaacta	4080
gttgataaga	taacctccga	tcaacacatc	ttcagtcctg	acaaaataga	catattaaca	4140
ctaggggaaga	tgcttatgcc	taccataaaa	gggtcaaaaaa	ctgatcagtt	cttaaaataag	4200
agagaaaact	atTTTcatgg	aaataattta	attgaatctt	tatctgcagc	acttgcagtc	4260
cactgggtgtg	ggatattaac	agaacagtgc	atagaaaaca	atatctttag	gaaagattgg	4320
ggtagtgggt	tcattctcaga	tcattgccttc	atggatttca	aggtatttct	atgtgtattt	4380
aaaaccaaac	ttttatgtag	ttggggatct	caaggaaaga	atgtaaaaga	tgaagatata	4440
atagatgaat	ccattgacaa	attattaaga	attgacaaca	ccttttgagg	aatgttcagc	4500
aaagtcatgt	ttgaatcaaa	agtcaaaaaa	agaataatgt	tatatgatgt	gaaattccta	4560
tcattagtag	gttatatagg	atttaaaaaa	tggtttatag	aacagtttaag	agtggtagaa	4620
ttgcatgagg	taccttggtg	tgtcaatgct	gaaggagagt	tagttgaaat	taaatcaatc	4680
aaaatttatc	tcaggttaat	tgacaaaagt	ctatccttga	gaataactgt	attgaattat	4740
acagacatgg	cacatgctct	tacacgatta	attaggaaaa	aattgatgtg	tgataatgca	4800
ctctttaatc	caagttcatc	accaatgttt	aatctaactc	aggttattga	tcccacaaca	4860
caactagact	atTTTcttag	gataatattt	gagagggtta	aaagttatga	taccagttca	4920
gactacaaca	aagggaagtt	aacaaggaat	tacatgacat	tattaccatg	gcaacacgta	4980
aacaggtaca	atTTTgtctt	tagttctaca	ggttgtaaaag	tcagtttgaa	gacatgcac	5040
gggaaattga	taaaggattt	aaatcctaaa	gttctttact	ttattggaga	aggagcaggt	5100
aactggatgg	caagaacagc	atgtgaatat	cctgatataa	aatttgtata	taggagttta	5160
aaggatgacc	ttgatcacca	ttaccattta	gaatatcaaa	gggtaatagg	tgatctaaat	5220
aggggtgatag	atagtgtgga	aggattatca	atggaaacca	cagatgcaac	tcaaaaaact	5280
cattgggact	tgatacacag	aataagtaaa	gatgctttat	tgataacatt	gtgtgatgca	5340
gaattcaaaa	acagagatga	tttctttaag	atggtaatcc	tttgagaaaa	acatgtatta	5400
tcttgtagaa	tctgtacagc	ttatggaaca	gatctttact	tatttgcaaa	gtatcatgcg	5460
gtggactgca	atataaaatt	accatttttt	gtaagatctg	tagctacttt	tattatgcaa	5520
ggaagcaaat	tatcagggtc	agaatgttac	atacttttaa	cattaggtca	tcacaataat	5580
ctaccctgtc	atggagaaat	acaaaattcc	aaaaatgagaa	tagcagtggtg	taatgatttc	5640
tatgcctcaa	agaaactgga	caacaaatca	attgaagcaa	actgcaaatc	tcttctatca	5700
ggatttgagaa	tacctataaa	caaaaaggag	ttaaaatagac	aaaagaaatt	gttaacacta	5760
caaagtaacc	attcttctat	agcaacagtt	ggcggcagta	agattataga	atccaaatgg	5820
ttaaagaata	aagcaagtac	aataattgat	tggttagagc	atattttgaa	ttctccaaaa	5880
gggtgaattaa	actatgattt	ctttgaagca	ttagagaaca	cataccccaa	tatgatcaag	5940
cttatagata	atTTTgggaaa	tgcagaaata	aagaaactaa	tcaaggtcac	tgggtatatg	6000
cttgtgagta	agaagtaa					6018

<210> 41
 <211> 6018
 <212> DNA
 <213> human Metapneumo virus

<400> 41
 atggatccat tttgtgaatc cactgtcaat gtttatcttc ctgactcata tctcaaagga 60
 gtaatatctt tcagtgaaac caatgcaatt ggctcatgcc ttttgaaaag accctatcta 120
 aaaaaagata acactgctaa agttgctgta gaaaaccctg ttgttgaaca tgtcaggctt 180
 agaaatgcag tcatgaccaa aatgaagata tcagattata aagtgggttga accaattaat 240
 atgcagcatg aaataatgaa aaataatacac agttgtgagc tcacattatt aaaacaattc 300
 ttaacaagaa gtaaaaacat tagctctcta aaattaagta tgatatgtga ttgggttacag 360
 ttaaaatcca cctcagataa cacatcaatt cttaatttta tagatgtgga gtttataacct 420
 gtttggggtga gcaattgggt tagtaactgg tataatctca ataaattaat cttagagttt 480
 agaagagagg aagtaataag aactgggttca attttatgta gatcactagg caagttagtt 540
 ttcattgtat catcttatgg gtgtgtagta aaaagcaaca aaagtaaaag agtaagtttt 600
 ttcacatata accaactggt aacatggaaa gatgtgatgt taagttaggt caatgcaaac 660
 ttttgtatat gggtaagtaa caacctgaac aaaaatcaag aaggactagg atttagaagt 720
 aatctgcaag gtatgttaac caataaatta tatgaaactg ttgattatat gtttaagtcta 780
 tgtagtaatg aagggttctc actagtgaag gagttcgaag gctttattat gagtgaatt 840
 cttaaaatta ctgagcatgc tcaattcagt actaggttta ggaatacttt attaaatggg 900
 ttgactgaac aattatcaat gttgaaagct aaaaacagat ctgagttct tggcactata 960
 tttagaaaaca atgattaccc catgtatgaa gtagtactta aattattagg ggacactttg 1020
 aaaagtataa aattattaat taacaagaat ttagaaaatg ctgcagaatt atattatata 1080
 ttcagaattt ttggacacc tatggttagat gagagggaag caatggatgc tgttaaatta 1140
 aataatgaga ttacaaaaat tcttaactg gagagcttaa cagaactaag aggagcattt 1200
 atactaagaa ttataaaagg gttttagat aataataaaa gatggcctaa aattaagaat 1260
 ttaaaagtgc tcagtaaaag atgggttatg tatttcaaag ccaaaagtta cctagccaa 1320
 cttgagctaa gtgtacaaga ttttttagaa cttgtctcag tacaattcga acaggaattt 1380
 tctgtccctg aaaaaaccaa ccttgagatg gtattaaatg ataaagcaat atctcctcca 1440
 aaaaagttaa tatggtcggg atatccaaaa aattatctac ctgaaattat aaaaaatcaa 1500
 tattttagaag aggtcttcaa tgcaagtgc agtcaaagaa cgaggagagt cttagaattt 1560
 tacttaaaag attgcaaatt tgatcaaaaa gaccttaaac gttatgtact taaacaagag 1620
 tatctaaatg acaaagacca cattgtctca ttaactggga aggaaagaga attaatgtta 1680
 ggcaaggatgt ttgcaatgca accaggcaaa caaagacaaa tacagatact agctgagaaa 1740
 cttctagctg ataatatgt accctttttc ccagaaactt taacaaagta tggtagcttg 1800
 gatctccaaa gaattatgga aatgaaatca gaactttctt ccattaaaac taggaagaat 1860
 gatagttaca acaattatat tgcaagagcc tccatagtaa cagacctaa gtaattcaat 1920
 caagccttta gatatgaaac cacagctatc tgtgcagatg tagcagatga gttacatgg 1980
 acgcaaagct tattttgttg gttacatctt attgttccca tgaccacaat gattatgtga 2040
 tacagacatg caccaccaga aacaaagggg gagtatgaca tagacaaaat agaagagcaa 2100
 agtgggctat acagatatca tatgggaggg attgaagggg ggtgtcagaa gttatggaca 2160
 atggaagcga tatccttggt agatgtagta tctgttaaga ctcgttgtca gatgacctc 2220
 ctattaaacg gagacaatca atcaatagat gtcagtaaac cagtaaaatt gtctgaagg 2280
 atagatgaag taaaagcaga ttatagctta gcaattaaaa tgcttaaaaga gataagagat 2340
 gcctataaaa acattggcca taaactcaaa gaaggtgaaa catatatatc aagagatctc 2400
 caatttataa gtaagggtgat tcaatctgag ggggtcatgc atoctacccc cataaaaaag 2460
 atattaaggg taggtccctg gataaataca atactagatg acattaaaac cagtgcagaa 2520
 tcaataggga gtctgtgtca agaactagag ttcagaggag aaagtatgct agttagcttg 2580
 atattaagga atttctgggt gtataactta tacatgcatg agtcaaaaaca gcatccgtta 2640
 gctggaaaac aactgtttta gcaattgaac aaaacactaa catctgtgca aagatttttt 2700
 gaggtgaaga aagaaaatga tgtggttgac ctatggatga atataccaat gcagtttgg 2760
 gggggagacc cagtagtttt ttacagatct ttttaagaaa ggactcctga tttcctgact 2820
 gaagcaatca gccatgtgga tttactgtta aaagtctcga acaatattaa aaatgagact 2880
 aagatacgat tctttaaaag cttattatct atagaaaaga atgaacgtgc aacattaaca 2940
 acactaatga gagaccccca ggcggttaga tccgaaagac aagctaaggt aacaagtgat 3000
 ataaatagaa cagcagttac tagcatactg agtctatctc cgaatcagct cttttgtgat 3060
 agtgcatac actatagcag aaatgaagaa gaagtcggga tcattgcaga caacataaca 3120
 cctgtttatc ctcacggatt gagagtgctc tatgtaacac taccttttca taaggctgaa 3180
 aaggttgtca atatgatatc aggtacaaag tctataacta acctattgca gagaacatct 3240
 gctatcaatg gtgaagatat tgatagagca gtgtctatga tgtagagaa cttagggttg 3300
 ttatctagga tattgtcagt aataattaat agtatagaaa taccaattaa gtccaatggc 3360

```

agattgatat gctgtcaaat ttctaagact ttgagagaaa aatcatggaa caatatggaa 3420
atagtaggag tgacatctcc aagtattgta acatgtatgg atgttgtgta tgcaactagt 3480
tctcatthaa aaggaataat tattgaaaaa ttcagtactg acaagaccac aagagggtcag 3540
aggggaccaa aaagccccctg ggtaggatca agcactcaag agaaaaaatt agttcctggt 3600
tataatagac aaattctttc aaaacaacaa aaggagcaac tggaagcaat agggaaaaatg 3660
aggtgggtgt ataaaggaac tccagggcta agaagattgc tcaataagat ttgcatagga 3720
agtttaggta ttagctataa atgtgtaaaa cctctattac caagattcat gagtgtaaac 3780
ttcttacata ggttatctgt tagtagcaga cccatggaaat tcccagcttc tgttccagct 3840
tataggacaa caaattacca ctttgacact agtccaatca accaagcatt aagtgtgagg 3900
ttcgggaacg aagacattaa tctagtgttc caaaatgcaa tcagctgcgg aattagtata 3960
atgagtgttg tagaacagtt aactggtaga agcccaaaac aattagtctt aatcccccaa 4020
ttagaagaga tagatattat gcctcctcct gtattttcaag gaaaattcaa ttataaacta 4080
gttgataaaa taacctctga tcaacacatc ttcagtcctg acaaaataga catattaaca 4140
ctaggggaaga tgcttatgcc tactataaaa ggtcaaaaaa ctgatcagtt cttaaataag 4200
agagaaaact atttccatgg aaataattta attgaaatctt tatctgcagc acttgcagtc 4260
cactgggtgt gaatattaac agaacagtgt gtagaaaaa atactctttag gaaagactgg 4320
ggtagatggg tcataacaga tcatgccttc atggatttca agatatttct atgtgtattt 4380
aaaaccaaac ttttatgtag ttggggatcc caagggaaaa atgtaaaaga tgaagatata 4440
atagatgaat ccattgacaa attattaaga attgacaaca ctttttggag aatgttcagc 4500
aaagtcatgt ttgaatcaaa ggtcaaaaaa agaataatgt tatatgatgt aaaattccta 4560
tcattagtag gttatatagg atttaaaaaa tggtttatag agcagttaag agtagtagaa 4620
ttgcatgaag tgccctggat tgtcaatgct gaaggggagc tagttgaaat taaaccaatc 4680
aaaatttatt tgcagttaat agaacaaagt ctatctttaa gaataactgt tttgaattat 4740
acagacatgg cacatgctct tacacgatta attaggaaga aattgatgtg tgataatgca 4800
ctcttcaatc caagtccatc accaatgttt agtctaactc aagttatcga tcctacaaca 4860
cagctagact attttcctaa ggtgatattt gaaaggttaa aaagttatga taccagttca 4920
gactacaaca aaggggaagt aacaagaaat tacatgacat tattaccatg gcagcacgta 4980
aacagggtata attttgtctt tagttcaaca ggatgtaaaa tcagcttgaa gacatgcac 5040
gggaaattga taaaggactt aaaccctaag gttctttact ttattggaga aggagcaggt 5100
aactggatgg caagaacagc atgtgagtat cctgacataa aatttgtata taggagttaa 5160
aaggatgata ttgatcatca ttaccatta gaatatcaaa gggtaatagg tgatttaaat 5220
agggtaatag atggtggtga aggactatca atggagacca cagatgcaac tcaaaagact 5280
cattgggact taatacacag aataagtaaa gatgctttat tgataacatt gtgtgatgca 5340
gaattcaaaa acagagatga tttcttttaa atggtaattc tttggagaaa acatgtatta 5400
tcagttagaa tctgtacagc ttatggaaca gatctttact tatttgcaa gtatcatgcy 5460
acggactgca atataaaatt accatttttt gtaaggtctg tagctacttt tattatgcaa 5520
ggaagcaaat tgtcaggatc agaattgttac atacttttaa cattaggtca tcacaataat 5580
ctgccatgcc atggagaaat acaaaattcc aaaatgagaa tagcagtggtg taatgatattc 5640
catgcctcaa aaaaactaga caacaaatca attgaagcta actgtaaatc tcttctatca 5700
ggattaagaa taccaataaa caaaaaagag ttaaataagac aaaagaaact gttaacacta 5760
caaagcaatc attcttccat agcaacagtt ggcggcagta agattataga atccaaatgg 5820
ttaagaata aagcaagtac aataattgat tggtagagc atactctgaa ttctccaaaa 5880
ggtgaattaa actatgattt ctttgaagca ttagagaaca catacccaa tatgatcaag 5940
cttatagata acctgggaaa tgcagagata aaaaaactaa tcaaagttcc tgggtatatg 6000
cttgtagta agaagtaa 6018

```

<210> 42

<211> 187

<212> PRT

<213> human Metapneumo virus

<400> 42

```

Met Ser Arg Lys Ala Pro Cys Lys Tyr Glu Val Arg Gly Lys Cys Asn
 1             5             10             15
Arg Gly Ser Glu Cys Lys Phe Asn His Asn Tyr Trp Ser Trp Pro Asp
      20             25             30
Arg Tyr Leu Leu Ile Arg Ser Asn Tyr Leu Leu Asn Gln Leu Leu Arg
      35             40             45
Asn Thr Asp Arg Ala Asp Gly Leu Ser Ile Ile Ser Gly Ala Gly Arg
      50             55             60

```

Glu Asp Arg Thr Gln Asp Phe Val Leu Gly Ser Thr Asn Val Val Gln
 65 70 75 80
 Gly Tyr Ile Asp Asp Asn Gln Ser Ile Thr Lys Ala Ala Ala Cys Tyr
 85 90 95
 Ser Leu His Asn Ile Ile Lys Gln Leu Gln Glu Val Glu Val Arg Gln
 100 105 110
 Ala Arg Asp Asn Lys Leu Ser Asp Ser Lys His Val Ala Leu His Asn
 115 120 125
 Leu Val Leu Ser Tyr Met Glu Met Ser Lys Thr Pro Ala Ser Leu Ile
 130 135 140
 Asn Asn Leu Lys Arg Leu Pro Arg Glu Lys Leu Lys Lys Leu Ala Lys
 145 150 155 160
 Leu Ile Ile Asp Leu Ser Ala Gly Ala Glu Asn Asp Ser Ser Tyr Ala
 165 170 175
 Leu Gln Asp Ser Glu Ser Thr Asn Gln Val Gln
 180 185

<210> 43

<211> 187

<212> PRT

<213> human Metapneumo virus

<400> 43

Met Ser Arg Lys Ala Pro Cys Lys Tyr Glu Val Arg Gly Lys Cys Asn
 1 5 10 15
 Arg Gly Ser Glu Cys Lys Phe Asn His Asn Tyr Trp Ser Trp Pro Asp
 20 25 30
 Arg Tyr Leu Leu Ile Arg Ser Asn Tyr Leu Leu Asn Gln Leu Leu Arg
 35 40 45
 Asn Thr Asp Arg Ala Asp Gly Leu Ser Ile Ile Ser Gly Ala Gly Arg
 50 55 60
 Glu Asp Arg Thr Gln Asp Phe Val Leu Gly Ser Thr Asn Val Val Gln
 65 70 75 80
 Gly Tyr Ile Asp Asp Asn Gln Ser Ile Thr Lys Ala Ala Ala Cys Tyr
 85 90 95
 Ser Leu His Asn Ile Ile Lys Gln Leu Gln Glu Val Glu Val Arg Gln
 100 105 110
 Ala Arg Asp Ser Lys Leu Ser Asp Ser Lys His Val Ala Leu His Asn
 115 120 125
 Leu Ile Leu Ser Tyr Met Glu Met Ser Lys Thr Pro Ala Ser Leu Ile
 130 135 140
 Asn Asn Leu Lys Arg Leu Pro Arg Glu Lys Leu Lys Lys Leu Ala Lys
 145 150 155 160
 Leu Ile Ile Asp Leu Ser Ala Gly Ala Asp Asn Asp Ser Ser Tyr Ala
 165 170 175
 Leu Gln Asp Ser Glu Ser Thr Asn Gln Val Gln
 180 185

<210> 44

<211> 187

<212> PRT

<213> human Metapneumo virus

<400> 44

Met Ser Arg Lys Ala Pro Cys Lys Tyr Glu Val Arg Gly Lys Cys Asn
 1 5 10 15
 Arg Gly Ser Asp Cys Lys Phe Asn His Asn Tyr Trp Ser Trp Pro Asp
 20 25 30
 Arg Tyr Leu Leu Leu Arg Ser Asn Tyr Leu Leu Asn Gln Leu Leu Arg
 35 40 45

Asn Thr Asp Lys Ala Asp Gly Leu Ser Ile Ile Ser Gly Ala Gly Arg
 50 55 60
 Glu Asp Arg Thr Gln Asp Phe Val Leu Gly Ser Thr Asn Val Val Gln
 65 70 75 80
 Gly Tyr Ile Asp Asp Asn Gln Gly Ile Thr Lys Ala Ala Ala Cys Tyr
 85 90 95
 Ser Leu His Asn Ile Ile Lys Gln Leu Gln Glu Thr Glu Val Arg Gln
 100 105 110
 Ala Arg Asp Asn Lys Leu Ser Asp Ser Lys His Val Ala Leu His Asn
 115 120 125
 Leu Ile Leu Ser Tyr Met Glu Met Ser Lys Thr Pro Ala Ser Leu Ile
 130 135 140
 Asn Asn Leu Lys Lys Leu Pro Arg Glu Lys Leu Lys Lys Leu Ala Arg
 145 150 155 160
 Leu Ile Ile Asp Leu Ser Ala Gly Thr Asp Asn Asp Ser Ser Tyr Ala
 165 170 175
 Leu Gln Asp Ser Glu Ser Thr Asn Gln Val Gln
 180 185

<210> 45
 <211> 187
 <212> PRT
 <213> human Metapneumo virus

<400> 45
 Met Ser Arg Lys Ala Pro Cys Lys Tyr Glu Val Arg Gly Lys Cys Asn
 1 5 10 15
 Arg Gly Ser Glu Cys Lys Phe Asn His Asn Tyr Trp Ser Trp Pro Asp
 20 25 30
 Arg Tyr Leu Leu Leu Arg Ser Asn Tyr Leu Leu Asn Gln Leu Leu Arg
 35 40 45
 Asn Thr Asp Lys Ala Asp Gly Leu Ser Ile Ile Ser Gly Ala Gly Arg
 50 55 60
 Glu Asp Arg Thr Gln Asp Phe Val Leu Gly Ser Thr Asn Val Val Gln
 65 70 75 80
 Gly Tyr Ile Asp Asn Asn Gln Gly Ile Thr Lys Ala Ala Ala Cys Tyr
 85 90 95
 Ser Leu His Asn Ile Ile Lys Gln Leu Gln Glu Ile Glu Val Arg Gln
 100 105 110
 Ala Arg Asp Asn Lys Leu Ser Asp Ser Lys His Val Ala Leu His Asn
 115 120 125
 Leu Ile Leu Ser Tyr Met Glu Met Ser Lys Thr Pro Ala Ser Leu Ile
 130 135 140
 Asn Asn Leu Lys Lys Leu Pro Arg Glu Lys Leu Lys Lys Leu Ala Lys
 145 150 155 160
 Leu Ile Ile Asp Leu Ser Ala Gly Thr Asp Asn Asp Ser Ser Tyr Ala
 165 170 175
 Leu Gln Asp Ser Glu Ser Thr Asn Gln Val Gln
 180 185

<210> 46
 <211> 564
 <212> DNA
 <213> human Metapneumo virus

<400> 46
 atgtctcgca aggctccgtg caaatatgaa gtgcggggca aatgcaatag aggaagtgag 60
 tgcaagtta accacaatta ctggagttgg ccagatagat acttattaat aagatcaa 120
 tatttattaa atcaactttt aaggaacact gatagagctg atggcttatc aataatatca 180

```

ggagcaggca gagaagatag gacacaagat tttgtcctag gttccaccaa tgtgggtcaa 240
ggttatattg atgataacca aagcataaca aaagctgcag cctggttacag tctacataat 300
ataatcaaac aactacaaga agttgaagtt aggcaggcta gagataacaa actatctgac 360
agcaaacatg tagcacttca caacttagtc ctatcttata tggagatgag caaaactcct 420
gcatctttaa tcaacaatct caagagactg ccgagagaga aactgaaaaa attagcaaag 480
ctcataattg acttatcagc aggtgctgaa aatgactctt catatgcctt gcaagacagt 540
gaaagcacta atcaagtgcg gtga
564

```

<210> 47

<211> 564

<212> DNA

<213> human Metapneumo virus

<400> 47

```

atgtctcgca aggtcccatg caaatatgaa gtgcggggca aatgcaacag aggaagtgcg 60
tgtaagttta accacaatta ctggagttgg ccagatagat acttattaat aagatcaaac 120
tatctattaa atcagctttt aaggaaactg gatagagctg atggcctatc aataatatca 180
ggcgcaggca gagaagacag aacgcaagat tttgttctag gttccaccaa tgtgggtcaa 240
ggttatattg atgataacca aagcataaca aaagctgcag cctgctacag tctacacaac 300
ataatcaagc aactacaaga agttgaagtt aggcaggcta gagatagcaa actatctgac 360
agcaagcatg tggcactcca taacttaatc ttatcttaca tggagatgag caaaactccc 420
gcatctttaa tcaacaatct taaaagactg ccgagagaaa aactgaaaaa attagcaaag 480
ctgataattg acttatcagc aggcgctgac aatgactctt catatgcctt gcaagacagt 540
gaaagcacta atcaagtgcg gtga
564

```

<210> 48

<211> 564

<212> DNA

<213> human Metapneumo virus

<400> 48

```

atgtctcgta aggtcccatg caaatatgaa gtgcggggca aatgcaacag agggagtgcg 60
tgcaaattca atcacaatta ctggagttgg cctgatagat atttattggt aagatcaaac 120
tatctcttaa atcagctttt aagaaacaca gataaggctg atggtttggtc aataatatca 180
ggagcaggta gagaagatag aactcaagac tttgttcttg gttctactaa tgtgggtcaa 240
gggtacattg atgacaacca aggaataacc aaggctgcag cttgctatag tctacacaac 300
ataatcaagc aactacaaga aacagaagta agacaggcta gagacaacaa gctttctgat 360
agcaaacatg tggcgctcca caacttgata ttatcctata tggagatgag caaaactcct 420
gcatctctaa tcaacaacct aaagaaacta ccaagggaaa aactgaagaa attagcaaga 480
ttaataattg atttatcagc aggaactgac aatgactctt catatgcctt gcaagacagt 540
gaaagcacta atcaagtgcg gtaa
564

```

<210> 49

<211> 564

<212> DNA

<213> human Metapneumo virus

<400> 49

```

atgtctcgca aagctccatg caaatatgaa gtacggggca agtgcaacag gggaagtgcg 60
tgcaaattca accacaatta ctggagctgg cctgataggt atttattggt aagatcaaac 120
tatctcttga atcagctttt aagaaacact gataaggctg atggtttggtc aataatatca 180
ggagcaggta gagaagatag gactcaagac tttgttcttg gttctactaa tgtgggtcaa 240
gggtacattg ataacaatca aggaataaca aaggctgcag cttgctatag tctacataac 300
ataataaaac agctacaaga aatagaagta agacaggcta gagataataa gctttctgac 360
agcaaacatg tggcacttca caacttgata ttatcctata tggagatgag caaaactcct 420
gcatccctga ttaataacct aaagaaacta ccaagagaaa aactgaagaa attagcgaaa 480
ttaataattg atttatcagc aggaactgat aatgactctt catatgcctt gcaagacagt 540
gaaagcacta atcaagtgcg gtaa
564

```

<210> 50

<211> 71

<212> PRT

<213> human Metapneumo virus

<400> 50

```

Met Thr Leu His Met Pro Cys Lys Thr Val Lys Ala Leu Ile Lys Cys
 1           5           10           15
Ser Glu His Gly Pro Val Phe Ile Thr Ile Glu Val Asp Asp Met Ile
          20           25           30
Trp Thr His Lys Asp Leu Lys Glu Ala Leu Ser Asp Gly Ile Val Lys
          35           40           45
Ser His Thr Asn Ile Tyr Asn Cys Tyr Leu Glu Asn Ile Glu Ile Ile
 50           55           60
Tyr Val Lys Ala Tyr Leu Ser
65           70

```

<210> 51

<211> 71

<212> PRT

<213> human Metapneumo virus

<400> 51

```

Met Thr Leu His Met Pro Cys Lys Thr Val Lys Ala Leu Ile Lys Cys
 1           5           10           15
Ser Glu His Gly Pro Val Phe Ile Thr Ile Glu Val Asp Glu Met Ile
          20           25           30
Trp Thr Gln Lys Glu Leu Lys Glu Ala Leu Ser Asp Gly Ile Val Lys
          35           40           45
Ser His Thr Asn Ile Tyr Asn Cys Tyr Leu Glu Asn Ile Glu Ile Ile
 50           55           60
Tyr Val Lys Ala Tyr Leu Ser
65           70

```

<210> 52

<211> 71

<212> PRT

<213> human Metapneumo virus

<400> 52

```

Met Thr Leu His Met Pro Cys Lys Thr Val Lys Ala Leu Ile Lys Cys
 1           5           10           15
Ser Lys His Gly Pro Lys Phe Ile Thr Ile Glu Ala Asp Asp Met Ile
          20           25           30
Trp Thr His Lys Glu Leu Lys Glu Thr Leu Ser Asp Gly Ile Val Lys
          35           40           45
Ser His Thr Asn Ile Tyr Ser Cys Tyr Leu Glu Asn Ile Glu Ile Ile
 50           55           60
Tyr Val Lys Thr Tyr Leu Ser
65           70

```

<210> 53

<211> 71

<212> PRT

<213> human Metapneumo virus

<400> 53

```

Met Thr Leu His Met Pro Cys Lys Thr Val Lys Ala Leu Ile Lys Cys
 1           5           10           15
Ser Lys His Gly Pro Lys Phe Ile Thr Ile Glu Ala Asp Asp Met Ile
          20           25           30
Trp Thr His Lys Glu Leu Lys Glu Thr Leu Ser Asp Gly Ile Val Lys

```

	35		40		45
Ser	His	Thr	Asn	Ile	Tyr
	50		55		60
Tyr	Val	Lys	Ala	Tyr	Leu
65			70		

<210> 54
 <211> 216
 <212> DNA
 <213> human Metapneumo virus

<400> 54
 atgactcttc atatgccttg caagacagtg aaagcactaa tcaagtgcag tgagcatggt 60
 ccagttttca ttactataga ggttgatgac atgatatgga ctcaaaagga cttaaaagaa 120
 gctttatctg atgggatagt gaagtctcac actaacattt acaattgtta tttagaaaac 180
 atagaaatta tatatgtcaa ggcttactta agtttag 216

<210> 55
 <211> 216
 <212> DNA
 <213> human Metapneumo virus

<400> 55
 atgactcttc atatgccttg caagacagtg aaagcactaa tcaagtgcag tgagcatggt 60
 cctgttttca ttactataga ggttgatgaa atgatatgga ctcaaaaaga attaaaagaa 120
 gctttgtccg atgggatagt gaagtctcac accaacattt acaattgtta tttagaaaac 180
 atagaaatta tatatgtcaa ggcttactta agtttag 216

<210> 56
 <211> 216
 <212> DNA
 <213> human Metapneumo virus

<400> 56
 atgactcttc atatgccttg caagacagtg aaagcactaa tcaagtgcag taaacatggt 60
 cccaaattca ttaccataga ggcagatgat atgatatgga ctcaaaaaga attaaaagaa 120
 acactgtctg atgggatagt aaaatcacac accaatattt atagttgtta cttagaaaaat 180
 atagaaataa tatatgttaa aacttactta agtttag 216

<210> 57
 <211> 216
 <212> DNA
 <213> human Metapneumo virus

<400> 57
 atgactcttc atatgccttg caagacagtg aaagcactaa tcaagtgcag taagcatggt 60
 cccaaattca ttaccataga ggcagatgat atgatatgga cacacaaaga attaaaggag 120
 acactgtctg atgggatagt aaaatcacac accaatattt acagttgtta tttagaaaaat 180
 atagaaataa tatatgttaa agcttactta agtttag 216

<210> 58
 <211> 727
 <212> DNA
 <213> human Metapneumo virus

<400> 58
 atgtctcgca aggctccgtg caaatatgaa gtgcggggca aatgcaatag aggaagtgag 60
 tgcaagttta accacaatta ctggagttgg ccagatagat acttattaat aagatcaaatt 120
 tattttattaa atcaactttt aaggaacact gatagagctg atggcttatc aataatatca 180
 ggagcaggca gagaagatag gacacaagat tttgtcctag gttccaccaa tgtggttcaa 240
 gggttatattg atgataacca aagcataaca aaagctgcag cctgttacag tctacataat 300

```

ataatcaaac aactacaaga agttgaagtt aggcaggcta gagataacaa actatctgac 360
agcaaacatg tagcacttca caacttagtc ctatcttata tggagatgag caaaactcct 420
gcatctttaa tcaacaatct caagagactg ccgagagaga aactgaaaaa attagcaaag 480
ctcataattg acttatcagc aggtgctgaa aatgactctt catatgcctt gcaagacagt 540
gaaagcacta atcaagtgcg gtgagcatgg tccagttttc attactatag aggttgatga 600
catgatattg actcacaagg acttaaaaga agctttatct gatgggatag tgaagtctca 660
tactaacatt tacaattggt atttagaaaa catagaaatt atatatgtca aggccttactt 720
aagttag 727

```

<210> 59

<211> 727

<212> DNA

<213> human Metapneumo virus

<400> 59

```

atgtctcgca aggcctccatg caaatatgaa gtgcgggggca aatgcaacag aggaagtga 60
tgtaagttaa accacaatta ctggagttgg ccagatagat acttattaat aagatcaaac 120
tatctattaa atcagctttt aaggaaact gatagagctg atggcctatc aataatatca 180
ggcgcaggca gagaagacag aacgcaagat tttgttctag gttccaccaa tgtggttcaa 240
ggttatattg atgataacca aagcataaca aaagctgcag cctgctacag tctacacaac 300
ataatcaagc aactacaaga agttgaagtt aggcaggcta gagatagcaa actatctgac 360
agcaagcatg tggcactcca taacttaatc ttatcttaca tggagatgag caaaactccc 420
gcatctttaa tcaacaatct taaaagactg ccgagagaaa aactgaaaaa attagcaaag 480
ctgataattg acttatcagc aggcgctgac aatgactctt catatgcctt gcaagacagt 540
gaaagcacta atcaagtgcg gtgagcatgg tcctgttttc attactatag aggttgatga 600
aatgatattg actcaaaaag aattaaaaga agctttgtcc gatgggatag tgaagtctca 660
caccaacatt tacaattggt atttagaaaa catagaaatt atatatgtca aggccttactt 720
aagttag 727

```

<210> 60

<211> 727

<212> DNA

<213> human Metapneumo virus

<400> 60

```

atgtctcgta aggcctccatg caaatatgaa gtgcgggggca aatgcaacag agggagtga 60
tgcaaatcca atcacaatta ctggagttgg cctgatagat atttattggt aagatcaaat 120
tatctcttaa atcagctttt aagaaacaca gataaggctg atgggttggt aataatatca 180
ggagcaggta gagaagatag aactcaagac tttgttcttg gttctactaa tgtggttcaa 240
gggtacattg atgacaacca aggaataacc aaggctgcag cttgctatag tctacacaac 300
ataatcaagc aactacaaga aacagaagta agacaggcta gagacaacaa gctttctgat 360
agcaaacatg tggcgtcca caacttgata ttatcctata tggagatgag caaaactcct 420
gcatctctaa tcaacaacct aaagaaacta ccaagggaaa aactgaagaa attagcaaga 480
ttaataattg atttatcagc aggaactgac aatgactctt catatgcctt gcaagacagt 540
gaaagcacta atcaagtgcg gtaaacatgg tcccaaattc attaccatag aggcagatga 600
tatgatattg actcacaag aattaaaaga aacactgtct gatgggatag taaaatcaca 660
caccaatatt tatagttggt acttagaaaa tatagaaata atatatgtta aaacttactt 720
aagttag 727

```

<210> 61

<211> 727

<212> DNA

<213> human Metapneumo virus

<400> 61

```

atgtctcgca aagctccatg caaatatgaa gtacgggggca agtgcaacag ggggaagtga 60
tgcaaatcca accacaatta ctggagctgg cctgataggt atttattggt aagatcaaat 120
tatctcttga atcagctttt aagaaacact gataaggctg atgggttggt aataatatca 180
ggagcaggta gagaagatag gactcaagac tttgttcttg gttctactaa tgtggttcaa 240
gggtacattg ataacaatca aggaataaca aaggctgcag cttgctatag tctacataac 300
ataataaac agctacaaga aatagaagta agacaggcta gagataataa gctttctgac 360
agcaaacatg tggcacttca caacttgata ttatcctata tggagatgag caaaactcct 420

```



```

gcatccctga ttaataacct aaagaaacta ccaagagaaa aactgaagaa attagcgaaa 480
ttaataattg atttatcagc aggaactgat aatgactctt catatgcctt gcaagacagt 540
gaaagcacta atcaagtgcg gtaagcatgg tcccaaattc attaccatag aggcagatga 600
tatgatattg acacacaaag aattaaagga gacactgtct gatgggatag taaaatcaca 660
caccaatatt tacagttggt atttagaaaa tatagaaata atatattgta aagcttactt 720
aagttag 727

```

<210> 62

<211> 254

<212> PRT

<213> human Metapneumo virus

<400> 62

```

Met Glu Ser Tyr Leu Val Asp Thr Tyr Gln Gly Ile Pro Tyr Thr Ala
1      5      10      15
Ala Val Gln Val Asp Leu Ile Glu Lys Asp Leu Leu Pro Ala Ser Leu
20      25      30
Thr Ile Trp Phe Pro Leu Phe Gln Ala Asn Thr Pro Pro Ala Val Leu
35      40      45
Leu Asp Gln Leu Lys Thr Leu Thr Ile Thr Thr Leu Tyr Ala Ala Ser
50      55      60
Gln Asn Gly Pro Ile Leu Lys Val Asn Ala Ser Ala Gln Gly Ala Ala
65      70      75      80
Met Ser Val Leu Pro Lys Lys Phe Glu Val Asn Ala Thr Val Ala Leu
85      90      95
Asp Glu Tyr Ser Lys Leu Glu Phe Asp Lys Leu Thr Val Cys Glu Val
100     105     110
Lys Thr Val Tyr Leu Thr Thr Met Lys Pro Tyr Gly Met Val Ser Lys
115     120     125
Phe Val Ser Ser Ala Lys Ser Val Gly Lys Lys Thr His Asp Leu Ile
130     135     140
Ala Leu Cys Asp Phe Met Asp Leu Glu Lys Asn Thr Pro Val Thr Ile
145     150     155     160
Pro Ala Phe Ile Lys Ser Val Ser Ile Lys Glu Ser Glu Ser Ala Thr
165     170     175
Val Glu Ala Ala Ile Ser Ser Glu Ala Asp Gln Ala Leu Thr Gln Ala
180     185     190
Lys Ile Ala Pro Tyr Ala Gly Leu Ile Met Ile Met Thr Met Asn Asn
195     200     205
Pro Lys Gly Ile Phe Lys Lys Leu Gly Ala Gly Thr Gln Val Ile Val
210     215     220
Glu Leu Gly Ala Tyr Val Gln Ala Glu Ser Ile Ser Lys Ile Cys Lys
225     230     235     240
Thr Trp Ser His Gln Gly Thr Arg Tyr Val Leu Lys Ser Arg
245     250

```

<210> 63

<211> 254

<212> PRT

<213> human Metapneumo virus

<400> 63

```

Met Glu Ser Tyr Leu Val Asp Thr Tyr Gln Gly Ile Pro Tyr Thr Ala
1      5      10      15
Ala Val Gln Val Asp Leu Val Glu Lys Asp Leu Leu Pro Ala Ser Leu
20      25      30
Thr Ile Trp Phe Pro Leu Phe Gln Ala Asn Thr Pro Pro Ala Val Leu
35      40      45
Leu Asp Gln Leu Lys Thr Leu Thr Ile Thr Thr Leu Tyr Ala Ala Ser
50      55      60
Gln Ser Gly Pro Ile Leu Lys Val Asn Ala Ser Ala Gln Gly Ala Ala

```

```

65          70          75          80
Met Ser Val Leu Pro Lys Lys Phe Glu Val Asn Ala Thr Val Ala Leu
      85          90          95
Asp Glu Tyr Ser Lys Leu Glu Phe Asp Lys Leu Thr Val Cys Glu Val
      100         105         110
Lys Thr Val Tyr Leu Thr Thr Met Lys Pro Tyr Gly Met Val Ser Lys
      115         120         125
Phe Val Ser Ser Ala Lys Ser Val Gly Lys Lys Thr His Asp Leu Ile
      130         135         140
Ala Leu Cys Asp Phe Met Asp Leu Glu Lys Asn Thr Pro Val Thr Ile
145         150         155         160
Pro Ala Phe Ile Lys Ser Val Ser Ile Lys Glu Ser Glu Ser Ala Thr
      165         170         175
Val Glu Ala Ala Ile Ser Ser Glu Ala Asp Gln Ala Leu Thr Gln Ala
      180         185         190
Lys Ile Ala Pro Tyr Ala Gly Leu Ile Met Ile Met Thr Met Asn Asn
      195         200         205
Pro Lys Gly Ile Phe Lys Lys Leu Gly Ala Gly Thr Gln Val Ile Val
      210         215         220
Glu Leu Gly Ala Tyr Val Gln Ala Glu Ser Ile Ser Lys Ile Cys Lys
225         230         235         240
Thr Trp Ser His Gln Gly Thr Arg Tyr Val Leu Lys Ser Ser
      245         250

```

<210> 64

<211> 254

<212> PRT

<213> human Metapneumo virus

<400> 64

```

Met Glu Ser Tyr Leu Val Asp Thr Tyr Gln Gly Ile Pro Tyr Thr Ala
1      5      10      15
Ala Val Gln Val Asp Leu Val Glu Lys Asp Leu Leu Pro Ala Ser Leu
      20      25      30
Thr Ile Trp Phe Pro Leu Phe Gln Ala Asn Thr Pro Pro Ala Val Leu
      35      40      45
Leu Asp Gln Leu Lys Thr Leu Thr Ile Thr Thr Leu Tyr Ala Ala Ser
      50      55      60
Gln Asn Gly Pro Ile Leu Lys Val Asn Ala Ser Ala Gln Gly Ala Ala
65      70      75      80
Met Ser Val Leu Pro Lys Lys Phe Glu Val Asn Ala Thr Val Ala Leu
      85      90      95
Asp Glu Tyr Ser Lys Leu Asp Phe Asp Lys Leu Thr Val Cys Asp Val
      100     105     110
Lys Thr Val Tyr Leu Thr Thr Met Lys Pro Tyr Gly Met Val Ser Lys
      115     120     125
Phe Val Ser Ser Ala Lys Ser Val Gly Lys Lys Thr His Asp Leu Ile
      130     135     140
Ala Leu Cys Asp Phe Met Asp Leu Glu Lys Asn Ile Pro Val Thr Ile
145     150     155     160
Pro Ala Phe Ile Lys Ser Val Ser Ile Lys Glu Ser Glu Ser Ala Thr
      165     170     175
Val Glu Ala Ala Ile Ser Ser Glu Ala Asp Gln Ala Leu Thr Gln Ala
      180     185     190
Lys Ile Ala Pro Tyr Ala Gly Leu Ile Met Ile Met Thr Met Asn Asn
      195     200     205
Pro Lys Gly Ile Phe Lys Lys Leu Gly Ala Gly Thr Gln Val Ile Val
      210     215     220
Glu Leu Gly Ala Tyr Val Gln Ala Glu Ser Ile Ser Arg Ile Cys Lys
225     230     235     240
Ser Trp Ser His Gln Gly Thr Arg Tyr Val Leu Lys Ser Arg

```

245

250

<210> 65
 <211> 254
 <212> PRT
 <213> human Metapneumo virus

<400> 65
 Met Glu Ser Tyr Leu Val Asp Thr Tyr Gln Gly Ile Pro Tyr Thr Ala
 1 5 10 15
 Ala Val Gln Val Asp Leu Val Glu Lys Asp Leu Leu Pro Ala Ser Leu
 20 25 30
 Thr Ile Trp Phe Pro Leu Phe Gln Ala Asn Thr Pro Pro Ala Val Leu
 35 40 45
 Leu Asp Gln Leu Lys Thr Leu Thr Ile Thr Thr Leu Tyr Ala Ala Ser
 50 55 60
 Gln Asn Gly Pro Ile Leu Lys Val Asn Ala Ser Ala Gln Gly Ala Ala
 65 70 75 80
 Met Ser Val Leu Pro Lys Lys Phe Glu Val Asn Ala Thr Val Ala Leu
 85 90 95
 Asp Glu Tyr Ser Lys Leu Asp Phe Asp Lys Leu Thr Val Cys Asp Val
 100 105 110
 Lys Thr Val Tyr Leu Thr Thr Met Lys Pro Tyr Gly Met Val Ser Lys
 115 120 125
 Phe Val Ser Ser Ala Lys Ser Val Gly Lys Lys Thr His Asp Leu Ile
 130 135 140
 Ala Leu Cys Asp Phe Met Asp Leu Glu Lys Asn Ile Pro Val Thr Ile
 145 150 155 160
 Pro Ala Phe Ile Lys Ser Val Ser Ile Lys Glu Ser Glu Ser Ala Thr
 165 170 175
 Val Glu Ala Ala Ile Ser Ser Glu Ala Asp Gln Ala Leu Thr Gln Ala
 180 185 190
 Lys Ile Ala Pro Tyr Ala Gly Leu Ile Met Ile Met Thr Met Asn Asn
 195 200 205
 Pro Lys Gly Ile Phe Lys Lys Leu Gly Ala Gly Thr Gln Val Ile Val
 210 215 220
 Glu Leu Gly Ala Tyr Val Gln Ala Glu Ser Ile Ser Arg Ile Cys Lys
 225 230 235 240
 Ser Trp Ser His Gln Gly Thr Arg Tyr Val Leu Lys Ser Arg
 245 250

<210> 66
 <211> 765
 <212> DNA
 <213> human Metapneumo virus

<400> 66
 atggagtcct acctagtaga cacctatcaa ggcattcctt acacagcagc tgttcaagtt 60
 gatctaataag aaaaggacct gttacctgca agcctaacia tatgggtccc tttgtttcag 120
 gccaacacac caccagcagt gctgctcgat cagctaaaaa ccctgacaat aaccactctg 180
 tatgctgcat cacaaaatgg tccaatactc aaagtgaatg catcagccca aggtgcagca 240
 atgtctgtac ttcccaaaaa atttgaagtc aatgcgactg tagcactcga tgaatatagc 300
 aaactggaat ttgacaaact cacagtctgt gaagtaaaaa cagtttactt aacaaccatg 360
 aaaccatacg ggatgggtatc aaaattttgtg agctcagcca aatcagttgg caaaaaaaca 420
 catgatctaa tcgcactatg tgattttatg gatctagaaa agaacacacc tgttacaata 480
 ccagcattca tcaaatcagt ttcaatcaaa gagagtgagt cagctactgt tgaagctgct 540
 ataagcagtg aagcagacca agctctaaca caggccaaaa ttgcacctta tgcgggatta 600
 attatgatca tgactatgaa caatcccaaaa ggcattattca aaaagcttgg agctgggact 660
 caagtcatag tagaactagg agcatatgtc caggctgaaa gcataagcaa aatatgcaag 720
 acttgaggac atcaaggagc aagatatgtc ttgaagtcca gataa 765

<210> 67
<211> 765
<212> DNA
<213> human Metapneumo virus

<400> 67
atggagtcct atctggtaga cacttatcaa ggcattccctt acacagcagc tgttcaagtt 60
gatctagtag aaaaggacct gttacctgca agcctaacaa tatgggttccc cttgtttcag 120
gccaatacac caccagcagt tctgcttgat cagctaaaga ctctgactat aactactctg 180
tatgctgcat cacaaaagtgg tccaatacta aaagtgaatg catcagccca ggggtgcagca 240
atgtctgtac ttcccaaaaa gtttgaagtc aatgcgactg tagcacttga cgaatatagc 300
aaattagaat ttgacaaact tacagtctgt gaagtaaaaa cagtttactt aacaaccatg 360
aaaccatatt ggatgggtatc aaagtttgtg agctcggcca aatcagtttg caaaaaaaca 420
catgatctaa tcgcattatg tgattttatg gatctagaaa agaacacacc agttacaata 480
ccagcattta tcaaatcagt ttctatcaag gagagtgaat cagccactgt tgaagctgca 540
ataagcagtg aagcagacca agctctaaca caagccaaaa ttgcacctta tgcgggagc 600
atcatgatta tgaccatgaa caatcccaaa ggcataattca agaagcttgg agctgggacc 660
caagttatag tagaactagg agcatatgtc caggctgaaa gcataagtaa aatatgcaag 720
acttggagcc atcaaggaac aagatatgtg ctgaagtcca gttaa 765

<210> 68
<211> 765
<212> DNA
<213> human Metapneumo virus

<400> 68
atggagtcct atctagtaga cacttatcaa ggcattcccat atacagctgc tgttcaagtt 60
gacctggtag aaaaagattt actgccagca agtttgacaa tatgggttccc tttatttcag 120
gccaacacac caccagcagt tctgcttgat cagctaaaaa ccttgacaat aacaactctg 180
tatgctgcat cacagaatgg tccaatactc aaggtaaatg catctgcccc aggtgctgcc 240
atgtctgtac ttcccaaaaa attcagaggta aatgcaactg tagcacttga tgaatacagt 300
aaacttgatt ttgacaagct gacggctctgc gatgttaaaa cagtttattt gacaactatg 360
aaaccgtacg ggatgggtgc aaaatttgtg agttcagcca aatcagtttg caaaaagaca 420
catgatctaa ttgcactatg tgacttcatg gacctagaga aaaatatacc tgtgacaata 480
ccagcattta taaagtcagt ttcaatcaaa gagagtgaat cagccactgt tgaagctgca 540
ataagcagcg aagccgacca agccttgaca caagccaaga ttgcgcctta tgcaggacta 600
attatgatca tgaccatgaa caatccaaaa ggtatattca agaaactagg ggctggaaca 660
caagtgatag tagagctggg ggcataatgtt caggctgaga gcatacagtag gatctgcaag 720
agctggagtc accaaggaac aagatacgtc ctaaaatcca gataa 765

<210> 69
<211> 765
<212> DNA
<213> human Metapneumo virus

<400> 69
atggagtcct atctagtggg cacttatcaa ggcattccctt acacagctgc tgttcaagtt 60
gatctggtag aaaaagactt actaccagca agtttgacaa tatgggttccc tctattccaa 120
gccaacacac caccagcggg tttgctcgat cagctaaaaa ccttgactat aacaactctg 180
tatgctgcat cacagaatgg tccaatactc aaagtaaatg catcagctca ggggtgctgct 240
atgtctgtac ttcccaaaaa attcgaagta aatgcaactg tggcacttga tgaatacagc 300
aaacttgact ttgacaagtt aacggtttgc gatgttataa cagtttattt gacaaccatg 360
aagccatatt ggatgggtgc aaaatttgtg agttcagcca aatcagtttg caaaaagaca 420
catgatctaa ttgcactgtg tgacttcatg gacctagaga aaaatatacc tgtgacaata 480
ccagcattta taaagtcagt ttcaatcaaa gagagtgaat cagccactgt tgaagctgca 540
ataagcagtg aggcgacca agcattaaca caagccaaaa ttgcacctta tgcaggacta 600
atcatgatca tgaccatgaa caatccaaaa ggtatattca agaaactagg agctggaaca 660
caagtgatag tagagctagg ggcataatgtt caagccgaga gcatacagcag gatctgcaag 720
agctggagtc accaaggaac aagatatgta ctaaaatcca gataa 765

<210> 70
<211> 394

<212> PRT

<213> human Metapneumo virus

<400> 70

```

Met Ser Leu Gln Gly Ile His Leu Ser Asp Leu Ser Tyr Lys His Ala
 1           5           10           15
Ile Leu Lys Glu Ser Gln Tyr Thr Ile Lys Arg Asp Val Gly Thr Thr
      20           25           30
Thr Ala Val Thr Pro Ser Ser Leu Gln Gln Glu Ile Thr Leu Leu Cys
      35           40           45
Gly Glu Ile Leu Tyr Ala Lys His Ala Asp Tyr Lys Tyr Ala Ala Glu
      50           55           60
Ile Gly Ile Gln Tyr Ile Ser Thr Ala Leu Gly Ser Glu Arg Val Gln
      65           70           75           80
Gln Ile Leu Arg Asn Ser Gly Ser Glu Val Gln Val Val Leu Thr Arg
      85           90           95
Thr Tyr Ser Leu Gly Lys Ile Lys Asn Asn Lys Gly Glu Asp Leu Gln
      100          105          110
Met Leu Asp Ile His Gly Val Glu Lys Ser Trp Val Glu Glu Ile Asp
      115          120          125
Lys Glu Ala Arg Lys Thr Met Ala Thr Leu Leu Lys Glu Ser Ser Gly
      130          135          140
Asn Ile Pro Gln Asn Gln Arg Pro Ser Ala Pro Asp Thr Pro Ile Ile
      145          150          155          160
Leu Leu Cys Val Gly Ala Leu Ile Phe Thr Lys Leu Ala Ser Thr Ile
      165          170          175
Glu Val Gly Leu Glu Thr Thr Val Arg Arg Ala Asn Arg Val Leu Ser
      180          185          190
Asp Ala Leu Lys Arg Tyr Pro Arg Met Asp Ile Pro Lys Ile Ala Arg
      195          200          205
Ser Phe Tyr Asp Leu Phe Glu Gln Lys Val Tyr His Arg Ser Leu Phe
      210          215          220
Ile Glu Tyr Gly Lys Ala Leu Gly Ser Ser Ser Thr Gly Ser Lys Ala
      225          230          235          240
Glu Ser Leu Phe Val Asn Ile Phe Met Gln Ala Tyr Gly Ala Gly Gln
      245          250          255
Thr Met Leu Arg Trp Gly Val Ile Ala Arg Ser Ser Asn Asn Ile Met
      260          265          270
Leu Gly His Val Ser Val Gln Ala Glu Leu Lys Gln Val Thr Glu Val
      275          280          285
Tyr Asp Leu Val Arg Glu Met Gly Pro Glu Ser Gly Leu Leu His Leu
      290          295          300
Arg Gln Ser Pro Lys Ala Gly Leu Leu Ser Leu Ala Asn Cys Pro Asn
      305          310          315          320
Phe Ala Ser Val Val Leu Gly Asn Ala Ser Gly Leu Gly Ile Ile Gly
      325          330          335
Met Tyr Arg Gly Arg Val Pro Asn Thr Glu Leu Phe Ser Ala Ala Glu
      340          345          350
Ser Tyr Ala Lys Ser Leu Lys Glu Ser Asn Lys Ile Asn Phe Ser Ser
      355          360          365
Leu Gly Leu Thr Asp Glu Glu Lys Glu Ala Ala Glu His Phe Leu Asn
      370          375          380
Val Ser Asp Asp Ser Gln Asn Asp Tyr Glu
      385          390

```

<210> 71

<211> 394

<212> PRT

<213> human Metapneumo virus

<400> 71

```

Met Ser Leu Gln Gly Ile His Leu Ser Asp Leu Ser Tyr Lys His Ala
 1           5           10           15
Ile Leu Lys Glu Ser Gln Tyr Thr Ile Lys Arg Asp Val Gly Thr Thr
          20           25           30
Thr Ala Val Thr Pro Ser Ser Leu Gln Gln Glu Ile Thr Leu Leu Cys
          35           40           45
Gly Glu Ile Leu Tyr Ala Lys His Ala Asp Tyr Lys Tyr Ala Ala Glu
 50           55           60
Ile Gly Ile Gln Tyr Ile Ser Thr Ala Leu Gly Ser Glu Arg Val Gln
 65           70           75           80
Gln Ile Leu Arg Asn Ser Gly Ser Glu Val Gln Val Val Leu Thr Arg
          85           90           95
Thr Tyr Ser Leu Gly Lys Val Lys Asn Asn Lys Gly Glu Asp Leu Gln
          100          105          110
Met Leu Asp Ile His Gly Val Glu Lys Ser Trp Val Glu Glu Ile Asp
          115          120          125
Lys Glu Ala Arg Lys Thr Met Ala Thr Leu Leu Lys Glu Ser Ser Gly
 130          135          140
Asn Ile Pro Gln Asn Gln Arg Pro Ser Ala Pro Asp Thr Pro Ile Ile
 145          150          155          160
Leu Leu Cys Val Gly Ala Leu Ile Phe Thr Lys Leu Ala Ser Thr Ile
          165          170          175
Glu Val Gly Leu Glu Thr Thr Val Arg Arg Ala Asn Arg Val Leu Ser
          180          185          190
Asp Ala Leu Lys Arg Tyr Pro Arg Met Asp Ile Pro Lys Ile Ala Arg
          195          200          205
Ser Phe Tyr Asp Leu Phe Glu Gln Lys Val Tyr Tyr Arg Ser Leu Phe
 210          215          220
Ile Glu Tyr Gly Lys Ala Leu Gly Ser Ser Ser Thr Gly Ser Lys Ala
 225          230          235          240
Glu Ser Leu Phe Val Asn Ile Phe Met Gln Ala Tyr Gly Ala Gly Gln
          245          250          255
Thr Met Leu Arg Trp Gly Val Ile Ala Arg Ser Ser Asn Asn Ile Met
          260          265          270
Leu Gly His Val Ser Val Gln Ala Glu Leu Lys Gln Val Thr Glu Val
          275          280          285
Tyr Asp Leu Val Arg Glu Met Gly Pro Glu Ser Gly Leu Leu His Leu
          290          295          300
Arg Gln Ser Pro Lys Ala Gly Leu Leu Ser Leu Ala Asn Cys Pro Asn
 305          310          315          320
Phe Ala Ser Val Val Leu Gly Asn Ala Ser Gly Leu Gly Ile Ile Gly
          325          330          335
Met Tyr Arg Gly Arg Val Pro Asn Thr Glu Leu Phe Ser Ala Ala Glu
          340          345          350
Ser Tyr Ala Lys Ser Leu Lys Glu Ser Asn Lys Ile Asn Phe Ser Ser
          355          360          365
Leu Gly Leu Thr Asp Glu Glu Lys Glu Ala Ala Glu His Phe Leu Asn
          370          375          380
Val Ser Asp Asp Ser Gln Asn Asp Tyr Glu
 385          390

```

<210> 72

<211> 394

<212> PRT

<213> human Metapneumo virus

<400> 72

```

Met Ser Leu Gln Gly Ile His Leu Ser Asp Leu Ser Tyr Lys His Ala
 1           5           10           15
Ile Leu Lys Glu Ser Gln Tyr Thr Ile Lys Arg Asp Val Gly Thr Thr
          20           25           30

```

Thr Ala Val Thr Pro Ser Ser Leu Gln Gln Glu Ile Thr Leu Leu Cys
 35 40 45
 Gly Glu Ile Leu Tyr Thr Lys His Thr Asp Tyr Lys Tyr Ala Ala Glu
 50 55 60
 Ile Gly Ile Gln Tyr Ile Cys Thr Ala Leu Gly Ser Glu Arg Val Gln
 65 70 75 80

 Gln Ile Leu Arg Asn Ser Gly Ser Glu Val Gln Val Val Leu Thr Lys
 85 90 95
 Thr Tyr Ser Leu Gly Lys Gly Lys Asn Ser Lys Gly Glu Glu Leu Gln
 100 105 110
 Met Leu Asp Ile His Gly Val Glu Lys Ser Trp Ile Glu Glu Ile Asp
 115 120 125
 Lys Glu Ala Arg Lys Thr Met Val Thr Leu Leu Lys Glu Ser Ser Gly
 130 135 140
 Asn Ile Pro Gln Asn Gln Arg Pro Ser Ala Pro Asp Thr Pro Ile Ile
 145 150 155 160
 Leu Leu Cys Val Gly Ala Leu Ile Phe Thr Lys Leu Ala Ser Thr Ile
 165 170 175
 Glu Val Gly Leu Glu Thr Thr Val Arg Arg Ala Asn Arg Val Leu Ser
 180 185 190
 Asp Ala Leu Lys Arg Tyr Pro Arg Ile Asp Ile Pro Lys Ile Ala Arg
 195 200 205
 Ser Phe Tyr Glu Leu Phe Glu Gln Lys Val Tyr Tyr Arg Ser Leu Phe
 210 215 220
 Ile Glu Tyr Gly Lys Ala Leu Gly Ser Ser Ser Thr Gly Ser Lys Ala
 225 230 235 240
 Glu Ser Leu Phe Val Asn Ile Phe Met Gln Ala Tyr Gly Ala Gly Gln
 245 250 255
 Thr Leu Leu Arg Trp Gly Val Ile Ala Arg Ser Ser Asn Asn Ile Met
 260 265 270
 Leu Gly His Val Ser Val Gln Ser Glu Leu Lys Gln Val Thr Glu Val
 275 280 285
 Tyr Asp Leu Val Arg Glu Met Gly Pro Glu Ser Gly Leu Leu His Leu
 290 295 300
 Arg Gln Ser Pro Lys Ala Gly Leu Leu Ser Leu Ala Asn Cys Pro Asn
 305 310 315 320
 Phe Ala Ser Val Val Leu Gly Asn Ala Ser Gly Leu Gly Ile Ile Gly
 325 330 335
 Met Tyr Arg Gly Arg Val Pro Asn Thr Glu Leu Phe Ser Ala Ala Glu
 340 345 350
 Ser Tyr Ala Arg Ser Leu Lys Glu Ser Asn Lys Ile Asn Phe Ser Ser
 355 360 365
 Leu Gly Leu Thr Asp Glu Glu Lys Glu Ala Ala Glu His Phe Leu Asn
 370 375 380
 Met Ser Gly Asp Asn Gln Asn Asp Tyr Glu
 385 390

<210> 73

<211> 394

<212> PRT

<213> human Metapneumo virus

<400> 73

Met Ser Leu Gln Gly Ile His Leu Ser Asp Leu Ser Tyr Lys His Ala
 1 5 10 15
 Ile Leu Lys Glu Ser Gln Tyr Thr Ile Lys Arg Asp Val Gly Thr Thr
 20 25 30
 Thr Ala Val Thr Pro Ser Ser Leu Gln Gln Glu Ile Thr Leu Leu Cys
 35 40 45
 Gly Glu Ile Leu Tyr Thr Lys His Thr Asp Tyr Lys Tyr Ala Ala Glu

50 55 60
 Ile Gly Ile Gln Tyr Ile Cys Thr Ala Leu Gly Ser Glu Arg Val Gln
 65 70 75 80
 Gln Ile Leu Arg Asn Ser Gly Ser Glu Val Val Leu Thr Lys
 85 90 95
 Thr Tyr Ser Leu Gly Lys Gly Lys Asn Ser Lys Gly Glu Glu Leu Gln
 100 105 110
 Met Leu Asp Ile His Gly Val Glu Lys Ser Trp Val Glu Glu Ile Asp
 115 120 125
 Lys Glu Ala Arg Lys Thr Met Val Thr Leu Leu Lys Glu Ser Ser Gly
 130 135 140
 Asn Ile Pro Gln Asn Gln Arg Pro Ser Ala Pro Asp Thr Pro Ile Ile
 145 150 155 160
 Leu Leu Cys Val Gly Ala Leu Ile Phe Thr Lys Leu Ala Ser Thr Ile
 165 170 175
 Glu Val Gly Leu Glu Thr Thr Val Arg Arg Ala Asn Arg Val Leu Ser
 180 185 190
 Asp Ala Leu Lys Arg Tyr Pro Arg Val Asp Ile Pro Lys Ile Ala Arg
 195 200 205
 Ser Phe Tyr Glu Leu Phe Glu Gln Lys Val Tyr Tyr Arg Ser Leu Phe
 210 215 220
 Ile Glu Tyr Gly Lys Ala Leu Gly Ser Ser Ser Thr Gly Ser Lys Ala
 225 230 235 240
 Glu Ser Leu Phe Val Asn Ile Phe Met Gln Ala Tyr Gly Ala Gly Gln
 245 250 255
 Thr Met Leu Arg Trp Gly Val Ile Ala Arg Ser Ser Asn Asn Ile Met
 260 265 270
 Leu Gly His Val Ser Val Gln Ala Glu Leu Lys Gln Val Thr Glu Val
 275 280 285
 Tyr Asp Leu Val Arg Glu Met Gly Pro Glu Ser Gly Leu Leu His Leu
 290 295 300
 Arg Gln Ser Pro Lys Ala Gly Leu Leu Ser Leu Ala Asn Cys Pro Asn
 305 310 315 320
 Phe Ala Ser Val Val Leu Gly Asn Ala Ser Gly Leu Gly Ile Ile Gly
 325 330 335
 Met Tyr Arg Gly Arg Val Pro Asn Thr Glu Leu Phe Ser Ala Ala Glu
 340 345 350
 Ser Tyr Ala Arg Ser Leu Lys Glu Ser Asn Lys Ile Asn Phe Ser Ser
 355 360 365
 Leu Gly Leu Thr Asp Glu Glu Lys Glu Ala Ala Glu His Phe Leu Asn
 370 375 380
 Met Ser Asp Asp Asn Gln Asp Asp Tyr Glu
 385 390

<210> 74

<211> 1185

<212> DNA

<213> human Metapneumo virus

<400> 74

atgtctcttc aagggattca cctgagtgat ttatcataca agcatgctat attaaaagag 60
 tctcagtaca caataaaaag agatgtgggt acaacaactg cagtgcacac ctcacattg 120
 caacaagaaa taacactggt gtgtggagaa attctgtatg ctaaaccatgc tgactacaaa 180
 tatgctgcag aaataggaat acaatatatt agcacagctt taggatcaga gagagtgcag 240
 cagattctga ggaactcagg cagtgaagtc caagtgggtct taaccagaac gtactctctg 300
 gggaaaatta aaaacaataa aggagaagat ttacagatgt tagacataca cggggtagag 360
 aagagctggg tagaagagat agacaaaagaa gcaaggaaaa caatggcaac cttgcttaag 420
 gaatcatcag gtaatatccc acaaaatcag aggccctcag caccagacac acccataatc 480
 ttattatgtg taggtgcctt aatattcact aaactagcat caaccataga agtgggacta 540
 gagaccacag tcagaagggc taaccgtgta ctaagtgtat cactcaagag ataccctaga 600
 atggacatac caaagattgc cagatccttc tatgacttat ttgaacaaaa agtgtatcac 660


```
<210> 75
<211> 1185
<212> DNA
<213> human Metapneumo virus
```

```
<210> .76
<211> 1185
<212> DNA
<213> human Metapneumo virus
```

BNSDOCID: 1W0 03072720A2 1

cacttcttaa acatgagtgg tgacaatcaa aatgattatg agtaa

1185

<210> 77

<211> 1185

<212> DNA

<213> human Metapneumo virus

<400> 77

```

atgtctcttc aagggattca cctaagtgat ctgtcatata aacatgctat attaaaagag 60
tctcaataca caataaaaag agatgtaggc accacaactg cagtgcacac ttcattcattg 120
cagcaagaga taacactttt gtgtggagag attcttttaca ctaaacatac tgattacaaa 180
tatgctgcag agatagggat acaatatatt tgcacagctc taggatcaga aagagtacaa 240
cagatttttaa gaaattcagg tagtgaggtt cagggtggtc taaccaagac atactcttta 300
gggaaaggta aaaatagtaa aggggaagag ttgcaaagt tagatataca tggagtggaa 360
aagagttggg tagaagaaat agacaaagag gcaagaaaaa caatggtgac tttgctaaaag 420
gaatcatcag gcaacatccc acaaaaccag aggccttcag caccagacac accaataatt 480
ttattgtgtg taggtgcttt aatattcact aaactagcat caacaataga agttggacta 540
gagactacag ttagaagggc taacagagtg ttaagtgatg cgctcaaaaag ataccctagg 600
gtagatatac caaagattgc tagatctttt tatgaactat ttgagcagaa agtggtattac 660
aggagtctat tcattgagta tgggaaagct ttaggctcat cttcaacagg aagcaaagca 720
gaaagtttgt ttgtaaatat atttatgcaa gcttatggag ccggtcagac aatgctaagg 780
tgggggtgtca ttgccagatc atctaacaac ataatgctag ggcatgtatc tgtgcaagct 840
gaattgaaac aagttacaga ggtttatgat ttggttaagag aaatgggtcc tgaatctggg 900
cttttacatc taagacaaag tccaaaggca ggactgttat cggttgctaa ttgccccaat 960
tttgctagtg ttgttcttgg taatgcttca ggtctaggtta taatcggaat gtacagggga 1020
agagtgccaa acacagagct attttctgca gcagaaagtt atgccagaag cttaaaagaa 1080
agcaacaaaa tcaacttctc ctcattaggg ctcacagacg aagaaaaaga agctgcagaa 1140
cacttcttaa acatgagtga tgacaatcaa gatgattatg agtaa 1185

```

<210> 78

<211> 294

<212> PRT

<213> human Metapneumo virus

<400> 78

```

Met Ser Phe Pro Glu Gly Lys Asp Ile Leu Phe Met Gly Asn Glu Ala
 1           5           10           15
Ala Lys Leu Ala Glu Ala Phe Gln Lys Ser Leu Arg Lys Pro Gly His
 20           25           30
Lys Arg Ser Gln Ser Ile Ile Gly Lys Val Asn Thr Val Ser Glu
 35           40           45
Thr Leu Glu Leu Pro Thr Ile Ser Arg Pro Ala Lys Pro Thr Ile Pro
 50           55           60
Ser Glu Pro Lys Leu Ala Trp Thr Asp Lys Gly Gly Ala Thr Lys Thr
 65           70           75           80
Glu Ile Lys Gln Ala Ile Lys Val Met Asp Pro Ile Glu Glu Glu Glu
 85           90           95
Ser Thr Glu Lys Lys Val Leu Pro Ser Ser Asp Gly Lys Thr Pro Ala
100           105           110
Glu Lys Lys Leu Lys Pro Ser Thr Asn Thr Lys Lys Lys Val Ser Phe
115           120           125
Thr Pro Asn Glu Pro Gly Lys Tyr Thr Lys Leu Glu Lys Asp Ala Leu
130           135           140
Asp Leu Leu Ser Asp Asn Glu Glu Glu Asp Ala Glu Ser Ser Ile Leu
145           150           155           160
Thr Phe Glu Glu Arg Asp Thr Ser Ser Leu Ser Ile Glu Ala Arg Leu
165           170           175
Glu Ser Ile Glu Glu Lys Leu Ser Met Ile Leu Gly Leu Leu Arg Thr
180           185           190
Leu Asn Ile Ala Thr Ala Gly Pro Thr Ala Ala Arg Asp Gly Ile Arg
195           200           205
Asp Ala Met Ile Gly Val Arg Glu Glu Leu Ile Ala Asp Ile Ile Lys

```

210	215	220
Glu Ala Lys Gly Lys	Ala Ala Glu Met Met	Glu Glu Glu Met Ser Gln
225	230	235
Arg Ser Lys Ile Gly	Asn Gly Ser Val Lys	Leu Thr Glu Lys Ala Lys
245	250	255
Glu Leu Asn Lys Ile Val	Glu Asp Glu Ser Thr	Ser Gly Glu Ser Glu
260	265	270
Glu Glu Glu Glu Pro Lys	Asp Thr Gln Asp Asn Ser	Gln Glu Asp Asp
275	280	285
Ile Tyr Gln Leu Ile Met		
290		

<210> 79
 <211> 294
 <212> PRT
 <213> human Metapneumo virus

<400> 79

Met Ser Phe Pro Glu Gly Lys Asp Ile Leu Phe Met Gly Asn Glu Ala	
1 5 10 15	
Ala Lys Leu Ala Glu Ala Phe Gln Lys Ser Leu Arg Lys Pro Asn His	
20 25 30	
Lys Arg Ser Gln Ser Ile Ile Gly Glu Lys Val Asn Thr Val Ser Glu	
35 40 45	
Thr Leu Glu Leu Pro Thr Ile Ser Arg Pro Thr Lys Pro Thr Ile Leu	
50 55 60	
Ser Glu Pro Lys Leu Ala Trp Thr Asp Lys Gly Gly Ala Ile Lys Thr	
65 70 75 80	
Glu Ala Lys Gln Thr Ile Lys Val Met Asp Pro Ile Glu Glu Glu Glu	
85 90 95	
Phe Thr Glu Lys Arg Val Leu Pro Ser Ser Asp Gly Lys Thr Pro Ala	
100 105 110	
Glu Lys Lys Leu Lys Pro Ser Thr Asn Thr Lys Lys Lys Val Ser Phe	
115 120 125	
Thr Pro Asn Glu Pro Gly Lys Tyr Thr Lys Leu Glu Lys Asp Ala Leu	
130 135 140	
Asp Leu Leu Ser Asp Asn Glu Glu Glu Asp Ala Glu Ser Ser Ile Leu	
145 150 155 160	
Thr Phe Glu Glu Arg Asp Thr Ser Ser Leu Ser Ile Glu Ala Arg Leu	
165 170 175	
Glu Ser Ile Glu Glu Lys Leu Ser Met Ile Leu Gly Leu Leu Arg Thr	
180 185 190	
Leu Asn Ile Ala Thr Ala Gly Pro Thr Ala Ala Arg Asp Gly Ile Arg	
195 200 205	
Asp Ala Met Ile Gly Ile Arg Glu Glu Leu Ile Ala Asp Ile Ile Lys	
210 215 220	
Glu Ala Lys Gly Lys Ala Ala Glu Met Met Glu Glu Glu Met Asn Gln	
225 230 235 240	
Arg Thr Lys Ile Gly Asn Gly Ser Val Lys Leu Thr Glu Lys Ala Lys	
245 250 255	
Glu Leu Asn Lys Ile Val Glu Asp Glu Ser Thr Ser Gly Glu Ser Glu	
260 265 270	
Glu Glu Glu Glu Pro Lys Asp Thr Gln Glu Asn Asn Gln Glu Asp Asp	
275 280 285	
Ile Tyr Gln Leu Ile Met	
290	

<210> 80
 <211> 294
 <212> PRT

<213> human Metapneumo virus

<400> 80

```

Met Ser Phe Pro Glu Gly Lys Asp Ile Leu Phe Met Gly Asn Glu Ala
 1           5           10           15
Ala Lys Ile Ala Glu Ala Phe Gln Lys Ser Leu Lys Lys Ser Gly His
          20           25           30
Lys Arg Thr Gln Ser Ile Val Gly Glu Lys Val Asn Thr Ile Ser Glu
          35           40           45
Thr Leu Glu Leu Pro Thr Ile Ser Lys Pro Ala Arg Ser Ser Thr Leu
          50           55           60
Leu Glu Pro Lys Leu Ala Trp Ala Asp Asn Ser Gly Ile Thr Lys Ile
65           70           75           80
Thr Glu Lys Pro Ala Thr Lys Thr Thr Asp Pro Val Glu Glu Glu Glu
          85           90           95
Phe Asn Glu Lys Lys Val Leu Pro Ser Ser Asp Gly Lys Thr Pro Ala
          100          105          110
Glu Lys Lys Ser Lys Phe Ser Thr Ser Val Lys Lys Lys Val Ser Phe
          115          120          125
Thr Ser Asn Glu Pro Gly Lys Tyr Thr Lys Leu Glu Lys Asp Ala Leu
          130          135          140
Asp Leu Leu Ser Asp Asn Glu Glu Glu Asp Ala Glu Ser Ser Ile Leu
145          150          155          160
Thr Phe Glu Glu Lys Asp Thr Ser Ser Leu Ser Ile Glu Ala Arg Leu
          165          170          175
Glu Ser Ile Glu Glu Lys Leu Ser Met Ile Leu Gly Leu Leu Arg Thr
          180          185          190
Leu Asn Ile Ala Thr Ala Gly Pro Thr Ala Ala Arg Asp Gly Ile Arg
          195          200          205
Asp Ala Met Ile Gly Ile Arg Glu Glu Leu Ile Ala Glu Ile Ile Lys
210          215          220
Glu Ala Lys Gly Lys Ala Ala Glu Met Met Glu Glu Glu Met Asn Gln
225          230          235          240
Arg Ser Lys Ile Gly Asn Gly Ser Val Lys Leu Thr Glu Lys Ala Lys
          245          250          255
Glu Leu Asn Lys Ile Val Glu Asp Glu Ser Thr Ser Gly Glu Ser Glu
          260          265          270
Glu Glu Glu Glu Pro Lys Glu Thr Gln Asp Asn Asn Gln Gly Glu Asp
          275          280          285
Ile Tyr Gln Leu Ile Met
          290

```

<210> 81

<211> 294

<212> PRT

<213> human Metapneumo virus

<400> 81

```

Met Ser Phe Pro Glu Gly Lys Asp Ile Leu Phe Met Gly Asn Glu Ala
 1           5           10           15
Ala Lys Ile Ala Glu Ala Phe Gln Lys Ser Leu Lys Arg Ser Gly His
          20           25           30
Lys Arg Thr Gln Ser Ile Val Gly Glu Lys Val Asn Thr Ile Ser Glu
          35           40           45
Thr Leu Glu Leu Pro Thr Ile Ser Lys Pro Ala Arg Ser Ser Thr Leu
          50           55           60
Leu Glu Pro Lys Leu Ala Trp Ala Asp Ser Ser Gly Ala Thr Lys Thr
65           70           75           80
Thr Glu Lys Gln Thr Lys Thr Thr Asp Pro Val Glu Glu Glu Glu
          85           90           95
Leu Asn Glu Lys Lys Val Ser Pro Ser Ser Asp Gly Lys Thr Pro Ala

```

```
<400> 83
atgtcattcc ctgaagggaaa agatattctt ttcatgggta atgaagcagc aaaattggca 60
gaagcttttc aaaaatcatt aagaaaacct aatcataaaa gatctcaatc tattatagga 120
gaaaaagtga acactgtatc tgaaacattg gaattaccta ctatcagtag acctaccaa 180
ccgaccatat tgtcagagcc gaagtttagca tggacagaca aagggtggggc aatcaaaaat 240
gaagcaaagg aaacaatcaa agttatggat cctattgaag aagaagagtt tactgagaaa 300
aggggtcgtc cctccagtag tgggaaaacct cctgcagaaa agaagttgaa accatcaacc 360
aacactaaaa agaaggtctc atttacacca aatgaaccag gaaaatacac aaagttggag 420
```

```

aaagatgctc tagacttgct ttcagacaat gaagaagaag atgcagaatc ctcaatctta 480
accttcgaag aaagagatac ttcattcatta agcattgaag ccagactaga atcgattgag 540
gagaaattaa gcatgatatt agggctatta agaactca acattgctac agcaggaccc 600
acagcagcaa gagatgggat cagagatgca atgattggca taaggaggga actaatagca 660
gacataataa aagaagccaa gggaaaagca gcagaaatga tggaagaaga aatgaaccag 720
cggacaaaaa taggaaacgg tagtgtaaaa ttaactgaaa aggcaaagga gctcaacaaa 780
attgttgaag acgaaagcac aagtgggtgaa tccgaagaag aagaagaacc aaaagacaca 840
caggaaaata atcaagaaga tgacatttac cagttaatta tgtag 885

```

<210> 84

<211> 885

<212> DNA

<213> human Metapneumo virus

<400> 84

```

atgtcattcc ctgaaggaaa ggatattctg ttcattgggta atgaagcagc aaaaatagcc 60
gaagctttcc agaaatcact gaaaaaatca ggtcacaaga gaactcaatc tattgtaggg 120
gaaaaagtta aactatatc agaaactcta gaactaccta ccatcagcaa acctgcacga 180
tcatctacac tgctggaacc aaaattggca tgggcagaca acagcgggat caccaaaatc 240
acagaaaaac cagcaaccac aacaacagat cctgttgaag aagaggaatt caatgaaaag 300
aaagtgttac cttccagtga tgggaagact cctgcagaga aaaaatcaaa gttttcaacc 360
agtgtaaaaa agaaagtttc ctttaccatca aatgaaccag ggaaatacac caaactagag 420
aaagatgccc tagatttgct ctgagacaat gaggaagaag acgcagaatc ctcaatccta 480
acttttgagg agaaagatac atcatcacta agcattgaag ctagactaga atctatagaa 540
gagaagttag gcatgatatt aggactgctt cgtacactta acattgcaac agcaggacca 600
acagctgcac gagatggaat tagggatgca atgattggta taagagaaga gctaataagca 660
gagataatta aggaagccaa gggaaaagca gctgaaatga tggaagaaga gatgaatcaa 720
agatcaaaaa taggaaatgg cagtgtaaaa ctaaccgaga aggcaaaaaga gctcaacaaa 780
attgttgaag acgagagcac aagcgggtgaa tcagaagaag aagaagaacc aaaagaaact 840
caggataaca atcaaggaga agatatttat cagttaatca tgtag 885

```

<210> 85

<211> 885

<212> DNA

<213> human Metapneumo virus

<400> 85

```

atgtcattcc ctgaaggaaa agatatcctg ttcattgggta atgaagcagc aaaaatagca 60
gaagctttcc agaaatcact aaaaagatca ggtcacaaga gaaccagtc tattgtaggg 120
gaaaaagtta aactatatc agaaactcta gagctaccta ccatcagcaa acctgcacga 180
tcatctacac tgctagagcc aaaattggca tgggcagaca gcagcggagc caccaaaacc 240
acagaaaaac aaacaacca aacaacagat cctgttgaag aagaggaact caatgaaaag 300
aaggtatcac cttccagtga tgggaagact cctgcagaga aaaaatcaaa atctccaacc 360
aatgtaaaaa agaaagtttc cttcacatca aatgaaccag ggaaatatac taaactagaa 420
aaagatgccc tagatttgct ctgagacaat gaggaagaag acgcagagtc ctcaatccta 480
acctttgaag agagagacac atcatcacta agcattgagg ctagactaga atcaatagaa 540
gagaagctaa gcatgatatt aggactgctt cgtacactta acattgcaac agcaggacca 600
acggctgcaa ggatggaat cagagatgca atgattggta taagagaaga actaatagca 660
gaaataataa aagaagcaaa gggaaaagca gccgaaatga tggaagagga aatgaatcaa 720
aggtcaaaaa taggtaatgg cagtgtaaaa ctaaccgaga aggcaaaaaga acttaataaa 780
attgttgaag acgagagcac aagtgggtgaa tcagaagaag aagaagaacc aaaagaaact 840
caggataaca atcaaggaga agatatctac cagttaatca tgtag 885

```

<210> 86

<211> 183

<212> PRT

<213> human Metapneumo virus

<400> 86

```

Met Ile Thr Leu Asp Val Ile Lys Ser Asp Gly Ser Ser Lys Thr Cys
  1             5             10             15
Thr His Leu Lys Lys Ile Ile Lys Asp His Ser Gly Lys Val Leu Ile

```

```

      20      25      30
Val Leu Lys Leu Ile Leu Ala Leu Leu Thr Phe Leu Thr Val Thr Ile
      35      40      45
Thr Ile Asn Tyr Ile Lys Val Glu Asn Asn Leu Gln Ile Cys Gln Ser
      50      55      60
Lys Thr Glu Ser Asp Lys Lys Asp Ser Ser Ser Asn Thr Thr Ser Val
      65      70      75      80
Thr Thr Lys Thr Thr Leu Asn His Asp Ile Thr Gln Tyr Phe Lys Ser
      85      90      95
Leu Ile Gln Arg Tyr Thr Asn Ser Ala Ile Asn Ser Asp Thr Cys Trp
      100      105      110
Lys Ile Asn Arg Asn Gln Cys Thr Asn Ile Thr Thr Tyr Lys Phe Leu
      115      120      125
Cys Phe Lys Ser Glu Asp Thr Lys Thr Asn Asn Cys Asp Lys Leu Thr
      130      135      140
Asp Leu Cys Arg Asn Lys Pro Lys Pro Ala Val Gly Val Tyr His Ile
      145      150      155      160
Val Glu Cys His Cys Ile Tyr Thr Val Lys Trp Lys Cys Tyr His Tyr
      165      170      175
Pro Thr Asp Glu Thr Gln Ser
      180

```

<210> 87
 <211> 179
 <212> PRT
 <213> human Metapneumo virus

```

<400> 87
Met Ile Thr Leu Asp Val Ile Lys Ser Asp Gly Ser Ser Lys Thr Cys
  1      5      10      15
Thr His Leu Lys Lys Ile Ile Lys Asp His Ser Gly Lys Val Leu Ile
      20      25      30
Ala Leu Lys Leu Ile Leu Ala Leu Leu Thr Phe Phe Thr Ile Thr Ile
      35      40      45
Thr Ile Asn Tyr Ile Lys Val Glu Asn Asn Leu Gln Ile Cys Gln Ser
      50      55      60
Lys Thr Glu Ser Asp Lys Glu Asp Ser Pro Ser Asn Thr Thr Ser Val
      65      70      75      80
Thr Thr Lys Thr Thr Leu Asp His Asp Ile Thr Gln Tyr Phe Lys Arg
      85      90      95
Leu Ile Gln Arg Tyr Thr Asp Ser Val Ile Asn Lys Asp Thr Cys Trp
      100      105      110
Lys Ile Ser Arg Asn Gln Cys Thr Asn Ile Thr Thr Tyr Lys Phe Leu
      115      120      125
Cys Phe Lys Pro Glu Asp Ser Lys Ile Asn Ser Cys Asp Arg Leu Thr
      130      135      140
Asp Leu Cys Arg Asn Lys Ser Lys Ser Ala Ala Glu Ala Tyr His Thr
      145      150      155      160
Val Glu Cys His Cys Ile Tyr Thr Ile Glu Trp Lys Cys Tyr His His
      165      170      175
Pro Ile Asp

```

<210> 88
 <211> 177
 <212> PRT
 <213> human Metapneumo virus

```

<400> 88
Met Lys Thr Leu Asp Val Ile Lys Ser Asp Gly Ser Ser Glu Thr Cys

```

```

1           5           10           15
Asn Gln Leu Lys Lys Ile Ile Lys Lys His Ser Gly Lys Val Leu Ile
20           25           30
Ala Leu Lys Leu Ile Leu Ala Leu Leu Thr Phe Phe Thr Ala Thr Ile
35           40           45
Thr Val Asn Tyr Ile Lys Val Glu Asn Asn Leu Gln Ala Cys Gln Pro
50           55           60
Lys Asn Glu Ser Asp Lys Lys Val Thr Lys Pro Asn Thr Thr Ser Thr
65           70           75           80
Thr Ile Arg Pro Thr Pro Asp Pro Thr Val Val His His Leu Lys Arg
85           90           95
Leu Ile Gln Arg His Thr Asn Ser Val Thr Lys Asp Ser Asp Thr Cys
100          105          110
Trp Arg Ile His Lys Asn Gln Arg Thr Asn Ile Lys Ile Tyr Lys Phe
115          120          125
Leu Cys Ser Gly Phe Thr Asn Ser Lys Gly Thr Asp Cys Glu Glu Pro
130          135          140
Thr Ala Leu Cys Asp Lys Lys Leu Lys Thr Ile Val Glu Lys His Arg
145          150          155          160
Lys Ala Glu Cys His Cys Leu His Thr Thr Glu Trp Gly Cys Leu His
165          170          175
Pro

```

<210> 89
 <211> 177
 <212> PRT
 <213> human Metapneumo virus

```

<400> 89
Met Lys Thr Leu Asp Val Ile Lys Ser Asp Gly Ser Ser Glu Thr Cys
1           5           10           15
Asn Gln Leu Lys Lys Ile Ile Lys Lys His Ser Gly Lys Leu Leu Ile
20           25           30
Ala Leu Lys Leu Ile Leu Ala Leu Leu Thr Phe Phe Thr Val Thr Ile
35           40           45
Thr Val Asn Tyr Ile Lys Val Glu Asn Asn Leu Gln Ala Cys Gln Leu
50           55           60
Lys Asn Glu Ser Asp Lys Lys Asp Thr Lys Leu Asn Thr Thr Ser Thr
65           70           75           80
Thr Ile Arg Pro Ile Pro Asp Leu Asn Ala Val Gln Tyr Leu Lys Arg
85           90           95
Leu Ile Gln Lys His Thr Asn Phe Val Ile Lys Asp Arg Asp Thr Cys
100          105          110
Trp Arg Ile His Thr Asn Gln Cys Thr Asn Ile Lys Ile Tyr Lys Phe
115          120          125
Leu Cys Phe Gly Phe Met Asn Ser Thr Asn Thr Asp Cys Glu Glu Leu
130          135          140
Thr Val Leu Cys Asp Lys Lys Ser Lys Thr Met Thr Glu Lys His Arg
145          150          155          160
Lys Ala Glu Cys His Cys Leu His Thr Thr Glu Trp Trp Cys Tyr Tyr
165          170          175
Leu

```

<210> 90
 <211> 552
 <212> DNA
 <213> human Metapneumo virus


```

<400> 90
atgataacat tagatgtcat taaaagtgat gggctcttcaa aaacatgtac tcacctcaaa 60
aaaataatta aagaccactc tggtaaagtg cttattgtac ttaagttaat attagcttta 120
ctaaccatttc tcacagtaac aatcaccatc aattatataa aagtggaaaa caatctgcaa 180
atatgccagt caaaaactga atcagacaaa aaggactcat catcaaatac cacatcagtc 240
acaaccaaga ctactctaaa tcatgatatc acacagtatt ttaaaagttt gattcaaagg 300
tatacaaact ctgcaataaa cagtgcacaa tgctggaaaa taaacagaaa tcaatgcaca 360
aatataacaa catacaaatt tttatgtttt aaatctgaag acacaaaaac caacaattgt 420
gataaaactga cagattttatg cagaaacaaa ccaaaaccag cagttggagt gtatcacata 480
gtagaatgcc attgtatata cacagttaaa tggaagtgtc atcattacc caccgatgaa 540
accaatcct aa 552

```

```

<210> 91
<211> 540
<212> DNA
<213> human Metapneumo virus

```

```

<400> 91
atgataacat tagatgtcat taaaagtgat gggctcttcaa aaacatgtac tcacctcaaa 60
aaaataatca aagaccattc tggtaaagtg cttattgcac ttaagttaat attagcttta 120
ctaaccatttt tcacaataac aatcactata aattacataa aagtagaaaa caatctacaa 180
atatgccagt caaaaactga atcagacaaa gaagactcac catcaaatac cacatccgctc 240
acaaccaaga ctactctaga ccatgatata acacagtatt ttaaaagatt aattcaaagg 300
tatacagatt ctgtgataaa caaggacaca tgctggaaaa taagcagaaa tcaatgcaca 360
aatataacaa catataaatt tttatgtttt aaacctgagg actcaaaaat caacagttgt 420
gataagactga cagatctatg cagaaacaaa tcaaaatcag cagctgaagc atatcatata 480
gtagaatgcc attgcatata cacaattgag tggaagtgtc atcaccacc ccaatagattaa 540

```

```

<210> 92
<211> 534
<212> DNA
<213> human Metapneumo virus

```

```

<400> 92
atgaaaacat tagatgtcat aaaaagtgat ggatcctcag aaacgtgtaa tcaactcaaa 60
aaaataataa aaaaacactc aggtaaagtg cttattgcac taaaactgat attggcctta 120
ctgacattttt tcacagcaac aatcactgtc aactatataa aagtagaaaa caatttgtag 180
gcatgtcaac caaaaaatga atcagacaaa aaggtcacaa agccaaatac cacatcaaca 240
acaatcagac ccacacccga tccaactgta gtacatcatt tgaaaaggct gattcagaga 300
cacaccaact ctgtcacaaa agacagcgat acttggttga gaatacacia gaatcaacgt 360
acaaatataa aaatatacaa gttcttatgc tctgggttca caaattcaaa aggtacagat 420
tgtgaggaac caacagccct atgcgacaaa aagttaaaaa ccatagtaga aaaacataga 480
aaagcagaat gtcactgtct acatacaacc gagtgggggt gccttcattc ctaa 534

```

```

<210> 93
<211> 534
<212> DNA
<213> human Metapneumo virus

```

```

<400> 93
atgaaaacat tagatgtcat aaaaagtgat ggatcctcag aaacatgtaa tcaactcaaa 60
aaaataataa aaaaacactc aggtaaattg cttattgcac taaaactgat attggcctta 120
ttgacgtttt tcacagtaac aattactgtt aactatataa aagtagaaaa caatttgtag 180
gcatgtcaat taaaaaatga atcagacaaa aaggacacaa agctaaatac cacatcaaca 240
acaatcagac ccattcctga tctaaatgca gtacagtact tgaaaaggct gattcagaaa 300
cacaccaact ttgtcataaa agacagagat acctgttga gaatacacac gaatcaatgc 360
acaaatataa aaatatacaa gttcttatgt ttcgggttta tgaattcaac aaatacagac 420
tgtgaagaac taacagtttt atgtgataaa aagtcaaaaa ccatgacaga aaaacatagg 480
aaagcagagt gtcactgtct acatacaacc gagtgggtgt gttattatct ttaa 534

```

<210> 94
<211> 13294
<212> DNA
<213> human metapneumo virus

<220>
<221> misc_feature
<222> (0)...(0)
<223> human MPV protein

<400> 94
acgcgaaaaa aacgcgtata aattaaattc caaacaaaaac gggacaaaata aaaatgtctc 60
ttcaagggat tcacctaagt gatctatcat ataaacatgc tatattaaaa gagtctcaat 120
acacaataaa aagagatgta ggcaccacaa ctgcagtgc accttcatca ttacaacaag 180
aaataacact tttgtgtggg gaaatacttt acactaaaca cactgattac aaatatgctg 240
ctgagatagg aatacaatat atttgcacag ctctaggatc agaaagagta caacagattt 300
tgagaaactc aggtagtga gttcaggtgg ttctaaccac aacatactcc ttagggaag 360
gcaaaaacag taaaggggaa gagctgcaga tgtagatat acatggagtg gaaaagagtt 420
ggatagaaga aatagacaaa gaggcaagaa agacaatggt aactttgctt aaggaatcat 480
caggtaacat cccacaaaac cagagacctt cagcaccaga cacaccaata attttattat 540
gtgtaggtgc cctaataattc actaaactag catcaacaat agaagttgga ttagagacta 600
cagttagaag agctaataga gtgctaagt atgcactcaa aagataccca aggatagata 660
taccaaagat tgctagatct ttttatgaac tatttgaaca aaaagtgtac tcagaaagtt 720
tattcattga gtacggaaaa gctttaggct catcttcaac aggaagcaaa gcagaagtt 780
tgtttgtaaa tatatttat caagcttat gagctggcca aacactgcta aggtggggtg 840
tcattgccag atcatccaac aacataatgc tagggcatgt atctgtgcaa tctgaattga 900
agcaagttac agaggtttat gacttgggtga gagaaatggg tcctgaatct gggcttttac 960
atctaagaca aagtccaaag gcagggctgt tatcattggc caattgcccc aattttgcta 1020
gtgttgttct tggcaatgct tcaggtctag gcataatcgg aatgtacaga gggagagtac 1080
caaacacaga gctattttct gcagcagaaa gttatgccag aagcttaaaa gaaagcaata 1140
aaatcaactt ctcttcgtta gggcttacag atgaagaaaa agaagctgca gaacacttct 1200
taaacatgag tggtgacaat caagatgatt atgagtaatt aaaaaactgg gacaagtcaa 1260
aatgtcattc cctgaaggaa aggatattct gtatcatgggt aatgaagcag caaaaatagc 1320
cgaagctttc cagaaatcac tgaaaaatc aggtcacaag agaactcaat ctattgtagg 1380
ggaaaaagtt aacactatat cagaaaactct agaactacct accatcagca aactgcacg 1440
atcatctaca ctgctggaac caaaaattggc atgggcagac aacagcggaa tcaccaaaaat 1500
cacagaaaaa ccagcaacca aaacaacaga tctgttgaa gaagaggaat tcaatgaaaa 1560
gaaagtgtta ccttccagtg atgggaagac tctgcagag aaaaaatcaa agttttcaac 1620
cagtgtaaaa aagaaagttt cctttacatc aaatgaacca gggaaatata ccaaactaga 1680
gaaagatgcc ctagatttgc tctcagacaa tgaggaagaa gacgcagaat cctcaatcct 1740
aacttttgag gagaaagata catcatcact aagcattgaa gctagactag aatcgtatca 1800
agagaagttg agcatgatag taggactgct tcgtacactt aacattgcaa cagcaggacc 1860
aacagctgca cgagatggaa ttagggatgc aatgattggt ataagagaag agctaatagc 1920
agagataatt aaggaagcca agggaaaagc agctgaaatg atggaagaag agatgaatca 1980
aagatcaaaa ataggaaatg gcagtgtaaa actaaccgag aaggcaaaaag agctcaacaa 2040
aattgttgaa gacgagagca caagcgggtga atcagaagaa gaagaagaac caaaaagaaac 2100
tcaggataac aatcaaggag aagatattta tcagttaatc atgtagttaa ataaaaataa 2160
acaatgggac aagtcaagat ggagtcctat ctgtagaca cttatcaagg cattccatat 2220
acagctgctg ttcaagttga cctggtagaa aaagatttac tgccagcaag tttgacaata 2280
tggtttcctt ttttcaggc caacacacca ccagcagttc tgcttgatca gctaaaaacc 2340
ctgacaataa ccactctgta tgctgcatca cagaatgggc caataactcaa ggtaaatgca 2400
tctgcccaag gtgctgccat gtctgtactt cccaaaaaat tcgaggtaaa tgcaactgta 2460
gcacttgatg aatacagtaa acttgatttt gacaagctga cggctctgca tgttaaaaa 2520
gtttatttga caactatgaa accgtacggg atggtgtcaa aatttgtgag ttcagccaaa 2580
tcagttggca aaaagacaca tgatctaatt gcaactatgt acttcatgga cctagagaaa 2640
aatatacctg tgacaatacc agcattcata aagtcagttt caatcaaaga gagtgaatca 2700
gccactgttg aagctgcaat aagcagcgaa gccgaccaag ccttgacaca agccaagatt 2760
gcgcacctat caggactaat tatgatcatg accatgaaca atccaaaagg tatattcaag 2820
aaactagggg ctggaacaca agtgatagta gagctggggg catatgttca ggctgagagc 2880
atcagtagga tctgcaagag ctggagtcac caaggaacaa gatacgtact aaaatccaga 2940
taaaaataac tgtcttaata aataattgct tatataactc tagagattaa taagcttatt 3000
attatagtta tataaaaaata aattagaatt agaagggcat caatagaaag cgggacaaat 3060

aaaaatgtct	tggaaagtga	tgatcatcat	ttcgttactc	ataacacccc	agcacgggct	3120
aaaggagagt	tatttggaag	aatcatgtag	tactataact	gagggatacc	tcagtgtttt	3180
aagaacaggc	tggtacacta	atgtcttcac	attagaagtt	ggtgatgttg	aaaatcttac	3240
atgtactgat	ggacctagct	taatacaaac	agaacttgat	ctaacaaaaa	gtgctttaag	3300
ggaactcaaa	acagtctctg	ctgatcagtt	ggcgagagag	gagcaaattg	aaaatcccag	3360
acaatcaaga	tttgtcttag	gtgcgatagc	tctcggagtt	gctacagcag	cagcagtcac	3420
agcaggcatt	gcaatagcca	aaaccataag	gcttgagagt	gaggtgaatg	caattaaagg	3480
tgctctcaaa	caaactaatg	aagcagtatc	cacattagggt	aatgggtgtgc	gggtcctagc	3540
cactgcagtg	agagagctaa	aagaatttgt	gagcaaaaac	ctgactagtgt	caatcaacag	3600
gaacaaaatgt	gacattgtctg	atctgaagat	ggctgtcagc	ttcagtcaat	tcaacagaag	3660
atcttctaaat	gttgtgcggc	agttttcaga	caatgcagggt	ataacaccag	caatatcatt	3720
ggacctgatg	actgatgtctg	agttggccag	agctgtatca	tacatgccaa	catctgcagg	3780
gcagataaaa	ctgatgttgg	agaaccgcgc	aatggtaagg	agaaaaggat	ttggaatcct	3840
gataggggtc	tacggaagct	ctgtgattta	catgggttcaa	ttgccgatct	ttgggtgtcat	3900
agatacacct	tgttggatca	tcaaggcagc	tccctcttgc	tcagaaaaaa	acgggaatta	3960
tgcttgccct	ctaagagagg	atcaaggggt	gtattgttaa	aatgcaggat	ctactgttta	4020
ctacccaaat	gaaaaagact	gcgaacaacg	aggtgatcat	gttttttgtg	acacagcagc	4080
agggatcaat	gttgctgagc	aatcaagaga	atgcaacatc	aacatatcta	ctaccaacta	4140
cccatgcaaa	gtcagcacag	gaagacaccc	tataagcatg	gttgcaactat	caactctcgg	4200
tgctttgggtg	gcttgctata	aaggggtaag	ctgctcgatt	ggcagcaatt	gggttggaaat	4260
catcaaacaa	ttacccaaag	gctgctcata	cataaccaac	caggatgcag	acactgtaac	4320
aattgacaat	accgtgtatc	aactaagcaa	agttgaagggt	gaacagcatg	taataaaagg	4380
gagaccagtt	tcaagcagtt	ttgatccaat	caagtttctt	gaggatcagt	tcaatgttgc	4440
gcttgatcaa	gtcttcgaaa	gcattgagaa	cagtcaggca	ctagtggacc	agtcaaacaa	4500
aattctaaac	agtgcagaaa	aaggaaacac	tggtttcatt	atcgtagtaa	ttttgggtgc	4560
tgttcttgggt	ctaaccatga	tttcagtgag	catcatcatc	ataatcaaga	aaacaaggaa	4620
gccacagga	gcacctccag	agctgaatgg	tgtcaccaac	ggcgggtttca	taccacatag	4680
ttagtttaatt	aaaaaatggg	acaaatcatc	atgtctcgta	aggctccatg	caaatatgaa	4740
gtgcggggca	aatgcaacag	agggagtgtat	tgcaaatcca	atcacaatta	ctggagtgtg	4800
cctgatagat	atttattgtt	aagatcaaat	tatctcttaa	atcagctttt	aagaaacaca	4860
gataaggctg	atggtttgtc	aataatatca	ggagcaggta	gagaagatag	aactcaagac	4920
tttgttcttg	gttctactaa	tggtggttcaa	gggtacattg	atgacaacca	aggaataacc	4980
aaggctgcag	cttgctatag	tctacacaac	ataatcaagc	aactacaaga	aacagaagta	5040
agacaggcta	ggagacaacaa	gctttctgat	agcaaacatg	tggcgctcca	caacttgata	5100
ttatcctata	tggagatgag	caaaactcct	gcattcttaa	tcaacaacct	aaagaaacta	5160
ccaagggaaa	aactgaagaa	attagcaaga	ttaataattg	atctatcagc	aggaactgac	5220
aatgactctt	catatgcctt	gcaagacagt	gaaagcacta	atcaagtgca	gtaaacatgg	5280
tcccaaatc	attaccatag	aggcagatga	tatgatattg	actcacaag	aattaaaaga	5340
aacactgtct	gatgggatag	taaaatcaca	caccaatatt	tatagttgtt	acttagaaaa	5400
tatagaaata	atatatgtta	aaacttactt	aagttagtaa	aaaataaaaa	tagaatggga	5460
taaatgacaa	tgaaaacatt	agatgtcata	aaaagtgtatg	gatacctcaga	aactgttaat	5520
caactcaaaa	aaataataaa	aaaacactca	ggtaaagtgc	ttattgcact	aaaactgata	5580
ttggccttac	tgacattttt	cacagcaaca	atcactgtca	actatataaa	agtagaaaac	5640
aatttgagg	catgtcaacc	aaaaaatgaa	tcagacaaaa	aggtcacaaa	gccaaatacc	5700
acatcaacaa	caatcagacc	cacacccgat	ccaactgtag	tacatcattt	gaaaaggctg	5760
attcagagac	acaccaactc	tgtcacaaaa	gcagcagata	cttggtggag	aatacacaa	5820
aatcaacgta	caaatataaa	aatatacaag	ttcttatgct	ctgggttcac	aaattcaaaa	5880
ggtacagatt	gtgaggaacc	aacagcccta	tgcgacaaaa	agttaaaaac	catagtagaa	5940
aaacatagaa	aagcagaatg	tactgttcta	catacaaccg	agtgggggtg	ccttcatccc	6000
taaaataaca	cggctttcaa	cattaaaatc	agaacaacct	ccaccagggt	ctatcaatac	6060
agtggtttag	ccattttaaa	accgaatatt	atctaggctg	cacgacactt	tgcaataata	6120
tgcaatagtg	aatagttaaa	ccactgtgtc	aaactcatcc	ataatataat	cactgagtaa	6180
tacaaaatca	agaaaatggg	acaagtggct	atggaagtaa	gagtgagaaa	cattcgagcg	6240
atagacatgt	tcaaagcaaa	gataaaaaac	cgtataagaa	gcagcagggtg	ctatagaaat	6300
gctacactga	tccttattgg	actaacagcg	ttaagcatgg	cacttaatat	tttcctgata	6360
atcgatcatg	caacattaag	aaacatgatc	aaaacagaaa	actgtgctaa	catgccgtcg	6420
gcagaaccaa	gcaaaaagac	cccaatgacc	tccacagcag	gccccaaacac	caaaaccaat	6480
ccacacagtg	caacacagtg	gaccacagag	aactcaacat	ccccagtagc	aacccagag	6540
ggccatccat	acacagggac	aactcaaaaca	tcagacacaa	cagctcccca	gcaaacacaa	6600
gacaaacaca	cagcaccgct	aaaatcaacc	aatgaacaga	tcacccagac	aaccacagag	6660
aaaaagacaa	tcagagcaac	aacccaaaaa	agggaaaaag	gaaaagaaaa	cacaaaccaa	6720
accacaagca	cagctgcaac	ccaaacaacc	aacaccacca	accaaatacag	aaatgcaagt	6780

gagacaatca	caacatccga	cagacccaga	actgacacca	caacccaaag	cagcgaacag	6840
acaacccggg	caacagaccc	aagctcccca	ccacaccatg	catagagagg	tgcaaaactc	6900
aaatgagcac	aacacacaaa	catcccatcc	aagtagttaa	caaaaaacca	caaaataacc	6960
ttgaaaacca	aaaaacccaa	acataaaccc	agaccagaa	aaacatagac	accatatgga	7020
aggttcttagc	atatgcacca	atgagatggc	atctgttcat	gtatcaatag	caccaccatc	7080
attcaaggaa	taagaagagg	cgaaaattta	agggataaat	gacaatggat	cccttttgtg	7140
aatctactgt	taatgtttat	ctccctgatt	catatctcaa	aggagtaata	tcttttagtg	7200
aaaccaatgc	aattggatca	tgtcttttga	aaagacccta	tctaaaaaat	gacaacactg	7260
ccaaagttgc	tgtagaaaac	cctgttggtg	aacatgtgag	gcttagaaat	gcagtcatga	7320
ccaaaatgaa	gatatacagat	tataaagtgg	ttgaaccagt	taatatgcag	catgaaataa	7380
tgaaaaatat	acatagttgt	gagcttacat	tattaaaaca	attcttaacg	agaagcaaaa	7440
acattagctc	tctaaaatta	aatatgatat	gtgattgggt	acagttaaaa	tccacttcag	7500
ataacacatc	aattctcaat	tttatagatg	tgaggttcat	accggtttgg	gtaagcaatt	7560
ggttcagtaa	ctgggtataat	ctcaataaat	taatcttaga	gtttagaaga	gaagaagtaa	7620
taagaactgg	ttcaatttta	tgtagatcac	taggcaagtt	agtttttatt	gtatcatctt	7680
atggatgtgt	agtaaaaaagc	aacaaaagta	aaagagtggg	ctttttcacc	tataaccaac	7740
tgttaacatg	gaaagatgtg	atgttaagta	gattcaatgc	aaacttttgt	atatgggtaa	7800
gtaacaacct	gaacaaaaat	caagaaggac	taggacttag	aagcaatctg	caagggtatg	7860
taaccaataa	attatatgaa	actgttgatt	acatgctaag	cctatgctgc	aatgaaggat	7920
tctctctggt	gaaagagttt	gaaggattta	ttatgagtga	aattctaaaa	attactgagc	7980
atgctcagtt	cagtactagg	tttaggaata	ctttattgaa	tggtgttaact	gaacaattat	8040
cagtgttgaa	agctaagaac	agatctagag	ttcttggaac	tatattagaa	aacaacaatt	8100
accctatgta	cgaagtagta	cttaaatatt	taggggacac	cttgaaaagc	ataaagttaa	8160
taatttaacaa	gaatttagaa	aatgctgcag	aattatatta	tatatccaga	atttttggac	8220
accctatggt	agatgagagg	gaagcaatgg	atgctgttaa	attaaacaat	gagattacaa	8280
aaattcttaa	attagagagt	ttaacagaac	taagaggagc	atttatacta	agaattataa	8340
aagggtttgt	agacaataat	aaaagatggc	ctaaaattaa	gaatttaaaa	gtgctcagca	8400
aaagatgggc	tatgtatttc	aaagctaaaa	gttaccctag	ccaacttgag	ctaagtgtac	8460
aagatttttt	agaacttgct	gcagtacaa	ttgagcagga	attctctgta	cctgaaaaaa	8520
ccaaccttga	gatggtatta	aatgataaag	caatatcacc	tccaaaaaag	ctaatatggt	8580
ctgtatatcc	aaaaaactac	ctgcctgaaa	ctataaaaaa	tcaatattta	gaagaggctt	8640
tcaatgcaag	tgacagccaa	agaacaagga	gagtcttaga	attttactta	aaagattgta	8700
aatttgatca	aaaagaactt	aaacgttatg	taattaaaca	agagtatctg	aatgacaaag	8760
accacattgt	ctcgttaact	gggaaggaaa	gagaattaag	tgtaggtagg	atgtttgcaa	8820
tgcaaccagg	aaaacaaaga	cagatacaga	tattagctga	gaaacttcta	gctgataata	8880
ttgtaccttt	tttcccagaa	actttaacaa	agttaggtga	cttagatctc	cagaagaatta	8940
tggaataaaa	atcagaactt	tcttccatta	aaactagaaa	gaatgatagc	tacaacaatt	9000
atattgcaag	ggcctctata	gtaacagact	taagtaagtt	caatcaggcc	tttagatatg	9060
aaaccacagc	tatatgtgca	gatgtagctg	atgagttaca	tggaacacaa	agcttattct	9120
gttggttaca	tcttattgtt	ccatgacta	caatgatatg	tgcatacaga	catgcaccac	9180
cagaaacaaa	aggggaatat	gatatagaca	aaatacaaga	gcaaagcgga	ttatacagat	9240
atcatatggg	agggattgaa	gggtggtgcc	agaagttatg	gacaatggaa	gcaatatcct	9300
tgttagatgg	agtatctgtg	aagactcgct	gtcagatgac	ctctctatta	aacggagaca	9360
atcagtcaat	agatgttagt	aaaccagtaa	aattgtctga	aggtatagat	gaagtaaaag	9420
cagactatag	cttagcaatt	agaatgctta	aagaaataag	agatgcttat	aaaaacattg	9480
gtcataaaact	caaagaaggt	gaaacatata	tatcaaggga	tctccaattt	ataagtaagg	9540
tgattcaatc	tgaaggagtc	atgcaccta	ccccataaaa	aaagatatata	agagttagtc	9600
cttgataaaa	tacaatacta	gatgatatta	aaaccagtgc	agaatcaata	ggaagtctat	9660
gtcaagaact	agaattcaga	ggggagagta	tactagttag	cttgatatta	aggaatttct	9720
ggctgtataa	cttgatcatg	tatgagtcaa	aacagcacc	attagctggg	aagcaactgt	9780
tcaagcaatt	gaacaaaaca	ttacatctg	tgcagagatt	ttttgaactg	aagaaagaaa	9840
atgatgtggt	tgacctatgg	atgaatatat	caatgcagtt	tggaggggga	gatccagtag	9900
ttttttacag	atctttttac	agaaggactc	cgaatttctt	aactgaagca	atcagccatg	9960
tggattttact	gttaaaagtg	tcaaacaata	tcaaagatga	gactaagata	cgatttttca	10020
aagccttatt	atctatagaa	aagaatgaac	gtgctacatt	aacaacacta	atgagagacc	10080
ctcaggcagt	aggatcagaa	cgacaagcta	aggtaacaag	tgatataaat	agaacagcag	10140
ttaccagcat	actgagtcta	tctccgaatc	agctcttctg	tgatagtgtc	atacattata	10200
gtagaaatga	ggaagaagtt	gggatcattg	cagacaacat	aacacctgtc	tatcctcatg	10260
ggctgagagt	gctctatgaa	tcactacctt	ttcataaggc	tgaaaagggt	gtcaatatga	10320
tatcaggcac	aaagtctata	actaatctat	tacagagaac	atctgctatc	aatgggtgaag	10380
atattgatag	agcagtgtct	atgatgttag	agaacttagg	gttggttatct	agaatattgt	10440
cagtaataat	taatagtata	gaaataccaa	tcaagtccaa	tggcagattg	atatgtctgc	10500

```

aaatttccaa gaccttgaga gaaaaatcat ggaacaatat ggaaatagta ggagtgacat 10560
ctcctagtag tgtgacatgt atggatgttg tgtatgcaac tagttctcat ttaaaaggaa 10620
taattattga aaaattcagt actgacaaga ccacaagagg tcagagggga ccaaaaagcc 10680
cctgggtagg atcaagcact caagagaaaa aattggttcc tgtttataat agacaaattc 10740
tttcaaaaaca acaaaaagag caactggaag caatagggaa aatgaggtgg gtgtacaaag 10800
gaactccagg gctaagaaga ttgctcaaca agatttgcac aggaagctta ggtattagct 10860
ataaatgtgt gaaaccttta ttaccaagat tcatgagtg aaacttctta cataggttat 10920
ctgttagtag tagacccatg gaattcccag cttctgttcc agcttacagg acaacaaatt 10980
accattttga cactagtcca atcaaccaag cattaagtga gaggttcggg aacgaagaca 11040
ttaatttagt gttccaaaat gcaatcagct gcggaattag tataatgagt gttgtagaac 11100
agttaactgg tagaagccca aaacaattag tcctaattccc tcaattagaa gagatagata 11160
ttatgctccc tctgtatttt caaggaaaaat tcaattataa actagttgat aagataacct 11220
cogatcaaca catcttcagt cctgacaaaa tagacatatt aacactaggg aagatgctta 11280
tgcttaccat aaaaggtcaa aaaactgatc agttcttaaa taagagagaa aactattttc 11340
atggaaataa ttaattgaa tctttatctg cagcacttgc atgccactgg tgtgggatct 11400
taacagaaca gtgcatagaa aacaatatct ttaggaaaaga ttggggtgat gggttcatct 11460
cagatcatgc cttcatggat ttcaaggat ttctatgtgt atttaaaacc aaacttttat 11520
gtagttgggg atctcaagga aagaatgtaa aagatgaaga tataatagat gaatccattg 11580
acaaattatt aagaattgac aacacctttt ggagaatgtt cagcaaagtc atgtttgaat 11640
caaaagtcaa aaaaagaata atgttatatg atgtgaaatt cctatcatta gtaggttata 11700
taggatttaa aaactggttt atagaacagt taagagtggg agaattgcat gaggtacctt 11760
ggattgtcaa tacagggttg gaagttagtt aaattaaatc aatcaaaatt tatctgcagt 11820
taatagaaca aagtctatct ttgagaataa ctgtattgaa ttatacagac atggcacatg 11880
ctcttacacg attaattagg aaaaaattga tgtgtgataa tgcactcttt aatccaagtt 11940
catccaat gtttaatcta actcaggtta ttgatccac aacacaacta gactattttc 12000
ctaggataat atttgagagg ttaaaaagtt atgataccag ttcagactac aacaaaggga 12060
agttaacaag gaattacatg acattattac catggcaaca cgtaaacagg tacaattttg 12120
tcttttagttc tacagggttg aaagtcagtt tgaagacatg catcgggaaa ttgataaagg 12180
atttaaatcc taaagttctt tactttattg gagaaggagc aggttaactgg atggcaagaa 12240
cagcatgtga atatcctgat ataaaatttg tatataggag tttaaaggat gaccttgatc 12300
accattaccc attagaatat caaagggtaa taggtgatct aaatagggtg atagatagtg 12360
gtgaaggatt atcaatggaa accacagatg caactcaaaa aactcattgg gacttgatac 12420
acagaataag taaagatgct ttattgataa cattgtgtga tgcagaattc aaaaacagag 12480
atgatttctt taagatggta atcctttgga gaaaacatgt attatcttgt agaactctga 12540
cagcttatgg aacagatctt tactttattg caaagtatca tgcggtggac tgcaatataa 12600
aattaccatt ttttgtaaga tctgtagcta cttttattat gcaaggaagc aaattatcag 12660
ggtcagaatg ttacatactt ttaacattag gtcacacaa taatctaccc tgtcatggag 12720
aaatacaaaa ttccaaaatg agaatagcag tgtgtaatga tttctatgcc tcaaagaaac 12780
tggaacaaca atcaattgaa gcaactgca aatctcttct atcaggattg agaataccta 12840
taaacaiaaaa ggagttaaat agacaaaaga aattgttaac actacaaagt aaccattctt 12900
ctatagcaac agttggcggc agtaagatta tagaatccaa atgggttaaag aataaagcaa 12960
gtacaataat tgattgggtta gagcatattt tgaattctcc aaaaggtgaa ttaaactatg 13020
atttctttga agcattagag aacacatacc ccaatatgat caagcttata gataatttgg 13080
gaaatgcaga aataaagaaa ctaatcaagg tcactgggtg tatgcttgtg agtaagaagt 13140
aataataatg ataattgatta accataatct cacacaactg agaaaataat cgtctaacag 13200
tttagttgat cattagttat ttaaaattat aaaatagtaa ctaactgata aaaaatcaga 13260
aattgaaatt gaattgtatac ggtttttttg ccgt 13294

```

<210> 95

<211> 13350

<212> DNA

<213> human metapneumo virus

<400> 95

```

gtataaatta gattccaaaa aaatatggga caagtgaata tgtctcttca agggattcac 60
ctgagtgatt tatcatacaa gcatgctata ttaaaagagt ctgagtacac aataaaaaga 120
gatgtgggtg caacaactgc agtgacaccc tcatcattgc aacaagaaat aacactgttg 180
tgtggagaaa ttctgtatgc taaacatgct gactacaaat atgctgcaga aataggaata 240
caatatatta gcacagcttt aggatcagag agagtgcagc agattctgag gaactcaggc 300
agtgaagtcc aagtgggtctt aaccagaacg tactctctgg ggaaaattaa aaacaataaa 360

```

ggagaagatt	tacagatggt	agacatacac	ggggtagaga	agagctgggt	agaagagata	420
gacaaaagag	caaggaaaac	aatggcaacc	ttgcttaagg	aatcatcagg	taatatccca	480
caaaatcaga	ggccctcagc	accagacaca	cccataatct	tattatgtgt	aggtgcctta	540
atattcacta	aactagcatc	aacctagaaa	gtgggactag	agaccacagt	cagaagggct	600
aaccgtgtac	taagtgatgc	actcaagaga	taccctagaa	tggacatacc	aaagattgcc	660
agatccttct	atgacttatt	tgaacaaaaa	gtgtatcaca	gaagtttgtt	cattgagtat	720
ggcaaagcat	taggctcatc	atctacaggc	agcaaagcag	aaagtctatt	tgttaatatata	780
ttcatgcaag	cttatggggc	cgggtcaaaaca	atgctaagggt	gggggggtcat	tgccagggtca	840
tccaacaata	taatgttagg	acatgtatcc	gtccaagctg	agttaaaaaca	ggtcacagaa	900
gtctatgact	tgggtgcgaga	aatgggcccct	gaatctggac	ttctacattt	aaggcaaacg	960
ccaaaagctg	gactgttatc	actagccaac	tgtcccaact	ttgcaagtgt	tgttctcgga	1020
aatgcctcag	gcttaggcatt	aatcggtagt	tatcgaggga	gagtaccaa	cacagaatta	1080
ttttcagcag	ctgaaagtta	tgccaaaagt	ttgaaagaaa	gcaataaaat	aaattttctct	1140
tcattaggac	ttacagatga	agagaaaagag	gctgcagaac	atttcttaaa	tgtgagtgac	1200
gacagtcaaa	atgattatga	gtaattaaaa	aagtgggaca	agtcaaaatg	tcattccctg	1260
aaggaaaaga	tattcttttc	atgggtaatg	aagcagcaaa	attagcagaa	gctttccaga	1320
aatcatttaag	aaaaccagggt	cataaaagat	ctcaatctat	tataggagaa	aaagtgaata	1380
ctgtatcaga	aacatttgga	ttacctacta	tcagtagacc	tgcaaaaacca	accataccgt	1440
cagaaccaaa	gttagcatgg	acagataaag	gtggggcaac	caaaactgaa	ataaagcaag	1500
caatcaaagt	catggatccc	attgaagaag	aagagtctac	cgagaagaag	gtgctaccct	1560
ccagtgatgg	gaaaacccct	gcagaaaaga	aactgaaacc	atcaactaac	acaaaaaaga	1620
aggtttcatt	tacaccaa	gaaccaggga	aataatacaa	gttggaaaaa	gatgcttag	1680
atltgtcttc	agataatgaa	gaagaagatg	cagaatcttc	aatcttaacc	tttggaagaa	1740
gagatacttc	atcatthaagc	attgaggcca	gatttgaatc	aatagaggag	aaattaagca	1800
tgatattagg	gctattaaga	acactcaaca	ttgtctacagc	aggaccacac	gcagcaagag	1860
atgggatcag	agatgcaatg	attggcgtaa	gagagggaat	aatagcagac	ataataaagg	1920
aagctaaagg	gaaagcagca	gaaatgatgg	aagagggaat	gagtcaacga	tcaaaaatag	1980
gaaatggtag	tgtaaaatta	acagaaaaag	caaaagagct	caacaaaatt	gttgaagatg	2040
aaagcacaag	tggagaatcc	gaagaagaag	aagaacccaa	agacacacaa	gacaatagtc	2100
aagaagatga	catttaccag	ttaattatgt	agtttaataa	aaataaacaa	tgggacaagt	2160
aaaaatggag	tcctacctag	tagacaccta	tcaaggcatt	ccttacacag	cagctgttca	2220
agttgatcta	atagaaaagg	acctgttacc	tgcaagccta	acaatatggt	tccctttgtt	2280
tcaggccaac	acaccaccag	cagtgtctgt	cgatcagcta	aaaaccctga	caataaccac	2340
tctgtatgct	gcatacacia	atgggtccaat	actcaaagtg	aatgcatcag	cccaagggtgc	2400
agcaatgtct	gtacttccca	aaaaatttga	agtcfaatcg	actgtagcac	tcgatgaata	2460
tagcaaatcg	gaatttgaca	aactcacagt	ctgtgaagta	aaaacagttt	acttaacaac	2520
catgaaacca	tacgggatgg	tatcaaaatt	tgtagagctca	gccaaatcag	ttggcaaaaa	2580
aacacatgat	ctaactgcac	tatgtgattt	tatggatcta	gaaaagaaca	cacctgttac	2640
aataccagca	ttcatcaaat	cagtttcaat	caaagagagt	gagtcagcta	ctgttgaagc	2700
tgctataagc	agtgaagcag	accaagctct	aacacaggcc	aaaattgcac	cttatgcggg	2760
attaattatg	atcatgacta	tgaacaatcc	caaaggcata	ttcaaaaagc	ttggagctgg	2820
gactcaagtc	atagtagaac	taggagcata	tgtccaggct	gaaagcataa	gcaaaatatg	2880
caagacttgg	agccatcaag	ggacaagata	tgtcttgaag	tccagataac	aaccaagcac	2940
cttggccaag	agctactaac	cctatctcat	agatcataaa	gtcaccattc	tagttatata	3000
aaaatcaagt	tagaacaaga	attaaatcaa	tcaagaacgg	gacaaaataa	aatgtcttgg	3060
aaagtggtag	tcattttttc	attgttaata	acacctcaac	acggtcttaa	agagagctac	3120
ttagaagagt	catgtagcac	tataactgaa	ggatatttca	gtgttctgag	gacaggttgg	3180
tacaccaatg	tttttacct	ggaggtaggc	aggttagaga	accttacatg	tgcgagtgga	3240
cccagcttaa	taaaaacaga	attagacctg	acaaaaagtg	cactaagaga	gctcagaaca	3300
gtttctgctg	atcaactggc	aagagaggag	caaattgaaa	atcccagaca	atctagattc	3360
gttctaggag	caatagcact	cgggtgttga	actgcagctg	cagttacagc	aggtgttgca	3420
attgccccaa	ccatccggct	tgaagtgaa	gtaacagcaa	ttaagaatgc	cctcaaaaag	3480
accaatgaag	cagtatctac	attggggaat	ggagtctctg	tgttggcaac	tcgagtga	3540
gagctgaaag	attttgtgag	caagaatcta	acacgtgcaa	tcaacaaaaa	caagtgcgac	3600
attgctgacc	tgaaaatggc	cgttagcttc	agtcaattca	acagaagggt	cctaaatgtt	3660
gtgcggcaat	tttcagacaa	cgctggaata	acaccagcaa	tatctttgga	cttaatgaca	3720
gatgctgaac	tagccagagc	tgtttccaac	atgccaacat	ctgcaggaca	aataaaaactg	3780
atgttggaga	accgtgcaat	ggtaagaaga	aaagggttcg	gattcctgat	aggagtttac	3840
ggaagctccg	taattttacat	gggtgcaactg	ccaatctttg	gggttataga	cacgccttgc	3900
tggaatagtaa	aagcagcccc	ttcttgttca	ggaaaaaagg	gaaactatgc	ttgcctctta	3960
agagaagacc	aaggatggta	ttgtcaaaat	gcagggtcaa	ctgtttacta	cccaaatgaa	4020
aaagactgtg	aaacaagagg	agaccatgtc	ttttgcgaca	cagcagcagg	aatcaatgtt	4080

gctgagcagt	caaaggagtg	caacataaac	atatctacta	ctaattaccc	atgcaaagtt	4140
agcacaggaa	gacatcctat	cagtatgggt	gcactatctc	ctcttggggc	tttggttgct	4200
tgctacaagg	gagtggagctg	ttccattggc	agcaacagag	tagggatcat	caagcaactg	4260
aacaaaggct	gctcttatat	aaccaaccaa	gacgcagaca	cagtgacaat	agacaacact	4320
gtataccagc	taagcaaaagt	tgaaggcgaa	cagcatgtta	taaaaggaag	gccagtgtca	4380
agcagctttg	accagtgcaa	gtttcctgaa	gatcaattca	atgttgcaact	tgaccaagtt	4440
ttcgagagca	ttgagaacag	tcaggccttg	gtggatcaat	caaacagaat	cctaagcagt	4500
gcagagaaaag	gaaacactgg	cttcatcatt	gtaataattc	taattgctgt	ccttggctct	4560
accatgatcc	tagtgagtggt	ttttatcata	ataaagaaaa	caaagaaacc	cacaggagca	4620
cctccagagc	tgagtgggtg	cacaaacaat	ggcttcatac	cacataatta	gttaattaaa	4680
aataaagtaa	attaaaataa	attaaaatta	aaaataaaaa	tttgggacaa	atcataatgt	4740
ctcgcaaggc	tccgtgcaaa	tatgaagtgc	ggggcaaatg	caatagagga	agtgagtgca	4800
agtttaacca	caattactgg	agttggccag	atagatactt	attaataaga	tcaaattatt	4860
tattaaatca	acttttaagg	aacactgata	gagctgatgg	cttatcaata	atatcaggag	4920
caggcagaga	agataggaca	caagattttg	tcctaggttc	caccaatgtg	gttcaagggt	4980
atattgatga	taaccaaagc	ataacaaaag	ctgcagcctg	ttacagtcta	cataatataa	5040
tcaaaacaact	acaagaagtt	gaagttaggc	aggctagaga	taacaaacta	ctgacagca	5100
aacatgtagc	acttcacaac	ttagtcctat	cttatatgga	gatgagcaaa	actcctgcat	5160
ctttaatcaa	caatctcaag	agactgccga	gagagaaact	gaaaaaatta	gcaaagctca	5220
taattgactt	atcagcaggt	gctgaaaatg	actcttcata	tgcccttgcaa	gacagtgaag	5280
gcactaatca	agtgcagtg	gcatgggtcca	gttttcatta	ctatagaggt	tgatgacatg	5340
atatggactc	acaaggactt	aaaagaagct	tatatctgat	ggatagtga	gtctcatact	5400
aacattttaca	attgttattt	agaaaacata	gaaattatat	atgtcaaggc	ttacttaagt	5460
tagtaaaaac	acatcagagt	gggataaatg	acaatgataa	cattagatgt	cattaaaagt	5520
gatgggtctt	caaaaacatg	tactcacctc	aaaaaaataa	ttaaagacca	ctctggtaaa	5580
gtgcttattg	tacttaagtt	aatattagct	ttactaacat	ttctcacagt	aacaatcacc	5640
atcaattata	taaaagtgg	aaacaatctg	caaatatgcc	agtcaaaaaac	tgaatcagac	5700
aaaaaggact	catcatcaaa	taccacatca	gtcacacaac	agactactct	aatcatgat	5760
atcacacagt	attttaaaag	tttgattcaa	aggatatacaa	actctgcaat	aaacagtgc	5820
acatgctgga	aaataaacag	aaatcaatgc	acaatatata	caacatacaa	atttttatgt	5880
tttaaatctg	aagacacaaa	aaccaacaat	tgtgataaac	tgacagattt	atgcagaaac	5940
aaaccaaacc	cagcagttgg	agtgtatcac	atagttagaat	gccattgtat	atacacagtt	6000
aaatgggaagt	gctatcatta	cccaaccgat	gaaacccaat	cctaaatgtt	aacaccagat	6060
taggatccat	ccaagtctgt	tagttcaaca	atttagttat	ttaaaaatat	tttgaaaaac	6120
agtaagtctt	catgataact	cataataata	agtaataatt	aattgcttaa	tcactcatcac	6180
aacattattc	gaaaccataa	ctattcaatt	taaaaagtaa	aaaacaataa	catggggacaa	6240
gtagttatgg	aggtgaaagt	ggagaacatt	cgaacaatag	atatgctcaa	agcaagagta	6300
aaaaatcggt	tggcacgcag	caaatgcttt	aaaaatgcct	ctttggtcct	cataggaata	6360
actacattga	gtattgcctt	caatatctat	ctgatcataa	actataaaaat	gcaaaaaaac	6420
acatctgaat	cagaacatca	caccagctca	tcaccatggg	aatccagcag	agaaactcca	6480
acggtcccca	cagacaactc	agacaccaac	tcaagcccac	agcatccaac	tcaacagtc	6540
acagaaggct	ccacactcta	ctttgcagcc	tcagcaagct	caccagagac	agaaccaaca	6600
tcaacaccag	atacaacaaa	ccgcccgcct	ttcgtcgaca	cacacacaac	accaccaagc	6660
gcaagcagaa	caaagacaag	tcgggcagtc	cacacaaaaa	acaacccaag	gacaagctct	6720
agaacacatt	ctccaccacg	ggcaacgaca	aggacggcac	gcagaaccac	cactctccgc	6780
acaagcagca	caagaaagag	accgtccaca	gcactagtc	aacctgacat	cagcgaaca	6840
accacaacaa	acgaagaagc	aagtcacg	agcccaacaa	catctgcaag	cacaacaaga	6900
atacaaaagga	aaagcgtgga	ggccaacaca	tcaacaacat	acaaccaaac	tagttaacaa	6960
aaaatacaaa	ataactctaa	gataaaccat	gcagacacca	acaatggaga	agccaaaaga	7020
caattcacaa	tctcccaaaa	aaggcaacaa	caccatatta	gctctgcca	aatctccctg	7080
gaaaaaacac	tcgcccata	acaaaaaata	ccacaaccac	cccaagaaaa	aaactgggca	7140
aaacaacacc	caagagacaa	ataacaatgg	atcctctcaa	tgaatccact	gttaatgtct	7200
atcttccctg	ctcatatctt	aaaggagtga	tttcttttag	tgagactaat	gcaattgggt	7260
catgtctctt	aaaaagacct	tacctaaaaa	atgacaacac	tgcaaaagtt	gccatagaga	7320
atcctgttat	cgagcatggt	agactcaaaa	atgcagtcaa	ttctaagatg	aaaatatcag	7380
attacaagat	agtagagcca	gtaaacatgc	aacatgaaat	tatgaagaat	gtacacagtt	7440
gtgagctcac	attattaaaa	cagtttttaa	caaggagtaa	aaatattagc	actctcaaat	7500
taaatatgat	atgtgattgg	ctgcagttaa	agtctacatc	agatgatacc	tcaatcctaa	7560
gttttataga	tgtagaattt	atacctagct	gggttaagcaa	ttgggttagt	ttaattgtaca	7620
atctcaacaa	gttgattctg	gaattcagga	aagaagaagt	aataagaact	ggttcaatct	7680
tgtgtaggtc	attgggtaaa	ttagtttttg	ttgtatcatc	atatggatgt	atagtcaaga	7740
gcaacaaaag	caaaagagtg	agcttcttca	catacaatca	actgttaaca	tggaagatg	7800

tgatgttaag	tagattcaat	gcaaattttt	gtatatgggt	aagcaacagt	ctgaatgaaa	7860
atcaagaagg	gctaggggtt	agaagtaatc	tgcaaggcat	attaactaat	aagctatatg	7920
aaactgtaga	ttatatgctt	agtttatgtt	gcaatgaagg	tttctcactt	gtgaaagagt	7980
tcgaaggcct	tattatgagt	gaaattctta	ggattactga	acatgctcaa	ttcagtacta	8040
gatttagaaa	tactttatta	aatggattaa	ctgatcaatt	aacaaaatta	aaaaataaaa	8100
acagactcag	agttcatggt	accgtgttag	aaaataatga	ttatccaatg	tacgaagttg	8160
tacttaagtt	attaggagat	actttgagat	gtattaaatt	attaatcaat	aaaaacttag	8220
agaatgctgc	tgaattatac	tatatattta	gaatattcgg	tcacccaatg	gtagatgaaa	8280
gagatgcaat	ggatgctgtc	aaattaaaca	atgaaatcac	aaaaatcctt	agggtgggaga	8340
gcttgacaga	actaagaggg	gcattcatat	taaggattat	caaaggattt	gtagacaaca	8400
acaaaagatg	gcccaaaatt	aaaaacttaa	aagtgccttag	taagagatgg	actatgtact	8460
tcaaagcaaaa	aagttacccc	agtcaacttg	aattaagcga	acaagatttt	ttagagcttg	8520
ctgcaataca	gtttgaacaa	gagttttctg	tccctgaaaa	aaccaacctt	gagatgggat	8580
taaatgataa	agctatatca	cctcctaaaa	gattaatatg	gtctgtgtat	ccaaaaaatt	8640
acttacctga	gaaaataaaa	aatcgatatc	tagaagagac	tttcaatgca	agtgatagtc	8700
tcaaaaacaag	aagagtacta	gagtactatt	tgaagataaa	taaattcgac	caaaaagaac	8760
ttaaaagtta	tggtgttaaa	caagaatatt	taaatgataa	ggatcatatt	gtctcgctaa	8820
ctggaaaaga	aagagaatta	agtgtaggta	aatgtttgct	tatgcaacca	ggaaaacagc	8880
gacaaataca	aatattggct	gaaaaattgt	tagctgataa	tattgtacct	tttttcccag	8940
aaaccttaac	aaagtatggt	gatctagatc	ttcagagaat	aatggaaatc	aaatcggaac	9000
tttcttctat	taaaactaga	agaaatgata	gttataataa	ttacattgca	agagcatcca	9060
tagtaacaga	tttaagtaag	ttcaaccaag	cctttaggta	tgaactaca	gcgatctgtg	9120
cggatgtagc	agatgaacta	catggaacac	aaagcctatt	ctggtgggta	catcttatcg	9180
tccctatgac	acaaatgata	tgtgcctata	gacatgcacc	accagaaaca	aaaggtgaat	9240
atgatataga	taagatagaa	gagcaaagtg	gtttatatag	atatcatatg	gggtggtattg	9300
aaggatgggtg	tcaaaaactc	tggacaatgg	aagctatatc	tctattagat	gttgtatctg	9360
taaaaacacg	atgtcaaagt	acatctttat	taaacggtga	caaccaatca	atagatgtaa	9420
gtaaacacgt	taagtatatc	gaggggttag	atgaagtga	agcagattat	agcttggctg	9480
taaaaatggt	aaaagaaata	agagatgcat	acagaaatat	aggccataaa	cttaaagaag	9540
gggaaaacata	tatatcaaga	gatcttcagt	ttataagtaa	ggtgattcaa	tctgaaggag	9600
taatgcatcc	taccctata	aaaaagatct	taagagtggg	accatggata	aacacaatat	9660
tagatgacat	taaaaccagt	gcagagtcaa	tagggagtct	atgtcaggaa	ttagaattta	9720
gggggggaaag	cataatagtt	agtctgatat	taaggaaatt	ttggctgtat	aattttatata	9780
tgcatgaatc	aaagcaacac	cccctagcag	ggaagcagtt	attcaaacaa	ctaaaataaaa	9840
cattaacatc	agtgcagaga	ttttttgaaa	taaaaaagga	aatgaagta	gtagatctat	9900
ggatgaacat	accaatgcag	tttgaggag	gagatccagt	agtcttctat	agatctttct	9960
atagaaggac	ccctgatttt	ttaactgaag	caatcagtc	tgtggatatt	ctggttaagaa	10020
tatcagccaa	cataagaaat	gaagcgaaaa	taagtttctt	caaagcctta	ctgtcaatag	10080
aaaaaaatga	acgtgctaca	ctgacaacac	taatgagaga	tcctcaagct	gttgggtcag	10140
agcgacaagc	aaaagtaaca	agtgatatca	atagaacagc	agttaccagc	atcttaagtc	10200
tttctccaaa	tcaacttttc	agcgatagtg	ctatacacta	cagtagaaat	gaagaagagg	10260
tcggaatcat	tgtgacaaac	ataacacctg	tttatcctca	tggactgaga	gtttttgtatg	10320
aatcattacc	ttttcataaa	gctgaaaaag	ttgtgaatat	gatatcagga	acgaaatcca	10380
taaccaactt	attacagaga	acatctgcta	ttaatgggtga	agatattgac	agagctgtat	10440
ccatgatgct	ggagaacctt	ggattattat	ctagaatatt	gtcagtagtt	gttgatagta	10500
tagaaattcc	aaccaaattc	aatggtaggc	tgatatgttg	tcagatatct	agaaccctaa	10560
gggagacatc	atggaataat	atggaaatag	ttggagtaac	atcccctagc	atcactacat	10620
gcattggatgt	catatatgca	actagctctc	atttgaaagg	gataatcatt	gaaaagttca	10680
gcaatgcag	aactacaaga	ggtcaaagag	gtccaaagag	cccttgggta	gggtcgagca	10740
ctcaagagaa	aaaattagtt	cctgtttata	acagacaaat	tctttcaaaa	caacaaagag	10800
aacagctaga	agcaattgga	aaaatgagat	gggtatataa	agggacacca	ggtttaagac	10860
gattactcaa	taagatttgt	cttggaagtt	taggcattag	ttacaaatgt	gtaaaacctt	10920
tattacctag	gtttatgagt	gtaaatttcc	tacacaggtt	atctgtcagt	agtagacctt	10980
tggaaattcc	agcatcagtt	ccagcttata	gaacaacaaa	ttaccatttt	gacactagtc	11040
ctattaatca	agcactaagt	gagagatttg	ggaatgaaga	tattaatttg	gtcttccaaa	11100
atgcaatcag	ctgtggaatt	agcataatga	gtgtagtaga	acaattaact	ggtaggagtc	11160
caaaacagtt	agtttttaata	cctcaattag	aagaaataga	cattatgcca	ccaccagtg	11220
ttcaaggggaa	attcaattat	aagctagtag	ataagataac	ttctgatcaa	catatcttca	11280
gtccagacaa	aatagatatg	ttaacactgg	ggaaaatgct	catgcccact	ataaaaggct	11340
agaaaaacaga	tcagttcctg	aacaagagag	agaattattt	ccatggggaat	aatcttattg	11400
agtcctttgtc	agcagcggtt	ggtgtgggat	attaacagag	caatgtatag	caatgtatag	11460
aaaataatat	tttcaagaaa	gactgggggtg	acgggttcat	atcggtatcat	gcttttatgg	11520


```

acttcaaaat attcctatgt gtcttttaaaa ctaaactttt atgtagttgg ggggtcccaag 11580
ggaaaaacat taaagatgaa gatatagtag atgaatcaat agataaactg ttaaggattg 11640
ataatacttt ttggagaatg ttcagcaagg ttatgtttga atcaaagggt aagaaaagga 11700
taatgttata tgatgtaaaa tttctatcat tagtaggtta tatagggttt aagaattggg 11760
ttatagaaca gttgagatca gctgagttgc atgaggtacc ttggattgtc aatgccgaag 11820
gtgatctggg tgagatcaag tcaattaaaa tctatttgca actgatagag caaagtttat 11880
ttttaagaat aactgttttg aactatacag atatggcaca tgctctcaca agattaatca 11940
gaaagaagtt gatgtgtgat aatgcactat taactccgat tccatcccca atgggttaatt 12000
taactcaagt tattgatcct acagaacaat tagcttattt ccctaagata acatttgaaa 12060
ggctaaaaaa ttatgacact agttcaaatt atgctaaagg aaagctaaca agcaaatgata 12120
tgatactgtt gccatggcaa catgttaata gatataactt tgtctttagt tctactggat 12180
gtaaaagttag tctaaaaaca tgcattggaa aacttatgaa agatctaacc cctaaagttc 12240
tgtactttat tggagaaggg gcaggaaatt ggatggccag aacagcatgt gaatatcctg 12300
acatcaaatt tgtatacaga agtttaaaag atgaccttga tcatcattat cctttggaat 12360
accagagagt tataggagaa ttaagcagga taatagatag cgggtgaagg ctttcaatgg 12420
aaacaacaga tgcaactcaa aaaactcatt gggatttgat acacagagta agcaaatgata 12480
ctttattaat aactttatgt gatgcagaat ttaaggacag agatgatttt tttaatgagg 12540
taattctatg gaggaacat gtattatcat gcagaatttg cactacttat gggacagacc 12600
tctatttatt cgcaaagtat catgctaaag actgcaatgt aaaattacct ttttttgtga 12660
gatcagtagc cacctttatt atgcaaggta gtaaaactgtc aggtcagaa tgctacatac 12720
tcttaacact aggccaccac aacaatttac cctgccatgg agaaatacaa aattctaaga 12780
tgaaaatagc agtgtgtaat gatttttatg ctgcaaaaaa acttgacaat aaatctattg 12840
aagccaactg taaatcactt ttatcagggc taagaatacc gataaataag aaagaattaa 12900
atagacagag aaggttatta acactacaaa gcaaccattc ttctgtagca acagtggag 12960
gtagcaaggt catagagtct aaatggttaa caaacaaggc aaacacaata attgattggt 13020
tagaacatat tttaaattct ccaaaagggt aattaaatta tgattttttt gaagcattag 13080
aaaatactta ccctaatatg attaaactaa tagataatct aggggaatgca gagataaaaa 13140
aactgatcaa agtaactgga tatatgcttg taagtaaaaa atgaaaaatg ataaaaatga 13200
taaaataggt gacaacttca tactattcca aagtaatcat ttgattatgc aattatgtaa 13260
tagttaatta aaaactaaaa atcaaaagtt agaaaactaac aactgtcatt aagtttatta 13320
aaaataagaa attataattg gatgtatagc 13350

```

<210> 96

<211> 13215

<212> DNA

<213> human metapneumo virus

<400> 96

```

acgcgaaaaa aacgcgtata aattaagtta caaaaaacca tgggacaagt gaaaatgtct 60
cttcaaggga ttcacctgag tgatctatca tacaagcatg ctatattaaa agagtctcag 120
tatacaataa agagagatgt aggcacaaca accgcagtga caccctcatc attgcaacaa 180
gaaataacac tattgtgtgg agaaattcta tatgctaagc atgctgatta caaatatgct 240
gcagaaatag gaatacaata tattagcaca gctctaggat cagagagagt acagcagatt 300
ctaagaaact caggtagtga agtccaagtg gttttaacca gaacgtactc cttggggaaa 360
gttaaaaaa acaaaggaga agatttacag atgttagaca tacacggagt agagaaaaagc 420
tggttggaag agatagacaa agaagcaaga aaaacaatgg caactttgct taaagaatca 480
tcaggcaata ttccacaaaa tcagaggcct tcagcaccag acacacccat aatcttatta 540
tgtgtagggt ccttaatat taccaaaacta gcatcaacta tagaagtggg attagagacc 600
acagtcagaa gagctaaccg tgtactaagt gatgcactca aaagataccc taggatggac 660
ataccaaaaa tcgctagatc tttctatgac ttatttgaac aaaaagtgtg ttacagaagt 720
ttgttcattg agtatggcaa agcattaggt tcatcctcta caggcagcaa agcagaaagt 780
ttattcgtta atatattcat gcaagcttac ggtgctgggc aaacaatgct gaggtgggga 840
gtcattgccca ggcatctaa caatataatg ttaggacatg tatctgttca agctgagtta 900
aaacaagtca cagaagtcta tgacctgggt cgagaaatgg gcctgaatc tgggctccta 960
catttaaggc aaagcccaaa agctggactg ttatcactag ccaattgtcc caactttgct 1020
agtgttgctc tcggcaatgc ctcaggctta ggcataatag gtatgtatcg cgggagagt 1080
ccaaacacag aactattttc agcagcagaa agctatgcca agagtgtgaa agaaagcaat 1140
aaaattaact tttcttcatt aggactcaca gatgaagaaa aagaggctgc agaacacttc 1200
ctaaatgtga gtgacgacag tcaaaatgat tatgagtaat taaaaaatg ggacaagtca 1260
aaatgtcatt ccctgaagga aaagatatct ttttcatggg taatgaagca gcaaaattgg 1320

```

cagaagcttt	tcaaaaatca	ttaagaaaac	ctaatacataa	aagatctcaa	tctatttatag	1380
gagaaaaagt	gaacactgta	tctgaaacat	tgggaattacc	tactatcagt	agacctacca	1440
aaccgacccat	attgtcagag	ccgaagttag	catggacaga	caaagggtggg	gcaatcaaaa	1500
ctgaagcaaaa	gcaaaacaatc	aaagtttatgg	atcctatttga	agaagaagag	tttactgaga	1560
aaaggggtgct	gccctccagt	gatgggaaaa	ctcctgcaga	aaagaagttg	aaacctcaaa	1620
ccaacactaaa	aaagaaggctc	tcattttacac	caaatagaacc	aggaaaatac	acaaagttgg	1680
agaaagatgc	tctagacttg	ctttcagaca	atgaagaaga	agatgcagaa	tcctcaatct	1740
taacctttcga	agaaagagat	acttcacatcat	taagcattga	agccagacta	gaatcgattg	1800
aggagaaaatt	aagcatgata	ttagggtctat	taagaacact	caacattgct	acagcaggac	1860
ccacagcagc	aagagatggg	atcagagatg	caatgattgg	cataagggag	gaactaatag	1920
cagacataat	aaaagaagcc	aagggaagaa	cagcagaaa	gatggaagaa	gaaatgaacc	1980
agcggacaaa	aataggaaac	ggtagtgtaa	aattaaactga	aaaggcaaa	gagctcaaca	2040
aaattgtttga	agacgaaagc	acaagtgggtg	aatccgaaga	agaagaagaa	ccaaaagaca	2100
cacaggaaaa	taatcaagaa	gatgacattt	accagttaat	tatgtagtgtt	aataaaaaata	2160
aaaatgggac	aagtgaagaa	ggagtcctat	ctggtagaca	cttatcaagg	catcccttac	2220
acagcagctg	ttcaagttga	tctagtagaa	aaggacctgt	tacctgcaag	cctaacaata	2280
tgggtccctt	tggttcaggc	caatacacca	ccagcagttc	tgcttgatca	gctaaagact	2340
ctgactataa	ctactctgta	tgctgcatca	caatactaaa	agtgaaatgca	tgcgactgta	2400
tcagcccagg	gtgcagcaat	gtctgtactt	cccaaaaagt	ttgaagtcaa	agtaaaaaaca	2460
gcacttgacg	aatatagcaa	attagaattt	gacaaactta	cagtctgtga	ctcggccaaa	2520
gtttacttaa	caaccatgaa	accatatggg	atgggtatcaa	agtttgtgag	tctagaaaag	2580
tcagttggca	aaaaaacaca	tgatctaatac	gcattatgtg	atcttatgga	gagtgaaatg	2640
aacacaccag	ttacaatacc	agcattttatc	aaatcagttt	ctatcaagga	agcgaataat	2700
gccactgttg	aagctgcaat	aagcagtgaa	gcagaccaag	ctctaacaca	catattcaag	2760
gcaccttatg	cgggactgat	catgattatg	accatgaaca	atcccaaagg	ggctgaaagc	2820
aagcttggag	ctgggaccca	agttatagta	gaactaggag	catatgtcca	gaagtccagt	2880
ataagtaaaa	tatgcaagac	ttggagccat	caaggaacaa	gatatgtgct	aaaagtcgcc	2940
taacagccaa	gcaacctggc	caagaactac	caactctatt	ctatagacta	tcaatcaaga	3000
attttagtta	tataaaaaatc	aagttagaat	aagaattaaa	tcaatcaaga	acgggacaaa	3060
taaaaatgtc	ttggaaagtg	gtgatcattt	ttctatgtgt	aataacacct	caacacgggtc	3120
ttaaagagag	ctacctagaa	gaatcatgta	gcactataac	tgagggatat	cttagtggtc	3180
tgaggacagg	ttggtatacc	aacgttttta	cattagaggt	gggtgatgta	gaaaaccta	3240
catgtttctga	tggacctagc	ctaataaaaa	cagaattaga	tctgacccaa	agtgactaa	3300
gagagctcaa	aacagtctct	gctgaccaat	tggcaagaga	ggaacaaatt	gagaatccca	3360
gacaatctag	gtttgttcta	ggagcaatag	cactcgggtg	tgcaacagca	gctgcagtca	3420
cagcaggtgt	tgcaattgcc	aaaaccatcc	ggcttgagag	tgaagtcaca	gcaattaaga	3480
atgccctcaa	aacgaccaat	gaagcagtat	ctacattggg	gaatggagtt	cgagtgttgg	3540
caactgcagt	gagagagcta	aaagactttg	tgagcaagaa	tttaactcgt	gcaatcaaca	3600
aaaacaagtg	cgacattgat	gacctaaaaa	tggctgttag	cttcagtcga	ttcaacagaa	3660
ggttttctaaa	tgttgtgcgg	caatttttcag	acaatgctgg	aataacacca	gcaatatctt	3720
tggacttaat	gacagatgct	gaactagcca	gggcccgtttc	taacatgccg	acatctgcag	3780
gacaaataaa	attgatgttg	gagaaccgtg	cgatggtgcg	aagaaagggg	ttcggaatcc	3840
tgataggggt	ctacgggagc	tccgtaattt	acacggtgca	gctgccaatc	tttggcgtaa	3900
tagacacgcc	ttgctggata	gtaaaagcag	ccccttcttg	ttccgaaaaa	aagggaaact	3960
atgcttgcc	cttaagagaa	gaccaagggg	ggtattgtca	gaatgcaggg	tcaactgttt	4020
actacccaaa	tgagaaagac	tgtgaaacaa	gaggagacca	tgtcttttgc	gacacagcag	4080
caggaattaa	tgttgctgag	caatcaaagg	agtgaacat	caacatatcc	actacaaatt	4140
acccatgcaa	agtcagcaca	ggaagacatc	ctatcagtat	ggttgcaactg	tctcctcttg	4200
gggctctgg	tgcttgctac	aaaggagtaa	gctgttccat	tggcagcaac	agagttaggga	4260
tcatcaagca	gctgaacaaa	ggttgctcct	atataaccaa	ccaagatgca	gacacagtga	4320
caatagacaa	cactgtatat	cagctaagca	aagttgaggg	tgaacagcat	gttataaaa	4380
gcagaccagt	gtcaagcagc	tttgatccaa	tcaagtttcc	tgaagatcaa	ttcaatgttg	4440
cacttgacca	agtttttgag	aacattgaaa	acagccaggc	cttagtagat	caatcaaaaca	4500
gaatcctaag	cagtgcagag	aaagggaata	ctggctttat	cattgtaata	attctaattg	4560
ctgtccttgg	ctctagcatg	atcctagtga	gcattctcat	tataatcaag	aaaacaaaga	4620
aaccaacggg	agcacctcca	gagctgagtg	gtgtcacaaa	caatggcttc	ataccacaca	4680
gtaggttaat	taaaaataaa	ataaaatttg	ggacaaatca	taatgtctcg	caaggctcca	4740
tgcaaatatg	aagtgcgggg	caaatgcaac	agaggaagtg	agtgtaaagt	taaccacaat	4800
tactggagtt	ggccagatag	atacttatta	ataagatcaa	actatctatt	aaatcagctt	4860
ttaaggaaca	ctgatagagc	tgatggccta	tcaataatat	caggcgagcag	cagagaagac	4920
agaacgcaag	attttgttct	aggttccacc	aatgtggttc	aagggttatat	tgatgataac	4980
caaagcataa	caaaagctgc	agcctgctac	agtctacaca	acataatcaa	gcaactacaa	5040

gaagttgaag	ttaggcaggc	tagagatagc	aaactatctg	acagcaagca	tgtggcactc	5100
cataacttaa	tcttatctta	catggagatg	agcaaaactc	cgcgcatctt	aatcaacaat	5160
cttaaaagac	tgccgagaga	aaaactgaaa	aaattagcaa	agctgataat	tgacttatca	5220
gcaggcgctg	acaatgactc	ttcatatgcc	ctgcaagaca	gtgaaagcac	taatcaagtg	5280
cagtgagcat	ggctctgttt	tcattactat	agagggtgat	gaaatgatat	ggactcaaaa	5340
agaattaaaa	gaagctttgt	ccgatgggat	agtgaagtct	cacaccaaca	tttacaattg	5400
ttatttagaa	aacatagaaa	ttatatatgt	caaggcttac	ttaagttagt	aaaaacacac	5460
atcagagtgg	gataagtga	aatgataaca	ttagatgtca	ttaaaagtga	tgggtcttca	5520
aaaacatgta	ctcacctcaa	aaaaataatc	aaagaccatt	ctggtaaagt	gcttatgtga	5580
cttaagttaa	tattagcttt	actaacatct	ttcacaataa	caatcactat	aaattacata	5640
aaagttagaaa	acaatctaca	aatatgccag	tcaaaaactg	aatcagacaa	agaagactca	5700
ccatcaaata	ccacatccgt	cacaaccaag	actactctag	accatgatat	aacacagtat	5760
tttaaaagat	taattcaaag	gtatacagat	tctgtgataa	acaaggacac	atgctggaaa	5820
ataagcagaa	atcaatgcac	aaatataaca	acatataaat	ttttatgctt	taaacctgag	5880
gactcaaaaa	tcaacagttg	tgatagactg	acagatctat	gcagaaacaa	atcaaaatca	5940
gcagctgaag	catatcatat	agtgaatgac	acttgcatat	acacaattga	gtggaagtgc	6000
tatcaccacc	caatagatta	aacccaattt	tgaatgttaa	aactagacta	ggatccgtct	6060
aagactatca	gttcaatagt	ttagttatct	aaaaatatct	gagaacaggt	aagtttctat	6120
ggcacttcat	agcaataggt	aataattaac	agcttaatta	taattaaaac	attattttaa	6180
accgtaacta	tttaattttac	aaagtaaaaa	caaaaatatg	ggacaagtag	ttatggaggt	6240
gaaagtagag	aacattcgag	caatagacat	gctcaaagca	agagtgaata	atcgtgtggc	6300
acgtagcaaa	tgctttaaaa	atgcttcttt	aatcttcata	ggaataacta	cactgtagat	6360
agctctcaat	atctatctga	tcataaacta	cacaatacaa	aaaaccacat	ccgaatcaga	6420
acaccacacc	agctcaccac	ccacagaacc	caacaaggaa	gcttcaacaa	tctccacaga	6480
caaccagac	atcaatccaa	gctcacagca	tccaactcaa	cagtcacacag	aaaaccccac	6540
actcaacccc	gcagcatcag	cgagcccatc	agaaacagaa	ccagcatcaa	caccagacac	6600
aacaaaaccg	ctgtcctccg	tagacaggtc	cacagcacia	ccaagtgaat	gcagaaacaa	6660
gacaaaaccg	acagtccaca	caatcaacaa	cccaaacaca	gcttccagta	cacaatcccc	6720
accacggaca	acaacgaagg	caatccgcag	agccaccact	ttccgcatga	gcagcacagg	6780
aaaaagacca	accacaacat	tagtccagtc	cgacagcagc	accacaaccc	aaaatcatga	6840
agaaaagagt	tcagcgaacc	cacaggcgct	tgcaagcaca	atgcaaaaact	agcacacca	6900
taatataaaa	ccaaattagt	taacaaaaaa	tgcgagatag	ctctaaagca	aaacatgtag	6960
gtaccaacaa	tcagaaacc	aaaagacaac	tcacaatctc	cctaaaacag	caacgcaccc	7020
atgtcagctt	tgtcaaatc	tctctgggag	aaacttctac	ccacatacta	acaacatcac	7080
aaccatctca	agaaaagaaa	ctgggcacaa	cagcatccaa	gagacaaata	gcaatggatc	7140
ctcttaatat	atccactgtt	aatgtctatc	tccttgattc	gtaccttaaa	ggagtaattt	7200
cttttagtga	aactaatgca	attgggtcat	gtctcttaaa	aagaccttac	ttaaaaaatg	7260
acaacactgc	aaaagttggc	atagagaatc	ctgttatgtg	gcagtgtgga	ctcaaaaatg	7320
cagtcaattc	taaaatgaaa	atatcagatt	acaaggtagt	agagccagta	aacatgcaac	7380
atgaaataat	gaagaatgta	cacagttgtg	agctcacact	attgaaacag	tttttaacaa	7440
ggagtaaaaa	cattagcact	ctcaaattaa	atatgatatt	tgattggctg	caattaaagt	7500
ctacatcaga	tgatacctca	atcctaagtt	tcatagatgt	agaattttata	cctagttggg	7560
taagcaactg	gttttagta	tggtacaatc	tcaataagtt	aattttggaa	ttcagaagag	7620
aggaagtta	aagaaccggt	tcaatcttat	gcaggtcatt	gggtaaatta	gttttttatt	7680
tatcatcata	cggatgtatc	gtcaagagca	acaaaagcaa	aagagtgagc	ttcttcacat	7740
acaatcaact	gttaacatgg	aaagatgtga	tgtttaagtag	atttaatgag	aatttttgta	7800
tatgggtta	caatagtctg	aatgaaaatc	aggaagggtc	aggggttaaga	agtaatctac	7860
aaggtatgtt	aactaataaa	ctatatgaaa	ctgtagatta	tatgctaagt	ttatgttgca	7920
atgaaggttt	ctcacttgta	aaagagttcg	aagggttttat	tatgagtga	atccttagga	7980
ttactgaaca	tgctcaattc	agtactagat	ttagaaaatc	tttatataat	ggattaacag	8040
atcaattaac	aaaattaaaa	aataaaaaaa	gactcagagt	tcattggtacc	gtattagaaa	8100
ataatgatta	tccaatgtat	gaagttgtac	ttaaattatt	aggagatact	ttgagatgta	8160
tcaaatattt	aatcaataaa	aacttagaga	atgctgcaga	attatactat	atattcagaa	8220
tttttggtca	tccaatggta	gatgaaagag	atgcaatgga	tgctgtcaaa	ttaaacaatg	8280
aaatcacaaa	aatcctaagg	ttggagagct	tgacagaact	aagaggagca	ttcatattaa	8340
ggattatcaa	aggattttgt	gacaacaaca	aaagggtggc	caaaaattaaa	aatttaatat	8400
tgcttagcaa	aagatggact	atgtacttca	aagctaaaaa	ttatcccagt	caactcgaat	8460
taagtgaaca	agactttcta	gagcttgctg	caatacaatt	tgaacaagag	tttctgttc	8520
ctgaaaaaac	caatcttgag	atggtattaa	atgacaaaag	catatcacct	cctaaaagat	8580
taatatggtc	tgtgtatcca	aagaattact	tacctgagac	gataaaaaat	cgatattttg	8640
aagaaacttt	caatgcgagt	gatagtctca	aaacaagaag	agtactagag	tactatttta	8700
aagacaataa	atttgatcaa	aaggaactta	aaagttatgt	agttagacaa	gaatatttta	8760

atgataagga	gcacattgtc	tcattaactg	gaaaagaaag	agaattaagt	gtaggtagaa	8820
tgtttgc	gcaaccagga	aaacagcgac	aaatacaaat	attggcagaa	aaattgttag	8880
ctgataacat	tgtaccttcc	ttcccggaaa	ccttaacaaa	gtatgggtgat	ctagatcttc	8940
agagaataat	ggaaatcaaa	tcagaacttt	cttctatcaa	aaccagaaga	aatgacagtt	9000
ataataatta	cattgcaaga	gcatccatag	taacagatgt	gagcaagttc	aaccaagcct	9060
ttagatatga	aactacagcg	atctgtgcgg	atgtagcaga	cgaattacat	ggaacacaaa	9120
gcttattctg	ttggttacat	cttatcggtc	ctatgactac	aatgatattg	gcctatagac	9180
atgcaccacc	agaaacaaaa	gggtgaatatg	atatagataa	gatagaagag	caaagtgggtc	9240
tatatagata	tcacatgggc	gggtattgaag	gatgggtgtca	aaaactctgg	acaatggaag	9300
ctatatcttt	attggatggt	gtatctgtaa	agacacgggtg	tcaaatagaca	tctttattaa	9360
acgggtgataa	ccaatcaata	gatgtaagta	aaccagtcac	ggttatctgaa	ggtttagatg	9420
aagtgaaggc	agattatcgc	ttagcaataa	aaatgtctaa	agaaataaga	gatgcataca	9480
gaaatatagg	ccataaaactt	aaagaagggg	aaacatatat	atcaagggat	cttcaattta	9540
taagcaaggt	gattcaatct	gaaggagtga	tgcacacctac	ccctataaaa	aagggtcttga	9600
gagtaggacc	atggataaac	acaatattag	atgacattaa	aactagtgtc	gagtcaatag	9660
ggagtctatg	tcaagaatta	gaatttaggg	gagaaagcat	aatagttagt	ctgatattaa	9720
gaaacttctg	gctgtataac	ttatacatgc	atgaatcaaa	gcaacatcct	ttggcagggg	9780
aacagtttatt	caaaacaacta	aataaaaacat	taacatcagt	gcagagatgt	tttgaaatta	9840
aaaaggaaaa	tgaggtagta	gatctatgga	tgaacatacc	aatgcaattt	ggaggaggag	9900
atccagtagt	cttctataga	tctttctata	gaaggacccc	tgatttttta	actgaggcaa	9960
tcagccatgt	agatattctg	ttaaaaatat	cagctaacat	aaaaaatgaa	acgaaagtaa	10020
gtttcttcaa	agccttacta	tcaatagaaa	aaaatgaacg	tgctacactg	acaacgctaa	10080
tgagagatcc	tcaagctggt	ggatcagaac	gacaagcaaa	agtaacaagt	gacatcaata	10140
gaacagcagt	taccagtatc	ttaaagtctt	ccccaaatca	acttttccagt	gatagtgtca	10200
tacactatag	caggaatgaa	gaagaagtgg	gaatcattgc	agaaaacata	acacctgttt	10260
atcctcatgg	gctgagagta	ttatatgaat	cattgccctt	tcacaaagct	gaaaaagttg	10320
taaacatgat	atcagggaca	aaatctataa	ccaacttatt	acagagaaca	tccgctatta	10380
atgggtgaaga	tattgacagg	gctgtatcta	tgatgttgga	gaatctagga	ttattatcta	10440
gaatattgtc	agtagttggt	gatagtatag	aaattccaat	caaactctaat	ggtaggctga	10500
tatgttgtca	aatctctagg	actttaagag	agacatcatg	gaataatatg	gaaatagttg	10560
gagtaacatc	tcctagcatc	actacatgta	tggtgtcat	atatgcaact	agttctcatt	10620
tgaaggggat	aattatagaa	aagttcagca	ctgacagaac	tacaaggggt	caaagagggtc	10680
caaaaagccc	ttgggtaggg	tcgagtactc	aagagaaaaa	attagtaacct	gtttataaca	10740
gacaaaattct	ttcaaaaaca	caaagagaac	agctagaagc	aatttgaaaa	atgagatggg	10800
tgtataaagg	gacaccaggc	ttgcgacgat	tactcaacaa	gatctgtctt	gggagtttag	10860
gcattagtta	caaagtgtga	aaacctttat	tacctagggt	tatgagtgtg	aatcttctac	10920
atagggtatc	tgtcagtagt	agacctatgg	aattcccagc	atcagttcca	gcttatagaa	10980
caacaaatta	ccatttcgac	actagtccct	ttaatcaagc	actaagttag	agatttgagg	11040
atgaagatat	taacttggtc	ttccaaaatg	cgatcagctg	tggaatttag	ataatgagtg	11100
tagtagaaca	attaacaggt	agaagcccaa	aacagttagt	tttaataccc	caattagaag	11160
aaatagacat	tatgccacca	ccagtgtttc	aagggaaaat	caattataaa	ttagtagata	11220
agataacttc	tgatcaacat	atcttcagtc	cggacaaaat	agatatgtta	acactagggg	11280
aaatgctcat	gcctactata	aaagggtcaga	aaacagatca	gttcttaaat	aagagagaga	11340
attatttcca	tggaacaat	cttattgagt	ctttatcagc	agcattagca	tgtcattggg	11400
gtgggatatt	aacagaacaa	tgcatagaaa	ataatatttt	caagaaggac	tgggggtgacg	11460
ggttttatatc	agatcatgct	tttatggact	tcaaaaatatt	cctatgtgtc	tttaaaaacta	11520
aactttttatg	tagttggggg	tcccaaggga	aaaacattaa	agatgaagat	atagtagatg	11580
aatcaataga	taaatgttta	aggattgaca	atactttttg	gagaatgttc	agcaaaagtt	11640
tgtttgaacc	aaaagttaag	aaaaggataa	tgttatatga	tgtaaaattc	ctatcactag	11700
taggctacat	agggtttaag	aactggttta	tagagcagtt	gagatcagct	gaattgcatg	11760
aaataccttg	gattgtcaat	gccgaagggtg	atgttggtga	gatcaagtca	attaaaaatct	11820
atgtgcaact	gatagaacaa	agcttatttt	taagaataac	tgttttgaac	tatacagata	11880
tggcacatgc	tctcacacga	ttaatcagaa	agaagttaat	gtgtgataat	gcactgttaa	11940
ccccaatctc	atccccaatg	gttaacttaa	ctcaagttat	tgatcccaca	acacaatttag	12000
attacttccc	caagataaca	ttcgaaaggc	taaaaaatta	tgacacaagt	tcaaattatg	12060
ctaaaggaaa	gctaacaaga	aattacatga	tactattgcc	atggcagcat	gttaatagat	12120
ataactttgt	ctttagttct	actggatgta	aagttagtct	gaaaacatgt	attggaaaac	12180
ttatgaaaga	cttaaatcct	aaagttttgt	actttatttg	agaaggagca	ggaaatttga	12240
tggccagaac	agcatgtgaa	tatcctgata	ttaaatttgt	atatagaagt	ctgaaagatg	12300
acettgatca	tcatatctct	ctggaatacc	agagagtgtg	agggtgaatta	agcagaatca	12360
tagatagtgg	tgaaggactt	tcaatggaaa	caacagacgc	aactcaaaaa	actcattggg	12420
atgtgataca	cagggttaagc	aaagatgctt	tattaataac	tttatgtgat	gcagaattta	12480

```

aggacagaga tgattttttt aagatggtaa ttctatggag aaaacatgta ttatcatgca 12540
gaatttgcac tacttatggg acggacctct atttatctgc aaagtatcat gctaaagact 12600
gcaattgtaaa attacctttt tttgtgagat cagttgctac tttcattatg cagggtagta 12660
agctgtcagg ttcagaatgc tacatactct taacactagg ccaccacaac agtttacctt 12720
gccatggaga aatacaaaat tctaagatga aaatagcagt gtgtaatgat ttttatgctg 12780
caaaaaaact cgacaataaa tcaattgaag ctaattgtaa atcacttttg tcagggctaa 12840
gaatacctat aaataagaag gaactagata gacagagaag attattaaca ctacaaagca 12900
atcattcttc tgtggcaaca gttggcggta gcaagatcat agagtctaaa tggttaacaa 12960
acaaagcaag tacaataatt gattggtagg aacatatattt aaattctcca aagggcgaaat 13020
taaattatga tttttttgaa gcattggaga acacttacct taatatgatt aaactaatag 13080
ataacttagg gaatgcagag attaaaaaac ttatcaaagt aacaggatac atgcttgtaa 13140
gtaaaaaatg aaaaatgatg aagatgacaa aatagatgac aacttcatac tattctaaat 13200
taattatttg attat                                     13215

```

<210> 97

<211> 13135

<212> DNA

<213> human metapneumo virus

<400> 97

```

acgcgaaaaa aacgcgtata aattaaattc caaacaaaac gggacaaata aaaatgtctc 60
ttcaagggat tcacctaagt gatctgtcat ataaacatgc tatattaaaa gagtctcaat 120
acacaataaa aagagatgta ggcaccacaa ctgcagtgac accttcatca ttgcagcaag 180
agataacact tttgtgtgga gagattcttt acactaaaca tactgattac aaatatgctg 240
cagagatagg gatacaatat atttgcacag ctctaggatc agaaagagta caacagattt 300
taagaatttc aggtagttag gttcaggtgg ttctaaccaa gacatactct ttaggggaaag 360
gtaaaaaatg taaaggggaa gaggtgcaaa tgtagatat acatggagtg gaaaagagtt 420
gggtagaaga aatagacaaa gaggaagaa aaacaatggt gactttgcta aaggaatcat 480
caggcaacat cccacaaaac cagaggcctt cagcaccaga cacaccaata attttattgt 540
gtgtaggtgc tttaatattc actaaactag catcaacaat agaagttgga ctagagacta 600
cagttagaag ggctaacaga gtgttaagtg atgcgctcaa aagataccct agggtagata 660
taccaaatag tgctagatct ttttatgaac tatttgagca gaaagtgtat tacaggagtc 720
tattcattga gtaggggaaa gctttaggct catcttcaac aggaagcaaa gcagaaagtt 780
tgtttgtaaa tatattttatg caagcttatg gagcgggtca gacaatgcta aggtgggggtg 840
tcattgccag atcatctaac aacataatgc tagggcatgt atctgtgcaa gctgaattga 900
aacaagttac agaggtttat gatttggtaa gagaaatggg tcctgaatct gggcttttac 960
atctaagaca aagtccaaag gcaggactgt tatcgttggc taattgcccc aatttttcta 1020
gtgttgttct tggtaatgct tcaggtctag gtataatcgg aatgtacagg ggaagagtcg 1080
caaacacaga gctattttct gcagcagaaa gttatgccag aagcttaaaa gaaagcaaca 1140
aaatcaactt ctctcatta gggctcacag acgaagaaaa agaagctgca gaacacttct 1200
taaactgag tgatgacaat caagatgatt atgagtaatt aaaaaactgg gacaagtcaa 1260
aatgtcattc cctgaaggaa aagatatcct gtatcatgggt aatgaagcag caaaaaatagc 1320
agaagctttc cagaaatcac taaaaagatc aggtcacaaa agaaccagat ctattgttag 1380
ggaaaaagta aacactatat cagaaactct agagctacct accatcagca aacctgcacg 1440
atcatctaca ctgctagagc caaaattggc atgggcagac agcagcggag ccacaaaaac 1500
cacagaaaaa caaacaacca aaacaacaga tcctgttgaa gaagaggaac tcaatgaaaa 1560
gaaggtatca ccttccagtg atgggaagac tcctgcagag aaaaaatcaa aatctccaac 1620
caatgtaaaa aagaaagttt ccttcacatc aaatgaacca gggaaatata ctaaactaga 1680
aaaagatgcc ctagatttgc tctcagacaa tgaggaagaa gacgcagagt cctcaatcct 1740
aacctttgaa gagagagaca catcatcact aagcattgag gctagactag aatcaataga 1800
agagaagcta agcatgatat taggactgct tcgtacactt aacattgcaa cagcaggacc 1860
aacggctgca agggatggaa tcagagatgc aatgattggg ataagagaag aactaatagc 1920
agaaataata aaagaagcaa agggaaaagc agccgaaatg atggaagagg aaatgaatca 1980
aaggtcaaaa ataggtaatg gcagtgtaaa actaaccgag aaggcaaaag aacttaataa 2040
aattgttgaa gacgagagca caagtggtag atcagaagaa gaagaagaac caaaagaaac 2100
tcaggataac aatcaaggag aagatatcta ccagttaatc atgtagttaa ataaaaataa 2160
acaatgggac aagtcaagat ggagtcctat ctagtggaca cttatcaagg attccctac 2220
acagctgctg ttcaagttga tctggtagaa aaagacttac taccagcaag tttgacaata 2280
tggtttcctc tattccaagc caacacacca ccagcggttt tgctcgatca gctaaaaacc 2340
ttgactataa caactctgta tgctgcatca cagaatgggtc caatactcaa agtaaatgca 2400

```

tcagctcagg	gtgctgctat	gtctgtactt	cccaaaaaat	tcgaagtaaa	tgcaactgtg	2460
gcacttgatg	aatacagcaa	acttgacttt	gacaagttaa	cggtttgca	tgtaaaaaa	2520
gtttatttga	caaccatgaa	gccatatggg	atgggtgcaa	aatttgtgag	ttcagccaaa	2580
tcagttggca	aaaagacaca	tgatctaatt	gcactgtgtg	acttcatgga	cctagagaaa	2640
aatataacctg	tgacaataacc	agcattcata	aagtcagttt	caatcaaaga	gagtgaagtca	2700
gccactgttg	aagctgcaat	aagcagtgag	gccgaccaag	cattaacaca	agccaaaatt	2760
gcaccctatg	caggactaat	catgatcatg	accatgaaca	atccaaaagg	tatatccaag	2820
aaactaggag	ctggaacaca	agtgatagta	gagctagggg	catatgttca	agccgagagc	2880
atcagcagga	tctgcaagag	ctggagtcac	caaggaacaa	gatatgtact	aaaatccaga	2940
taaaaataac	tgtcctaata	aataattgct	tataataatc	taaagatcaa	tgagcttatt	3000
attatagtta	tataaaaaata	atctagaact	agaaagggtat	taatagaaaag	cgggacaaag	3060
aaaaatgtct	tggaaagtga	tgattatcat	ttcgttactc	ataacacctc	agcacggact	3120
aaaagaaagt	tatttagaag	aatcatgtag	tactataact	gaaggatata	tcagtgtttt	3180
aagaacaggt	tggtagacca	atgtctttac	attagaagtt	gggtgatgtg	aaaatcttac	3240
atgtactgat	ggacctagct	taatcaaaac	agaacttgac	ctaaccaaaa	gtgctctgag	3300
agaactcaaa	acagtttctg	ctgatcagtt	agcgagagaa	gaacaaattg	aaaatcccag	3360
acaatcaagg	ttgttcctag	gtgcaatgac	tcttgaggtt	gccacagcag	cagcagtcac	3420
agcaggcatt	gcaatagcca	aaaccataag	acttgagagt	gaagtgaatg	caatcaaagg	3480
tgctctcaaa	acaaccaacg	aggcagtatc	cacactagga	aatggagtgc	gagtcctagc	3540
cactgcagta	agagagctga	aagaatttgt	gagcaaaaac	ctgactagt	cgatcaacaa	3600
gaacaaatgt	gacattgctg	atctgaagat	ggctgtcagc	ttcagtcaat	tcaacagaag	3660
attcctaaat	gttggtcggc	agttttcaga	caatgcaggg	ataacaccag	caatatcatt	3720
ggacctaagt	actgatgctg	agctggccag	agctgtatca	tacatgccaa	catctgcagg	3780
acagataaaa	ctaattgttag	agaaccgtgc	aatgggtgagg	agaaaaggat	ttggaatctt	3840
gataggggtc	tacggaagct	ctgtgattta	catgggtccag	ctgccgatct	ttggtgtcat	3900
agatacacct	tgttggataa	tcaaggcagc	tccctcttgt	tcagaaaaag	atggaaatta	3960
tgcttgccctc	ctaagagagg	atcaagggtg	gtattgcaaa	aatgcaggat	ccactgttta	4020
ctacccaaat	gaaaaagact	gcgaaacaag	agggtgatcat	gttttttgtg	acacagcagc	4080
agggatcaat	gttgctgagc	aatcaagaga	atgcaacatc	aacatatcta	ccaccaacta	4140
cccctgcaaa	ctcagcacag	gaagacaccc	tatcagcatg	gttgcaactat	cacctctcgg	4200
tgcttttggt	gcttgctaca	aggggggttag	ctgctcgatt	ggcagtaatc	gggttggaat	4260
aatcaaacaa	ctacctaag	gctgctcata	cataactaac	caggacgcag	acactgtaac	4320
aattgacaac	actgtgtatc	aactaagcaa	agttgagggt	gaacagcatg	taataaaagg	4380
gagaccagtt	tcaagcagtt	ttgatccaat	caggtttcct	gaggatcagt	tcaatgttgc	4440
gcttgatcaa	gtctttgaaa	gcattgaaaa	cagtcgaagca	ctagtggacc	agtcaaaacta	4500
aattctgaac	agtgcgaaaa	aaggaaacac	tggtttcatt	attgtaataa	ttttgattgc	4560
tgttcttggg	tttaaccatga	tttcagttag	catcatcatc	ataatcaaaa	aaacaaggaa	4620
gcccacaggg	gcacctccag	agctgaatgg	tgttaccaac	ggcgggttta	taccgcatag	4680
ttagtttaatt	aaaaaatggg	acaaatcatc	atgtctcgca	aagctccatg	caaataatgaa	4740
gtacggggca	agtgcacacg	gggaagttag	tgcaaatcca	accacaatta	ctggagctgg	4800
cctgataggt	atcttattgtt	aagatcaaat	tatctcttga	atcagctttt	aagaaacact	4860
gataaggctg	atggtttgtc	aataatatca	ggagcaggta	gagaagatag	gactcaagac	4920
tttgttcttg	gttctactaa	tgtggttcaa	gggtacattg	ataacaatca	aggaataaca	4980
aaggctgcag	cttgctatag	tctacataac	ataataaaac	agctacaaga	aatagaagta	5040
agacaggcta	gagataataa	gctttctgac	agcaaacatg	tggcacttca	caacttgata	5100
ttatcctata	tggagatgag	caaaactcct	gcactccctga	ttaataacct	aaagaaacta	5160
ccaagagaaa	aactgaagaa	attagcgaaa	ttaataattg	atcttatcagc	aggaactgat	5220
aatgactctt	catatgcctt	gcaagacagt	gaaagcacta	atcaagtgca	gtaagcatgg	5280
tcccaaatcc	attaccatag	aggcagatga	tatgatattg	acacacaaag	aattaaagga	5340
gacactgtct	gatgggatag	taaaatcaca	caccaatatt	tacagttgtt	atctagaaaa	5400
tatagaaata	atatatgtta	aagcttactt	aagttagtaa	aaaataaata	gaatgggata	5460
aatgacaatg	aaaacattag	atgtcataaa	aagtgatgga	tcctcagaaa	catgtaatca	5520
actcaaaaaa	ataataaaaa	aacactcagg	ttaattgctt	attgcattaa	aactgatatt	5580
ggccttattg	acgtttttca	cagtaacaat	tactgttaac	tatataaaag	tagaaaaaca	5640
tttgaggcca	tgtcaattaa	aaaatgaatc	agacaaaaag	gacacaaagc	taaataccac	5700
atcaacaaca	atcagaccca	ttcctgatct	aaatgcagta	cagtacttga	aaaggctgat	5760
tcagaaacac	accaactttg	tcataaaaga	cagagatacc	tgttggagaa	tacacacgaa	5820
tcaatgcaca	aatataaaaa	tatataagtt	cttatgtttc	gggtttatga	attcaacaaa	5880
tacagactgt	gaagaactaa	cagttttatg	tgataaaaaag	tcaaaaaacca	tgacagaaaa	5940
acataggaaa	gcagagtgtc	actgtctaca	tacaaccgag	tggtggtggt	attatcttta	6000
agagaaaact	cggctttcaa	cattaaaatc	agaacaaatc	ctatccagat	ctattaatat	6060
aatagtttag	tcattcaaaa	actctaataa	ttgtctagac	ttcacaaac	tttgcggtca	6120

tatgcaataa	tcaatggtca	aaccactgtt	gcaaactcac	ccataatata	atcactgagt	6180
aatacaaaac	aagaaaatgg	gacaagtggc	catggaagta	agagtggaga	acattcgggc	6240
aatagacatg	ttcaaagcaa	aaatgaaaaa	ccgtataaga	agtagcaagt	gctatagaaa	6300
tgctacactg	atccttattg	gattaacagc	attaagtatg	gcacttaata	tttttttaat	6360
cattgattat	gcaatgttaa	aaaacatgac	caaagtggaa	cactgtgtta	atatgccgcc	6420
ggtagaacca	agcaagaaga	ccccaatgac	ctctgcagta	gacttaaaca	ccaaacccaa	6480
tccacagcag	gcaacacagt	tggccgcaga	ggattcaaca	tctctagcag	caacctcaga	6540
ggaccatcta	cacacagggg	caactccaac	accagatgca	acagtctctc	agcaaacacc	6600
agacgagtag	acaacattgc	tgagatcaac	caacagacag	accacccaaa	caaccacaga	6660
gaaaaagcca	accggagcaa	caaccaaaaa	agaaaccaca	actcgaacta	caagcacaga	6720
tgcaacccaa	acactcaaca	ctaccaacca	aactagctat	gtgagagagg	caaccacaac	6780
atccgccaga	tccagaaaca	gtgccacaac	tcaaagcagc	gaccaaacia	cccaggcagc	6840
agacccaagc	tcccaaccac	accatacaca	gaaaagcaca	acaacaacat	acaacacaga	6900
cacatcctct	ccaagtagtt	aacaaaaaaa	ctataaaaata	atcatgaaaa	ccgaaaaaat	6960
agaaaagtta	atttgaactc	agaaaagaac	acaaacacta	tatgaattgt	ttgagcgtat	7020
atactaattga	aatagcatct	gtttgtgcat	caataatacc	atcattatct	aagaaataag	7080
aagaagctaa	aattcaaggg	acaaataaca	atggatccat	tttgtgaatc	cactgtcaat	7140
gtttatcttc	ctgactcata	tctcaaagga	gtaatatctt	tcagtgaaac	caatgcaatt	7200
ggctcatgcc	ttttgaaaag	accctatcta	aaaaaagata	acactgctaa	agttgctgta	7260
gaaaaccctg	ttgttgaaca	tgtcaggcct	agaaatgcag	tcatgaccaa	aatgaagata	7320
tcagattata	aagtggttga	accaattaat	atgcagcatg	aaataatgaa	aaatatcac	7380
agttgtgagc	tcacattatt	aaaacaattc	ttaacaagaa	gtaaaaacat	tagtctctta	7440
aaattaagta	tgatatgtga	ttgggttacag	ttaaaatcca	cctcagataa	cacatcaatt	7500
cttaatttta	tagatgtgga	gtttatacct	gtttgggtga	gcaattgggt	tagtaactgg	7560
tataatctca	ataaattaat	cttagagttt	agaagagagg	aagtaataag	aactggttca	7620
attttatgta	gatcactagg	caagttagtt	ttcattgtat	catcttatgg	gtgtgtagta	7680
aaaagcaaca	aaagtaaaag	agtaagtttt	ttcacatata	accaactggt	aacatggaaa	7740
gatgtgatgt	taagtagggt	caatgcaaac	ttttgtatat	gggtaagtaa	caacctgaac	7800
aaaaatcaag	aaggactagg	atttagaagt	aatctgcaag	gtatgttaac	caataaatta	7860
tatgaaactg	ttgattatat	gttaagtcta	tgtagtaatg	aagggttctc	actagtgaac	7920
gagttcgaag	gctttattat	gagtgaat	cttaaaatta	ctgagcatgc	tcaattcagt	7980
actaggttta	ggaatacttt	attaaatggg	ttgactgaac	aattatcaat	gttgaaagct	8040
aaaaacagat	ctagagttct	tggcactata	ttagaaaaca	atgattacce	gtgtatgaa	8100
gtagtactta	aattattagg	ggacactttg	aaaagtataa	aattattaat	taacaagaat	8160
ttagaaaatg	ctgcagaatt	atattatata	ttcagaattt	ttggacaccc	tatggtagat	8220
gagaggggag	caatggatgc	tgttaaatta	aataatgaga	ttacaaaaat	tcttaaacctg	8280
gagaggttaa	cagaactaag	aggagcattt	atactaagaa	ttataaaagg	gtttgtagat	8340
ataaataaaa	gatggcctaa	aatagaat	ttaaaagtgc	tcagtaaaag	atgggttatg	8400
tatttcaaa	ccaaaagtta	ccctagccaa	cttgagctaa	gtgtacaaga	ttttttagaa	8460
cttgctgcag	tacaattcga	acaggaattt	tctgtccctg	aaaaaaccaa	ecttgagatg	8520
gtattaaatg	ataaagcaat	atctcctcca	aaaaagttaa	tatgggtcgg	atatccaaaa	8580
aattatctac	ctgaaattat	aaaaaatcaa	tatttagaag	aggtcttcaa	tgcaagtgc	8640
agtcaaaaga	cgaggagagt	cttagaattt	tacttaaaag	attgcaaat	tgatcaaaaa	8700
gaccttaaac	gttatgtact	taaacagag	tatctaaatg	acaaagacca	cattgtctca	8760
ttaactggga	aggaaagaga	attaagtgtg	ggcaggatgt	ttgcaatgca	accaggcaaa	8820
caaagacaaa	tacagatact	agctgagaaa	cttctagctg	ataatattgt	acccttttct	8880
ccagaaactt	taacaaagta	tggtgacttg	gatctccaaa	gaattatgga	aatgaaatca	8940
gaactttctt	ccattaaaac	taggaagaat	gatagttaca	acaattatat	tgcaagagcc	9000
tccatagtaa	cagacctaa	taaattcaat	caagccttta	gatatgaaac	cacagctatc	9060
tgtgcagatg	tagcagatga	gttacatggt	acgcaaagct	tattttgttg	gttacatctt	9120
attgttccca	tgaccacaat	gatagtgtga	tacagacatg	caccaccaga	aacaaagggg	9180
gagtatgaca	tagacaaaat	agaagagcaa	agtgggctat	acagatatca	tatgggaggg	9240
attgaagggg	ggtgtcagaa	gttatggaca	atggaagcga	tatccttggt	agatgtagta	9300
tctgttaaga	ctcgttgtca	gatgacctct	ctattaaacg	gagacaatca	atcaatagat	9360
gtcagtaaac	cagtaaaatt	gtctgaaggt	atagatgaag	taaaagcaga	ttatagctta	9420
gcaattaaaa	tgcttaaaaga	gataagagat	gcctataaaa	acattggcca	taaactcaaa	9480
gaagggtgaa	catatatatc	aagagatctc	caatttataa	gtaagggtgat	tcaatctgag	9540
ggggtcatgc	atcctacccc	cataaaaaag	atattaaagg	taggtccctg	gataaataca	9600
atactagatg	acattaaaac	cagtgcagaa	tcaataggga	gtctgtgtca	agaactagag	9660
ttcagaggag	aaagtatgct	agttagcttg	atattaagga	atttctggct	gtataactta	9720
tacatgcatg	agtcaaaaaca	gcatccgtta	gctggaaaac	aactggttaa	gcaattgaac	9780
aaaacactaa	catctgtgca	aagatTTTTT	gagctgaaga	aagaaaatga	tgtggttgac	9840

```

ctatggatga atataccaat gcagtttggg ggggggagacc cagtagtttt ttacagatct 9900
ttttacagaa ggactcctga tttcctgact gaagcaatca gccatgtgga tttactgtta 9960
aaagtttctga acaatattaa aaatgagact aagatacga tctttaaagc cttattatct 10020
atagaaaaga atgaacgtgc aacattaaca acactaatga gagaccccca ggcggttagga 10080
tcggaaaagac aagctaaggc aacaagtgat ataaatagaa cagcagttac tagcatactg 10140
agtctatctc cgaatcagct cttttgtgat agtgctatac actatagcag aaatgaagaa 10200
gaagtcggga tcattgcaga caacataaca cctgtttatc ctcacggatt gagagtgtct 10260
tatgaatcac taccttttca taaggctgaa aagggttgta atatgatc aggtacaaag 10320
tctataacta acctattgca gagaacatct gctatcaatg gtgaagatat tgatagagca 10380
gtgtctatga tgtagagaa cttagggttg ttatctagga tattgtcagt aataattaat 10440
agtatagaaa taccaattaa gtccaatggc agattgatag gctgtcaaat ttctaagact 10500
ttgagagaaa aatcatggaa caatatggaa atagtaggag tgacatctcc aagtattgta 10560
acatgtatgg atgttgtgta tgcaactagt tctcatttaa aaggaataat tattgaaaaa 10620
ttcagtagctg acaagaccac aagaggtcag agggggacca aaagcccctg ggtaggatca 10680
agcactcaag agaaaaaatt agttcctgtt tataatagac aaattccttc aaaacaacaa 10740
aaggagcaac tggaagcaat agggaaaaat aggtgggtgt ataaaggaac tccagggtca 10800
agaagattgc tcaataagat ttgcatagga agtttaggta tttagctataa atgtgtaaaa 10860
cctctattac caagattcat gagtgtaaac ttcttacata gggtatctgt tagtagcaga 10920
cccattggaat tcccagcttc tgttccagct tataggacaa caaattacca ctttgacact 10980
agtcctaatca accaagcatt aagttagagg ttcggaacg aagacattaa tctagtgttc 11040
caaaatgcaa tcagctgcgg aattagtata atgagtgttg tagaacagtt aactggtaga 11100
agcccaaaac aattagtctt aatcccccaa ttagaagaga tagatattat gctcctctct 11160
gtattttcaag gaaaaattcaa ttataaaaaa gttgataaaa taacctctga tcaacacatc 11220
ttcagtcctg acaaaataga catattaaca ctagggaaga tgcttatgcc tactataaaa 11280
gggtcaaaaa ctgatcagtt cttaaataag agagaaaact atttccatgg aaataattta 11340
attgaatctt tatctgcagc acttgcagtc cactggtgtg gaatatatac agaacagtgt 11400
gtagaaaaca atatctttag gaaagactgg ggtgatgggt tcatatcaga tcatgccttc 11460
atggatttca agatatttct atgtgtattt aaaaccaaac ttttatgtag ttggggatcc 11520
caaggggaaa atgtaaaaga tgaagatata aaggtgaat ccattgacaa attattaga 11580
attgacaaca ctttttgagg aatgttcagc aaagtcagtt ttgaatcaaa ggtcaaaaaa 11640
agaataatgt tatatgatgt aaaattccta tcattagtag gttatatagg atttaaaaaa 11700
tggttttatag agcagttaag agtagtagaa ttgcatgaag tgccctggat tgtcaatgct 11760
gaaggggagc tagttgaaat taaaccaatc aaaatttatt tgcagttaat agaacaaagt 11820
ctatctttaa gaataactgt tttgaattat acagacatgg cacatgctct cacacgatta 11880
attaggaaga aattgatgtg tgataatgca ccttccaatc caagttcatc accaatgttt 11940
agtctaactc aagttatcga tcctacaaca cagctagact attttcttaa ggtgatattt 12000
gaaagggttaa aaagttatga taccagttca gactacaaca aagggaggtt aacaagaaat 12060
tacatgacat tattaccatg gcagcacgta aacaggtata attttgtctt tagttcaaca 12120
ggatgtaaaa tcagcttgaa gacatgcac gggaaattga taaaggactt aaaccctaag 12180
gttctttact ttattggaga aggagcaggt aactggatgg caagaacagc atgtgagtat 12240
cctgatcataa aatttgata taggagttta aaggtgatc ttgatcatca ttaccatta 12300
gaatatcaaa gggtaatagg tgatttaaat agggtaatag atgggtggtga aggactatca 12360
atggagacca cagatgcaac tcaaaagact cattgggact taatacacag aataagtaaa 12420
gatgctttat tgataacatt gtgtgatgca gaattcaaaa acagagatga tttctttaa 12480
atggtaattc tttggagaaa acatgtatta tcatgtagaa tctgtacagc ttatggaaca 12540
gatctttact tatttgcaaa gtatcatgca acggactgca atataaaaat accatttttt 12600
gtaaggtctg tagctacttt tattatgcaa ggaagcaaat tgtcaggatc agaattgtac 12660
atacttttaa ctaggttca tcacaataat ctgccatgcc atggagaaat acaaaattcc 12720
aaaatgagaa tagcagtggtg taatgatttc catgcctcaa aaaaactaga caacaaatca 12780
attgaagcta actgtaaatc tcttctatca ggattaagaa taccaataaa caaaaaagag 12840
ttaaatagac aaaagaaact gttaacacta caaagcaatc attcttccat agcaacagtt 12900
ggcggcagta agattataga atccaaatgg ttaaagaata aagcaagtac aataattgat 12960
tggttagagc atatcttgaa ttctccaaaa ggtgaattaa actatgattt ctttgaagca 13020
ttagagaaca catacccaa tatgatcaag cttatagata acctgggaaa tgcagagata 13080
aaaaaactaa tcaaagttcc tgggtatatg cttgtgagta agaagtaata ataata 13135

```

<210> 98

<211> 907

<212> DNA

<213> Human metapneumo virus

<400> 98


```

atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtaaaaaat 60
cgtgtgggcac gcagcaaattg ctttaaaaaat gcctcttttg tctcatagg aataactaca 120
ttgagtattg ccctcaatat ctatctgatc ataaactata aaatgcaaaa aaacacatct 180
gaatcagaac atcacaccag ctcatcacc atggaatcca gcagagaaac tccaacgggtc 240
cccacagaca actcagacac caactcaagc ccacagcatc caactcaaca gtccacagaa 300
ggctccacac tctactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
ccagatacaa caaacggccc gcccttcgtc gacacacaca caacaccacc aagcgcaagc 420
agaacaaaga caagtccggc agtccacaca aaaaacaacc caaggacaag ctctagaaca 480
cattctccac cacggggcaac gacaaggagc gcacgcagaa ccaccactct ccgcacaagc 540
agcacaagaa agagaccgtc cacagcatca gtccaacctg acatcagcgc aacaacccac 600
aaaaacgaag aagcaagtcc agcgagccca caaacatctg caagcacaac aagaatacaa 660
aggaaaagcg tggaggccaa cacatcaaca acatacaacc aaactagtta acaaaaaata 720
caaaaataact ctaagataaa ccatgcagac accaacaatg gagaagccaa aagacaattc 780
acaatctccc caaaaaggca acaacaccat attagctctg cccaaatctc cctggaaaaa 840
acactcgccc atataccaaa aataccacaa ccaccccaag aaaaaaactg ggcaaaaaca 900
cacccaa

```

<210> 99

<211> 908

<212> DNA

<213> Human metapneumo virus

<400> 99

```

atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag tgtaaaaaat 60
cgtgtgggcac gcagcaaattg ctttaaaaaat gcctcttttg tctcatagg aataactaca 120
ttgagtattg ccctcaatat ctatctgatc ataaactata aaatgcaaaa aaacacatct 180
gaatcagaac atcacaccag ctcatcacc atggaatcca gcagagaaac tccaacgggtc 240
cccacagaca actcagacac caactcaagc ccacagcatc caactcaaca gtccacagaa 300
ggctccacac tctactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
ccagatacaa caaacggccc gcccttcgtc gacacacaca caacaccacc aagcgcaagc 420
agaacaaaga caagtccggc agtccacaca aaaaacaacc caaggacaag ctctagaaca 480
cattctccac cacggggcaac gacaaggagc gcacgcagaa accaccactc tccgcacaag 540
cagcacaaga aagagaccgt ccacagcatc agtccaacct gacatcagcg caacaaccca 600
caaaaacgaag gaagcaagtc cagcgagccc acaaacatct gcaagcacia caagaataca 660
aaggaaaagc gtggaggcca acacatcaac aacatacaac caaactagt aacaaaaaat 720
acaaaataac tctaagataa accatgcaga caccaacaat ggagaagcca aaagacaatt 780
cacaatctcc ccaaaaaggc aacaacacca tattagctct gcccaaatct cctggaaaaa 840
aacactcgcc catataccaa aaataccaca accaccccaa gaaaaaact gggcaaaaaca 900
acacccaa

```

<210> 100

<211> 907

<212> DNA

<213> Human metapneumo virus

<400> 100

```

atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtaaaaaat 60
cgtgtgggcac gcagcaaattg ctttaaaaaat gcctcttttg tctcatagg aataactaca 120
ctgagtattg ccctcaatat ctatctgatc ataaactata aaatgcaaaa aaacacatct 180
gaatcagaac atcacaccag ctcatcacc atggaatcca gcagagaaac tccaacgggtc 240
cccacagata attcagacac caactcaagc ccacaacatc caactcaaca gtccacagaa 300
ggctccacac tctactttgc agcctcagca aactcaccag agacagaacc aacatcaaca 360
ccagacacaa caaacggccc gcccttcgtc gacacacaca caacaccacc aagcgcaagc 420
agaacaaaga caagtccggc agtccacaca aaaaacaacc caaggataag ctccagaaca 480
cactctccac catggggcaac gacaaggagc gcacgcagaa ccaccactct ccgcacaagc 540
agcacaagaa agagaccgtc cacagcatca gcccaacctg acatcagcgc aacaacccac 600
aaaaacgaag aagcaagtcc agcgagccca caaacatctg caagcacaac aagaacacaa 660
aggaaaagcg tggaggccaa cacatcaaca acatacaacc aaactagtta acaaaaaata 720
caaaaataact ctaagataaa ccatgcagac accaacaatg gagaagtcaa aagacaattc 780
acaatctccc caaaaaggca acaacaccat attagctctg cccaaatctc cctggaaaaa 840
acactcgccc atataccaaa aataccacaa ccaccccaag aaaaaaactg ggcaaaaaca 900
cacccaa

```

<210> 101
 <211> 907
 <212> DNA
 <213> Human metapneumo virus

<400> 101
 atggaggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtaaaaaat 60
 cgtgtggcac gcagcaaattg ctttaaaaaat gcctcttttg tccatcatagg aataactaca 120
 ttgagtattg ccctcaatat ctatctgata ataaactata aaatgcaaaa aaacacatct 180
 gaatcagaac atcacaccag ctcatcaccg atggaatcca gcagagaaac tccaacggtc 240
 cccacagata attcagacac caactcaagc ccacaacatc caactcaaca gtccacagaa 300
 ggctccacac tctactttgc agcctcagca aactcaccag agacagaacc aacatcaaca 360
 ccagacacaa cagaccgccc gcccttcgtc gacacacaca caacaccacc aagcgcaagc 420
 agaacaaaga caagtccggc agtccacaca aaaaacaacc caaggataag ctccagaaca 480
 cattctccac catgggcaac gacaaggacg gcacgcagaa ccaccactct cgcgacaagc 540
 agcacaagaa agagaccgtc cacagcatca gtccaaccgc acatcagcgc aacaaccac 600
 aaaaacgaag aagcaagtcc agcgagccca caaacatctg caagcacaac aagaacacaa 660
 aggaaaagcg tggaggccaa cacatcaaca acatacaacc aaactagtta acaaaaaata 720
 caaaataact ctaagataaa ccatgcagac accaacaatg gagaagtcaa aagacaattc 780
 acaatctccc caaaaaggca acaacaccat attagctctg cccaaatctc cctggaaaaa 840
 acactcgccc atataccaaa aataccacaa ccacccaag aaaaaaactg ggcaaaaaca 900
 cacccaa 907

<210> 102
 <211> 907
 <212> DNA
 <213> Human metapneumo virus

<400> 102
 atggaggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtaaaaaat 60
 cgtgtggcac gcagcaaattg ctttaaaaaat gcctcttttg tccatcatagg aataactaca 120
 ttgagtattg ccctcaatat ctatctgata ataaactata aaatgcaaaa aaacacatct 180
 gaatcagaac atcacaccag ctcatcaccg atggaatcca gcagagaaac tccaacggtc 240
 cccacagata attcagacac caactcaagc ccacaacatc caactcaaca gtccacagaa 300
 ggctccacac tctactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
 ccagacacaa cagaccgccc gcccttcgtc gacacacaca caacaccacc aagcgcaagc 420
 agaacaaaga caagtccggc agtccacaca aaaaacaacc caaggataag ctccagaaca 480
 cattctccac catgggcaac gacaaggacg gcacgcagaa ccaccactct cgcgacaagc 540
 agcacaagaa agagaccgtc cacagcatca gtccaaccgc acatcagcgc aacaaccac 600
 aaaaacgaag aagcaagtcc agcgagccca caaacatctg caagcacaac aagaacacaa 660
 aggaaaagcg tggaggccaa cacatcaaca acatacaacc aaactagtta acaaaaaata 720
 caaaataact ctaagataaa ccatgcagac accaacaatg gagaagtcaa aagacaattc 780
 acaatctccc caaaaaggca acaacaccat attagctctg cccaaatctc cctggaaaaa 840
 acactcgccc atataccaaa aataccacaa ccacccaag aaaaaaactg ggcaaaaaca 900
 cacccaa 907

<210> 103
 <211> 907
 <212> DNA
 <213> Human metapneumo virus

<400> 103
 atggaggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gcagcaaattg ctttaaaaaat gcctctttga tccatcatagg aataactaca 120
 ttgagtattg ccctcaatat ctatctgata ataaactata caatgcaaga aaacacatcc 180
 gaatcagaac atcacaccag ctcatcaccg atggaatcca gcagggaac tccaacggtc 240
 cccatagaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
 gactccacac tccactctgc agcttcagca agctcaccag agacagaacc aacatcaaca 360
 ccagacacaa caagccgccc gcccttcgtc gacacacaca caacaccacc aagtgcagc 420
 aggacaagga caagtccggc agtccacaca aaaaacaatc caagggttaag cccagaaca 480
 cattccccac catgggcaat gacaaggacg gtccgcggaa ccaccactct cgcgacaagc 540
 agcacaagaa aaagactgtc tacagcatca gtccaaccgc acagcagcgc aacaaccac 600

```

aaacacgaag aaacaagccc agtgagccca caaacatctg caagcacagc aagaccacaa 660
aggaaggcca tggaggccag cacatcaaca acatacaacc aaactagtta acaaaaaata 720
caaaataaact ctaagataaa ccatgtagac accaacaatt gagaagccaa aaggcaattc 780
acaatctccc aaaaaagcaa caacaccata ttagctccgc ttaaatctcc ctgaaaaaaa 840
cactcaccca tataccaact ataccacaac catcccaaga aaaaaggctg ggcaaaaaca 900
cacccaa 907

```

<210> 104

<211> 908

<212> DNA

<213> Human metapneumo virus

<400> 104

```

atggaggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gcagcaaatg ctttaaaaat gcctctttga tcctaataagg aataactaca 120
ttgagttag ccctcaatat ctatctgac ataaactata caatgcaaga aaacacatcc 180
gaatcagaac atcacaccag ttcacacccc atggaatcca gcagggaac tccaacggtc 240
cctatggaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
ggctccacac tccactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
ccagacacaa caagccgccc gcccttcgct gacacacaca caacaccatc aagtgaagc 420
agaacaaaga caagtccggc agtccacaca aaaaacaatc taaggataag cccagaaca 480
cattccccac catgggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaagc 540
agcataagaa aaagaccgct cacagcatca gtccaacctg acagcagcgc aacaaccac 600
aaacacgaag aagcaagccc agtgagcccg caagcatctg caagcacagc aagaccacaa 660
aggaaggcca tggaggccag cacatcaaca acatacaacc aaactagtta acaaaaaata 720
taaaataaact ctaagataaa ccatgtagac accaacaatt gagaagccaa aaggcaattc 780
acaatctccc caaaaaggca acaacaccat attagctccg cttaaatctc cctggaaaaa 840
acactcgccc atataccaac tataccacaa ccatcccaag gaaaaaagct gggtaaaaaa 900
acacccaa 908

```

<210> 105

<211> 908

<212> DNA

<213> Human metapneumo virus

<400> 105

```

atggaggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gcagcaaatg ctttaaaaat gcctctttga tcctaataagg aataactaca 120
ttgagttag ccctcaatat ctatctgac ataaactata caatgcaaga aaacacatcc 180
gaatcagaac atcacaccag ttcacacccc atggaatcca gcagagaaac tccaacggtc 240
cctatggaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
ggctccacac tccactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
ccagacacaa caagccgccc gcccttcgct gacacacaca caacaccatc aagtgaagc 420
agaataagga caagtccggc agtccacaca aaaaacaatc taaggataag cccagaaca 480
cattccccac catgggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaagc 540
agcataagaa aaagaccgct cacagcatca gtccaacctg acagcagcgc aacaaccac 600
aaacacgaag aagcaagccc agtgagcccg caagcatctg caagcacagc aagaccacaa 660
aggaaggcca tggaggccag cacatcaaca acatacaacc aaactagtta acaaaaaata 720
tacaataaact ctaagataaa ccatgtagac accaacaatt gagaagccaa aaggcaattc 780
acaatctccc caaaaaggca acaacaccat attagctccg cttaagtctc cctggaaaaa 840
acactcgccc atataccaac tataccacaa ccatcccaag aaaaaaagct gggcaaaaaca 900
acacccaa 908

```

<210> 106

<211> 888

<212> DNA

<213> Human metapneumo virus

<400> 106

```

atggaggtga aagtagagaa cattcgagca atagacatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gtagcaaatg ctttaaaaat gcttctttaa tcctcatagg aataactaca 120
ctgagttag ctctcaatat ctatctgac ataaactaca caatacaaaa aaccacatcc 180

```

```

gaatcagaac accacaccag ctcaccaccc acagaaccca acaaggaagc ttcaacaatc 240
tccacagaca acccagacat caatccaagc tcacagcatc caactcaaca gtccacagaa 300
aaccacacac tcaaccccg cgcagcatcag agcccatcag aaacagaacc agcatcaaca 360
ccagacacaa caaacccgct gtcctccgta gacaggtcca cagcacaacc aagtgaagc 420
agaacaaaga caaacccgac agtccacaca atcaacaacc caaacacagc ttccagtaca 480
caatccccac caccgacaac aacgaaggca atccgcagag ccaccacttt ccgcatgagc 540
agcacaggaa aaagaccaac cacaacatta gtccagtccg acagcagcac cacaacccaa 600
aatcatgaag aaacagggttc agcgaaccca caggcgtctg caagcacaat gcaaaactag 660
cacaccaata atataaaacc aaattagtta acaaaaaatg cgagatagct ctaaagcaaa 720
acatgtaggt accaacaatc aagaaaccaa aagacaactc acaatctccc taaaacagca 780
acgacaccat gtcagctttg ctcaaatctc tctggggagaa acttctaccc acatactaac 840
aacatcacaa ccattctcaag aaaagaaact gggcaaaaaca gcatccaa 888

```

<210> 107

<211> 888

<212> DNA

<213> Human metapneumo virus

<400> 107

```

atggagggtga aagtagagaa cattcgagca atagacatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gcagcaaatg ctttaaaaaat gcttctttaa tctctatagg aataactaca 120
ctgagtatag ccctcaatat ctatctgac ataaactaca caatacaaaa aaccacatct 180
gaatcagaac accacactag ctcaccaccc acagaatcca acaaagaaac ttcaacaatc 240
cccatagaca acccagacat caatccaaac tcacagcatc caaccaaca gtccacagaa 300
agccccacac tcaaccccg cgcagcatcag agcccatcag aaacagaacc agcatcaaca 360
ccagacacaa caaacccgct gtcctccgta gacagatcca caacacaacc aagtgaagc 420
agaacaaaga caaacccaac agtccacaca aaaaaacaatc caagtacagt ttccagaaca 480
caatccccac tacgggcaac aacgaaggcg gtcctcagag ccaccgcttt ccgacagagc 540
agcacaagaa aaagaccaac cacaacatca gtccagtctg acagcagcac cacaacccaa 600
aatcatgaag aaacaagttc agcgaaccca caggcatctg caagcacaat gcaaaagccag 660
cacaccaaca acataaaacc aaattagtta acaaaaaata cgagatagct ctaaagtaaa 720
acatgtaggt accaacaatc aaggaatcaa aagacaactc acaatctccc taaaacagca 780
acaacatcat gtcagttttg ctcaaatctc cctggggagaa actttcgccc acatactaac 840
aacatcacaa ccattctcaag aaaagaaact gggcaaaaaca gcacccaa 888

```

<210> 108

<211> 888

<212> DNA

<213> Human metapneumo virus

<400> 108

```

atggagggtga aagtagagaa catccgagca gtagacatgc tcaaagcaag agtcaaaaaat 60
cgtgtggcac gcagcaaatg ctttaaaaaat gcctccttaa tctctgtagg aataactaca 120
ctgagcatag ccctcaatat ctatctgac gtaaaactaca caatacaaaa aaccacatcc 180
gaatcagaac accacaccag ctcatcacc acagaatcca acaaaggaac ttcaacaatc 240
cccacagaca acccagacat caatccaaat tcacaacatc caactcaaca gtccacagaa 300
agccccacac tcaacaccgc agcctcggtg agcccatcag aaacagaacc agcatcaaca 360
ccagacacaa caaacccgct gtcctccgca gacagatcca caacacaacc aagtgaagc 420
agaacaaaga caaagctgac agtccacaca aaaaacaacc taagtacagc ctccagaaca 480
caatcaccac caccgggcaac aacgaaggcg gtcctcagag acaccgcctt ccacacgagc 540
agcacaggaa aaagaccaac cacaacatca gtccagtctg gcagcagcac cacaactcaa 600
aatcatgaag aaacaagttc atcgaaccca caggcatctg caagcacaat gcaagaccag 660
gacaccaaca atacaaaaca aaattagtta acaaaaaata caagatagct ctaaagtaaa 720
acatgtaggt accaacagta aagaaatcaa aagacaactc acaatctccc caaaacagca 780
acaacatcat gtcagcttcg ctcaaatctc cctggggagaa actctcgccc acatactaac 840
aacatcacaa ctattctcaag aaaagaaact gggcaaaaaa acactcaa 888

```

<210> 109

<211> 887

<212> DNA

<213> Human metapneumo virus

<400> 109

```

atggaggtga aagtagagaa catccgagca gtagacatgc tcaaagcaag agttaaaaaat 60
cgtgtggcac gcagcaaatt ctttaaaaaat gctcttttaa tctctgtagg aataactaca 120
ctgagtatat ccctcaatat ctatctgata gtaaaactaca caatacaaaa aaccacatcc 180
gaatcagaac accacactag ctcatcacc acagaatcca acaaaggaac ttcaacaatc 240
ccacagacaa cccagacatc aatccaaatt cacaacatcc aactcaacag tccacagaaa 300
gccccacact caacaccgca gcctcgggtga gcccatcaga aacagaacca gcatcaacac 360
cagacacaa acaccgcctg tctctcgcag acagatccac aacacaacca agtgaaagca 420
gaacaaagac aaagctgaca gtccacacaa aaaacaacct aagtacagcc tccagaacac 480
aatcaccacc acgggcaaca acgaaggcgg tctctagaga caccgccttc cacacgagca 540
gcacaggaaa aagaccaacc acaacatcag tccagtctgg cagcagcacc acaactcaaa 600
atcatgaaga aacaagttca tcgaacccac aggcattctgc aagcacaatg caagaccagg 660
acaccaacaa taaaaacaa aattagttaa caaaaaatac aagatagctc taaagtaaaa 720
catgtaggta ccaacagtaa agaaatcaaa agacaactca taatctcccc aaaacagcaa 780
caacatcatg tcagcttcgc tcaaatctcc ctgggagaaa ctctcgccca cataactaaca 840
acatcacaa tatctcaaga aaagaaactg ggcaaaaaaa cactcaa 887

```

<210> 110

<211> 888

<212> DNA

<213> Human metapneumo virus

<400> 110

```

atggaggtga aagtagagaa cattcgagca atagacatgc tcaaagcaag aatgaaaaat 60
cgtgtggcac gcagcaaatt ctttaaaaaat gcttctttta tctctatagg aataactact 120
ctgagtatat ccctcaatat ctatctgata ataaactaca caatacaaaa aaccacatct 180
gaatcagaac accacactag ctcaccaccc acagaatcca acaaagaaac ttcaacaatc 240
cctatagaca acccagacat caatccaaac tcacagcatc caactcaaca gtccacagaa 300
agcctcacac tcaacccgcg agcctcgggt agcccatcag aaacagaacc agcatcaaca 360
ccagacacaa caaacgcctt gtctccgta gacagatcca caacacaacc aagtgaagc 420
agaacaaaga caaaactgac agtccacaaa aaaaacatcc caagtacagt ctctagaaca 480
caatctcaa tacgggcaac aacgaaggcg gtctctagag ccaccgcctt tcgcacgagc 540
agcacaggag aaagaccaac tacaacatca gtccagtctg acagcagcac cacaacccaa 600
aatcatgaag aaacaggttc agcgaaccca caggcatctg caagcacaat gcaaaaactag 660
cacaccaaca ttgtaaaacc aaattagtta acaaaaaata tgaaatagct ctaaagtaaa 720
acatgtaggt gctaacaatc aagaaatcaa aagacatctc ataactcttc caaaacagca 780
acaacatcat gtcaactttg ctcaaatctc cctgggagaa actttcgccc ccatactgac 840
aacatcacaa tcattctcaag aaaagaaact gggcaaaaaca gcaccaa 888

```

<210> 111

<211> 888

<212> DNA

<213> Human metapneumo virus

<400> 111

```

atggaggtga aagtagagaa cattcgagca atagacatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gcagcaaatt ctttaaaaaat gcttctttta tctctatagg aataactact 120
ctgagtatat ccctcaacat ctatctgata ataaactaca caatacaaaa aaccacatct 180
gaatcagaac accacactag ctcaccaccc acagaatcta acaaagaaac ttcaacaatc 240
tctatagaca acccagacat caatccaaac tcacagcatc caactcaaca gtccacagaa 300
agcctcacac tcagccccac agcctcgggt agcccatcag aaacagaacc agcatcaaca 360
tcagacacaa caagccgcct gtcttcgta gacagatcca caacacaacc aagtgaagc 420
agagcaagga caaaaccgac agtccacaag aaaaacatcc caagtacagt ttctagaaca 480
caatccccac tacgggcaac aacgaaggcg gtctctagag ccaccgcctt tcgcacgagc 540
agcacaggag agggaccaac cacaacatcg gtccagtctg acagcagcac cacaacccaa 600
aatcatgaag aaacaggttc agcgaaccca caggcatctg caagcacaat gcaaaaactag 660
cacaccaaca ttgtaaaacc aaattagtta acaaaaaata tgaaatagtt ctaaagtaaa 720
acatgtaggt gctaacaatc aagaaatcaa aagacaactc ataactctcc taaaacagca 780
acaacatcat gtcaactttg ctcaaatctc cctgggagaa actttcgccc ccatactgac 840
aacatcacaa tcattctcaag aaaagaaact gggcaaaaaca gcaccaa 888

```

<210> 112

<211> 888
 <212> DNA
 <213> Human metapneumo virus

<400> 112
 atggaggtga aagtagagaa cattcgagca atagacatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gtagcaaatg ctttaaaaaat gcttctttaa tcctcatagg aataactaca 120
 ctgagtatag ctctcaatat ctatctgata ataaactaca caatacaaaa aaccacatct 180
 gaatcagaac accacaccag ctcaccaccc acagaatcca acaaggaagc ttcaacaatc 240
 tccacagaca atccagacat caatccaaac tcacagcatc caactcaaca gtccacagaa 300
 aacccacac taaacccgc agcatcgggt agctcatcag aaacagaacc agcatcaaca 360
 ccagacacaa caaacgcct gtctccgta gacagggtcca cagcacaacc aagtgaagc 420
 agaacaaaga caaacccgac agtccacaca agaaacaacc caagcacagc ttccagcaca 480
 caatccccac cacgggtaac aacgaaggca atcctcagag ccaccgtctt ccgcatgagc 540
 agcacaggaa aaagaccagc cacaacatta gtccagtccg acagcagcac cacaacccaa 600
 aatcatgaag aaacagggtc agcaaaactc caggcatctg caagcacaat gcaaaactag 660
 cactccaaca atataaaacc aaattagtta acaaaaaata cgagatagct ctaaagtaaa 720
 acatgtaggc accaacaatc aggaaattaa aagacaactc acaacctccc taaaacagca 780
 acgacaccat gtcaactttg ctcaaatctc tctgggagaa acttttgccc acatactaac 840
 aacatcacia tcattctcaag aaaagaaact gggcaaaaaca gcatccaa 888

<210> 113
 <211> 888
 <212> DNA
 <213> Human metapneumo virus

<400> 113
 atggaggtga aagtagagaa cattcgagca atagacatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gcagcaaatg ctttaaaaaat gcttctttaa tcctcatagg aataactact 120
 ctgagtatag cctcaacat ctatctgata ataaactaca caatacaaaa aaccacatct 180
 gaatcagaac accacactag ctcaccaccc acagaatcta acaaggaac ttcaacaatc 240
 tctatagaca actcagacat caatccaaac tcacagcatc caactcaaca gtccacagaa 300
 agcctcacac tcagccccac agcctcgggt agcccatcag aaacagaacc agcatcaaca 360
 tcagacacaa caaacgcct gtctccgta gacagatcca caacacaacc aagtgaagc 420
 agagcaagaa caaacccgac agtccacaag aaaaacatcc caagtacagt ttctagaaca 480
 caatccccac tacggggaac aacgaaggcg gtctcagag ccaccgcctt tgcgcatgagc 540
 agcacaggag agggaccaac cacaacatcg gtccagtctg acagcagcac cacaacccaa 600
 aatcatgaag aaacagggtc agcgaaccca caggcatctg caagcacaat gcaaaaccag 660
 cacaccaaca ttgcaaaacc aaattagtta acaaaaaata tgaaatagtt ctaaagtaaa 720
 acatgtagggt gccacaatc aagaaatcaa aagacaactc acaatctccc taaaacagca 780
 acaacatcat gccaaacttg ctcaaatctc cctgggagaa accctcgccc ccatactgac 840
 aacatcacia tcattctcaag aaaagaaact gggcaaaaaca gcaccaa 888

<210> 114
 <211> 888
 <212> DNA
 <213> Human metapneumo virus

<400> 114
 atggaggtga aagtagagaa cattcgagca atagacatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gcagcaaatg ctttaaaaaat gcttctttaa tcctcatagg aataactact 120
 ctgagtatag cctcaatat ctatctgata ataaactaca caatacaaaa aaccacatct 180
 gaatcagaac accacactag ctcaccaccc acagaatcta acaaggaac ttcaacaatc 240
 cctatagaca acccagacat caatccaaac tcacagcatc caactcaaca gtccacagaa 300
 agcctcacac tctaccccac atcctcgggt agctcatcag aaacagaacc agcatcaaca 360
 ccaggcataa caaacacact gtcttttgta gacagatcca caacacaacc aagtgaagc 420
 agaacaaaga caaacccgac agtccacaaa aaaaacatct caagtacagt ttctagaaca 480
 cagtccccac cacggacaac agcgaaggcg gtccccagag ccaccgcctt tgcgacgagc 540
 agcacaggag aaagaccaac cacaacacca gtccagcccg atagcagcac cacaacacaa 600
 aatcatgaag aaacagggtc agcgaaccca caggcatccg caagcacaat gcaaaaccag 660
 cacaccaaca ttgcaagacc aaattagtta acaaaaaata tgaaatagct ctaaagtaaa 720
 acatgtagggt gccacaatc aagaaatcaa aagataactc ataactctctc taaaacatca 780

acaacatcat gttaactttg ctcaaacttc tctgggagaa accttcgccc ccatactggc 840
 aacatcacaa tcattctcaag aaaagaaact gggcaaaaca acaccaa 888

<210> 115

<211> 888

<212> DNA

<213> Human metapneumo virus

<400> 115

atggaggtga aagtagagaa cattcgagca atagacatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gcagcaaagt ctttaaaaat gcttctttta tcctcatagg aataactact 120
 ctgagtatat ccctcaatat ctatctgac ataaactaca caatacaaaa aaccacatct 180
 gaatcagaac accacactag ctaccacccc acagaatcta acaaggaaac ttcaacaatc 240
 cctatagaca acccagacat caatccaaac tcacagcatc caactcaaca gtccgcagaa 300
 agcctcacac tctaccccac atcctcgggtg agctcatcag aaacagaacc agcatcaaca 360
 ccaggcataa caaacccact gtcctttgta gacagatcca caacacaacc aagtgaagc 420
 agaacaaaga caaacccgac agtccacaaa aaaaacatct caagtacagt ttctagaaca 480
 cagtccccac cacggacaac agcgaaggcg gtccccagag ccaccgcct tgcgacgagc 540
 agcacaggag aaagaccaac cacaacacca gtccagccc atagcagcac cacaacacaa 600
 aatcatgaag aaacaggctc agcgaaccca caggcatccg caagcacaat gcaaaaccag 660
 cacaccaaca ttgcaagacc aaattagtta acaaaaaata tgaaatagct cttaaagtaaa 720
 acatgtagggt gccaacaatc aagaaatcaa aagataactc ataattcttc taaaacatca 780
 acaacatcat gttaactttg ctcaaacttc tctgggagaa accttcgccc ccatactggc 840
 aacatcacaa tcattctcaag aaaagaaact gggcaaaaca acaccaa 888

<210> 116

<211> 888

<212> DNA

<213> Human metapneumo virus

<400> 116

atggaggtga aagtagagaa tattcgagca atagacatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gcagcaaagt ctttaaaaat gcttctttta tcctcatagg aataactact 120
 ctgagtatat ccctcaatat ctatctgac ataaactaca caatacaaaa aaccacatct 180
 gaatcagaac accacactag ctaccacccc acagaatcta acaaggaaac ttcaacaatc 240
 cctatagaca acccagacat caatccaaac tcacagcatc caactcaaca gtccacagaa 300
 agcctcacac tctaccccac atcctcgggtg agctcatcag aaacagaacc agcatcaaca 360
 ccaggcataa caaacccact gtcctttgta gacagatcca caacacaacc aagtgaagc 420
 agaacaaaga caaacccgac agtccacaaa aaaaacatct caagtacagt ttctagaaca 480
 cagtccccac cacggacaac agcgaaggcg gtccccagag ccaccgcct tgcgacgagc 540
 agcacaggag aaagaccaac cacaacacca gtccagccc atagcagcac cacaacacaa 600
 aatcatgaag aaacaggctc agcgaaccca caggcatccg caagcacaat gcaaaaccag 660
 cacaccaaca ttgcaagacc aaattagtta acaaaaaata tgaaatagct cttaaagtaaa 720
 acatgtagggt gccaacaatc aagaaatcaa aagataactc ataattcttc taaaacatca 780
 acaacatcat gttaactttg ctcaaacttc tctgggagaa accttcgccc ccatactggc 840
 aacatcacaa tcattctcaag aaaagaaact gggcaaaaca acaccaa 888

<210> 117

<211> 888

<212> DNA

<213> Human metapneumo virus

<400> 117

atggaggtga aagtagagaa cattcgagca atagacatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gtagcaaagt ctttaaaaat gcttctttta tcctcatagg aataactaca 120
 ctgagcatag ccctcaatat ctatctgac ataaactaca caatacaaaa aaccacatct 180
 gaatcagaac accacaccag ctaccacccc acagaatcca acaaggaaac ttcaacaatc 240
 tccacagaca acccagacat caatccaaac tcacagcatc caactcaaca gtccacagaa 300
 aacccacac tcaacccagc agcatcagcg gtccccagag ccaccgcct tgcgacgagc 360
 ccagatacaa caaacccgct gtcctccgta gacaggtcca cgggtacaacc aagtgaagc 420
 agaacaaaga caaaactgac agtccacaca agaaacaacc taagcacagc ctccagtaca 480
 caatccccac cacgggcaac aacgaaggca atccgcagag ccaccaccct ccgcatgagc 540

```

agcacaggaa gaagaccaac cacaacacta gtccagtcg acagcagcac cacaacccaa 600
aatcatgaag aaacaggctc agcgaaccca caggcatctg caagcacaat gcaaaaccag 660
cacaccaaca atataaaacc aaattagtta acaaaaaata cgagatagct ctaaagttaa 720
acatgtaggc accaacaatc aagaaaccaa aagataactc acaatcccc caaaacagca 780
acgacaccat gtcagctttg ctcaaattctc tctggggagaa acttttgccc acatactaac 840
aacatcacia ccattctcaag aaaagaaact gggcaaaaaca gcatccaa 888

```

<210> 118

<211> 888

<212> DNA

<213> Human metapneumo virus

<400> 118

```

atggagggtga aagtagagaa cattcgagca atagacatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gtagcaaatg ctttaaaaaat gcttctttaa tcctcatagg aataactaca 120
ctgagcatag ccctcaatat ctatctgatt ataaactaca caatacaaaa aaccacatct 180
gaatcagaac accacaccag ctaccacccc acagaatcca acaagggaagc ttcaacaatc 240
tccacagaca acccagacat caatccaaac tcacagcatc caactcaaca gtccacagaa 300
aaccacacac tcaacccagc agcatcagcg agcccatcag aaacagaatc agcatcaaca 360
ccagatacaa caaacgcctt gtcctccgta gacaggtcca cgggtacaacc aagtgaaaac 420
agaacaaaga caaaactgac agtccacaca agaaacaacc taagcacagc ctccagtaca 480
caatccccac caggggcaac aacgaaggca atccgcagag ccaccaccct ccgcatgagc 540
agcacaggaa gaagaccaac cacaacacta gtccagtcg acagcagcac cacaacccaa 600
aatcatgaag aaacaggctc agcgaaccca caggcatctg caagcacaat gcaaaaccag 660
cacaccaaca atataaaacc aaattagtta acaaaaaata cgagatagct ctaaagttaa 720
acatgtaggc accaacaatc aagaaaccaa aagataactc acaatcccc caaaacagca 780
acgacaccat gtcagctttg ctcaaattctc tctggggagaa acttttgccc acatactaac 840
aacatcacia ccattctcaag aaaagaaact gggcaaaaaca gcatccaa 888

```

<210> 119

<211> 901

<212> DNA

<213> Human metapneumo virus

<400> 119

```

atggaagtaa gaggtaggaa cattcgagcg atagacatgt tcaaagcaaa gataaaaaaac 60
cgtataagaa gcagcagggtg ctatagaaat gctacactga tccttatttg actaacagcg 120
ttaagcatgg cacttaatat tttcctgatt atcgatcatg caacattaag aaacatgatt 180
aaaacagaaa actgtgctaa catgccgtcg gcagaaccaa gcaaaaagac cccaatgacc 240
tccacagcag gcccaaacac caaacccaat ccacagcaag caacacagtg gaccacagag 300
aactcaacat cccagtagc aacccacagag ggccatccat acacagggag aactcaaac 360
tcagacacaa cagctcccca gcaaacacac gacaaacaca cagcaccgct aaaatcaacc 420
aatgaacaga tcaaccagac aaccacagag aaaaagacaa tcagagcaac aacccaaaaa 480
agggaaaaag gaaaagaaaa cacaaccaa accacaagca cagctgcaac ccaaaccaacc 540
aacaccacca accaaatcag aaatgcaagt gagacaatca caacatccga cagacccaga 600
actgacacca caaccacaaag cagcgaacag acaaccggg caacagaccc aagctcccc 660
ccacaccatg catagagagg tgcaaaactc aaatgagcac aacacacaaa catcccatcc 720
aagtagttaa caaaaaacca caaataaacc ttgaaaaacca aaaaaccaaa acataaaccc 780
agacccagaa aaacatagac accatatgga aggttctagc atatgcacca atgagatggc 840
atctgttcat gtatcaatag caccaccatc attcaaggaa taagaagagg cgaaaattta 900
a

```

<210> 120

<211> 901

<212> DNA

<213> Human metapneumo virus

<400> 120

```

atggaagtaa gaggtaggaa cattcgagcg atagacatgt tcaaagcaaa gataaagaac 60
cgtataagaa gcagcagggtg ctatagaaat gctacactga tccttatttg actaacagcg 120
ttaagcatgg cacttaatat tttcctgatt atcgatcatg caacattaag aaacatgatt 180
aaaacagaaa actgtgctaa catgccgtcg gcagaaccaa gcaaaaagac cccaatgacc 240

```



```

tccacagcag gcccaagcac cgaacccaat ccacagcaag caacacaatg gaccacagag 300
aactcaacat ccccagcagc aaccctagag agccatccat acacagggac aacccaaaca 360
ccagacataa cagctcccca acaaaccaca gacaaacaca cagcactgcc aaaatcaacc 420
aatgaacaga tcacccagac aaccacagag aaaaagacaa ccagagcaac aacccaaaaa 480
agggaaaaag aaaaagaaaa caaaaaccaa accacaagca cagctgcaac ccaaaacaacc 540
aacaccacca accaaaccag aatgcaagt gagacaatca caacatccga cagaccaga 600
attgacacca caacccaaag cagcgatcag acaacccggg caacagaccc aagctcccca 660
ccacaccatg cacagagtgg tgcaaaaccc aaatgaacac aacacacaaa catctcatcc 720
aagtagttaa caaaaaacca caaaataacc ttgaaaacca aaaaacaaa ccacaaactt 780
agaccagaa aaacatagac actatatgga aggtttgagc atatgcacca atgaaatggt 840
atctgttcat gtatcaatag cgccaccatt atttaaggaa taagaagagg caaaaattca 900
a

```

<210> 121

<211> 860

<212> DNA

<213> Human metapneumo virus

<400> 121

```

atggaagtaa gagtggagaa cattcgagcg atagacatgt tcaaagcaaa gataaaaaaac 60
cgtataagaa gcagcaggtg ctatagaaat gctacactga tccttatttg actaacagcg 120
ttaagcatgg cacttaatat tttcctgatc atcgatcatg caacattaag aaacatgac 180
aaaacagaaa attgtgctaa catgccgccg gcagaaccaa gcaaaaagac cccaatgacc 240
tctacagcag gcccaaacac caaacccaat ccacagcaag caacacagtg gaccacggag 300
aactcaacat tcccagcagc aacctcagag ggccatctac acacagggac aactcaaaca 360
ccagacacaa cagctcctca gcaaacacaa gacaaacaca cagcactgcc aaaatcaacc 420
aatgaacaaa tcacccagac aaccacagag aaaaagacaa ccagagcaac aacccaaaga 480
agggaaaaag ggaaagaaaa caaaaaccaa accacaagca cagctgctac ccaaaacaacc 540
aacaccacca accaaatcag aaatgcaagc gagacaatca caacatccga cagaccaga 600
actgactcca caacccaaag cagcgaacag acaacccggg caacagaccc aagctcccca 660
ccacatcatg cacaggggaag tgcaaaaccc aaatgaacac aacacacaaa catcccatcc 720
aagtagttaa caaaaaatca gaccagaaa aacatagaca ctatatggaa ggtccgagca 780
tatgcaccga tgaaatggca tttgttcatg tatcaatage gccaccatta ttttaaggaa 840
aagaagaggc aaaaattcaa

```

<210> 122

<211> 861

<212> DNA

<213> Human metapneumo virus

<400> 122

```

atggaagtaa gagtggagaa cattcgagcg atagacatgt tcaaagcaaa gataaaaaaac 60
cgtataagaa gcagcaggtg ctatagaaat gctacactga tccttatttg actaacagcg 120
ttaagcatgg cacttaatat tttcctgatc atcgatcatg caacattaag aaacatgac 180
aaaacagaaa attgtgctaa catgccgccg gcagaaccaa gcagaaagac cccaatgacc 240
tccacagcag gcccaaacac caaacccaat ccacagcaag caacacagtg gaccacggag 300
aactcaacat ccccagcagc aaccccaagc ggccatctac acacagggac aactcaaaca 360
ccagacacaa cagctcctca gcaaacacaa gacaaacaca cagcactgcc aaaatcaacc 420
aatgaacaga tcacccaggc aaccacagag aaaaagacaa ccagagaaac aacccaaaga 480
agggaaaaag gaaaagaaaa caaaaaccaa accacaagca cagctgcaac ccaaaacaacc 540
aacaccacca accaaatcag aaatgcaagc gagacaatca caacatccga cagaccaga 600
actgactcca caacccaaag cagcgaacag acaacccagg caacagaccc aagctcccca 660
gcacaccatg cacaggggaag tgcaaaaccc aaatgaacac aacacacaaa catcccatcc 720
aagtagttaa caaaaaaatc agaccagaa aaacacagac actatatgga aggtccgagc 780
atatgcaccg atgaaatggc atctgttcat gtatcaatag caccaccatt atttaaggaa 840
taagaagagg caaaaattca a

```

<210> 123

<211> 860

<212> DNA

<213> Human metapneumo virus

<400> 123

```

atggaagtaa gagtggagaa cattcgagcg atagacatgt tcaaagcaaa gataaaaaac 60
cgtataagaa gcagcagggtg ctatagaaat gctacattga tccttattgg actaacagcg 120
ttaagcatgg cacttaatat tttcctgac atcgatcatg caacattaag aaacatgac 180
aaaacagaaa attgtgctaa catgccaccg gcagaaccaa gcaaaaagac cccaatgacc 240
tccacagcag gcctaataac taaacccaat ccacagcaag caacacagtg gaccacggag 300
aactcaacat ccccagcagc aaccccagag ggccatctac acacagggac aactcaaaaca 360
ccagacacaa cagctcctca gcaaaccaca gacaagcaca cagcactgcc aaaatcaacc 420
aatgaacaga tcacccagac aaccacagag aaaaagacaa ccagagcaac aacccaaaga 480
agggaaaaag gaaaagaaaa cacaaccaa accacaagca cagctgcaac ccaaacaacc 540
aacaccacca accaaatcag aaatgcaagc gagacaatca caacatccga cagaccaga 600
actgactcca caacccaaag cagcgaacag acaacccggg caacagaccc aagctcccca 660
ccacaccatg cacagggag tgcaaaaccc aaatgaacac aacacacaaa catcccatcc 720
aagtagttaa caaaaaatca gaccagaaa aacatagaca ctatatggaa ggtccgagca 780
tatgcaccga tgaaatggca tctgttcatt tatcaatagc gccaccatta ttttaaggaa 840
aagaagaggc aaaaattcaa
860

```

<210> 124

<211> 860

<212> DNA

<213> Human metapneumo virus

<400> 124

```

atggaagtaa gagtggagaa cattcgagcg atagacatgt tcaaagcaaa gataaaaaac 60
cgtataagaa gcagcagggtg ctatagaaat gctacactga tccttattgg actaacagcg 120
ttaagcatgg cacttaatat tttcctgac atcgatcatg caacattaag aaacatgac 180
aaaacagaaa attgtgctaa catgccaccg gcagaaccaa gcaaaaagac cccaatgacc 240
tccacagcag gcccaaacac caaacccaat ccacagcaag caacacagtg gaccacggag 300
aactcaacat ccccagcagc aaccccagag ggccatctac acacagggac aactcaaaaca 360
ccagacacaa cagctcctca gcaaaccaca gacaaacaca cagcactgcc aaaatcaacc 420
aatgaacaga tcacccagac aaccacagag aaaaagacaa ccagagcaac aacccaaaga 480
agggaaaaag gaaaagaaaa cacaaccaa accacaagca cagctgcaac ccaaacaacc 540
aacaccacca accaaatcag aaatgcaatt gagacaatca caacatccga cagaccaga 600
actgactcca caacccaaag cagcgaacag acaacccggg caacagaccc aagctcccca 660
ccacaccatg cacagggag tgcaaaaccc aaatgaacac aacacacaaa catcccatcc 720
aagtagttaa caaaaaatca gaccagaaa aacatagaca ctatatggaa ggtccgagca 780
tatgcaccga tgaaatggca tctgttcatt tatcaatagc gccaccatta ttttaaggaa 840
aagaagaggc aagaattcaa
860

```

<210> 125

<211> 886

<212> DNA

<213> Human metapneumo virus

<400> 125

```

atggaagtaa gagtggagaa cattcgggca atagacatgt tcaaagcaaa aatgaaaaac 60
cgtataagaa gtagcaagtg ctatagaaat gctacactga tccttattgg attaacagca 120
ttaagtatgg cacttaatat ttttttaatc attgattatg caatgttaaa aaacatgacc 180
aaagtggaa actgtgttaa tatgcccggt gtagaaccaa gcaagaagac cccaatgacc 240
tctgcagtag acttaaacac caaacccaat ccacagcagg caacacagtt ggccgagag 300
gattcaacat ctctagcagc aacctcagag gaccatctac acacagggac aactccaaca 360
ccagatgcaa cagtctctca gcaaaccaca gacgagtaca caacattgct gagatcaacc 420
aacagacaga ccacccaaac aaccacagag aaaaagccaa ccggagcaac aacccaaaaa 480
gaaaccacaa ctggaactac aagcacagct gcaacccaaa cactcaacac taccaaccaa 540
actagctatg tgagagaggc aaccacaaca tccgccagat ccagaaacag tgccacaact 600
caaagcagcg accaaacaac ccaggcagca gacccaagct cccaaccaca ccatacacag 660
aaaagcacia caacaacata caacacagac acatcctctc caagtagtta acaaaaaaac 720
tataaaataa tcatgaaaac cgaaaaacta gaaaagttaa tttgaactca gaaaagaaca 780
caaacactat atgaattgtt tgagcgtata tactaatgaa atagcatctg tttgtgcatt 840
aataatacca tcattattta agaaataaga agaagctaaa attcaa
886

```

<210> 126

<211> 889
 <212> DNA
 <213> Human metapneumo virus

<400> 126
 atggaagtaa gaggaggagaa cattcgggaca atagacatgt tcaaagcaaa gatgaaaaac 60
 cgtataagaa gcagcaagtg ctatagaaat gctacactga tccttattgg actgacagca 120
 ttaagtatgg cacttaatat tttcttgatc atcgattatg caacatttaa aaacatgacc 180
 aaagtggaaac actgtgctaa tatgccgccg gtagaaccga gtaagaagac cccaatgacc 240
 tctacagtag actcaagcac cggacccaat ccacagcaga caacacagtg gaccacagag 300
 gattcaacat ctctagcagc aacctcagag gaccatctac acacagggac aactccaaca 360
 ctagatgcaa cagttttctca gcaaacccca gacaagcaca caacaccgct gagatcaacc 420
 aatggacaga ccacccagac aaccacagag aaaaagccaa ccagagcaat agccaaaaaa 480
 gaaaccacaa accaaaccac aagcacagct gcaacccaaa cattcaacac caccaatcaa 540
 accagaaatg gaagagagac aaccataaca tctgccagat ccagaaacga cgccacaact 600
 caaagcagcg aacaaacaaa ccagacaaca gacccaagct cccaaccaca tcatgcatag 660
 ataagcaciaa taacaatatg aacacaacac agacacatct tctccaagta gttaacaaaa 720
 aactataaaa taacatgaa aacaaaaaaa ctagaaaagt aaatttgaac tcagaaaaga 780
 acacaaacac taaatgaatt gtttgagcat atatactaat gaaatagcat ctgttcatgc 840
 atcaataata ccatcattac ttaagaaata agaagaagca aaaattcaa 889

<210> 127
 <211> 885
 <212> DNA
 <213> Human metapneumo virus

<400> 127
 atggaagtaa gaggaggagaa cattcgggca atagacatgt tcaaagcaaa gatgaaaaac 60
 cgtataagaa gtagcaagtg ctatagaaat gctacactga tccttattgg attaacagca 120
 ttaagtatgg cacttaatat ttttttaatc attgattatg caatgttaaa aaacatgacc 180
 aaagtggaaac actgtgttaa tatgccgccg gtagaaccac gcaagaagac cccaatgacc 240
 tctgcagtag acttaaacac caaactcaat ccacagcagg caacacagtt gaccacagag 300
 gattcaacat ctctagcagc aacctcggag gatcatttac tcacagggac aactccaaca 360
 ccagatgcaa cagtctctca gcaaacccca gacgagcaca caacactgct gagatcaacc 420
 aacagacaga ccacccaaac aaccacagag aaaaagccaa ccggagcaac aacccaaaaa 480
 gaaaccacaa ctcgaaccac aagcacagct gcaacccaaa cactcaacac caccaacca 540
 actagcaatg gaagagaggc aaccacaaca tccaccagat ccagaaacgg tgccacaact 600
 caaaacagcg atcaaaacac ctagacagca gacccaagct cccaaccaca ccatacacag 660
 aaaagcaciaa caacaacata caacacagac acatcttctc caagtagtta acaaaaaaact 720
 ataaaaaac catgaaaact aaaaaactag aaaaagttaat ttgaactcag aaaagaacac 780
 aaacactata tgaattgttt gagcgatat actaatgaaa tagcatctgt ttgtgcatca 840
 ataataccat cattatttaa gaaataagaa gaagctaaaa ttcaa 885

<210> 128
 <211> 885
 <212> DNA
 <213> Human metapneumo virus

<400> 128
 atggaagtaa gaggaggagaa cattcgggca atagacatgt tcaaagcaaa gatgaaaaac 60
 cgcataagaa gtagcaagtg ctatagaaat gctacactga tccttattgg attaacagca 120
 ttaagtatgg cacttaatat ttttttaatc attgattatg caacatttaa aaacatgacc 180
 aaagtggaaac actgtgttaa tatgccgccg gtagaaccac gcaagaagac cccaatgacc 240
 tctgcagtag acttaaacac caaactcaat ccacagcagg caacacagtt gaccacagag 300
 gattcaacat ctctagcagc aacctcagag ggccatccac acacaggaac aactccaaca 360
 ccagacgcaa cagtctctca gcaaacccca gacgagcaca caacactgct gagatcaacc 420
 aacagacaga ccacccaaac agccacagag aaaaagccaa ctggagcaac aacccaaaaa 480
 gaaaccacaa cccgaactac aagtacagct gcaacccaaa caccacacac caccaccaa 540
 accagcaatg ccagagaggc aaccacaaca tccgccaggt ccagaaacgg tgccacaact 600
 caaaacagcg atcaaaacac ccaggcagca gactcaagct cccaaccaca ccatacacag 660
 aaaagcaciaa caacagcata caacacagac acatcttttc caagtagtta acaaaaaaact 720
 ataaaaaac catgaaaacc aaaaaactag aaaagttaat ttgaactcag aaaagaacac 780

aaacactata tgaattgttt gagcgtatat actaatgaaa tagcatctgt ttgtgcatca 840
 ataataccat cattatttta gaaataagaa gaagctaaaa ttcaa 885

<210> 129

<211> 886

<212> DNA

<213> Human metapneumo virus

<400> 129

atggaagtaa gaggaggagaa cattcgggca atagacatgt tcaaagcaaa gatgaaaaac 60
 cgtataagaa gtagcaagtg ctatagaaat gctacactga tccttattgg attaacagca 120
 ctaagtatgg cacttaatat ttttttaatc attgattatg caacattaaa aaacatgacc 180
 aaagtggaa actgtgttaa tatgccgccc gtagaaccaa gcaagaagac cccaatgacc 240
 tctgcagtag actcaaacac caaacccaat ccacagcagg caacacagtt gaccacagag 300
 gattctacat ctttagcagc aaccctagag gaccatccac acacagggac aactccaaca 360
 ccagatgcaa cagtctctca gcaaaccaca gacgagcaca caacactgct gagatcaacc 420
 aacagacaga ccacccaaac aactgcagag aaaaagccaa ccaggggcaac aaccaaaaaa 480
 gaaaccataa ctggaaccac aagcacagct gcaacccaaa cactcaacac caccaacca 540
 actagcaatg gaagagaggc aaccacaaca tctgccagat ccagaaacaa tgccacaact 600
 caaagcagcg atcaaacac ccaggcagca gaaccaagct cccaatcaca acatacacag 660
 aaaagcacia caacaacata caacacagac acatcttctc taagtagtta acaaaaaaac 720
 tataaaataa ccatgaaaac caaaaaacta gaaaagttaa tttgaactca gaaaagaaca 780
 caaacactat atgaattatt tgagcgtata tactaatgaa atagcatctg tttgtgcatc 840
 aataatacca tcattattta agaaataaga agaagctaaa attcaa 886

<210> 130

<211> 887

<212> DNA

<213> Human metapneumo virus

<400> 130

atggaagtaa gaggaggagaa cattcgggca atagacatgt tcaaagcaaa gatgaaaaac 60
 cgtataagaa gtagcaagtg ctatagaaat gctacactga tccttattgg attatcagca 120
 ctaagtatgg cacttaatat ttttttaatc attgattatg caaaatcaaa aaacatgacc 180
 agagtggaa actgtgtcaa tatgccgccc gtagaaccaa gcaagaagac cccaatgacc 240
 tctgcagtag acttaaacac caaacccaat ccacagcagg caacacagtt gaccacagag 300
 gattcaacat ctctagcagc aaccctagag ggccatctac acacagggac aactccaaca 360
 ccagatgtaa cagtctctca gcaaaccaca gacgagcaca caacactgct gagatcaacc 420
 aacagacaga ccacccaaac agccgcagag aaaaagccaa ccagagtaac aactaacaac 480
 gaaaccataa ctggaaccac aagcacagcc gcaacccaaa cactcaacac caccaacca 540
 accaacaatg gaagagaggc aaccacaaca tctgccagat ccagaaacaa tgccacaact 600
 caaagcagcg accaaacaac ccaggcagca gacccaagct cccaatcaca acatacacag 660
 aaaagcacia caacaacata caacacagac acatcttctc caagtagtta acaaaaaaac 720
 tataaaataa ccatgaaaac caaaaaacta agaaaagtta attgaactc agaaaagaac 780
 acaaacacta tatgaattgt ttgagcgtat atactaatga aatagcatct gtttgtgcat 840
 caataatacc atcattattt aagaattaag aagaagctaa aattcaa 887

<210> 131

<211> 887

<212> DNA

<213> Human metapneumo virus

<400> 131

atggaagtaa gaggaggagaa cattcgggca atagacatgt tcaaagcaaa gatgaaaaac 60
 cgtataagaa gtagcaagtg ctatagaaat gctacactga tccttattgg attatcagca 120
 ctaagtatgg cacttaatat ttttttaatc attgattatg caaaatcaaa aaccatgacc 180
 agagtggaa actgtgttaa tatgccgccc gtagaaccaa gcaagaagac cccaatgacc 240
 tctgcagtag acttaaacac caaacccaat ccacagcagg caacacagtt gaccacagag 300
 gattcaacat ctccagcagc aaccctagag ggccatctac acacagggac aactccaaca 360
 ccagatgcaa cagtctctca gcaaaccaca gacgagcaca caacactgct gagatcaacc 420
 aacagacaga ccacccaaac aaccgcagag aaaaagccaa ccagagcaac aaccaaaaaa 480
 gaaaccataa ctggaaccac aagcacagct gcaacccaaa cactcaacac caccaacca 540

```

accagcaatg gaagagaggc aaccacaaca tctgccagat ccagaaacaa tgccacaact 600
caaagcagcg accaaacaac ccaggcagca gacccaagct cccaatcaca acatacaaaag 660
aaaagcacaa caacaacata caacacagac acatcttctc caagtagtta acaaaaaaac 720
tataaaataa ccatgaaaac caaaaaaact agaaaagtta atttgaactc agaaaagaac 780
acaaacacta tatgaattgt ttgagcgtat atactaatga aatagcatct gtttgtgcat 840
caataatacc atcattattht aagaattaag aagaagctaa aattcaa 887

```

<210> 132

<211> 886

<212> DNA

<213> Human metapneumo virus

<400> 132

```

atggaagtaa gaggaggagaa cattcgggca atagacatgt tcaaagcaaa gatgaaaaaac 60
cgtataagaa gtagcaagtg ctatagaaat gctacactga tccttatttg attaacagca 120
ctaaagtatgg cacttaatat ttttttaatc attgattatg caacattaaa aaacatgacc 180
aaagtggaaac actgtgttaa tatgccgccc gtagaaccaa gcaagaagac cccaatgacc 240
tctgcagtag acttaaacac caaacccaat ccacagcagg caacacagtt gaccacagag 300
gactctacat ctttagcagc aaccctagag gaccatccac acacagggac aactccaaca 360
ccagatgcaa cagtctctca gcaaaccaaa gacgagcaca caacactgct gagatcaacc 420
aacagacaga ccaccccaac aactgcagag aaaaagccaa ccagagcaac aacaaaaaaa 480
gaaaccacaa ctggaaccac aagcacagct gcaaccctaaa cactcaacac caccaacca 540
actagcaatg gaagagaggc aaccacaaca tctgccagat ccagaaacaa tgccacaact 600
caaagcagcg atcaacaac ccaagcagca gaaccaaact cccaatcaca acatacacag 660
aaaagcacaa caacaacata caacacagac acatcttctc taagtagtta acaaaaaaac 720
tataaaataa ccatgaaaac caaaaaacta gaaaagttaa tttgaactca gaaaggaaca 780
caaacactat atgaattatt tgagcgtata tactaatgaa atagcatctg tttgtgcatc 840
aataatacca tcattattht agaaataaga agaagctaaa attcaa 886

```

<210> 133

<211> 236

<212> PRT

<213> Human metapneumo virus

<400> 133

```

Met Glu Val Lys Val Glu Asn Ile Arg Thr Ile Asp Met Leu Lys Ala
1      5      10      15
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
20     25     30
Leu Val Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
35     40     45
Leu Ile Ile Asn Tyr Lys Met Gln Lys Asn Thr Ser Glu Ser Glu His
50     55     60
His Thr Ser Ser Ser Pro Met Glu Ser Ser Arg Glu Thr Pro Thr Val
65     70     75     80
Pro Thr Asp Asn Ser Asp Thr Asn Ser Ser Pro Gln His Pro Thr Gln
85     90     95
Gln Ser Thr Glu Gly Ser Thr Leu Tyr Phe Ala Ala Ser Ala Ser Ser
100    105    110
Pro Glu Thr Glu Pro Thr Ser Thr Pro Asp Thr Thr Asn Arg Pro Pro
115    120    125
Phe Val Asp Thr His Thr Thr Pro Pro Ser Ala Ser Arg Thr Lys Thr
130    135    140
Ser Pro Ala Val His Thr Lys Asn Asn Pro Arg Thr Ser Ser Arg Thr
145    150    155    160
His Ser Pro Pro Arg Ala Thr Thr Arg Thr Ala Arg Arg Thr Thr Thr
165    170    175
Leu Arg Thr Ser Ser Thr Arg Lys Arg Pro Ser Thr Ala Ser Val Gln
180    185    190
Pro Asp Ile Ser Ala Thr Thr His Lys Asn Glu Glu Ala Ser Pro Ala
195    200    205
Ser Pro Gln Thr Ser Ala Ser Thr Thr Arg Ile Gln Arg Lys Ser Val

```

210 215 220
 Glu Ala Asn Thr Ser Thr Thr Tyr Asn Gln Thr Ser
 225 230 235

<210> 134
 <211> 236
 <212> PRT
 <213> Human metapneumo virus

<400> 134
 Met Glu Val Lys Val Glu Asn Ile Arg Thr Ile Asp Met Leu Lys Ala
 1 5 10 15
 Ser Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
 20 25 30
 Leu Val Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
 35 40 45
 Leu Ile Ile Asn Tyr Lys Met Gln Lys Asn Thr Ser Glu Ser Glu His
 50 55 60
 His Thr Ser Ser Ser Pro Met Glu Ser Ser Arg Glu Thr Pro Thr Val
 65 70 75 80
 Pro Thr Asp Asn Ser Asp Thr Asn Ser Ser Pro Gln His Pro Thr Gln
 85 90 95
 Gln Ser Thr Glu Gly Ser Thr Leu Tyr Phe Ala Ala Ser Ala Ser Ser
 100 105 110
 Pro Glu Thr Glu Pro Thr Ser Thr Pro Asp Thr Thr Asn Arg Pro Pro
 115 120 125
 Phe Val Asp Thr His Thr Thr Pro Pro Ser Ala Ser Arg Thr Lys Thr
 130 135 140
 Ser Pro Ala Val His Thr Lys Asn Asn Pro Arg Thr Ser Ser Arg Thr
 145 150 155 160
 His Ser Pro Pro Arg Ala Thr Thr Arg Thr Ala Arg Arg Thr Thr Thr
 165 170 175
 Leu Arg Thr Ser Ser Thr Arg Lys Arg Pro Ser Thr Ala Ser Val Gln
 180 185 190
 Pro Asp Ile Ser Ala Thr Thr His Lys Asn Glu Glu Ala Ser Pro Ala
 195 200 205
 Ser Pro Gln Thr Ser Ala Ser Thr Thr Arg Ile Gln Arg Lys Ser Val
 210 215 220
 Glu Ala Asn Thr Ser Thr Thr Tyr Asn Gln Thr Ser
 225 230 235

<210> 135
 <211> 236
 <212> PRT
 <213> Human metapneumo virus

<400> 135
 Met Glu Val Lys Val Glu Asn Ile Arg Thr Ile Asp Met Leu Lys Ala
 1 5 10 15
 Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
 20 25 30
 Leu Val Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
 35 40 45
 Leu Ile Ile Asn Tyr Lys Met Gln Lys Asn Thr Ser Glu Ser Glu His
 50 55 60
 His Thr Ser Ser Ser Pro Met Glu Ser Ser Arg Glu Thr Pro Thr Val
 65 70 75 80
 Pro Thr Asp Asn Ser Asp Thr Asn Ser Ser Pro Gln His Pro Thr Gln
 85 90 95
 Gln Ser Thr Glu Gly Ser Thr Leu Tyr Phe Ala Ala Ser Ala Asn Ser

```

      100      105      110
Pro Glu Thr Glu Pro Thr Ser Thr Pro Asp Thr Thr Asn Arg Pro Pro
      115      120      125
Phe Val Asp Thr His Thr Thr Pro Pro Ser Ala Ser Arg Thr Lys Thr
      130      135      140
Ser Pro Ala Val His Thr Lys Asn Asn Pro Arg Ile Ser Ser Arg Thr
145      150      155      160
His Ser Pro Pro Trp Ala Thr Thr Arg Thr Ala Arg Arg Thr Thr Thr
      165      170      175
Leu Arg Thr Ser Ser Thr Arg Lys Arg Pro Ser Thr Ala Ser Ala Gln
      180      185      190
Pro Asp Ile Ser Ala Thr Thr His Lys Asn Glu Glu Ala Ser Pro Ala
      195      200      205
Ser Pro Gln Thr Ser Ala Ser Thr Thr Arg Thr Gln Arg Lys Ser Val
      210      215      220
Glu Ala Asn Thr Ser Thr Thr Tyr Asn Gln Thr Ser
225      230      235

```

<210> 136

<211> 236

<212> PRT

<213> Human metapneumo virus

<400> 136

```

Met Glu Val Lys Val Glu Asn Ile Arg Thr Ile Asp Met Leu Lys Ala
 1      5      10      15
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
      20      25      30
Leu Val Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
      35      40      45
Leu Ile Ile Asn Tyr Lys Met Gln Lys Asn Thr Ser Glu Ser Glu His
      50      55      60
His Thr Ser Ser Ser Pro Met Glu Ser Ser Arg Glu Thr Pro Thr Val
      65      70      75      80
Pro Thr Asp Asn Ser Asp Thr Asn Ser Ser Pro Gln His Pro Thr Gln
      85      90      95
Gln Ser Thr Glu Gly Ser Thr Leu Tyr Phe Ala Ala Ser Ala Asn Ser
      100      105      110
Pro Glu Thr Glu Pro Thr Ser Thr Pro Asp Thr Thr Asp Arg Pro Pro
      115      120      125
Phe Val Asp Thr His Thr Thr Pro Pro Ser Ala Ser Arg Thr Lys Thr
      130      135      140
Ser Pro Ala Val His Thr Lys Asn Asn Pro Arg Ile Ser Ser Arg Thr
145      150      155      160
His Ser Pro Pro Trp Ala Thr Thr Arg Thr Ala Arg Arg Thr Thr Thr
      165      170      175
Leu Arg Thr Ser Ser Thr Arg Lys Arg Pro Ser Thr Ala Ser Val Gln
      180      185      190
Pro Asp Ile Ser Ala Thr Thr His Lys Asn Glu Glu Ala Ser Pro Ala
      195      200      205
Ser Pro Gln Thr Ser Ala Ser Thr Thr Arg Thr Gln Arg Lys Ser Val
      210      215      220
Glu Ala Asn Thr Ser Thr Thr Tyr Asn Gln Thr Ser
225      230      235

```

<210> 137

<211> 236

<212> PRT

<213> Human metapneumo virus

<400> 137

```

Met Glu Val Lys Val Glu Asn Ile Arg Thr Ile Asp Met Leu Lys Ala
 1              5              10              15
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
              20              25              30
Leu Val Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
              35              40              45
Leu Ile Ile Asn Tyr Lys Met Gln Lys Asn Thr Ser Glu Ser Glu His
              50              55              60
His Thr Ser Ser Ser Pro Met Glu Ser Ser Arg Glu Thr Pro Thr Val
65              70              75              80
Pro Thr Asp Asn Ser Asp Thr Asn Ser Ser Pro Gln His Pro Thr Gln
              85              90              95
Gln Ser Thr Glu Gly Ser Thr Leu Tyr Phe Ala Ala Ser Ala Ser Ser
              100              105              110
Pro Glu Thr Glu Pro Thr Ser Thr Pro Asp Thr Thr Asp Arg Pro Pro
              115              120              125
Phe Val Asp Thr His Thr Thr Pro Pro Ser Ala Ser Arg Thr Lys Thr
130              135              140
Ser Pro Ala Val His Thr Lys Asn Asn Pro Arg Ile Ser Ser Arg Thr
145              150              155              160
His Ser Pro Pro Trp Ala Thr Thr Arg Thr Ala Arg Arg Thr Thr Thr
              165              170              175
Leu Arg Thr Ser Ser Thr Arg Lys Arg Pro Ser Thr Ala Ser Val Gln
              180              185              190
Pro Asp Ile Ser Ala Thr Thr His Lys Asn Glu Glu Ala Ser Pro Ala
              195              200              205
Ser Pro Gln Thr Ser Ala Ser Thr Thr Arg Thr Gln Arg Lys Ser Val
210              215              220
Glu Ala Asn Thr Ser Thr Thr Tyr Asn Gln Thr Ser
225              230              235

```

<210> 138

<211> 236

<212> PRT

<213> Human metapneumo virus

<400> 138

```

Met Glu Val Lys Val Glu Asn Ile Arg Thr Ile Asp Met Leu Lys Ala
 1              5              10              15
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
              20              25              30
Leu Ile Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
              35              40              45
Leu Ile Ile Asn Tyr Thr Met Gln Glu Asn Thr Ser Glu Ser Glu His
              50              55              60
His Thr Ser Ser Ser Pro Met Glu Ser Ser Arg Glu Thr Pro Thr Val
65              70              75              80
Pro Ile Asp Asn Ser Asp Thr Asn Pro Gly Ser Gln Tyr Pro Thr Gln
              85              90              95
Gln Ser Thr Glu Asp Ser Thr Leu His Ser Ala Ala Ser Ala Ser Ser
              100              105              110
Pro Glu Thr Glu Pro Thr Ser Thr Pro Asp Thr Thr Ser Arg Pro Pro
              115              120              125
Phe Val Asp Thr His Thr Thr Pro Pro Ser Ala Ser Arg Thr Arg Thr
130              135              140
Ser Pro Ala Val His Thr Lys Asn Asn Pro Arg Val Ser Pro Arg Thr
145              150              155              160
His Ser Pro Pro Trp Ala Met Thr Arg Thr Val Arg Gly Thr Thr Thr
              165              170              175
Leu Arg Thr Ser Ser Thr Arg Lys Arg Leu Ser Thr Ala Ser Val Gln

```



```
<210> 139
<211> 236
<212> PRT
<213> Human metapneumo virus
```

```
<210> 140
<211> 236
<212> PRT
<213> Human metapneumo virus
```

<400> 140															
Met	Glu	Val	Lys	Val	Glu	Asn	Ile	Arg	Thr	Ile	Asp	Met	Leu	Lys	Ala
1				5					10					15	
Arg	Val	Lys	Asn	Arg	Val	Ala	Arg	Ser	Lys	Cys	Phe	Lys	Asn	Ala	Ser
			20					25					30		
Leu	Ile	Leu	Ile	Gly	Ile	Thr	Thr	Leu	Ser	Ile	Ala	Leu	Asn	Ile	Tyr
		35				40						45			
Leu	Ile	Ile	Asn	Tyr	Thr	Met	Gln	Glu	Asn	Thr	Ser	Glu	Ser	Glu	His
	50					55					60				
His	Thr	Ser	Ser	Ser	Pro	Met	Glu	Ser	Ser	Arg	Glu	Thr	Pro	Thr	Val

```

65          70          75          80
Pro Met Asp Asn Ser Asp Thr Asn Pro Gly Ser Gln Tyr Pro Thr Gln
          85          90          95
Gln Ser Thr Glu Gly Ser Thr Leu His Phe Ala Ala Ser Ala Ser Ser
          100          105          110
Pro Glu Thr Glu Pro Thr Ser Thr Pro Asp Thr Thr Ser Arg Pro Pro
          115          120          125
Phe Val Asp Thr His Thr Thr Pro Ser Ser Ala Ser Arg Ile Arg Thr
          130          135          140
Ser Pro Ala Val His Thr Lys Asn Asn Leu Arg Ile Ser Pro Arg Thr
145          150          155          160
His Ser Pro Pro Trp Ala Met Thr Arg Thr Val Arg Gly Thr Thr Thr
          165          170          175
Leu Arg Thr Ser Ser Ile Arg Lys Arg Pro Ser Thr Ala Ser Val Gln
          180          185          190
Pro Asp Ser Ser Ala Thr Thr His Lys His Glu Glu Ala Ser Pro Val
          195          200          205
Ser Pro Gln Ala Ser Ala Ser Thr Ala Arg Pro Gln Arg Lys Gly Met
          210          215          220
Glu Ala Ser Thr Ser Thr Thr Tyr Asn Gln Thr Ser
225          230          235

```

<210> 141
 <211> 228
 <212> PRT
 <213> Human metapneumovirus

<220>
 <221> VARIANT
 <222> 220
 <223> Xaa = unknown amino acid or other

```

<400> 141
Met Glu Val Lys Val Glu Asn Ile Arg Ala Ile Asp Met Leu Lys Ala
1          5          10          15
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
          20          25          30
Leu Ile Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
          35          40          45
Leu Ile Ile Asn Tyr Thr Ile Gln Lys Thr Thr Ser Glu Ser Glu His
          50          55          60
His Thr Ser Ser Pro Pro Thr Glu Pro Asn Lys Glu Ala Ser Thr Ile
65          70          75          80
Ser Thr Asp Asn Pro Asp Ile Asn Pro Ser Ser Gln His Pro Thr Gln
          85          90          95
Gln Ser Thr Glu Asn Pro Thr Leu Asn Pro Ala Ala Ser Ala Ser Pro
          100          105          110
Ser Glu Thr Glu Pro Ala Ser Thr Pro Asp Thr Thr Asn Arg Leu Ser
          115          120          125
Ser Val Asp Arg Ser Thr Ala Gln Pro Ser Glu Ser Arg Thr Lys Thr
          130          135          140
Lys Pro Thr Val His Thr Ile Asn Asn Pro Asn Thr Ala Ser Ser Thr
145          150          155          160
Gln Ser Pro Pro Arg Thr Thr Thr Lys Ala Ile Arg Arg Ala Thr Thr
          165          170          175
Phe Arg Met Ser Ser Thr Gly Lys Arg Pro Thr Thr Thr Leu Val Gln
          180          185          190
Ser Asp Ser Ser Thr Thr Thr Gln Asn His Glu Glu Thr Gly Ser Ala
          195          200          205
Asn Pro Gln Ala Ser Ala Ser Thr Met Gln Asn Xaa His Thr Asn Asn
210          215          220

```

Ile Lys Pro Asn
225

<210> 142
<211> 228
<212> PRT
<213> Human metapneumo virus

<400> 142
Met Glu Val Lys Val Glu Asn Ile Arg Ala Ile Asp Met Leu Lys Ala
1 5 10 15
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
20 25 30
Leu Ile Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
35 40 45
Leu Ile Ile Asn Tyr Thr Ile Gln Lys Thr Thr Ser Glu Ser Glu His
50 55 60
His Thr Ser Ser Pro Pro Thr Glu Ser Asn Lys Glu Thr Ser Thr Ile
65 70 75 80
Pro Ile Asp Asn Pro Asp Ile Asn Pro Asn Ser Gln His Pro Thr Gln
85 90 95
Gln Ser Thr Glu Ser Pro Thr Leu Asn Pro Ala Ala Ser Val Ser Pro
100 105 110
Ser Glu Thr Glu Pro Ala Ser Thr Pro Asp Thr Thr Asn Arg Leu Ser
115 120 125
Ser Val Asp Arg Ser Thr Thr Gln Pro Ser Glu Ser Arg Thr Lys Thr
130 135 140
Lys Pro Thr Val His Thr Lys Asn Asn Pro Ser Thr Val Ser Arg Thr
145 150 155 160
Gln Ser Pro Leu Arg Ala Thr Thr Lys Ala Val Leu Arg Ala Thr Ala
165 170 175
Phe Arg Thr Ser Ser Thr Arg Lys Arg Pro Thr Thr Thr Ser Val Gln
180 185 190
Ser Asp Ser Ser Thr Thr Thr Gln Asn His Glu Glu Thr Ser Ser Ala
195 200 205
Asn Pro Gln Ala Ser Ala Ser Thr Met Gln Ser Gln His Thr Asn Asn
210 215 220
Ile Lys Pro Asn
225

<210> 143
<211> 228
<212> PRT
<213> Human metapneumo virus

<400> 143
Met Glu Val Lys Val Glu Asn Ile Arg Ala Val Asp Met Leu Lys Ala
1 5 10 15
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
20 25 30
Leu Ile Leu Val Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
35 40 45
Leu Ile Val Asn Tyr Thr Ile Gln Lys Thr Thr Ser Glu Ser Glu His
50 55 60
His Thr Ser Ser Ser Pro Thr Glu Ser Asn Lys Gly Thr Ser Thr Ile
65 70 75 80
Pro Thr Asp Asn Pro Asp Ile Asn Pro Asn Ser Gln His Pro Thr Gln
85 90 95
Gln Ser Thr Glu Ser Pro Thr Leu Asn Thr Ala Ala Ser Val Ser Pro
100 105 110

Ser Glu Thr Glu Pro Ala Ser Thr Pro Asp Thr Thr Asn Arg Leu Ser
 115 120 125
 Ser Ala Asp Arg Ser Thr Thr Gln Pro Ser Glu Ser Arg Thr Lys Thr
 130 135 140
 Lys Leu Thr Val His Thr Lys Asn Asn Leu Ser Thr Ala Ser Arg Thr
 145 150 155 160
 Gln Ser Pro Pro Arg Ala Thr Thr Lys Ala Val Leu Arg Asp Thr Ala
 165 170 175
 Phe His Thr Ser Ser Thr Gly Lys Arg Pro Thr Thr Thr Ser Val Gln
 180 185 190
 Ser Gly Ser Ser Thr Thr Thr Gln Asn His Glu Glu Thr Ser Ser Ser
 195 200 205
 Asn Pro Gln Ala Ser Ala Ser Thr Met Gln Asp Gln Asp Thr Asn Asn
 210 215 220
 Thr Lys Gln Asn
 225

<210> 144

<211> 228

<212> PRT

<213> Human metapneumo virus

<220>

<221> VARIANT

<222> 81

<223> Xaa = Any Amino Acid

<400> 144

Met Glu Val Lys Val Glu Asn Ile Arg Ala Val Asp Met Leu Lys Ala
 1 5 10 15
 Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
 20 25 30
 Leu Ile Leu Val Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
 35 40 45
 Leu Ile Val Asn Tyr Thr Ile Gln Lys Thr Thr Ser Glu Ser Glu His
 50 55 60
 His Thr Ser Ser Ser Pro Thr Glu Ser Asn Lys Gly Thr Ser Thr Ile
 65 70 75 80
 Xaa Thr Asp Asn Pro Asp Ile Asn Pro Asn Ser Gln His Pro Thr Gln
 85 90 95
 Gln Ser Thr Glu Ser Pro Thr Leu Asn Thr Ala Ala Ser Val Ser Pro
 100 105 110
 Ser Glu Thr Glu Pro Ala Ser Thr Pro Asp Thr Thr Asn Arg Leu Ser
 115 120 125
 Ser Ala Asp Arg Ser Thr Thr Gln Pro Ser Glu Ser Arg Thr Lys Thr
 130 135 140
 Lys Leu Thr Val His Thr Lys Asn Asn Leu Ser Thr Ala Ser Arg Thr
 145 150 155 160
 Gln Ser Pro Pro Arg Ala Thr Thr Lys Ala Val Leu Arg Asp Thr Ala
 165 170 175
 Phe His Thr Ser Ser Thr Gly Lys Arg Pro Thr Thr Thr Ser Val Gln
 180 185 190
 Ser Gly Ser Ser Thr Thr Thr Gln Asn His Glu Glu Thr Ser Ser Ser
 195 200 205
 Asn Pro Gln Ala Ser Ala Ser Thr Met Gln Asp Gln Asp Thr Asn Asn
 210 215 220
 Thr Lys Gln Asn
 225

<210> 145

<211> 228
 <212> PRT
 <213> Human metapneumovirus

<220>
 <221> VARIANT
 <222> 220
 <223> Xaa = unknown amino acid or other

<400> 145
 Met Glu Val Lys Val Glu Asn Ile Arg Ala Ile Asp Met Leu Lys Ala
 1 5 10 15
 Arg Met Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
 20 25 30
 Leu Ile Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
 35 40 45
 Leu Ile Ile Asn Tyr Thr Ile Gln Lys Thr Thr Ser Glu Ser Glu His
 50 55 60
 His Thr Ser Ser Pro Pro Thr Glu Ser Asn Lys Glu Thr Ser Thr Ile
 65 70 75 80
 Pro Ile Asp Asn Pro Asp Ile Asn Pro Asn Ser Gln His Pro Thr Gln
 85 90 95
 Gln Ser Thr Glu Ser Leu Thr Leu Asn Pro Ala Ala Ser Val Ser Pro
 100 105 110
 Ser Glu Thr Glu Pro Ala Ser Thr Pro Asp Thr Thr Asn Arg Leu Ser
 115 120 125
 Ser Val Asp Arg Ser Thr Thr Gln Pro Ser Glu Ser Arg Thr Lys Thr
 130 135 140
 Lys Leu Thr Val His Lys Lys Asn Ile Pro Ser Thr Val Ser Arg Thr
 145 150 155 160
 Gln Ser Ser Ile Arg Ala Thr Thr Lys Ala Val Leu Arg Ala Thr Ala
 165 170 175
 Phe Arg Thr Ser Ser Thr Gly Glu Arg Pro Thr Thr Thr Ser Val Gln
 180 185 190
 Ser Asp Ser Ser Thr Thr Thr Gln Asn His Glu Glu Thr Gly Ser Ala
 195 200 205
 Asn Pro Gln Ala Ser Ala Ser Thr Met Gln Asn Xaa His Thr Asn Ile
 210 215 220
 Val Lys Pro Asn
 225

<210> 146
 <211> 228
 <212> PRT
 <213> Human metapneumovirus

<220>
 <221> VARIANT
 <222> 220
 <223> Xaa = unknown amino acid or other

<400> 146
 Met Glu Val Lys Val Glu Asn Ile Arg Ala Ile Asp Met Leu Lys Ala
 1 5 10 15
 Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
 20 25 30
 Leu Ile Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
 35 40 45
 Leu Ile Ile Asn Tyr Thr Ile Gln Lys Thr Thr Ser Glu Ser Glu His
 50 55 60
 His Thr Ser Ser Pro Pro Thr Glu Ser Asn Lys Glu Thr Ser Thr Ile

```

65          70          75          80
Ser Ile Asp Asn Pro Asp Ile Asn Pro Asn Ser Gln His Pro Thr Gln
          85          90          95
Gln Ser Thr Glu Ser Leu Thr Leu Ser Pro Thr Ala Ser Val Ser Pro
          100          105          110
Ser Glu Thr Glu Pro Ala Ser Thr Ser Asp Thr Thr Ser Arg Leu Ser
          115          120          125
Ser Val Asp Arg Ser Thr Thr Gln Pro Ser Glu Ser Arg Ala Arg Thr
          130          135          140
Lys Pro Thr Val His Lys Lys Asn Ile Pro Ser Thr Val Ser Arg Thr
          145          150          155          160
Gln Ser Pro Leu Arg Ala Thr Thr Lys Ala Val Leu Arg Ala Thr Ala
          165          170          175
Phe Arg Thr Ser Ser Thr Gly Glu Gly Pro Thr Thr Thr Ser Val Gln
          180          185          190
Ser Asp Ser Ser Thr Thr Thr Gln Asn His Glu Glu Thr Gly Ser Ala
          195          200          205
Asn Pro Gln Ala Ser Ala Ser Thr Met Gln Asn Xaa His Thr Asn Ile
          210          215          220
Val Lys Pro Asn
225

```

```

<210> 147
<211> 228
<212> PRT
<213> Human metapneumovirus

```

```

<220>
<221> VARIANT
<222> 220
<223> Xaa = unknown amino acid or other

```

```

<400> 147
Met Glu Val Lys Val Glu Asn Ile Arg Ala Ile Asp Met Leu Lys Ala
1          5          10          15
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
          20          25          30
Leu Ile Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
          35          40          45
Leu Ile Ile Asn Tyr Thr Ile Gln Lys Thr Thr Ser Glu Ser Glu His
          50          55          60
His Thr Ser Ser Pro Pro Thr Glu Ser Asn Lys Glu Ala Ser Thr Ile
          65          70          75          80
Ser Thr Asp Asn Pro Asp Ile Asn Pro Asn Ser Gln His Pro Thr Gln
          85          90          95
Gln Ser Thr Glu Asn Pro Thr Leu Asn Pro Ala Ala Ser Val Ser Ser
          100          105          110
Ser Glu Thr Glu Pro Ala Ser Thr Pro Asp Thr Thr Asn Arg Leu Ser
          115          120          125
Ser Val Asp Arg Ser Thr Ala Gln Pro Ser Glu Ser Arg Thr Lys Thr
          130          135          140
Lys Pro Thr Val His Thr Arg Asn Asn Pro Ser Thr Ala Ser Ser Thr
          145          150          155          160
Gln Ser Pro Pro Arg Val Thr Thr Lys Ala Ile Leu Arg Ala Thr Val
          165          170          175
Phe Arg Met Ser Ser Thr Gly Lys Arg Pro Ala Thr Thr Leu Val Gln
          180          185          190
Ser Asp Ser Ser Thr Thr Thr Gln Asn His Glu Glu Thr Gly Ser Ala
          195          200          205
Asn Ser Gln Ala Ser Ala Ser Thr Met Gln Asn Xaa His Ser Asn Asn
          210          215          220

```

Ile Lys Pro Asn
225

<210> 148
<211> 228
<212> PRT
<213> Human metapneumo virus

<400> 148
Met Glu Val Lys Val Glu Asn Ile Arg Ala Ile Asp Met Leu Lys Ala
1 5 10 15
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
20 25 30
Leu Ile Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
35 40 45
Leu Ile Ile Asn Tyr Thr Ile Gln Lys Thr Thr Ser Glu Ser Glu His
50 55 60
His Thr Ser Ser Pro Pro Thr Glu Ser Asn Lys Glu Thr Ser Thr Ile
65 70 75 80
Ser Ile Asp Asn Ser Asp Ile Asn Pro Asn Ser Gln His Pro Thr Gln
85 90 95
Gln Ser Thr Glu Ser Leu Thr Leu Ser Pro Thr Ala Ser Val Ser Pro
100 105 110
Ser Glu Thr Glu Pro Ala Ser Thr Ser Asp Thr Thr Asn Arg Leu Ser
115 120 125
Ser Val Asp Arg Ser Thr Thr Gln Pro Ser Glu Ser Arg Ala Arg Thr
130 135 140
Lys Pro Thr Val His Lys Lys Asn Ile Pro Ser Thr Val Ser Arg Thr
145 150 155 160
Gln Ser Pro Leu Arg Ala Thr Thr Lys Ala Val Leu Arg Ala Thr Ala
165 170 175
Phe Arg Met Ser Ser Thr Gly Glu Gly Pro Thr Thr Thr Ser Val Gln
180 185 190
Ser Asp Ser Ser Thr Thr Thr Gln Asn His Glu Glu Thr Gly Ser Ala
195 200 205
Asn Pro Gln Ala Ser Ala Ser Thr Met Gln Asn Gln His Thr Asn Ile
210 215 220
Ala Lys Pro Asn
225

<210> 149
<211> 228
<212> PRT
<213> Human metapneumo virus

<400> 149
Met Glu Val Lys Val Glu Asn Ile Arg Ala Ile Asp Met Leu Lys Ala
1 5 10 15
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
20 25 30
Leu Ile Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
35 40 45
Leu Ile Ile Asn Tyr Thr Ile Gln Lys Thr Thr Ser Glu Ser Glu His
50 55 60
His Thr Ser Ser Pro Pro Thr Glu Ser Asn Lys Glu Thr Ser Thr Ile
65 70 75 80
Pro Ile Asp Asn Pro Asp Ile Asn Pro Asn Ser Gln His Pro Thr Gln
85 90 95
Gln Ser Thr Glu Ser Leu Thr Leu Tyr Pro Thr Ser Ser Val Ser Ser
100 105 110

```

Ser Glu Thr Glu Pro Ala Ser Thr Pro Gly Ile Thr Asn His Leu Ser
      115                      120                      125
Phe Val Asp Arg Ser Thr Thr Gln Pro Ser Glu Ser Arg Thr Lys Thr
      130                      135                      140
Asn Arg Thr Val His Lys Lys Asn Ile Ser Ser Thr Val Ser Arg Thr
      145                      150                      155                      160
Gln Ser Pro Pro Arg Thr Thr Ala Lys Ala Val Pro Arg Ala Thr Ala
      165                      170                      175
Leu Arg Thr Ser Ser Thr Gly Glu Arg Pro Thr Thr Thr Pro Val Gln
      180                      185                      190
Pro Asp Ser Ser Thr Thr Thr Gln Asn His Glu Glu Thr Gly Ser Ala
      195                      200                      205
Asn Pro Gln Ala Ser Ala Ser Thr Met Gln Asn Gln His Thr Asn Ile
      210                      215                      220
Ala Arg Pro Asn
225

```

```

<210> 150
<211> 228
<212> PRT
<213> Human metapneumo virus

```

```

<400> 150
Met Glu Val Lys Val Glu Asn Ile Arg Ala Ile Asp Met Leu Lys Ala
  1                      5                      10                      15
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
      20                      25                      30
Leu Ile Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
      35                      40                      45
Leu Ile Ile Asn Tyr Thr Ile Gln Lys Thr Thr Ser Glu Ser Glu His
      50                      55                      60
His Thr Ser Ser Pro Pro Thr Glu Ser Asn Lys Glu Thr Ser Thr Ile
      65                      70                      75                      80
Pro Ile Asp Asn Pro Asp Ile Asn Pro Asn Ser Gln His Pro Thr Gln
      85                      90                      95
Gln Ser Ala Glu Ser Leu Thr Leu Tyr Pro Thr Ser Ser Val Ser Ser
      100                      105                      110
Ser Glu Thr Glu Pro Ala Ser Thr Pro Gly Ile Thr Asn His Leu Ser
      115                      120                      125
Phe Val Asp Arg Ser Thr Thr Gln Pro Ser Glu Ser Arg Thr Lys Thr
      130                      135                      140
Asn Arg Thr Val His Lys Lys Asn Ile Ser Ser Thr Val Ser Arg Thr
      145                      150                      155                      160
Gln Ser Pro Pro Arg Thr Thr Ala Lys Ala Val Pro Arg Ala Thr Ala
      165                      170                      175
Leu Arg Thr Ser Ser Thr Gly Glu Arg Pro Thr Thr Thr Pro Val Gln
      180                      185                      190
Pro Asp Ser Ser Thr Thr Thr Thr Gln Asn His Glu Glu Thr Gly Ser Ala
      195                      200                      205
Asn Pro Gln Ala Ser Ala Ser Thr Met Gln Asn Gln His Thr Asn Ile
      210                      215                      220
Ala Arg Pro Asn
225

```

```

<210> 151
<211> 228
<212> PRT
<213> Human metapneumo virus

```

```

<400> 151

```



```

Met Glu Val Lys Val Glu Asn Ile Arg Ala Ile Asp Met Leu Lys Ala
 1          5          10
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
 20          25          30
Leu Ile Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
 35          40          45
Leu Ile Ile Asn Tyr Thr Ile Gln Lys Thr Thr Ser Glu Ser Glu His
 50          55          60
His Thr Ser Ser Pro Pro Thr Glu Ser Asn Lys Glu Thr Ser Thr Ile
 65          70          75          80
Pro Ile Asp Asn Pro Asp Ile Asn Pro Asn Ser Gln His Pro Thr Gln
 85          90          95
Gln Ser Thr Glu Ser Leu Thr Leu Tyr Pro Thr Ser Ser Val Ser Ser
 100          105          110
Ser Glu Thr Glu Pro Ala Ser Thr Pro Gly Ile Thr Asn His Leu Ser
 115          120          125
Phe Val Asp Arg Ser Thr Thr Gln Pro Ser Glu Ser Arg Thr Lys Thr
 130          135          140
Asn Arg Thr Val His Lys Lys Asn Ile Ser Ser Thr Val Ser Arg Thr
 145          150          155          160
Gln Ser Pro Pro Arg Thr Thr Ala Lys Ala Val Pro Arg Ala Thr Ala
 165          170          175
Leu Arg Thr Ser Ser Thr Gly Glu Arg Pro Thr Thr Thr Pro Val Gln
 180          185          190
Pro Asp Ser Ser Thr Thr Thr Gln Asn His Glu Glu Thr Gly Ser Ala
 195          200          205
Asn Pro Gln Ala Ser Ala Ser Thr Met Gln Asn Gln His Thr Asn Ile
 210          215          220
Ala Arg Pro Asn
225

```

<210> 152

<211> 228

<212> PRT

<213> Human metapneumo virus

<400> 152

```

Met Glu Val Lys Val Glu Asn Ile Arg Ala Ile Asp Met Leu Lys Ala
 1          5          10
Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
 20          25          30
Leu Ile Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
 35          40          45
Leu Ile Ile Asn Tyr Thr Ile Gln Gln Thr Thr Ser Glu Ser Glu His
 50          55          60
His Thr Ser Ser Pro Pro Thr Glu Ser Asn Lys Glu Ala Ser Thr Ile
 65          70          75          80
Ser Thr Asp Asn Pro Asp Ile Asn Pro Asn Ser Gln His Pro Thr Gln
 85          90          95
Gln Ser Thr Glu Asn Pro Thr Leu Asn Pro Ala Ala Ser Ala Ser Pro
 100          105          110
Ser Glu Thr Glu Ser Ala Ser Thr Pro Asp Thr Thr Asn Arg Leu Ser
 115          120          125
Ser Val Asp Arg Ser Thr Val Gln Pro Ser Glu Asn Arg Thr Lys Thr
 130          135          140
Lys Leu Thr Val His Thr Arg Asn Asn Leu Ser Thr Ala Ser Ser Thr
 145          150          155          160
Gln Ser Pro Pro Arg Ala Thr Thr Lys Ala Ile Arg Arg Ala Thr Thr
 165          170          175
Leu Arg Met Ser Ser Thr Gly Arg Arg Pro Thr Thr Thr Leu Val Gln
 180          185          190

```

Ser Asp Ser Ser Thr Thr Thr Gln Asn His Glu Glu Thr Gly Ser Ala
 195 200 205
 Asn Pro Gln Ala Ser Ala Ser Thr Met Gln Asn Gln His Thr Asn Asn
 210 215 220
 Ile Lys Pro Asn
 225

<210> 153
 <211> 228
 <212> PRT
 <213> Human metapneumo virus

<400> 153
 Met Glu Val Lys Val Glu Asn Ile Arg Ala Ile Asp Met Leu Lys Ala
 1 5 10 15
 Arg Val Lys Asn Arg Val Ala Arg Ser Lys Cys Phe Lys Asn Ala Ser
 20 25 30
 Leu Ile Leu Ile Gly Ile Thr Thr Leu Ser Ile Ala Leu Asn Ile Tyr
 35 40 45
 Leu Ile Ile Asn Tyr Thr Ile Gln Lys Thr Thr Ser Glu Ser Glu His
 50 55 60
 His Thr Ser Ser Pro Pro Thr Glu Ser Asn Lys Glu Ala Ser Thr Ile
 65 70 75 80
 Ser Thr Asp Asn Pro Asp Ile Asn Pro Asn Ser Gln His Pro Thr Gln
 85 90 95
 Gln Ser Thr Glu Asn Pro Thr Leu Asn Pro Ala Ala Ser Ala Ser Pro
 100 105 110
 Ser Glu Thr Glu Ser Ala Ser Thr Pro Asp Thr Thr Asn Arg Leu Ser
 115 120 125
 Ser Val Asp Arg Ser Thr Val Gln Pro Ser Glu Asn Arg Thr Lys Thr
 130 135 140
 Lys Leu Thr Val His Thr Arg Asn Asn Leu Ser Thr Ala Ser Ser Thr
 145 150 155 160
 Gln Ser Pro Pro Arg Ala Thr Thr Lys Ala Ile Arg Arg Ala Thr Thr
 165 170 175
 Leu Arg Met Ser Ser Thr Gly Arg Arg Pro Thr Thr Thr Leu Val Gln
 180 185 190
 Ser Asp Ser Ser Thr Thr Thr Gln Asn His Glu Glu Thr Gly Ser Ala
 195 200 205
 Asn Pro Gln Ala Ser Ala Ser Thr Met Gln Asn Gln His Thr Asn Asn
 210 215 220
 Ile Lys Pro Asn
 225

<210> 154
 <211> 231
 <212> PRT
 <213> Human metapneumovirus

<220>
 <221> VARIANT
 <222> 225
 <223> Xaa = unknown amino acid or other

<400> 154
 Met Glu Val Arg Val Glu Asn Ile Arg Ala Ile Asp Met Phe Lys Ala
 1 5 10 15
 Lys Ile Lys Asn Arg Ile Arg Ser Ser Arg Cys Tyr Arg Asn Ala Thr
 20 25 30
 Leu Ile Leu Ile Gly Leu Thr Ala Leu Ser Met Ala Leu Asn Ile Phe

```

      35      40      45
Leu Ile Ile Asp His Ala Thr Leu Arg Asn Met Ile Lys Thr Glu Asn
 50      55      60
Cys Ala Asn Met Pro Ser Ala Glu Pro Ser Lys Lys Thr Pro Met Thr
65      70      75      80
Ser Thr Ala Gly Pro Asn Thr Lys Pro Asn Pro Gln Gln Ala Thr Gln
      85      90      95
Trp Thr Thr Glu Asn Ser Thr Ser Pro Val Ala Thr Pro Glu Gly His
      100      105      110
Pro Tyr Thr Gly Thr Thr Gln Thr Ser Asp Thr Thr Ala Pro Gln Gln
      115      120      125
Thr Thr Asp Lys His Thr Ala Pro Leu Lys Ser Thr Asn Glu Gln Ile
      130      135      140
Thr Gln Thr Thr Thr Glu Lys Lys Thr Ile Arg Ala Thr Thr Gln Lys
145      150      155      160
Arg Glu Lys Gly Lys Glu Asn Thr Asn Gln Thr Thr Ser Thr Ala Ala
      165      170      175
Thr Gln Thr Thr Asn Thr Thr Asn Gln Ile Arg Asn Ala Ser Glu Thr
      180      185      190
Ile Thr Thr Ser Asp Arg Pro Arg Thr Asp Thr Thr Thr Gln Ser Ser
      195      200      205
Glu Gln Thr Thr Arg Ala Thr Asp Pro Ser Ser Pro Pro His His Ala
      210      215      220
Xaa Arg Gly Ala Lys Leu Lys
225      230

```

<210> 155

<211> 231

<212> PRT

<213> Human metapneumo virus

<400> 155

```

Met Glu Val Arg Val Glu Asn Ile Arg Ala Ile Asp Met Phe Lys Ala
 1      5      10      15
Lys Ile Lys Asn Arg Ile Arg Ser Ser Arg Cys Tyr Arg Asn Ala Thr
      20      25      30
Leu Ile Leu Ile Gly Leu Thr Ala Leu Ser Met Ala Leu Asn Ile Phe
      35      40      45
Leu Ile Ile Asp His Ala Thr Leu Arg Asn Met Ile Lys Thr Glu Asn
      50      55      60
Cys Ala Asn Met Pro Ser Ala Glu Pro Ser Lys Lys Thr Pro Met Thr
65      70      75      80
Ser Thr Ala Gly Pro Ser Thr Glu Pro Asn Pro Gln Gln Ala Thr Gln
      85      90      95
Trp Thr Thr Glu Asn Ser Thr Ser Pro Ala Ala Thr Leu Glu Ser His
      100      105      110
Pro Tyr Thr Gly Thr Thr Gln Thr Pro Asp Ile Thr Ala Pro Gln Gln
      115      120      125
Thr Thr Asp Lys His Thr Ala Leu Pro Lys Ser Thr Asn Glu Gln Ile
      130      135      140
Thr Gln Thr Thr Thr Glu Lys Lys Thr Thr Arg Ala Thr Thr Gln Lys
145      150      155      160
Arg Glu Lys Glu Lys Glu Asn Thr Asn Gln Thr Thr Ser Thr Ala Ala
      165      170      175
Thr Gln Thr Thr Asn Thr Thr Asn Gln Thr Arg Asn Ala Ser Glu Thr
      180      185      190
Ile Thr Thr Ser Asp Arg Pro Arg Ile Asp Thr Thr Thr Gln Ser Ser
      195      200      205
Asp Gln Thr Thr Arg Ala Thr Asp Pro Ser Ser Pro Pro His His Ala
      210      215      220
Gln Ser Gly Ala Lys Pro Lys

```

225

230

<210> 156
 <211> 231
 <212> PRT
 <213> Human metapneumo virus

<400> 156
 Met Glu Val Arg Val Glu Asn Ile Arg Ala Ile Asp Met Phe Lys Ala
 1 5 10 15
 Lys Ile Lys Asn Arg Ile Arg Ser Ser Arg Cys Tyr Arg Asn Ala Thr
 20 25 30
 Leu Ile Leu Ile Gly Leu Thr Ala Leu Ser Met Ala Leu Asn Ile Phe
 35 40 45
 Leu Ile Ile Asp His Ala Thr Leu Arg Asn Met Ile Lys Thr Glu Asn
 50 55 60
 Cys Ala Asn Met Pro Pro Ala Glu Pro Ser Lys Lys Thr Pro Met Thr
 65 70 75 80
 Ser Thr Ala Gly Pro Asn Thr Lys Pro Asn Pro Gln Gln Ala Thr Gln
 85 90 95
 Trp Thr Thr Glu Asn Ser Thr Phe Pro Ala Ala Thr Ser Glu Gly His
 100 105 110
 Leu His Thr Gly Thr Thr Gln Thr Pro Asp Thr Thr Ala Pro Gln Gln
 115 120 125
 Thr Thr Asp Lys His Thr Ala Leu Pro Lys Ser Thr Asn Glu Gln Ile
 130 135 140
 Thr Gln Thr Thr Thr Glu Lys Lys Thr Thr Arg Ala Thr Thr Gln Arg
 145 150 155 160
 Arg Glu Lys Gly Lys Glu Asn Thr Asn Gln Thr Thr Ser Thr Ala Ala
 165 170 175
 Thr Gln Thr Thr Asn Thr Thr Asn Gln Ile Arg Asn Ala Ser Glu Thr
 180 185 190
 Ile Thr Thr Ser Asp Arg Pro Arg Thr Asp Ser Thr Thr Gln Ser Ser
 195 200 205
 Glu Gln Thr Thr Arg Ala Thr Asp Pro Ser Ser Pro Pro His His Ala
 210 215 220
 Gln Gly Ser Ala Lys Pro Lys
 225 230

<210> 157
 <211> 231
 <212> PRT
 <213> Human metapneumo virus

<400> 157
 Met Glu Val Arg Val Glu Asn Ile Arg Ala Ile Asp Met Phe Lys Ala
 1 5 10 15
 Lys Ile Lys Asn Arg Ile Arg Ser Ser Arg Cys Tyr Arg Asn Ala Thr
 20 25 30
 Leu Ile Leu Ile Gly Leu Thr Ala Leu Ser Met Ala Leu Asn Ile Phe
 35 40 45
 Leu Ile Ile Asp His Ala Thr Leu Arg Asn Met Ile Lys Thr Glu Asn
 50 55 60
 Cys Ala Asn Met Pro Pro Ala Glu Pro Ser Arg Lys Thr Pro Met Thr
 65 70 75 80
 Ser Thr Ala Gly Pro Asn Thr Lys Pro Asn Pro Gln Gln Ala Thr Gln
 85 90 95
 Trp Thr Thr Glu Asn Ser Thr Ser Pro Ala Ala Thr Pro Glu Gly His
 100 105 110
 Leu His Thr Gly Thr Thr Gln Thr Pro Asp Thr Thr Ala Pro Gln Gln

115	120	125
Thr Thr Asp Lys His Thr	Ala Leu Pro Lys Ser	Thr Asn Glu Gln Ile
130	135	140
Thr Gln Ala Thr Thr Glu	Lys Lys Thr Thr Arg	Glu Thr Thr Gln Arg
145	150	155
Arg Glu Lys Gly Lys Glu	Asn Thr Asn Gln Thr	Thr Ser Thr Ala Ala
165	170	175
Thr Gln Thr Thr Asn Thr	Thr Asn Gln Ile Arg	Asn Ala Ser Glu Thr
180	185	190
Ile Thr Thr Ser Asp Arg	Pro Arg Thr Asp Ser	Thr Thr Gln Ser Ser
195	200	205
Glu Gln Thr Thr Gln Ala	Thr Asp Pro Ser Ser	Pro Ala His His Ala
210	215	220
Gln Gly Ser Ala Lys Pro	Lys	
225	230	

<210> 158

<211> 231

<212> PRT

<213> Human metapneumo virus

<400> 158

Met Glu Val Arg Val Glu	Asn Ile Arg Ala Ile	Asp Met Phe Lys Ala
1	5	10
Lys Ile Lys Asn Arg Ile	Arg Ser Ser Arg Cys	Tyr Arg Asn Ala Thr
20	25	30
Leu Ile Leu Ile Gly Leu	Thr Ala Leu Ser Met	Ala Leu Asn Ile Phe
35	40	45
Leu Ile Ile Asp His Ala	Thr Leu Arg Asn Met	Ile Lys Thr Glu Asn
50	55	60
Cys Ala Asn Met Pro Pro	Ala Glu Pro Ser Lys	Lys Thr Pro Met Thr
65	70	75
Ser Thr Ala Gly Leu Asn	Thr Lys Pro Asn Pro	Gln Gln Ala Thr Gln
85	90	95
Trp Thr Thr Glu Asn Ser	Thr Ser Pro Ala Ala	Thr Pro Glu Gly His
100	105	110
Leu His Thr Gly Thr Thr	Gln Thr Pro Asp Thr	Thr Ala Pro Gln Gln
115	120	125
Thr Thr Asp Lys His Thr	Ala Leu Pro Lys Ser	Thr Asn Glu Gln Ile
130	135	140
Thr Gln Thr Thr Thr Glu	Lys Lys Thr Thr Arg	Ala Thr Thr Gln Arg
145	150	155
Arg Glu Lys Gly Lys Glu	Asn Thr Asn Gln Thr	Thr Ser Thr Ala Ala
165	170	175
Thr Gln Thr Thr Asn Thr	Thr Asn Gln Ile Arg	Asn Ala Ser Glu Thr
180	185	190
Ile Thr Thr Ser Asp Arg	Pro Arg Thr Asp Ser	Thr Thr Gln Ser Ser
195	200	205
Glu Gln Thr Thr Arg Ala	Thr Asp Pro Ser Ser	Pro Pro His His Ala
210	215	220
Gln Gly Ser Ala Lys Pro	Lys	
225	230	

<210> 159

<211> 231

<212> PRT

<213> Human metapneumo virus

<400> 159

Met Glu Val Arg Val Glu Asn Ile Arg Ala Ile Asp Met Phe Lys Ala

```

1           5           10           15
Lys Ile Lys Asn Arg Ile Arg Ser Ser Arg Cys Tyr Arg Asn Ala Thr
20           25           30
Leu Ile Leu Ile Gly Leu Thr Ala Leu Ser Met Ala Leu Asn Ile Phe
35           40           45
Leu Ile Ile Asp His Ala Thr Leu Arg Asn Met Ile Lys Thr Glu Asn
50           55           60
Cys Ala Asn Met Pro Pro Ala Glu Pro Ser Lys Lys Thr Pro Met Thr
65           70           75           80
Ser Thr Ala Gly Pro Asn Thr Lys Pro Asn Pro Gln Gln Ala Thr Gln
85           90           95
Trp Thr Thr Glu Asn Ser Thr Ser Pro Ala Ala Thr Pro Glu Gly His
100          105          110
Leu His Thr Gly Thr Thr Gln Thr Pro Asp Thr Thr Ala Pro Gln Gln
115          120          125
Thr Thr Asp Lys His Thr Ala Leu Pro Lys Ser Thr Asn Glu Gln Ile
130          135          140
Thr Gln Thr Thr Thr Glu Lys Lys Thr Thr Arg Ala Thr Thr Gln Arg
145          150          155          160
Arg Glu Lys Gly Lys Glu Asn Thr Asn Gln Thr Thr Ser Thr Ala Ala
165          170          175
Thr Gln Thr Thr Asn Thr Thr Asn Gln Ile Arg Asn Ala Ile Glu Thr
180          185          190
Ile Thr Thr Ser Asp Arg Pro Arg Thr Asp Ser Thr Thr Gln Ser Ser
195          200          205
Glu Gln Thr Thr Arg Ala Thr Asp Pro Ser Ser His Pro His His Ala
210          215          220
Gln Gly Ser Ala Lys Pro Lys
225          230

```

<210> 160

<211> 236

<212> PRT

<213> Human metapneumo virus

<400> 160

```

Met Glu Val Arg Val Glu Asn Ile Arg Ala Ile Asp Met Phe Lys Ala
1           5           10           15
Lys Met Lys Asn Arg Ile Arg Ser Ser Lys Cys Tyr Arg Asn Ala Thr
20           25           30
Leu Ile Leu Ile Gly Leu Thr Ala Leu Ser Met Ala Leu Asn Ile Phe
35           40           45
Leu Ile Ile Asp Tyr Ala Met Leu Lys Asn Met Thr Lys Val Glu His
50           55           60
Cys Val Asn Met Pro Pro Val Glu Pro Ser Lys Lys Thr Pro Met Thr
65           70           75           80
Ser Ala Val Asp Leu Asn Thr Lys Pro Asn Pro Gln Gln Ala Thr Gln
85           90           95
Leu Ala Ala Glu Asp Ser Thr Ser Leu Ala Ala Thr Ser Glu Asp His
100          105          110
Leu His Thr Gly Thr Thr Pro Thr Pro Asp Ala Thr Val Ser Gln Gln
115          120          125
Thr Thr Asp Glu Tyr Thr Thr Leu Leu Arg Ser Thr Asn Arg Gln Thr
130          135          140
Thr Gln Thr Thr Thr Glu Lys Lys Pro Thr Gly Ala Thr Thr Lys Lys
145          150          155          160
Glu Thr Thr Thr Arg Thr Thr Ser Thr Ala Ala Thr Gln Thr Leu Asn
165          170          175
Thr Thr Asn Gln Thr Ser Tyr Val Arg Glu Ala Thr Thr Thr Ser Ala
180          185          190
Arg Ser Arg Asn Ser Ala Thr Thr Gln Ser Ser Asp Gln Thr Thr Gln

```

<400> 162
Met Glu Val Arg Val Glu Asn Ile Arg Ala Ile Asp Met Phe Lys Ala

```

1           5           10           15
Lys Met Lys Asn Arg Ile Arg Ser Ser Lys Cys Tyr Arg Asn Ala Thr
20           25           30
Leu Ile Leu Ile Gly Leu Thr Ala Leu Ser Met Ala Leu Asn Ile Phe
35           40           45
Leu Ile Ile Asp Tyr Ala Met Leu Lys Asn Met Thr Lys Val Glu His
50           55           60
Cys Val Asn Met Pro Pro Val Glu Pro Ser Lys Lys Thr Pro Met Thr
65           70           75           80
Ser Ala Val Asp Leu Asn Thr Lys Leu Asn Pro Gln Gln Ala Thr Gln
85           90           95
Leu Thr Thr Glu Asp Ser Thr Ser Leu Ala Ala Thr Ser Glu Asp His
100          105          110
Leu Leu Thr Gly Thr Thr Pro Thr Pro Asp Ala Thr Val Ser Gln Gln
115          120          125
Thr Thr Asp Glu His Thr Thr Leu Leu Arg Ser Thr Asn Arg Gln Thr
130          135          140
Thr Gln Thr Thr Thr Glu Lys Lys Pro Thr Gly Ala Thr Thr Lys Lys
145          150          155          160
Glu Thr Thr Thr Arg Thr Thr Ser Thr Ala Ala Thr Gln Thr Leu Asn
165          170          175
Thr Thr Asn Gln Thr Ser Asn Gly Arg Glu Ala Thr Thr Thr Ser Thr
180          185          190
Arg Ser Arg Asn Gly Ala Thr Thr Gln Asn Ser Asp Gln Thr Thr Xaa
195          200          205
Thr Ala Asp Pro Ser Ser Gln Pro His His Thr Gln Lys Ser Thr Thr
210          215          220
Thr Thr Tyr Asn Thr Asp Thr Ser Ser Pro Ser Ser
225          230          235

```

<210> 163

<211> 236

<212> PRT

<213> Human metapneumo virus

<400> 163

```

Met Glu Val Arg Val Glu Asn Ile Arg Ala Ile Asp Met Phe Lys Ala
1           5           10           15
Lys Met Lys Asn Arg Ile Arg Ser Ser Lys Cys Tyr Arg Asn Ala Thr
20           25           30
Leu Ile Leu Ile Gly Leu Thr Ala Leu Ser Met Ala Leu Asn Ile Phe
35           40           45
Leu Ile Ile Asp Tyr Ala Thr Leu Lys Asn Met Thr Lys Val Glu His
50           55           60
Cys Val Asn Met Pro Pro Val Glu Pro Ser Lys Lys Thr Pro Met Thr
65           70           75           80
Ser Ala Val Asp Leu Asn Thr Lys Leu Asn Pro Gln Gln Ala Thr Gln
85           90           95
Leu Thr Thr Glu Asp Ser Thr Ser Leu Ala Ala Thr Ser Glu Gly His
100          105          110
Pro His Thr Gly Thr Thr Pro Thr Pro Asp Ala Thr Val Ser Gln Gln
115          120          125
Thr Thr Asp Glu His Thr Thr Leu Leu Arg Ser Thr Asn Arg Gln Thr
130          135          140
Thr Gln Thr Ala Thr Glu Lys Lys Pro Thr Gly Ala Thr Thr Lys Lys
145          150          155          160
Glu Thr Thr Thr Arg Thr Thr Ser Thr Ala Ala Thr Gln Thr Pro Asn
165          170          175
Thr Thr Asn Gln Thr Ser Asn Gly Arg Glu Ala Thr Thr Thr Ser Ala
180          185          190
Arg Ser Arg Asn Gly Ala Thr Thr Gln Asn Ser Asp Gln Ile Thr Gln

```


	195		200		205										
Ala	Ala	Asp	Ser	Ser	Ser	Gln	Pro	His	His	Thr	Gln	Lys	Ser	Thr	Thr
	210					215					220				
Thr	Ala	Tyr	Asn	Thr	Asp	Thr	Ser	Phe	Pro	Ser	Ser				
225					230						235				

<210> 164
 <211> 236
 <212> PRT
 <213> Human metapneumo virus

<400> 164
 Met Glu Val Arg Val Glu Asn Ile Arg Ala Ile Asp Met Phe Lys Ala
 1 5 10 15
 Lys Met Lys Asn Arg Ile Arg Ser Ser Lys Cys Tyr Arg Asn Ala Thr
 20 25 30
 Leu Ile Leu Ile Gly Leu Thr Ala Leu Ser Met Ala Leu Asn Ile Phe
 35 40 45
 Leu Ile Ile Asp Tyr Ala Thr Leu Lys Asn Met Thr Lys Val Glu His
 50 55 60
 Cys Val Asn Met Pro Pro Val Glu Pro Ser Lys Lys Thr Pro Met Thr
 65 70 75 80
 Ser Ala Val Asp Ser Asn Thr Lys Pro Asn Pro Gln Gln Ala Thr Gln
 85 90 95
 Leu Thr Thr Glu Asp Ser Thr Ser Leu Ala Ala Thr Leu Glu Asp His
 100 105 110
 Pro His Thr Gly Thr Thr Pro Thr Pro Asp Ala Thr Val Ser Gln Gln
 115 120 125
 Thr Thr Asp Glu His Thr Thr Leu Leu Arg Ser Thr Asn Arg Gln Thr
 130 135 140
 Thr Gln Thr Thr Ala Glu Lys Lys Pro Thr Arg Ala Thr Thr Lys Lys
 145 150 155 160
 Glu Thr Thr Thr Arg Thr Thr Ser Thr Ala Ala Thr Gln Thr Leu Asn
 165 170 175
 Thr Thr Asn Gln Thr Ser Asn Gly Arg Glu Ala Thr Thr Thr Ser Ala
 180 185 190
 Arg Ser Arg Asn Asn Ala Thr Thr Gln Ser Ser Asp Gln Thr Thr Gln
 195 200 205
 Ala Ala Glu Pro Ser Ser Gln Ser Gln His Thr Gln Lys Ser Thr Thr
 210 215 220
 Thr Thr Tyr Asn Thr Asp Thr Ser Ser Leu Ser Ser
 225 230 235

<210> 165
 <211> 236
 <212> PRT
 <213> Human metapneumo virus

<400> 165
 Met Glu Val Arg Val Glu Asn Ile Arg Ala Ile Asp Met Phe Lys Ala
 1 5 10 15
 Lys Met Lys Asn Arg Ile Arg Ser Ser Lys Cys Tyr Arg Asn Ala Thr
 20 25 30
 Leu Ile Leu Ile Gly Leu Ser Ala Leu Ser Met Ala Leu Asn Ile Phe
 35 40 45
 Leu Ile Ile Asp Tyr Ala Lys Ser Lys Asn Met Thr Arg Val Glu His
 50 55 60
 Cys Val Asn Met Pro Pro Val Glu Pro Ser Lys Lys Thr Pro Met Thr
 65 70 75 80
 Ser Ala Val Asp Leu Asn Thr Lys Pro Asn Pro Gln Arg Ala Thr Gln

					85					90					95		
Leu	Thr	Thr	Glu	Asp	Ser	Thr	Ser	Leu	Ala	Ala	Thr	Leu	Glu	Gly	His		
			100					105					110				
Leu	His	Thr	Gly	Thr	Thr	Pro	Thr	Pro	Asp	Val	Thr	Val	Ser	Gln	Gln		
			115				120					125					
Thr	Thr	Asp	Glu	His	Thr	Thr	Leu	Leu	Arg	Ser	Thr	Asn	Arg	Gln	Thr		
			130			135					140						
Thr	Gln	Thr	Ala	Ala	Glu	Lys	Lys	Pro	Thr	Arg	Val	Thr	Thr	Asn	Lys		
145					150					155					160		
Glu	Thr	Ile	Thr	Arg	Thr	Thr	Ser	Thr	Ala	Ala	Thr	Gln	Thr	Leu	Asn		
				165					170					175			
Thr	Thr	Asn	Gln	Thr	Asn	Asn	Gly	Arg	Glu	Ala	Thr	Thr	Thr	Ser	Ala		
			180				185					190					
Arg	Ser	Arg	Asn	Asn	Ala	Thr	Thr	Gln	Ser	Ser	Asp	Gln	Thr	Thr	Gln		
			195				200					205					
Ala	Ala	Asp	Pro	Ser	Ser	Gln	Ser	Gln	His	Thr	Gln	Lys	Ser	Ile	Thr		
						215					220						
Thr	Thr	Tyr	Asn	Thr	Asp	Thr	Ser	Ser	Pro	Ser	Ser						
225					230						235						

```
<210> 166
<211> 236
<212> PRT
<213> Human metapneumo virus
```

<400>	166																
Met	Glu	Val	Arg	Val	Glu	Asn	Ile	Arg	Ala	Ile	Asp	Met	Phe	Lys	Ala		
1				5					10					15			
Lys	Met	Lys	Asn	Arg	Ile	Arg	Ser	Ser	Lys	Cys	Tyr	Arg	Asn	Ala	Thr		
			20					25					30				
Leu	Ile	Leu	Ile	Gly	Leu	Ser	Ala	Leu	Ser	Met	Ala	Leu	Asn	Ile	Phe		
		35					40					45					
Leu	Ile	Ile	Asp	Tyr	Ala	Lys	Ser	Lys	Thr	Met	Thr	Arg	Val	Glu	His		
	50					55					60						
Cys	Val	Asn	Met	Pro	Pro	Val	Glu	Pro	Ser	Lys	Lys	Thr	Pro	Met	Thr		
65					70					75					80		
Ser	Ala	Val	Asp	Leu	Asn	Thr	Lys	Pro	Asn	Pro	Gln	Gln	Ala	Thr	Gln		
			85						90					95			
Leu	Thr	Thr	Glu	Asp	Ser	Thr	Ser	Pro	Ala	Ala	Thr	Leu	Glu	Gly	His		
			100					105					110				
Leu	His	Thr	Gly	Thr	Thr	Pro	Thr	Pro	Asp	Ala	Thr	Val	Ser	Gln	Gln		
		115					120					125					
Thr	Thr	Asp	Glu	His	Thr	Thr	Leu	Leu	Arg	Ser	Thr	Asn	Arg	Gln	Thr		
	130					135					140						
Thr	Gln	Thr	Thr	Ala	Glu	Lys	Lys	Pro	Thr	Arg	Ala	Thr	Thr	Lys	Lys		
145					150					155					160		
Glu	Thr	Ile	Thr	Arg	Thr	Thr	Ser	Thr	Ala	Ala	Thr	Gln	Thr	Leu	Asn		
			165						170					175			
Thr	Thr	Asn	Gln	Thr	Ser	Asn	Gly	Arg	Glu	Ala	Thr	Thr	Thr	Ser	Ala		
			180					185					190				
Arg	Ser	Arg	Asn	Asn	Ala	Thr	Thr	Gln	Ser	Ser	Asp	Gln	Thr	Thr	Gln		
		195					200					205					
Ala	Ala	Asp	Pro	Ser	Ser	Gln	Ser	Gln	His	Thr	Lys	Lys	Ser	Thr	Thr		
	210					215					220						
Thr	Thr	Tyr	Asn	Thr	Asp	Thr	Ser	Ser	Pro	Ser	Ser						
225					230					235							

```
<210> 167
<211> 236
<212> PRT
```

<213> Human metapneumo virus

<400> 167

```

Met Glu Val Arg Val Glu Asn Ile Arg Ala Ile Asp Met Phe Lys Ala
 1           5           10           15
Lys Met Lys Asn Arg Ile Arg Ser Ser Lys Cys Tyr Arg Asn Ala Thr
 20           25           30
Leu Ile Leu Ile Gly Leu Thr Ala Leu Ser Met Ala Leu Asn Ile Phe
 35           40           45
Leu Ile Ile Asp Tyr Ala Thr Leu Lys Asn Met Thr Lys Val Glu His
 50           55           60
Cys Val Asn Met Pro Pro Val Glu Pro Ser Lys Lys Thr Pro Met Thr
 65           70           75           80
Ser Ala Val Asp Leu Asn Thr Lys Pro Asn Pro Gln Gln Ala Thr Gln
 85           90           95
Leu Thr Thr Glu Asp Ser Thr Ser Leu Ala Ala Thr Leu Glu Asp His
100           105           110
Pro His Thr Gly Thr Thr Pro Thr Pro Asp Ala Thr Val Ser Gln Gln
115           120           125
Thr Thr Asp Glu His Thr Thr Leu Leu Arg Ser Thr Asn Arg Gln Thr
130           135           140
Thr Gln Thr Thr Ala Glu Lys Lys Pro Thr Arg Ala Thr Thr Lys Lys
145           150           155           160
Glu Thr Thr Thr Arg Thr Thr Ser Thr Ala Ala Thr Gln Thr Leu Asn
165           170           175
Thr Thr Asn Gln Thr Ser Asn Gly Arg Glu Ala Thr Thr Thr Ser Ala
180           185           190
Arg Ser Arg Asn Asn Ala Thr Thr Gln Ser Ser Asp Gln Thr Thr Gln
195           200           205
Ala Ala Glu Pro Asn Ser Gln Ser Gln His Thr Gln Lys Ser Thr Thr
210           215           220
Thr Thr Tyr Asn Thr Asp Thr Ser Ser Leu Ser Ser
225           230           235

```

<210> 168

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 168

```

ataggagttt acggaagctc cgtaatttac atggtgcaac tgccaatctt tgggggttata 60
gacacgcctt gctggatagt aaaagcagcc ccttcttggt caggaaaaaa gggaaactat 120
gcttgccctc taagagaaga ccaaggatgg tattgtcaaa atgcagggtc aactgtttac 180
taccctaatg aaaaagactg tgaaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacataa acatatctac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcactatc tcctcttggg 360
gctttggttg cttgctacaa gggagtgagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

```

<210> 169

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 169

```

ataggagttt acggaagctc cgtaatttac atggtgcaac tgccaatctt tgggggttata 60
gacacgcctt gctggatagt aaaagcagcc ccttcttgct cagaaaaaaa gggaaactat 120
gcttgccctc taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcactgtc tcctcttggg 360

```

gctttggttg cttgctacaa gggagtgagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

<210> 170

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 170

ataggagttt acggaagctc cgtaattttac atggtgcaac tgccaatctt tggggttata 60
gacacgcctt gctggatagt aaaagcagcc ctttcttgct cagaaaaaaa gggaaactat 120
gcttgccctt taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagattg cgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgtc tcctcttggg 360
gctttggttg cttgctacaa gggagtgagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

<210> 171

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 171

ataggagttt acggaagctc cgtaattttac atggtgcaac tgccaatctt tggggttata 60
gacacgcctt gctggatagt aaaagcagcc ctttcttgct cagaaaaaaa gggaaactat 120
gcttgccctt taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg cgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgtc tcctcttggg 360
gctttggttg cttgctacaa gggagtgagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

<210> 172

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 172

ataggagttt acggaagctc cgtaattttac atggtgcaac tgccaatctt tggggttata 60
gacacgcctt gctggatagt aaaagcagcc ctttcttgct cagaaaaaaa gggaaactat 120
gcttgccctt taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagattg cgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgtc tcctcttggg 360
gctttggttg cttgctacaa gggagtgagc tgttccattg gtagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

<210> 173

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 173

ataggagttt acggaagctc cgtaattttac atggtgcaac tgccaatctt tggggttata 60
gacacgcctt gctggatagt aaaagcagcc ctttcttgct cagaaaaaaa gggaaactat 120
gcttgccctt taagagaaga ccaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacataa acatatctac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgtc tcctcttggg 360
gctttggttg cttgctacaa gggagtgagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

<210> 174
<211> 449
<212> DNA
<213> Human metapneumo virus

<400> 174
ataggagttt acggaagctc cgtaattttac atggtgcaac tgccaatctt tgggggttata 60
gacacgcctt gctggatagt aaaagcagcc ccttcttggt cagaaaaaaa gggaaactat 120
gcttgccctt taagagaaga ccaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacataa acatatctac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
gctttgggtg cttgctacaa gggagtggc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaagg ctgctctta 449

<210> 175
<211> 449
<212> DNA
<213> Human metapneumo virus

<400> 175
ataggagttt acggaagctc cgtaattttac atggtgcaac tgccaatctt tgggggttata 60
gacacgcctt gctggatagt aaaagcagcc ccttcttggt cagaaaaaaa gggaaactat 120
gcttgccctt taagagaaga ccaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacataa acatatctac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
gctttgggtg cttgctacaa gggagtggc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaagg ctgctctta 449

<210> 176
<211> 449
<212> DNA
<213> Human metapneumo virus

<400> 176
ataggagttt acggaagctc cgtaattttac atggtgcaac tgccaatctt tgggggttata 60
gacacgcctt gctggatagt aaaagcagcc ccttcttgct cagaaaaaaa gggaaactat 120
gcttgccctt taagagaaga tcaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
gctttgggtg cttgctacaa gggagtggc tgttccattg gcagcaacag agtaggaatc 420
atcaagcaac tgaacaagg ctgctctta 449

<210> 177
<211> 449
<212> DNA
<213> Human metapneumo virus

<400> 177
ataggagttt acggaagctc cgtaattttac atggtgcaac tgccaatctt tggagttata 60
gacacgcctt gctggatagt aaaagcagcc ccttcttgct cagaaaaaaa gggaaactat 120
gcttgccctt taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg cgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
gctttgggtg cttgctacaa gggagtggc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaagg ctgctctta 449

<210> 178
<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 178

```
ataggagttt acggaagctc cgtaatttac atggtgcaac tgccaatctt tggggttata 60
gacacgcctt gttggatagt aaaagcagcc ctttcttgct cagaaaaaaa ggggaactat 120
gcttgccctc taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgtc tcctcttggg 360
gctttggttg cttgctacaa gggagtggagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449
```

<210> 179

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 179

```
ataggagttt acggaagctc cgtaatttac atggtgcaac tgccaatctt tggagttata 60
gacacgcctt gctggatagt aaaagcggcc ctttcttgct cagaaaaaaa gggaaactat 120
gcttgccctc taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgtc tcctcttggg 360
gctttggttg cttgctacaa gggagtggagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449
```

<210> 180

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 180

```
ataggagttt acggaagctc cgtaatttac atggtgcaac tgccaatctt tggggttata 60
gacacgcctt gctggatagt aaaagcagcc ctttcttgct cagaaaaaaa gggaaactat 120
gcttgccctt taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca atatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgtc tcctcttggg 360
gctttggttg cttgctacaa gggagtggagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449
```

<210> 181

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 181

```
ataggagttt acggaagctc cgtaatttac atggtgcaac tgccaatctt tggagttata 60
gacacgcctt gctggatagt aaaagcggcc ctttcttgct cggaaaaaaa gggaaactat 120
gcttgccctc taagagaaga tcaaagatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgtc tcctcttggg 360
gctttggttg cttgctacaa gggagtggagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449
```

<210> 182

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 182
 ataggagttt atggaagctc cgtaatttac atggtgcaac tgccaatctt tggagttata 60
 gacacgcctt gctggatagt aaaagcggcc ccttcttgct cagaaaaaaa gggaaactat 120
 gcttgccctc taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
 taccctaaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
 ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
 ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
 gctttggttg cttgctacaa gggagtggc tgttctattg gcagcaacag agtagggatc 420
 atcaagcaac tgaacaaagg ctgctctta 449

<210> 183
 <211> 449
 <212> DNA
 <213> Human metapneumo virus

<400> 183
 ataggagttt atggaagctc cgtaatttac atggtgcaac tgccaatctt tggagttata 60
 gacacgcctt gctggatagt aaaagcggcc ccttcttgct cagaaaaaaa gggaaactat 120
 gcttgccctc taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
 taccctaaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
 ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
 ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
 gctttggttg cttgctacaa gggagtggc tgttccattg gcagcaacag agtagggatc 420
 atcaagcaac tgaacaaagg ctgctctta 449

<210> 184
 <211> 449
 <212> DNA
 <213> Human metapneumo virus

<400> 184
 ataggagttt acggaagctc cgtaatttac atggtgcaac tgccaatctt tggagttata 60
 gacacgcctt gctggatagt aaaagcggcc ccttcttgct cagaaaaaaa gggaaactat 120
 gcttgccctc taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
 taccctaaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
 ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
 ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
 gctttggttg cttgctacaa gggagtggc tgttccattg gcagcaacag agtagggatc 420
 atcaagcaac tgaacaaagg ctgctctta 449

<210> 185
 <211> 449
 <212> DNA
 <213> Human metapneumo virus

<400> 185
 ataggagttt atggaagctc cgtaatttac atggtgcaac tgccaatctt tggagttata 60
 gacacgcctt gctggatagt aaaagcggcc ccttcttgct cagaaaaaaa gggaaactat 120
 gcttgccctc taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
 taccctaaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
 ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
 ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
 gctttggttg cttgctacaa gggagtggc tgttccattg gcagcaacag agtagggatc 420
 atcaagcaac tgaacaaagg ctgctctta 449

<210> 186
 <211> 449
 <212> DNA
 <213> Human metapneumo virus

<400> 186
 ataggagttt atggaagctc cgtaatttac atggtgcaac tgccaatctt tggagttata 60

```

gacacgcctt gctggatagt aaaagcggcc ccttcttgct cagaaaaaaa gggaaactat 120
gcttgccctc taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgc tcctcttggg 360
gctttggttg cttgctacaa gggagtggagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

```

<210> 187

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 187

```

ataggagttt atggaagctc cgtaatttac atggtgcaac tgccaatctt tggagttata 60
gacacgcctt gctggatagt aaaagcggcc ccttcttgct cagaaaaaaa gggaaactat 120
gcttgccctc taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgc tcctcttggg 360
gctttggttg cttgctacaa gggagtggagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

```

<210> 188

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 188

```

ataggagttt acggaagctc cgtaatttac atggtgcaac tgccaatctt tggggttata 60
gacacgcctt gctggatagt aaaagcagcc ccttcttggt caggaaaaaa gggaaactat 120
gcttgccctc taagagaaga ccaaggatgg tattgtcaaa atgcagggtc aactgtttac 180
taccctaatg aaaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacataa acatatctac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgc tcctcttggg 360
gctttggttg cttgctacaa gggagtggagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

```

<210> 189

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 189

```

ataggagttt acggaagctc cgtaatttac atggtgcaac tgccaatctt tggggttata 60
gacacgcctt gctggatagt aaaagcagcc ccttcttggt caggaaaaaa gggaaactat 120
gcttgccctc taagagaaga ccaaggatgg tattgtcaaa atgcagggtc aactgtttac 180
taccctaatg aaaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacataa acatatctac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgc tcctcttggg 360
gctttggttg cttgctacaa gggagtggagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

```

<210> 190

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 190

```

ataggagttt acggaagctc cgtaatttac atggtgcaac tgccaatctt tggagttata 60
gacacgcctt gctggatagt aaaagcggcc ccttcttgct cagaaaaaaa gggaaactat 120
gcttgccctc taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180

```



```

taccctaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac cactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
gctttggttg cttgctacaa gggagtgagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

```

<210> 191

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 191

```

ataggagttt acggaagctc cgtaattttac atggtgcaac tgccaatctt tggggttata 60
gacacgcctt gctggatagt aaaagcagcc cttcttctg cagaaaaaaa gggaaactat 120
gcttgctctt taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
gctctggttg cttgctacaa gggagtgagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

```

<210> 192

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 192

```

ataggagttt acggaagctc cgtaattttac atggtgcaac tgccaatctt tggagttata 60
gacacgcctt gctggatagt aaaagcggcc cttcttctg cagaaaaaaa gggaaactat 120
gcttgctctt taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac cactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
gctttggttg cttgctacaa gggagtgagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

```

<210> 193

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 193

```

ataggagttt acggaagctc cgtaattttac atggtgcaac tgccaatctt tggagttata 60
gacacgcctt gctggatagt aaaagcggcc cttcttctg cagaaaaaaa gggaaactat 120
gcttgctctt taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac cactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
gctttggttg cttgctacaa gggagtgagc tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449

```

<210> 194

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 194

```

ataggagttt acggaagctc cgtaattttac atggtgcaac tgccaatctt tggggttata 60
gacacgcctt gctggatagt aaaagcagcc cttcttctg caggaaaaaa gggaaactat 120
gcttgctctt taagagaaga ccaaggatgg tattgtcaaa atgcagggtc aactgtttac 180
taccctaatg aaaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacataa acatatctac tactaattac 300

```

```
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactatc tcctcttggg 360
gcttttggttg cttgctacaa gggagtgage tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449
```

<210> 195

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 195

```
ataggagttt atggaagctc cgtaatttac atggtgcaac tgccaatctt tggagttata 60
gacacgcctt gctggatagt aaaagcggcc ccttcttgct cagaaaaaaa gggaaactat 120
gcttgctctt taagagaaga tcaaggatgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacatca acatatccac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgc tcctcttggg 360
gcttttggttg cttgctacaa gggagtgage tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449
```

<210> 196

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 196

```
ataggagttt acggaagctc cgtaatttac atggtgcaac tgccaatctt tggggttata 60
gacacgcctt gctggatagt aaaagcagcc ccttcttggt caggaaaaaa gggaaactat 120
gcttgctctt taagagaaga ccaaggatgg tattgtcaaa atgcagggtc aactgtttac 180
taccctaatg aaaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaatcaatg ttgctgagca gtcaaaggag tgcaacataa acatatctac tactaattac 300
ccatgcaaag ttagcacagg aagacatcct atcagtatgg ttgcaactgc tcctcttggg 360
gcttttggttg cttgctacaa gggagtgage tgttccattg gcagcaacag agtagggatc 420
atcaagcaac tgaacaaagg ctgctctta 449
```

<210> 197

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 197

```
atagggggtct acgggagctc tgtaatttac atggtgcagc tgccaatctt tggcggtata 60
gacacgcctt gctggatagt aaaagcagcc ccctcttggt ccgaaaaaaa gggaaactat 120
gcttgctctt taagagaaga ccaagggtgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg agaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaattaatg ttgctgagca atcaaaggag tgcaacatca acatatccac tacaattac 300
ccatgcaaag tcagcacagg aagacatcct atcagtatgg ttgcaactgc ccctcttggg 360
gctctggttg cttgctacaa aggagtaagc tgttccattg gcagcaatag agtagggatt 420
atcaagcagc tgaacaaagg ttgctctta 449
```

<210> 198

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 198

```
atagggggtct acgggagctc cgtaatttac atggtgcagc tgccaatctt tggcgtcata 60
gacacgcctt gctggatagt aaaagcagcc ccctcttggt ccgaaaaaaa gggaaactat 120
gcttgctctt taagagaaga tcaagggtgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg agaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaattaatg ttgctgagca atcaaaggag tgcaacatca acatatccac tacaattac 300
ccatgcaaag tcagcacagg aagacatcct atcagtatgg ttgcaactgc ccctcttggg 360
gctctagttg cttgctacaa aggagtaagc tgttccattg gcagcaatag agtagggatc 420
```

atcaagcagc tgaacaaagg ttgctccta

449

<210> 199

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 199

```

ataggggtct acgggagctc cgtaattttac atggtgcagc tgccaatctt tggcgtcata 60
gacacgcctt gctggatagt aaaagcagcc ccctcttggt ccgaaaaaaa gggaaactat 120
gcttgccctt taagagaaga tcaaggggtg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg agaaagactg tgaacaaga ggagaccatg tcttttgca cacagtagca 240
ggaattaatg ttgctgagca atcaaaagag tgcaacatca acatatccac tacaaattac 300
ccatgcaaag tcagcacagg aagacatcct atcagtatgg ttgactgtc ccctcttggg 360
gctctagttg cttgctacaa aggagtaagc tgttccattg gcagcaatag agtagggatc 420
atcaagcagc tgaacaaagg ttgctccta 449

```

<210> 200

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 200

```

ataggggtct acgggagctc cgtaattttac atggtgcagc tgccaatctt tggcgtcata 60
gacacgcctt gctggatagt aaaagcagcc ccctcttggt ccgaaaaaaa gggaaactat 120
gcttgccctt taagagaaga tcaaggggtg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg agaaagactg tgaacaaga ggagaccatg tcttttgca cacagtagca 240
ggaattaatg ttgctgagca atcaaaagag tgcaacatca acatatccac tacaaattac 300
ccatgcaaag tcagcacagg aagacatcct atcagtatgg ttgactgtc ccctcttggg 360
gctctagttg cttgctacaa aggagtaagc tgttccattg gcagcaatag agtagggatc 420
atcaagcagc tgaacaaagg ttgctccta 449

```

<210> 201

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 201

```

ataggggtct acgggagctc cgtaattttac atggtgcagc tgccaatctt tggcgttata 60
gacacgcctt gctggatagt aaaagcagcc ccctcttggt ccgaaaaaaa gggaaactat 120
gcttgccctt taagagaaga ccaaggggtg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg agaaggactg tgaacaaga ggagaccatg tcttttgca cacagtagca 240
ggaattaatg ttgctgagca atcaaaaggag tgcaacatca acatatccac cacaaattac 300
ccatgcaaag tcagcacagg aaggcatcct atcagtatgg ttgactgtc ccctcttggg 360
gctctggttg cttgttataa aggagtaagc tgttctattg gcagcaatag agtagggatc 420
atcaagcagc tgaacaaagg ttgctccta 449

```

<210> 202

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 202

```

ataggggtct acgggagctc cgtaattttac atggtgcagc tgccaatctt tggcgttata 60
gacacgcctt gctggatagt aaaagcagcc ccctcttggt ccgaaaaaaa gggaaactat 120
gcttgccctt taagagaaga ccaaggggtg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg agaaagactg tgaacaaga ggagaccatg tcttttgca cacagtagca 240
ggaattaatg ttgctgagca atcaaaaggag tgcaacatca acatatccac tacaaattac 300
ccatgcaaag tcagcacagg aagacatcct atcagtatgg ttgactgtc ccctcttggg 360
gctctagttg cttgctacaa aggagtaagc tgttccattg gcagcaacag agtagggatc 420
atcaagcagc tgaacaaagg ttgctccta 449

```

<210> 203
 <211> 449
 <212> DNA
 <213> Human metapneumo virus

<400> 203
 ataggggtct acgggagctc cgtaattttac atggtgcagc tgccaatctt tggcgttata 60
 gacacgcctt gctggatagt aaaagcagcc ccttcttggt ccgaaaaaaaaa gggaaactat 120
 gcttgccctc taagagaaga ccaagggtgg tattgtcaga atgcagggtc aactgtttac 180
 tacccaaatg agaaggactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
 ggaattaatg ttgctgagca atcaaaggag tgcaacatca acatatccac cacaattac 300
 ccatgcaaag tcagcacagg aaggcatcct atcagtatgg ttgactgtc cctcttggg 360
 gctctggttg cttgttaca aggagtaagc tgttctattg gcagcaatag agtagggatc 420
 atcaagcagc tgaacaaagg ttgctctta 449

<210> 204
 <211> 449
 <212> DNA
 <213> Human metapneumo virus

<400> 204
 ataggggtct acgggagctc cgtaattttac atggtgcagc tgccaatctt tggcgttata 60
 gacacgcctt gctggatagt aaaagcagcc ccttcttggt ccgaaaaaaaaa gggaaactat 120
 gcttgccctc taagagaaga ccaagggtgg tattgtcaga atgcagggtc aactgtttac 180
 tacccaaatg agaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
 ggaattaatg ttgctgagca atcaaaggag tgcaacatca acatatccac tacaattac 300
 ccatgcaaag tcagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
 gctctggttg cttgttaca aggagtaagc tgttccattg gcagcaacag agtagggatc 420
 atcaagcagc tgaacaaagg ttgctctta 449

<210> 205
 <211> 449
 <212> DNA
 <213> Human metapneumo virus

<400> 205
 ataggggtct acgggagctc cgtaattttac atggtgcagc tgccaatctt tggcgttata 60
 gacacgcctt gctggatagt aaaagcagcc ccttcttggt ccgaaaaaaaaa gggaaactat 120
 gcttgccctc taagagaaga ccaagggtgg tattgtcaga atgcagggtc aactgtttac 180
 tacccaaatg agaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
 ggaattaatg ttgctgagca atcaaaggag tgcaacatca acatatccac tacaattac 300
 ccatgcaaag tcagcacagg aagacatcct atcagtatgg ttgactgtc tcctcttggg 360
 gctctggttg cttgttaca aggagtaagc tgttccattg gcagcaacag agtagggatc 420
 atcaagcagc tgaacaaagg ttgctctta 449

<210> 206
 <211> 449
 <212> DNA
 <213> Human metapneumo virus

<400> 206
 ataggggtct acgggagctc cgtaattttac atggtgcagc tgccaatctt tggcgttata 60
 gacacgcctt gctggatagt aaaagcagcc ccttcttggt ccgaaaaaaaaa gggaaactat 120
 gcttgccctc taagagaaga ccaaggatgg tattgtcaga atgcagggtc aactgtttac 180
 tacccaaatg agaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
 ggaattaatg ttgctgagca atcaaaggag tgcaacatca acatatccac cacaattac 300
 ccatgcaaag tcagcacagg aaggcatcct atcagtatgg ttgactgtc cctctcggg 360
 gctctggttg cctgttaca aggagtaagt tgttccattg gcagcaatag agtagggatc 420
 atcaagcagc tgaacaaagg ttgctctta 449

<210> 207
 <211> 449

<212> DNA

<213> Human metapneumo virus

<400> 207

```

ataggggtct acgggagctc cgtaatttac atggtgcagc tgccaatctt tggcggtata 60
gacacgcctt gctggatagt aaaagcagcc ccttcttggt ccgaaaaaaaaa gggaaactat 120
gcttgccctt taagagaaga ccaagggtgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg agaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaattaatg ttgctgagca atcaaaggag tgcaacatca acatatccac tacaaattac 300
ccatgcaaag tcagcacagg aagacatcct atcagtatgg ttgcaactgtc tcctcttggg 360
gctctggttg cttgctacaa aggagtaagc tgttccattg gcagcaacag agtagggatc 420
ataaagcagc tgaacaaagg ttgctccta 449

```

<210> 208

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 208

```

ataggggtct acgggagctc cgtaatttac atggtgcagc tgccaatctt tggcggtata 60
gacacgcctt gctggatagt aaaagcagcc ccttcttggt ccgaaaaaaaaa gggaaactat 120
gcttgccctt taagagaaga ccaagggtgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg agaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaattaatg ttgctgagca atcaaaggag tgcaacatca acatatccac cacaaattac 300
ccatgcaaag tcagcacagg aaggcatcct atcagtatgg ttgcaactgtc ccctctcggg 360
gctctggttg cctgttacaa aggagtaagt tgttccattg gcagcaatag agtagggatc 420
atcaagcagc tgaacaaagg ttgctccta 449

```

<210> 209

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 209

```

ataggggtct acgggagctc cgtaatttac atggtgcagc tgccaatctt tggcggtata 60
gacacacctt gctggatagt aaaagcagcc ccttcttggt ccgaaaaaaaaa gggaaattat 120
gcttgccctt taagagaaga ccaagggtgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg agaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaattaatg ttgctgagca atcaaaggaa tgcaacatca acatatccac tacaaattac 300
ccatgcaaag tcagcacagg aagacatcct atcagtatgg ttgcaactgtc tcctcttggg 360
gctctggttg cttgctacaa aggagtaagc tgttccattg gcagcaacag agtagggatc 420
atcaagcagc tgaacaaagg ttgctccta 449

```

<210> 210

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 210

```

ataggggtct acgggagctc cgtaatttac atggtgcagc tgccaatctt tggcggtata 60
gacacgcctt gctggatagt aaaagcagcc ccttcttggt ccgaaaaaaaaa gggaaactat 120
gcttgccctt taagagaaga ccaagggtgg tattgtcaga atgcagggtc aactgtttac 180
taccctaatg agaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
ggaattaatg ttgctgagca atcaaaggag tgcaacatca acatatccac cacaaattac 300
ccatgcaaag tcagcacagg aaggcatcct atcagtatgg ttgcaactgtc ccctctcggg 360
gctctggttg cctgttacaa aggagtaagt tgttccattg gcagcaatag agtagggatc 420
atcaagcagc tgaacaaagg ttgctccta 449

```

<210> 211

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 211
 ataggggtct acgggagctc cgtaatttac atgggtgcagc tgccaatctt tggcgttata 60
 gacacgcctt gctggatagt aaaagcagcc ccttcttggt ccgaaaaaaaaa gggaaactat 120
 gcttgccctt taagagaaga ccaagggtgg tattgtcaga atgcagggtc aactgtttac 180
 taccctaaatg agaaaagactg tgaacaaga ggagaccatg tcttttgca cacagcagca 240
 ggaattaatg ttgctgagca atcaaaggag tgcaacatca acatatccac tacaaattac 300
 ccatgcaaag tcagcacagg aagacatcct atcagtatgg ttgcaactgc tcctcttggg 360
 gctctggttg cttgctataa aggagtaagc tgttccattg gcagcaacag agtagggatc 420
 ataaagcagc tgaacaaagg ttgctccta 449

<210> 212

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 212
 ataggggtct acggaagctc cgtgatttac atggttcaat tgccgatctt tgggtgtcata 60
 gatacacctt gttggataat caaggcagct ccctcttgct cagaaaaaaaaa cggaattat 120
 gcttgccctc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
 taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgta cacagcagca 240
 gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
 ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcaactac acctctcggt 360
 gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg ggttggaatc 420
 atcaacaat tacctaaagg ctgctcata 449

<210> 213

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 213
 ataggggtct acggaagctc tgtgatttac atggttcaat tgccgatctt tgggtgtcata 60
 gatacacctt gttggatcat caaggcagct ccctcttgct cagaaaaaaaaa cggaattat 120
 gcttgccctc taagagagga tcaagggtgg tattgtaaaa atgcaggatc tactgtttac 180
 taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgta cacagcagca 240
 gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
 ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcaactac acctctcggt 360
 gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaattg ggttggaatc 420
 atcaacaat taccctaaagg ctgctcata 449

<210> 214

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 214
 ataggggtct acggaagctc tgtgatttac atggttcaat tgccgatctt tgggtgtcata 60
 gatacacctt gttggatcat caaggcagct ccctcttgct cagaaaaaaaaa cggaattat 120
 gcttgccctc taagagagga tcaagggtgg tattgtaaaa atgcaggatc tactgtttac 180
 taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgta cacagcagca 240
 gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
 ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcaactac acctctcggt 360
 gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg ggttggaatc 420
 atcaacaat taccctaaagg ctgctcata 449

<210> 215

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 215
 ataggggtct acggaagctc tgtgatttac atggttcaat tgccgatctt tgggtgtcata 60

```

gatacacctt gttggatcat caaggcagct ccctcttgct cagaaaaaaa cgggaattat 120
gcttgccctc taagagagga tcaagggtgg tattgtaaaa atgcaggatc tactgtttac 180
taccctaaatg aaaaagactg cgaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcactatc acctctcggt 360
gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg ggttggaatc 420
atcaacaat taccctaaag ctgctcata 449

```

<210> 216

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 216

```

ataggggtct acggaagctc tgtgatttac atggttcaat tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttgct cagaaaaaaa cgggaattat 120
gcttgccctc taagagagga tcaagggtgg tattgtaaaa atgcaggatc tactgtttac 180
taccctaaatg aaaaagactg cgaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcactatc acctctcggt 360
gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg ggttggaatc 420
atcaacaat tacctaaagg ctgctcata 449

```

<210> 217

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 217

```

ataggggtct acggaagctc cgtgatttac atggttcaat tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttgct cagaaaaaaa cgggaattat 120
gcttgccctc taagagagga tcaagggtgg tattgtaaaa atgcaggatc tactgtttac 180
taccctaaatg aaaaagactg cgaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcactatc acctctcggt 360
gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg ggttggaatc 420
atcaacaat tacctaaagg ctgctcata 449

```

<210> 218

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 218

```

ataggggtct acggaagctc tgtaatttac atggttcaat tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttgct cagaaaaaaa cgggaattat 120
gcttgccctc taagagagga tcaagggtgg tattgtaaaa atgcaggatc tactgtttac 180
taccctaaatg aaaaagactg cgaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcactatc acctctcggt 360
gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg ggttggaatc 420
atcaacaat tacctaaagg ctgctcata 449

```

<210> 219

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 219

```

ataggggtct acggaagctc cgtgatttac atggttcaat tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttgct cagaaaaaaa cgggaattat 120
gcttgccctc taagagagga tcaagggtgg tattgtaaaa atgcaggatc tactgtttac 180

```

```

taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacacctt ataagcatgg ttgcactatc acctctcggt 360
gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg ggttggaatc 420
atcaacaat tacctaaagg ctgctcata 449

```

<210> 220

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 220

```

ataggggtct acggaagctc cgtgatttac atggttcaat tgccgatctt tgggtgcata 60
gatacacctt gttggataat caaggcagct cctcttgct cagaaaaaaaa cggaattat 120
gcttgccctc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacacctt ataagcatgg ttgcactatc acctctcggt 360
gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg ggttggaatc 420
atcaacaat tacctaaagg ctgctcata 449

```

<210> 221

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 221

```

ataggggtct acggaagctc tgtgatttac atggttcaat tgccgatctt tgggtgcata 60
gatacacctt gttggataat caaggcagct cctcttgct cagaaaaaaaa cggaattat 120
gcttgccctc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg tgaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacacctt ataagcatgg ttgcactatc acctctcggt 360
gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg ggttggaatc 420
atcaacaat tacctaaagg ctgctcata 449

```

<210> 222

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 222

```

ataggggtct acggaagctc cgtgatttac atggttcaat tgccgatctt tgggtgcata 60
gatacacctt gttggataat caaggcagct cctcttgct cagaaaaaaaa cggaattat 120
gcttgccctc taagagagga tcaagggtgg tactgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacacctt ataagcatgg ttgcactatc acctctcggt 360
gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg ggttggaatc 420
atcaacaat tacctaaagg ctgctcata 449

```

<210> 223

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 223

```

ataggggtct acggaagctc tgtgatttac atggttcaat tgccgatctt tggggtcata 60
gatacacctt gttggataat caaggcagct cctcttgct cagaaaaaaaa cggaattat 120
gcttgccctc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga tacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300

```



```

ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcactatc acctctcggt 360
gcttttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg gggttgaatc 420
atcaaacaat tacccaaagg ctgctcata 449

```

<210> 224

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 224

```

ataggggtct acggaagctc tgtgatttac atggttcaat tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagcc cctcttgct cagagaaaaa cggaattat 120
gcttgctccc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg tgttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcactatc acctctcggt 360
gcttttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg gggttgaatc 420
atcaaacaat tacctaaagg ctgctcata 449

```

<210> 225

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 225

```

ataggggtct acggaagctc tgtgatttac atggttcaat tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct cctcttgct cagagaaaaa cggaattat 120
gcttgctccc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg tgttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcactatc acctctcggt 360
gcttttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg gggttgaatc 420
atcaaacaat tacctaaagg ctgctcata 449

```

<210> 226

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 226

```

ataggggtct acggaagctc tgtgatttac atggttcaat tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct cctcttgct cagaaaaaaa cggaattat 120
gcttgctccc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg tgaaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcactatc acctctcggt 360
gcttttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg gggttgaatc 420
atcaaacaat tacctaaagg ctgctcata 449

```

<210> 227

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 227

```

ataggggtct acggaagctc cgtgatttac atggttcaat tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct cctcttgct cagaaaaaaa cggaattat 120
gcttgctccc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcactatc acctctcggt 360
gcttttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg gggttgaatc 420

```

atcaaacaat tacctaaagg ctgctcata

449

<210> 228

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 228

```

ataggggtct acggaagctc tgtgatttac atggttcaat tgccgatctt tgggtgcata 60
gatacacctt gttggataat caaggcagct ccctcttgct cagagaaaaa cgggaattat 120
gcttgccctc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggtgatcatg tgttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcactatc acctctcggt 360
gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg ggttggaatc 420
atcaaacaat tacctaaagg ctgctcata 449

```

<210> 229

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 229

```

ataggggtct acggaagctc tgtgatttac atggttcaat tgccgatctt tgggtgcata 60
gatacacctt gttggataat caaggcagct ccctcttgct cagaaaaaaa cgggaattat 120
gcttgccctc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga tacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcactatc acctctcggt 360
gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg ggttggaatc 420
atcaaacaat tacctaaagg ctgctcata 449

```

<210> 230

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 230

```

ataggggtct acggaagctc cgtgatttac atggttcaat tgccgatctt tgggtgcata 60
gatacacctt gttggataat caaggcagct ccctcttgct cagaaaaaaa cgggaattat 120
gcttgccctc taagagagga tcaagggtgg tactgtaaaa atgcaggatc cactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacaccct ataagcatgg ttgcactatc acctctcggt 360
gctttggtgg cttgctataa aggggtaagc tgctcgattg gcagcaatcg ggttggaatc 420
atcaaacaat tacctaaagg ctgctcata 449

```

<210> 231

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 231

```

ataggggtct acggaagctc tgtgatttac atggtccagc tgccgatctt tgggtgcata 60
gatacacctt gttggataat caaggcagct ccctcttgct cagaaaaaga tggaaattat 120
gcttgccctc taagagagga tcaagggtgg tattgcaaaa atgcaggatc cactgtttac 180
taccctaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac caccactac 300
ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcactatc acctctcggt 360
gctttggtag cttgctataa aggggttagc tgctcgattg gcagtaatcg ggttggaata 420
atcaaacaac tacctaaagg ctgctcata 449

```

<210> 232
<211> 449
<212> DNA
<213> Human metapneumo virus

<400> 232
ataggggtct acggaagctc tgtgatttac atgggtccagc tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
gcttgccctcc taagagagga tcaaggggtgg tattgtaaaa atgcaggatc cactgtttac 180
tacccaaagt aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac caccaactac 300
ccatgcaaag tcagcacagg aagacacccc atcagcatgg ttgcactatc acctctcggt 360
gctttggtag cttgctacaa aggggttagc tgctcgattg gcagtaatcg gggtggaata 420
atcaaacaac tacctaaagg ctgtcata 449

<210> 233
<211> 449
<212> DNA
<213> Human metapneumo virus

<400> 233
ataggggtct acggaagctc tgtgatttac atgggtccagc tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
gcttgccctcc taagagagga tcaaggggtgg tattgtaaaa atgcaggatc cactgtttac 180
tacccaaagt aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac caccaactac 300
ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcactatc acctctcggt 360
gctttggtag cttgctacaa aggggttagc tgctcgattg gcagtaatcg gggtggaata 420
atcaaacaac tacctaaagg ctgtcata 449

<210> 234
<211> 449
<212> DNA
<213> Human metapneumo virus

<400> 234
ataggggtct acggaagctc cgtgatttac atgggtccagc tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
gcttgccctcc taagagagga ccaaggggtgg tattgtaaaa atgcgggatc cactgtttac 180
tacccaaagt aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac aaccaactac 300
ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcactatc acctctcggt 360
gctttggtag cttgctacaa aggggttagc tgctcgattg gcagtaatcg gggtggaata 420
atcaaacaac tacctaaagg ctgtcata 449

<210> 235
<211> 449
<212> DNA
<213> Human metapneumo virus

<400> 235
ataggggtct acggaagctc cgtgatttac atgggtccagc taccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
gcttgccctcc taagagagga tcaaggggtgg tattgtaaaa atgcaggatc cactgtttac 180
tacccaaagt aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagctgca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatccac aaccaactac 300
ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcactgtc acctctcggt 360
gctttggtag cttgctacaa aggggttagc tgctcgattg gcagtaatcg gggtggaata 420
atcaaacaac tacctaaagg ctgtcata 449

<210> 236
<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 236

```
ataggggtct acggaagctc cgtgatttac atgggtccagc tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
gcttgccctcc taagagagga tcaaggggtgg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac taccaactac 300
ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcactatc acctctcggt 360
gctttggtag cttgctacaa aggggttagc tgttcgattg gcagtaatcg ggttggaata 420
atcaacaac tacctaaagg ctgctcata 449
```

<210> 237

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 237

```
ataggggtct acggaagctc cgtgatttac atgggtccagc tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
gcttgccctcc taagagagga tcaaggggtgg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg tgaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac aaccaactac 300
ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcactatc acctctcggt 360
gctttggtag cttgctacaa aggggttagc tgttcgattg gcagtaatcg ggttggaata 420
atcaacaac tacctaaagg ctgctcata 449
```

<210> 238

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 238

```
ataggggtct acggaagctc cgtgatttac atgggtccagc tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
gcttgccctcc taagagagga ccaaggggtgg tattgtaaaa atgcgggatc cactgtttac 180
taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac aaccaactac 300
ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcactatc acctctcggt 360
gctttggtag cttgctacaa aggggttagc tgttcgattg gcagtaatcg ggttggaata 420
atcaacaac tacctaaagg ctgctcata 449
```

<210> 239

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 239

```
ataggggtct acggaagctc cgtgatttac atgggtccagc tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
gcttgccctcc taagagagga tcaaggggtgg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagcagca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac aaccaactac 300
ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcactatc acctctcggt 360
gctttggtag cttgctacaa aggggttagc tgttcgattg gcagtaatcg ggttggaata 420
atcaacaac tacctaaagg ctgctcata 449
```

<210> 240

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 240
 ataggggtct acggaagctc cgtgatttac atgggtccagc tgccgatctt tgggtgtcata 60
 gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
 gcttgctccc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
 taccctaatg aaaaagactg tgaacaaga ggtgatcatg ttttttgtga cacagcagca 240
 gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac aaccaactac 300
 ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcaactatc acctctcggg 360
 gctttggtag cttgctacaa aggggttagc tgttcgattg gcagtaatcg ggttggaata 420
 atcaaacaac tacctaaagg ctgctcata 449

<210> 241

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 241
 ataggggtct acggaagctc cgtgatttac atgggtccagc tgccgatctt tgggtgtcata 60
 gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
 gcttgctccc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
 taccctaatg aaaaagactg cgaacaaga ggtgatcatg ttttttgtga cacagctgca 240
 gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac aaccaactac 300
 ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcaactatc acctctcggg 360
 gctttggtag cttgctacaa aggggttagc tgttcaattg gcagtaatcg ggttggaata 420
 atcaaacaac tacctaaagg ctgctcata 449

<210> 242

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 242
 ataggggtct acggaagctc cgtgatttac atgggtccagc tgccgatctt tgggtgtcata 60
 gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
 gcttgctccc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
 taccctaatg aaaaagactg cgaacaaga ggtgatcatg ttttttgtga cacagctgca 240
 gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac aaccaactac 300
 ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcaactatc acctctcggg 360
 gctttggtag cttgctacaa aggggttagc tgttcaattg gcagtaatcg ggttggaata 420
 atcaaacaac tacctaaagg ctgctcata 449

<210> 243

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 243
 ataggggtct acggaagctc cgtgatttac atgggtccagc tgccgatctt tgggtgtcata 60
 gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
 gcttgctccc taagagagga tcaagggtgg tattgtaaaa atgcaggatc cactgtttac 180
 taccctaatg aaaaagactg cgaacaaga ggtgatcatg ttttttgtga cacagctgca 240
 gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac aaccaactac 300
 ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcaactatc acctctcggg 360
 gctttggtag cttgctacaa ggggttagc tgttcgattg gcagtaatcg ggttggaata 420
 atcaaacaac tacctaaagg ctgctcata 449

<210> 244

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 244
 ataggggtct acggaagctc tgtgatttac atgggtccagc tgccgatctt tgggtgtcata 60

```

gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
gcttgccctc taagagagga tcaaggggtg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagctgca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatccac aaccaactac 300
ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcactgtc acctctcggc 360
gctttggtag cttgctacaa aggggttagc tgctcgattg gcagtaatcg ggttgggaata 420
atcaacaac tacctaaagg ctgctcata 449

```

<210> 245

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 245

```

ataggggtct acggaagctc tgtgatttac atgggccagc tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
gcttgccctc taagagagga tcaaggggtg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagctgca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac caccaactat 300
ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcactatc acctctcggt 360
gctttggtag cttgctacaa aggggttagc tgctcgattg gcagtaatcg ggttgggaata 420
atcaacaac tacctaaagg ctgctcata 449

```

<210> 246

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 246

```

ataggggtct acggaagctc cgtgatttac atgggccagc tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
gcttgccctc taagagagga tcaaggggtg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagctgca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac aaccaactac 300
ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcactatc acctctcggt 360
gctttggtag cttgctacaa aggggttagc tggtcaattg gcagtaatcg ggttgggaata 420
atcaacaac tacctaaagg ctgctcata 449

```

<210> 247

<211> 449

<212> DNA

<213> Human metapneumo virus

<400> 247

```

ataggggtct acggaagctc cgtgatttac atgggccagc tgccgatctt tgggtgtcata 60
gatacacctt gttggataat caaggcagct ccctcttggt cagaaaaaga tggaaattat 120
gcttgccctc taagagagga tcaaggggtg tattgtaaaa atgcaggatc cactgtttac 180
taccctaaatg aaaaagactg cgaaacaaga ggtgatcatg ttttttgtga cacagctgca 240
gggatcaatg ttgctgagca atcaagagaa tgcaacatca acatatctac aaccaactac 300
ccatgcaaag tcagcacagg aagacaccct atcagcatgg ttgcactatc acctctcggt 360
gctttggtag cttgctacaa aggggttagc tggtcgattg gcagtaatcg ggttgggaata 420
atcaacaac tacctaaagg ctgctcata 449

```

<210> 248

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 248

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1             5             10             15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser

```

```

      20      25      30
Cys Ser Gly Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35      40      45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50      55      60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
      65      70      75      80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
      85      90      95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
      100      105      110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
      115      120      125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
      130      135      140
Asn Lys Gly Cys Ser
145

```

<210> 249
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

```

<400> 249
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
  1      5      10      15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
      20      25      30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35      40      45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50      55      60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
      65      70      75      80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
      85      90      95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
      100      105      110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
      115      120      125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
      130      135      140
Asn Lys Gly Cys Ser
145

```

<210> 250
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

```

<400> 250
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
  1      5      10      15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
      20      25      30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35      40      45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50      55      60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala

```

```

65      70      75      80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
      85      90      95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
      100      105      110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
      115      120      125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
      130      135      140
Asn Lys Gly Cys Ser
145

```

<210> 251
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

```

<400> 251
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1      5      10      15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
      20      25      30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35      40      45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50      55      60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65      70      75      80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
      85      90      95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
      100      105      110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
      115      120      125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
      130      135      140
Asn Lys Gly Cys Ser
145

```

<210> 252
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

```

<400> 252
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1      5      10      15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
      20      25      30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35      40      45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50      55      60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65      70      75      80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
      85      90      95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
      100      105      110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly

```


115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 253
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 253
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 254
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 254
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 255
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 255
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 256
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 256
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 257
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 257

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1          5          10          15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
          20          25          30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
          35          40          45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50          55          60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65          70          75          80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
          85          90          95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
          100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
          115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
          130          135          140
Asn Lys Gly Cys Ser
145

```

<210> 258
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

```

<400> 258
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1          5          10          15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
          20          25          30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
          35          40          45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50          55          60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65          70          75          80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
          85          90          95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
          100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
          115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
          130          135          140
Asn Lys Gly Cys Ser
145

```

<210> 259
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

```

<400> 259
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1          5          10          15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
          20          25          30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
          35          40          45

```

Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 260
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 260
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 261
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 261
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Arg Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95

Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 262

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 262

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 263

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 263

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140

Asn Lys Gly Cys Ser
145

<210> 264
<211> 149
<212> PRT
<213> Human metapneumo virus

<400> 264
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
1 5 10 15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
20 25 30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
35 40 45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
50 55 60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65 70 75 80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
85 90 95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
100 105 110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
115 120 125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
130 135 140
Asn Lys Gly Cys Ser
145

<210> 265
<211> 149
<212> PRT
<213> Human metapneumo virus

<400> 265
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
1 5 10 15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
20 25 30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
35 40 45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
50 55 60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65 70 75 80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
85 90 95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
100 105 110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
115 120 125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
130 135 140
Asn Lys Gly Cys Ser
145

<210> 266
<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 266

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
      20           25           30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35           40           45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50           55           60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
      65           70           75           80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
      85           90           95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
      100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
      115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
      130          135          140
Asn Lys Gly Cys Ser
145

```

<210> 267

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 267

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
      20           25           30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35           40           45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50           55           60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
      65           70           75           80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
      85           90           95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
      100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
      115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
      130          135          140
Asn Lys Gly Cys Ser
145

```

<210> 268

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 268

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15

```

```

Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
      20      25      30
Cys Ser Gly Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35      40      45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50      55      60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
      65      70      75      80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
      85      90      95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
      100      105      110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
      115      120      125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
      130      135      140
Asn Lys Gly Cys Ser
145

```

```

<210> 269
<211> 149
<212> PRT
<213> Human metapneumo virus

```

```

<400> 269
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
  1      5      10      15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
      20      25      30
Cys Ser Gly Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35      40      45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50      55      60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
      65      70      75      80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
      85      90      95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
      100      105      110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
      115      120      125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
      130      135      140
Asn Lys Gly Cys Ser
145

```

```

<210> 270
<211> 149
<212> PRT
<213> Human metapneumo virus

```

```

<400> 270
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
  1      5      10      15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
      20      25      30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35      40      45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50      55      60

```


Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 271
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 271
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 272
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 272
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110

Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 273
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 273
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 274
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 274
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Gly Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 275
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 275
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 276
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 276
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Gly Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 277
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 277

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
           20           25           30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
           35           40           45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Pro Asn Glu
           50           55           60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65           70           75           80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
           85           90           95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
           100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
           115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
           130          135          140
Asn Lys Gly Cys Ser
145

```

<210> 278

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 278

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
           20           25           30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
           35           40           45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
           50           55           60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65           70           75           80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
           85           90           95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
           100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
           115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
           130          135          140
Asn Lys Gly Cys Ser
145

```

<210> 279

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 279

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
           20           25           30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln

```

```

          35          40          45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
  50          55          60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Val Ala
  65          70          75          80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
          85          90          95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
          100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
          115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
          130          135          140
Asn Lys Gly Cys Ser
145

```

<210> 280

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 280

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
  1          5          10          15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
          20          25          30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
          35          40          45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
          50          55          60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
          65          70          75          80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
          85          90          95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
          100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
          115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
          130          135          140
Asn Lys Gly Cys Ser
145

```

<210> 281

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 281

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
  1          5          10          15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
          20          25          30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
          35          40          45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
          50          55          60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
          65          70          75          80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser

```


130
Asn Lys Gly Cys Ser
145

135

140

<210> 284
<211> 149
<212> PRT
<213> Human metapneumo virus

<400> 284
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
1 5 10 15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
20 25 30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
35 40 45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
50 55 60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65 70 75 80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
85 90 95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
100 105 110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
115 120 125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
130 135 140
Asn Lys Gly Cys Ser
145

<210> 285
<211> 149
<212> PRT
<213> Human metapneumo virus

<400> 285
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
1 5 10 15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
20 25 30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
35 40 45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
50 55 60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65 70 75 80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
85 90 95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
100 105 110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
115 120 125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
130 135 140
Asn Lys Gly Cys Ser
145

<210> 286

<211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 286
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 287
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 287
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Asn Lys Gly Cys Ser
 145

<210> 288
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 288
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile


```

1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
20           25           30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
35           40           45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
50           55           60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65           70           75           80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
85           90           95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
130          135          140
Asn Lys Gly Cys Ser
145

```

<210> 289

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 289

```

1           5           10           15
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
20           25           30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
35           40           45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
50           55           60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65           70           75           80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
85           90           95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
130          135          140
Asn Lys Gly Cys Ser
145

```

<210> 290

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 290

```

1           5           10           15
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
20           25           30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
35           40           45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu

```

```

      50              55              60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65              70              75              80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
      85              90              95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
      100             105             110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
      115             120             125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
      130             135             140
Asn Lys Gly Cys Ser
145

```

<210> 291
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

```

<400> 291
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
1      5      10      15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala Ala Pro Ser
      20      25      30
Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35      40      45
Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50      55      60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65      70      75      80
Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile Asn Ile Ser
      85      90      95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
      100     105     110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
      115     120     125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
      130     135     140
Asn Lys Gly Cys Ser
145

```

<210> 292
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

```

<400> 292
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
1      5      10      15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
      20      25      30
Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35      40      45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50      55      60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65      70      75      80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
      85      90      95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser

```

100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 293
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 293
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Trp Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 294
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 294
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser

145

<210> 295
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 295
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 296
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 296
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 297
 <211> 149
 <212> PRT

165

<213> Human metapneumo virus

<400> 297

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
          20           25           30
Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
          35           40           45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
          50           55           60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65           70           75           80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
          85           90           95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
          100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
          115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
          130          135          140
Pro Lys Gly Cys Ser
145

```

<210> 298

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 298

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
          20           25           30
Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
          35           40           45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
          50           55           60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65           70           75           80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
          85           90           95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
          100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
          115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
          130          135          140
Pro Lys Gly Cys Ser
145

```

<210> 299

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 299

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser

```

```

                20                25                30
Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
                35                40                45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
                50                55                60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65                70                75                80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
                85                90                95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Ser Ile Ser
                100                105                110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
                115                120                125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
                130                135                140
Pro Lys Gly Cys Ser
145

```

<210> 300
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

```

<400> 300
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
1                5                10                15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
                20                25                30
Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
                35                40                45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
50                55                60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65                70                75                80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
                85                90                95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
                100                105                110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
                115                120                125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
                130                135                140
Pro Lys Gly Cys Ser
145

```

<210> 301
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

```

<400> 301
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
1                5                10                15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
                20                25                30
Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
35                40                45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
50                55                60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala

```

```

65          70          75          80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
85          90          95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
100        105        110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
115        120        125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
130        135        140
Pro Lys Gly Cys Ser
145

```

<210> 302
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

```

<400> 302
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
1          5          10          15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
20        25        30
Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
35        40        45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
50        55        60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65        70        75        80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
85        90        95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
100       105       110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
115       120       125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
130       135       140
Pro Lys Gly Cys Ser
145

```

<210> 303
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

```

<400> 303
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
1          5          10          15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
20        25        30
Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
35        40        45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
50        55        60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65        70        75        80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
85        90        95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
100       105       110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly

```

115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 304
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 304
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 305
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 305
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 306
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 306
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 307
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 307
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 308
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 308

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
      20           25           30
Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35           40           45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50           55           60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
      65           70           75           80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
      85           90           95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
      100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
      115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
      130          135          140
Pro Lys Gly Cys Ser
145

```

<210> 309

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 309

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
      20           25           30
Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35           40           45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
      50           55           60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
      65           70           75           80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
      85           90           95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
      100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
      115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
      130          135          140
Pro Lys Gly Cys Ser
145

```

<210> 310

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 310

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
      20           25           30
Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
      35           40           45

```

Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 311
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 311
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 312
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 312
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95

Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 313
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 313
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 314
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 314
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140

Pro Lys Gly Cys Ser
145

<210> 315
<211> 149
<212> PRT
<213> Human metapneumo virus

<400> 315
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
1 5 10 15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
20 25 30
Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
35 40 45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
50 55 60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65 70 75 80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
85 90 95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
100 105 110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
115 120 125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
130 135 140
Pro Lys Gly Cys Ser
145

<210> 316
<211> 149
<212> PRT
<213> Human metapneumo virus

<400> 316
Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
1 5 10 15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
20 25 30
Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
35 40 45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
50 55 60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65 70 75 80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
85 90 95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
100 105 110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
115 120 125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
130 135 140
Pro Lys Gly Cys Ser
145

<210> 317
<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 317

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
          20           25           30
Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
          35           40           45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
          50           55           60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65           70           75           80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
          85           90           95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
          100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
          115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
          130          135          140
Pro Lys Gly Cys Ser
145

```

<210> 318

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 318

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15
Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
          20           25           30
Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
          35           40           45
Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
          50           55           60
Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
65           70           75           80
Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
          85           90           95
Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
          100          105          110
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
          115          120          125
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
          130          135          140
Pro Lys Gly Cys Ser
145

```

<210> 319

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 319

```

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1           5           10           15

```

Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 320

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 320

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 321

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 321

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60

Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 322
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 322
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 323
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 323
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110

Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 324

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 324

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 325

<211> 149

<212> PRT

<213> Human metapneumo virus

<400> 325

Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 326
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 326
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

<210> 327
 <211> 149
 <212> PRT
 <213> Human metapneumo virus

<400> 327
 Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln Leu Pro Ile
 1 5 10 15
 Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala Ala Pro Ser
 20 25 30
 Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg Glu Asp Gln
 35 40 45
 Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr Pro Asn Glu
 50 55 60
 Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp Thr Ala Ala
 65 70 75 80
 Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile Asn Ile Ser
 85 90 95
 Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His Pro Ile Ser
 100 105 110
 Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys Tyr Lys Gly
 115 120 125
 Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile Lys Gln Leu
 130 135 140
 Pro Lys Gly Cys Ser
 145

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number
WO 2003/072720 A3

- (51) International Patent Classification⁷: C12N 7/00, A61K 39/12, 39/15 (74) Agents: CORUZZI, Laura, A. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).
- (21) International Application Number: PCT/US2003/005276 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 21 February 2003 (21.02.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/358,934 21 February 2002 (21.02.2002) US (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicants (*for all designated States except US*): MED-IMMUNE VACCINES, INC. [US/US]; 35 W. Watkins Mill Road, Gaithersburg, MD 20878 (US). VIRONOVATIVE BV [NL/NL]; P.O. Box 1738, NL-3000 DR Rotterdam (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): HALLER, Aurelia [AT/US]; 313 Hillview Avenue, Redwood City, CA 94062 (US). TANG, Roderick [MY/US]; 730 Chestnut Street, #3, San Carlos, CA 94070 (US). FOUCHIER, Ronaldus, Adrianus, Maria [NL/NL]; Essenburgsingel 44a, NL-3021 AR Rotterdam (NL). VAN DEN HOGEN, Bernadetta, Gerarda [NL/NL]; Essenburgsingel 44a, NL-3021 AR Rotterdam (NL). OSTERHAUS, Albertus, Dominicus, Marcellinus, Erasmus [NL/NL]; Dr. Breveestraat 16, NL-3981 CH Bunnik (NL).
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 19 August 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RECOMBINANT PARAINFLUENZA VIRUS EXPRESSION SYSTEMS AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM METAPNEUMOVIRUS

(57) Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.

WO 2003/072720 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/05276

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 7/00; A61K 39/12, 39/15

US CL : 435/ 235.1, 236, 320.1; 424199.1, 202.1, 204.1, 211.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/ 235.1, 236, 320.1; 424199.1, 202.1, 204.1, 211.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98/53078 (THE GOVERNMENT OF THE UNITED STATES OF AMERICA) 26 November 1998 (26.11.98), see pages 6- 10 and examples XII and XIII.	1- 3, 22, 27- 44
Y	NISSEN, M.D. et al., Evidence of human metapneumovirus in Australian children. The Medical Journal of Australia 18 February 2002, Vol. 176, No. 4, page 188, see entire document.	1- 3, 22, 27- 44
A	SKIADAPOULOS, M.H. et al., A Chimeric Human-Bovine Parainfluenza Virus Type 3 Expressing Measles Virus Hemagglutinin Is Attenuated for Replication but Is Still Immunogenic in Rhesus Monkeys. Journal of Virology 2001 Vol. 75, pages 10498-10504.	
A	SCHMIDT, A. C. et al., Mucosal Immunization of Rhesus Monkeys against Respiratory Syncytial Virus Subgroups A and B and Human Parainfluenza Virus Type 3 by Using a Live cDNA-Derived Vaccine Based on a Host Range-Attenuated Bovine Parainfluenza Virus Type 3 Vector Backbone. Journal of Virology 2002 Vol. 76, pages 1089-1099.	
A	WO 03/043587 (THE GOVERNMENT OF THE UNITED STATES OF AMERICA) 30 May 2003 (30.05.2003).	1- 48

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

12 December 2003 (12.12.2003)

Date of mailing of the international search report

01 JUL 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Myron G. Hill

Telephone No. 703-308-0196

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

PCT/US03/05276

Continuation of B. FIELDS SEARCHED Item 3:

WEST and MEDLINE STN

parainfluenza, bovine, chimeric, metapneumovirus, recombinant, vaccine, leukemia, lymphoma, asthma